<html>
<head><meta http-equiv=Content-Type content="text/html; charset=UTF-8">
<style type="text/css">
<!--
span.cls_002{font-family:Arial,serif;font-size:10.1px;color:rgb(23,73,139);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_002{font-family:Arial,serif;font-size:10.1px;color:rgb(23,73,139);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_003{font-family:"Book Antiqua",serif;font-size:72.0px;color:rgb(23,73,139);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_003{font-family:"Book Antiqua",serif;font-size:72.0px;color:rgb(23,73,139);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_004{font-family:Arial,serif;font-size:14.1px;color:rgb(254,255,255);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_004{font-family:Arial,serif;font-size:14.1px;color:rgb(254,255,255);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_005{font-family:Arial,serif;font-size:14.1px;color:rgb(254,255,255);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_005{font-family:Arial,serif;font-size:14.1px;color:rgb(254,255,255);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_006{font-family:Arial,serif;font-size:9.9px;color:rgb(254,255,255);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_006{font-family:Arial,serif;font-size:9.9px;color:rgb(254,255,255);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_007{font-family:Arial,serif;font-size:11.1px;color:rgb(23,73,139);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_007{font-family:Arial,serif;font-size:11.1px;color:rgb(23,73,139);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_008{font-family:Times,serif;font-size:22.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_008{font-family:Times,serif;font-size:22.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_009{font-family:Times,serif;font-size:12.9px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_009{font-family:Times,serif;font-size:12.9px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_010{font-family:Arial,serif;font-size:8.1px;color:rgb(23,73,139);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_010{font-family:Arial,serif;font-size:8.1px;color:rgb(23,73,139);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_015{font-family:Times,serif;font-size:20.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_015{font-family:Times,serif;font-size:20.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_011{font-family:Arial,serif;font-size:19.7px;color:rgb(23,73,139);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_011{font-family:Arial,serif;font-size:19.7px;color:rgb(23,73,139);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_012{font-family:Arial,serif;font-size:17.1px;color:rgb(23,73,139);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_012{font-family:Arial,serif;font-size:17.1px;color:rgb(23,73,139);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_013{font-family:"Goudy Old Style Bold",serif;font-size:10.1px;color:rgb(23,73,139);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_013{font-family:"Goudy Old Style Bold",serif;font-size:10.1px;color:rgb(23,73,139);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_014{font-family:"Book Antiqua",serif;font-size:10.1px;color:rgb(23,73,139);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_014{font-family:"Book Antiqua",serif;font-size:10.1px;color:rgb(23,73,139);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_016{font-family:Arial,serif;font-size:10.9px;color:rgb(23,73,139);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_016{font-family:Arial,serif;font-size:10.9px;color:rgb(23,73,139);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_017{font-family:"Verdana",serif;font-size:7.0px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_017{font-family:"Verdana",serif;font-size:7.0px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_018{font-family:"Verdana",serif;font-size:7.0px;color:rgb(65,75,143);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_018{font-family:"Verdana",serif;font-size:7.0px;color:rgb(65,75,143);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_019{font-family:"Verdana Italic",serif;font-size:7.0px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_019{font-family:"Verdana Italic",serif;font-size:7.0px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_020{font-family:"Verdana Italic",serif;font-size:4.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_020{font-family:"Verdana Italic",serif;font-size:4.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_021{font-family:Times,serif;font-size:8.4px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_021{font-family:Times,serif;font-size:8.4px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_022{font-family:Times,serif;font-size:8.4px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_022{font-family:Times,serif;font-size:8.4px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_023{font-family:Times,serif;font-size:11.2px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_023{font-family:Times,serif;font-size:11.2px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_024{font-family:Times,serif;font-size:9.6px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_024{font-family:Times,serif;font-size:9.6px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_031{font-family:Times,serif;font-size:9.2px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_031{font-family:Times,serif;font-size:9.2px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_025{font-family:Times,serif;font-size:9.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_025{font-family:Times,serif;font-size:9.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_030{font-family:Times,serif;font-size:9.2px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_030{font-family:Times,serif;font-size:9.2px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_026{font-family:Times,serif;font-size:9.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_026{font-family:Times,serif;font-size:9.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_027{font-family:Times,serif;font-size:5.3px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_027{font-family:Times,serif;font-size:5.3px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_051{font-family:Times,serif;font-size:9.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: underline}
div.cls_051{font-family:Times,serif;font-size:9.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_028{font-family:Times,serif;font-size:4.7px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_028{font-family:Times,serif;font-size:4.7px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_029{font-family:Times,serif;font-size:8.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_029{font-family:Times,serif;font-size:8.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_033{font-family:Times,serif;font-size:9.6px;color:rgb(43,42,41);font-weight:bold;font-style:italic;text-decoration: none}
div.cls_033{font-family:Times,serif;font-size:9.6px;color:rgb(43,42,41);font-weight:bold;font-style:italic;text-decoration: none}
span.cls_032{font-family:Times,serif;font-size:8.2px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_032{font-family:Times,serif;font-size:8.2px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_034{font-family:Times,serif;font-size:5.4px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_034{font-family:Times,serif;font-size:5.4px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_035{font-family:"Perpetua",serif;font-size:7.2px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_035{font-family:"Perpetua",serif;font-size:7.2px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_036{font-family:Times,serif;font-size:7.2px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_036{font-family:Times,serif;font-size:7.2px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_037{font-family:Times,serif;font-size:6.1px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_037{font-family:Times,serif;font-size:6.1px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_038{font-family:Times,serif;font-size:6.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_038{font-family:Times,serif;font-size:6.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_039{font-family:Times,serif;font-size:3.6px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_039{font-family:Times,serif;font-size:3.6px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_040{font-family:Times,serif;font-size:7.2px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_040{font-family:Times,serif;font-size:7.2px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_041{font-family:Times,serif;font-size:5.3px;color:rgb(28,29,29);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_041{font-family:Times,serif;font-size:5.3px;color:rgb(28,29,29);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_042{font-family:Times,serif;font-size:4.7px;color:rgb(28,29,29);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_042{font-family:Times,serif;font-size:4.7px;color:rgb(28,29,29);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_043{font-family:Times,serif;font-size:8.2px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_043{font-family:Times,serif;font-size:8.2px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_044{font-family:Times,serif;font-size:4.2px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_044{font-family:Times,serif;font-size:4.2px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_052{font-family:Times,serif;font-size:8.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: underline}
div.cls_052{font-family:Times,serif;font-size:8.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_046{font-family:Times,serif;font-size:9.9px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_046{font-family:Times,serif;font-size:9.9px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_048{font-family:Times,serif;font-size:7.5px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_048{font-family:Times,serif;font-size:7.5px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_049{font-family:"Perpetua",serif;font-size:7.0px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_049{font-family:"Perpetua",serif;font-size:7.0px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_050{font-family:Times,serif;font-size:7.5px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_050{font-family:Times,serif;font-size:7.5px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
-->
</style>
<script type="text/javascript" src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/wz_jsgraphics.js"></script>
</head>
<body>
<div style="position:absolute;left:50%;margin-left:-297px;top:0px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background01.jpg" width=595 height=793></div>
<div style="position:absolute;left:20.44px;top:29.13px" class="cls_002"><span class="cls_002">ISSN 0001-5555</span></div>
<div style="position:absolute;left:33.99px;top:57.91px" class="cls_003"><span class="cls_003">ActaDV</span></div>
<div style="position:absolute;left:326.62px;top:150.85px" class="cls_004"><span class="cls_004">Volume 98 2018 </span><span class="cls_005">Supplement No. 219</span></div>
<div style="position:absolute;left:35.32px;top:176.13px" class="cls_005"><span class="cls_005">A</span><span class="cls_006">dvances</span><span class="cls_005"> </span><span class="cls_006">in</span><span class="cls_005"> D</span><span class="cls_006">ermatology</span><span class="cls_005"> </span><span class="cls_006">and</span><span class="cls_005"> V</span><span class="cls_006">enereology</span></div>
<div style="position:absolute;left:34.61px;top:217.63px" class="cls_002"><span class="cls_002">A Non-profit International Journal for</span></div>
<div style="position:absolute;left:34.61px;top:230.63px" class="cls_007"><span class="cls_007">Interdisciplinary Skin Research, Clinical and Experimental</span></div>
<div style="position:absolute;left:34.61px;top:244.63px" class="cls_007"><span class="cls_007">Dermatology and Sexually Transmitted Diseases</span></div>
<div style="position:absolute;left:349.20px;top:337.04px" class="cls_008"><span class="cls_008">Abstracts from the</span></div>
<div style="position:absolute;left:293.36px;top:363.44px" class="cls_008"><span class="cls_008">5</span><span class="cls_009"><sup>th</sup></span><span class="cls_008"> World Psoriasis & Psoriatic</span></div>
<div style="position:absolute;left:314.99px;top:389.84px" class="cls_008"><span class="cls_008">Arthritis Conference 2018</span></div>
<div style="position:absolute;left:34.61px;top:435.78px" class="cls_010"><span class="cls_010">Official Journal of</span></div>
<div style="position:absolute;left:364.53px;top:425.84px" class="cls_015"><span class="cls_015">June 27-30, 2018</span></div>
<div style="position:absolute;left:34.61px;top:444.78px" class="cls_002"><span class="cls_002">- European Society for Dermatology and</span></div>
<div style="position:absolute;left:37.39px;top:455.78px" class="cls_002"><span class="cls_002">Psychiatry</span></div>
<div style="position:absolute;left:354.25px;top:459.84px" class="cls_015"><span class="cls_015">Stockholm, Sweden</span></div>
<div style="position:absolute;left:34.61px;top:475.45px" class="cls_010"><span class="cls_010">Affiliated with</span></div>
<div style="position:absolute;left:34.61px;top:484.45px" class="cls_002"><span class="cls_002">- The International Forum for the Study of Itch</span></div>
<div style="position:absolute;left:423.30px;top:643.00px" class="cls_011"><span class="cls_011">Immediate</span></div>
<div style="position:absolute;left:421.76px;top:663.54px" class="cls_012"><span class="cls_012">Open Access</span></div>
<div style="position:absolute;left:412.04px;top:726.62px" class="cls_013"><span class="cls_013">Acta Dermato</span><span class="cls_014">-</span><span class="cls_013">Venereologica</span></div>
<div style="position:absolute;left:407.38px;top:751.25px" class="cls_016"><span class="cls_016"> </span><A HREF="http://www.medicaljournals.se/adv/">www.medicaljournals.se/adv</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:803px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background02.jpg" width=595 height=793></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:803px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background03.jpg" width=595 height=793></div>
<div style="position:absolute;left:62.29px;top:47.20px" class="cls_008"><span class="cls_008">Abstracts from the 5</span><span class="cls_009"><sup>th</sup></span><span class="cls_008"> World Psoriasis & Psoriatic</span></div>
<div style="position:absolute;left:175.05px;top:73.60px" class="cls_008"><span class="cls_008">Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.05px;top:739.31px" class="cls_017"><span class="cls_017"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
<div style="position:absolute;left:440.10px;top:739.26px" class="cls_017"><span class="cls_017">doi: 10.2340/00015555-2978</span></div>
<div style="position:absolute;left:413.49px;top:747.40px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018; Suppl 219</span></div>
<div style="position:absolute;left:50.05px;top:750.54px" class="cls_017"><span class="cls_017">Journal Compilation © 2018 Acta Dermato-Venereologica.</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:1606px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background04.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">2</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:49.79px;top:51.51px" class="cls_021"><span class="cls_021">Ref.no</span></div>
<div style="position:absolute;left:79.78px;top:51.51px" class="cls_021"><span class="cls_021">Title</span></div>
<div style="position:absolute;left:79.78px;top:62.67px" class="cls_021"><span class="cls_021">Biomarkers and Imaging</span></div>
<div style="position:absolute;left:49.79px;top:73.82px" class="cls_022"><span class="cls_022">001</span></div>
<div style="position:absolute;left:79.78px;top:73.82px" class="cls_022"><span class="cls_022">A metagenomics study of the elbow of psoriasis subjects and their healthy relatives</span></div>
<div style="position:absolute;left:79.78px;top:84.98px" class="cls_021"><span class="cls_021">Clinical phenotypes</span></div>
<div style="position:absolute;left:49.79px;top:96.13px" class="cls_022"><span class="cls_022">002</span></div>
<div style="position:absolute;left:79.78px;top:96.13px" class="cls_022"><span class="cls_022">Nail disorders in patients with Psoriasis vulgaris</span></div>
<div style="position:absolute;left:49.79px;top:107.28px" class="cls_022"><span class="cls_022">003</span></div>
<div style="position:absolute;left:79.78px;top:107.28px" class="cls_022"><span class="cls_022">Psoriasis hidden in Gottron’s papules</span></div>
<div style="position:absolute;left:79.78px;top:118.44px" class="cls_021"><span class="cls_021">Comorbidities</span></div>
<div style="position:absolute;left:49.79px;top:129.59px" class="cls_022"><span class="cls_022">004</span></div>
<div style="position:absolute;left:79.78px;top:129.59px" class="cls_022"><span class="cls_022">Characteristics of psoriasis in obese patients versus non-obese patients; a multicenter study</span></div>
<div style="position:absolute;left:49.79px;top:140.75px" class="cls_022"><span class="cls_022">005</span></div>
<div style="position:absolute;left:79.78px;top:140.75px" class="cls_022"><span class="cls_022">Psoriasis and comorbidity</span></div>
<div style="position:absolute;left:49.79px;top:151.90px" class="cls_022"><span class="cls_022">006</span></div>
<div style="position:absolute;left:79.78px;top:151.90px" class="cls_022"><span class="cls_022">Risk of periodontal disease in patients with chronic plaque psoriasis</span></div>
<div style="position:absolute;left:49.79px;top:163.05px" class="cls_022"><span class="cls_022">007</span></div>
<div style="position:absolute;left:79.78px;top:163.05px" class="cls_022"><span class="cls_022">Splenomegaly and Psoriasis - A case report</span></div>
<div style="position:absolute;left:49.79px;top:174.21px" class="cls_022"><span class="cls_022">008</span></div>
<div style="position:absolute;left:79.78px;top:174.21px" class="cls_022"><span class="cls_022">Psoriasis as predictor for cardiovascular and metabolic comorbidity in middle-aged women</span></div>
<div style="position:absolute;left:49.79px;top:185.36px" class="cls_022"><span class="cls_022">009</span></div>
<div style="position:absolute;left:79.78px;top:185.36px" class="cls_022"><span class="cls_022">A Case of Concurrent Psoriasis and Vitiligo</span></div>
<div style="position:absolute;left:49.79px;top:196.52px" class="cls_022"><span class="cls_022">010</span></div>
<div style="position:absolute;left:79.78px;top:196.52px" class="cls_022"><span class="cls_022">Successful long-term double disease control by adalimumab in a patient with psoriasis vulgaris and hidradenitis suppurativa</span></div>
<div style="position:absolute;left:49.79px;top:207.67px" class="cls_022"><span class="cls_022">011</span></div>
<div style="position:absolute;left:79.78px;top:207.67px" class="cls_022"><span class="cls_022">Clinical and epidemiological caracterization of psoriasis and psoriatic arthritis on a multidisciplinary assesment model.</span></div>
<div style="position:absolute;left:49.79px;top:218.82px" class="cls_022"><span class="cls_022">012</span></div>
<div style="position:absolute;left:79.78px;top:218.82px" class="cls_022"><span class="cls_022">Alcohol and Psoriasis- a Prospective Swedish Study</span></div>
<div style="position:absolute;left:49.79px;top:229.98px" class="cls_022"><span class="cls_022">013</span></div>
<div style="position:absolute;left:79.78px;top:229.98px" class="cls_022"><span class="cls_022">¨Psoriasis and Cancer. Retrospective study in the Psoriasis sector of the Dermatology Service at Ramos Mejia Hospital¨</span></div>
<div style="position:absolute;left:49.79px;top:241.13px" class="cls_022"><span class="cls_022">014</span></div>
<div style="position:absolute;left:79.78px;top:241.13px" class="cls_022"><span class="cls_022">Hematological disorders in the patient with psoriatic arthritis treated with methotrexate and tumor necrosis alpha (TNFalpha) inhibitor</span></div>
<div style="position:absolute;left:49.79px;top:252.29px" class="cls_022"><span class="cls_022">015</span></div>
<div style="position:absolute;left:79.78px;top:252.29px" class="cls_022"><span class="cls_022">The relationship between psoriasis, comorbidities, and depression onset: A nationwide observational control study</span></div>
<div style="position:absolute;left:79.78px;top:263.44px" class="cls_021"><span class="cls_021">Current and new therapeutic modalities</span></div>
<div style="position:absolute;left:49.79px;top:274.59px" class="cls_022"><span class="cls_022">016</span></div>
<div style="position:absolute;left:79.79px;top:274.59px" class="cls_022"><span class="cls_022">Efficacy of Adalimumab plus Methotrexate in Patients with Moderate to Severe Plaque Psoriasis</span></div>
<div style="position:absolute;left:49.79px;top:285.75px" class="cls_022"><span class="cls_022">018</span></div>
<div style="position:absolute;left:79.78px;top:285.75px" class="cls_022"><span class="cls_022">Attainment of remission and minimal disease activity after starting methotrexate subcutaneous therap</span></div>
<div style="position:absolute;left:49.79px;top:296.90px" class="cls_022"><span class="cls_022">019</span></div>
<div style="position:absolute;left:79.78px;top:296.90px" class="cls_022"><span class="cls_022">Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database</span></div>
<div style="position:absolute;left:49.79px;top:308.06px" class="cls_022"><span class="cls_022">020</span></div>
<div style="position:absolute;left:79.78px;top:308.06px" class="cls_022"><span class="cls_022">Ixekizumab improves impact of genital psoriasis on sexual activity: Results from a Phase 3b study</span></div>
<div style="position:absolute;left:49.79px;top:319.21px" class="cls_022"><span class="cls_022">021</span></div>
<div style="position:absolute;left:79.78px;top:319.21px" class="cls_022"><span class="cls_022">Dose optimization of Secukinumab in subjects with moderate to severe plaque psoriasis: OPTIMISE study</span></div>
<div style="position:absolute;left:49.79px;top:330.36px" class="cls_022"><span class="cls_022">022</span></div>
<div style="position:absolute;left:79.78px;top:330.36px" class="cls_022"><span class="cls_022">Inhibition of anti-TNF-alpha cytokine in the treatment of psoriasis and the analysis of infectious complications</span></div>
<div style="position:absolute;left:49.79px;top:341.52px" class="cls_022"><span class="cls_022">023</span></div>
<div style="position:absolute;left:79.78px;top:341.52px" class="cls_022"><span class="cls_022">Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis in Scandinavia</span></div>
<div style="position:absolute;left:49.79px;top:352.67px" class="cls_022"><span class="cls_022">024</span></div>
<div style="position:absolute;left:79.78px;top:352.67px" class="cls_022"><span class="cls_022">First Patient-Reported Insights From a Multinational, Retrospective, Cross-Sectional Study of Real-World Experience of Psoriasis Patients</span></div>
<div style="position:absolute;left:84.78px;top:361.82px" class="cls_022"><span class="cls_022">Treated With Apremilast in Clinical Dermatology Practice (APPRECIATE)</span></div>
<div style="position:absolute;left:49.78px;top:372.97px" class="cls_022"><span class="cls_022">025</span></div>
<div style="position:absolute;left:79.78px;top:372.97px" class="cls_022"><span class="cls_022">Physician- and Patient-Reported Outcomes With Apremilast for Patients With Plaque Psoriasis During Routine Dermatology Care in</span></div>
<div style="position:absolute;left:84.77px;top:382.12px" class="cls_022"><span class="cls_022">Germany: A Second Interim Analysis</span></div>
<div style="position:absolute;left:49.77px;top:393.28px" class="cls_022"><span class="cls_022">026</span></div>
<div style="position:absolute;left:79.77px;top:393.28px" class="cls_022"><span class="cls_022">Improvements in Work Productivity With Up to 104 Weeks of Apremilast Monotherapy: Results From a Phase 3b, Randomized, Controlled</span></div>
<div style="position:absolute;left:84.76px;top:402.43px" class="cls_022"><span class="cls_022">Study in Biologic-Naive Subjects With Active Psoriatic Arthritis</span></div>
<div style="position:absolute;left:49.76px;top:413.58px" class="cls_022"><span class="cls_022">027</span></div>
<div style="position:absolute;left:79.76px;top:413.58px" class="cls_022"><span class="cls_022">Examining Disease Severity and Symptom Improvement With Patient and Physician Assessments: Results From a Phase IV Analysis of</span></div>
<div style="position:absolute;left:84.75px;top:422.73px" class="cls_022"><span class="cls_022">Apremilast in Patients With Moderate Plaque Psoriasis</span></div>
<div style="position:absolute;left:49.75px;top:433.88px" class="cls_022"><span class="cls_022">028</span></div>
<div style="position:absolute;left:79.75px;top:433.88px" class="cls_022"><span class="cls_022">Hemoglobin A1c and Weight Changes With Apremilast in Patients With Psoriasis and Psoriatic Arthritis: Pooled Laboratory Analysis of</span></div>
<div style="position:absolute;left:84.75px;top:443.03px" class="cls_022"><span class="cls_022">the Phase 3 ESTEEM and PALACE Trials</span></div>
<div style="position:absolute;left:49.75px;top:454.19px" class="cls_022"><span class="cls_022">029</span></div>
<div style="position:absolute;left:79.74px;top:454.19px" class="cls_022"><span class="cls_022">Canadian Humira Post-Marketing Observational Epidemiological Study Assessing the Effectiveness of Adalimumab vs Non-Biologic</span></div>
<div style="position:absolute;left:84.74px;top:463.34px" class="cls_022"><span class="cls_022">DMARDs in Psoriatic Arthritis (Complete-PsA): 12-Month Effectiveness Data</span></div>
<div style="position:absolute;left:49.74px;top:474.49px" class="cls_022"><span class="cls_022">030</span></div>
<div style="position:absolute;left:79.74px;top:474.49px" class="cls_022"><span class="cls_022">Secukinumab Efficacy in Patients with Active Psoriatic Arthritis: Meta-analysis of 4 Phase 3 Trials</span></div>
<div style="position:absolute;left:49.74px;top:485.65px" class="cls_022"><span class="cls_022">031</span></div>
<div style="position:absolute;left:79.73px;top:485.65px" class="cls_022"><span class="cls_022">Impact of adalimumab vs. non-biologic treatments on skin outcomes of psoriatic arthritis patients: real-world data from the COMPLETE Study</span></div>
<div style="position:absolute;left:49.74px;top:496.80px" class="cls_022"><span class="cls_022">032</span></div>
<div style="position:absolute;left:79.73px;top:496.80px" class="cls_022"><span class="cls_022">Ixekizumab Improves Nail and Skin Psoriasis through 52 Weeks of Treatment in Patients with Active Psoriatic Arthritis: Results from Two</span></div>
<div style="position:absolute;left:84.73px;top:505.95px" class="cls_022"><span class="cls_022">Randomized, Double-Blind, Phase 3, Clinical Trials (SPIRIT-P1 and SPIRIT-P2)</span></div>
<div style="position:absolute;left:49.73px;top:517.10px" class="cls_022"><span class="cls_022">034</span></div>
<div style="position:absolute;left:79.72px;top:517.10px" class="cls_022"><span class="cls_022">Ixekizumab Makes Therapeutic Thresholds Possible in Active Psoriatic Arthritis Patients: Results from SPIRIT Trials</span></div>
<div style="position:absolute;left:49.73px;top:528.26px" class="cls_022"><span class="cls_022">035</span></div>
<div style="position:absolute;left:79.73px;top:528.26px" class="cls_022"><span class="cls_022">The macrophage modulator MP1032 shows safety and efficacy in a human phase IIa study for the treatment of moderate-to-severe plaque</span></div>
<div style="position:absolute;left:84.74px;top:537.41px" class="cls_022"><span class="cls_022">psoriasis</span></div>
<div style="position:absolute;left:49.74px;top:548.56px" class="cls_022"><span class="cls_022">036</span></div>
<div style="position:absolute;left:79.73px;top:548.56px" class="cls_022"><span class="cls_022">Secukinumab Improves Signs and Symptoms of Psoriatic Arthritis: Results from a Phase 3 Study, FUTURE 5</span></div>
<div style="position:absolute;left:49.74px;top:559.71px" class="cls_022"><span class="cls_022">037</span></div>
<div style="position:absolute;left:79.74px;top:559.71px" class="cls_022"><span class="cls_022">Incidence of Inflammatory Bowel Disease In Patients Treated With Secukinumab: Pooled Analysis of 21 Randomised Controlled Phase</span></div>
<div style="position:absolute;left:84.75px;top:568.86px" class="cls_022"><span class="cls_022">3/4 Clinical Trials of Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis</span></div>
<div style="position:absolute;left:49.75px;top:580.02px" class="cls_022"><span class="cls_022">038</span></div>
<div style="position:absolute;left:79.75px;top:580.02px" class="cls_022"><span class="cls_022">Analysis of the position of the fumaric acid esters in current European psoriasis guidelines</span></div>
<div style="position:absolute;left:49.75px;top:591.17px" class="cls_022"><span class="cls_022">039</span></div>
<div style="position:absolute;left:79.75px;top:591.17px" class="cls_022"><span class="cls_022">Secukinumab Provides Rapid and Sustained Resolution of Enthesitis in Psoriatic Arthritis Patients: Pooled Analysis of Two Phase 3 Studies,</span></div>
<div style="position:absolute;left:84.75px;top:600.32px" class="cls_022"><span class="cls_022">FUTURE 2 and FUTURE 3</span></div>
<div style="position:absolute;left:49.75px;top:611.47px" class="cls_022"><span class="cls_022">041</span></div>
<div style="position:absolute;left:79.74px;top:611.47px" class="cls_022"><span class="cls_022">Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated</span></div>
<div style="position:absolute;left:84.74px;top:620.62px" class="cls_022"><span class="cls_022">Analysis in 29,987 Patients Representing 56,951 Patient-years</span></div>
<div style="position:absolute;left:49.74px;top:631.78px" class="cls_022"><span class="cls_022">042</span></div>
<div style="position:absolute;left:79.73px;top:631.78px" class="cls_022"><span class="cls_022">Clinical response after guselkumab treatment among adalimumab PASI 90 non- responders: Results from the VOYAGE 1 and 2 trials</span></div>
<div style="position:absolute;left:49.74px;top:642.93px" class="cls_022"><span class="cls_022">043</span></div>
<div style="position:absolute;left:79.73px;top:642.93px" class="cls_022"><span class="cls_022">Consistency of response by weight across subgroups of patients with psoriasis treated with guselkumab: Results from the VOYAGE 1 and</span></div>
<div style="position:absolute;left:84.73px;top:652.08px" class="cls_022"><span class="cls_022">2 trials</span></div>
<div style="position:absolute;left:49.73px;top:663.23px" class="cls_022"><span class="cls_022">044</span></div>
<div style="position:absolute;left:79.72px;top:663.23px" class="cls_022"><span class="cls_022">Impact of Clinical Specialty Setting on Disease Management in Patients with Psoriatic Arthritis</span></div>
<div style="position:absolute;left:49.73px;top:674.39px" class="cls_022"><span class="cls_022">045</span></div>
<div style="position:absolute;left:79.72px;top:674.39px" class="cls_022"><span class="cls_022">Speed of response of guselkumab compared with adalimumab for the treatment of moderate-to-severe psoriasis: results through Week 24</span></div>
<div style="position:absolute;left:84.72px;top:683.54px" class="cls_022"><span class="cls_022">from the phase 3, double-blinded, placebo- and active comparator-controlled VOYAGE 1 and VOYAGE 2 trials</span></div>
<div style="position:absolute;left:49.72px;top:694.69px" class="cls_022"><span class="cls_022">046</span></div>
<div style="position:absolute;left:79.72px;top:694.69px" class="cls_022"><span class="cls_022">Safety of Certolizumab Pegol over 48 Weeks in Chronic Plaque Psoriasis Phase 3 Trials</span></div>
<div style="position:absolute;left:49.72px;top:705.85px" class="cls_022"><span class="cls_022">047</span></div>
<div style="position:absolute;left:79.72px;top:705.85px" class="cls_022"><span class="cls_022">Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis</span></div>
<div style="position:absolute;left:84.71px;top:715.00px" class="cls_022"><span class="cls_022">(DAPSA): 2-year Results from a Phase 3 Study</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:2409px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background05.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.65px;top:28.81px" class="cls_019"><span class="cls_019">List of Abstracts</span></div>
<div style="position:absolute;left:540.93px;top:28.81px" class="cls_017"><span class="cls_017">3</span></div>
<div style="position:absolute;left:50.00px;top:51.65px" class="cls_022"><span class="cls_022">048</span></div>
<div style="position:absolute;left:80.00px;top:51.65px" class="cls_022"><span class="cls_022">Predictors of Response to Tildrakizumab for Moderate to Severe Chronic Plaque Psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:62.80px" class="cls_022"><span class="cls_022">049</span></div>
<div style="position:absolute;left:80.00px;top:62.80px" class="cls_022"><span class="cls_022">Long-term efficacy of guselkumab treatment after drug withdrawal and retreatment in patients with moderate-severe plaque psoriasis:</span></div>
<div style="position:absolute;left:85.02px;top:71.95px" class="cls_022"><span class="cls_022">results from VOYAGE 2</span></div>
<div style="position:absolute;left:50.02px;top:83.10px" class="cls_022"><span class="cls_022">050</span></div>
<div style="position:absolute;left:80.01px;top:83.10px" class="cls_022"><span class="cls_022">Outcomes Associated with Achievement of Various Treatment Targets in Patients With Psoriatic Arthritis Receiving Adalimumab</span></div>
<div style="position:absolute;left:50.02px;top:94.26px" class="cls_022"><span class="cls_022">051</span></div>
<div style="position:absolute;left:80.02px;top:94.26px" class="cls_022"><span class="cls_022">Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: Three Year Results from a Phase 3 Study (SPIRIT-P1)</span></div>
<div style="position:absolute;left:50.02px;top:105.41px" class="cls_022"><span class="cls_022">052</span></div>
<div style="position:absolute;left:80.01px;top:105.41px" class="cls_022"><span class="cls_022">Incidence of Serious Gastrointestinal Events Among Tildrakizumab-Treated Patients With Psoriasis</span></div>
<div style="position:absolute;left:50.02px;top:116.57px" class="cls_022"><span class="cls_022">053</span></div>
<div style="position:absolute;left:80.01px;top:116.57px" class="cls_022"><span class="cls_022">Durable Reduction in Absolute PASI with Certolizumab Pegol in Patients with Chronic Plaque Psoriasis</span></div>
<div style="position:absolute;left:50.02px;top:127.72px" class="cls_022"><span class="cls_022">054</span></div>
<div style="position:absolute;left:80.02px;top:127.72px" class="cls_022"><span class="cls_022">Relationships Between Tildrakizumab Dose, Exposure, Efficacy and Safety in Psoriasis Phase 3 Studies</span></div>
<div style="position:absolute;left:50.02px;top:138.87px" class="cls_022"><span class="cls_022">055</span></div>
<div style="position:absolute;left:80.02px;top:138.87px" class="cls_022"><span class="cls_022">Long-Term Safety and Efficacy of Adalimumab from the Phase 3 Randomized, Placebo-Controlled Trial in Patients with Nail and Skin</span></div>
<div style="position:absolute;left:84.99px;top:148.02px" class="cls_022"><span class="cls_022">Psoriasis</span></div>
<div style="position:absolute;left:49.99px;top:159.18px" class="cls_022"><span class="cls_022">056</span></div>
<div style="position:absolute;left:79.99px;top:159.18px" class="cls_022"><span class="cls_022">Eight-Year Interim Results from the ESPRIT 10-Year Postmarketing Surveillance Registry of Adalimumab for Moderate to Severe Psoriasis</span></div>
<div style="position:absolute;left:49.99px;top:170.33px" class="cls_022"><span class="cls_022">057</span></div>
<div style="position:absolute;left:79.99px;top:170.33px" class="cls_022"><span class="cls_022">Durability of Response in Certolizumab Pegol-Treated Patients over 48 Weeks in CIMPASI-1 & 2 Trials</span></div>
<div style="position:absolute;left:49.99px;top:181.49px" class="cls_022"><span class="cls_022">058</span></div>
<div style="position:absolute;left:79.99px;top:181.49px" class="cls_022"><span class="cls_022">Primary Efficacy and Safety of Adalimumab in Nail Psoriasis From the First 26 Weeks of a Phase-3, Randomized, Placebo-Controlled</span></div>
<div style="position:absolute;left:84.98px;top:190.63px" class="cls_022"><span class="cls_022">Trial With Subanalysis in Patients With and Without Psoriatic Arthritis</span></div>
<div style="position:absolute;left:49.97px;top:201.79px" class="cls_022"><span class="cls_022">059</span></div>
<div style="position:absolute;left:79.97px;top:201.79px" class="cls_022"><span class="cls_022">Certolizumab Pegol Is Effective for Chronic Plaque Psoriasis Across Patient Subgroups</span></div>
<div style="position:absolute;left:49.97px;top:212.94px" class="cls_022"><span class="cls_022">060</span></div>
<div style="position:absolute;left:79.97px;top:212.94px" class="cls_022"><span class="cls_022">Discontinuation of Biologic Therapies in Chronic Plaque Psoriasis: A Retrospective Cohort</span></div>
<div style="position:absolute;left:49.97px;top:224.10px" class="cls_022"><span class="cls_022">061</span></div>
<div style="position:absolute;left:79.97px;top:224.10px" class="cls_022"><span class="cls_022">Incidence of Infections in Clinical Trials of Tildrakizumab for Moderate to Severe Plaque Psoriasis</span></div>
<div style="position:absolute;left:49.97px;top:235.25px" class="cls_022"><span class="cls_022">062</span></div>
<div style="position:absolute;left:79.97px;top:235.25px" class="cls_022"><span class="cls_022">Efficacy and Safety of Risankizumab: Results from Two Double-Blind, Placebo- and Ustekinumab-Controlled, Phase 3 Trials in Moderate-</span></div>
<div style="position:absolute;left:85.00px;top:244.40px" class="cls_022"><span class="cls_022">to-Severe Plaque Psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:255.55px" class="cls_022"><span class="cls_022">063</span></div>
<div style="position:absolute;left:80.00px;top:255.55px" class="cls_022"><span class="cls_022">Efficacy and safety of guselkumab administered with a novel self-injection device for the treatment of moderate-to-severe psoriasis: Results</span></div>
<div style="position:absolute;left:84.97px;top:264.70px" class="cls_022"><span class="cls_022">from the Phase III ORION self-dose study through Week 16</span></div>
<div style="position:absolute;left:49.97px;top:275.86px" class="cls_022"><span class="cls_022">064</span></div>
<div style="position:absolute;left:79.97px;top:275.86px" class="cls_022"><span class="cls_022">Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders</span></div>
<div style="position:absolute;left:49.97px;top:287.01px" class="cls_022"><span class="cls_022">065</span></div>
<div style="position:absolute;left:79.97px;top:287.01px" class="cls_022"><span class="cls_022">Efficacy of Tildrakizumab in Moderate to Severe Psoriasis Patients With Prior Exposure to Apremilast</span></div>
<div style="position:absolute;left:49.97px;top:298.16px" class="cls_022"><span class="cls_022">066</span></div>
<div style="position:absolute;left:79.97px;top:298.16px" class="cls_022"><span class="cls_022">Risankizumab Efficacy/Safety in Moderate-to-Severe Plaque Psoriasis: 16-Week Results from IMMhance</span></div>
<div style="position:absolute;left:49.97px;top:309.32px" class="cls_022"><span class="cls_022">067</span></div>
<div style="position:absolute;left:79.97px;top:309.32px" class="cls_022"><span class="cls_022">Disease Severity and Efficacy Insights: Patient-Level PASI Scores in Tildrakizumab Psoriasis Trials</span></div>
<div style="position:absolute;left:49.97px;top:320.47px" class="cls_022"><span class="cls_022">068</span></div>
<div style="position:absolute;left:79.97px;top:320.47px" class="cls_022"><span class="cls_022">Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis</span></div>
<div style="position:absolute;left:49.96px;top:331.63px" class="cls_022"><span class="cls_022">070</span></div>
<div style="position:absolute;left:79.95px;top:331.63px" class="cls_022"><span class="cls_022">Better Skin Clearance is Associated with Improved Quality of Life in Moderate-to-Severe Psoriasis Patients Treated with Tildrakizumab</span></div>
<div style="position:absolute;left:49.96px;top:342.78px" class="cls_022"><span class="cls_022">071</span></div>
<div style="position:absolute;left:79.95px;top:342.78px" class="cls_022"><span class="cls_022">Statistic review of psoriasis systematic therapies in North Greece</span></div>
<div style="position:absolute;left:49.96px;top:353.93px" class="cls_022"><span class="cls_022">073</span></div>
<div style="position:absolute;left:79.95px;top:353.93px" class="cls_022"><span class="cls_022">Pharmakovigilance of systemic antipsoritic drugs: an update from routine care</span></div>
<div style="position:absolute;left:49.96px;top:365.09px" class="cls_022"><span class="cls_022">074</span></div>
<div style="position:absolute;left:79.95px;top:365.09px" class="cls_022"><span class="cls_022">The Impact of Patient Requests on Psoriatic Arthritis Treatment</span></div>
<div style="position:absolute;left:79.95px;top:376.24px" class="cls_021"><span class="cls_021">Epidemiology</span></div>
<div style="position:absolute;left:49.96px;top:387.40px" class="cls_022"><span class="cls_022">075</span></div>
<div style="position:absolute;left:79.95px;top:387.40px" class="cls_022"><span class="cls_022">The Risk Of KC In Psoriasis Patients Receiving Biologics Compared To Conventional Systemic Therapies</span></div>
<div style="position:absolute;left:49.96px;top:398.55px" class="cls_022"><span class="cls_022">076</span></div>
<div style="position:absolute;left:79.95px;top:398.55px" class="cls_022"><span class="cls_022">Patient perceptions of psoriasis severity in Sweden, Norway, and Denmark</span></div>
<div style="position:absolute;left:49.96px;top:409.70px" class="cls_022"><span class="cls_022">077</span></div>
<div style="position:absolute;left:79.95px;top:409.70px" class="cls_022"><span class="cls_022">Patient expectations and satisfaction in psoriasis treatment: A survey from Europe and Canada</span></div>
<div style="position:absolute;left:49.96px;top:420.86px" class="cls_022"><span class="cls_022">078</span></div>
<div style="position:absolute;left:79.95px;top:420.86px" class="cls_022"><span class="cls_022">Socioeconomic determinants of paediatric psoriasis</span></div>
<div style="position:absolute;left:49.96px;top:432.01px" class="cls_022"><span class="cls_022">079</span></div>
<div style="position:absolute;left:79.95px;top:432.01px" class="cls_022"><span class="cls_022">Obesity and the risk of psoriasis: A Korean nationwide, population-based study</span></div>
<div style="position:absolute;left:49.96px;top:443.17px" class="cls_022"><span class="cls_022">080</span></div>
<div style="position:absolute;left:79.95px;top:443.17px" class="cls_022"><span class="cls_022">Clinical characterization of Psoriatic Arthritis in a multidisciplinary care model of patients with Psoriasis</span></div>
<div style="position:absolute;left:49.96px;top:454.32px" class="cls_022"><span class="cls_022">081</span></div>
<div style="position:absolute;left:79.95px;top:454.32px" class="cls_022"><span class="cls_022">Triggering factors in childhood psoriasis</span></div>
<div style="position:absolute;left:49.96px;top:465.47px" class="cls_022"><span class="cls_022">082</span></div>
<div style="position:absolute;left:79.95px;top:465.47px" class="cls_022"><span class="cls_022">Quality of care for psoriasis in the past 12 years - results from a series of nationwide health care studies in Germany</span></div>
<div style="position:absolute;left:49.96px;top:476.63px" class="cls_022"><span class="cls_022">083</span></div>
<div style="position:absolute;left:79.95px;top:476.63px" class="cls_022"><span class="cls_022">Global Psoriasis Atlas - Work Stream 2</span></div>
<div style="position:absolute;left:49.96px;top:487.78px" class="cls_022"><span class="cls_022">084</span></div>
<div style="position:absolute;left:79.95px;top:487.78px" class="cls_022"><span class="cls_022">Global Burden of Disease: A Systematic Literature Review on Disability Weights for Skin Diseases</span></div>
<div style="position:absolute;left:79.95px;top:498.94px" class="cls_021"><span class="cls_021">Genetics</span></div>
<div style="position:absolute;left:49.96px;top:510.09px" class="cls_022"><span class="cls_022">085</span></div>
<div style="position:absolute;left:79.95px;top:510.09px" class="cls_022"><span class="cls_022">MIR-499 polymorphism is associated with susceptibility to psoriatic arthritis - preliminary study</span></div>
<div style="position:absolute;left:49.96px;top:521.24px" class="cls_022"><span class="cls_022">086</span></div>
<div style="position:absolute;left:79.96px;top:521.24px" class="cls_022"><span class="cls_022">Association between inflammasome-related polymorphisms and clinical phenotypes of Psoriatic arthritis</span></div>
<div style="position:absolute;left:79.95px;top:532.40px" class="cls_021"><span class="cls_021">Health Economics and Health Policies</span></div>
<div style="position:absolute;left:49.96px;top:543.55px" class="cls_022"><span class="cls_022">088</span></div>
<div style="position:absolute;left:79.95px;top:543.55px" class="cls_022"><span class="cls_022">Frequency of Inadequate Response to Treatment among Psoriasis Patients on First-Line Biologics</span></div>
<div style="position:absolute;left:49.96px;top:554.71px" class="cls_022"><span class="cls_022">089</span></div>
<div style="position:absolute;left:79.95px;top:554.71px" class="cls_022"><span class="cls_022">Barriers of guideline-compliant care for psoriasis in Germany - Results of the European study PsoBarrier</span></div>
<div style="position:absolute;left:79.95px;top:565.86px" class="cls_021"><span class="cls_021">Interesting Clinical Cases</span></div>
<div style="position:absolute;left:49.96px;top:577.01px" class="cls_022"><span class="cls_022">090</span></div>
<div style="position:absolute;left:79.95px;top:577.01px" class="cls_022"><span class="cls_022">Individualised Therapy for Psoriasis - Case series</span></div>
<div style="position:absolute;left:49.96px;top:588.17px" class="cls_022"><span class="cls_022">091</span></div>
<div style="position:absolute;left:79.95px;top:588.17px" class="cls_022"><span class="cls_022">A Unique Clinical Case of Psoriatic Arthritis and Relapsing Polychondritis</span></div>
<div style="position:absolute;left:49.96px;top:599.32px" class="cls_022"><span class="cls_022">092</span></div>
<div style="position:absolute;left:79.95px;top:599.32px" class="cls_022"><span class="cls_022">Spiny follicular hyperkeratosis in a psoriasis patient treated with ustekinumab</span></div>
<div style="position:absolute;left:49.96px;top:610.48px" class="cls_022"><span class="cls_022">093</span></div>
<div style="position:absolute;left:79.95px;top:610.48px" class="cls_022"><span class="cls_022">Combination therapy of apremilast and biological product in a patient with psoriasis.</span></div>
<div style="position:absolute;left:49.96px;top:621.63px" class="cls_022"><span class="cls_022">094</span></div>
<div style="position:absolute;left:79.95px;top:621.63px" class="cls_022"><span class="cls_022">Psoriasis worst-case scenarios: A series of 3 case reports</span></div>
<div style="position:absolute;left:49.96px;top:632.78px" class="cls_022"><span class="cls_022">095</span></div>
<div style="position:absolute;left:79.96px;top:632.78px" class="cls_022"><span class="cls_022">Successful switching to biosimilar in psoriatic patient with severe drug reaction to infliximab. A case report</span></div>
<div style="position:absolute;left:49.96px;top:643.94px" class="cls_022"><span class="cls_022">096</span></div>
<div style="position:absolute;left:79.95px;top:643.94px" class="cls_022"><span class="cls_022">Safety of Apremilast in the treatment of a psoriasis patient with chronic Hepatitis B</span></div>
<div style="position:absolute;left:79.95px;top:655.09px" class="cls_021"><span class="cls_021">Pathophysiology and immunobiology</span></div>
<div style="position:absolute;left:49.96px;top:666.25px" class="cls_022"><span class="cls_022">098</span></div>
<div style="position:absolute;left:79.95px;top:666.25px" class="cls_022"><span class="cls_022">IL-22 induces keratinocytes hyperproliferation in psoriasis via miR-21 and miR-31 upregulation</span></div>
<div style="position:absolute;left:49.96px;top:677.40px" class="cls_022"><span class="cls_022">099</span></div>
<div style="position:absolute;left:79.95px;top:677.40px" class="cls_022"><span class="cls_022">Serum concentracion of IFN-gamma in patients with psoriasis: correlation with clinical type and severity of disease</span></div>
<div style="position:absolute;left:49.96px;top:688.55px" class="cls_022"><span class="cls_022">100</span></div>
<div style="position:absolute;left:79.95px;top:688.55px" class="cls_022"><span class="cls_022">Immunological memory exists in the recurrent lesion and nonrecurrent skin after remission in psoriatic patients</span></div>
<div style="position:absolute;left:49.96px;top:699.71px" class="cls_022"><span class="cls_022">101</span></div>
<div style="position:absolute;left:79.96px;top:699.71px" class="cls_022"><span class="cls_022">Investigating systemic inflammation as the common link between depression, Psoriasis, and Psoriatic arthritis in US Veterans.</span></div>
<div style="position:absolute;left:49.96px;top:710.86px" class="cls_022"><span class="cls_022">102</span></div>
<div style="position:absolute;left:79.95px;top:710.86px" class="cls_022"><span class="cls_022">The Immune-phenotype of Small Plaque Psoriasis</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:3212px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background06.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">4</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.65px" class="cls_022"><span class="cls_022">104</span></div>
<div style="position:absolute;left:80.00px;top:51.65px" class="cls_022"><span class="cls_022">Serum Glucocorticoid-inducible Kinase-1(SGK1) Levels in Patients with Psoriatic Arthritis</span></div>
<div style="position:absolute;left:50.00px;top:62.80px" class="cls_022"><span class="cls_022">105</span></div>
<div style="position:absolute;left:80.00px;top:62.80px" class="cls_022"><span class="cls_022">Differential NH2-terminal autoantigen trimming may explain epistasis between HLA-C*06:02 and ERAP1 variants in psoriasis risk</span></div>
<div style="position:absolute;left:50.00px;top:73.95px" class="cls_022"><span class="cls_022">106</span></div>
<div style="position:absolute;left:80.00px;top:73.95px" class="cls_022"><span class="cls_022">Environmental triggers of an HLA-C*06:02-restricted autoimmune response in psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:85.11px" class="cls_022"><span class="cls_022">107</span></div>
<div style="position:absolute;left:80.00px;top:85.11px" class="cls_022"><span class="cls_022">A skewed pool of resident T cells triggers disease-associated tissue responses in never- lesional psoriasis</span></div>
<div style="position:absolute;left:80.00px;top:96.26px" class="cls_021"><span class="cls_021">Psoriasis and Psoriatic Arthritis relationship</span></div>
<div style="position:absolute;left:50.00px;top:107.42px" class="cls_022"><span class="cls_022">108</span></div>
<div style="position:absolute;left:80.00px;top:107.42px" class="cls_022"><span class="cls_022">Nail involvement in psoriasis; is it a predictor of psoriatic arthritis?</span></div>
<div style="position:absolute;left:50.00px;top:118.57px" class="cls_022"><span class="cls_022">109</span></div>
<div style="position:absolute;left:80.00px;top:118.57px" class="cls_022"><span class="cls_022">Absolute and relative PASI improvements with ixekizumab treatment: Results at Week 12 from IXORA-P</span></div>
<div style="position:absolute;left:50.00px;top:129.72px" class="cls_022"><span class="cls_022">110</span></div>
<div style="position:absolute;left:80.00px;top:129.72px" class="cls_022"><span class="cls_022">Prevalence and sex differences of psoriatic arthritis in patients with severe plaque psoriasis.</span></div>
<div style="position:absolute;left:50.00px;top:140.88px" class="cls_022"><span class="cls_022">111</span></div>
<div style="position:absolute;left:80.00px;top:140.88px" class="cls_022"><span class="cls_022">Skin Lesion Severity In Early Axial and Peripheral Psoriatic Arthritis Patients</span></div>
<div style="position:absolute;left:50.00px;top:152.03px" class="cls_022"><span class="cls_022">112</span></div>
<div style="position:absolute;left:80.00px;top:152.03px" class="cls_022"><span class="cls_022">Gastrointestinal symptoms are common in U.S. patients with moderate-severe psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:163.19px" class="cls_022"><span class="cls_022">113</span></div>
<div style="position:absolute;left:80.00px;top:163.19px" class="cls_022"><span class="cls_022">Secukinumab’s Long-Term Safety Remains Favorable up to 5 Years of Treatment</span></div>
<div style="position:absolute;left:50.00px;top:174.34px" class="cls_022"><span class="cls_022">114</span></div>
<div style="position:absolute;left:80.00px;top:174.34px" class="cls_022"><span class="cls_022">Impact of Improvement in Skin and Joint on Quality of Life in Active Psoriatic Arthritis Patients</span></div>
<div style="position:absolute;left:50.00px;top:185.49px" class="cls_022"><span class="cls_022">115</span></div>
<div style="position:absolute;left:80.00px;top:185.49px" class="cls_022"><span class="cls_022">Secukinumab Shows High and Sustained Efficacy in Subjects with Moderate to Severe Palmoplantar Psoriasis: 2.5-Year Results From the</span></div>
<div style="position:absolute;left:84.98px;top:194.64px" class="cls_022"><span class="cls_022">GESTURE Study</span></div>
<div style="position:absolute;left:49.98px;top:205.80px" class="cls_022"><span class="cls_022">116</span></div>
<div style="position:absolute;left:79.98px;top:205.80px" class="cls_022"><span class="cls_022">Secukinumab Shows High and Sustained Efficacy in Nail Psoriasis: 2.5-Year TRANSFIGURE Study Results</span></div>
<div style="position:absolute;left:49.98px;top:216.95px" class="cls_022"><span class="cls_022">117</span></div>
<div style="position:absolute;left:79.98px;top:216.95px" class="cls_022"><span class="cls_022">The obesity and prevalence psoriatic arthritis in patients with plaque psoriasis: dermatological real-setting data.</span></div>
<div style="position:absolute;left:49.98px;top:228.11px" class="cls_022"><span class="cls_022">118</span></div>
<div style="position:absolute;left:79.98px;top:228.05px" class="cls_022"><span class="cls_022">Diagnosis of Psoriatic Arthritis in Patients with Moderate to Severe Chronic Plaque Psoriasis Treated with Secukinumab vs. Other Treat-</span></div>
<div style="position:absolute;left:85.00px;top:237.20px" class="cls_022"><span class="cls_022">ments in the PURE Registry: Indication of Selection Preferences and Underdiagnosis</span></div>
<div style="position:absolute;left:50.00px;top:248.35px" class="cls_022"><span class="cls_022">119</span></div>
<div style="position:absolute;left:80.00px;top:248.35px" class="cls_022"><span class="cls_022">Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks</span></div>
<div style="position:absolute;left:50.00px;top:259.50px" class="cls_022"><span class="cls_022">120</span></div>
<div style="position:absolute;left:80.00px;top:259.50px" class="cls_022"><span class="cls_022">Tildrakizumab efficacy over time by week 28 response levels in two Phase 3 clinical trials in patients with chronic plaque psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:270.66px" class="cls_022"><span class="cls_022">122</span></div>
<div style="position:absolute;left:79.99px;top:270.66px" class="cls_022"><span class="cls_022">Potential Disconnect: Co-Management of Patients with Psoriatic Arthritis Between Rheumatologists and Dermatologists</span></div>
<div style="position:absolute;left:50.00px;top:281.81px" class="cls_022"><span class="cls_022">123</span></div>
<div style="position:absolute;left:79.99px;top:281.81px" class="cls_022"><span class="cls_022">The Use of Tumor Necrosis Factor Inhibitors (TNF) in the Second-Line Biologic/Small Molecule Setting: A Cross-Specialty Comparison</span></div>
<div style="position:absolute;left:50.00px;top:292.97px" class="cls_022"><span class="cls_022">124</span></div>
<div style="position:absolute;left:79.99px;top:292.97px" class="cls_022"><span class="cls_022">Impact of Guselkumab versus Placebo and Adalimumab on Patient Reported Outcomes in Patients with and without Psoriatic Arthritis in</span></div>
<div style="position:absolute;left:84.99px;top:302.12px" class="cls_022"><span class="cls_022">VOYAGE 2</span></div>
<div style="position:absolute;left:79.99px;top:313.27px" class="cls_021"><span class="cls_021">Quality of Life</span></div>
<div style="position:absolute;left:49.99px;top:324.42px" class="cls_022"><span class="cls_022">125</span></div>
<div style="position:absolute;left:79.99px;top:324.42px" class="cls_022"><span class="cls_022">The Dermatology Life Quality Index in Russian patients with psoriasis and psoriatic arthritis.</span></div>
<div style="position:absolute;left:49.99px;top:335.58px" class="cls_022"><span class="cls_022">126</span></div>
<div style="position:absolute;left:79.99px;top:335.58px" class="cls_022"><span class="cls_022">Effects of mindfulness-based cognitive therapy on self-reported psoriasis and psychological symptoms</span></div>
<div style="position:absolute;left:49.99px;top:346.73px" class="cls_022"><span class="cls_022">127</span></div>
<div style="position:absolute;left:79.99px;top:346.73px" class="cls_022"><span class="cls_022">A mixed methods study exploring the impact of mindfulness on psoriasis, anxiety, depression and QoL</span></div>
<div style="position:absolute;left:49.99px;top:357.89px" class="cls_022"><span class="cls_022">128</span></div>
<div style="position:absolute;left:79.99px;top:357.89px" class="cls_022"><span class="cls_022">A link between quality of patient-physician communication and patient healthcare needs in PsA</span></div>
<div style="position:absolute;left:49.99px;top:369.04px" class="cls_022"><span class="cls_022">129</span></div>
<div style="position:absolute;left:79.99px;top:369.04px" class="cls_022"><span class="cls_022">Psoriasis Patients Point of View: What bare we Missing when Managing Them?</span></div>
<div style="position:absolute;left:49.99px;top:380.19px" class="cls_022"><span class="cls_022">130</span></div>
<div style="position:absolute;left:79.99px;top:380.19px" class="cls_022"><span class="cls_022">The impact of psoriasis and psoriatic arthritis on quality of life and career in Scandinavia</span></div>
<div style="position:absolute;left:49.99px;top:391.35px" class="cls_022"><span class="cls_022">131</span></div>
<div style="position:absolute;left:79.99px;top:391.35px" class="cls_022"><span class="cls_022">Quality of life of patients with psoriasis in Khartoum dermatology hospital, December 2017</span></div>
<div style="position:absolute;left:49.99px;top:402.50px" class="cls_022"><span class="cls_022">132</span></div>
<div style="position:absolute;left:79.99px;top:402.45px" class="cls_022"><span class="cls_022">Mirikizumab Significantly Improves Self-Reported Disease Severity and General Health Status in Patients with Moderate-to-Severe Pso-</span></div>
<div style="position:absolute;left:85.00px;top:411.60px" class="cls_022"><span class="cls_022">riasis</span></div>
<div style="position:absolute;left:50.00px;top:422.75px" class="cls_022"><span class="cls_022">133</span></div>
<div style="position:absolute;left:79.99px;top:422.75px" class="cls_022"><span class="cls_022">Effect of Tildrakizumab on Personal Relationships in Patients with Moderate-to-Severe Chronic Plaque Psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:433.90px" class="cls_022"><span class="cls_022">134</span></div>
<div style="position:absolute;left:79.99px;top:433.90px" class="cls_022"><span class="cls_022">Pruritus severity assessment and correlation with baseline characteristics of patients with psoriasis vulgaris: an exploratory analysis of the</span></div>
<div style="position:absolute;left:84.99px;top:443.05px" class="cls_022"><span class="cls_022">Phase IIIb, PSORITUS study</span></div>
<div style="position:absolute;left:49.99px;top:454.21px" class="cls_022"><span class="cls_022">135</span></div>
<div style="position:absolute;left:79.99px;top:454.21px" class="cls_022"><span class="cls_022">Quality of life and psychosocial implications in patients with psoriasis</span></div>
<div style="position:absolute;left:49.99px;top:465.36px" class="cls_022"><span class="cls_022">136</span></div>
<div style="position:absolute;left:79.99px;top:465.36px" class="cls_022"><span class="cls_022">Swedish psoriatic patients’ perspective of their disease. Results from an observational patient survey.</span></div>
<div style="position:absolute;left:49.99px;top:476.52px" class="cls_022"><span class="cls_022">137</span></div>
<div style="position:absolute;left:79.99px;top:476.52px" class="cls_022"><span class="cls_022">Ixekizumab Provides Greater Cumulative Benefits versus Ustekinumab over 24 Weeks for Patients with Moderate-to-Severe Psoriasis in</span></div>
<div style="position:absolute;left:85.01px;top:485.67px" class="cls_022"><span class="cls_022">a Randomized, Double-Blind Phase 3b Clinical Trial</span></div>
<div style="position:absolute;left:50.01px;top:496.82px" class="cls_022"><span class="cls_022">138</span></div>
<div style="position:absolute;left:80.00px;top:496.82px" class="cls_022"><span class="cls_022">Coach@Home: A Support Program for Patients Treated With Certolizumab Pegol</span></div>
<div style="position:absolute;left:50.01px;top:507.97px" class="cls_022"><span class="cls_022">139</span></div>
<div style="position:absolute;left:80.00px;top:507.97px" class="cls_022"><span class="cls_022">A Comprehensive Survey Assessing the Family Planning Needs of Women with Psoriasis</span></div>
<div style="position:absolute;left:50.01px;top:519.13px" class="cls_022"><span class="cls_022">140</span></div>
<div style="position:absolute;left:80.00px;top:519.13px" class="cls_022"><span class="cls_022">The Psychosocial Impact of Psoriasis: Differential Experiences of Men and Women in Early Adulthood</span></div>
<div style="position:absolute;left:50.01px;top:530.28px" class="cls_022"><span class="cls_022">141</span></div>
<div style="position:absolute;left:80.00px;top:530.28px" class="cls_022"><span class="cls_022">Certolizumab Pegol Improves Patient-Reported Outcomes in Chronic Plaque Psoriasis Over 1 Year</span></div>
<div style="position:absolute;left:50.01px;top:541.44px" class="cls_022"><span class="cls_022">142</span></div>
<div style="position:absolute;left:80.00px;top:541.44px" class="cls_022"><span class="cls_022">Translating WHO resolution into the public: the German program against stigmatization of people with chronic visible skin diseases</span></div>
<div style="position:absolute;left:50.01px;top:552.59px" class="cls_022"><span class="cls_022">143</span></div>
<div style="position:absolute;left:80.00px;top:552.59px" class="cls_022"><span class="cls_022">The Global Research on the Impact of Dermatological Diseases (GRIDD)</span></div>
<div style="position:absolute;left:80.00px;top:563.74px" class="cls_021"><span class="cls_021">Young scientists (born on or after January 1, 1983)</span></div>
<div style="position:absolute;left:50.01px;top:574.90px" class="cls_022"><span class="cls_022">144</span></div>
<div style="position:absolute;left:80.00px;top:574.90px" class="cls_022"><span class="cls_022">Treatment of Nail Psoriasis with Different Pulse Durations of Pulsed Dye Laser</span></div>
<div style="position:absolute;left:50.01px;top:586.05px" class="cls_022"><span class="cls_022">145</span></div>
<div style="position:absolute;left:80.01px;top:586.05px" class="cls_022"><span class="cls_022">Neutropenia in a psoriasis patient: Secukinumab or micronutrient deficiency?</span></div>
<div style="position:absolute;left:50.01px;top:597.21px" class="cls_022"><span class="cls_022">146</span></div>
<div style="position:absolute;left:80.01px;top:597.21px" class="cls_022"><span class="cls_022">Establishment of a Psoriatic Skin Model for α-Irradiation</span></div>
<div style="position:absolute;left:50.01px;top:608.36px" class="cls_022"><span class="cls_022">147</span></div>
<div style="position:absolute;left:80.00px;top:608.36px" class="cls_022"><span class="cls_022">The History of Psoriasis</span></div>
<div style="position:absolute;left:50.01px;top:619.51px" class="cls_022"><span class="cls_022">148</span></div>
<div style="position:absolute;left:80.00px;top:619.51px" class="cls_022"><span class="cls_022">Comorbidities and treatments in patients with inverse psoriasis</span></div>
<div style="position:absolute;left:80.00px;top:630.67px" class="cls_021"><span class="cls_021">Late Breakers</span></div>
<div style="position:absolute;left:50.01px;top:641.82px" class="cls_022"><span class="cls_022">150</span></div>
<div style="position:absolute;left:80.00px;top:641.82px" class="cls_022"><span class="cls_022">Development of the “PsO Sleepy-Q” and the “PsA Sleepy-Q”: two questionnaires to characterize sleep in patients with psoriatic disease</span></div>
<div style="position:absolute;left:50.01px;top:652.98px" class="cls_022"><span class="cls_022">151</span></div>
<div style="position:absolute;left:80.00px;top:652.98px" class="cls_022"><span class="cls_022">Unstable forms of psoriasis - indicator of an intermediate state of systemic disease</span></div>
<div style="position:absolute;left:50.01px;top:664.13px" class="cls_022"><span class="cls_022">152</span></div>
<div style="position:absolute;left:80.00px;top:664.13px" class="cls_022"><span class="cls_022">Could biological agents foster suicide through its potential antidepressant mechanism? A Psychodermatological approach.</span></div>
<div style="position:absolute;left:50.01px;top:675.28px" class="cls_022"><span class="cls_022">153</span></div>
<div style="position:absolute;left:80.00px;top:675.28px" class="cls_022"><span class="cls_022">Treating the pain, not the problem? Results from a Swedish online survey on psoriatic arthritis and psoriasis with joint pain.</span></div>
<div style="position:absolute;left:50.01px;top:686.44px" class="cls_022"><span class="cls_022">154</span></div>
<div style="position:absolute;left:80.01px;top:686.44px" class="cls_022"><span class="cls_022">An International Delphi survey to define screening for psoriatic arthritis and measurement of psoriatic arthritis symptoms in psoriasis</span></div>
<div style="position:absolute;left:85.02px;top:695.59px" class="cls_022"><span class="cls_022">clinical trials</span></div>
<div style="position:absolute;left:50.02px;top:706.74px" class="cls_022"><span class="cls_022">155</span></div>
<div style="position:absolute;left:80.01px;top:706.74px" class="cls_022"><span class="cls_022">The impact of a diagnosis on the patients’ perception of treatment and care. Results from an online survey on psoriatic arthritis and psoriasis</span></div>
<div style="position:absolute;left:85.01px;top:715.89px" class="cls_022"><span class="cls_022">with joint pain.</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:4015px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background07.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:540.93px;top:28.81px" class="cls_017"><span class="cls_017">5</span></div>
<div style="position:absolute;left:276.95px;top:51.29px" class="cls_023"><span class="cls_023">POSTERS</span></div>
<div style="position:absolute;left:50.00px;top:77.23px" class="cls_024"><span class="cls_024">P001</span></div>
<div style="position:absolute;left:306.64px;top:76.56px" class="cls_031"><span class="cls_031">Service with diagnosis of Psoriasis vulgaris from January 2017</span></div>
<div style="position:absolute;left:50.00px;top:88.63px" class="cls_025"><span class="cls_025">A METAGENOMICS STUDY OF THE ELBOW OF PSORIA­</span></div>
<div style="position:absolute;left:306.64px;top:86.56px" class="cls_031"><span class="cls_031">to July 2017 at Dermatology Department, University Clinical of</span></div>
<div style="position:absolute;left:306.64px;top:96.56px" class="cls_031"><span class="cls_031">Sarajevo.We searched for specific nail dissorders.</span></div>
<div style="position:absolute;left:50.00px;top:99.53px" class="cls_025"><span class="cls_025">SIS SUBJECTS AND THEIR HEALTHY RELATIVES</span></div>
<div style="position:absolute;left:306.64px;top:106.56px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">A total number of 60 patients with Psoriasis vulgaris,</span></div>
<div style="position:absolute;left:50.00px;top:109.43px" class="cls_026"><span class="cls_026">Hailun Wang</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Michael Ni</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Japio Fung</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Kang Yan</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Xiaoxin Yao</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:116.56px" class="cls_031"><span class="cls_031">both male and female aged 15-75 werw examined. Out of that</span></div>
<div style="position:absolute;left:50.00px;top:119.33px" class="cls_026"><span class="cls_026">Yinpeng Wang</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Martin Kriegel</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Henry Chan</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, </span><span class="cls_051">Herbert Pang</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:50.00px;top:129.93px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">The University of Hong Kong, and </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Yale University</span></div>
<div style="position:absolute;left:306.64px;top:126.56px" class="cls_031"><span class="cls_031">number, 43 patients reported to have specific nail dissorders and/</span></div>
<div style="position:absolute;left:306.63px;top:136.56px" class="cls_031"><span class="cls_031">or psoriatic arthritis, and 17 of them were without any nail diss-</span></div>
<div style="position:absolute;left:50.00px;top:140.80px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Psoriasis is a multifaceted immune-mediated skin</span></div>
<div style="position:absolute;left:306.64px;top:146.56px" class="cls_031"><span class="cls_031">orders or psoriatic arthritis. Among the number of 43 examined</span></div>
<div style="position:absolute;left:50.00px;top:150.80px" class="cls_031"><span class="cls_031">disease and has been associated with other comorbidities. Previous</span></div>
<div style="position:absolute;left:306.64px;top:156.56px" class="cls_031"><span class="cls_031">psoriatis patients with nail dissorders, there were 23 female and</span></div>
<div style="position:absolute;left:50.00px;top:160.80px" class="cls_031"><span class="cls_031">studies in psoriasis reported the abundance of microbial taxa above</span></div>
<div style="position:absolute;left:306.64px;top:166.56px" class="cls_031"><span class="cls_031">20 male patients, all of them aged between 45-60. Seven female</span></div>
<div style="position:absolute;left:50.00px;top:170.80px" class="cls_031"><span class="cls_031">the species rank (family </span><span class="cls_030">Firmicutes</span><span class="cls_031"> and genus </span><span class="cls_030">Staphylococcus</span><span class="cls_031">),</span></div>
<div style="position:absolute;left:306.64px;top:176.56px" class="cls_031"><span class="cls_031">and eight male patients had previously diagnosed psoriatic arthritis</span></div>
<div style="position:absolute;left:50.00px;top:180.79px" class="cls_031"><span class="cls_031">or the combined abundance of multiple taxa (</span><span class="cls_030">Corynebacterium</span><span class="cls_031">,</span></div>
<div style="position:absolute;left:306.64px;top:186.56px" class="cls_031"><span class="cls_031">combined with psoriasis and nail disorders, while the rest of them,</span></div>
<div style="position:absolute;left:50.00px;top:190.79px" class="cls_030"><span class="cls_030">Propionibacterium</span><span class="cls_031">, </span><span class="cls_030">Staphylococcus</span><span class="cls_031">, and </span><span class="cls_030">Streptococcus</span><span class="cls_031">) were</span></div>
<div style="position:absolute;left:306.64px;top:196.56px" class="cls_031"><span class="cls_031">28 patients, only had psoriasis followed by progressive changes</span></div>
<div style="position:absolute;left:50.00px;top:200.79px" class="cls_031"><span class="cls_031">associated with psoriasis [1-3]. Characterizing the skin micro-</span></div>
<div style="position:absolute;left:306.64px;top:206.56px" class="cls_031"><span class="cls_031">on their nails, but without any signs of psoriatic arthritis. The</span></div>
<div style="position:absolute;left:50.00px;top:210.80px" class="cls_031"><span class="cls_031">biome of psoriasis subjects and family controls can further our</span></div>
<div style="position:absolute;left:306.64px;top:216.56px" class="cls_031"><span class="cls_031">presented nail dissorders in all patients included in these two</span></div>
<div style="position:absolute;left:50.00px;top:220.80px" class="cls_031"><span class="cls_031">understanding of microbiota’s role in this disease.</span></div>
<div style="position:absolute;left:306.64px;top:226.56px" class="cls_031"><span class="cls_031">groups were: subungual hyperkeratosis, onicolysis and pitting</span></div>
<div style="position:absolute;left:50.00px;top:230.80px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">This study aims to reveal the difference of skin mi-</span></div>
<div style="position:absolute;left:306.64px;top:236.55px" class="cls_031"><span class="cls_031">all combined in 14 patients, only subungual hyperkeratosis in 10</span></div>
<div style="position:absolute;left:50.00px;top:240.80px" class="cls_031"><span class="cls_031">crobiome between skin lesion area and normal area of the elbow</span></div>
<div style="position:absolute;left:306.64px;top:246.55px" class="cls_031"><span class="cls_031">patients, pitting in 7 patients, 7 of them showed only onycholysis</span></div>
<div style="position:absolute;left:50.00px;top:250.80px" class="cls_031"><span class="cls_031">as well as family controls.</span></div>
<div style="position:absolute;left:306.64px;top:256.55px" class="cls_031"><span class="cls_031">on both hands and 6 patients had oil spotting and pitting together.</span></div>
<div style="position:absolute;left:50.00px;top:260.80px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">DNA samples was extracted from 21 elbow-skin. 14 of</span></div>
<div style="position:absolute;left:306.64px;top:266.55px" class="cls_031"><span class="cls_031">In patients without psoriatic arthritis the prevalence of dissorders</span></div>
<div style="position:absolute;left:50.00px;top:270.80px" class="cls_031"><span class="cls_031">21 were from 7 psoriasis subjects’ lesion side and normal side.</span></div>
<div style="position:absolute;left:306.64px;top:276.55px" class="cls_031"><span class="cls_031">in all affected groups was in male patients.</span></div>
<div style="position:absolute;left:50.00px;top:280.79px" class="cls_031"><span class="cls_031">The rest were from a healthy family member whom the subject</span></div>
<div style="position:absolute;left:306.64px;top:286.55px" class="cls_030"><span class="cls_030">Conclusion:</span><span class="cls_031"> Nail psoriasis engenders both physical and psycho-</span></div>
<div style="position:absolute;left:50.00px;top:290.79px" class="cls_031"><span class="cls_031">lives with. Shotgun metagenomic sequencing was adapted to</span></div>
<div style="position:absolute;left:306.64px;top:296.56px" class="cls_031"><span class="cls_031">logical handicap, leading to significant negative repercussions in</span></div>
<div style="position:absolute;left:50.00px;top:300.79px" class="cls_031"><span class="cls_031">resolute the skin microbiota. Partially overlapping t-test was used</span></div>
<div style="position:absolute;left:306.63px;top:306.56px" class="cls_031"><span class="cls_031">the quolity of life. The presence of nail disease in a patient with</span></div>
<div style="position:absolute;left:50.00px;top:310.79px" class="cls_031"><span class="cls_031">to investigate differentially abundant taxa. PERMANOVA was</span></div>
<div style="position:absolute;left:306.63px;top:316.56px" class="cls_031"><span class="cls_031">psoriasis may indicate a severe form of the disease and must be</span></div>
<div style="position:absolute;left:50.00px;top:320.79px" class="cls_031"><span class="cls_031">used to test the difference of microbial community composition</span></div>
<div style="position:absolute;left:306.63px;top:326.56px" class="cls_031"><span class="cls_031">taken into account when selecting a treatment otion, with an aim to</span></div>
<div style="position:absolute;left:50.00px;top:330.79px" class="cls_031"><span class="cls_031">influenced by psoriasis and sampling families.</span></div>
<div style="position:absolute;left:306.63px;top:336.56px" class="cls_031"><span class="cls_031">reduce pain, functional impairment as well as emotional distress.</span></div>
<div style="position:absolute;left:50.00px;top:340.79px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Bacteria phyla </span><span class="cls_030">Proteobacteria</span><span class="cls_031">, </span><span class="cls_030">Actinobacteria</span><span class="cls_031">, and </span><span class="cls_030">Bac-</span></div>
<div style="position:absolute;left:50.00px;top:350.80px" class="cls_030"><span class="cls_030">teroidetes</span><span class="cls_031"> were three most abundant microbial taxa in both lesion</span></div>
<div style="position:absolute;left:306.64px;top:356.20px" class="cls_033"><span class="cls_033">P003</span></div>
<div style="position:absolute;left:50.00px;top:360.80px" class="cls_031"><span class="cls_031">and normal skin. Bacteria phyla </span><span class="cls_030">Cyanobacteria</span><span class="cls_031"> and </span><span class="cls_030">Candidatus</span></div>
<div style="position:absolute;left:306.64px;top:367.60px" class="cls_025"><span class="cls_025">PSORIASIS HIDDEN IN GOTTRON’S PAPULES</span></div>
<div style="position:absolute;left:50.00px;top:370.80px" class="cls_030"><span class="cls_030">Parcubacteria</span><span class="cls_031">, family </span><span class="cls_030">Hymenobacteraceae</span><span class="cls_031"> were less abundant</span></div>
<div style="position:absolute;left:306.64px;top:377.50px" class="cls_026"><span class="cls_026">Florentina Berianu, </span><span class="cls_051">Juan J. Maya</span></div>
<div style="position:absolute;left:50.00px;top:380.80px" class="cls_031"><span class="cls_031">on lesion skin than normal skin (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.05). Sampling families</span></div>
<div style="position:absolute;left:306.64px;top:388.10px" class="cls_029"><span class="cls_029">Mayo Clinic Florida</span></div>
<div style="position:absolute;left:50.00px;top:390.79px" class="cls_031"><span class="cls_031">had significantly different elbow-skin microbial composition for</span></div>
<div style="position:absolute;left:50.00px;top:400.79px" class="cls_031"><span class="cls_031">bacterial genus level profile (</span><span class="cls_030">p = </span><span class="cls_031">0.001).</span></div>
<div style="position:absolute;left:306.64px;top:398.96px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Patients with Dermatomyositis (DM) present with</span></div>
<div style="position:absolute;left:50.00px;top:410.79px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Several bacterial taxa different from those previously</span></div>
<div style="position:absolute;left:306.64px;top:408.96px" class="cls_031"><span class="cls_031">rashes in a photosensitive distribution and occasionally a scaly</span></div>
<div style="position:absolute;left:50.00px;top:420.79px" class="cls_031"><span class="cls_031">discovered are more abundant on normal skin than lesion skin in</span></div>
<div style="position:absolute;left:306.64px;top:418.96px" class="cls_031"><span class="cls_031">rash over elbows, knees and scalp can resemble psoriasis. The</span></div>
<div style="position:absolute;left:50.00px;top:430.79px" class="cls_031"><span class="cls_031">the elbow.</span></div>
<div style="position:absolute;left:306.64px;top:428.96px" class="cls_031"><span class="cls_031">biopsy of such lesions shows interface dermatitis which is highly</span></div>
<div style="position:absolute;left:50.00px;top:440.79px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:306.64px;top:438.96px" class="cls_031"><span class="cls_031">distinguishing for DM. In rare occasions, patients can suffer</span></div>
<div style="position:absolute;left:50.00px;top:450.81px" class="cls_032"><span class="cls_032">[1] Unexplored diversity and strain-level structure of the skin microbiome</span></div>
<div style="position:absolute;left:306.64px;top:448.96px" class="cls_031"><span class="cls_031">from both DM and psoriasis (Ps). Objectives: To report a case of</span></div>
<div style="position:absolute;left:50.00px;top:459.81px" class="cls_032"><span class="cls_032">associated with psoriasis. NPJ Biofilms Microbiomes. 3,14 (2017).</span></div>
<div style="position:absolute;left:306.64px;top:458.96px" class="cls_031"><span class="cls_031">Dermatomyositis and Psoriatic arthritis</span></div>
<div style="position:absolute;left:50.00px;top:468.81px" class="cls_032"><span class="cls_032">[2] Statnikov, A. et al. Microbiomic signatures of psoriasis: feasibility and</span></div>
<div style="position:absolute;left:306.64px;top:468.96px" class="cls_030"><span class="cls_030">Method: </span><span class="cls_031">45 years old female presented with a red, itchy rash with</span></div>
<div style="position:absolute;left:50.00px;top:477.81px" class="cls_032"><span class="cls_032">methodology comparison. Sci. Rep. 3, 2620 (2013).</span></div>
<div style="position:absolute;left:306.64px;top:478.96px" class="cls_031"><span class="cls_031">diffuse swelling over the entire body associated with swallowing</span></div>
<div style="position:absolute;left:50.00px;top:486.81px" class="cls_032"><span class="cls_032">[3] Alekseyenko, A. V. et al. Community differentiation of the cutaneous</span></div>
<div style="position:absolute;left:306.64px;top:488.95px" class="cls_031"><span class="cls_031">difficulties and weakness affecting mainly the proximal muscles</span></div>
<div style="position:absolute;left:50.00px;top:495.81px" class="cls_032"><span class="cls_032">microbiota in psoriasis. Microbiome. 1, 31 (2013).</span></div>
<div style="position:absolute;left:306.65px;top:498.95px" class="cls_031"><span class="cls_031">of upper and lower extremities. She has pain and stiffness in her</span></div>
<div style="position:absolute;left:306.65px;top:508.95px" class="cls_031"><span class="cls_031">hands and feet. DM was confirmed based on specific findings on</span></div>
<div style="position:absolute;left:50.00px;top:513.43px" class="cls_033"><span class="cls_033">P002</span></div>
<div style="position:absolute;left:306.65px;top:518.95px" class="cls_031"><span class="cls_031">skin biopsy, EMG with myopathic features and a muscle biopsy</span></div>
<div style="position:absolute;left:50.00px;top:524.83px" class="cls_025"><span class="cls_025">NAIL DISORDERS IN PATIENTS WITH PSORIASIS</span></div>
<div style="position:absolute;left:306.65px;top:528.95px" class="cls_031"><span class="cls_031">that confirmed the myopathy. Patient had insulin dependent dia-</span></div>
<div style="position:absolute;left:50.00px;top:535.73px" class="cls_025"><span class="cls_025">VULGARIS</span></div>
<div style="position:absolute;left:306.64px;top:538.96px" class="cls_031"><span class="cls_031">betes and IVIG was the initial choice of therapy to avoid steroid</span></div>
<div style="position:absolute;left:50.00px;top:545.63px" class="cls_026"><span class="cls_026">Jasmina Muhovic</span></div>
<div style="position:absolute;left:306.64px;top:548.96px" class="cls_031"><span class="cls_031">use. Patient responded excellent in regards to generalized rash</span></div>
<div style="position:absolute;left:50.00px;top:556.23px" class="cls_029"><span class="cls_029">University Clinical Centre Sarajevo</span></div>
<div style="position:absolute;left:306.64px;top:558.96px" class="cls_031"><span class="cls_031">and had reported improvement in regards to proximal muscle</span></div>
<div style="position:absolute;left:50.00px;top:567.10px" class="cls_030"><span class="cls_030">Introduction: Psoriasis</span><span class="cls_031"> vulgaris is a chronic inflammatory skin</span></div>
<div style="position:absolute;left:306.64px;top:568.96px" class="cls_031"><span class="cls_031">weakness and swallowing difficulties but she had persistence of</span></div>
<div style="position:absolute;left:50.01px;top:577.10px" class="cls_031"><span class="cls_031">disease characterized by T-cell-mediated hyperpfoliferation of</span></div>
<div style="position:absolute;left:306.63px;top:578.96px" class="cls_031"><span class="cls_031">the scaly rash over elbows, knees and developed what resembled</span></div>
<div style="position:absolute;left:50.01px;top:587.10px" class="cls_031"><span class="cls_031">keratinocytes in the skin. Approximately, 10-78% of patients</span></div>
<div style="position:absolute;left:306.63px;top:588.96px" class="cls_031"><span class="cls_031">dactylitis along with worsened asymmetric inflammatory arthritis</span></div>
<div style="position:absolute;left:50.01px;top:597.10px" class="cls_031"><span class="cls_031">with psoriasis have concurrent nail psoriasis while isolated nail</span></div>
<div style="position:absolute;left:306.63px;top:598.96px" class="cls_031"><span class="cls_031">of ankle, hand and feet joints. Based on her presentation, Ps and</span></div>
<div style="position:absolute;left:50.01px;top:607.09px" class="cls_031"><span class="cls_031">involvement is seen in 5-10% of patients. Affected nail plates often</span></div>
<div style="position:absolute;left:306.63px;top:608.96px" class="cls_031"><span class="cls_031">psoriatic arthritis (PsA) were diagnosed. Methotrexate was added</span></div>
<div style="position:absolute;left:50.01px;top:617.09px" class="cls_031"><span class="cls_031">thicken and crumble and because they are very visible patients</span></div>
<div style="position:absolute;left:306.63px;top:618.96px" class="cls_031"><span class="cls_031">and patient had improved in skin psoriasis along with inflammatory</span></div>
<div style="position:absolute;left:50.01px;top:627.09px" class="cls_031"><span class="cls_031">tend to avoid normal day-to-day activities and social interactions.</span></div>
<div style="position:absolute;left:306.62px;top:628.95px" class="cls_031"><span class="cls_031">arthritis. Results: Ps and PsA were associated with DM in this</span></div>
<div style="position:absolute;left:50.01px;top:637.09px" class="cls_031"><span class="cls_031">Importantly, 70-80% of patients with psoriatic arthritis have nail</span></div>
<div style="position:absolute;left:306.62px;top:638.95px" class="cls_031"><span class="cls_031">patient. These are distinct diseases that have parallel courses and</span></div>
<div style="position:absolute;left:50.01px;top:647.09px" class="cls_031"><span class="cls_031">psoriasis. In this overview, we review the clinical manifestations</span></div>
<div style="position:absolute;left:306.62px;top:648.95px" class="cls_031"><span class="cls_031">require different therapeutic approaches.</span></div>
<div style="position:absolute;left:50.01px;top:657.09px" class="cls_031"><span class="cls_031">of psoriasis affecting the nails.</span></div>
<div style="position:absolute;left:306.62px;top:658.95px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Ps has been reported in association with Connective</span></div>
<div style="position:absolute;left:50.01px;top:667.09px" class="cls_030"><span class="cls_030">Objectives:</span><span class="cls_031"> To correlate frequency of certain nail dissorders</span></div>
<div style="position:absolute;left:306.62px;top:668.95px" class="cls_031"><span class="cls_031">Tissue Diseases. Gotron’s papules can resemble Ps in patients</span></div>
<div style="position:absolute;left:50.01px;top:677.09px" class="cls_031"><span class="cls_031">in patients with psoriasis vulgaris. The observed dissorders</span></div>
<div style="position:absolute;left:306.62px;top:678.95px" class="cls_031"><span class="cls_031">with DM but rare case reports have described concomitant DM</span></div>
<div style="position:absolute;left:50.01px;top:687.09px" class="cls_031"><span class="cls_031">were:onicholysis, subungual hyperkeratosis, oil spots, and pitting</span></div>
<div style="position:absolute;left:306.62px;top:688.95px" class="cls_031"><span class="cls_031">and Ps. The association of DM, Ps and PsA was even more rarely</span></div>
<div style="position:absolute;left:50.01px;top:697.09px" class="cls_031"><span class="cls_031">in both male and female patients aged 15-75 and combined with</span></div>
<div style="position:absolute;left:306.62px;top:698.95px" class="cls_031"><span class="cls_031">described.</span></div>
<div style="position:absolute;left:50.01px;top:707.08px" class="cls_031"><span class="cls_031">psoriatic arthritis.</span></div>
<div style="position:absolute;left:306.62px;top:708.95px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.01px;top:717.08px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> A total of 60 patients who were treated in our Inpatients</span></div>
<div style="position:absolute;left:306.64px;top:718.98px" class="cls_032"><span class="cls_032">1. Tselios K, Yap KS, Pakchotanon R et al. Psoriasis in systemic lu-</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:4818px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background08.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">6</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.73px" class="cls_032"><span class="cls_032">pus erythematosus: a single-center experience. Clin Rheumatol. 2017</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">control group consisted of patients with allergic contact dermatitis,</span></div>
<div style="position:absolute;left:50.00px;top:60.73px" class="cls_032"><span class="cls_032">Apr;36(4):879-884.</span></div>
<div style="position:absolute;left:306.64px;top:61.43px" class="cls_031"><span class="cls_031">comparable in age and sex, in an amount of 397 people.</span></div>
<div style="position:absolute;left:50.00px;top:69.73px" class="cls_032"><span class="cls_032">2. Inkeles MS, No D, Wu JJ. Clinical improvement of a patient with both</span></div>
<div style="position:absolute;left:306.64px;top:71.46px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Specific gravity and incidence of comorbidity in patients</span></div>
<div style="position:absolute;left:50.00px;top:78.73px" class="cls_032"><span class="cls_032">amyopathic dermatomyositis and psoriasis following treatment with</span></div>
<div style="position:absolute;left:306.65px;top:81.48px" class="cls_031"><span class="cls_031">with psoriasis: cardiovascular damage 41% (331), gastrointestinal</span></div>
<div style="position:absolute;left:50.00px;top:87.73px" class="cls_032"><span class="cls_032">cyclosporine. Dermatol Online J. 2017 Aug 15;23(8)</span></div>
<div style="position:absolute;left:306.65px;top:91.51px" class="cls_031"><span class="cls_031">tract - 30.4% (245), endocrine system - 22.7% (183), metabolic</span></div>
<div style="position:absolute;left:50.00px;top:96.73px" class="cls_032"><span class="cls_032">3. Kato Y, Yamamoto T . Development of psoriasis with relapse of</span></div>
<div style="position:absolute;left:306.65px;top:101.54px" class="cls_031"><span class="cls_031">syndrome - 28.2% (227), chronic otorhinolaryngological diseases</span></div>
<div style="position:absolute;left:50.00px;top:105.73px" class="cls_032"><span class="cls_032">dermatomyositis-associated interstitial lung disease. Int J Rheum Dis.</span></div>
<div style="position:absolute;left:50.00px;top:114.73px" class="cls_032"><span class="cls_032">2017 May;20(5):660-661.</span></div>
<div style="position:absolute;left:306.65px;top:111.56px" class="cls_031"><span class="cls_031">- 11.4% (92), diseases of urinary system - 6.2% (50), respiratory</span></div>
<div style="position:absolute;left:50.00px;top:123.73px" class="cls_032"><span class="cls_032">4. Ueno T, Kanzaki A et al. Association of psoriasis with Hashimoto’s</span></div>
<div style="position:absolute;left:306.65px;top:121.59px" class="cls_031"><span class="cls_031">system - 4.7% (38). Significant differences between the groups</span></div>
<div style="position:absolute;left:50.00px;top:132.73px" class="cls_032"><span class="cls_032">thyroiditis, Sjögren’s syndrome and dermatomyositis. J Dermatol. 2016</span></div>
<div style="position:absolute;left:306.65px;top:131.61px" class="cls_031"><span class="cls_031">were obtained for all the comorbidity except respiratory diseases.</span></div>
<div style="position:absolute;left:50.00px;top:141.73px" class="cls_032"><span class="cls_032">Jun;43(6):711-2.</span></div>
<div style="position:absolute;left:306.65px;top:141.64px" class="cls_031"><span class="cls_031">Psoriatic polyarthritis were observed in 219 patients (27.3%), nail</span></div>
<div style="position:absolute;left:306.65px;top:151.67px" class="cls_031"><span class="cls_031">psoriasis - in 117 patients (14.6%). The average body mass index</span></div>
<div style="position:absolute;left:50.00px;top:159.35px" class="cls_033"><span class="cls_033">P004</span></div>
<div style="position:absolute;left:306.65px;top:161.69px" class="cls_031"><span class="cls_031">in the psoriasis group was 27.2, in the allergic contact dermatitis</span></div>
<div style="position:absolute;left:50.00px;top:170.75px" class="cls_025"><span class="cls_025">CHARACTERISTICS OF PSORIASIS IN OBESE</span></div>
<div style="position:absolute;left:306.65px;top:171.72px" class="cls_031"><span class="cls_031">group - 25.3. Significant differences between the groups were</span></div>
<div style="position:absolute;left:50.00px;top:181.65px" class="cls_025"><span class="cls_025">PATIENTS VERSUS NON-OBESE PATIENTS; A</span></div>
<div style="position:absolute;left:306.63px;top:181.74px" class="cls_031"><span class="cls_031">obtained for all the laboratory test changes except the general</span></div>
<div style="position:absolute;left:50.00px;top:192.54px" class="cls_025"><span class="cls_025">MULTICENTER STUDY</span></div>
<div style="position:absolute;left:306.63px;top:191.75px" class="cls_031"><span class="cls_031">bilirubin, C-reactive protein and urinalysis. The percentage of di-</span></div>
<div style="position:absolute;left:50.00px;top:202.44px" class="cls_051"><span class="cls_051">Omid Zargari</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Seyyede Zeinab Azimi</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Tara Barat</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Vahideh La-</span></div>
<div style="position:absolute;left:306.64px;top:201.78px" class="cls_031"><span class="cls_031">seases changed with increasing age: diseases of the cardiovascular</span></div>
<div style="position:absolute;left:50.00px;top:212.35px" class="cls_026"><span class="cls_026">jevardi</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Ehsan Kazemnejad</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Mohamad Shahidi Dadras</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:306.64px;top:211.80px" class="cls_031"><span class="cls_031">system from 10% to 87%, gastrointestinal diseases from 20% to</span></div>
<div style="position:absolute;left:50.00px;top:222.95px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Dermatology, Skin Research Center, Shahid Beheshti Uni-</span></div>
<div style="position:absolute;left:306.64px;top:221.83px" class="cls_031"><span class="cls_031">61%, endocrine system diseases - from 14.5% to 38%, metabolic</span></div>
<div style="position:absolute;left:50.00px;top:232.55px" class="cls_029"><span class="cls_029">versity of Medical Sciences, Tehran, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Dermatology and </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">De-</span></div>
<div style="position:absolute;left:306.64px;top:231.85px" class="cls_031"><span class="cls_031">syndrome - from 11% to 34%, otorhinolaryngological diseases -</span></div>
<div style="position:absolute;left:50.00px;top:242.15px" class="cls_029"><span class="cls_029">partment of Biostatistics, Guilan University of Medical Sciences, Rasht,</span></div>
<div style="position:absolute;left:306.64px;top:241.88px" class="cls_031"><span class="cls_031">from 15% to 8.5%, diseases of the urinary system - from 1.8% to</span></div>
<div style="position:absolute;left:50.00px;top:251.75px" class="cls_029"><span class="cls_029">and </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Department of Dermatology, Tehran University of Medical Sciences,</span></div>
<div style="position:absolute;left:306.64px;top:251.91px" class="cls_031"><span class="cls_031">8.5%, respiratory system diseases - from 1.8% to 13%.</span></div>
<div style="position:absolute;left:50.00px;top:261.35px" class="cls_029"><span class="cls_029">Tehran, Iran</span></div>
<div style="position:absolute;left:306.64px;top:261.93px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> The analysis showed that in patients with psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:272.21px" class="cls_030"><span class="cls_030">Introduction</span><span class="cls_031">: Psoriasis is a common chronic inflammatory skin</span></div>
<div style="position:absolute;left:306.64px;top:271.95px" class="cls_031"><span class="cls_031">the most frequent comorbidity are: cardiovascular and gastroin-</span></div>
<div style="position:absolute;left:50.00px;top:282.21px" class="cls_031"><span class="cls_031">disease, which is gradually being recognized as a systemic inflam-</span></div>
<div style="position:absolute;left:306.64px;top:281.97px" class="cls_031"><span class="cls_031">testinal diseases, endocrine disorders, polyarthritis, nail psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:292.21px" class="cls_031"><span class="cls_031">matory disorder. Psoriasis and obesity are strongly linked, but</span></div>
<div style="position:absolute;left:306.64px;top:292.00px" class="cls_031"><span class="cls_031">and metabolic syndrome. A rather high risk of comorbidity is</span></div>
<div style="position:absolute;left:50.00px;top:302.21px" class="cls_031"><span class="cls_031">there is not enough data whether obese psoriatic patients present</span></div>
<div style="position:absolute;left:306.64px;top:302.03px" class="cls_031"><span class="cls_031">established, in comparison with the population, which can directly</span></div>
<div style="position:absolute;left:50.00px;top:312.21px" class="cls_031"><span class="cls_031">differently from non-obese psoriatic patients.</span></div>
<div style="position:absolute;left:306.64px;top:312.05px" class="cls_031"><span class="cls_031">affects the severity of the course of the disease, the effectiveness</span></div>
<div style="position:absolute;left:50.00px;top:322.21px" class="cls_030"><span class="cls_030">Objective: </span><span class="cls_031">To compare the phenotype, clinical features, severity,</span></div>
<div style="position:absolute;left:306.64px;top:322.08px" class="cls_031"><span class="cls_031">of the therapy and life expectancy.</span></div>
<div style="position:absolute;left:50.00px;top:332.21px" class="cls_031"><span class="cls_031">baseline comorbidities and laboratory findings among psoriatic</span></div>
<div style="position:absolute;left:306.64px;top:332.10px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.00px;top:342.21px" class="cls_031"><span class="cls_031">patients with/without obesity.</span></div>
<div style="position:absolute;left:306.64px;top:342.14px" class="cls_032"><span class="cls_032">1. Potekaev N., Kruglova L. Psoriatic Disease. - Moscow. - 2014.- P. 94</span></div>
<div style="position:absolute;left:50.00px;top:352.21px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> All the psoriatic patients, from three centers, who were</span></div>
<div style="position:absolute;left:306.64px;top:351.16px" class="cls_032"><span class="cls_032">(in Russian)</span></div>
<div style="position:absolute;left:306.64px;top:360.19px" class="cls_032"><span class="cls_032">2. Cohen A.D., Sherf M., Vidavsky L., Vardy D.A. Association between</span></div>
<div style="position:absolute;left:50.00px;top:362.21px" class="cls_031"><span class="cls_031">receiving systemic therapy were included in the study. Patients</span></div>
<div style="position:absolute;left:306.64px;top:369.21px" class="cls_032"><span class="cls_032">psoriasis and the metabolic syndrome. A crosssectional study // Derma-</span></div>
<div style="position:absolute;left:50.00px;top:372.20px" class="cls_031"><span class="cls_031">were divided into two groups: those with obesity and those with­</span></div>
<div style="position:absolute;left:306.64px;top:378.24px" class="cls_032"><span class="cls_032">tology.— 2008.— Vol. 216(2).—Р. 152</span></div>
<div style="position:absolute;left:50.00px;top:382.20px" class="cls_031"><span class="cls_031">out obesity.</span></div>
<div style="position:absolute;left:306.64px;top:387.26px" class="cls_032"><span class="cls_032">3. Eng S., Xing B., Caro I., Werther W. Selected cardiovascular diseases</span></div>
<div style="position:absolute;left:50.00px;top:392.20px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">We included 497 patients: 154 (31%) patients were obese</span></div>
<div style="position:absolute;left:306.64px;top:396.28px" class="cls_032"><span class="cls_032">in psoriasis, nonpsoriasis, and efalizumabtreated psoriasis patients // Acad.</span></div>
<div style="position:absolute;left:50.00px;top:402.20px" class="cls_031"><span class="cls_031">and 343 (69%) were non-obese. Obese patients had more comorbi-</span></div>
<div style="position:absolute;left:306.64px;top:405.31px" class="cls_032"><span class="cls_032">Dermatol.— 2009.— P. 3381</span></div>
<div style="position:absolute;left:50.00px;top:412.21px" class="cls_031"><span class="cls_031">dities, particularly hyperlipidemia, followed by hypertension and</span></div>
<div style="position:absolute;left:50.00px;top:422.21px" class="cls_031"><span class="cls_031">diabetes. Fasting blood sugar and serum lipids were significantly</span></div>
<div style="position:absolute;left:306.64px;top:423.95px" class="cls_033"><span class="cls_033">P006</span></div>
<div style="position:absolute;left:50.01px;top:432.21px" class="cls_031"><span class="cls_031">higher among obese subjects.</span></div>
<div style="position:absolute;left:306.64px;top:435.38px" class="cls_025"><span class="cls_025">RISK OF PERIODONTAL DISEASE IN PATIENTS WITH</span></div>
<div style="position:absolute;left:50.01px;top:442.21px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> Given the differences between obese patients and</span></div>
<div style="position:absolute;left:306.64px;top:446.30px" class="cls_025"><span class="cls_025">CHRONIC PLAQUE PSORIASIS</span></div>
<div style="position:absolute;left:50.01px;top:452.21px" class="cls_031"><span class="cls_031">non-obese patients, the former group should be followed and</span></div>
<div style="position:absolute;left:306.64px;top:456.23px" class="cls_051"><span class="cls_051">Veronica Lopez Castillo</span><span class="cls_026">, Inmaculada Lopez Castillo, Pedro Rodri-</span></div>
<div style="position:absolute;left:50.01px;top:462.21px" class="cls_031"><span class="cls_031">managed more closely and with specific attention.</span></div>
<div style="position:absolute;left:306.64px;top:466.16px" class="cls_026"><span class="cls_026">guez, Jose Maria Ricart Vaya</span></div>
<div style="position:absolute;left:50.01px;top:472.21px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:306.64px;top:476.04px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is a common, chronic, inflammatory,</span></div>
<div style="position:absolute;left:50.00px;top:482.23px" class="cls_032"><span class="cls_032">1. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ et al. National</span></div>
<div style="position:absolute;left:306.63px;top:486.07px" class="cls_031"><span class="cls_031">multisystem disease affecting approximately 2% of population. It</span></div>
<div style="position:absolute;left:50.00px;top:491.23px" class="cls_032"><span class="cls_032">Psoriasis Foundation clinical consensus on psoriasis comorbidities and re-</span></div>
<div style="position:absolute;left:306.63px;top:496.10px" class="cls_031"><span class="cls_031">has been associated with certain diseases and there is a strong link</span></div>
<div style="position:absolute;left:50.00px;top:500.23px" class="cls_032"><span class="cls_032">commendations for screening. J Am Acad Dermatol. 2008; 58(6):1031-42.</span></div>
<div style="position:absolute;left:50.00px;top:509.23px" class="cls_032"><span class="cls_032">2. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence</span></div>
<div style="position:absolute;left:306.63px;top:506.12px" class="cls_031"><span class="cls_031">between metabolic syndrome and psoriasis. Chronic periodontitis</span></div>
<div style="position:absolute;left:50.00px;top:518.23px" class="cls_032"><span class="cls_032">of the metabolic syndrome in psoriasis: results from the National Health</span></div>
<div style="position:absolute;left:306.63px;top:516.14px" class="cls_031"><span class="cls_031">is an infectious disease resulting in inflammation within the sup-</span></div>
<div style="position:absolute;left:50.00px;top:527.23px" class="cls_032"><span class="cls_032">and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011;</span></div>
<div style="position:absolute;left:306.64px;top:526.17px" class="cls_031"><span class="cls_031">porting tissues of the teeth, progressive attachment loss, and bone</span></div>
<div style="position:absolute;left:50.00px;top:536.23px" class="cls_032"><span class="cls_032">147(4):419-24</span></div>
<div style="position:absolute;left:306.64px;top:536.19px" class="cls_031"><span class="cls_031">resorption and clinically characterized by pocket formation and/</span></div>
<div style="position:absolute;left:306.64px;top:546.22px" class="cls_031"><span class="cls_031">or gingival recession. Psoriasis and chronic periodontitis share</span></div>
<div style="position:absolute;left:50.00px;top:553.85px" class="cls_033"><span class="cls_033">P005</span></div>
<div style="position:absolute;left:306.64px;top:556.25px" class="cls_031"><span class="cls_031">common risk factors and co-morbidities.</span></div>
<div style="position:absolute;left:50.00px;top:565.25px" class="cls_025"><span class="cls_025">PSORIASIS AND COMORBIDITY</span></div>
<div style="position:absolute;left:306.64px;top:566.27px" class="cls_030"><span class="cls_030">Objective: </span><span class="cls_031">The aim of our study was to determine how frequently</span></div>
<div style="position:absolute;left:50.00px;top:575.15px" class="cls_051"><span class="cls_051">Veranika Liubiankova</span><span class="cls_026">, Sviatlana Makarava</span></div>
<div style="position:absolute;left:306.64px;top:576.30px" class="cls_031"><span class="cls_031">chronic periodontitis is associated with patients with psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:585.75px" class="cls_029"><span class="cls_029">Mogilev Regional Centre of Dermatology and Venerology</span></div>
<div style="position:absolute;left:306.64px;top:586.32px" class="cls_031"><span class="cls_031">compared to systemic healthy subjects and if its presence is as-</span></div>
<div style="position:absolute;left:50.00px;top:596.61px" class="cls_030"><span class="cls_030">Introduction.</span><span class="cls_031"> In recent years special attention has been paid not</span></div>
<div style="position:absolute;left:306.64px;top:596.34px" class="cls_031"><span class="cls_031">sociated to severity of psoriatic lesions.</span></div>
<div style="position:absolute;left:50.00px;top:606.61px" class="cls_031"><span class="cls_031">only to the systemic nature of the process in psoriasis, but also</span></div>
<div style="position:absolute;left:306.64px;top:606.37px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> Baseline demographic data including sex, age, smoking</span></div>
<div style="position:absolute;left:50.00px;top:616.61px" class="cls_031"><span class="cls_031">to its association with comorbidities. Comorbidity is a regular</span></div>
<div style="position:absolute;left:306.64px;top:616.39px" class="cls_031"><span class="cls_031">habits, family history of psoriasis or periodontal disease was</span></div>
<div style="position:absolute;left:50.00px;top:626.61px" class="cls_031"><span class="cls_031">combination of various diseases or conditions in one patient, it</span></div>
<div style="position:absolute;left:306.64px;top:626.41px" class="cls_031"><span class="cls_031">recorded in 40 psoriasis subjects and 40 healthy subjects. Infor-</span></div>
<div style="position:absolute;left:50.00px;top:636.61px" class="cls_031"><span class="cls_031">occurs in many inflammatory processes.</span></div>
<div style="position:absolute;left:306.64px;top:636.44px" class="cls_031"><span class="cls_031">mation on comorbidities and pharmacological treatment, daily</span></div>
<div style="position:absolute;left:50.00px;top:646.61px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">The study of the incidence of concomitant diseases in</span></div>
<div style="position:absolute;left:306.64px;top:646.47px" class="cls_031"><span class="cls_031">tooth brushing, the presence of gingival bleeding, location of skin</span></div>
<div style="position:absolute;left:50.00px;top:656.61px" class="cls_031"><span class="cls_031">patients with psoriasis in relation to patients with allergic contact</span></div>
<div style="position:absolute;left:306.64px;top:656.49px" class="cls_031"><span class="cls_031">lesions, weight and height were also evaluated. The periodontal</span></div>
<div style="position:absolute;left:50.00px;top:666.61px" class="cls_031"><span class="cls_031">dermatitis, analysis by age group.</span></div>
<div style="position:absolute;left:306.64px;top:666.52px" class="cls_031"><span class="cls_031">clinical parameters probing depth, periodontal attachment level,</span></div>
<div style="position:absolute;left:50.00px;top:676.60px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">A retrospective analysis of data of 804 patients, who</span></div>
<div style="position:absolute;left:306.64px;top:676.54px" class="cls_031"><span class="cls_031">plaque index and presence or absence of radiographic bone loss</span></div>
<div style="position:absolute;left:50.00px;top:686.60px" class="cls_031"><span class="cls_031">were treated in 2016-2017 in Mogilev Regional Dermatology and</span></div>
<div style="position:absolute;left:306.64px;top:686.57px" class="cls_031"><span class="cls_031">were recorded. The severity of psoriasis was assessed by Psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:696.60px" class="cls_031"><span class="cls_031">Venerology Centre with different forms of psoriasis, was conduc-</span></div>
<div style="position:absolute;left:306.64px;top:696.60px" class="cls_031"><span class="cls_031">Area and Severity Index. A complete blood test was asked for all</span></div>
<div style="position:absolute;left:50.00px;top:706.61px" class="cls_031"><span class="cls_031">ted. 492 males, 312 females. The mean age was 43.05 years. The</span></div>
<div style="position:absolute;left:306.64px;top:706.62px" class="cls_031"><span class="cls_031">subjects included in the study.</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:5621px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background09.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:540.93px;top:28.81px" class="cls_017"><span class="cls_017">7</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">During the study enrolment period 40 patients with</span></div>
<div style="position:absolute;left:306.64px;top:51.23px" class="cls_033"><span class="cls_033">P008</span></div>
<div style="position:absolute;left:50.00px;top:61.51px" class="cls_031"><span class="cls_031">psoriasis and 40 age- and gender-matched controls were included</span></div>
<div style="position:absolute;left:306.64px;top:62.63px" class="cls_025"><span class="cls_025">PSORIASIS AS PREDICTOR FOR CARDIOVASCULAR</span></div>
<div style="position:absolute;left:50.00px;top:71.61px" class="cls_031"><span class="cls_031">in this study. Probing depth and periodontal attachment level</span></div>
<div style="position:absolute;left:306.64px;top:73.53px" class="cls_025"><span class="cls_025">AND METABOLIC COMORBIDITY IN MIDDLE-AGED</span></div>
<div style="position:absolute;left:50.00px;top:81.71px" class="cls_031"><span class="cls_031">showed significant higher values in psoriasis group compared to</span></div>
<div style="position:absolute;left:306.64px;top:84.43px" class="cls_025"><span class="cls_025">WOMEN</span></div>
<div style="position:absolute;left:50.00px;top:91.81px" class="cls_031"><span class="cls_031">healthy subjects.</span></div>
<div style="position:absolute;left:306.64px;top:94.33px" class="cls_051"><span class="cls_051">Christoffer Blegvad</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Anne-Marie Nybo Andersen</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Abdulfatah</span></div>
<div style="position:absolute;left:50.00px;top:101.90px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> We found evidence of a psoriasis-associated in-</span></div>
<div style="position:absolute;left:306.63px;top:104.23px" class="cls_026"><span class="cls_026">Adam</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Claus Zachariae</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Lone Skov</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:50.00px;top:112.02px" class="cls_031"><span class="cls_031">creased risk of periodontitis. Thus, dermatologists should be</span></div>
<div style="position:absolute;left:306.64px;top:114.83px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Copenhagen Research Group for Inflammatory Skin (CORGIS), Depart-</span></div>
<div style="position:absolute;left:50.00px;top:122.12px" class="cls_031"><span class="cls_031">aware of this comorbidity because these patients should be closely</span></div>
<div style="position:absolute;left:306.64px;top:124.43px" class="cls_029"><span class="cls_029">ment of Dermatology and Allergy, Herlev and Gentofte Hospital, Univer-</span></div>
<div style="position:absolute;left:50.00px;top:132.22px" class="cls_031"><span class="cls_031">followed-up by a dentist for the adequate and early treatment of</span></div>
<div style="position:absolute;left:306.64px;top:134.03px" class="cls_029"><span class="cls_029">sity of Copenhagen, Copenhagen, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Section of Epidemiology, Department of</span></div>
<div style="position:absolute;left:50.00px;top:142.32px" class="cls_031"><span class="cls_031">periodontitis. Periodontitis may be associated with psoriasis but</span></div>
<div style="position:absolute;left:306.64px;top:143.63px" class="cls_029"><span class="cls_029">Public Health, University of Copenhagen, Denmark</span></div>
<div style="position:absolute;left:50.00px;top:152.41px" class="cls_031"><span class="cls_031">further studies are needed to elucidate their relationship.</span></div>
<div style="position:absolute;left:306.64px;top:154.50px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Cardiovascular and metabolic comorbidities such as</span></div>
<div style="position:absolute;left:50.00px;top:162.51px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:306.64px;top:164.50px" class="cls_031"><span class="cls_031">ischemic heart disease and diabetes are known to be associated</span></div>
<div style="position:absolute;left:50.00px;top:172.65px" class="cls_032"><span class="cls_032">1. Egeberg A, Mallbris L, Gislason G et al. Risk of periodontitis in patients</span></div>
<div style="position:absolute;left:306.64px;top:174.50px" class="cls_031"><span class="cls_031">with psoriasis. However, it is less clear whether this is due to com-</span></div>
<div style="position:absolute;left:50.00px;top:181.75px" class="cls_032"><span class="cls_032">with psoriasis and psoriatic arthritis. JEADV 2017, 31: 288-293.</span></div>
<div style="position:absolute;left:306.64px;top:184.50px" class="cls_031"><span class="cls_031">mon life-style related risk factors such as overweight and smoking.</span></div>
<div style="position:absolute;left:50.00px;top:190.85px" class="cls_032"><span class="cls_032">2. Ungprasert P, Wijampreecha K, Wetter DA. Periodontitis and risk of pso-</span></div>
<div style="position:absolute;left:306.64px;top:194.50px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">We wished to investigate the association between</span></div>
<div style="position:absolute;left:50.00px;top:199.95px" class="cls_032"><span class="cls_032">riasis: a systematic review and meta-analysis. JEADV 2017, 31: 857-862.</span></div>
<div style="position:absolute;left:306.64px;top:204.50px" class="cls_031"><span class="cls_031">psoriasis and cardiovascular and metabolic comorbidity in a cohort</span></div>
<div style="position:absolute;left:306.64px;top:214.50px" class="cls_031"><span class="cls_031">of middle-aged women, and at the same time taking the effect of</span></div>
<div style="position:absolute;left:50.00px;top:218.67px" class="cls_033"><span class="cls_033">P007</span></div>
<div style="position:absolute;left:306.64px;top:224.50px" class="cls_031"><span class="cls_031">body mass index (BMI) and smoking into account.</span></div>
<div style="position:absolute;left:50.00px;top:230.17px" class="cls_025"><span class="cls_025">SPLENOMEGALY AND PSORIASIS - A CASE REPORT</span></div>
<div style="position:absolute;left:306.64px;top:234.49px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">The study population consisted of expectant mothers</span></div>
<div style="position:absolute;left:50.00px;top:240.17px" class="cls_026"><span class="cls_026">Suzana Ozanic Bulic</span></div>
<div style="position:absolute;left:306.64px;top:244.49px" class="cls_031"><span class="cls_031">in a large nationwide birth cohort established between 1996 and</span></div>
<div style="position:absolute;left:50.00px;top:250.87px" class="cls_029"><span class="cls_029">Department  of  Dermatovenerology,  KBC  Sestre  milosrdnice,  Zagreb,</span></div>
<div style="position:absolute;left:306.64px;top:254.49px" class="cls_031"><span class="cls_031">2002. During pregnancy, the women were asked whether they</span></div>
<div style="position:absolute;left:50.00px;top:260.58px" class="cls_029"><span class="cls_029">Croatia</span></div>
<div style="position:absolute;left:306.64px;top:264.49px" class="cls_031"><span class="cls_031">have ever had any skin diseases including psoriasis, and whether</span></div>
<div style="position:absolute;left:50.00px;top:271.54px" class="cls_031"><span class="cls_031">Psoriasis is a chronic, systemic, inflammatory disease associated</span></div>
<div style="position:absolute;left:306.64px;top:274.49px" class="cls_031"><span class="cls_031">the disease was diagnosed by a physician. The relation to self-</span></div>
<div style="position:absolute;left:50.00px;top:281.64px" class="cls_031"><span class="cls_031">with numerous comorbidities that have been well documented in</span></div>
<div style="position:absolute;left:306.64px;top:284.49px" class="cls_031"><span class="cls_031">reported cardiovascular and metabolic comorbidity 11 years</span></div>
<div style="position:absolute;left:50.00px;top:291.74px" class="cls_031"><span class="cls_031">the literature. Comorbidities often become clinically evident years</span></div>
<div style="position:absolute;left:306.64px;top:294.49px" class="cls_031"><span class="cls_031">after giving birth was assessed by multiple logistic regression.</span></div>
<div style="position:absolute;left:50.00px;top:301.84px" class="cls_031"><span class="cls_031">after the onset of psoriasis and are related to persistent low-grade</span></div>
<div style="position:absolute;left:306.64px;top:304.49px" class="cls_031"><span class="cls_031">Furthermore, we performed an analysis where the cohort was</span></div>
<div style="position:absolute;left:50.00px;top:311.93px" class="cls_031"><span class="cls_031">inflammation with secretion of proinflamamtory cytokines, as</span></div>
<div style="position:absolute;left:306.64px;top:314.49px" class="cls_031"><span class="cls_031">followed up for hospital-diagnosed comorbidity including cardiac</span></div>
<div style="position:absolute;left:50.00px;top:322.03px" class="cls_031"><span class="cls_031">seen in metabolic syndrome(1). Nevertheless, the evidence shows</span></div>
<div style="position:absolute;left:306.64px;top:324.49px" class="cls_031"><span class="cls_031">death until 31st December 2014. Here the risk was assessed by</span></div>
<div style="position:absolute;left:50.00px;top:332.13px" class="cls_031"><span class="cls_031">new emerging comorbidities that share link with psoriasis. Hjuler</span></div>
<div style="position:absolute;left:306.64px;top:334.48px" class="cls_031"><span class="cls_031">Cox proportional hazards regression. All analyses were adjusted</span></div>
<div style="position:absolute;left:50.00px;top:342.23px" class="cls_031"><span class="cls_031">et al. observed increased splenic inflammation in patients with</span></div>
<div style="position:absolute;left:306.64px;top:344.48px" class="cls_031"><span class="cls_031">for age, pre-pregnant BMI, and smoking status collected at time</span></div>
<div style="position:absolute;left:50.00px;top:352.33px" class="cls_031"><span class="cls_031">moderate-to-severe psoriasis (2). They also showed that splenic</span></div>
<div style="position:absolute;left:306.64px;top:354.48px" class="cls_031"><span class="cls_031">of inclusion during pregnancy.</span></div>
<div style="position:absolute;left:50.00px;top:362.42px" class="cls_031"><span class="cls_031">activity was correlating with aortic wall inflammation in psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:364.48px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> We identified 2,435 (2.90%) women with a history of</span></div>
<div style="position:absolute;left:50.00px;top:372.52px" class="cls_031"><span class="cls_031">patients, explaining the increased risk of heart disease (2).</span></div>
<div style="position:absolute;left:306.64px;top:374.48px" class="cls_031"><span class="cls_031">psoriasis and 81,388 women without psoriasis. The women with</span></div>
<div style="position:absolute;left:50.00px;top:382.62px" class="cls_031"><span class="cls_031">A 56-year old patient with chronic plaque psoriasis (Fig 1) for</span></div>
<div style="position:absolute;left:306.64px;top:384.48px" class="cls_031"><span class="cls_031">and without psoriasis were on average respectively 30.4 (SD</span></div>
<div style="position:absolute;left:50.00px;top:392.72px" class="cls_031"><span class="cls_031">more than thirty years, presented with splenomegaly, diabetes</span></div>
<div style="position:absolute;left:306.64px;top:394.48px" class="cls_031"><span class="cls_031">4.5) and 29.9 (SD 4.3) years old at time of inclusion in the study.</span></div>
<div style="position:absolute;left:50.00px;top:402.82px" class="cls_031"><span class="cls_031">type two, arterial hypertension, chronic kidney disease stage III,</span></div>
<div style="position:absolute;left:306.64px;top:404.48px" class="cls_031"><span class="cls_031">Women with psoriasis had slightly higher BMI and smoked mar-</span></div>
<div style="position:absolute;left:50.00px;top:412.91px" class="cls_031"><span class="cls_031">obesity, with BMI </span><span class="cls_030"> > </span><span class="cls_031">40, and depression. Psoriasis severely flared</span></div>
<div style="position:absolute;left:306.64px;top:414.50px" class="cls_031"><span class="cls_031">kedly more than women without psoriasis (38.1% vs. 26.4%). A</span></div>
<div style="position:absolute;left:49.99px;top:423.01px" class="cls_031"><span class="cls_031">up in 2012, and on workup up for cataract operation, enlarged</span></div>
<div style="position:absolute;left:306.64px;top:424.50px" class="cls_031"><span class="cls_031">history of psoriasis was significantly associated with self-reported</span></div>
<div style="position:absolute;left:49.99px;top:433.11px" class="cls_031"><span class="cls_031">lymph nodes were observed and further confirmed on CT scans in</span></div>
<div style="position:absolute;left:306.64px;top:434.50px" class="cls_031"><span class="cls_031">hypercholesterolemia (adjusted odds ratio 1.31; 1.01-1.70) and</span></div>
<div style="position:absolute;left:50.02px;top:443.21px" class="cls_031"><span class="cls_031">axillae, inguinum, mediastinum and upper abdomen. Patient was</span></div>
<div style="position:absolute;left:306.64px;top:444.50px" class="cls_031"><span class="cls_031">hospital-diagnosed hypertension (adjusted hazard ratio 1.33;</span></div>
<div style="position:absolute;left:50.02px;top:453.31px" class="cls_031"><span class="cls_031">hospitalized at haematology department and reactive lymphade-</span></div>
<div style="position:absolute;left:306.64px;top:454.49px" class="cls_031"><span class="cls_031">1.08-1.65). A positive association was also found with respectively</span></div>
<div style="position:absolute;left:50.00px;top:463.47px" class="cls_031"><span class="cls_031">nopathy due to skin inflammation was diagnosed. Acitretin was</span></div>
<div style="position:absolute;left:306.64px;top:464.49px" class="cls_031"><span class="cls_031">hospital-diagnosed ischaemic heart disease, type 2 diabetes, and</span></div>
<div style="position:absolute;left:49.99px;top:473.57px" class="cls_031"><span class="cls_031">started and stopped after a week for worsening of pancytopenia,</span></div>
<div style="position:absolute;left:306.64px;top:474.49px" class="cls_031"><span class="cls_031">hypercholesterolemia, however, these findings were not statis-</span></div>
<div style="position:absolute;left:49.99px;top:483.66px" class="cls_031"><span class="cls_031">and Methotrexate was stopped after two weeks for triple increase</span></div>
<div style="position:absolute;left:306.64px;top:484.50px" class="cls_031"><span class="cls_031">tically significant. No associations were found for self-reported</span></div>
<div style="position:absolute;left:49.99px;top:493.76px" class="cls_031"><span class="cls_031">in liver enzymes, although the dose was of only 5 mg weekly. In</span></div>
<div style="position:absolute;left:306.65px;top:494.50px" class="cls_031"><span class="cls_031">hypertension, thrombosis, or type 2 diabetes.</span></div>
<div style="position:absolute;left:49.99px;top:503.86px" class="cls_031"><span class="cls_031">August 2017, repeated blood tests were normal and abdominal</span></div>
<div style="position:absolute;left:306.65px;top:504.50px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> Women with psoriasis are at increased risk of</span></div>
<div style="position:absolute;left:49.99px;top:513.96px" class="cls_031"><span class="cls_031">US showed no progression in hepato-splenomegaly, with spleen</span></div>
<div style="position:absolute;left:306.65px;top:514.50px" class="cls_031"><span class="cls_031">developing cardiovascular and metabolic comorbidity in early</span></div>
<div style="position:absolute;left:49.99px;top:524.06px" class="cls_031"><span class="cls_031">measuring 23 cm. Psoriasis was severe, with PASI 36, BSA 31%</span></div>
<div style="position:absolute;left:306.65px;top:524.49px" class="cls_031"><span class="cls_031">adult life. This may suggest an importance of awareness of these</span></div>
<div style="position:absolute;left:49.99px;top:534.15px" class="cls_031"><span class="cls_031">and DLQI 19. Ustekinumab 90 mg was started in October 2017</span></div>
<div style="position:absolute;left:306.65px;top:534.49px" class="cls_031"><span class="cls_031">comorbidities also in younger patients with early screening for</span></div>
<div style="position:absolute;left:49.99px;top:544.25px" class="cls_031"><span class="cls_031">with PASI75 achieved after 12 weeks of treatment. Patient has</span></div>
<div style="position:absolute;left:306.65px;top:544.49px" class="cls_031"><span class="cls_031">hypertension, hyperglycemia, and hypercholesterolemia.</span></div>
<div style="position:absolute;left:49.99px;top:554.35px" class="cls_031"><span class="cls_031">been closely monitored with no haematological side-effects on</span></div>
<div style="position:absolute;left:49.99px;top:564.45px" class="cls_031"><span class="cls_031">last assessment.</span></div>
<div style="position:absolute;left:306.64px;top:563.13px" class="cls_033"><span class="cls_033">P009</span></div>
<div style="position:absolute;left:49.99px;top:574.55px" class="cls_031"><span class="cls_031">Significant splenomegaly and lymphadenopathy with no underly-</span></div>
<div style="position:absolute;left:306.64px;top:574.53px" class="cls_025"><span class="cls_025">A CASE OF CONCURRENT PSORIASIS AND VITILIGO</span></div>
<div style="position:absolute;left:50.00px;top:584.68px" class="cls_031"><span class="cls_031">ing haematological disease has not been described as a comorbidity</span></div>
<div style="position:absolute;left:306.64px;top:584.43px" class="cls_026"><span class="cls_026">Selma Poparic</span></div>
<div style="position:absolute;left:50.00px;top:594.78px" class="cls_031"><span class="cls_031">of psoriasis. The treatment with biologics was delayed in our</span></div>
<div style="position:absolute;left:306.64px;top:595.03px" class="cls_029"><span class="cls_029">Dermatology Department University Clinical Center of Ssrajevo</span></div>
<div style="position:absolute;left:50.00px;top:604.88px" class="cls_031"><span class="cls_031">patient as underlying haematological malignancy was suspected.</span></div>
<div style="position:absolute;left:306.64px;top:605.90px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Psoriasis and vitiligo are common dermatoses that</span></div>
<div style="position:absolute;left:50.00px;top:614.98px" class="cls_031"><span class="cls_031">The untreated severe psoriasis flared up in the mean time the whole</span></div>
<div style="position:absolute;left:306.64px;top:615.90px" class="cls_031"><span class="cls_031">affect 1~3% (psoriasis) and 0.5% (vitiligo) of the general popula-</span></div>
<div style="position:absolute;left:50.00px;top:625.08px" class="cls_031"><span class="cls_031">spectrum of comorbidities, led by depression. Ustekinumab has</span></div>
<div style="position:absolute;left:306.64px;top:625.90px" class="cls_031"><span class="cls_031">tion, respectively. Yet the pathogenesis of the association between</span></div>
<div style="position:absolute;left:50.00px;top:635.17px" class="cls_031"><span class="cls_031">significantly improved his psoriasis (Fig 2), with improvement in</span></div>
<div style="position:absolute;left:306.64px;top:635.90px" class="cls_031"><span class="cls_031">these two dermatoses is still unknown.</span></div>
<div style="position:absolute;left:50.02px;top:645.27px" class="cls_031"><span class="cls_031">depression that was best observed in patient’s motivation to lose</span></div>
<div style="position:absolute;left:306.64px;top:645.90px" class="cls_030"><span class="cls_030">Case report: </span><span class="cls_031">We report a case of a 52-year-old patient who was</span></div>
<div style="position:absolute;left:50.02px;top:655.37px" class="cls_031"><span class="cls_031">weight and be referred for gastric bypass.</span></div>
<div style="position:absolute;left:306.64px;top:655.90px" class="cls_031"><span class="cls_031">admitted to our department with a 6-month history of squamous</span></div>
<div style="position:absolute;left:50.02px;top:665.47px" class="cls_031"><span class="cls_031">Effective control of psoriasis and associated conditions requires not</span></div>
<div style="position:absolute;left:306.64px;top:665.90px" class="cls_031"><span class="cls_031">papules and plaques on his right elbow region and both right and</span></div>
<div style="position:absolute;left:50.02px;top:675.57px" class="cls_031"><span class="cls_031">only appropriate treatment, but also management of comorbidities,</span></div>
<div style="position:absolute;left:306.64px;top:675.89px" class="cls_031"><span class="cls_031">left lower leg. He was also noticed with hypopigmented patches</span></div>
<div style="position:absolute;left:50.02px;top:685.66px" class="cls_031"><span class="cls_031">including screening and treatment by various specialists, as disease</span></div>
<div style="position:absolute;left:306.64px;top:685.85px" class="cls_031"><span class="cls_031">on his right and left wrist. Anamnestic questionnaire revealed that</span></div>
<div style="position:absolute;left:50.02px;top:695.76px" class="cls_031"><span class="cls_031">is known for its cumulative impairment over patient’s lifetime (3).</span></div>
<div style="position:absolute;left:306.64px;top:695.80px" class="cls_031"><span class="cls_031">his mother has had similar discolorations on her skin, but never</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:6424px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background10.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">8</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:50.91px" class="cls_031"><span class="cls_031">underwent any diagnostic procedure, nor treatment. Clinical and</span></div>
<div style="position:absolute;left:306.64px;top:51.23px" class="cls_033"><span class="cls_033">P011</span></div>
<div style="position:absolute;left:50.00px;top:60.86px" class="cls_031"><span class="cls_031">hystopathological diagnosis of erythematosquamous areas on the</span></div>
<div style="position:absolute;left:306.64px;top:62.70px" class="cls_025"><span class="cls_025">CLINICAL AND EPIDEMIOLOGICAL</span></div>
<div style="position:absolute;left:50.00px;top:70.81px" class="cls_031"><span class="cls_031">patients right elbow and right and left lower leg was a plaque pso-</span></div>
<div style="position:absolute;left:306.64px;top:73.66px" class="cls_025"><span class="cls_025">CARACTERIZATION OF PSORIASIS AND PSORIATIC</span></div>
<div style="position:absolute;left:50.00px;top:80.76px" class="cls_031"><span class="cls_031">riasis, while hypopigmented patches on his wrists were diagnosed</span></div>
<div style="position:absolute;left:306.64px;top:84.62px" class="cls_025"><span class="cls_025">ARTHRITIS ON A MULTIDISCIPLINARY ASSESMENT</span></div>
<div style="position:absolute;left:50.00px;top:90.71px" class="cls_031"><span class="cls_031">as vitiligo. Blood work up and T3, fT4, TSH, ANA laboratory tests</span></div>
<div style="position:absolute;left:306.64px;top:95.58px" class="cls_025"><span class="cls_025">MODEL</span></div>
<div style="position:absolute;left:50.00px;top:100.67px" class="cls_031"><span class="cls_031">were within normal ranges.</span></div>
<div style="position:absolute;left:306.64px;top:105.55px" class="cls_051"><span class="cls_051">Karla Del Rocio Macias-Garcia</span><span class="cls_026">, Dalila Alejandra Lopez Rodri-</span></div>
<div style="position:absolute;left:50.00px;top:110.62px" class="cls_030"><span class="cls_030">Conclusion:</span><span class="cls_031"> Psoriasis and vitiligo, although seemingly unrelated</span></div>
<div style="position:absolute;left:306.64px;top:115.51px" class="cls_026"><span class="cls_026">guez</span></div>
<div style="position:absolute;left:50.00px;top:120.57px" class="cls_031"><span class="cls_031">skin disorders, have a lot in common. Causes, incidence, and even</span></div>
<div style="position:absolute;left:306.64px;top:126.19px" class="cls_029"><span class="cls_029">Dermatologico Country</span></div>
<div style="position:absolute;left:50.00px;top:130.53px" class="cls_031"><span class="cls_031">distribution seem to strongly correlate between these two.</span></div>
<div style="position:absolute;left:306.64px;top:137.13px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Presentation and clinical course in Psoriasis are</span></div>
<div style="position:absolute;left:306.64px;top:147.09px" class="cls_031"><span class="cls_031">heterogeneos. A multidisciplinary assessment model was designed</span></div>
<div style="position:absolute;left:50.00px;top:150.14px" class="cls_033"><span class="cls_033">P010</span></div>
<div style="position:absolute;left:306.64px;top:157.05px" class="cls_031"><span class="cls_031">by five specialties: dermatology, rheumatology, internal medicine,</span></div>
<div style="position:absolute;left:50.00px;top:161.54px" class="cls_025"><span class="cls_025">SUCCESSFUL LONG-TERM DOUBLE DISEASE</span></div>
<div style="position:absolute;left:306.63px;top:167.01px" class="cls_031"><span class="cls_031">nutrition and psychiatry, to evaluate at the same time and place,</span></div>
<div style="position:absolute;left:50.00px;top:172.44px" class="cls_025"><span class="cls_025">CONTROL BY ADALIMUMAB IN A PATIENT WITH</span></div>
<div style="position:absolute;left:306.63px;top:176.98px" class="cls_031"><span class="cls_031">patients with psoriasis.</span></div>
<div style="position:absolute;left:50.00px;top:183.34px" class="cls_025"><span class="cls_025">PSORIASIS VULGARIS AND HIDRADENITIS</span></div>
<div style="position:absolute;left:306.63px;top:186.94px" class="cls_030"><span class="cls_030">Objetive: </span><span class="cls_031">To ascertain frequency of comorbilities in psoriatic pa-</span></div>
<div style="position:absolute;left:50.00px;top:194.24px" class="cls_025"><span class="cls_025">SUPPURATIVA</span></div>
<div style="position:absolute;left:306.64px;top:196.92px" class="cls_031"><span class="cls_031">tients and conduct a clinical and epidemiological characterization.</span></div>
<div style="position:absolute;left:50.00px;top:204.14px" class="cls_051"><span class="cls_051">Melita Vuksic Polic</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Zlatica Jukic</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Andrea Krnic</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Renata Vuka-</span></div>
<div style="position:absolute;left:306.64px;top:206.88px" class="cls_030"><span class="cls_030">Methods</span><span class="cls_031">: Prospective study, from August 2016 to february 2018,</span></div>
<div style="position:absolute;left:50.00px;top:214.04px" class="cls_026"><span class="cls_026">din</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Ivana Patrk</span><span class="cls_027"><sup>2</sup></span></div>
<div style="position:absolute;left:306.64px;top:216.85px" class="cls_031"><span class="cls_031">patients attending to Multidisciplinary Clinic for psoriasis in</span></div>
<div style="position:absolute;left:50.00px;top:224.64px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Osijek University Hospital: Faculty of Medicine Osijek, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Privat dermato-</span></div>
<div style="position:absolute;left:306.64px;top:226.81px" class="cls_031"><span class="cls_031">Dermatologico Country were included.</span></div>
<div style="position:absolute;left:50.00px;top:234.24px" class="cls_029"><span class="cls_029">venerological clinic dr Ivana Patrk, Zadar</span></div>
<div style="position:absolute;left:306.64px;top:236.77px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> 53 patients were included. Median age was 42 years old</span></div>
<div style="position:absolute;left:50.00px;top:245.06px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Psoriasis vulgaris /PV/ is a chronic inflammatory</span></div>
<div style="position:absolute;left:306.64px;top:246.73px" class="cls_031"><span class="cls_031">and 62.3% were female. Family history of psoriasis was found</span></div>
<div style="position:absolute;left:49.99px;top:255.01px" class="cls_031"><span class="cls_031">skin disease</span><span class="cls_034"><sup>1</sup></span><span class="cls_031">. Studies have shown the role of genes important for</span></div>
<div style="position:absolute;left:306.64px;top:256.70px" class="cls_031"><span class="cls_031">in 26.4% patients and 19.4% had spodyloarthropathy family</span></div>
<div style="position:absolute;left:50.00px;top:264.96px" class="cls_031"><span class="cls_031">the transcription of inflammatory citokines, such as TNF alpha</span></div>
<div style="position:absolute;left:306.64px;top:266.66px" class="cls_031"><span class="cls_031">history. Most common comorbidities found obesity, metabolic</span></div>
<div style="position:absolute;left:50.01px;top:274.91px" class="cls_031"><span class="cls_031">and IL-23, which play main role in the patoghenesis of psoriasis</span><span class="cls_034"><sup>2</sup></span><span class="cls_031">.</span></div>
<div style="position:absolute;left:306.64px;top:276.62px" class="cls_031"><span class="cls_031">syndrome, diabetes mellitus, dyslipidemia, hypertension and fatty</span></div>
<div style="position:absolute;left:50.00px;top:284.86px" class="cls_031"><span class="cls_031">Hidradenitis suppurativa /HS/ is chronic inflammatory skin di-</span></div>
<div style="position:absolute;left:306.64px;top:286.59px" class="cls_031"><span class="cls_031">liver. Affective assessment was found for 49.1% met criteria for</span></div>
<div style="position:absolute;left:50.00px;top:294.81px" class="cls_031"><span class="cls_031">sease</span><span class="cls_034"><sup>3</sup></span><span class="cls_031">, in which pathogenesis are IL-23 and TNF alpha, supporting</span></div>
<div style="position:absolute;left:306.64px;top:296.55px" class="cls_031"><span class="cls_031">anxiety. Psoriasis found 96.2% with psoriasis in skin and 56.6%</span></div>
<div style="position:absolute;left:50.00px;top:304.76px" class="cls_031"><span class="cls_031">the theory of the immunologic disease</span><span class="cls_034"><sup>4</sup></span><span class="cls_031">. Adalimumab is human</span></div>
<div style="position:absolute;left:306.64px;top:306.51px" class="cls_031"><span class="cls_031">in nails. Most common presentation of psoriasis, was plaque</span></div>
<div style="position:absolute;left:50.00px;top:314.71px" class="cls_031"><span class="cls_031">monoclonal antibody that has a great affinity for the membrane of</span></div>
<div style="position:absolute;left:306.64px;top:316.48px" class="cls_031"><span class="cls_031">psoriasis in 66%. PASI score showed 50.9% with mild disease,</span></div>
<div style="position:absolute;left:50.00px;top:324.66px" class="cls_031"><span class="cls_031">TNF alpha</span><span class="cls_034"><sup>5</sup></span><span class="cls_031">. We report the case of a 44-year-old Caucasian woman</span></div>
<div style="position:absolute;left:306.64px;top:326.44px" class="cls_031"><span class="cls_031">15.1% moderate, and 34% had severe. NAPSI score was from 0</span></div>
<div style="position:absolute;left:50.00px;top:334.61px" class="cls_031"><span class="cls_031">with a history of PV and HS, both diseases are in remission during</span></div>
<div style="position:absolute;left:306.64px;top:336.40px" class="cls_031"><span class="cls_031">to 61, with a median of 3 (0.13). DLQI indicated that only 13.2%</span></div>
<div style="position:absolute;left:50.00px;top:344.57px" class="cls_031"><span class="cls_031">the therapy with adalimumab.</span></div>
<div style="position:absolute;left:306.64px;top:346.36px" class="cls_031"><span class="cls_031">had no condition in life quality, meanwhile 86.8% patients had</span></div>
<div style="position:absolute;left:50.00px;top:354.51px" class="cls_030"><span class="cls_030">Case report:</span><span class="cls_035"> </span><span class="cls_031">We report the case of a 44-year-old Caucasian woman</span></div>
<div style="position:absolute;left:306.64px;top:356.33px" class="cls_031"><span class="cls_031">impaired quality of life. Psoriatic arthritis, and identify 58.5%</span></div>
<div style="position:absolute;left:50.00px;top:364.46px" class="cls_031"><span class="cls_031">with a history of PV and HS that started adalimumab therapy 3</span></div>
<div style="position:absolute;left:306.64px;top:366.29px" class="cls_031"><span class="cls_031">patients that met CASPAR criteria, axial disease was present in</span></div>
<div style="position:absolute;left:50.00px;top:374.42px" class="cls_031"><span class="cls_031">years ago. PV started 14 years ago and was verified by skin biopsy.</span></div>
<div style="position:absolute;left:306.64px;top:376.25px" class="cls_031"><span class="cls_031">51.6%, peripheral joint disease in 71% and in 13.2% both were</span></div>
<div style="position:absolute;left:50.00px;top:384.37px" class="cls_031"><span class="cls_031">Initially, the clinical course of psoriasis was mild and later she took</span></div>
<div style="position:absolute;left:306.64px;top:386.22px" class="cls_031"><span class="cls_031">present. 54.8%(17) patients had enthesitis and 16.1% had dactilitis.</span></div>
<div style="position:absolute;left:50.00px;top:394.32px" class="cls_031"><span class="cls_031">course to moderate psoriasis with PASI 10. Psoriasis was treated</span></div>
<div style="position:absolute;left:306.64px;top:396.18px" class="cls_031"><span class="cls_031">DAS28 was performed, and showed 45.2% with severe activity.</span></div>
<div style="position:absolute;left:50.00px;top:404.28px" class="cls_031"><span class="cls_031">only with local therapy. HS started when she was 38-years-old in</span></div>
<div style="position:absolute;left:306.64px;top:406.14px" class="cls_031"><span class="cls_031">Total number of subjects with peripheral disease 100%, did not</span></div>
<div style="position:absolute;left:50.00px;top:414.23px" class="cls_031"><span class="cls_031">her left groin, as swelling and pain on palpation and in movement.</span></div>
<div style="position:absolute;left:306.64px;top:416.11px" class="cls_031"><span class="cls_031">met criteria for MDA. HAQ score to assess PsA patients quality</span></div>
<div style="position:absolute;left:50.00px;top:424.19px" class="cls_031"><span class="cls_031">Skin changes started to develop also on the right groin and perianal</span></div>
<div style="position:absolute;left:306.64px;top:426.07px" class="cls_031"><span class="cls_031">of life, revealed a median of 1.38 (1.10, 2.25).</span></div>
<div style="position:absolute;left:50.00px;top:434.14px" class="cls_031"><span class="cls_031">region as painful nodules, with pus draining, and fistula tracts.</span></div>
<div style="position:absolute;left:306.64px;top:436.03px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> we found that more than half of the patients presented</span></div>
<div style="position:absolute;left:49.99px;top:444.09px" class="cls_031"><span class="cls_031">Skin biopsy confirmed HS.Chest X-ray and gastroenterology</span></div>
<div style="position:absolute;left:306.64px;top:445.99px" class="cls_031"><span class="cls_031">a severe form of psoriasis with significant quality of life impair-</span></div>
<div style="position:absolute;left:50.01px;top:454.05px" class="cls_031"><span class="cls_031">examination were performed to exclude any additional illnesses</span></div>
<div style="position:absolute;left:306.64px;top:456.03px" class="cls_031"><span class="cls_031">ment. The number of psoriatic arthritis was higher than expected</span></div>
<div style="position:absolute;left:50.01px;top:463.96px" class="cls_031"><span class="cls_031">and she also did a psychologcal testing. She was treated with dif-</span></div>
<div style="position:absolute;left:306.64px;top:465.99px" class="cls_031"><span class="cls_031">with both axial and peripheral manifestations. We have found a</span></div>
<div style="position:absolute;left:50.00px;top:473.91px" class="cls_031"><span class="cls_031">ferent antibiotics also prednisone and isotretinoin at a dose 1mg/</span></div>
<div style="position:absolute;left:306.64px;top:475.96px" class="cls_031"><span class="cls_031">high proportion of patients with comorbidities such as metabolic</span></div>
<div style="position:absolute;left:50.00px;top:483.86px" class="cls_031"><span class="cls_031">kg/day. Topical therapy was consisting of antibiotics, antiseptics</span></div>
<div style="position:absolute;left:306.64px;top:485.92px" class="cls_031"><span class="cls_031">syndrome, diabetes mellitus, hypertension, dyslipidemia and</span></div>
<div style="position:absolute;left:50.00px;top:493.82px" class="cls_031"><span class="cls_031">and hydrocolloid dressings. She had 3 surgical interventions. In</span></div>
<div style="position:absolute;left:306.64px;top:495.88px" class="cls_031"><span class="cls_031">obesity. We also found a high frequency of psychiatric illness.</span></div>
<div style="position:absolute;left:50.00px;top:503.77px" class="cls_031"><span class="cls_031">2015, she started adalimumab according to the scheme. On the</span></div>
<div style="position:absolute;left:306.64px;top:505.84px" class="cls_031"><span class="cls_031">The limitations of our study are the small sample to highlight</span></div>
<div style="position:absolute;left:50.00px;top:513.71px" class="cls_031"><span class="cls_031">day of the initial aplication of adalimumab, patient had 4 absces-</span></div>
<div style="position:absolute;left:306.64px;top:515.81px" class="cls_031"><span class="cls_031">if comorbidities had an impact on the severity of skin and joint</span></div>
<div style="position:absolute;left:50.00px;top:523.66px" class="cls_031"><span class="cls_031">ses, 13 nodules and 16 fistula tracts. She had successful clinical</span></div>
<div style="position:absolute;left:306.64px;top:525.77px" class="cls_031"><span class="cls_031">disease. This multidisciplinary model has identified psoriasis as</span></div>
<div style="position:absolute;left:50.00px;top:533.61px" class="cls_031"><span class="cls_031">response to the drug and is without psoriatic symptoms or HS</span></div>
<div style="position:absolute;left:306.64px;top:535.73px" class="cls_031"><span class="cls_031">a disease with an unpredictable course, which requires several</span></div>
<div style="position:absolute;left:50.00px;top:543.57px" class="cls_031"><span class="cls_031">active lesions. Both diseases are successfuly controled and quality</span></div>
<div style="position:absolute;left:306.64px;top:545.70px" class="cls_031"><span class="cls_031">evaluations by a multidisciplinary model, with a group of experts</span></div>
<div style="position:absolute;left:50.00px;top:553.52px" class="cls_031"><span class="cls_031">of life has improved.</span></div>
<div style="position:absolute;left:306.64px;top:555.76px" class="cls_031"><span class="cls_031">beyond Dermatologist and Rheumatologist.</span></div>
<div style="position:absolute;left:50.00px;top:563.52px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.00px;top:573.52px" class="cls_032"><span class="cls_032">1.Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence,</span></div>
<div style="position:absolute;left:306.64px;top:575.49px" class="cls_033"><span class="cls_033">P012</span></div>
<div style="position:absolute;left:50.00px;top:582.52px" class="cls_032"><span class="cls_032">severity and patient´s beliefs and attidudes towards he disease. Br J Der-</span></div>
<div style="position:absolute;left:306.64px;top:586.95px" class="cls_025"><span class="cls_025">ALCOHOL AND PSORIASIS- A PROSPECTIVE SWEDISH</span></div>
<div style="position:absolute;left:50.00px;top:591.52px" class="cls_032"><span class="cls_032">matol 1996;135:533-7.</span></div>
<div style="position:absolute;left:50.00px;top:600.52px" class="cls_032"><span class="cls_032">2.Reich K, Hüffmeier U, König IR, Lasorz J, Lohman J, Wendler J, Traupe</span></div>
<div style="position:absolute;left:306.64px;top:597.91px" class="cls_025"><span class="cls_025">STUDY</span></div>
<div style="position:absolute;left:50.00px;top:609.52px" class="cls_032"><span class="cls_032">H, Mössner R, Reis A, Burhardt H.TNF polymorphisms in psoriasis as-</span></div>
<div style="position:absolute;left:306.64px;top:607.88px" class="cls_051"><span class="cls_051">Caroline Svanström</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Sol-Britt Lonne-Rahm</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Ebru Bircan</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Knut</span></div>
<div style="position:absolute;left:50.00px;top:618.52px" class="cls_032"><span class="cls_032">sociation of psoriatic arthritis with the promoter polymorphism TNF-857</span></div>
<div style="position:absolute;left:306.64px;top:617.85px" class="cls_026"><span class="cls_026">Stokkeland</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Johan Franck</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Klas Nordlind</span><span class="cls_027"><sup>5</sup></span></div>
<div style="position:absolute;left:50.00px;top:627.52px" class="cls_032"><span class="cls_032">independent of th PSORS1 risk allele. Arthritis Rheum 2007,56:2056-64.</span></div>
<div style="position:absolute;left:306.64px;top:628.52px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Dermatology, Mälarsjukhuset, Eskilstuna, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department</span></div>
<div style="position:absolute;left:50.00px;top:636.52px" class="cls_032"><span class="cls_032">3. Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa</span></div>
<div style="position:absolute;left:306.64px;top:638.18px" class="cls_029"><span class="cls_029">of Medicine, Solna, Dermatology and Venereology Unit, Karolinska Insti-</span></div>
<div style="position:absolute;left:50.00px;top:645.52px" class="cls_032"><span class="cls_032">(acne inversa). Dermatoendocrinol 2010;2:9-16.</span></div>
<div style="position:absolute;left:306.64px;top:647.84px" class="cls_029"><span class="cls_029">tutet, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Department of Medicine, Gastroenterology and Hepatology Unit,</span></div>
<div style="position:absolute;left:50.00px;top:654.52px" class="cls_032"><span class="cls_032">4. Matusiak I, Bieniek A, Szepietowski JC. Increaed serum tumour ne-</span></div>
<div style="position:absolute;left:306.63px;top:657.51px" class="cls_029"><span class="cls_029">Karolinska Institutet, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Department of Clinical Neuroscience, Division of</span></div>
<div style="position:absolute;left:50.00px;top:663.52px" class="cls_032"><span class="cls_032">crosis factor-alpha in hidradenitis suppurativa patients: is there a basis</span></div>
<div style="position:absolute;left:306.64px;top:667.18px" class="cls_029"><span class="cls_029">Psychiatry, Karolinska Institutet, Stockholm, and Department of Medicine,</span></div>
<div style="position:absolute;left:50.00px;top:672.52px" class="cls_032"><span class="cls_032">for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm</span></div>
<div style="position:absolute;left:306.64px;top:676.84px" class="cls_029"><span class="cls_029">Visby Hospital, Visby, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Department of Medicine, Solna, Dermatology and</span></div>
<div style="position:absolute;left:50.00px;top:681.52px" class="cls_032"><span class="cls_032">Venereol 2009;89:601-3.</span></div>
<div style="position:absolute;left:306.63px;top:686.51px" class="cls_029"><span class="cls_029">Venereology Unit, Karolinska Institutet, Stockholm, Sweden</span></div>
<div style="position:absolute;left:50.00px;top:690.52px" class="cls_032"><span class="cls_032">5. Haslund P, Lee Ra, Jemec GB. Treatment of hidradenitis suppura-</span></div>
<div style="position:absolute;left:50.00px;top:699.52px" class="cls_032"><span class="cls_032">tiva with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol</span></div>
<div style="position:absolute;left:306.64px;top:697.44px" class="cls_030"><span class="cls_030">Background:</span><span class="cls_031"> We have earlier in a limited cross-sectional study</span></div>
<div style="position:absolute;left:50.00px;top:708.52px" class="cls_032"><span class="cls_032">2009;89:595-600.</span></div>
<div style="position:absolute;left:306.64px;top:707.50px" class="cls_031"><span class="cls_031">shown a correlation in females for alcohol consumption and extent</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:7227px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background11.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:540.93px;top:28.81px" class="cls_017"><span class="cls_017">9</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">of psoriasis. There are few prospective studies on the relation of</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">The incidence of cancer in the general population</span></div>
<div style="position:absolute;left:50.00px;top:61.40px" class="cls_031"><span class="cls_031">alcohol with the extent of psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:61.41px" class="cls_031"><span class="cls_031">in Argentina, according to the Ministry of Health is 172.3-242.9</span></div>
<div style="position:absolute;left:50.00px;top:71.40px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">The purpose of this prospective study was to further</span></div>
<div style="position:absolute;left:306.64px;top:71.41px" class="cls_031"><span class="cls_031">per 100,000 inhabitants. In our study population, we found an</span></div>
<div style="position:absolute;left:50.00px;top:81.40px" class="cls_031"><span class="cls_031">investigate how alcohol affects psoriasis in female patients.</span></div>
<div style="position:absolute;left:306.64px;top:81.41px" class="cls_031"><span class="cls_031">incidence of 3.098%, which would support the hypothesis of an</span></div>
<div style="position:absolute;left:50.00px;top:91.40px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Twenty-two female psoriasis patients with light to</span></div>
<div style="position:absolute;left:306.64px;top:91.41px" class="cls_031"><span class="cls_031">increased risk of developing cancer in patients with psoriasis. The</span></div>
<div style="position:absolute;left:50.00px;top:101.40px" class="cls_031"><span class="cls_031">moderate psoriasis, with only local treatment and with a regular</span></div>
<div style="position:absolute;left:306.64px;top:101.41px" class="cls_031"><span class="cls_031">risk was identical in both sexes and directly proportional to the</span></div>
<div style="position:absolute;left:50.00px;top:111.40px" class="cls_031"><span class="cls_031">alcohol intake, were recruited. The study was run for three years,</span></div>
<div style="position:absolute;left:306.64px;top:111.41px" class="cls_031"><span class="cls_031">degree of severity of the psoriasis.</span></div>
<div style="position:absolute;left:50.00px;top:121.40px" class="cls_031"><span class="cls_031">starting in 2014. We used Christmas and New Year, as intervention</span></div>
<div style="position:absolute;left:306.64px;top:121.41px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:50.00px;top:131.40px" class="cls_031"><span class="cls_031">period, when the amount of alcohol is expected to exceed normal</span></div>
<div style="position:absolute;left:306.64px;top:131.43px" class="cls_032"><span class="cls_032">Pouplard C, Brenaut E, et al. Risk of cancer in psoriasis: a systematic</span></div>
<div style="position:absolute;left:50.00px;top:141.40px" class="cls_031"><span class="cls_031">consumption. The total study period was 8 weeks. During the study</span></div>
<div style="position:absolute;left:306.64px;top:140.43px" class="cls_032"><span class="cls_032">review and meta-analysis of epidemiological studies. JEADV 27 (Suppl.</span></div>
<div style="position:absolute;left:306.64px;top:149.43px" class="cls_032"><span class="cls_032">3), 36-46, 2013Ramos Mejia, Service of Dermatology</span></div>
<div style="position:absolute;left:50.00px;top:151.40px" class="cls_031"><span class="cls_031">period, the alcohol intake was measured by the patients filling a</span></div>
<div style="position:absolute;left:49.98px;top:161.39px" class="cls_031"><span class="cls_031">calendar, specifying the alcohol intake per day, moreover, the de-</span></div>
<div style="position:absolute;left:306.64px;top:168.05px" class="cls_033"><span class="cls_033">P014</span></div>
<div style="position:absolute;left:50.00px;top:171.41px" class="cls_031"><span class="cls_031">gree of severity of psoriasis, degree of pruritus, and of perceived</span></div>
<div style="position:absolute;left:50.00px;top:181.40px" class="cls_031"><span class="cls_031">stress, using a visual analog scale. In addition, the patients once a</span></div>
<div style="position:absolute;left:306.64px;top:179.45px" class="cls_025"><span class="cls_025">HEMATOLOGICAL DISORDERS IN THE PATIENT</span></div>
<div style="position:absolute;left:50.00px;top:191.40px" class="cls_031"><span class="cls_031">week determined Self-Administered Psoriasis Area and Severity</span></div>
<div style="position:absolute;left:306.64px;top:190.35px" class="cls_025"><span class="cls_025">WITH PSORIATIC ARTHRITIS TREATED WITH</span></div>
<div style="position:absolute;left:50.00px;top:201.40px" class="cls_031"><span class="cls_031">Index (SAPASI).</span></div>
<div style="position:absolute;left:306.64px;top:201.25px" class="cls_025"><span class="cls_025">METHOTREXATE AND TUMOR NECROSIS ALPHA</span></div>
<div style="position:absolute;left:50.00px;top:211.40px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">The alcohol intake, which was generally low to moderate,</span></div>
<div style="position:absolute;left:306.64px;top:212.15px" class="cls_025"><span class="cls_025">(TNFALPHA) INHIBITOR</span></div>
<div style="position:absolute;left:50.00px;top:221.40px" class="cls_031"><span class="cls_031">increased during Christmas and New Year, reaching its maximum</span></div>
<div style="position:absolute;left:306.64px;top:222.05px" class="cls_051"><span class="cls_051">Renata Sokolik</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Aleksandra Butrym</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Grzegorz Mazur</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Piotr Wi-</span></div>
<div style="position:absolute;left:50.00px;top:231.40px" class="cls_031"><span class="cls_031">during week 52 (Christmas week). There was a marginal increase</span></div>
<div style="position:absolute;left:306.63px;top:231.95px" class="cls_026"><span class="cls_026">land</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:50.00px;top:241.40px" class="cls_031"><span class="cls_031">in the extent of psoriasis, determined by SAPASI, during week 52.</span></div>
<div style="position:absolute;left:306.64px;top:242.55px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department and Clinic of Rheumatology and Internal Medicine, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Depart-</span></div>
<div style="position:absolute;left:50.00px;top:251.40px" class="cls_031"><span class="cls_031">There was no correlation with alcohol intake nor pruritus. The level</span></div>
<div style="position:absolute;left:306.64px;top:252.15px" class="cls_029"><span class="cls_029">ment and Clinic of Internal and Occupational Diseases and Hypertension,</span></div>
<div style="position:absolute;left:50.00px;top:261.40px" class="cls_031"><span class="cls_031">of perceived stress decreased shortly after week 52, and reached</span></div>
<div style="position:absolute;left:306.64px;top:261.75px" class="cls_029"><span class="cls_029">Wroclaw Medical University, Wroclaw Poland</span></div>
<div style="position:absolute;left:50.00px;top:271.40px" class="cls_031"><span class="cls_031">its lowest value during week 1, after that increasing.</span></div>
<div style="position:absolute;left:306.64px;top:272.61px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Non-Hodgkin lymphomas are a heterogenous group</span></div>
<div style="position:absolute;left:50.00px;top:281.39px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Even if there is an increased alcohol consumption</span></div>
<div style="position:absolute;left:306.64px;top:282.61px" class="cls_031"><span class="cls_031">of neoplastic disorders characterized by clonal limphoid cell</span></div>
<div style="position:absolute;left:50.00px;top:291.39px" class="cls_031"><span class="cls_031">during Christmas and New Year, there is no evident worsening</span></div>
<div style="position:absolute;left:306.64px;top:292.61px" class="cls_031"><span class="cls_031">proliferation. They rank sixth among the cancers in terms of the</span></div>
<div style="position:absolute;left:50.00px;top:301.39px" class="cls_031"><span class="cls_031">of psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:302.61px" class="cls_031"><span class="cls_031">frequency of occurrence in adults. Waldenstrom macroglobuline-</span></div>
<div style="position:absolute;left:306.64px;top:312.61px" class="cls_031"><span class="cls_031">mia is lymphoplasmic hyperplasia with excessive production of</span></div>
<div style="position:absolute;left:50.00px;top:321.04px" class="cls_033"><span class="cls_033">P013</span></div>
<div style="position:absolute;left:306.64px;top:322.61px" class="cls_031"><span class="cls_031">monoclonal M-protein. According to literature data, patients with</span></div>
<div style="position:absolute;left:50.00px;top:332.44px" class="cls_025"><span class="cls_025">PSORIASIS  AND  CANCER.  RETROSPECTIVE  STUDY</span></div>
<div style="position:absolute;left:306.64px;top:332.61px" class="cls_031"><span class="cls_031">psoriasis have more frequent lymphomas than healthy population.</span></div>
<div style="position:absolute;left:50.00px;top:343.34px" class="cls_025"><span class="cls_025">IN THE PSORIASIS SECTOR OF THE DERMATOLOGY</span></div>
<div style="position:absolute;left:306.64px;top:342.61px" class="cls_031"><span class="cls_031">The real risk of lymphoproliferative disease in psoriatic arthritis</span></div>
<div style="position:absolute;left:50.00px;top:354.24px" class="cls_025"><span class="cls_025">SERVICE AT RAMOS MEJIA HOSPITAL</span></div>
<div style="position:absolute;left:306.64px;top:352.61px" class="cls_031"><span class="cls_031">patients has not yet been defined.</span></div>
<div style="position:absolute;left:50.00px;top:364.14px" class="cls_051"><span class="cls_051">Jennifer Kreimer</span><span class="cls_026">, Alejandra Crespo, Elena Chaparro, Daniela</span></div>
<div style="position:absolute;left:306.64px;top:362.61px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">The aim of the study was to describe a case of a patient</span></div>
<div style="position:absolute;left:50.00px;top:374.04px" class="cls_026"><span class="cls_026">Gonzalez, Veira Rosana, Kogan Nora</span></div>
<div style="position:absolute;left:306.64px;top:372.61px" class="cls_031"><span class="cls_031">with psoriatic arthritis and concurent monoclonal gammopathy,</span></div>
<div style="position:absolute;left:50.00px;top:383.91px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is a chronic, systemic, immune-mediated</span></div>
<div style="position:absolute;left:306.64px;top:382.61px" class="cls_031"><span class="cls_031">who did not respond to treatment with TNFalpha inhibitor in</span></div>
<div style="position:absolute;left:50.00px;top:393.90px" class="cls_031"><span class="cls_031">inflammatory disease that compromises the skin, attachments,</span></div>
<div style="position:absolute;left:306.64px;top:392.61px" class="cls_031"><span class="cls_031">combination with methotrexate.</span></div>
<div style="position:absolute;left:50.01px;top:403.90px" class="cls_031"><span class="cls_031">semi-mucosal, mucous membranes and joints. There are different</span></div>
<div style="position:absolute;left:306.64px;top:402.61px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">A 57 year old woman with psoriasis and psoriatic arthritis</span></div>
<div style="position:absolute;left:50.01px;top:413.90px" class="cls_031"><span class="cls_031">clinical forms that can vary in the same patient at different times</span></div>
<div style="position:absolute;left:306.64px;top:412.60px" class="cls_031"><span class="cls_031">diagnosed in 2012 (presence of HLA B27 antigen, arthritis of the</span></div>
<div style="position:absolute;left:50.01px;top:423.90px" class="cls_031"><span class="cls_031">of life. It is accompanied by comorbidities that affect the quality</span></div>
<div style="position:absolute;left:306.64px;top:422.60px" class="cls_031"><span class="cls_031">sacroiliac joints, peripheral arthritis) with monoclonal gammopa-</span></div>
<div style="position:absolute;left:50.01px;top:433.90px" class="cls_031"><span class="cls_031">and survival of patients. Within the comorbidities associated with</span></div>
<div style="position:absolute;left:306.64px;top:432.61px" class="cls_031"><span class="cls_031">thy of undeterminated significance, was treated with non-steroid</span></div>
<div style="position:absolute;left:50.01px;top:443.90px" class="cls_031"><span class="cls_031">psoriasis, malignancies constitute a prominent and controversial</span></div>
<div style="position:absolute;left:306.64px;top:442.61px" class="cls_031"><span class="cls_031">anti-inflammatory drugs, methotrexate (20 mg once a week), folic</span></div>
<div style="position:absolute;left:50.01px;top:453.90px" class="cls_031"><span class="cls_031">group. In the review of the current literature, there would be</span></div>
<div style="position:absolute;left:306.65px;top:452.61px" class="cls_031"><span class="cls_031">acid 15 mg and inhibitor of TNFalpha.</span></div>
<div style="position:absolute;left:50.01px;top:463.90px" class="cls_031"><span class="cls_031">evidence of a relationship between psoriasis and cancer, given</span></div>
<div style="position:absolute;left:306.65px;top:462.61px" class="cls_031"><span class="cls_031">At the beginning of biological therapy she presented with labora-</span></div>
<div style="position:absolute;left:50.01px;top:473.90px" class="cls_031"><span class="cls_031">the existence of structural and molecular similarities between the</span></div>
<div style="position:absolute;left:306.64px;top:472.61px" class="cls_031"><span class="cls_031">tory results: ESR 126, total protein 8 g/dl, abnormal IgM 11.6 g/l</span></div>
<div style="position:absolute;left:50.01px;top:483.90px" class="cls_031"><span class="cls_031">two pathologies. Objectives: To assess the prevalence of cancer</span></div>
<div style="position:absolute;left:306.64px;top:482.61px" class="cls_031"><span class="cls_031">(normal range 0.4-2.3 g/l), IgG 2.25 g/l (normal range 7-16g/l),</span></div>
<div style="position:absolute;left:50.01px;top:493.89px" class="cls_031"><span class="cls_031">development in patients with psoriasis in our population.</span></div>
<div style="position:absolute;left:306.64px;top:492.61px" class="cls_031"><span class="cls_031">IgA 0.32 g/l (normal range 0.7-4 g/l). Immunofixation test revea-</span></div>
<div style="position:absolute;left:50.01px;top:503.89px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">A retrospective epidemiological analysis of the total</span></div>
<div style="position:absolute;left:306.64px;top:502.61px" class="cls_031"><span class="cls_031">led possitivity for IgM kappa monoclonal protein. There were no</span></div>
<div style="position:absolute;left:50.01px;top:513.89px" class="cls_031"><span class="cls_031">population of 1969 patients with psoriasis is carried out, attended</span></div>
<div style="position:absolute;left:306.64px;top:512.61px" class="cls_031"><span class="cls_031">abnormalities in the bone marrow aspiration biopsy, no lympha-</span></div>
<div style="position:absolute;left:50.01px;top:523.89px" class="cls_031"><span class="cls_031">in the psoriasis sector of the dermatology service of Ramos Mejía</span></div>
<div style="position:absolute;left:306.64px;top:522.61px" class="cls_031"><span class="cls_031">denopathy was observed. She complained of general weakness</span></div>
<div style="position:absolute;left:50.01px;top:533.89px" class="cls_031"><span class="cls_031">Hospital in the period between January 2008 and January 2018.</span></div>
<div style="position:absolute;left:306.64px;top:532.61px" class="cls_031"><span class="cls_031">and polineuropathy. Analysis of spino-cerebral fluid showed type</span></div>
<div style="position:absolute;left:50.01px;top:543.89px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">We identified 56 patients who presented coexistence of</span></div>
<div style="position:absolute;left:306.64px;top:542.61px" class="cls_031"><span class="cls_031">V of oligoclonal band.</span></div>
<div style="position:absolute;left:50.01px;top:553.89px" class="cls_031"><span class="cls_031">oncological pathology and psoriasis of different severity: 38 se-</span></div>
<div style="position:absolute;left:306.64px;top:552.61px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> In 2017, after 2 years of TNFalpha inhibitor combi-</span></div>
<div style="position:absolute;left:50.00px;top:563.91px" class="cls_031"><span class="cls_031">vere, 14 moderate and 4 mild. The population was divided equally</span></div>
<div style="position:absolute;left:306.64px;top:562.61px" class="cls_031"><span class="cls_031">ned with methotrexate therapy, the diagnosis of Waldenstrom</span></div>
<div style="position:absolute;left:50.00px;top:573.90px" class="cls_031"><span class="cls_031">between both sexes. Of these 56 patients, 61 tumors were detected</span></div>
<div style="position:absolute;left:306.64px;top:572.61px" class="cls_031"><span class="cls_031">macroglobulinemia has been done. The patient presented with</span></div>
<div style="position:absolute;left:50.00px;top:583.90px" class="cls_031"><span class="cls_031">(non-melanoma skin cancer, solid tumors and lymphomas). The</span></div>
<div style="position:absolute;left:306.64px;top:582.61px" class="cls_031"><span class="cls_031">high ESR 103 and monoclonal IgM 33 g/l. Repeated aspiration</span></div>
<div style="position:absolute;left:50.00px;top:593.90px" class="cls_031"><span class="cls_031">oncological manifestations are the following: table 1.</span></div>
<div style="position:absolute;left:306.64px;top:592.61px" class="cls_031"><span class="cls_031">bone marrow biopsy showed 3% of plasmocytes and 21% of</span></div>
<div style="position:absolute;left:50.00px;top:603.90px" class="cls_031"><span class="cls_031">Table 1. Oncological manifestations Oncological manifestations</span></div>
<div style="position:absolute;left:306.64px;top:602.61px" class="cls_031"><span class="cls_031">lymphocytes.</span></div>
<div style="position:absolute;left:50.00px;top:613.90px" class="cls_031"><span class="cls_031">Tumor quantification Total % Cutaneous Squamous Cell Carci-</span></div>
<div style="position:absolute;left:306.64px;top:612.61px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> The patient started standard RCD chemotherapy</span></div>
<div style="position:absolute;left:50.00px;top:623.91px" class="cls_031"><span class="cls_031">noma 4 7% Basal Cell Carcinoma 12 20% Breast Cancer 9 15%</span></div>
<div style="position:absolute;left:306.64px;top:622.61px" class="cls_031"><span class="cls_031">regimen (rituximab, cyclophosphamide, dexamethason) with good</span></div>
<div style="position:absolute;left:50.00px;top:633.90px" class="cls_031"><span class="cls_031">Prostate Cancer 12 20% Thyroid Cancer 6 10% Endometrial</span></div>
<div style="position:absolute;left:306.64px;top:632.61px" class="cls_031"><span class="cls_031">clinical response to therapy.</span></div>
<div style="position:absolute;left:50.00px;top:643.90px" class="cls_031"><span class="cls_031">Cancer 3 5% Lung Cancer 1 2% Colon Cancer 4 7% Lymphoma</span></div>
<div style="position:absolute;left:50.00px;top:653.90px" class="cls_031"><span class="cls_031">No Hodgkin 1 2% Cervical Cancer 2 3% Kidney Cancer 1 2%</span></div>
<div style="position:absolute;left:306.64px;top:652.25px" class="cls_033"><span class="cls_033">P015</span></div>
<div style="position:absolute;left:50.00px;top:663.90px" class="cls_031"><span class="cls_031">Multiple Myeloma 1 2% Testicular Cancer 2 3% Tumoral Micosis</span></div>
<div style="position:absolute;left:306.64px;top:663.65px" class="cls_025"><span class="cls_025">THE RELATIONSHIP BETWEEN PSORIASIS,</span></div>
<div style="position:absolute;left:50.00px;top:673.90px" class="cls_031"><span class="cls_031">Fungoide 1 2% Acute Myeloid Leukemia 1 2% Bladder Cancer 1</span></div>
<div style="position:absolute;left:306.64px;top:674.55px" class="cls_025"><span class="cls_025">COMORBIDITIES, AND DEPRESSION ONSET: A</span></div>
<div style="position:absolute;left:50.00px;top:683.90px" class="cls_031"><span class="cls_031">2% TOTAL 61 100% The epidemiological analysis of this group</span></div>
<div style="position:absolute;left:306.64px;top:685.45px" class="cls_025"><span class="cls_025">NATIONWIDE OBSERVATIONAL CONTROL STUDY</span></div>
<div style="position:absolute;left:50.00px;top:693.90px" class="cls_031"><span class="cls_031">of patients showed an incidence for all types of malignancies of</span></div>
<div style="position:absolute;left:306.64px;top:695.35px" class="cls_051"><span class="cls_051">Kirk Geale</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Martin Henriksson</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Jussi Jokinen</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Marcus Schmitt-</span></div>
<div style="position:absolute;left:50.00px;top:703.90px" class="cls_031"><span class="cls_031">3.098% in this population. The diagnosis of psoriasis preceded the</span></div>
<div style="position:absolute;left:306.63px;top:705.25px" class="cls_026"><span class="cls_026">Egenolf</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:50.00px;top:713.90px" class="cls_031"><span class="cls_031">oncological diagnosis in 50 of the patients studied.</span></div>
<div style="position:absolute;left:306.64px;top:715.85px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Dermatology, Department of Public Health and Clinical Medicine, Umeå</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:8030px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background12.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">10</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.85px" class="cls_029"><span class="cls_029">University, Umeå, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Medical and Health Sciences, Linköping</span></div>
<div style="position:absolute;left:306.53px;top:51.41px" class="cls_031"><span class="cls_031">75) response after 12 weeks. The secondary outcomes included</span></div>
<div style="position:absolute;left:50.00px;top:61.47px" class="cls_029"><span class="cls_029">University, Linköping, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Department of Clinical Neuroscience, Karolinska</span></div>
<div style="position:absolute;left:306.53px;top:61.42px" class="cls_031"><span class="cls_031">PASI 75 at week 6 (onset of action) and week 12, Investigator’s</span></div>
<div style="position:absolute;left:50.00px;top:71.09px" class="cls_029"><span class="cls_029">Institutet, Stockholm, Sweden</span></div>
<div style="position:absolute;left:306.53px;top:71.44px" class="cls_031"><span class="cls_031">Global Assessment (IGA), Patient Global Assessment, impact on</span></div>
<div style="position:absolute;left:50.00px;top:81.98px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Psoriasis is a complex, systemic disease associated</span></div>
<div style="position:absolute;left:306.53px;top:81.46px" class="cls_031"><span class="cls_031">quality of life (Skindex-17 and SF-36), Treatment Satisfaction</span></div>
<div style="position:absolute;left:50.00px;top:92.00px" class="cls_031"><span class="cls_031">with comorbidities extending beyond the skin, often affecting</span></div>
<div style="position:absolute;left:306.53px;top:91.47px" class="cls_031"><span class="cls_031">Questionnaire of Medication, duration of remission, maintenance</span></div>
<div style="position:absolute;left:50.00px;top:102.01px" class="cls_031"><span class="cls_031">psychological well-being which may manifest as clinical depres-</span></div>
<div style="position:absolute;left:306.53px;top:101.49px" class="cls_031"><span class="cls_031">treatment and safety.</span></div>
<div style="position:absolute;left:50.00px;top:112.04px" class="cls_031"><span class="cls_031">sion. Psoriasis can be viewed narrowly by focusing on the skin,</span></div>
<div style="position:absolute;left:306.53px;top:111.51px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> In the study group, 86.9% (20 out of 23 patients) reached</span></div>
<div style="position:absolute;left:50.00px;top:122.06px" class="cls_031"><span class="cls_031">or holistically to include associated comorbidities. To date, the</span></div>
<div style="position:absolute;left:306.53px;top:121.52px" class="cls_031"><span class="cls_031">PASI-75 at week 12. The longitudinal analysis showed a PASI</span></div>
<div style="position:absolute;left:50.00px;top:132.07px" class="cls_031"><span class="cls_031">complex interplay between psoriasis, comorbidities, and depres-</span></div>
<div style="position:absolute;left:306.53px;top:131.54px" class="cls_031"><span class="cls_031">reduction of 6.42% per week. The onset of action was achieved</span></div>
<div style="position:absolute;left:50.00px;top:142.10px" class="cls_031"><span class="cls_031">sion has not been adequately described, and an innovative approach</span></div>
<div style="position:absolute;left:306.53px;top:141.56px" class="cls_031"><span class="cls_031">in 65.2%. At week 12, IGA ‘clear or almost clear’ was observed</span></div>
<div style="position:absolute;left:50.00px;top:152.11px" class="cls_031"><span class="cls_031">is necessary to understand interrelationship between them.</span></div>
<div style="position:absolute;left:306.53px;top:151.58px" class="cls_031"><span class="cls_031">in 91.3% (</span><span class="cls_030">p &lt; </span><span class="cls_031">0·01). Skindex-17 symptom score was significant</span></div>
<div style="position:absolute;left:50.00px;top:162.13px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">Calculate incidence rates of depression in psoriasis</span></div>
<div style="position:absolute;left:306.53px;top:161.59px" class="cls_031"><span class="cls_031">with combination therapy (</span><span class="cls_030">p &lt; </span><span class="cls_031">0·01). Maintenance treatment ac-</span></div>
<div style="position:absolute;left:50.00px;top:172.15px" class="cls_031"><span class="cls_031">patients compared to the general population and subsequently ex-</span></div>
<div style="position:absolute;left:306.53px;top:171.61px" class="cls_031"><span class="cls_031">hieved PASI 75 for 82.6% (</span><span class="cls_030">p &lt; </span><span class="cls_031">0·01). Mild adverse events were</span></div>
<div style="position:absolute;left:50.00px;top:182.18px" class="cls_031"><span class="cls_031">plore the risk factors associated with depression onset. Determine</span></div>
<div style="position:absolute;left:306.53px;top:181.63px" class="cls_031"><span class="cls_031">reported in 79.5%.</span></div>
<div style="position:absolute;left:50.00px;top:192.19px" class="cls_031"><span class="cls_031">the contributions of comorbidities compared to narrowly defined,</span></div>
<div style="position:absolute;left:306.53px;top:191.65px" class="cls_030"><span class="cls_030">Conclusion:</span><span class="cls_031"> Combination therapy of adalimumab plus methotrex-</span></div>
<div style="position:absolute;left:50.00px;top:202.21px" class="cls_031"><span class="cls_031">psoriasis-only symptoms.</span></div>
<div style="position:absolute;left:306.53px;top:201.66px" class="cls_031"><span class="cls_031">ate is a highly effective, well-tolerated, maintenance therapy in</span></div>
<div style="position:absolute;left:50.00px;top:212.23px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> 96,666 psoriasis patients were matched to 15 controls</span></div>
<div style="position:absolute;left:306.53px;top:211.68px" class="cls_031"><span class="cls_031">patients with moderate to severe plaque psoriasis.</span></div>
<div style="position:absolute;left:50.00px;top:222.24px" class="cls_031"><span class="cls_031">and followed from psoriasis onset until incident depression di-</span></div>
<div style="position:absolute;left:306.53px;top:221.70px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.00px;top:232.28px" class="cls_031"><span class="cls_031">agnosis or censoring using population-based routine care data.</span></div>
<div style="position:absolute;left:306.53px;top:231.73px" class="cls_032"><span class="cls_032">1. Mease P, Hall S, FitzGerald O et al. Tofacitinib or Adalimumab versus</span></div>
<div style="position:absolute;left:306.53px;top:240.75px" class="cls_032"><span class="cls_032">Placebo for Psoriatic Arthritis. N Engl J Med 2017 Oct 19. 377;1537-1550.</span></div>
<div style="position:absolute;left:50.00px;top:242.29px" class="cls_031"><span class="cls_031">Incidence of depression was calculated using Poisson regres-</span></div>
<div style="position:absolute;left:306.53px;top:249.76px" class="cls_032"><span class="cls_032">2. Papp K, Bachelez H, Costanzo A et al. Clinical similarity of biosimilar</span></div>
<div style="position:absolute;left:50.00px;top:252.32px" class="cls_031"><span class="cls_031">sion models. Risk of depression onset using a narrow definition</span></div>
<div style="position:absolute;left:306.53px;top:258.78px" class="cls_032"><span class="cls_032">ABP 501 to adalimumab in the treatment of patients with moderate to</span></div>
<div style="position:absolute;left:50.00px;top:262.33px" class="cls_031"><span class="cls_031">of psoriasis was compared to a holistic definition including all</span></div>
<div style="position:absolute;left:306.53px;top:267.80px" class="cls_032"><span class="cls_032">severe plaque psoriasis: A randomized, double-blind, multicenter, phase</span></div>
<div style="position:absolute;left:49.99px;top:272.35px" class="cls_031"><span class="cls_031">comorbidities using a Cox proportional hazards model, with ad-</span></div>
<div style="position:absolute;left:306.53px;top:276.81px" class="cls_032"><span class="cls_032">III study. J Am Acad Dermatol 2017 Jun. 1976;1093-1102.</span></div>
<div style="position:absolute;left:50.00px;top:282.37px" class="cls_031"><span class="cls_031">ditional adjustment for sociodemographic factors. Comorbidities</span></div>
<div style="position:absolute;left:50.00px;top:292.39px" class="cls_031"><span class="cls_031">were represented by ICD chapters with more than 5% correlation</span></div>
<div style="position:absolute;left:306.53px;top:294.45px" class="cls_033"><span class="cls_033">P018</span></div>
<div style="position:absolute;left:50.00px;top:302.41px" class="cls_031"><span class="cls_031">with psoriasis. Sensitivity analysis examined the role of psoriatic</span></div>
<div style="position:absolute;left:306.53px;top:305.87px" class="cls_025"><span class="cls_025">ATTAINMENT OF REMISSION AND MINIMAL DISEASE</span></div>
<div style="position:absolute;left:50.00px;top:312.43px" class="cls_031"><span class="cls_031">arthropathy, alternative depression definitions, and searched for</span></div>
<div style="position:absolute;left:306.53px;top:316.79px" class="cls_025"><span class="cls_025">ACTIVITY AFTER STARTING METHOTREXATE</span></div>
<div style="position:absolute;left:50.01px;top:322.44px" class="cls_031"><span class="cls_031">unobserved confounding.</span></div>
<div style="position:absolute;left:306.53px;top:327.71px" class="cls_025"><span class="cls_025">SUBCUTANEOUS THERAPY</span></div>
<div style="position:absolute;left:50.01px;top:332.46px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Patients with psoriasis have a higher incidence of clinical</span></div>
<div style="position:absolute;left:306.53px;top:337.62px" class="cls_051"><span class="cls_051">Elena Loginova</span><span class="cls_026">, Tatiana Korotaeva, Elena Gubar, Svetlana Gluk-</span></div>
<div style="position:absolute;left:50.01px;top:342.48px" class="cls_031"><span class="cls_031">depression than those without the disease. Holistically, psoriasis</span></div>
<div style="position:absolute;left:306.53px;top:347.54px" class="cls_026"><span class="cls_026">hova, Eugeny Nasonov</span></div>
<div style="position:absolute;left:50.01px;top:352.49px" class="cls_031"><span class="cls_031">was associated with an increased risk of depression onset of 40%</span></div>
<div style="position:absolute;left:306.53px;top:358.16px" class="cls_029"><span class="cls_029">Nasonova Research Institute of Rheumatology, Moscow</span></div>
<div style="position:absolute;left:50.01px;top:362.51px" class="cls_031"><span class="cls_031">(HR</span><span class="cls_030"> = </span><span class="cls_031">1.404, </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001), compared to 12% increase (HR</span><span class="cls_030"> = </span><span class="cls_031">1.115,</span></div>
<div style="position:absolute;left:306.53px;top:368.95px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Methotrexate (MTX) is the first-choice therapy in</span></div>
<div style="position:absolute;left:50.01px;top:372.53px" class="cls_030"><span class="cls_030">p &lt; </span><span class="cls_031">0.001) when narrowly defined. The proportional hazards as-</span></div>
<div style="position:absolute;left:306.53px;top:378.88px" class="cls_031"><span class="cls_031">psoriatic arthritis (PsA). There is limited data concerning efficacy</span></div>
<div style="position:absolute;left:50.00px;top:382.57px" class="cls_031"><span class="cls_031">sumption appeared to hold in each survival analysis. A substantial</span></div>
<div style="position:absolute;left:306.51px;top:388.80px" class="cls_031"><span class="cls_031">of early administration and rapidly dose escalation of MTX sub-</span></div>
<div style="position:absolute;left:50.00px;top:392.59px" class="cls_031"><span class="cls_031">portion, but not all, of psoriasis patients’ risk of depression onset</span></div>
<div style="position:absolute;left:306.53px;top:398.73px" class="cls_031"><span class="cls_031">cutaneous (s/c) in early (E) PsA patients (pts).</span></div>
<div style="position:absolute;left:50.00px;top:402.61px" class="cls_031"><span class="cls_031">was attributable to comorbidities, and sociodemographic factors</span></div>
<div style="position:absolute;left:306.53px;top:408.66px" class="cls_030"><span class="cls_030">Objective: </span><span class="cls_031">to study attainment of remission (REM) or minimal</span></div>
<div style="position:absolute;left:50.00px;top:412.62px" class="cls_031"><span class="cls_031">did not appear to affect the estimates of association between</span></div>
<div style="position:absolute;left:306.53px;top:418.59px" class="cls_031"><span class="cls_031">disease activity (MDA) after starting MTX s/c therapy in EPsA</span></div>
<div style="position:absolute;left:50.00px;top:422.64px" class="cls_031"><span class="cls_031">depression and psoriasis. Major differences were found between</span></div>
<div style="position:absolute;left:306.53px;top:428.51px" class="cls_031"><span class="cls_031">pts treated according to treat-to-target (T2T) strategy.</span></div>
<div style="position:absolute;left:50.00px;top:432.66px" class="cls_031"><span class="cls_031">antidepressant- and diagnosis-based definitions of depression,</span></div>
<div style="position:absolute;left:306.53px;top:438.44px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">77 (M-37/F-40) pts with active EPsA, according to the</span></div>
<div style="position:absolute;left:50.01px;top:442.67px" class="cls_031"><span class="cls_031">while inclusion of psoriatic arthropathy did not affect the results.</span></div>
<div style="position:absolute;left:306.53px;top:448.37px" class="cls_031"><span class="cls_031">CASPAR criteria were included. Mean age 37.4</span><span class="cls_035">±</span><span class="cls_031">10.8 years (yrs.),</span></div>
<div style="position:absolute;left:50.01px;top:452.69px" class="cls_031"><span class="cls_031">No unmeasured confounding was identified.</span></div>
<div style="position:absolute;left:306.53px;top:458.30px" class="cls_031"><span class="cls_031">PsA duration 11</span><span class="cls_035">±</span><span class="cls_031">10 months (mon.), psoriasis duration 86</span><span class="cls_035">±</span><span class="cls_031">96.1</span></div>
<div style="position:absolute;left:50.01px;top:462.71px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> Due to the elevated risk of depression in psoriasis</span></div>
<div style="position:absolute;left:306.52px;top:468.22px" class="cls_031"><span class="cls_031">mon., DAPSA 32.45</span><span class="cls_035">±</span><span class="cls_031">12.7. At baseline all pts started MTX s/c</span></div>
<div style="position:absolute;left:50.01px;top:472.73px" class="cls_031"><span class="cls_031">patients, treating physicians should ensure patients’ psychologi-</span></div>
<div style="position:absolute;left:306.53px;top:478.15px" class="cls_031"><span class="cls_031">therapy. The dose of MTX s/c was escalated by 5 mg every 2</span></div>
<div style="position:absolute;left:50.00px;top:482.77px" class="cls_031"><span class="cls_031">cal well-being is addressed, especially in those presenting with</span></div>
<div style="position:absolute;left:306.53px;top:488.08px" class="cls_031"><span class="cls_031">weeks from 10 mg/wk to appropriate dose 20-25 mg/wk according</span></div>
<div style="position:absolute;left:50.00px;top:492.79px" class="cls_031"><span class="cls_031">additional risk factors, to break the cyclical relationship between</span></div>
<div style="position:absolute;left:306.53px;top:498.00px" class="cls_031"><span class="cls_031">to the drug intolerance. If the patient did not achieve remission</span></div>
<div style="position:absolute;left:50.00px;top:502.80px" class="cls_031"><span class="cls_031">depression and psoriasis and improve patients’ quality of life.</span></div>
<div style="position:absolute;left:306.53px;top:507.93px" class="cls_031"><span class="cls_031">or MDA on MTX mono-therapy, biological (b)DMARDs was</span></div>
<div style="position:absolute;left:50.00px;top:512.82px" class="cls_031"><span class="cls_031">Contemporary, holistic management of psoriasis patients should</span></div>
<div style="position:absolute;left:306.53px;top:517.86px" class="cls_031"><span class="cls_031">added. At baseline and every 3 mon. of study (till 24 mon.) all</span></div>
<div style="position:absolute;left:50.00px;top:522.84px" class="cls_031"><span class="cls_031">encourage routine screening for depression.</span></div>
<div style="position:absolute;left:306.53px;top:527.79px" class="cls_031"><span class="cls_031">pts underwent assessment of PsA activity by DAPSA and MDA</span></div>
<div style="position:absolute;left:306.53px;top:537.71px" class="cls_031"><span class="cls_031">criteria (tender joint count</span><span class="cls_030"> ≤ </span><span class="cls_031">1, swollen joint count</span><span class="cls_030"> ≤ </span><span class="cls_031">1, PASI</span><span class="cls_030"> ≤ </span><span class="cls_031">1 or</span></div>
<div style="position:absolute;left:50.00px;top:541.50px" class="cls_033"><span class="cls_033">P016</span></div>
<div style="position:absolute;left:306.53px;top:547.64px" class="cls_031"><span class="cls_031">BSA</span><span class="cls_030"> ≤ </span><span class="cls_031">3, patient pain global assessment VAS</span><span class="cls_030"> ≤ </span><span class="cls_031">15, patient´s global</span></div>
<div style="position:absolute;left:50.00px;top:552.92px" class="cls_025"><span class="cls_025">EFFICACY OF ADALIMUMAB PLUS METHOTREXATE</span></div>
<div style="position:absolute;left:306.53px;top:557.57px" class="cls_031"><span class="cls_031">disease activity VAS</span><span class="cls_030"> ≤ </span><span class="cls_031">20, HAQ</span><span class="cls_030"> ≤ </span><span class="cls_031">0.5, enthesitis count</span><span class="cls_030"> ≤ </span><span class="cls_031">1). The</span></div>
<div style="position:absolute;left:50.00px;top:563.84px" class="cls_025"><span class="cls_025">IN PATIENTS WITH MODERATE TO SEVERE PLAQUE</span></div>
<div style="position:absolute;left:306.52px;top:567.49px" class="cls_031"><span class="cls_031">proportion of pts who achieved REM by DAPSA</span><span class="cls_030"> ≤ </span><span class="cls_031">4 and MDA (5</span></div>
<div style="position:absolute;left:50.00px;top:574.76px" class="cls_025"><span class="cls_025">PSORIASIS</span></div>
<div style="position:absolute;left:306.52px;top:577.42px" class="cls_031"><span class="cls_031">of 7 cutpoints), the timing of REM/MDA, the mean dose of MTX</span></div>
<div style="position:absolute;left:50.00px;top:584.67px" class="cls_026"><span class="cls_026">Ghasem Rahmatpour Rokni, </span><span class="cls_051">Mohamad Goldust</span></div>
<div style="position:absolute;left:306.52px;top:587.35px" class="cls_031"><span class="cls_031">during the study were performed. M</span><span class="cls_035">±</span><span class="cls_031">SD, Me [Q75; Q50], (%),</span></div>
<div style="position:absolute;left:50.00px;top:595.30px" class="cls_029"><span class="cls_029">Mazandaran University of Medical Sciences</span></div>
<div style="position:absolute;left:306.53px;top:597.28px" class="cls_031"><span class="cls_031">W-test were calculated. All </span><span class="cls_030">p &lt; </span><span class="cls_031">0.05 were considered to indicate</span></div>
<div style="position:absolute;left:50.00px;top:606.19px" class="cls_030"><span class="cls_030">Background:</span><span class="cls_031"> Adalimumab, a high-affinity monoclonal antibody</span></div>
<div style="position:absolute;left:306.53px;top:607.20px" class="cls_031"><span class="cls_031">statistical significance.</span></div>
<div style="position:absolute;left:49.99px;top:616.20px" class="cls_031"><span class="cls_031">that selectively targets tumor necrosis factor alpha, is efficacious</span></div>
<div style="position:absolute;left:306.53px;top:617.13px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> 36 out of 77 pts (46.75%) did not achieve REM or MDA in</span></div>
<div style="position:absolute;left:49.99px;top:626.22px" class="cls_031"><span class="cls_031">in treating moderate-to-severe plaque psoriasis. Currently there</span></div>
<div style="position:absolute;left:306.53px;top:627.06px" class="cls_031"><span class="cls_031">MTX therapy within 7</span><span class="cls_035">±</span><span class="cls_031">5 mon. and bDMARDs were added. 5 out</span></div>
<div style="position:absolute;left:49.99px;top:636.24px" class="cls_031"><span class="cls_031">are some reports regarding drug resistance to adalimumab (1,2).</span></div>
<div style="position:absolute;left:306.53px;top:636.99px" class="cls_031"><span class="cls_031">of 77 pts (6.5%) stopped MTX therapy due to intolerance within</span></div>
<div style="position:absolute;left:49.99px;top:646.26px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031"> This study aimed at evaluating the efficacy of ada-</span></div>
<div style="position:absolute;left:306.53px;top:646.91px" class="cls_031"><span class="cls_031">6</span><span class="cls_035">±</span><span class="cls_031">2 mon. 36 out of 77 pts (46.75%) went on taking MTX-mono-</span></div>
<div style="position:absolute;left:50.00px;top:656.29px" class="cls_031"><span class="cls_031">limumab plus methotrexate in patients with moderate to severe</span></div>
<div style="position:absolute;left:306.52px;top:656.84px" class="cls_031"><span class="cls_031">therapy. In 22 out of 36 pts, who had mean DAPSA 27.7</span><span class="cls_035">±</span><span class="cls_031">10.0 at</span></div>
<div style="position:absolute;left:50.00px;top:666.30px" class="cls_031"><span class="cls_031">plaque psoriasis.</span></div>
<div style="position:absolute;left:306.53px;top:666.77px" class="cls_031"><span class="cls_031">baseline, data was available by the 24 mon. of study. At baseline</span></div>
<div style="position:absolute;left:50.00px;top:676.32px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> In this cross sectional study, 23 patients suffering from</span></div>
<div style="position:absolute;left:306.53px;top:676.70px" class="cls_031"><span class="cls_031">median dose of MTX s/c was 15 [10;20], Min 10-Max 20 mg/</span></div>
<div style="position:absolute;left:50.00px;top:686.34px" class="cls_031"><span class="cls_031">moderate to severe psoriasis were recruited. Patients received</span></div>
<div style="position:absolute;left:306.53px;top:686.62px" class="cls_031"><span class="cls_031">wk. At the third mon. of study median dose of MTX s/c was</span></div>
<div style="position:absolute;left:50.00px;top:696.35px" class="cls_031"><span class="cls_031">adalimumab 80 mg week 0, 1 and then 40 mg every 2 weeks and</span></div>
<div style="position:absolute;left:306.53px;top:696.55px" class="cls_031"><span class="cls_031">escalated to 20 [20;20], Min 0-Max 25 mg/wk. After attainment</span></div>
<div style="position:absolute;left:50.00px;top:706.37px" class="cls_031"><span class="cls_031">methotrexate up to 25 mg/week. The primary outcome measure</span></div>
<div style="position:absolute;left:306.53px;top:706.48px" class="cls_031"><span class="cls_031">of REM/MDA the dose of MTX was decreased. At the end of the</span></div>
<div style="position:absolute;left:50.00px;top:716.39px" class="cls_031"><span class="cls_031">was the difference in Psoriasis area and severity index (PASI-</span></div>
<div style="position:absolute;left:306.53px;top:716.40px" class="cls_031"><span class="cls_031">study median dose of MTX s/c was 7.5 [0;15], Min 0-Max 20</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:8833px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background13.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">11</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">mg/wk (fig.1). After starting MTX disease activity by DAPSA</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">review of the safety database. Given the limited exposure repor-</span></div>
<div style="position:absolute;left:50.01px;top:61.40px" class="cls_031"><span class="cls_031">significantly decreased by the third mon. and maintained till the</span></div>
<div style="position:absolute;left:306.64px;top:61.41px" class="cls_031"><span class="cls_031">ted to date, the safe continuous use of secukinumab throughout</span></div>
<div style="position:absolute;left:50.02px;top:71.40px" class="cls_031"><span class="cls_031">end of the study (fig.2). DAPSA-REM and МDA was reached</span></div>
<div style="position:absolute;left:306.64px;top:71.40px" class="cls_031"><span class="cls_031">pregnancy requires further research.</span></div>
<div style="position:absolute;left:50.02px;top:81.40px" class="cls_031"><span class="cls_031">within 9.7</span><span class="cls_035">±</span><span class="cls_031">7.7 and 13.7</span><span class="cls_035">±</span><span class="cls_031">7.6 mon. accordingly. By the 24 mon.</span></div>
<div style="position:absolute;left:50.00px;top:91.40px" class="cls_031"><span class="cls_031">of therapy stable REM by DAPSA and MDA was seen in 10 out</span></div>
<div style="position:absolute;left:306.64px;top:91.04px" class="cls_033"><span class="cls_033">P020</span></div>
<div style="position:absolute;left:50.00px;top:101.40px" class="cls_031"><span class="cls_031">of 22 pts (45.5%) and in 16 out of 22 pts (72.7%) accordingly.</span></div>
<div style="position:absolute;left:306.64px;top:102.44px" class="cls_025"><span class="cls_025">IXEKIZUMAB IMPROVES IMPACT OF GENITAL</span></div>
<div style="position:absolute;left:50.00px;top:111.40px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> In half of EPsA pts early administration of MTX</span></div>
<div style="position:absolute;left:306.64px;top:113.34px" class="cls_025"><span class="cls_025">PSORIASIS ON SEXUAL ACTIVITY: RESULTS FROM A</span></div>
<div style="position:absolute;left:50.00px;top:121.40px" class="cls_031"><span class="cls_031">s/c and rapidly dose escalation is effective and well tolerated.</span></div>
<div style="position:absolute;left:306.64px;top:124.24px" class="cls_025"><span class="cls_025">PHASE 3B STUDY</span></div>
<div style="position:absolute;left:50.00px;top:131.40px" class="cls_031"><span class="cls_031">After achieving REM or MDA, a decrease of the dose of MTX is</span></div>
<div style="position:absolute;left:306.64px;top:134.14px" class="cls_026"><span class="cls_026">Jennifer Clay Cather</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Kim Meeuwis</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Russel Burge</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Alison Potts</span></div>
<div style="position:absolute;left:50.00px;top:141.40px" class="cls_031"><span class="cls_031">possible in most cases.</span></div>
<div style="position:absolute;left:306.63px;top:144.04px" class="cls_026"><span class="cls_026">Bleakman</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Chen-Yen Lin</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">,</span><span class="cls_051"> Alice Gottlieb</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Catriona Ryan</span><span class="cls_027"><sup>5</sup></span></div>
<div style="position:absolute;left:306.64px;top:154.64px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Modern Dermatology and Modern Research Associates, Dallas, TX, USA,</span></div>
<div style="position:absolute;left:50.00px;top:162.04px" class="cls_033"><span class="cls_033">P019</span></div>
<div style="position:absolute;left:306.64px;top:164.24px" class="cls_028"><span class="cls_028"><sup>2</sup></span><span class="cls_029">Radboud University Medical Center, Nijmegen, The Netherlands, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Eli Lilly</span></div>
<div style="position:absolute;left:50.00px;top:173.44px" class="cls_025"><span class="cls_025">SECUKINUMAB IN PREGNANCY: OUTCOMES IN</span></div>
<div style="position:absolute;left:306.64px;top:173.84px" class="cls_029"><span class="cls_029">and Company, Indianapolis, IN, USA, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Department of Dermatology, New</span></div>
<div style="position:absolute;left:50.00px;top:184.34px" class="cls_025"><span class="cls_025">PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING</span></div>
<div style="position:absolute;left:306.64px;top:183.44px" class="cls_029"><span class="cls_029">York Medical College at Metropolitan Hospital, New York, NY, USA, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">St.</span></div>
<div style="position:absolute;left:306.64px;top:193.04px" class="cls_029"><span class="cls_029">Vincent’s University Hospital, Dublin, Ireland</span></div>
<div style="position:absolute;left:50.00px;top:195.24px" class="cls_025"><span class="cls_025">SPONDYLITIS FROM THE GLOBAL SAFETY</span></div>
<div style="position:absolute;left:50.00px;top:206.14px" class="cls_025"><span class="cls_025">DATABASE</span></div>
<div style="position:absolute;left:306.64px;top:203.91px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Genital psoriasis (GP) is often associated with impai-</span></div>
<div style="position:absolute;left:50.00px;top:216.04px" class="cls_026"><span class="cls_026">Richard Warren</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Kristian Reich</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Richard Langley</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Bruce Strob-</span></div>
<div style="position:absolute;left:306.64px;top:213.91px" class="cls_031"><span class="cls_031">red sexual health. Ixekizumab (IXE) is a high-affinity monoclonal</span></div>
<div style="position:absolute;left:49.99px;top:225.94px" class="cls_026"><span class="cls_026">er</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, </span><span class="cls_051">Dafna Gladman</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Atul Deodhar</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Teresa Bachhuber</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Weibin</span></div>
<div style="position:absolute;left:306.66px;top:223.90px" class="cls_031"><span class="cls_031">antibody that selectively targets interleukin-17A.</span></div>
<div style="position:absolute;left:49.99px;top:235.84px" class="cls_026"><span class="cls_026">Bao</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, Evelyn Altemeyer</span><span class="cls_027"><sup>9</sup></span><span class="cls_026">, Samina Hussain</span><span class="cls_027"><sup>10</sup></span><span class="cls_026">, Jorge Safi</span><span class="cls_027"><sup>8</sup></span></div>
<div style="position:absolute;left:306.66px;top:233.90px" class="cls_030"><span class="cls_030">Objective: </span><span class="cls_031">To evaluate the effect of IXE on the impact of GP on</span></div>
<div style="position:absolute;left:50.00px;top:246.44px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">The Dermatology Centre, Salford Royal NHS Foundation Trust, The Uni-</span></div>
<div style="position:absolute;left:306.66px;top:243.90px" class="cls_031"><span class="cls_031">sexual activity during 12 weeks of treatment compared to placebo</span></div>
<div style="position:absolute;left:50.00px;top:256.04px" class="cls_029"><span class="cls_029">versity of Manchester, UK, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Dermatologikum Berlin and Georg-August-</span></div>
<div style="position:absolute;left:306.66px;top:253.90px" class="cls_031"><span class="cls_031">(PBO) in patients with moderate-to-severe GP.</span></div>
<div style="position:absolute;left:50.00px;top:265.64px" class="cls_029"><span class="cls_029">University Gottingen, Germany, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Dalhousie University, Halifax NS, Can-</span></div>
<div style="position:absolute;left:306.66px;top:263.90px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">In this double-blind, placebo-controlled study, patients</span></div>
<div style="position:absolute;left:50.00px;top:275.24px" class="cls_029"><span class="cls_029">ada, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">University of Connecticut Health Center, Farmington, CT, USA and</span></div>
<div style="position:absolute;left:306.66px;top:273.90px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">n = </span><span class="cls_031">149) with moderate-to-severe GP were randomized (1:1) to</span></div>
<div style="position:absolute;left:50.00px;top:284.84px" class="cls_029"><span class="cls_029">Probity Medical Research, Canada, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Toronto Western Hospital, Toronto,</span></div>
<div style="position:absolute;left:306.66px;top:283.90px" class="cls_031"><span class="cls_031">receive PBO or 80 mg IXE every 2 weeks following an initial</span></div>
<div style="position:absolute;left:50.00px;top:294.44px" class="cls_029"><span class="cls_029">Canada, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Division of Arthritis & Rheumatic Diseases, Oregon Health &</span></div>
<div style="position:absolute;left:306.66px;top:293.90px" class="cls_031"><span class="cls_031">dose of PBO or 160 mg IXE. The impact of GP on sexual activity</span></div>
<div style="position:absolute;left:50.00px;top:304.04px" class="cls_029"><span class="cls_029">Science University, USA, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Novartis Pharma GmbH, Nuremberg, Germany,</span></div>
<div style="position:absolute;left:306.66px;top:303.90px" class="cls_031"><span class="cls_031">was measured by pre-specified patient-reported outcomes inclu-</span></div>
<div style="position:absolute;left:50.00px;top:313.64px" class="cls_028"><span class="cls_028"><sup>8</sup></span><span class="cls_029">Novartis Pharmaceuticals Corporation, East Hanover, USA, </span><span class="cls_028"><sup>9</sup></span><span class="cls_029">Novartis Ire-</span></div>
<div style="position:absolute;left:306.64px;top:313.91px" class="cls_031"><span class="cls_031">ding the Genital Psoriasis Sexual Impact Scale (GPSIS), which</span></div>
<div style="position:absolute;left:50.00px;top:323.24px" class="cls_029"><span class="cls_029">land Ltd, Dublin, Ireland, </span><span class="cls_028"><sup>10</sup></span><span class="cls_029">Novartis Healthcare Pvt. Ltd, Hyderabad, India</span></div>
<div style="position:absolute;left:306.64px;top:323.90px" class="cls_031"><span class="cls_031">is composed of the Sexual Activity Avoidance (Avoidance) and</span></div>
<div style="position:absolute;left:50.00px;top:334.11px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Secukinumab, a fully human monoclonal antibody</span></div>
<div style="position:absolute;left:306.64px;top:333.90px" class="cls_031"><span class="cls_031">Impact of Sexual Activity on Genital Psoriasis Symptoms (Impact)</span></div>
<div style="position:absolute;left:50.00px;top:344.10px" class="cls_031"><span class="cls_031">selectively targeting IL-17A, is highly efficacious in the treatment</span></div>
<div style="position:absolute;left:306.64px;top:343.90px" class="cls_031"><span class="cls_031">subscales, the Sexual Frequency Questionnaire (SFQ) item 2, and</span></div>
<div style="position:absolute;left:50.01px;top:354.10px" class="cls_031"><span class="cls_031">of moderate to severe psoriasis, psoriatic arthritis (PsA) and an-</span></div>
<div style="position:absolute;left:306.64px;top:353.90px" class="cls_031"><span class="cls_031">the Dermatology Life Quality Index (DLQI) item 9. Of patients</span></div>
<div style="position:absolute;left:50.00px;top:364.11px" class="cls_031"><span class="cls_031">kylosing spondylitis (AS), with sustained efficacy and favorable</span></div>
<div style="position:absolute;left:306.64px;top:363.90px" class="cls_031"><span class="cls_031">with a baseline SFQ item 2 score ≥2, the percentage of patients</span></div>
<div style="position:absolute;left:49.98px;top:374.10px" class="cls_031"><span class="cls_031">safety profile. Long term treatment with targeted therapies such</span></div>
<div style="position:absolute;left:306.63px;top:373.90px" class="cls_031"><span class="cls_031">whose frequency of sexual activity was never (0) or rarely (1)</span></div>
<div style="position:absolute;left:49.98px;top:384.10px" class="cls_031"><span class="cls_031">as secukinumab may be necessary in women of childbearing</span></div>
<div style="position:absolute;left:306.63px;top:383.90px" class="cls_031"><span class="cls_031">limited by GP (SFQ item 2 0/1) was examined. Among patients</span></div>
<div style="position:absolute;left:49.98px;top:394.10px" class="cls_031"><span class="cls_031">age. Pre-clinical animal studies with secukinumab, which can</span></div>
<div style="position:absolute;left:306.63px;top:393.90px" class="cls_031"><span class="cls_031">with respective GPSIS subscale scores ≥3 at baseline, response</span></div>
<div style="position:absolute;left:49.98px;top:404.10px" class="cls_031"><span class="cls_031">cross the placenta, do not indicate harmful effects with respect to</span></div>
<div style="position:absolute;left:306.63px;top:403.90px" class="cls_031"><span class="cls_031">was measured as the percentage of patients whose frequency of</span></div>
<div style="position:absolute;left:49.98px;top:414.10px" class="cls_031"><span class="cls_031">pregnancy, embryonic/fetal development, parturition or postnatal</span></div>
<div style="position:absolute;left:306.63px;top:413.90px" class="cls_031"><span class="cls_031">avoiding sexual activity was never (1) or rarely (2) impacted by GP</span></div>
<div style="position:absolute;left:49.98px;top:424.10px" class="cls_031"><span class="cls_031">development, however only limited data has been reported on</span></div>
<div style="position:absolute;left:306.63px;top:423.89px" class="cls_031"><span class="cls_031">(GPSIS-Avoidance 1/2) and whose GP symptom worsening after</span></div>
<div style="position:absolute;left:49.98px;top:434.10px" class="cls_031"><span class="cls_031">human pregnancies.</span></div>
<div style="position:absolute;left:306.63px;top:433.89px" class="cls_031"><span class="cls_031">sexual activity was very low/none at all (1) or low (2) (GPSIS-</span></div>
<div style="position:absolute;left:49.98px;top:444.10px" class="cls_031"><span class="cls_031">Objectives: Using the Novartis global safety database, we analyzed</span></div>
<div style="position:absolute;left:306.63px;top:443.89px" class="cls_031"><span class="cls_031">Impact 1/2). DLQI item 9 response was measured as the percentage</span></div>
<div style="position:absolute;left:49.98px;top:454.10px" class="cls_031"><span class="cls_031">the outcome of pregnancies where there was maternal or paternal</span></div>
<div style="position:absolute;left:306.63px;top:453.89px" class="cls_031"><span class="cls_031">of patients with no (0) or a little (1) impairment of sexual activity.</span></div>
<div style="position:absolute;left:49.98px;top:464.10px" class="cls_031"><span class="cls_031">exposure to secukinumab.</span></div>
<div style="position:absolute;left:306.63px;top:463.89px" class="cls_031"><span class="cls_031">Treatment comparisons were made using a logistic regression</span></div>
<div style="position:absolute;left:49.98px;top:474.09px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">The Novartis global safety database (covering all</span></div>
<div style="position:absolute;left:306.63px;top:473.89px" class="cls_031"><span class="cls_031">model with missing values imputed by non-responder imputation.</span></div>
<div style="position:absolute;left:49.98px;top:484.09px" class="cls_031"><span class="cls_031">secukinumab indications and including clinical trial and post-</span></div>
<div style="position:absolute;left:306.63px;top:483.89px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> IXE treatment reduced the impact of GP on sexual activity</span></div>
<div style="position:absolute;left:49.98px;top:494.09px" class="cls_031"><span class="cls_031">marketing data) was searched for cases reporting pregnancy and</span></div>
<div style="position:absolute;left:306.63px;top:493.89px" class="cls_031"><span class="cls_031">at Week 12 versus PBO as assessed by SFQ item 2 0/1 (IXE 78.4%,</span></div>
<div style="position:absolute;left:49.98px;top:504.09px" class="cls_031"><span class="cls_031">neonatal topics. All pregnancies where there was either maternal</span></div>
<div style="position:absolute;left:306.63px;top:503.89px" class="cls_031"><span class="cls_031">PBO 21.4%; </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001), GPSIS-Avoidance 1/2 (IXE 76.7%, PBO</span></div>
<div style="position:absolute;left:49.98px;top:514.09px" class="cls_031"><span class="cls_031">or paternal exposure to secukinumab were included in the sys-</span></div>
<div style="position:absolute;left:306.63px;top:513.89px" class="cls_031"><span class="cls_031">25.7%; </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001), and DLQI item 9 0/1 (IXE 92.0%, PBO 56.8%;</span></div>
<div style="position:absolute;left:50.00px;top:524.11px" class="cls_031"><span class="cls_031">tematic, independently validated analysis. The cut-off date was</span></div>
<div style="position:absolute;left:306.63px;top:523.88px" class="cls_030"><span class="cls_030">p &lt; </span><span class="cls_031">0.001). IXE was superior to PBO as early as Week 1 for SFQ</span></div>
<div style="position:absolute;left:50.00px;top:534.10px" class="cls_031"><span class="cls_031">25th June, 2017.</span></div>
<div style="position:absolute;left:306.63px;top:533.88px" class="cls_031"><span class="cls_031">item 2 0/1 (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.05), Week 2 for DLQI item 9 0/1 (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001),</span></div>
<div style="position:absolute;left:50.00px;top:544.10px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Of 292 pregnancies reported, 141 (48.3%) came from</span></div>
<div style="position:absolute;left:306.63px;top:543.88px" class="cls_031"><span class="cls_031">and Week 4 for GPSIS-Avoidance 1/2 (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.01). GPSIS-Impact</span></div>
<div style="position:absolute;left:50.00px;top:554.10px" class="cls_031"><span class="cls_031">clinical trials, 79 (27.1%) were spontaneous reports and 72</span></div>
<div style="position:absolute;left:306.63px;top:553.88px" class="cls_031"><span class="cls_031">1/2 response rates suggested a trend of reduced impact of sexual</span></div>
<div style="position:absolute;left:50.00px;top:564.10px" class="cls_031"><span class="cls_031">(24.7%) were from post-marketing surveillance, with 238 cases</span></div>
<div style="position:absolute;left:306.63px;top:563.88px" class="cls_031"><span class="cls_031">activity on GP symptoms (IXE 85.7%, PBO 52.9%; </span><span class="cls_030">p = </span><span class="cls_031">0.062).</span></div>
<div style="position:absolute;left:50.00px;top:574.10px" class="cls_031"><span class="cls_031">of maternal and 54 cases of paternal exposure. 175 patients recei-</span></div>
<div style="position:absolute;left:306.63px;top:573.88px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">During 12 weeks of treatment, IXE resulted in a rapid</span></div>
<div style="position:absolute;left:50.00px;top:584.11px" class="cls_031"><span class="cls_031">ved secukinumab for psoriasis, 38 for PsA, 15 for AS and 62 for</span></div>
<div style="position:absolute;left:306.63px;top:583.88px" class="cls_031"><span class="cls_031">and significant decrease in the impact of GP on sexual activity,</span></div>
<div style="position:absolute;left:50.00px;top:594.10px" class="cls_031"><span class="cls_031">other/unknown indications. The majority of patients discontinued</span></div>
<div style="position:absolute;left:306.63px;top:593.88px" class="cls_031"><span class="cls_031">including how often GP limited sexual frequency among patients</span></div>
<div style="position:absolute;left:50.00px;top:604.10px" class="cls_031"><span class="cls_031">secukinumab in the first trimester of pregnancy; 18 did not discon-</span></div>
<div style="position:absolute;left:306.63px;top:603.88px" class="cls_031"><span class="cls_031">with moderate-to-severe GP.</span></div>
<div style="position:absolute;left:50.00px;top:614.11px" class="cls_031"><span class="cls_031">tinue. Of 153 cases where the outcome was known, there were 73</span></div>
<div style="position:absolute;left:306.64px;top:613.92px" class="cls_032"><span class="cls_032">Cather J, Meeuwis K, Burge R, Bleakman AP, Lin C-Y, Ryan C. Ixeki-</span></div>
<div style="position:absolute;left:50.00px;top:624.10px" class="cls_031"><span class="cls_031">full term normal neonates and 37 elective terminations. Rates of</span></div>
<div style="position:absolute;left:306.64px;top:622.92px" class="cls_032"><span class="cls_032">zumab Provides Greater Improvement Versus Placebo on the Impact of</span></div>
<div style="position:absolute;left:306.64px;top:631.92px" class="cls_032"><span class="cls_032">Genital Psoriasis on Sexual Activity for Patients with Moderate-to-Severe</span></div>
<div style="position:absolute;left:50.00px;top:634.10px" class="cls_031"><span class="cls_031">spontaneous abortions were 30/292, 10.3% overall (30/153 known</span></div>
<div style="position:absolute;left:306.64px;top:640.92px" class="cls_032"><span class="cls_032">Genital Psoriasis in a Randomized, Double-Blind Phase 3b Clinical Trial.</span></div>
<div style="position:absolute;left:50.00px;top:644.10px" class="cls_031"><span class="cls_031">outcomes, 19.6%). These are in line with previously reported rates</span></div>
<div style="position:absolute;left:306.64px;top:649.92px" class="cls_032"><span class="cls_032">American Academy of Dermatology-76th Annual Meeting 2018.</span></div>
<div style="position:absolute;left:50.00px;top:654.10px" class="cls_031"><span class="cls_031">(15-20%) for the general population with maternal age of 30.6</span></div>
<div style="position:absolute;left:50.00px;top:664.10px" class="cls_031"><span class="cls_031">(study mean). No still births (</span><span class="cls_030"> > </span><span class="cls_031">20 weeks) were reported. Three</span></div>
<div style="position:absolute;left:306.64px;top:668.54px" class="cls_033"><span class="cls_033">P021</span></div>
<div style="position:absolute;left:50.00px;top:674.10px" class="cls_031"><span class="cls_031">congenital abnormalities were reported following maternal and</span></div>
<div style="position:absolute;left:306.64px;top:679.94px" class="cls_025"><span class="cls_025">DOSE OPTIMIZATION OF SECUKINUMAB IN</span></div>
<div style="position:absolute;left:50.00px;top:684.10px" class="cls_031"><span class="cls_031">1 paternal exposure, with no repeated pattern of abnormality. At</span></div>
<div style="position:absolute;left:306.64px;top:690.84px" class="cls_025"><span class="cls_025">SUBJECTS WITH MODERATE TO SEVERE PLAQUE</span></div>
<div style="position:absolute;left:50.00px;top:694.10px" class="cls_031"><span class="cls_031">data cut-off, 32 pregnancies were ongoing.</span></div>
<div style="position:absolute;left:306.64px;top:701.74px" class="cls_025"><span class="cls_025">PSORIASIS: OPTIMISE STUDY</span></div>
<div style="position:absolute;left:50.00px;top:704.10px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> There was no evidence for increased rates of adverse</span></div>
<div style="position:absolute;left:306.64px;top:711.64px" class="cls_051"><span class="cls_051">Kristian Reich</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Lluis Puig</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Jacek Szepietowski</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Carle Paul</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:50.00px;top:714.10px" class="cls_031"><span class="cls_031">pregnancy outcomes across indications with secukinumab in this</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:9636px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background14.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">12</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.55px" class="cls_026"><span class="cls_026">Michael Rissler</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Christian Sieder</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Roberto Orsenigo</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Kamel</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">complications. Interferon-gamma release assay (IGRA) test was</span></div>
<div style="position:absolute;left:50.00px;top:61.48px" class="cls_026"><span class="cls_026">Chaouche-Teyara</span><span class="cls_027"><sup>5</sup></span></div>
<div style="position:absolute;left:306.64px;top:61.40px" class="cls_031"><span class="cls_031">performed before the start of the treatment and then every year,</span></div>
<div style="position:absolute;left:50.00px;top:72.11px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">SCIderm Research Institute Hamburg and Dermatologikum Berlin, Ger-</span></div>
<div style="position:absolute;left:306.64px;top:71.40px" class="cls_031"><span class="cls_031">in accordance with The Tuberculosis Network European Trials</span></div>
<div style="position:absolute;left:50.00px;top:81.74px" class="cls_029"><span class="cls_029">many, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Dermatology, Hospital de la Santa Creu I Sant Pau,</span></div>
<div style="position:absolute;left:306.64px;top:81.40px" class="cls_031"><span class="cls_031">Group (TBNET) consensus. Statistical analysis was performed</span></div>
<div style="position:absolute;left:50.00px;top:91.37px" class="cls_029"><span class="cls_029">Barcelona, Spain, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Department of Dermatology, Venereology and Allergo-</span></div>
<div style="position:absolute;left:306.64px;top:91.40px" class="cls_031"><span class="cls_031">on the results.</span></div>
<div style="position:absolute;left:50.00px;top:101.01px" class="cls_029"><span class="cls_029">logy, Wroclaw Medical University, Wroclaw, Poland, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Department of Der-</span></div>
<div style="position:absolute;left:306.64px;top:101.40px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> 3% of patients had permanently positive IGRA test (before</span></div>
<div style="position:absolute;left:49.99px;top:110.64px" class="cls_029"><span class="cls_029">matology, Larrey University Hospital, Toulouse, France, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Novartis Pharma</span></div>
<div style="position:absolute;left:306.64px;top:111.40px" class="cls_031"><span class="cls_031">and after beginning of the treatmet) and in 28% of patients treated</span></div>
<div style="position:absolute;left:50.00px;top:120.27px" class="cls_029"><span class="cls_029">AG, Basel, Switzerland, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Novartis Pharma GmbH, Nuernberg, Germany,</span></div>
<div style="position:absolute;left:306.64px;top:121.40px" class="cls_031"><span class="cls_031">by TNF inhibitors, conversion of IGRA test appeared with nega-</span></div>
<div style="position:absolute;left:50.00px;top:129.90px" class="cls_028"><span class="cls_028"><sup>7</sup></span><span class="cls_029">Novartis Farma S.p.A, Origgio, Italy</span></div>
<div style="position:absolute;left:306.64px;top:131.41px" class="cls_031"><span class="cls_031">tive test before treatment and positive test after administration of</span></div>
<div style="position:absolute;left:50.00px;top:140.80px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Secukinumab is a fully human monoclonal antibody</span></div>
<div style="position:absolute;left:306.64px;top:141.40px" class="cls_031"><span class="cls_031">biologics. No active tuberculosis was detected. The average time</span></div>
<div style="position:absolute;left:50.00px;top:150.83px" class="cls_031"><span class="cls_031">that selectively neutralizes IL-17A, a key cytokine involved in</span></div>
<div style="position:absolute;left:306.64px;top:151.40px" class="cls_031"><span class="cls_031">of IGRA conversion was 3 years after beginning of treatment. The</span></div>
<div style="position:absolute;left:50.00px;top:160.87px" class="cls_031"><span class="cls_031">the development of psoriasis. Heterogeneity in clinical response</span></div>
<div style="position:absolute;left:306.64px;top:161.40px" class="cls_031"><span class="cls_031">only statistically significant predictor was age, with an increase</span></div>
<div style="position:absolute;left:50.00px;top:170.90px" class="cls_031"><span class="cls_031">to targeted therapies such as secukinumab may be addressed by</span></div>
<div style="position:absolute;left:306.62px;top:171.40px" class="cls_031"><span class="cls_031">of age by one year associated with the 5.8% increase of risk of</span></div>
<div style="position:absolute;left:50.00px;top:180.94px" class="cls_031"><span class="cls_031">flexible dosing.</span></div>
<div style="position:absolute;left:306.62px;top:181.40px" class="cls_031"><span class="cls_031">IGRA conversion. Regarding other infectious complications, the</span></div>
<div style="position:absolute;left:50.00px;top:190.97px" class="cls_030"><span class="cls_030">Objectives:</span><span class="cls_031"> To compare downtitration of PASI90 responders to</span></div>
<div style="position:absolute;left:306.62px;top:191.40px" class="cls_031"><span class="cls_031">most common infections in patients treated with biologics were</span></div>
<div style="position:absolute;left:50.00px;top:201.01px" class="cls_031"><span class="cls_031">6-weekly and uptitration of PASI≥75 to </span><span class="cls_030"> &lt; </span><span class="cls_031">90 responders to two-</span></div>
<div style="position:absolute;left:306.62px;top:201.40px" class="cls_031"><span class="cls_031">respiratory and HPV infections. No severe infection leading to the</span></div>
<div style="position:absolute;left:49.99px;top:211.04px" class="cls_031"><span class="cls_031">weekly secukinumab dosing with standard 4-weekly dosing.</span></div>
<div style="position:absolute;left:306.62px;top:211.40px" class="cls_031"><span class="cls_031">permanent discontinuation of treatment was observed.</span></div>
<div style="position:absolute;left:49.99px;top:221.08px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> OPTIMISE was a randomized, multicenter, open-label,</span></div>
<div style="position:absolute;left:306.62px;top:221.40px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Treatment with TNF-alpha inhibitors was associated</span></div>
<div style="position:absolute;left:49.99px;top:231.11px" class="cls_031"><span class="cls_031">rater blinded Phase 3b study. 1647 subjects received secukinumab</span></div>
<div style="position:absolute;left:306.62px;top:231.40px" class="cls_031"><span class="cls_031">with statistically significant risk of IGRA test conversion. The only</span></div>
<div style="position:absolute;left:49.99px;top:241.15px" class="cls_031"><span class="cls_031">300 mg at baseline, Weeks 1, 2, 3 and 4 then 4-weekly to Week 24.</span></div>
<div style="position:absolute;left:306.62px;top:241.39px" class="cls_031"><span class="cls_031">established predictor of risk was age of patient, with no influence of</span></div>
<div style="position:absolute;left:49.99px;top:251.18px" class="cls_031"><span class="cls_031">At Week 24, PASI90 responders were randomized to secukinumab</span></div>
<div style="position:absolute;left:306.61px;top:251.39px" class="cls_031"><span class="cls_031">previous or concomittant systemic tretament. However, the limita-</span></div>
<div style="position:absolute;left:49.99px;top:261.22px" class="cls_031"><span class="cls_031">300 mg q4w (</span><span class="cls_030">n = </span><span class="cls_031">644) or q6w (</span><span class="cls_030">n = </span><span class="cls_031">662) to Week 52; PASI≥75</span></div>
<div style="position:absolute;left:306.64px;top:261.41px" class="cls_031"><span class="cls_031">tion was size of group of patients. The most common infections</span></div>
<div style="position:absolute;left:49.99px;top:271.25px" class="cls_031"><span class="cls_031">to </span><span class="cls_030"> &lt; </span><span class="cls_031">90 responders were randomized to secukinumab 300 mg q4w</span></div>
<div style="position:absolute;left:306.64px;top:271.40px" class="cls_031"><span class="cls_031">were common respiratory infections and viral HPV infections.</span></div>
<div style="position:absolute;left:49.99px;top:281.29px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">n = </span><span class="cls_031">114) or 2-weekly (q2w) (</span><span class="cls_030">n = </span><span class="cls_031">92) to Week 52. Groups were</span></div>
<div style="position:absolute;left:306.64px;top:281.40px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:49.99px;top:291.32px" class="cls_031"><span class="cls_031">stratified by body weight (</span><span class="cls_030"> &lt; </span><span class="cls_031">90kg, ≥90kg).</span></div>
<div style="position:absolute;left:306.64px;top:291.42px" class="cls_032"><span class="cls_032">Andersen P, Munk ME, Polock JM et al. Specific immune-based diagnosis</span></div>
<div style="position:absolute;left:49.99px;top:301.36px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">PASI90 response was maintained at Week 52 by 85.7%</span></div>
<div style="position:absolute;left:306.63px;top:300.42px" class="cls_032"><span class="cls_032">of tuberculosis. Lancet 2000; 356:1099-1104.</span></div>
<div style="position:absolute;left:306.63px;top:309.42px" class="cls_032"><span class="cls_032">Bieber J, Kavanaugh A. Tuberculosis and opportunistic infections: rele-</span></div>
<div style="position:absolute;left:49.99px;top:311.39px" class="cls_031"><span class="cls_031">subjects with q4w dosing vs 74.9% with q6w dosing; OR 1.91</span></div>
<div style="position:absolute;left:306.64px;top:318.42px" class="cls_032"><span class="cls_032">vance to biologic agents. Clin Exp Rheumatol. 2004; 22:126-133.</span></div>
<div style="position:absolute;left:49.99px;top:321.43px" class="cls_031"><span class="cls_031">(95% CI 1.44, 2.55). The primary endpoint, non-inferiority of q6w</span></div>
<div style="position:absolute;left:306.64px;top:327.42px" class="cls_032"><span class="cls_032">Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foun-</span></div>
<div style="position:absolute;left:49.99px;top:331.46px" class="cls_031"><span class="cls_031">vs q4w dosing in PASI90 responders, was not met. In PASI≥75</span></div>
<div style="position:absolute;left:306.64px;top:336.42px" class="cls_032"><span class="cls_032">dation consensus statement on screening for latent tuberculosis infection</span></div>
<div style="position:absolute;left:49.99px;top:341.50px" class="cls_031"><span class="cls_031">to </span><span class="cls_030"> &lt; </span><span class="cls_031">90 responders, 46.5% of subjects achieved PASI90 response</span></div>
<div style="position:absolute;left:306.64px;top:345.42px" class="cls_032"><span class="cls_032">in patients with psoriasis treated with systemic and biologic agents. J Am</span></div>
<div style="position:absolute;left:49.99px;top:351.53px" class="cls_031"><span class="cls_031">by Week 52 with q4w dosing. PASI90 response at Week 52 was</span></div>
<div style="position:absolute;left:306.64px;top:354.42px" class="cls_032"><span class="cls_032">Acad Dermatol 2008; 59:209-217.</span></div>
<div style="position:absolute;left:49.99px;top:361.57px" class="cls_031"><span class="cls_031">numerically higher for q2w compared to q4w dosing (56.5% vs.</span></div>
<div style="position:absolute;left:306.64px;top:363.42px" class="cls_032"><span class="cls_032">Drago L, Nicola L, Signori V et al. Dynamic QuantiFERON response</span></div>
<div style="position:absolute;left:49.99px;top:371.60px" class="cls_031"><span class="cls_031">46.5%), but this difference did not reach statistical significance</span></div>
<div style="position:absolute;left:306.64px;top:372.42px" class="cls_032"><span class="cls_032">in psoriasis patients taking long-term biologic therapy. Dermatol Ther</span></div>
<div style="position:absolute;left:49.98px;top:381.64px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">p = </span><span class="cls_031">0.1013). This numerical benefit of q2w dosing was even</span></div>
<div style="position:absolute;left:306.64px;top:381.42px" class="cls_032"><span class="cls_032">2013; 3:73-81.</span></div>
<div style="position:absolute;left:49.98px;top:391.67px" class="cls_031"><span class="cls_031">higher in subjects weighing ≥ 90 kg (</span><span class="cls_030">n = </span><span class="cls_031">49; 57.1% vs. 39.6%;</span></div>
<div style="position:absolute;left:306.64px;top:390.42px" class="cls_032"><span class="cls_032">Hernandez C, Cetner AS, Jordan JE, et al. Tuberculosis in the age of</span></div>
<div style="position:absolute;left:306.64px;top:399.42px" class="cls_032"><span class="cls_032">biologic therapy. J Am Acad Dermatol 2008; 9:363-380.</span></div>
<div style="position:absolute;left:50.00px;top:401.71px" class="cls_030"><span class="cls_030">p = </span><span class="cls_031">0.1053). No new or unexpected safety signals were observed.</span></div>
<div style="position:absolute;left:306.64px;top:408.42px" class="cls_032"><span class="cls_032">Solovič I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis rela-</span></div>
<div style="position:absolute;left:50.00px;top:411.74px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> Non-inferiority of q6w vs. q4w dosing cannot be</span></div>
<div style="position:absolute;left:306.64px;top:417.42px" class="cls_032"><span class="cls_032">ted to tumour necrosis factor antagonist therapies: a TBNET consensus</span></div>
<div style="position:absolute;left:50.00px;top:421.78px" class="cls_031"><span class="cls_031">claimed in maintaining PASI90 response achieved at Week 24.</span></div>
<div style="position:absolute;left:306.64px;top:426.42px" class="cls_032"><span class="cls_032">statement. Eur Respir J 2010; 36:1185-1206.</span></div>
<div style="position:absolute;left:50.00px;top:431.81px" class="cls_031"><span class="cls_031">Around half of PASI≥75 to </span><span class="cls_030"> &lt; </span><span class="cls_031">90 responders at 24 weeks, can</span></div>
<div style="position:absolute;left:50.02px;top:441.85px" class="cls_031"><span class="cls_031">achieve PASI90 response with continued q4w dosing. Subjects</span></div>
<div style="position:absolute;left:306.64px;top:444.04px" class="cls_033"><span class="cls_033">P023</span></div>
<div style="position:absolute;left:50.02px;top:451.88px" class="cls_031"><span class="cls_031">with higher body weight may benefit from the q2w dosing.</span></div>
<div style="position:absolute;left:306.64px;top:455.44px" class="cls_025"><span class="cls_025">TREATMENT USE AND SATISFACTION AMONG</span></div>
<div style="position:absolute;left:306.64px;top:466.34px" class="cls_025"><span class="cls_025">PATIENTS WITH PSORIASIS AND PSORIATIC</span></div>
<div style="position:absolute;left:50.00px;top:471.44px" class="cls_033"><span class="cls_033">P022</span></div>
<div style="position:absolute;left:306.64px;top:477.24px" class="cls_025"><span class="cls_025">ARTHRITIS IN SCANDINAVIA</span></div>
<div style="position:absolute;left:50.00px;top:482.87px" class="cls_025"><span class="cls_025">INHIBITION OF ANTI-TNF-ALPHA CYTOKINE IN THE</span></div>
<div style="position:absolute;left:306.64px;top:487.14px" class="cls_051"><span class="cls_051">Kåre Steinar Tveit</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Albert Duvetorp</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Mikkel Østergaard</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Lone</span></div>
<div style="position:absolute;left:50.00px;top:493.81px" class="cls_025"><span class="cls_025">TREATMENT OF PSORIASIS AND THE ANALYSIS OF</span></div>
<div style="position:absolute;left:306.64px;top:497.04px" class="cls_026"><span class="cls_026">Skov</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Kjersti Danielsen</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Lars Iversen</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Oliver Seifert</span><span class="cls_027"><sup>7</sup></span></div>
<div style="position:absolute;left:50.00px;top:504.74px" class="cls_025"><span class="cls_025">INFECTIOUS COMPLICATIONS</span></div>
<div style="position:absolute;left:306.64px;top:507.64px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Haukeland University Hospital, Bergen, Norway, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Linköping University,</span></div>
<div style="position:absolute;left:50.00px;top:514.67px" class="cls_051"><span class="cls_051">Tatiana Péčová</span><span class="cls_026">, Karolína Vorčáková</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Marián Grendár</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Juraj</span></div>
<div style="position:absolute;left:306.64px;top:517.24px" class="cls_029"><span class="cls_029">Linköping, Sweden; Skånes Universitetssjukhus, Malmö, Sweden, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Copen-</span></div>
<div style="position:absolute;left:50.00px;top:524.60px" class="cls_026"><span class="cls_026">Péč</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:306.64px;top:526.84px" class="cls_029"><span class="cls_029">hagen Center for Arthritis Research, Center for Rheumatology and Spine</span></div>
<div style="position:absolute;left:50.00px;top:535.23px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Dermatovenereology, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Biomedical Center Martin, Jesse-</span></div>
<div style="position:absolute;left:306.64px;top:536.44px" class="cls_029"><span class="cls_029">Diseases, Rigshospitalet, Glostrup, University of Copenhagen, Copenha-</span></div>
<div style="position:absolute;left:50.00px;top:544.86px" class="cls_029"><span class="cls_029">nius Faculty of Medicine in Martin, Comenius University in Bratislava,</span></div>
<div style="position:absolute;left:306.64px;top:546.04px" class="cls_029"><span class="cls_029">gen, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Herlev and Gentofte Hospital, University of Copenhagen, Copenha-</span></div>
<div style="position:absolute;left:50.00px;top:554.50px" class="cls_029"><span class="cls_029">Slovakia</span></div>
<div style="position:absolute;left:306.64px;top:555.64px" class="cls_029"><span class="cls_029">gen, Denmark, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">UiT The Arctic University of Norway, Tromsø, Norway;</span></div>
<div style="position:absolute;left:50.00px;top:565.39px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> TNF-alpha cytokine plays an important role in the</span></div>
<div style="position:absolute;left:306.64px;top:565.24px" class="cls_029"><span class="cls_029">University Hospital of North Norway, Tromsø, Norway, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Aarhus University</span></div>
<div style="position:absolute;left:50.00px;top:575.43px" class="cls_031"><span class="cls_031">regulation of activation, proliferation, differentiation and apoptosis</span></div>
<div style="position:absolute;left:306.64px;top:574.84px" class="cls_029"><span class="cls_029">Hospital, Aarhus, Denmark, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Linköping University, Linköping, Sweden;</span></div>
<div style="position:absolute;left:50.00px;top:585.46px" class="cls_031"><span class="cls_031">of the immune cells. It is an important therapeutical target in the</span></div>
<div style="position:absolute;left:306.64px;top:584.44px" class="cls_029"><span class="cls_029">Ryhov Hospital, Jönköping, Sweden</span></div>
<div style="position:absolute;left:50.00px;top:595.50px" class="cls_031"><span class="cls_031">treatment of chronic plaque psoriasis. From its other roles, it plays</span></div>
<div style="position:absolute;left:306.64px;top:595.31px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Patients’ perspectives on psoriasis (PsO) and pso-</span></div>
<div style="position:absolute;left:50.00px;top:605.53px" class="cls_031"><span class="cls_031">key part in formation and maintenance of granuloma through the</span></div>
<div style="position:absolute;left:306.64px;top:605.31px" class="cls_031"><span class="cls_031">riatic arthritis (PsA) treatment are important in establishing better</span></div>
<div style="position:absolute;left:50.00px;top:615.57px" class="cls_031"><span class="cls_031">increased fagocytic capacity of macrophages and eradication of</span></div>
<div style="position:absolute;left:306.64px;top:615.30px" class="cls_031"><span class="cls_031">approaches to their care.</span></div>
<div style="position:absolute;left:50.00px;top:625.60px" class="cls_031"><span class="cls_031">intracellular pathogens, therefore its inhibitors pose a risk for</span></div>
<div style="position:absolute;left:306.64px;top:625.30px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To assess treatment use and satisfaction among patients</span></div>
<div style="position:absolute;left:50.00px;top:635.64px" class="cls_031"><span class="cls_031">granulomatous infections and reactivation of latent tuberculosis.</span></div>
<div style="position:absolute;left:306.64px;top:635.30px" class="cls_031"><span class="cls_031">with PsO/PsA in Scandinavia.</span></div>
<div style="position:absolute;left:50.00px;top:645.65px" class="cls_030"><span class="cls_030">Objectives:</span><span class="cls_031"> The main focus was to assess the infectious compli-</span></div>
<div style="position:absolute;left:306.64px;top:645.30px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">NORPAPP was an on-line survey carried out in Nov/</span></div>
<div style="position:absolute;left:50.00px;top:655.68px" class="cls_031"><span class="cls_031">cations of biologic anti-TNF-alpha treatment of chronic plaque</span></div>
<div style="position:absolute;left:306.64px;top:655.30px" class="cls_031"><span class="cls_031">Dec 2015 using YouGov panels in Sweden, Denmark, and Norway.</span></div>
<div style="position:absolute;left:50.00px;top:665.71px" class="cls_031"><span class="cls_031">psoriasis with focus on the tuberculosis and reactivation of its</span></div>
<div style="position:absolute;left:306.64px;top:665.30px" class="cls_031"><span class="cls_031">Adults with physician-diagnosed PsO or PsA (</span><span class="cls_030">n = </span><span class="cls_031">1221), answered</span></div>
<div style="position:absolute;left:50.00px;top:675.75px" class="cls_031"><span class="cls_031">latent form. Moreover, the authors tried to establish possible risk</span></div>
<div style="position:absolute;left:306.66px;top:675.30px" class="cls_031"><span class="cls_031">questions about contact with the healthcare system, and treatment</span></div>
<div style="position:absolute;left:50.00px;top:685.78px" class="cls_031"><span class="cls_031">factors on the reactivation of latent tuberculosis.</span></div>
<div style="position:absolute;left:306.66px;top:685.30px" class="cls_031"><span class="cls_031">experience and satisfaction. Self-perceived disease severity was</span></div>
<div style="position:absolute;left:50.00px;top:695.82px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">The authors analyzed the group of 190 patients from</span></div>
<div style="position:absolute;left:306.66px;top:695.30px" class="cls_031"><span class="cls_031">dichotomised to severe (responses of “quite severe”, “very severe”</span></div>
<div style="position:absolute;left:50.00px;top:705.85px" class="cls_031"><span class="cls_031">Middle-European population treated with TNF-alpha inhibitors,</span></div>
<div style="position:absolute;left:306.66px;top:705.30px" class="cls_031"><span class="cls_031">or “extremely severe”) and non-severe (“not particularly severe”</span></div>
<div style="position:absolute;left:50.00px;top:715.89px" class="cls_031"><span class="cls_031">as compared to other biologics, for the occurence of infectious</span></div>
<div style="position:absolute;left:306.66px;top:715.29px" class="cls_031"><span class="cls_031">or “not severe at all”).</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:10439px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background15.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">13</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> Among respondents with PsO alone 38.9% had seen a</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">a normal everyday life (83%), and needing less time for daily</span></div>
<div style="position:absolute;left:50.00px;top:61.41px" class="cls_031"><span class="cls_031">dermatologist in the past year, and 10.7% had never seen a derma-</span></div>
<div style="position:absolute;left:306.64px;top:61.53px" class="cls_031"><span class="cls_031">treatment (80%). Based on a clinically meaningful PBI score</span></div>
<div style="position:absolute;left:50.00px;top:71.41px" class="cls_031"><span class="cls_031">tologist; 60.9% of those with PsA</span><span class="cls_035">±</span><span class="cls_031">PsO had seen a rheumatologist</span></div>
<div style="position:absolute;left:306.64px;top:71.66px" class="cls_031"><span class="cls_031">≥1, 78% of pts achieved a benefit with APR after 6 mo. Mean</span></div>
<div style="position:absolute;left:50.00px;top:81.41px" class="cls_031"><span class="cls_031">in the past year; 14.3% had never seen a rheumatologist. Systemic</span></div>
<div style="position:absolute;left:306.65px;top:81.78px" class="cls_031"><span class="cls_031">(SD) PBI score was 2.2 (1.3) and increased to 2.5 (1.2) for pts</span></div>
<div style="position:absolute;left:50.00px;top:91.41px" class="cls_031"><span class="cls_031">treatments had been used by 14.6% of respondents with PsO alone</span></div>
<div style="position:absolute;left:306.65px;top:91.91px" class="cls_031"><span class="cls_031">on continued APR at 6 mo vs 1.6 (1.3) for pts who discontinued</span></div>
<div style="position:absolute;left:50.00px;top:101.41px" class="cls_031"><span class="cls_031">and 58.5% with PsA</span><span class="cls_035">±</span><span class="cls_031">PsO. Respondents with self-perceived severe</span></div>
<div style="position:absolute;left:306.65px;top:102.03px" class="cls_031"><span class="cls_031">APR. Pts achieved benefit related to skin involvement (60%),</span></div>
<div style="position:absolute;left:50.00px;top:111.41px" class="cls_031"><span class="cls_031">symptoms and patient organization members (POMs) were more</span></div>
<div style="position:absolute;left:306.65px;top:112.15px" class="cls_031"><span class="cls_031">confidence in healing (70%), itch (69%), side effects (60%), be-</span></div>
<div style="position:absolute;left:50.00px;top:121.41px" class="cls_031"><span class="cls_031">likely than those with non-severe symptoms or non-members, to</span></div>
<div style="position:absolute;left:306.64px;top:122.28px" class="cls_031"><span class="cls_031">ing able to lead a normal everyday life (72%), and needing less</span></div>
<div style="position:absolute;left:50.00px;top:131.41px" class="cls_031"><span class="cls_031">have discussed systemic treatments with their physician and to</span></div>
<div style="position:absolute;left:306.64px;top:132.40px" class="cls_031"><span class="cls_031">time for daily treatment (65%). Consistent with phase 3 studies,</span></div>
<div style="position:absolute;left:50.00px;top:141.41px" class="cls_031"><span class="cls_031">have used the treatments; however, 35.2% of respondents with</span></div>
<div style="position:absolute;left:306.64px;top:142.53px" class="cls_031"><span class="cls_031">most frequently reported AEs were diarrhea (19.2%), nausea</span></div>
<div style="position:absolute;left:50.00px;top:151.41px" class="cls_031"><span class="cls_031">self-perceived severe symptoms had never discussed systemic</span></div>
<div style="position:absolute;left:306.64px;top:152.65px" class="cls_031"><span class="cls_031">(16.4%), and headache (11.5%); 25% of pts reported weight loss</span></div>
<div style="position:absolute;left:50.00px;top:161.41px" class="cls_031"><span class="cls_031">treatment with their physician. Asked about long-term health risks</span></div>
<div style="position:absolute;left:306.64px;top:162.78px" class="cls_031"><span class="cls_031">(no change, 71%; gain, 4%).</span></div>
<div style="position:absolute;left:50.00px;top:171.41px" class="cls_031"><span class="cls_031">of systemic treatments, 18-44 year-olds and POMs were less likely</span></div>
<div style="position:absolute;left:306.64px;top:172.90px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">This interim analysis indicates main pt needs from a</span></div>
<div style="position:absolute;left:50.00px;top:181.41px" class="cls_031"><span class="cls_031">to answer “don’t know” than 45-74 year-olds (47.7%-49.1% vs</span></div>
<div style="position:absolute;left:306.64px;top:183.03px" class="cls_031"><span class="cls_031">therapy extend beyond skin improvement. Findings indicate APR</span></div>
<div style="position:absolute;left:50.00px;top:191.41px" class="cls_031"><span class="cls_031">66.7%-72.9%) or non-members (26.1%-30.7% vs 66.8%-70.4%).</span></div>
<div style="position:absolute;left:306.64px;top:193.15px" class="cls_031"><span class="cls_031">may address diverse pt needs.</span></div>
<div style="position:absolute;left:50.00px;top:201.40px" class="cls_031"><span class="cls_031">Biologics had been used by 40.7% of POMs vs 6.9% of non-</span></div>
<div style="position:absolute;left:306.64px;top:203.29px" class="cls_032"><span class="cls_032">Prior Presentation: EADV 2017</span></div>
<div style="position:absolute;left:50.00px;top:211.40px" class="cls_031"><span class="cls_031">members, and 21.5% of 18-44 year-olds vs 8.1% of 45-74 year-</span></div>
<div style="position:absolute;left:50.00px;top:221.40px" class="cls_031"><span class="cls_031">olds. Among respondents using oral/injectable methotrexate 30.5%</span></div>
<div style="position:absolute;left:306.64px;top:224.03px" class="cls_033"><span class="cls_033">P025</span></div>
<div style="position:absolute;left:50.00px;top:231.40px" class="cls_031"><span class="cls_031">were dissatisfied, 60.2% citing side-effects as the reason; 22.9%</span></div>
<div style="position:absolute;left:306.64px;top:235.55px" class="cls_025"><span class="cls_025">PHYSICIAN- AND PATIENT-REPORTED OUTCOMES</span></div>
<div style="position:absolute;left:50.00px;top:241.40px" class="cls_031"><span class="cls_031">of biologics users were dissatisfied, 28.9% citing lack of effect</span></div>
<div style="position:absolute;left:306.64px;top:246.58px" class="cls_025"><span class="cls_025">WITH APREMILAST FOR PATIENTS WITH PLAQUE</span></div>
<div style="position:absolute;left:50.00px;top:251.40px" class="cls_031"><span class="cls_031">and 28.1% citing side-effects.</span></div>
<div style="position:absolute;left:306.64px;top:257.60px" class="cls_025"><span class="cls_025">PSORIASIS DURING ROUTINE DERMATOLOGY CARE</span></div>
<div style="position:absolute;left:50.00px;top:261.40px" class="cls_030"><span class="cls_030">Conclusion:</span><span class="cls_031"> In Scandinavia POMs and young patients are more</span></div>
<div style="position:absolute;left:306.64px;top:268.63px" class="cls_025"><span class="cls_025">IN GERMANY: A SECOND INTERIM ANALYSIS</span></div>
<div style="position:absolute;left:50.00px;top:271.40px" class="cls_031"><span class="cls_031">likely to receive systemic treatment. A high proportion of patients</span></div>
<div style="position:absolute;left:306.64px;top:278.65px" class="cls_051"><span class="cls_051">Kristian Reich</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Stefanie Bomas</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Bernhard Korge</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Uwe Schwich-</span></div>
<div style="position:absolute;left:50.00px;top:281.40px" class="cls_031"><span class="cls_031">are dissatisfied with their treatment because of side effects.</span></div>
<div style="position:absolute;left:306.64px;top:288.67px" class="cls_026"><span class="cls_026">tenberg</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Hannah Mentz</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Kathrin Groegel</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Natalie Núnez Gómez</span><span class="cls_027"><sup>5</sup></span></div>
<div style="position:absolute;left:50.00px;top:299.05px" class="cls_033"><span class="cls_033">P024</span></div>
<div style="position:absolute;left:306.64px;top:299.40px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Dermatologikum Hamburg and SCIderm Research Institute, Hamburg,</span></div>
<div style="position:absolute;left:50.00px;top:310.45px" class="cls_025"><span class="cls_025">FIRST PATIENT-REPORTED INSIGHTS FROM</span></div>
<div style="position:absolute;left:306.64px;top:309.12px" class="cls_028"><span class="cls_028"><sup>2</sup></span><span class="cls_029">Praxis Dr. med. S. Rotterdam, Gelsenkirchen-Feldmark, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Priv. Doz. Dr.</span></div>
<div style="position:absolute;left:306.64px;top:318.85px" class="cls_029"><span class="cls_029">med. Korge, Düren, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Derma Nord Hautarztpraxen Dr. med. Schwichten-</span></div>
<div style="position:absolute;left:50.00px;top:321.35px" class="cls_025"><span class="cls_025">A MULTINATIONAL, RETROSPECTIVE, CROSS-</span></div>
<div style="position:absolute;left:306.64px;top:328.57px" class="cls_029"><span class="cls_029">berg, Bremen, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Celgene GmbH, Munich, Germany</span></div>
<div style="position:absolute;left:50.00px;top:332.25px" class="cls_025"><span class="cls_025">SECTIONAL STUDY OF REAL-WORLD EXPERIENCE</span></div>
<div style="position:absolute;left:306.64px;top:339.56px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">LAPIS-PSO is an ongoing, 52-week, prospective,</span></div>
<div style="position:absolute;left:50.00px;top:343.15px" class="cls_025"><span class="cls_025">OF PSORIASIS PATIENTS TREATED WITH</span></div>
<div style="position:absolute;left:306.64px;top:349.69px" class="cls_031"><span class="cls_031">multicenter, observational cohort study in real-world dermatology</span></div>
<div style="position:absolute;left:50.00px;top:354.04px" class="cls_025"><span class="cls_025">APREMILAST IN CLINICAL DERMATOLOGY</span></div>
<div style="position:absolute;left:306.64px;top:359.81px" class="cls_031"><span class="cls_031">clinical settings in Germany.</span></div>
<div style="position:absolute;left:50.00px;top:364.94px" class="cls_025"><span class="cls_025">PRACTICE (APPRECIATE)</span></div>
<div style="position:absolute;left:306.64px;top:369.94px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To present a 4-month interim analysis of patient (pt)-</span></div>
<div style="position:absolute;left:50.00px;top:374.84px" class="cls_051"><span class="cls_051">Matthias Augustin</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Marc Alexander Radtke</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Kilian Eyerich</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:380.06px" class="cls_031"><span class="cls_031">reported outcomes and efficacy assessments of apremilast (APR)</span></div>
<div style="position:absolute;left:50.00px;top:384.75px" class="cls_026"><span class="cls_026">Mona Ståhle</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Christine Bundy</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Myriam Cordey</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Volker Kosci-</span></div>
<div style="position:absolute;left:306.63px;top:390.19px" class="cls_031"><span class="cls_031">among pts (</span><span class="cls_030">n = </span><span class="cls_031">294; full analysis set [FAS], </span><span class="cls_030">n = </span><span class="cls_031">196) who were</span></div>
<div style="position:absolute;left:49.99px;top:394.65px" class="cls_026"><span class="cls_026">elny</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, C. Elise Kleyn</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Christopher EM Griffiths</span><span class="cls_027"><sup>6</sup></span></div>
<div style="position:absolute;left:306.63px;top:400.31px" class="cls_031"><span class="cls_031">continuing APR at 4 mo.</span></div>
<div style="position:absolute;left:50.00px;top:405.25px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Institute for Health Services Research in Dermatology and Nursing,</span></div>
<div style="position:absolute;left:306.63px;top:410.44px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Physician- and pt-reported outcomes for QOL, treatment</span></div>
<div style="position:absolute;left:50.00px;top:414.85px" class="cls_029"><span class="cls_029">University Medical Center Hamburg-Eppendorf, Hamburg, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department</span></div>
<div style="position:absolute;left:306.63px;top:420.56px" class="cls_031"><span class="cls_031">effectiveness, and treatment satisfaction were evaluated in pts with</span></div>
<div style="position:absolute;left:50.00px;top:424.45px" class="cls_029"><span class="cls_029">of Dermatology and Allergy, Technical University of Munich, Munich,</span></div>
<div style="position:absolute;left:306.63px;top:430.69px" class="cls_031"><span class="cls_031">psoriasis vulgaris during long-term APR treatment. The primary</span></div>
<div style="position:absolute;left:50.00px;top:434.05px" class="cls_029"><span class="cls_029">Germany,</span><span class="cls_028"><sup> 3</sup></span><span class="cls_029">Department of Medicine, Karolinska Institute, Solna, Sweden,</span></div>
<div style="position:absolute;left:50.00px;top:443.65px" class="cls_028"><span class="cls_028"><sup>4</sup></span><span class="cls_029">School of Healthcare Sciences, College of Biomedical and Life Sciences,</span></div>
<div style="position:absolute;left:306.63px;top:440.81px" class="cls_031"><span class="cls_031">endpoint at Visit 2 (~4 mo after baseline [BL]) is the proportion</span></div>
<div style="position:absolute;left:50.00px;top:453.25px" class="cls_029"><span class="cls_029">Cardiff University, Cardiff, UK, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Celgene International, Boudry, Switzer-</span></div>
<div style="position:absolute;left:306.63px;top:450.94px" class="cls_031"><span class="cls_031">of pts who achieve DLQI score </span><span class="cls_030"> ≤ </span><span class="cls_031">5 or improvement from BL in</span></div>
<div style="position:absolute;left:50.00px;top:462.85px" class="cls_029"><span class="cls_029">land, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Dermatology Centre, Salford Royal NHS Foundation Trust, Univer-</span></div>
<div style="position:absolute;left:306.63px;top:461.06px" class="cls_031"><span class="cls_031">DLQI score ≥5 points.</span></div>
<div style="position:absolute;left:50.00px;top:472.45px" class="cls_029"><span class="cls_029">sity of Manchester, Manchester Academic Health Science Centre, Man-</span></div>
<div style="position:absolute;left:306.63px;top:471.19px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">At BL, mean (SD) age was 51.7 (13.20) years in the FAS;</span></div>
<div style="position:absolute;left:50.00px;top:482.05px" class="cls_029"><span class="cls_029">chester, UK</span></div>
<div style="position:absolute;left:306.63px;top:481.31px" class="cls_031"><span class="cls_031">90 pts (45.9%) were female. At APR initiation, 171 pts (87.3%)</span></div>
<div style="position:absolute;left:50.00px;top:492.91px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Patient (pt)-centered care is gaining traction in</span></div>
<div style="position:absolute;left:306.63px;top:491.44px" class="cls_031"><span class="cls_031">had Physician’s Global Assessment of disease severity (PGA)</span></div>
<div style="position:absolute;left:50.00px;top:502.91px" class="cls_031"><span class="cls_031">long-term disease management. We report on a multinational,</span></div>
<div style="position:absolute;left:306.63px;top:501.56px" class="cls_031"><span class="cls_031">≥3 and 174 (89.2%) had Patient’s Global Assessment of disease</span></div>
<div style="position:absolute;left:50.00px;top:512.91px" class="cls_031"><span class="cls_031">retrospective, cross-sectional study in psoriasis pts treated with</span></div>
<div style="position:absolute;left:306.63px;top:511.69px" class="cls_031"><span class="cls_031">severity (PaGA) ≥3; mean psoriasis-involved BSA was 22.2%,</span></div>
<div style="position:absolute;left:50.00px;top:522.91px" class="cls_031"><span class="cls_031">apremilast (APR), an oral phosphodiesterase 4 inhibitor, in a real-</span></div>
<div style="position:absolute;left:306.62px;top:521.81px" class="cls_031"><span class="cls_031">mean pruritus VAS score was 56.6 mm, and mean DLQI score</span></div>
<div style="position:absolute;left:50.00px;top:532.91px" class="cls_031"><span class="cls_031">world clinical setting.</span></div>
<div style="position:absolute;left:306.62px;top:531.94px" class="cls_031"><span class="cls_031">was 14.1. In all, 62.7% of pts had scalp PGA (ScPGA) ≥3; 42.5%</span></div>
<div style="position:absolute;left:50.00px;top:542.91px" class="cls_030"><span class="cls_030">Objectives:</span><span class="cls_031"> The study aims to identify important pt needs and</span></div>
<div style="position:absolute;left:306.64px;top:542.06px" class="cls_031"><span class="cls_031">had palmoplantar PGA (PPPGA) ≥3. Among pts continuing APR</span></div>
<div style="position:absolute;left:50.00px;top:552.91px" class="cls_031"><span class="cls_031">therapeutic benefits of APR.</span></div>
<div style="position:absolute;left:306.63px;top:552.19px" class="cls_031"><span class="cls_031">at 4 mo, 120/181 (66.3%) achieved DLQI score </span><span class="cls_030"> ≤ </span><span class="cls_031">5 or reduction</span></div>
<div style="position:absolute;left:50.00px;top:562.91px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> Consecutive pts with chronic plaque psoriasis treated</span></div>
<div style="position:absolute;left:306.63px;top:562.31px" class="cls_031"><span class="cls_031">by ≥5 points. Mean (SD) improvement in BSA was −9.5% (14.91)</span></div>
<div style="position:absolute;left:50.00px;top:572.91px" class="cls_031"><span class="cls_031">according to routine clinical practice who could be contacted</span></div>
<div style="position:absolute;left:306.63px;top:572.44px" class="cls_031"><span class="cls_031">and mean (SD) percentage improvement in pruritus VAS score</span></div>
<div style="position:absolute;left:50.00px;top:582.91px" class="cls_031"><span class="cls_031">6</span><span class="cls_035">±</span><span class="cls_031">1 mo after APR initiation were enrolled. Medical chart review,</span></div>
<div style="position:absolute;left:306.63px;top:582.56px" class="cls_031"><span class="cls_031">was −47.3% (32.29). A total of 32.1% of pts achieved PGA 0</span></div>
<div style="position:absolute;left:50.00px;top:592.91px" class="cls_031"><span class="cls_031">standardized pt-reported outcome tools (PBI, TSQM-9), and pt/</span></div>
<div style="position:absolute;left:306.61px;top:592.69px" class="cls_031"><span class="cls_031">(clear) or 1 (minimal); 32.6% achieved PaGA 0 or 1. NAPSI-50</span></div>
<div style="position:absolute;left:50.00px;top:602.91px" class="cls_031"><span class="cls_031">physician questionnaires were used. An interim analysis of the first</span></div>
<div style="position:absolute;left:306.61px;top:602.81px" class="cls_031"><span class="cls_031">was achieved by 62.4% (53/85) of pts. In all, 58.4% (87/149) of</span></div>
<div style="position:absolute;left:50.00px;top:612.91px" class="cls_031"><span class="cls_031">104 pts from 40 sites in Germany (42), UK (31), and Sweden (31)</span></div>
<div style="position:absolute;left:306.61px;top:612.94px" class="cls_031"><span class="cls_031">pts achieved ScPGA 0 or 1 and 69.0% (29/42) had PPPGA 0 or</span></div>
<div style="position:absolute;left:50.00px;top:622.91px" class="cls_031"><span class="cls_031">was performed using predefined descriptive statistics.</span></div>
<div style="position:absolute;left:306.61px;top:623.06px" class="cls_031"><span class="cls_031">1. AEs were consistent with the known safety profile of APR.</span></div>
<div style="position:absolute;left:50.00px;top:632.91px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">102 pt questionnaires were analyzed (98%). At 6</span><span class="cls_035">±</span><span class="cls_031">1 mo,</span></div>
<div style="position:absolute;left:306.62px;top:633.19px" class="cls_031"><span class="cls_031">Eighty pts (27.8%) reported ≥1 AE; 1 AE occurred in ≥5% of pts</span></div>
<div style="position:absolute;left:50.00px;top:642.91px" class="cls_031"><span class="cls_031">74 pts (71%) continued APR; 30 (29%) had discontinued APR</span></div>
<div style="position:absolute;left:306.59px;top:643.31px" class="cls_031"><span class="cls_031">(diarrhea, </span><span class="cls_030">n = </span><span class="cls_031">21 [7.3%]).</span></div>
<div style="position:absolute;left:50.00px;top:652.91px" class="cls_031"><span class="cls_031">(lack of efficacy [14%], safety/tolerability [11%], other [4%]).</span></div>
<div style="position:absolute;left:306.59px;top:653.44px" class="cls_030"><span class="cls_030">Conclusion:</span><span class="cls_031"> In routine clinical care in Germany, APR treatment</span></div>
<div style="position:absolute;left:50.01px;top:662.91px" class="cls_031"><span class="cls_031">Assessment of pts’ main needs from a therapy (quite/very im-</span></div>
<div style="position:absolute;left:306.59px;top:663.56px" class="cls_031"><span class="cls_031">outcomes for pts with psoriasis vulgaris, including difficult-to-treat</span></div>
<div style="position:absolute;left:50.00px;top:672.91px" class="cls_031"><span class="cls_031">portant on the PBI) revealed the importance pts attributed to skin</span></div>
<div style="position:absolute;left:306.59px;top:673.69px" class="cls_031"><span class="cls_031">locations such as the nails, scalp, palms, and soles, confirm the</span></div>
<div style="position:absolute;left:50.00px;top:682.91px" class="cls_031"><span class="cls_031">involvement (93% of responders), confidence in healing (92%),</span></div>
<div style="position:absolute;left:306.60px;top:683.81px" class="cls_031"><span class="cls_031">broad efficacy of APR observed in clinical trials.</span></div>
<div style="position:absolute;left:50.01px;top:692.91px" class="cls_031"><span class="cls_031">being itch free (85%), fewer side effects (84%), being able to lead</span></div>
<div style="position:absolute;left:306.64px;top:693.93px" class="cls_032"><span class="cls_032">Prior Presentation: AAD 2018</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:11242px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background16.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">14</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.23px" class="cls_033"><span class="cls_033">P026</span></div>
<div style="position:absolute;left:306.64px;top:51.85px" class="cls_029"><span class="cls_029">sity of Cincinnati, Department of Dermatology, Cincinnati, OH, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Forward</span></div>
<div style="position:absolute;left:50.00px;top:62.75px" class="cls_025"><span class="cls_025">IMPROVEMENTS  IN  WORK  PRODUCTIVITY  WITH</span></div>
<div style="position:absolute;left:306.64px;top:61.45px" class="cls_029"><span class="cls_029">Clinical Trials, Tampa, FL, </span><span class="cls_028"><sup>8</sup></span><span class="cls_029">DermAssociates, Rockville, MD, </span><span class="cls_028"><sup>9</sup></span><span class="cls_029">University of</span></div>
<div style="position:absolute;left:306.64px;top:71.05px" class="cls_029"><span class="cls_029">Utah, Salt Lake City, UT, USA</span></div>
<div style="position:absolute;left:50.00px;top:73.76px" class="cls_025"><span class="cls_025">UP TO 104 WEEKS OF APREMILAST MONOTHERAPY:</span></div>
<div style="position:absolute;left:50.00px;top:84.78px" class="cls_025"><span class="cls_025">RESULTS   FROM   A   PHASE</span></div>
<div style="position:absolute;left:198.74px;top:84.78px" class="cls_025"><span class="cls_025">3B,   RANDOMIZED,</span></div>
<div style="position:absolute;left:306.64px;top:81.92px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">UNVEIL is the first study of apremilast in patients</span></div>
<div style="position:absolute;left:306.65px;top:91.92px" class="cls_031"><span class="cls_031">(pts) with moderate psoriasis (BSA 5%-10%) naive to biologic</span></div>
<div style="position:absolute;left:50.00px;top:95.80px" class="cls_025"><span class="cls_025">CONTROLLED STUDY IN BIOLOGIC-NAIVE SUBJECTS</span></div>
<div style="position:absolute;left:306.65px;top:101.92px" class="cls_031"><span class="cls_031">and systemic therapy.</span></div>
<div style="position:absolute;left:50.00px;top:106.81px" class="cls_025"><span class="cls_025">WITH ACTIVE PSORIATIC ARTHRITIS</span></div>
<div style="position:absolute;left:306.65px;top:111.92px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">Improvements on physician and pt assessments over</span></div>
<div style="position:absolute;left:50.00px;top:116.82px" class="cls_051"><span class="cls_051">Philip J. Mease</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Dafna D. Gladman</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Eric K. Davenport</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Xiaolei</span></div>
<div style="position:absolute;left:306.65px;top:121.92px" class="cls_031"><span class="cls_031">52wks are described.</span></div>
<div style="position:absolute;left:50.00px;top:126.84px" class="cls_026"><span class="cls_026">Zhou</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Benoit Guerette</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Lichen Teng</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Satyin Kaura</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Peter Nash</span><span class="cls_027"><sup>5</sup></span></div>
<div style="position:absolute;left:306.65px;top:131.91px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Pts with chronic moderate plaque psoriasis (BSA 5%-</span></div>
<div style="position:absolute;left:50.00px;top:137.55px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Swedish Medical Center and University of Washington School of Medi-</span></div>
<div style="position:absolute;left:306.65px;top:141.91px" class="cls_031"><span class="cls_031">10%; sPGA</span><span class="cls_030"> = </span><span class="cls_031">3 [0-5 scale]) were randomized (2:1) to apremilast</span></div>
<div style="position:absolute;left:50.00px;top:147.27px" class="cls_029"><span class="cls_029">cine, Seattle, WA, USA, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Krembil Research Institute, Toronto Western</span></div>
<div style="position:absolute;left:306.65px;top:151.91px" class="cls_031"><span class="cls_031">30 mg BID (APR) or placebo (PBO) for 16wks. Pts continued APR</span></div>
<div style="position:absolute;left:50.00px;top:156.98px" class="cls_029"><span class="cls_029">Hospital, Toronto, ON, Canada, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">RTI Health Solutions, Research Triangle</span></div>
<div style="position:absolute;left:306.65px;top:161.91px" class="cls_031"><span class="cls_031">(APR/APR) or switched from PBO to APR (PBO/APR) through</span></div>
<div style="position:absolute;left:50.00px;top:166.70px" class="cls_029"><span class="cls_029">Park, NC, USA, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Celgene Corporation, Summit, NJ, USA, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">University of</span></div>
<div style="position:absolute;left:306.65px;top:171.91px" class="cls_031"><span class="cls_031">Wk52 (open-label treatment). Physician assessments were product</span></div>
<div style="position:absolute;left:50.00px;top:176.41px" class="cls_029"><span class="cls_029">Queensland, Brisbane, Australia</span></div>
<div style="position:absolute;left:306.65px;top:181.91px" class="cls_031"><span class="cls_031">of sPGA and BSA (PGAxBSA), proportion of pts who achieved</span></div>
<div style="position:absolute;left:50.00px;top:187.40px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">PsA patients may have impaired functioning in home</span></div>
<div style="position:absolute;left:306.65px;top:191.91px" class="cls_031"><span class="cls_031">sPGA score 0 (clear) or 1 (almost clear) and PGAxBSA-75 (≥75%</span></div>
<div style="position:absolute;left:50.00px;top:197.51px" class="cls_031"><span class="cls_031">or work activities. The phase 3b ACTIVE study assessed efficacy</span></div>
<div style="position:absolute;left:306.65px;top:201.91px" class="cls_031"><span class="cls_031">improvement from baseline [BL]). Pt assessments were Derma-</span></div>
<div style="position:absolute;left:50.01px;top:207.63px" class="cls_031"><span class="cls_031">of apremilast (APR) monotherapy in biologic-naive subjects</span></div>
<div style="position:absolute;left:306.64px;top:211.92px" class="cls_031"><span class="cls_031">tology Life Quality Index (DLQI), pruritus VAS (0-100 mm),</span></div>
<div style="position:absolute;left:50.01px;top:217.74px" class="cls_031"><span class="cls_031">with active PsA who may have had exposure to 1 conventional</span></div>
<div style="position:absolute;left:306.64px;top:221.92px" class="cls_031"><span class="cls_031">Treatment Satisfaction Questionnaire for Medication (TSQM),</span></div>
<div style="position:absolute;left:50.01px;top:227.86px" class="cls_031"><span class="cls_031">DMARD.</span></div>
<div style="position:absolute;left:306.64px;top:231.92px" class="cls_031"><span class="cls_031">and Pt’s Global Assessment (PtGA [0-4 scale]).</span></div>
<div style="position:absolute;left:50.01px;top:237.98px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">Assess work productivity through Wk104.</span></div>
<div style="position:absolute;left:306.64px;top:241.92px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">In randomized pts (PBO </span><span class="cls_030">n = </span><span class="cls_031">73; APR </span><span class="cls_030">n = </span><span class="cls_031">148), mean BL</span></div>
<div style="position:absolute;left:50.01px;top:248.09px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Subjects were randomized (1:1) to APR 30 mg BID or</span></div>
<div style="position:absolute;left:306.64px;top:251.92px" class="cls_031"><span class="cls_031">BSA was 7.2%, PGAxBSA was 21.8, DLQI was 11.0, and pruritus</span></div>
<div style="position:absolute;left:50.01px;top:258.21px" class="cls_031"><span class="cls_031">placebo (PBO). Subjects whose SJC/TJC did not improve ≥10%</span></div>
<div style="position:absolute;left:306.64px;top:261.91px" class="cls_031"><span class="cls_031">VAS was 56.6mm. At Wk16, mean improvement in PGAxBSA</span></div>
<div style="position:absolute;left:50.01px;top:268.32px" class="cls_031"><span class="cls_031">at Wk16 were eligible for early escape. At Wk24, remaining</span></div>
<div style="position:absolute;left:306.64px;top:271.91px" class="cls_031"><span class="cls_031">was greater with APR vs PBO (−48.1% vs −10.2%; P</span><span class="cls_030"> &lt; </span><span class="cls_031">0.0001);</span></div>
<div style="position:absolute;left:50.01px;top:278.44px" class="cls_031"><span class="cls_031">PBO subjects switched to APR. Work productivity and activity</span></div>
<div style="position:absolute;left:306.65px;top:281.91px" class="cls_031"><span class="cls_031">more pts achieved sPGA 0 or 1 and PGAxBSA-75 with APR vs</span></div>
<div style="position:absolute;left:50.01px;top:288.56px" class="cls_031"><span class="cls_031">impairment were assessed at baseline (BL) and Wk16 using the</span></div>
<div style="position:absolute;left:306.65px;top:291.91px" class="cls_031"><span class="cls_031">PBO (30.4% vs 9.6% and 35.1% vs 12.3%). At Wk16 achievement</span></div>
<div style="position:absolute;left:50.01px;top:298.66px" class="cls_031"><span class="cls_031">WPAI:PsA; WPAI:PsA Absenteeism, Presenteeism, Work Pro-</span></div>
<div style="position:absolute;left:306.65px;top:301.91px" class="cls_031"><span class="cls_031">of DLQI response (≥5-point decrease in pts with BL DLQI </span><span class="cls_030"> > </span><span class="cls_031">5)</span></div>
<div style="position:absolute;left:50.00px;top:308.78px" class="cls_031"><span class="cls_031">ductivity Loss, and Activity Impairment subscale scores range</span></div>
<div style="position:absolute;left:306.65px;top:311.91px" class="cls_031"><span class="cls_031">was greater with APR vs PBO (63.8% vs 34.5%), as were pruritus</span></div>
<div style="position:absolute;left:50.00px;top:318.89px" class="cls_031"><span class="cls_031">from 0% to 100%; higher scores indicate greater impairment.</span></div>
<div style="position:absolute;left:306.65px;top:321.91px" class="cls_031"><span class="cls_031">VAS response (improvement ≥20%: 62.8% vs 45.2%) and TSQM</span></div>
<div style="position:absolute;left:50.00px;top:329.01px" class="cls_031"><span class="cls_031">Work-related subscales were assessed in employed subjects; ac-</span></div>
<div style="position:absolute;left:306.65px;top:331.91px" class="cls_031"><span class="cls_031">global satisfaction (63.2 vs 48.7) and effectiveness (57.3 vs 38.8).</span></div>
<div style="position:absolute;left:50.00px;top:339.12px" class="cls_031"><span class="cls_031">tivity impairment was assessed in all subjects. Correlations were</span></div>
<div style="position:absolute;left:306.65px;top:341.91px" class="cls_031"><span class="cls_031">More pts had PtGA </span><span class="cls_030"> ≤ </span><span class="cls_031">1 with APR vs PBO (33.8% vs 20.5%). At</span></div>
<div style="position:absolute;left:50.00px;top:349.24px" class="cls_031"><span class="cls_031">examined at Wk16 between WPAI:PsA subscale and SF-36v2</span></div>
<div style="position:absolute;left:306.65px;top:351.91px" class="cls_031"><span class="cls_031">Wk52, PGAxBSA changes were −42.2% (PBO/APR) and −55.5%</span></div>
<div style="position:absolute;left:50.00px;top:359.35px" class="cls_031"><span class="cls_031">domain scores (Physical Functioning [PF], Bodily Pain [Pain],</span></div>
<div style="position:absolute;left:306.63px;top:361.90px" class="cls_031"><span class="cls_031">(APR/APR); 45.3% (PBO/APR) and 42.1% (APR/APR) of pts</span></div>
<div style="position:absolute;left:50.00px;top:369.47px" class="cls_031"><span class="cls_031">and Vitality [VIT]) associations with ACR20 response. Work</span></div>
<div style="position:absolute;left:306.63px;top:371.90px" class="cls_031"><span class="cls_031">achieved PGAxBSA-75, 35.9% (PBO/APR) and 33.1% (APR/</span></div>
<div style="position:absolute;left:50.00px;top:379.59px" class="cls_031"><span class="cls_031">productivity improvement was assessed to Wk104.</span></div>
<div style="position:absolute;left:306.63px;top:381.90px" class="cls_031"><span class="cls_031">APR) achieved sPGA response, 55.6% (PBO/APR) and 59.4%</span></div>
<div style="position:absolute;left:50.00px;top:389.70px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">BL characteristics were similar between groups. At Wk16,</span></div>
<div style="position:absolute;left:306.63px;top:391.90px" class="cls_031"><span class="cls_031">(APR/APR) achieved DLQI response, and 68.8% (PBO/APR) and</span></div>
<div style="position:absolute;left:50.00px;top:399.82px" class="cls_031"><span class="cls_031">APR improved work productivity and ability to carry out daily</span></div>
<div style="position:absolute;left:306.63px;top:401.90px" class="cls_031"><span class="cls_031">66.9% (APR/APR) achieved pruritus VAS response. TSQM global</span></div>
<div style="position:absolute;left:50.00px;top:409.93px" class="cls_031"><span class="cls_031">activities vs PBO, with greater mean improvements in overall</span></div>
<div style="position:absolute;left:306.63px;top:411.90px" class="cls_031"><span class="cls_031">satisfaction (PBO/APR 59.2; APR/APR 59.9) and effectiveness</span></div>
<div style="position:absolute;left:50.00px;top:420.05px" class="cls_031"><span class="cls_031">Work Productivity Loss (</span><span class="cls_030">p = </span><span class="cls_031">0.001) and Activity Impairment</span></div>
<div style="position:absolute;left:306.63px;top:421.90px" class="cls_031"><span class="cls_031">(PBO/APR 57.7; APR/APR 54.1) were similar between groups at</span></div>
<div style="position:absolute;left:50.00px;top:430.17px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001). Estimated mean change in Absenteeism score was</span></div>
<div style="position:absolute;left:306.63px;top:431.90px" class="cls_031"><span class="cls_031">Wk52; 42.2% (PBO/APR) vs 37.2% (APR/APR) had PtGA </span><span class="cls_030"> ≤ </span><span class="cls_031">1.</span></div>
<div style="position:absolute;left:50.00px;top:440.28px" class="cls_031"><span class="cls_031">similar with APR vs PBO (</span><span class="cls_030">p = </span><span class="cls_031">0.679). The Presenteeism score</span></div>
<div style="position:absolute;left:306.63px;top:441.90px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Physician and pt assessments improved with APR</span></div>
<div style="position:absolute;left:50.00px;top:450.40px" class="cls_031"><span class="cls_031">showed significant improvement with APR vs worsening with PBO</span></div>
<div style="position:absolute;left:306.63px;top:451.90px" class="cls_031"><span class="cls_031">up to 52wks in biologic- and systemic-naive pts with moderate</span></div>
<div style="position:absolute;left:50.01px;top:460.51px" class="cls_031"><span class="cls_031">(−10.8% vs 4.1%; P</span><span class="cls_030"> = </span><span class="cls_031">0.002). At Wk16, statistically significant</span></div>
<div style="position:absolute;left:306.63px;top:461.89px" class="cls_031"><span class="cls_031">psoriasis.</span></div>
<div style="position:absolute;left:50.02px;top:470.63px" class="cls_031"><span class="cls_031">correlations were observed between WPAI:PsA subscale (except</span></div>
<div style="position:absolute;left:306.64px;top:471.93px" class="cls_032"><span class="cls_032">Prior Presentation: AAD 2018</span></div>
<div style="position:absolute;left:50.02px;top:480.75px" class="cls_031"><span class="cls_031">Absenteeism) and SF-36v2 domain scores, as were associations</span></div>
<div style="position:absolute;left:50.02px;top:490.86px" class="cls_031"><span class="cls_031">with ACR20 response. In subjects randomized to APR at BL,</span></div>
<div style="position:absolute;left:306.64px;top:491.55px" class="cls_033"><span class="cls_033">P028</span></div>
<div style="position:absolute;left:50.02px;top:500.98px" class="cls_031"><span class="cls_031">Wk16 improvements were generally maintained to Wk104 in</span></div>
<div style="position:absolute;left:306.64px;top:502.95px" class="cls_025"><span class="cls_025">HEMOGLOBIN A1C AND WEIGHT CHANGES WITH</span></div>
<div style="position:absolute;left:50.02px;top:511.09px" class="cls_031"><span class="cls_031">those continuing APR.</span></div>
<div style="position:absolute;left:306.64px;top:513.85px" class="cls_025"><span class="cls_025">APREMILAST IN PATIENTS WITH PSORIASIS AND</span></div>
<div style="position:absolute;left:50.02px;top:521.19px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">In biologic-naive subjects with PsA, APR contri-</span></div>
<div style="position:absolute;left:306.64px;top:524.75px" class="cls_025"><span class="cls_025">PSORIATIC ARTHRITIS: POOLED LABORATORY</span></div>
<div style="position:absolute;left:50.00px;top:531.31px" class="cls_031"><span class="cls_031">buted to overall improvement in work productivity at Wk16,</span></div>
<div style="position:absolute;left:306.64px;top:535.65px" class="cls_025"><span class="cls_025">ANALYSIS OF THE PHASE 3 ESTEEM AND PALACE</span></div>
<div style="position:absolute;left:50.00px;top:541.43px" class="cls_031"><span class="cls_031">which correlated with SF-36v2 PF, Pain, and VIT scores and was</span></div>
<div style="position:absolute;left:306.64px;top:546.55px" class="cls_025"><span class="cls_025">TRIALS</span></div>
<div style="position:absolute;left:50.00px;top:551.54px" class="cls_031"><span class="cls_031">associated with ACR20 response; improvements in WPAI:PsA</span></div>
<div style="position:absolute;left:306.64px;top:556.45px" class="cls_026"><span class="cls_026">Luis Puig</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Neil Korman</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Chiara Greggio</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Joshua Cirulli</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Li-</span></div>
<div style="position:absolute;left:50.00px;top:561.66px" class="cls_031"><span class="cls_031">subscale scores were generally maintained to Wk104.</span></div>
<div style="position:absolute;left:306.64px;top:566.35px" class="cls_026"><span class="cls_026">chen Teng</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, </span><span class="cls_051">Vinod Chandran</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Majed Khraishi</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Nehal N. Mehta</span><span class="cls_027"><sup>6</sup></span></div>
<div style="position:absolute;left:50.00px;top:571.78px" class="cls_032"><span class="cls_032">Prior Presentation: EULAR 2018</span></div>
<div style="position:absolute;left:306.64px;top:576.95px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Case Western</span></div>
<div style="position:absolute;left:306.64px;top:586.55px" class="cls_029"><span class="cls_029">University and University Hospitals Cleveland Medical Center, Cleveland,</span></div>
<div style="position:absolute;left:50.00px;top:591.52px" class="cls_033"><span class="cls_033">P027</span></div>
<div style="position:absolute;left:306.64px;top:596.15px" class="cls_029"><span class="cls_029">OH, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Celgene Corporation, Summit, NJ, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">University of Toronto and Krem-</span></div>
<div style="position:absolute;left:50.00px;top:603.03px" class="cls_025"><span class="cls_025">EXAMINING DISEASE SEVERITY AND SYMPTOM</span></div>
<div style="position:absolute;left:306.64px;top:605.75px" class="cls_029"><span class="cls_029">bil Research Institute, University Health Network, Toronto, ON, Canada,</span></div>
<div style="position:absolute;left:50.00px;top:614.05px" class="cls_025"><span class="cls_025">IMPROVEMENT WITH PATIENT AND PHYSICIAN</span></div>
<div style="position:absolute;left:306.64px;top:615.35px" class="cls_028"><span class="cls_028"><sup>5</sup></span><span class="cls_029">Memorial University of Newfoundland, St. Johns, NL, Canada, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">National</span></div>
<div style="position:absolute;left:50.00px;top:625.07px" class="cls_025"><span class="cls_025">ASSESSMENTS: RESULTS FROM A PHASE IV ANALYSIS</span></div>
<div style="position:absolute;left:306.64px;top:624.95px" class="cls_029"><span class="cls_029">Heart, Lung and Blood Institute, Bethesda, MD</span></div>
<div style="position:absolute;left:50.00px;top:636.08px" class="cls_025"><span class="cls_025">OF APREMILAST IN PATIENTS WITH MODERATE</span></div>
<div style="position:absolute;left:306.64px;top:635.82px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis and psoriatic arthritis (PsA) are associated</span></div>
<div style="position:absolute;left:50.00px;top:647.10px" class="cls_025"><span class="cls_025">PLAQUE PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:645.82px" class="cls_031"><span class="cls_031">with high prevalence of obesity and metabolic syndrome. In phase</span></div>
<div style="position:absolute;left:50.00px;top:657.11px" class="cls_051"><span class="cls_051">Mark Lebwohl</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, J. Mark Jackson</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Jerry Bagel</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Eugenia Levi</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:655.82px" class="cls_031"><span class="cls_031">3 trials, apremilast, an oral PDE4 inhibitor, was efficacious in</span></div>
<div style="position:absolute;left:50.00px;top:667.12px" class="cls_026"><span class="cls_026">Jerry Weaver</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Linda Stein Gold</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Ali Alikhan</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Seth Forman</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Ben-</span></div>
<div style="position:absolute;left:306.65px;top:665.82px" class="cls_031"><span class="cls_031">patients (pts) with moderate to severe plaque psoriasis (ESTEEM</span></div>
<div style="position:absolute;left:50.00px;top:677.14px" class="cls_026"><span class="cls_026">jamin Lockshin</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, Kristina Callis Duffin</span><span class="cls_027"><sup>9</sup></span></div>
<div style="position:absolute;left:306.65px;top:675.82px" class="cls_031"><span class="cls_031">1 and 2 [EST]) and active PsA (PALACE 1-3 [PAL]).</span></div>
<div style="position:absolute;left:50.00px;top:687.85px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Icahn School of Medicine at Mount Sinai, New York, NY, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">University of</span></div>
<div style="position:absolute;left:306.65px;top:685.81px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To explore potential effects of apremilast on metabolic</span></div>
<div style="position:absolute;left:50.00px;top:697.57px" class="cls_029"><span class="cls_029">Louisville, Forefront Dermatology, Louisville, KY, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Psoriasis Treatment</span></div>
<div style="position:absolute;left:306.65px;top:695.81px" class="cls_031"><span class="cls_031">parameters, we assessed weight change and A1c in pts receiving</span></div>
<div style="position:absolute;left:50.00px;top:707.28px" class="cls_029"><span class="cls_029">Center of Central New Jersey, East Windsor, NJ, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Celgene Corporation,</span></div>
<div style="position:absolute;left:306.65px;top:705.81px" class="cls_031"><span class="cls_031">placebo (PBO) or apremilast 30 mg twice daily (APR) in a pooled</span></div>
<div style="position:absolute;left:50.00px;top:717.00px" class="cls_029"><span class="cls_029">Summit, NJ, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Henry Ford Health System, West Bloomfield, MI, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Univer-</span></div>
<div style="position:absolute;left:306.65px;top:715.81px" class="cls_031"><span class="cls_031">analysis of EST and PAL.</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:12045px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background17.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">15</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Mean A1c change and mean percent weight change at</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">groups. However, patients initiating ADA were more likely to be</span></div>
<div style="position:absolute;left:50.00px;top:61.41px" class="cls_031"><span class="cls_031">Wk16 were compared among pts with baseline (BL) A1c </span><span class="cls_030"> &lt; </span><span class="cls_031">5.7%,</span></div>
<div style="position:absolute;left:306.64px;top:61.44px" class="cls_031"><span class="cls_031">unemployed (47.3% ADA vs 34.9% nbDMARD, </span><span class="cls_030">p = </span><span class="cls_031">0.015), had</span></div>
<div style="position:absolute;left:50.00px;top:71.41px" class="cls_031"><span class="cls_031">5.7% to 6.4% (prediabetes), and ≥6.5% (diabetes) and between pts</span></div>
<div style="position:absolute;left:306.64px;top:71.48px" class="cls_031"><span class="cls_031">higher DAS28 (4.8 vs 4.4, </span><span class="cls_030">p = </span><span class="cls_031">0.002) and total DLQI score (6.1</span></div>
<div style="position:absolute;left:49.99px;top:81.41px" class="cls_031"><span class="cls_031">reporting/not reporting concomitant insulin use. Spearman rank cor-</span></div>
<div style="position:absolute;left:306.64px;top:81.51px" class="cls_031"><span class="cls_031">vs 4.3, </span><span class="cls_030">p = </span><span class="cls_031">0.007), and were more likely to have BSA≥3% (44.6%</span></div>
<div style="position:absolute;left:50.00px;top:91.41px" class="cls_031"><span class="cls_031">relations between percent change from BL in weight and change in</span></div>
<div style="position:absolute;left:306.66px;top:91.55px" class="cls_031"><span class="cls_031">vs 35.0%, </span><span class="cls_030">p = </span><span class="cls_031">0.063) and high DAPSA disease activity (50.8%</span></div>
<div style="position:absolute;left:50.00px;top:101.41px" class="cls_031"><span class="cls_031">A1c at Wk16 were calculated; </span><span class="cls_030">p &lt; </span><span class="cls_031">0.05 was considered significant.</span></div>
<div style="position:absolute;left:306.66px;top:101.58px" class="cls_031"><span class="cls_031">vs 32.3%, </span><span class="cls_030">p = </span><span class="cls_031">0.015). A higher proportion of nbDMARD patients</span></div>
<div style="position:absolute;left:50.00px;top:111.41px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">In the pooled EST-PAL population, 2,242 pts (PBO</span></div>
<div style="position:absolute;left:306.66px;top:111.62px" class="cls_031"><span class="cls_031">had dactylitis (36.1% vs 25.3%, </span><span class="cls_030">p = </span><span class="cls_031">0.023). No differences were</span></div>
<div style="position:absolute;left:50.00px;top:121.41px" class="cls_030"><span class="cls_030">n = </span><span class="cls_031">913; APR </span><span class="cls_030">n = </span><span class="cls_031">1,329) received study medication at BL. In all,</span></div>
<div style="position:absolute;left:306.66px;top:121.65px" class="cls_031"><span class="cls_031">observed between groups in enthesitis, overall EAMs, or QoL</span></div>
<div style="position:absolute;left:50.00px;top:131.41px" class="cls_031"><span class="cls_031">230 pts had BL A1c ≥6.5%. At Wk16, A1c change in pts with</span></div>
<div style="position:absolute;left:306.66px;top:131.69px" class="cls_031"><span class="cls_031">at BL. Following 12 months, mean adjusted DAS28 (2.6 vs 3.4,</span></div>
<div style="position:absolute;left:50.02px;top:141.41px" class="cls_031"><span class="cls_031">BL A1c </span><span class="cls_030"> &lt; </span><span class="cls_031">5.7% was 0.02 with PBO and 0.04 with APR. In pts</span></div>
<div style="position:absolute;left:306.66px;top:141.72px" class="cls_030"><span class="cls_030">p &lt; </span><span class="cls_031">0.001) and DLQI (2.2 vs 2.9, </span><span class="cls_030">p = </span><span class="cls_031">0.530) scores, but not SF-12,</span></div>
<div style="position:absolute;left:50.02px;top:151.41px" class="cls_031"><span class="cls_031">with BL A1c 5.7% to 6.4%, small changes were observed (PBO</span></div>
<div style="position:absolute;left:306.66px;top:151.76px" class="cls_031"><span class="cls_031">were lower in the ADA group. Furthermore, even though statistical</span></div>
<div style="position:absolute;left:50.02px;top:161.41px" class="cls_031"><span class="cls_031">−0.07; APR −0.12). Greatest A1c changes were in pts with BL</span></div>
<div style="position:absolute;left:306.66px;top:161.79px" class="cls_031"><span class="cls_031">significance was not always met, ADA patients had lower DAPSA</span></div>
<div style="position:absolute;left:50.01px;top:171.41px" class="cls_031"><span class="cls_031">A1c ≥6.5% (PBO −0.08; APR −0.31). At Wk16, mean weight</span></div>
<div style="position:absolute;left:306.67px;top:171.83px" class="cls_031"><span class="cls_031">score (</span><span class="cls_030">p = </span><span class="cls_031">0.025) (LDA/REM: 64.9% vs 58.6%; REM: 37.7% vs</span></div>
<div style="position:absolute;left:50.00px;top:181.41px" class="cls_031"><span class="cls_031">change was 0.11% (PBO) and −1.32% (APR). In pts reporting</span></div>
<div style="position:absolute;left:306.67px;top:181.86px" class="cls_031"><span class="cls_031">17.1%), were more likely to be in modified remission (14.7% vs</span></div>
<div style="position:absolute;left:50.00px;top:191.40px" class="cls_031"><span class="cls_031">and not reporting concomitant insulin use, mean weight change</span></div>
<div style="position:absolute;left:306.66px;top:191.90px" class="cls_031"><span class="cls_031">9.7%, </span><span class="cls_030">p = </span><span class="cls_031">0.311), and to have mMDA (mMDA 1: 15.6% vs 12.6%,</span></div>
<div style="position:absolute;left:50.00px;top:201.40px" class="cls_031"><span class="cls_031">was 0.05% and 0.12% with PBO, respectively, and −1.83% and</span></div>
<div style="position:absolute;left:306.66px;top:201.93px" class="cls_030"><span class="cls_030">p = </span><span class="cls_031">0.529; mMDA 2: 17% vs 11.5%, </span><span class="cls_030">p = </span><span class="cls_031">0.253) and BSA</span><span class="cls_030"> &lt; </span><span class="cls_031">3%</span></div>
<div style="position:absolute;left:50.02px;top:211.40px" class="cls_031"><span class="cls_031">−1.31% with APR. Weight change in pts with BL A1c </span><span class="cls_030"> &lt; </span><span class="cls_031">5.7%,</span></div>
<div style="position:absolute;left:306.66px;top:211.97px" class="cls_031"><span class="cls_031">(89.3% vs 83.9%, </span><span class="cls_030">p = </span><span class="cls_031">0.207). Also, EAM prevalence decreased in</span></div>
<div style="position:absolute;left:50.03px;top:221.40px" class="cls_031"><span class="cls_031">5.7% to 6.4%, and ≥6.5% was 0.02%, 0.26%, and 0.11% with</span></div>
<div style="position:absolute;left:306.66px;top:222.00px" class="cls_031"><span class="cls_031">both groups but was significantly lower in the ADA group (17.4%</span></div>
<div style="position:absolute;left:50.00px;top:231.40px" class="cls_031"><span class="cls_031">PBO, respectively, and −1.24%, −1.35%, and −1.68% with APR.</span></div>
<div style="position:absolute;left:306.65px;top:232.04px" class="cls_031"><span class="cls_031">vs 35.8%, </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001). Over time, 9.6% of ADA patients initiated</span></div>
<div style="position:absolute;left:49.99px;top:241.40px" class="cls_031"><span class="cls_031">Correlations between changes in weight and A1c were generally</span></div>
<div style="position:absolute;left:306.65px;top:242.07px" class="cls_031"><span class="cls_031">another biologic and 32.2% of patients in the nbDMARD group</span></div>
<div style="position:absolute;left:49.99px;top:251.40px" class="cls_031"><span class="cls_031">low, with greater correlation in APR pts with higher BL A1c. Corre-</span></div>
<div style="position:absolute;left:306.65px;top:252.11px" class="cls_031"><span class="cls_031">initiated biologic treatment (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001).</span></div>
<div style="position:absolute;left:50.00px;top:261.41px" class="cls_031"><span class="cls_031">lation was statistically significant in APR pts with BL A1c ≥6.5%.</span></div>
<div style="position:absolute;left:306.65px;top:262.14px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">PsA patients initiating ADA in Canadian routine</span></div>
<div style="position:absolute;left:50.01px;top:271.41px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">With APR, decreases in weight and A1c were greater</span></div>
<div style="position:absolute;left:306.65px;top:272.17px" class="cls_031"><span class="cls_031">clinical care have significantly greater BL disease severity com-</span></div>
<div style="position:absolute;left:50.01px;top:281.41px" class="cls_031"><span class="cls_031">in pts with higher BL A1c. Pts receiving APR and insulin had</span></div>
<div style="position:absolute;left:306.64px;top:282.21px" class="cls_031"><span class="cls_031">pared with those initiating nbDMARDs. However, 12-month</span></div>
<div style="position:absolute;left:50.01px;top:291.41px" class="cls_031"><span class="cls_031">weight loss despite the association between insulin use and weight</span></div>
<div style="position:absolute;left:306.64px;top:292.24px" class="cls_031"><span class="cls_031">ADA treatment resulted in improved disease control and EAMs.</span></div>
<div style="position:absolute;left:50.01px;top:301.41px" class="cls_031"><span class="cls_031">gain. Future studies may be warranted to determine whether re-</span></div>
<div style="position:absolute;left:306.64px;top:302.28px" class="cls_031"><span class="cls_031">DAPSA-REM evaluation seems more sensitive than mMDA in</span></div>
<div style="position:absolute;left:50.00px;top:311.41px" class="cls_031"><span class="cls_031">ductions in A1c with APR are independent of weight loss.</span></div>
<div style="position:absolute;left:306.64px;top:312.31px" class="cls_031"><span class="cls_031">differentiating both populations.</span></div>
<div style="position:absolute;left:50.00px;top:321.43px" class="cls_032"><span class="cls_032">Prior presentation: AAD 2018</span></div>
<div style="position:absolute;left:306.64px;top:332.98px" class="cls_033"><span class="cls_033">P030</span></div>
<div style="position:absolute;left:50.00px;top:340.05px" class="cls_033"><span class="cls_033">P029</span></div>
<div style="position:absolute;left:306.64px;top:344.41px" class="cls_025"><span class="cls_025">SECUKINUMAB EFFICACY IN PATIENTS WITH</span></div>
<div style="position:absolute;left:50.00px;top:351.45px" class="cls_025"><span class="cls_025">CANADIAN HUMIRA POST-MARKETING</span></div>
<div style="position:absolute;left:306.64px;top:355.35px" class="cls_025"><span class="cls_025">ACTIVE PSORIATIC ARTHRITIS: META-ANALYSIS OF</span></div>
<div style="position:absolute;left:50.00px;top:362.35px" class="cls_025"><span class="cls_025">OBSERVATIONAL EPIDEMIOLOGICAL STUDY</span></div>
<div style="position:absolute;left:306.64px;top:366.28px" class="cls_025"><span class="cls_025">4 PHASE 3 TRIALS</span></div>
<div style="position:absolute;left:50.00px;top:373.25px" class="cls_025"><span class="cls_025">ASSESSING THE EFFECTIVENESS OF ADALIMUMAB</span></div>
<div style="position:absolute;left:306.64px;top:376.22px" class="cls_051"><span class="cls_051">Philip Mease</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Bruce Kirkham</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Peter Nash</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Alejandro Balsa</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:50.00px;top:384.15px" class="cls_025"><span class="cls_025">VS NON-BIOLOGIC DMARDS IN PSORIATIC</span></div>
<div style="position:absolute;left:306.64px;top:386.15px" class="cls_026"><span class="cls_026">Bernard Combe</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Jürgen Rech</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Ruvie Martin</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Gregory Ligozio</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:50.00px;top:395.04px" class="cls_025"><span class="cls_025">ARTHRITIS (COMPLETE-PSA): 12-MONTH</span></div>
<div style="position:absolute;left:306.64px;top:396.09px" class="cls_026"><span class="cls_026">Ken Abrams</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Luminita Pricop</span><span class="cls_027"><sup>7</sup></span></div>
<div style="position:absolute;left:50.00px;top:405.94px" class="cls_025"><span class="cls_025">EFFECTIVENESS DATA</span></div>
<div style="position:absolute;left:306.64px;top:406.72px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Swedish Medical Centre and University of Washington, Seattle, USA,</span></div>
<div style="position:absolute;left:50.00px;top:415.84px" class="cls_051"><span class="cls_051">Majed Khraishi</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Louis Bessette</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Andrew Chow</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Boulos Ha-</span></div>
<div style="position:absolute;left:306.64px;top:416.36px" class="cls_028"><span class="cls_028"><sup>2</sup></span><span class="cls_029">Guy’s & St Thomas’ NHS Foundation Trust, London, UK, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Department of</span></div>
<div style="position:absolute;left:50.00px;top:425.75px" class="cls_026"><span class="cls_026">raouil</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Viktoria Pavlova</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Jacqueline Stewart</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Valencia Remple</span><span class="cls_027"><sup>7</sup></span></div>
<div style="position:absolute;left:306.64px;top:425.99px" class="cls_029"><span class="cls_029">Medicine, University of Queensland, Brisbane, Australia, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Hospital Uni-</span></div>
<div style="position:absolute;left:50.00px;top:436.35px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Memorial University of Newfoundland, St. John’s NL, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Laval University,</span></div>
<div style="position:absolute;left:306.64px;top:435.62px" class="cls_029"><span class="cls_029">versitario La Paz, Instituto de Investigación Sanitaria (IdiPAZ), Madrid,</span></div>
<div style="position:absolute;left:50.00px;top:445.95px" class="cls_029"><span class="cls_029">Centre Hospitalier de l’Université Laval, Quebec QC, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">University of To-</span></div>
<div style="position:absolute;left:306.64px;top:445.26px" class="cls_029"><span class="cls_029">Spain, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Hôpital Lapeyronie, Université Montpellier 1, Montpellier, France,</span></div>
<div style="position:absolute;left:50.00px;top:455.55px" class="cls_029"><span class="cls_029">ronto ON, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Centre hospitalier de l’Université de Montréal, Montreal QC,</span></div>
<div style="position:absolute;left:306.64px;top:454.90px" class="cls_028"><span class="cls_028"><sup>6</sup></span><span class="cls_029">Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Monash Uni-</span></div>
<div style="position:absolute;left:50.00px;top:465.15px" class="cls_028"><span class="cls_028"><sup>5</sup></span><span class="cls_029">McMaster University, Hamilton ON, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">University of British Columbia, Pen-</span></div>
<div style="position:absolute;left:306.64px;top:464.53px" class="cls_029"><span class="cls_029">versity, Germany, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Novartis Pharmaceuticals Corporation, East Hanover,</span></div>
<div style="position:absolute;left:50.00px;top:474.75px" class="cls_029"><span class="cls_029">ticton BC, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">AbbVie Corporation, Montreal QC, Canada</span></div>
<div style="position:absolute;left:306.64px;top:474.16px" class="cls_029"><span class="cls_029">USA</span></div>
<div style="position:absolute;left:50.00px;top:485.61px" class="cls_030"><span class="cls_030">Background: </span><span class="cls_031">Observational studies comparing the effectiveness</span></div>
<div style="position:absolute;left:306.64px;top:485.07px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Secukinumab (SEC) has exhibited rapid, significant</span></div>
<div style="position:absolute;left:50.00px;top:495.61px" class="cls_031"><span class="cls_031">of adalimumab (ADA) to non-biologic DMARDs (nbDMARD) in</span></div>
<div style="position:absolute;left:306.64px;top:495.10px" class="cls_031"><span class="cls_031">and sustained improvement in the signs and symptoms of psoriatic</span></div>
<div style="position:absolute;left:50.00px;top:505.61px" class="cls_031"><span class="cls_031">PsA patients failing prior treatment are scarce. COMPLETE-PSA</span></div>
<div style="position:absolute;left:306.64px;top:505.14px" class="cls_031"><span class="cls_031">arthritis (PsA) in 4 Phase 3 studies.1-4</span></div>
<div style="position:absolute;left:50.00px;top:515.61px" class="cls_031"><span class="cls_031">is a Canadian observational study which assessed effectiveness</span></div>
<div style="position:absolute;left:306.64px;top:515.17px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031"> To report meta-analyzed efficacy results for SEC ver-</span></div>
<div style="position:absolute;left:50.00px;top:525.61px" class="cls_031"><span class="cls_031">of ADA and non-biological therapies (NSAIDs and DMARDs)</span></div>
<div style="position:absolute;left:306.64px;top:525.21px" class="cls_031"><span class="cls_031">sus placebo at Week (Wk) 16 in PsA patients (pts) by prior TNF</span></div>
<div style="position:absolute;left:50.00px;top:535.61px" class="cls_031"><span class="cls_031">among PsA patients failing previous therapy.</span></div>
<div style="position:absolute;left:306.64px;top:535.24px" class="cls_031"><span class="cls_031">inhibitor (TNFi) use and with/without concomitant methotrexate</span></div>
<div style="position:absolute;left:50.00px;top:545.61px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To describe the baseline (BL) demographic and disease</span></div>
<div style="position:absolute;left:306.64px;top:545.28px" class="cls_031"><span class="cls_031">(MTX) use from 4 Phase 3 studies: FUTURE 2,3,4,5.</span></div>
<div style="position:absolute;left:50.00px;top:555.61px" class="cls_031"><span class="cls_031">parameters and to compare 12-month real-life effectiveness of</span></div>
<div style="position:absolute;left:306.64px;top:555.31px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">A total of 2148 pts with active PsA were randomised in</span></div>
<div style="position:absolute;left:50.00px;top:565.61px" class="cls_031"><span class="cls_031">patients initiating nbDMARD or ADA.</span></div>
<div style="position:absolute;left:306.64px;top:565.34px" class="cls_031"><span class="cls_031">FUTURE 2, 3, 4 and 5 studies (397, 414, 341 and 996, respecti-</span></div>
<div style="position:absolute;left:50.00px;top:575.61px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Eligible patients eligible are anti-TNFα naïve adults,</span></div>
<div style="position:absolute;left:306.64px;top:575.38px" class="cls_031"><span class="cls_031">vely). Study designs were described elsewhere.1-4 Assessments</span></div>
<div style="position:absolute;left:50.00px;top:585.60px" class="cls_031"><span class="cls_031">with active PsA requiring a treatment regimen change, per the</span></div>
<div style="position:absolute;left:306.64px;top:585.41px" class="cls_031"><span class="cls_031">included ACR20/50 by prior TNFi use (naïve/inadequate response</span></div>
<div style="position:absolute;left:50.00px;top:595.60px" class="cls_031"><span class="cls_031">treating physician’s judgment. This analysis included patients</span></div>
<div style="position:absolute;left:306.64px;top:595.45px" class="cls_031"><span class="cls_031">or intolerance [-IR]) and with/without MTX use.</span></div>
<div style="position:absolute;left:50.00px;top:605.60px" class="cls_031"><span class="cls_031">enrolled during Jul/2011-Jun/2016. Outcome measures analyzed</span></div>
<div style="position:absolute;left:306.64px;top:605.48px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Out of 2049 pts in analysis, 461, 572, 335, and 681 pts</span></div>
<div style="position:absolute;left:50.00px;top:615.60px" class="cls_031"><span class="cls_031">were: DAS28, SF-12, DLQI, presence of extra-articular manifesta-</span></div>
<div style="position:absolute;left:306.64px;top:615.52px" class="cls_031"><span class="cls_031">received SEC 300mg, 150mg, 150mg without load (NL) and pla-</span></div>
<div style="position:absolute;left:50.00px;top:625.61px" class="cls_031"><span class="cls_031">tions (EAMs; enthesitis & dactylitis), psoriasis BSA, achievement</span></div>
<div style="position:absolute;left:306.64px;top:625.55px" class="cls_031"><span class="cls_031">cebo (PBO), respectively. ACR 20/50 responses were improved</span></div>
<div style="position:absolute;left:50.00px;top:635.61px" class="cls_031"><span class="cls_031">of modified MDA (achievement of [i] 4/6 (MDA 1) and [ii] 5/6</span></div>
<div style="position:absolute;left:306.64px;top:635.59px" class="cls_031"><span class="cls_031">with SEC vs PBO at Wk 16 in both TNFi-naive/-IR pts and pts</span></div>
<div style="position:absolute;left:49.98px;top:645.61px" class="cls_031"><span class="cls_031">following criteria (MDA 2): TJC</span><span class="cls_030"> ≤ </span><span class="cls_031">1, SJC</span><span class="cls_030"> ≤ </span><span class="cls_031">1, BSA</span><span class="cls_030"> ≤ </span><span class="cls_031">3%, pain</span></div>
<div style="position:absolute;left:306.64px;top:645.62px" class="cls_031"><span class="cls_031">with/without concomitant MTX use (Table); improvements were</span></div>
<div style="position:absolute;left:49.98px;top:655.61px" class="cls_031"><span class="cls_031">VAS</span><span class="cls_030"> ≤ </span><span class="cls_031">15mm, PtGA</span><span class="cls_030"> ≤ </span><span class="cls_031">20 and HAQ</span><span class="cls_030"> ≤ </span><span class="cls_031">0.5), modified remission</span></div>
<div style="position:absolute;left:306.64px;top:655.66px" class="cls_031"><span class="cls_031">also observed with SEC vs PBO for all other secondary endpoints.</span></div>
<div style="position:absolute;left:49.97px;top:665.61px" class="cls_031"><span class="cls_031">(SJC</span><span class="cls_030"> = </span><span class="cls_031">0, TJC</span><span class="cls_030"> = </span><span class="cls_031">0, absence of enthesitis and dactylitis, BSA</span><span class="cls_030"> ≤ </span><span class="cls_031">3%</span></div>
<div style="position:absolute;left:306.64px;top:665.69px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">SEC provided improvement in the signs and</span></div>
<div style="position:absolute;left:49.97px;top:675.61px" class="cls_031"><span class="cls_031">and HAQ</span><span class="cls_030"> ≤ </span><span class="cls_031">0.5), DAPSA LDA (</span><span class="cls_030"> ≤ </span><span class="cls_031">14), and DAPSA remission</span></div>
<div style="position:absolute;left:306.64px;top:675.73px" class="cls_031"><span class="cls_031">symptoms of active PsA regardless of previous TNFi therapy or</span></div>
<div style="position:absolute;left:49.97px;top:685.61px" class="cls_031"><span class="cls_031">(REM; </span><span class="cls_030"> ≤ </span><span class="cls_031">4). Analyses were conducted by initial group assignment</span></div>
<div style="position:absolute;left:306.64px;top:685.76px" class="cls_031"><span class="cls_031">concomitant MTX use. Higher response rates were observed in</span></div>
<div style="position:absolute;left:49.97px;top:695.61px" class="cls_031"><span class="cls_031">(intent-to-treat approach).</span></div>
<div style="position:absolute;left:306.64px;top:695.80px" class="cls_031"><span class="cls_031">TNFi-naïve pts compared to TNFi-IR pts. SEC 300mg was as-</span></div>
<div style="position:absolute;left:49.97px;top:705.61px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">406 patients were included (nbDMARD </span><span class="cls_030">n = </span><span class="cls_031">146, ADA</span></div>
<div style="position:absolute;left:306.64px;top:705.83px" class="cls_031"><span class="cls_031">sociated with higher responses compared to 150mg in pts with</span></div>
<div style="position:absolute;left:49.97px;top:715.61px" class="cls_030"><span class="cls_030">n = </span><span class="cls_031">260). BL demographics were comparable between treatment</span></div>
<div style="position:absolute;left:306.64px;top:715.87px" class="cls_031"><span class="cls_031">TNFi-IR and no concomitant MTX use.</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:12848px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background18.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">16</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:306.36px;top:51.23px" class="cls_033"><span class="cls_033">P032</span></div>
<div style="position:absolute;left:50.00px;top:61.43px" class="cls_032"><span class="cls_032">1) J Rheumatol. 2017; 56(11):1993-03. 2) Rheumatology 2017;56:1993-03;</span></div>
<div style="position:absolute;left:306.36px;top:62.74px" class="cls_025"><span class="cls_025">IXEKIZUMAB IMPROVES NAIL AND SKIN PSORIASIS</span></div>
<div style="position:absolute;left:50.00px;top:70.43px" class="cls_032"><span class="cls_032">3) Arthritis Rheumatol. 2017;69 (s10); 4) PANLAR 2018, A718</span></div>
<div style="position:absolute;left:306.36px;top:73.73px" class="cls_025"><span class="cls_025">THROUGH 52 WEEKS OF TREATMENT IN PATIENTS</span></div>
<div style="position:absolute;left:50.00px;top:81.44px" class="cls_036"><span class="cls_036">Table: ACR20/50 responses at Week 16 by TNFi status and concomitant MTX use</span></div>
<div style="position:absolute;left:306.36px;top:84.73px" class="cls_025"><span class="cls_025">WITH   ACTIVE   PSORIATIC   ARTHRITIS:   RESULTS</span></div>
<div style="position:absolute;left:124.64px;top:92.87px" class="cls_037"><span class="cls_037">ACR20/50 Response [Treatment Effect vs. PBO at Week 16 (%)]</span></div>
<div style="position:absolute;left:306.36px;top:95.73px" class="cls_025"><span class="cls_025">FROM TWO RANDOMIZED, DOUBLE-BLIND, PHASE 3,</span></div>
<div style="position:absolute;left:51.38px;top:101.03px" class="cls_037"><span class="cls_037">Pts subgroup</span></div>
<div style="position:absolute;left:124.64px;top:101.03px" class="cls_037"><span class="cls_037">SEC 300mg</span></div>
<div style="position:absolute;left:191.36px;top:101.03px" class="cls_037"><span class="cls_037">SEC 150mg</span></div>
<div style="position:absolute;left:245.37px;top:101.03px" class="cls_037"><span class="cls_037">SEC 150mg (NL)</span></div>
<div style="position:absolute;left:51.38px;top:107.19px" class="cls_037"><span class="cls_037">TNFi naïve</span></div>
<div style="position:absolute;left:124.64px;top:107.19px" class="cls_037"><span class="cls_037">34.6/30.1</span></div>
<div style="position:absolute;left:191.36px;top:107.19px" class="cls_037"><span class="cls_037">31.6/25.1</span></div>
<div style="position:absolute;left:245.37px;top:107.19px" class="cls_037"><span class="cls_037">34.5/22.6</span></div>
<div style="position:absolute;left:306.36px;top:106.73px" class="cls_025"><span class="cls_025">CLINICAL TRIALS (SPIRIT-P1 AND SPIRIT-P2)</span></div>
<div style="position:absolute;left:51.38px;top:113.35px" class="cls_037"><span class="cls_037">TNFi-IR</span></div>
<div style="position:absolute;left:124.64px;top:113.35px" class="cls_037"><span class="cls_037">29.3/18.1</span></div>
<div style="position:absolute;left:191.36px;top:113.35px" class="cls_037"><span class="cls_037">24.5/14.7</span></div>
<div style="position:absolute;left:245.37px;top:113.35px" class="cls_037"><span class="cls_037">17.8/8.3</span></div>
<div style="position:absolute;left:51.38px;top:119.52px" class="cls_037"><span class="cls_037">With MTX</span></div>
<div style="position:absolute;left:124.64px;top:119.52px" class="cls_037"><span class="cls_037">23.1/20.1</span></div>
<div style="position:absolute;left:191.36px;top:119.52px" class="cls_037"><span class="cls_037">28.1/20.1</span></div>
<div style="position:absolute;left:245.37px;top:119.52px" class="cls_037"><span class="cls_037">23.5/11.3</span></div>
<div style="position:absolute;left:306.36px;top:116.73px" class="cls_051"><span class="cls_051">Joseph F. Merola</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Mitsumasha Kishimoto</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, David Adams</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, So</span></div>
<div style="position:absolute;left:51.38px;top:125.68px" class="cls_037"><span class="cls_037">Without MTX</span></div>
<div style="position:absolute;left:124.64px;top:125.68px" class="cls_037"><span class="cls_037">41.6/29.1</span></div>
<div style="position:absolute;left:191.36px;top:125.68px" class="cls_037"><span class="cls_037">29.7/20.6</span></div>
<div style="position:absolute;left:245.37px;top:125.68px" class="cls_037"><span class="cls_037">34.5/22.6</span></div>
<div style="position:absolute;left:306.37px;top:126.74px" class="cls_026"><span class="cls_026">Young Park</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Diamant Thaçi</span><span class="cls_027"><sup>4</sup></span></div>
<div style="position:absolute;left:306.36px;top:137.45px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Dermatology and Medicine, Division of Rheumatology,</span></div>
<div style="position:absolute;left:50.00px;top:140.51px" class="cls_033"><span class="cls_033">P031</span></div>
<div style="position:absolute;left:306.37px;top:147.15px" class="cls_029"><span class="cls_029">Harvard Medical School, Brigham and Women’s Hospital, Boston, MA,</span></div>
<div style="position:absolute;left:50.00px;top:151.91px" class="cls_025"><span class="cls_025">IMPACT OF ADALIMUMAB VS. NON-BIOLOGIC</span></div>
<div style="position:absolute;left:306.37px;top:156.85px" class="cls_029"><span class="cls_029">USA, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Immuno-Rheumatology Center, St. Luke’s International University,</span></div>
<div style="position:absolute;left:50.00px;top:162.81px" class="cls_025"><span class="cls_025">TREATMENTS ON SKIN OUTCOMES OF PSORIATIC</span></div>
<div style="position:absolute;left:306.37px;top:166.55px" class="cls_029"><span class="cls_029">St. Luke’s International Hospital, Tokyo, Japan, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Eli Lilly and Company,</span></div>
<div style="position:absolute;left:50.00px;top:173.71px" class="cls_025"><span class="cls_025">ARTHRITIS PATIENTS: REAL-WORLD DATA FROM</span></div>
<div style="position:absolute;left:306.36px;top:176.26px" class="cls_029"><span class="cls_029">Indianapolis, IN, USA, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Comprehensive Center for Inflammation Medicine,</span></div>
<div style="position:absolute;left:50.00px;top:184.61px" class="cls_025"><span class="cls_025">THE COMPLETE STUDY</span></div>
<div style="position:absolute;left:306.36px;top:185.96px" class="cls_029"><span class="cls_029">University Hospital, Schleswig-Holstein Campus Luebeck, Luebeck, Ger-</span></div>
<div style="position:absolute;left:50.00px;top:194.51px" class="cls_051"><span class="cls_051">Majed  Khraishi</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">,  Louis  Bessette</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">,  Boulos  Haraoui</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">,  Valencia</span></div>
<div style="position:absolute;left:306.36px;top:195.66px" class="cls_029"><span class="cls_029">many</span></div>
<div style="position:absolute;left:50.00px;top:204.41px" class="cls_026"><span class="cls_026">Remple</span><span class="cls_027"><sup>4</sup></span></div>
<div style="position:absolute;left:306.36px;top:206.63px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Ixekizumab (IXE), a high-affinity monoclonal</span></div>
<div style="position:absolute;left:50.00px;top:215.01px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Memorial University of Newfoundland, St. John’s NL, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Laval University,</span></div>
<div style="position:absolute;left:306.36px;top:216.73px" class="cls_031"><span class="cls_031">antibody that selectively targets interleukin-17A, is approved for</span></div>
<div style="position:absolute;left:50.00px;top:224.61px" class="cls_029"><span class="cls_029">Centre Hospitalier de l’Université Laval, Quebec, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Centre hospitalier de</span></div>
<div style="position:absolute;left:306.36px;top:226.82px" class="cls_031"><span class="cls_031">treatment of patients (pts) with active psoriatic arthritis (PsA) and</span></div>
<div style="position:absolute;left:50.00px;top:234.21px" class="cls_029"><span class="cls_029">l’Université de Montréal, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">AbbVie Corporation, Montreal, QC, Canada</span></div>
<div style="position:absolute;left:306.36px;top:236.92px" class="cls_031"><span class="cls_031">provides persistent efficacy through 52 weeks (wks) of treatment.</span></div>
<div style="position:absolute;left:50.00px;top:245.08px" class="cls_030"><span class="cls_030">Background: </span><span class="cls_031">Previous studies have shown the efficacy of anti-</span></div>
<div style="position:absolute;left:306.36px;top:247.02px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To evaluate the efficacy of IXE treatment over 52 wks on</span></div>
<div style="position:absolute;left:50.00px;top:255.07px" class="cls_031"><span class="cls_031">TNFα agents in improving nail, skin and joint manifestations of</span></div>
<div style="position:absolute;left:306.36px;top:257.12px" class="cls_031"><span class="cls_031">nail and skin psoriasis in biologic disease-modifying anti-rheuma-</span></div>
<div style="position:absolute;left:50.01px;top:265.07px" class="cls_031"><span class="cls_031">psoriatic arthritis (PsA). However, real-world data on the com-</span></div>
<div style="position:absolute;left:306.36px;top:267.24px" class="cls_031"><span class="cls_031">tic drug (bDMARD)-naïve and -experienced pts with active PsA.</span></div>
<div style="position:absolute;left:50.00px;top:275.08px" class="cls_031"><span class="cls_031">parative effectiveness of switching to or adding these agents vs.</span></div>
<div style="position:absolute;left:306.36px;top:277.34px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Adult pts with active PsA were bDMARD-naïve (SPI-</span></div>
<div style="position:absolute;left:50.00px;top:285.07px" class="cls_031"><span class="cls_031">continuing non-biologic treatments in patients having failed prior</span></div>
<div style="position:absolute;left:306.36px;top:287.44px" class="cls_031"><span class="cls_031">RIT-P1) or -experienced (SPIRIT-P2, TNF inhibitor inadequate</span></div>
<div style="position:absolute;left:50.00px;top:295.07px" class="cls_031"><span class="cls_031">non-biologic treatment are necessary to support the integration of</span></div>
<div style="position:absolute;left:306.36px;top:297.54px" class="cls_031"><span class="cls_031">responders [TNFi-IR] or intolerant). Pts were randomized to IXE</span></div>
<div style="position:absolute;left:50.00px;top:305.07px" class="cls_031"><span class="cls_031">treatment algorithms into routine care.</span></div>
<div style="position:absolute;left:306.36px;top:307.64px" class="cls_031"><span class="cls_031">80 mg every 2 (Q2W) or 4 wks (Q4W), placebo, or (in SPIRIT-</span></div>
<div style="position:absolute;left:50.00px;top:315.07px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">The aim of this analysis was to compare the effect</span></div>
<div style="position:absolute;left:306.36px;top:317.74px" class="cls_031"><span class="cls_031">P1) 40 mg adalimumab Q2W. Efficacy of IXE on nail and skin</span></div>
<div style="position:absolute;left:50.00px;top:325.07px" class="cls_031"><span class="cls_031">of adalimumab (ADA) vs. non-biologic treatments (nbDMARD:</span></div>
<div style="position:absolute;left:306.36px;top:327.84px" class="cls_031"><span class="cls_031">psoriasis in patients randomized to IXE was measured by the Nail</span></div>
<div style="position:absolute;left:50.00px;top:335.07px" class="cls_031"><span class="cls_031">NSAIDs and DMARDs) on skin outcomes and patient reported</span></div>
<div style="position:absolute;left:306.36px;top:337.93px" class="cls_031"><span class="cls_031">Psoriasis Severity Index (NAPSI), Psoriasis Area and Severity</span></div>
<div style="position:absolute;left:50.00px;top:345.07px" class="cls_031"><span class="cls_031">outcomes following initial treatment failure. In addition, the im-</span></div>
<div style="position:absolute;left:306.36px;top:348.03px" class="cls_031"><span class="cls_031">Index (PASI), and static Physician Global Assessment (sPGA).</span></div>
<div style="position:absolute;left:50.00px;top:355.08px" class="cls_031"><span class="cls_031">pact of the extent of baseline skin disease on treatment outcomes</span></div>
<div style="position:absolute;left:306.36px;top:358.13px" class="cls_031"><span class="cls_031">Missing data were imputed using nonresponder imputation for</span></div>
<div style="position:absolute;left:50.00px;top:365.07px" class="cls_031"><span class="cls_031">was examined.</span></div>
<div style="position:absolute;left:306.36px;top:368.23px" class="cls_031"><span class="cls_031">categorical variables and modified baseline observation carried</span></div>
<div style="position:absolute;left:50.00px;top:375.07px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Patients eligible for COMPLETE PsA are anti-TNFα</span></div>
<div style="position:absolute;left:306.36px;top:378.33px" class="cls_031"><span class="cls_031">forward for continuous variables.</span></div>
<div style="position:absolute;left:49.98px;top:385.07px" class="cls_031"><span class="cls_031">naïve adults, with active PsA who require change in their treatment</span></div>
<div style="position:absolute;left:306.36px;top:388.42px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">IXE provided high clinical response in skin and nail</span></div>
<div style="position:absolute;left:49.96px;top:395.07px" class="cls_031"><span class="cls_031">regimen, per the judgment of the treating physician. In the current</span></div>
<div style="position:absolute;left:306.36px;top:398.52px" class="cls_031"><span class="cls_031">psoriasis that persisted through 52 wks of treatment, regardless</span></div>
<div style="position:absolute;left:49.96px;top:405.07px" class="cls_031"><span class="cls_031">analysis patients enrolled between July/2011 - Jun/2016 who had</span></div>
<div style="position:absolute;left:306.36px;top:408.62px" class="cls_031"><span class="cls_031">of IXE dosing or prior bDMARD use (Table).</span></div>
<div style="position:absolute;left:49.96px;top:415.07px" class="cls_031"><span class="cls_031">available information on baseline psoriasis body surface area (BSA)</span></div>
<div style="position:absolute;left:387.08px;top:422.22px" class="cls_037"><span class="cls_037">SPIRIT-P1</span></div>
<div style="position:absolute;left:467.08px;top:422.22px" class="cls_037"><span class="cls_037">SPIRIT-P2</span></div>
<div style="position:absolute;left:49.96px;top:425.07px" class="cls_031"><span class="cls_031">were included. Outcome measures analyzed were: BSA, Derma-</span></div>
<div style="position:absolute;left:387.08px;top:429.23px" class="cls_037"><span class="cls_037">(bDMARD Naïve)</span></div>
<div style="position:absolute;left:467.08px;top:429.23px" class="cls_037"><span class="cls_037">(TNFi-IR or Intolerant)</span></div>
<div style="position:absolute;left:50.00px;top:435.08px" class="cls_031"><span class="cls_031">tology Life Quality Index (DLQI), Short Form Health Survey</span></div>
<div style="position:absolute;left:387.08px;top:437.39px" class="cls_037"><span class="cls_037">IXE Q4W</span></div>
<div style="position:absolute;left:427.81px;top:437.39px" class="cls_037"><span class="cls_037">IXE Q2W</span></div>
<div style="position:absolute;left:467.08px;top:437.39px" class="cls_037"><span class="cls_037">IXE Q4W</span></div>
<div style="position:absolute;left:508.81px;top:437.39px" class="cls_037"><span class="cls_037">IXE Q2W</span></div>
<div style="position:absolute;left:387.08px;top:444.39px" class="cls_038"><span class="cls_038">n = </span><span class="cls_037">107</span></div>
<div style="position:absolute;left:427.81px;top:444.39px" class="cls_038"><span class="cls_038">n = </span><span class="cls_037">103</span></div>
<div style="position:absolute;left:467.08px;top:444.39px" class="cls_038"><span class="cls_038">n = </span><span class="cls_037">122</span></div>
<div style="position:absolute;left:508.81px;top:444.39px" class="cls_038"><span class="cls_038">n = </span><span class="cls_037">123</span></div>
<div style="position:absolute;left:50.00px;top:445.07px" class="cls_031"><span class="cls_031">(SF-12), and the Beck Depression Inventory (BDI). Analyses were</span></div>
<div style="position:absolute;left:307.36px;top:454.55px" class="cls_037"><span class="cls_037">PASI 75</span><span class="cls_039"><sup>a</sup></span></div>
<div style="position:absolute;left:387.09px;top:454.55px" class="cls_037"><span class="cls_037">52/73 (71.2)</span></div>
<div style="position:absolute;left:427.81px;top:454.55px" class="cls_037"><span class="cls_037">45/59 (76.3)</span></div>
<div style="position:absolute;left:467.09px;top:454.55px" class="cls_037"><span class="cls_037">41/68 (60.3)</span></div>
<div style="position:absolute;left:508.81px;top:454.55px" class="cls_037"><span class="cls_037">37/68 (54.4)</span></div>
<div style="position:absolute;left:50.00px;top:455.07px" class="cls_031"><span class="cls_031">conducted by initial group assignment (intent-to-treat approach).</span></div>
<div style="position:absolute;left:307.36px;top:460.71px" class="cls_037"><span class="cls_037">PASI 90</span><span class="cls_039"><sup>a</sup></span></div>
<div style="position:absolute;left:387.09px;top:460.71px" class="cls_037"><span class="cls_037">44/73 (60.3)</span></div>
<div style="position:absolute;left:427.81px;top:460.71px" class="cls_037"><span class="cls_037">43/59 (72.9)</span></div>
<div style="position:absolute;left:467.09px;top:460.71px" class="cls_037"><span class="cls_037">34/68 (50.0)</span></div>
<div style="position:absolute;left:508.81px;top:460.71px" class="cls_037"><span class="cls_037">27/68 (39.7)</span></div>
<div style="position:absolute;left:50.00px;top:465.07px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">A total of 392 patients were included (ADA </span><span class="cls_030">n = </span><span class="cls_031">249,</span></div>
<div style="position:absolute;left:307.36px;top:466.87px" class="cls_037"><span class="cls_037">PASI 100</span><span class="cls_039"><sup>a</sup></span></div>
<div style="position:absolute;left:387.09px;top:466.87px" class="cls_037"><span class="cls_037">37/73 (50.7)</span></div>
<div style="position:absolute;left:427.81px;top:466.87px" class="cls_037"><span class="cls_037">37/59 (62.7)</span></div>
<div style="position:absolute;left:467.09px;top:466.87px" class="cls_037"><span class="cls_037">27/68 (39.7)</span></div>
<div style="position:absolute;left:508.81px;top:466.87px" class="cls_037"><span class="cls_037">24/68 (35.3)</span></div>
<div style="position:absolute;left:307.36px;top:473.03px" class="cls_037"><span class="cls_037">sPGA 0/1</span><span class="cls_039"><sup>b</sup></span></div>
<div style="position:absolute;left:387.09px;top:473.03px" class="cls_037"><span class="cls_037">39/52 (75.0)</span></div>
<div style="position:absolute;left:427.81px;top:473.03px" class="cls_037"><span class="cls_037">29/41 (70.7)</span></div>
<div style="position:absolute;left:467.09px;top:473.03px" class="cls_037"><span class="cls_037">37/60 (61.7)</span></div>
<div style="position:absolute;left:508.81px;top:473.03px" class="cls_037"><span class="cls_037">41/62 (66.1)</span></div>
<div style="position:absolute;left:50.00px;top:475.07px" class="cls_031"><span class="cls_031">nbDMARD </span><span class="cls_030">n = </span><span class="cls_031">143). Baseline demographics and disease duration</span></div>
<div style="position:absolute;left:307.36px;top:479.19px" class="cls_037"><span class="cls_037">sPGA 0</span><span class="cls_039"><sup>b</sup></span></div>
<div style="position:absolute;left:387.09px;top:479.19px" class="cls_037"><span class="cls_037">29/52 (55.8)</span></div>
<div style="position:absolute;left:427.81px;top:479.19px" class="cls_037"><span class="cls_037">23/41 (56.1)</span></div>
<div style="position:absolute;left:467.09px;top:479.19px" class="cls_037"><span class="cls_037">26/60 (43.3)</span></div>
<div style="position:absolute;left:508.81px;top:479.19px" class="cls_037"><span class="cls_037">27/62 (43.5)</span></div>
<div style="position:absolute;left:307.36px;top:485.35px" class="cls_037"><span class="cls_037">NAPSI </span><span class="cls_038"> = </span><span class="cls_037">0</span><span class="cls_039"><sup>c</sup></span></div>
<div style="position:absolute;left:387.09px;top:485.35px" class="cls_037"><span class="cls_037">30/69 (43.5)</span></div>
<div style="position:absolute;left:427.81px;top:485.35px" class="cls_037"><span class="cls_037">28/74 (37.8)</span></div>
<div style="position:absolute;left:467.09px;top:485.35px" class="cls_037"><span class="cls_037">41/89 (46.1)</span></div>
<div style="position:absolute;left:508.81px;top:485.35px" class="cls_037"><span class="cls_037">24/74 (32.4)</span></div>
<div style="position:absolute;left:50.00px;top:485.07px" class="cls_031"><span class="cls_031">were comparable between treatment groups. However, patients</span></div>
<div style="position:absolute;left:307.36px;top:491.51px" class="cls_037"><span class="cls_037">NAPSI mean (SD) change from -15.9 (18.3)</span></div>
<div style="position:absolute;left:427.81px;top:491.51px" class="cls_037"><span class="cls_037">-20.0</span></div>
<div style="position:absolute;left:442.23px;top:491.51px" class="cls_037"><span class="cls_037">(20.8)</span></div>
<div style="position:absolute;left:467.09px;top:491.51px" class="cls_037"><span class="cls_037">-15.2</span></div>
<div style="position:absolute;left:481.50px;top:491.51px" class="cls_037"><span class="cls_037">(19.7)</span></div>
<div style="position:absolute;left:508.81px;top:491.51px" class="cls_037"><span class="cls_037">-14.4</span></div>
<div style="position:absolute;left:523.23px;top:491.51px" class="cls_037"><span class="cls_037">(19.0)</span></div>
<div style="position:absolute;left:50.00px;top:495.07px" class="cls_031"><span class="cls_031">initiating ADA were more likely to have BSA≥3% (44.6% vs.</span></div>
<div style="position:absolute;left:307.36px;top:498.52px" class="cls_037"><span class="cls_037">baselinec</span></div>
<div style="position:absolute;left:49.98px;top:505.07px" class="cls_031"><span class="cls_031">35%, </span><span class="cls_030">p = </span><span class="cls_031">0.063) and had higher DLQI (6.2 vs. 4.3, </span><span class="cls_030">p = </span><span class="cls_031">0.006)</span></div>
<div style="position:absolute;left:307.36px;top:506.67px" class="cls_037"><span class="cls_037">Unless otherwise indicated, values are presented as: n/Nx (%), where Nx is </span><span class="cls_039"><sup>a</sup></span><span class="cls_037">pts with baseline</span></div>
<div style="position:absolute;left:307.36px;top:512.67px" class="cls_037"><span class="cls_037">BSA≥3%, </span><span class="cls_039"><sup>b</sup></span><span class="cls_037">pts with baseline sPGA≥3, or </span><span class="cls_039"><sup>c</sup></span><span class="cls_037">pts with baseline fingernail psoriasis</span></div>
<div style="position:absolute;left:49.98px;top:515.07px" class="cls_031"><span class="cls_031">scores. No differences were observed in SF-12 physical (PCS)</span></div>
<div style="position:absolute;left:306.36px;top:520.73px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">In these two phase 3 clinical trials in patients with</span></div>
<div style="position:absolute;left:49.98px;top:525.07px" class="cls_031"><span class="cls_031">and mental (MCS) component scores at baseline.</span></div>
<div style="position:absolute;left:306.36px;top:530.83px" class="cls_031"><span class="cls_031">active PsA, ixekizumab provided persistent high clinical response</span></div>
<div style="position:absolute;left:49.98px;top:535.07px" class="cls_031"><span class="cls_031">During treatment, BSA levels significantly improved in both</span></div>
<div style="position:absolute;left:306.36px;top:540.93px" class="cls_031"><span class="cls_031">for improvement or clearance of nail and skin psoriasis through</span></div>
<div style="position:absolute;left:49.98px;top:545.06px" class="cls_031"><span class="cls_031">groups but more patients achieved a BSA</span><span class="cls_030"> &lt; </span><span class="cls_031">3% when treated</span></div>
<div style="position:absolute;left:306.36px;top:551.02px" class="cls_031"><span class="cls_031">52 wks of treatment.</span></div>
<div style="position:absolute;left:49.98px;top:555.06px" class="cls_031"><span class="cls_031">with ADA vs. nbDMARD both at 6 months (89.7% vs. 80.2%,</span></div>
<div style="position:absolute;left:49.98px;top:565.06px" class="cls_030"><span class="cls_030">p = </span><span class="cls_031">0.027) and 12 months (89.0% vs. 83.7%, </span><span class="cls_030">p = </span><span class="cls_031">0.222). Further-</span></div>
<div style="position:absolute;left:306.36px;top:570.77px" class="cls_033"><span class="cls_033">P034</span></div>
<div style="position:absolute;left:50.00px;top:575.08px" class="cls_031"><span class="cls_031">more, upon adjusting for baseline scores, patients in the ADA</span></div>
<div style="position:absolute;left:306.36px;top:582.27px" class="cls_025"><span class="cls_025">IXEKIZUMAB MAKES THERAPEUTIC THRESHOLDS</span></div>
<div style="position:absolute;left:50.00px;top:585.07px" class="cls_031"><span class="cls_031">group experienced greater improvements in DLQI (ΔLSM</span><span class="cls_030"> = </span><span class="cls_031">-1.62,</span></div>
<div style="position:absolute;left:50.00px;top:595.07px" class="cls_030"><span class="cls_030">p = </span><span class="cls_031">0.004), particularly in the daily activities, leisure, and work/</span></div>
<div style="position:absolute;left:306.36px;top:593.27px" class="cls_025"><span class="cls_025">POSSIBLE IN ACTIVE PSORIATIC ARTHRITIS</span></div>
<div style="position:absolute;left:50.00px;top:605.07px" class="cls_031"><span class="cls_031">school domains, and SF-12 PCS (ΔLSM</span><span class="cls_030"> = </span><span class="cls_031">0.36, </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001). These</span></div>
<div style="position:absolute;left:306.36px;top:604.27px" class="cls_025"><span class="cls_025">PATIENTS: RESULTS FROM SPIRIT TRIALS</span></div>
<div style="position:absolute;left:50.01px;top:615.07px" class="cls_031"><span class="cls_031">differences between groups in BSA levels and DLQI improvement</span></div>
<div style="position:absolute;left:306.36px;top:614.27px" class="cls_026"><span class="cls_026">Laura C Coates</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, M. Elaine Husni</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Eric Lespessailles</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Lisa Kerr</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:50.01px;top:625.07px" class="cls_031"><span class="cls_031">were more profound among patients with BSA≥3% at baseline.</span></div>
<div style="position:absolute;left:306.36px;top:624.28px" class="cls_051"><span class="cls_051">Gaia Gallo</span><span class="cls_027"><sup>4</sup></span></div>
<div style="position:absolute;left:50.01px;top:635.07px" class="cls_031"><span class="cls_031">During follow-up, 9.2% of ADA patients initiated another biologic</span></div>
<div style="position:absolute;left:306.36px;top:634.98px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">University of Oxford, Leeds, UK, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Cleveland Clinic, Cleveland, OH, USA,</span></div>
<div style="position:absolute;left:50.01px;top:645.07px" class="cls_031"><span class="cls_031">and 32.2% of patients in the nbDMARD group initiated biologic</span></div>
<div style="position:absolute;left:306.36px;top:644.69px" class="cls_028"><span class="cls_028"><sup>3</sup></span><span class="cls_029">Université d’Orléans, Orléans, EA, France, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Eli Lilly and Company, In-</span></div>
<div style="position:absolute;left:50.01px;top:655.07px" class="cls_031"><span class="cls_031">treatment (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001).</span></div>
<div style="position:absolute;left:306.37px;top:654.39px" class="cls_029"><span class="cls_029">dianapolis, IN, USA</span></div>
<div style="position:absolute;left:50.01px;top:665.07px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">PsA patients starting ADA following initial fai-</span></div>
<div style="position:absolute;left:306.36px;top:665.36px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Treatment goals in psoriatic arthritis (PsA) are mo-</span></div>
<div style="position:absolute;left:50.00px;top:675.08px" class="cls_031"><span class="cls_031">lure of non-biologic treatment in Canadian routine clinical care</span></div>
<div style="position:absolute;left:306.36px;top:675.46px" class="cls_031"><span class="cls_031">ving toward attainment of absolute therapeutic thresholds rather</span></div>
<div style="position:absolute;left:50.00px;top:685.07px" class="cls_031"><span class="cls_031">experience greater benefits in skin outcomes and quality of life</span></div>
<div style="position:absolute;left:306.36px;top:685.56px" class="cls_031"><span class="cls_031">than relative improvement.</span></div>
<div style="position:absolute;left:50.00px;top:695.07px" class="cls_031"><span class="cls_031">compared to switching to different non-biologic treatment. These</span></div>
<div style="position:absolute;left:306.36px;top:695.65px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To explore the effect of ixekizumab (IXE), an anti-IL-</span></div>
<div style="position:absolute;left:50.00px;top:705.07px" class="cls_031"><span class="cls_031">benefits are particularly evident among patients with more severe</span></div>
<div style="position:absolute;left:306.36px;top:705.75px" class="cls_031"><span class="cls_031">17A monoclonal antibody, as assessed by composite endpoints,</span></div>
<div style="position:absolute;left:50.00px;top:715.07px" class="cls_031"><span class="cls_031">skin disease at baseline.</span></div>
<div style="position:absolute;left:306.36px;top:715.85px" class="cls_031"><span class="cls_031">up to 52 weeks (wks) for the SPIRIT-P1 and SPIRIT-P2 trials.</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:13651px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background19.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">17</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Data were analyzed from 2 double-blind, phase 3 trials</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">receive either 100 mg MP1032 or placebo by twice daily oral</span></div>
<div style="position:absolute;left:50.00px;top:61.41px" class="cls_031"><span class="cls_031">investigating the efficacy and safety of IXE in active PsA patients</span></div>
<div style="position:absolute;left:306.64px;top:61.40px" class="cls_031"><span class="cls_031">administration. The study design consisted of a 42 day treatment</span></div>
<div style="position:absolute;left:49.98px;top:71.41px" class="cls_031"><span class="cls_031">(pts). For SPIRIT-1 [1] biologic disease-modifying antirheumatic</span></div>
<div style="position:absolute;left:306.64px;top:71.40px" class="cls_031"><span class="cls_031">period with a follow-up of 28 days. Pharmacokinetic sampling</span></div>
<div style="position:absolute;left:49.98px;top:81.41px" class="cls_031"><span class="cls_031">drug-naïve pts were randomized to placebo (PBO, </span><span class="cls_030">n = </span><span class="cls_031">106) or</span></div>
<div style="position:absolute;left:306.64px;top:81.40px" class="cls_031"><span class="cls_031">occurred on day 1 at 15, 30, 60, and 120 min post-dose. Adverse</span></div>
<div style="position:absolute;left:49.98px;top:91.41px" class="cls_031"><span class="cls_031">80 mg IXE every 4 wks (Q4W, </span><span class="cls_030">n = </span><span class="cls_031">107) or every 2 wks (Q2W,</span></div>
<div style="position:absolute;left:306.64px;top:91.40px" class="cls_031"><span class="cls_031">events were coded according to the Medical Dictionary for Regu-</span></div>
<div style="position:absolute;left:49.98px;top:101.41px" class="cls_030"><span class="cls_030">n = </span><span class="cls_031">103) post 160 mg starting dose. For SPIRIT-2 [2] (inadequate</span></div>
<div style="position:absolute;left:306.64px;top:101.41px" class="cls_031"><span class="cls_031">latory Activities. Efficacy parameters were assessed at screening</span></div>
<div style="position:absolute;left:49.98px;top:111.41px" class="cls_031"><span class="cls_031">responders to tumor necrosis factor inhibitors [TNFi]) pts were</span></div>
<div style="position:absolute;left:306.65px;top:111.40px" class="cls_031"><span class="cls_031">and on day 1, 15, 29, 43, 57, and 71.</span></div>
<div style="position:absolute;left:49.98px;top:121.41px" class="cls_031"><span class="cls_031">randomized to PBO (</span><span class="cls_030">n = </span><span class="cls_031">118) or 80 mg IXE Q4W (</span><span class="cls_030">n = </span><span class="cls_031">122) or</span></div>
<div style="position:absolute;left:306.65px;top:121.40px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Enrolled patients had an average age of 40 years (21-65</span></div>
<div style="position:absolute;left:49.98px;top:131.41px" class="cls_031"><span class="cls_031">Q2W (</span><span class="cls_030">n = </span><span class="cls_031">123) post 160 mg starting dose. Minimal disease ac-</span></div>
<div style="position:absolute;left:306.65px;top:131.40px" class="cls_031"><span class="cls_031">years) and a median baseline PASI of 13.6 (ranging from 10.1 to</span></div>
<div style="position:absolute;left:50.00px;top:141.41px" class="cls_031"><span class="cls_031">tivity (MDA), MDA very low disease activity (VLDA), Disease</span></div>
<div style="position:absolute;left:306.65px;top:141.40px" class="cls_031"><span class="cls_031">40.8). Pharmacokinetic evaluation demonstrated that MP1032</span></div>
<div style="position:absolute;left:50.00px;top:151.41px" class="cls_031"><span class="cls_031">Activity in Psoriatic Arthritis (DAPSA) LDA, DAPSA remission,</span></div>
<div style="position:absolute;left:306.65px;top:151.40px" class="cls_031"><span class="cls_031">was rapidly absorbed, reaching maximum plasma concentrations</span></div>
<div style="position:absolute;left:50.00px;top:161.41px" class="cls_031"><span class="cls_031">Psoriatic Arthritis Disease Activity Score (PASDAS) LDA, and</span></div>
<div style="position:absolute;left:306.65px;top:161.40px" class="cls_031"><span class="cls_031">within 15 min after administration. Then, MP1032 plasma levels</span></div>
<div style="position:absolute;left:50.00px;top:171.41px" class="cls_031"><span class="cls_031">PASDAS VLDA composite endpoints were evaluated. Imputa-</span></div>
<div style="position:absolute;left:306.65px;top:171.40px" class="cls_031"><span class="cls_031">were quickly declining, indicating a fast elimination. Safety</span></div>
<div style="position:absolute;left:50.00px;top:181.41px" class="cls_031"><span class="cls_031">tion for categorical responses was non-responder imputation.</span></div>
<div style="position:absolute;left:306.65px;top:181.40px" class="cls_031"><span class="cls_031">analysis did not reveal any clinically important safety issues. No</span></div>
<div style="position:absolute;left:50.00px;top:191.41px" class="cls_031"><span class="cls_031">Treatment comparisons (with placebo up to Wk 24) based on the</span></div>
<div style="position:absolute;left:306.65px;top:191.40px" class="cls_031"><span class="cls_031">serious adverse events or deaths were reported and the incidence</span></div>
<div style="position:absolute;left:50.00px;top:201.41px" class="cls_031"><span class="cls_031">intent-to-treat population were made using a logistic regression</span></div>
<div style="position:absolute;left:306.65px;top:201.40px" class="cls_031"><span class="cls_031">of treatment emergent adverse events (TEAEs) between placebo</span></div>
<div style="position:absolute;left:50.00px;top:211.41px" class="cls_031"><span class="cls_031">model. Data up to Wk52 are summarized.</span></div>
<div style="position:absolute;left:306.65px;top:211.39px" class="cls_031"><span class="cls_031">and the MP1032 treatment group was comparable. The majority</span></div>
<div style="position:absolute;left:50.00px;top:221.41px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">At Wk 24, percentage of pts achieving MDA (SPIRIT-P1</span></div>
<div style="position:absolute;left:306.65px;top:221.39px" class="cls_031"><span class="cls_031">of TEAEs were mild to moderate in nature (mostly common cold,</span></div>
<div style="position:absolute;left:50.00px;top:231.41px" class="cls_031"><span class="cls_031">Q4W: 29.9; Q2W: 40.8; PBO: 15.1; SPIRIT-P2 Q4W: 27.9; Q2W:</span></div>
<div style="position:absolute;left:306.65px;top:231.39px" class="cls_031"><span class="cls_031">headache, and itching). Analysis of clinical laboratory data and</span></div>
<div style="position:absolute;left:50.00px;top:241.41px" class="cls_031"><span class="cls_031">31.9; PBO: 3.4), MDA VLDA (SPIRIT-P1 Q4W: 10.3; Q2W:</span></div>
<div style="position:absolute;left:306.65px;top:241.39px" class="cls_031"><span class="cls_031">vital signs did also not reveal any adverse effects of MP1032. After</span></div>
<div style="position:absolute;left:50.00px;top:251.41px" class="cls_031"><span class="cls_031">11.7; PBO: 0.9; SPIRIT-P2 Q4W: 12.3; IXEQ2W: 3.3; PBO: 0.8),</span></div>
<div style="position:absolute;left:306.65px;top:251.39px" class="cls_031"><span class="cls_031">only six weeks of treatment, MP1032 led to a PASI reduction of</span></div>
<div style="position:absolute;left:50.00px;top:261.41px" class="cls_031"><span class="cls_031">DAPSA LDA (SPIRIT-P1 Q4W: 31.8; Q2W: 34.0; PBO: 17.9;</span></div>
<div style="position:absolute;left:306.65px;top:261.39px" class="cls_031"><span class="cls_031">about 25% in patients who entered the study with a PASI of 10-15.</span></div>
<div style="position:absolute;left:50.00px;top:271.41px" class="cls_031"><span class="cls_031">SPIRIT-P2 Q4W: 25.4; Q2W: 27.6; PBO: 11.1), DAPSA remission</span></div>
<div style="position:absolute;left:306.65px;top:271.39px" class="cls_031"><span class="cls_031">In contrast, placebo administration reduced the respective PASI</span></div>
<div style="position:absolute;left:50.00px;top:281.40px" class="cls_031"><span class="cls_031">(SPIRIT-P1 Q4W: 15.9; Q2W: 24.3; PBO: 4.7; SPIRIT-P2 Q4W:</span></div>
<div style="position:absolute;left:306.65px;top:281.39px" class="cls_031"><span class="cls_031">only about 12%. During the four-week follow-up period, median</span></div>
<div style="position:absolute;left:50.00px;top:291.40px" class="cls_031"><span class="cls_031">14.8; Q2W: 7.3; PBO: 0.8), PASDAS LDA (SPIRIT-P1 Q4W:</span></div>
<div style="position:absolute;left:306.65px;top:291.39px" class="cls_031"><span class="cls_031">PASI scores in the MP1032 group trended back upward while the</span></div>
<div style="position:absolute;left:50.00px;top:301.40px" class="cls_031"><span class="cls_031">42.1; Q2W: 50.5; PBO: 18.9; SPIRIT-P2 Q4W: 39.3; Q2W: 35.0;</span></div>
<div style="position:absolute;left:306.65px;top:301.39px" class="cls_031"><span class="cls_031">placebo group remained unchanged, suggesting a positive thera-</span></div>
<div style="position:absolute;left:50.00px;top:311.40px" class="cls_031"><span class="cls_031">PBO: 6.8), and PASDAS VLDA (SPIRIT-P1 Q4W: 11.2; Q2W:</span></div>
<div style="position:absolute;left:306.64px;top:311.41px" class="cls_031"><span class="cls_031">peutic effect of MP1032. Since, patients with a lower basal PASI</span></div>
<div style="position:absolute;left:50.00px;top:321.40px" class="cls_031"><span class="cls_031">20.4; PBO: 1.9; SPIRIT-P2 Q4W: 13.1; Q2W: 7.3; PBO: 0.0) was</span></div>
<div style="position:absolute;left:306.64px;top:321.40px" class="cls_031"><span class="cls_031">had greater improvements during therapy than those with higher</span></div>
<div style="position:absolute;left:50.00px;top:331.40px" class="cls_031"><span class="cls_031">greater with Q4W and Q2W versus placebo.</span></div>
<div style="position:absolute;left:306.64px;top:331.40px" class="cls_031"><span class="cls_031">scores, MP1032 seems to be a treatment option for patients with</span></div>
<div style="position:absolute;left:50.00px;top:341.40px" class="cls_031"><span class="cls_031">Similarly, at Wk 52 the response rates were either sustained or</span></div>
<div style="position:absolute;left:306.64px;top:341.40px" class="cls_031"><span class="cls_031">mainly moderate psoriasis.</span></div>
<div style="position:absolute;left:50.00px;top:351.40px" class="cls_031"><span class="cls_031">improved: MDA (SPIRIT-P1 Q4W: 39.3; Q2W: 36.9; SPIRIT-P2</span></div>
<div style="position:absolute;left:306.64px;top:351.40px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">After six weeks of treatment, there was a clinically</span></div>
<div style="position:absolute;left:50.00px;top:361.40px" class="cls_031"><span class="cls_031">Q4W: 34.4; Q2W: 23.6), MDA VLDA (SPIRIT-P1 Q4W: 14.0;</span></div>
<div style="position:absolute;left:306.64px;top:361.40px" class="cls_031"><span class="cls_031">relevant response in patients who entered the study with PASI</span></div>
<div style="position:absolute;left:50.00px;top:371.40px" class="cls_031"><span class="cls_031">Q2W: 15.5; SPIRIT-P2 Q4W: 12.3; Q2W: 6.5), DAPSA LDA</span></div>
<div style="position:absolute;left:306.64px;top:371.40px" class="cls_031"><span class="cls_031">scores of 10-15. Overall, MP1032 demonstrated an excellent</span></div>
<div style="position:absolute;left:50.00px;top:381.39px" class="cls_031"><span class="cls_031">(SPIRIT-P1 Q4W: 30.8; Q2W: 29.1; SPIRIT-P2 Q4W: 34.4; Q2W:</span></div>
<div style="position:absolute;left:306.64px;top:381.40px" class="cls_031"><span class="cls_031">safety profile and was well tolerated. Hence, redox modulation</span></div>
<div style="position:absolute;left:50.00px;top:391.39px" class="cls_031"><span class="cls_031">26.0), DAPSA remission (SPIRIT-P1 Q4W: 22.4; Q2W: 29.1;</span></div>
<div style="position:absolute;left:306.65px;top:391.40px" class="cls_031"><span class="cls_031">targeted at the innate immune response represents a promising</span></div>
<div style="position:absolute;left:50.00px;top:401.39px" class="cls_031"><span class="cls_031">SPIRIT-P2 Q4W: 18.9; Q2W: 11.4), PASDAS LDA (SPIRIT-P1</span></div>
<div style="position:absolute;left:306.65px;top:401.40px" class="cls_031"><span class="cls_031">new therapeutic mechanism for psoriasis and other chronic in-</span></div>
<div style="position:absolute;left:50.00px;top:411.39px" class="cls_031"><span class="cls_031">Q4W: 43.0; Q2W: 50.5; SPIRIT-P2 Q4W: 45.1; Q2W: 30.9), and</span></div>
<div style="position:absolute;left:306.64px;top:411.41px" class="cls_031"><span class="cls_031">flammatory diseases.</span></div>
<div style="position:absolute;left:50.00px;top:421.39px" class="cls_031"><span class="cls_031">PASDAS VLDA (SPIRIT-P1 Q4W: 17.8; Q2W: 26.2; SPIRIT-P2</span></div>
<div style="position:absolute;left:50.00px;top:431.39px" class="cls_031"><span class="cls_031">Q4W: 17.2; Q2W: 11.4).</span></div>
<div style="position:absolute;left:306.64px;top:432.04px" class="cls_033"><span class="cls_033">P036</span></div>
<div style="position:absolute;left:50.00px;top:441.39px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Regardless of previous TNFi exposure, a higher</span></div>
<div style="position:absolute;left:306.64px;top:443.44px" class="cls_025"><span class="cls_025">SECUKINUMAB IMPROVES SIGNS AND SYMPTOMS</span></div>
<div style="position:absolute;left:50.00px;top:451.39px" class="cls_031"><span class="cls_031">proportion of IXE-treated pts achieved MDA and MDA VLDA,</span></div>
<div style="position:absolute;left:306.64px;top:454.34px" class="cls_025"><span class="cls_025">OF PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3</span></div>
<div style="position:absolute;left:50.00px;top:461.39px" class="cls_031"><span class="cls_031">DAPSA LDA and DAPSA remission, and PASDAS LDA and</span></div>
<div style="position:absolute;left:306.64px;top:465.24px" class="cls_025"><span class="cls_025">STUDY, FUTURE 5</span></div>
<div style="position:absolute;left:50.00px;top:471.39px" class="cls_031"><span class="cls_031">PASDAS VLDA at Wk 24 versus placebo. At Wk 52, the extent</span></div>
<div style="position:absolute;left:306.64px;top:475.14px" class="cls_051"><span class="cls_051">Philip J. Mease</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, D van der Heijde</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, R Landewé</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, S Mpofu</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, P Rah-</span></div>
<div style="position:absolute;left:50.00px;top:481.38px" class="cls_031"><span class="cls_031">of IXE clinical response sustained or further improved.</span></div>
<div style="position:absolute;left:306.64px;top:485.04px" class="cls_026"><span class="cls_026">man</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, H Tahir</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, A Singhal</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, S Navarra</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, E Boettcher</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, X Zhu</span><span class="cls_027"><sup>10</sup></span><span class="cls_026">, A</span></div>
<div style="position:absolute;left:50.00px;top:491.38px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:306.64px;top:494.94px" class="cls_026"><span class="cls_026">Readie</span><span class="cls_027"><sup>10</sup></span><span class="cls_026">, L Pricop</span><span class="cls_027"><sup>10</sup></span><span class="cls_026">, K Abrams</span><span class="cls_027"><sup>10</sup></span></div>
<div style="position:absolute;left:50.00px;top:501.43px" class="cls_032"><span class="cls_032">1. Mease PJ et al. Ann Rheum Dis. 2017;76(1):79-87. 2. Nash P et al.</span></div>
<div style="position:absolute;left:306.64px;top:505.54px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Swedish Medical Center and University of Washington, Seattle, WA, USA,</span></div>
<div style="position:absolute;left:50.00px;top:510.43px" class="cls_032"><span class="cls_032">Lancet. 2017;389(10086):2317-2327.</span></div>
<div style="position:absolute;left:306.64px;top:515.14px" class="cls_028"><span class="cls_028"><sup>2</sup></span><span class="cls_029">Leiden University Medical Center, Leiden, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">University of Amsterdam and</span></div>
<div style="position:absolute;left:306.64px;top:524.74px" class="cls_029"><span class="cls_029">Atrium Medical Center, Amsterdam, the Netherlands, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Novartis, Pharma</span></div>
<div style="position:absolute;left:50.00px;top:528.05px" class="cls_033"><span class="cls_033">P035</span></div>
<div style="position:absolute;left:306.64px;top:534.34px" class="cls_029"><span class="cls_029">AG, Basel, Switzerland, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Memorial University, Newfoundland and Labra-</span></div>
<div style="position:absolute;left:50.00px;top:539.45px" class="cls_025"><span class="cls_025">THE MACROPHAGE MODULATOR MP1032 SHOWS</span></div>
<div style="position:absolute;left:306.63px;top:543.94px" class="cls_029"><span class="cls_029">dor, Canada, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Whipps, Cross Hospital, London, UK, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Southwest Rheu-</span></div>
<div style="position:absolute;left:50.00px;top:550.35px" class="cls_025"><span class="cls_025">SAFETY AND EFFICACY IN A HUMAN PHASE IIA</span></div>
<div style="position:absolute;left:306.63px;top:553.54px" class="cls_029"><span class="cls_029">matology, Dallas, TX, USA, </span><span class="cls_028"><sup>8</sup></span><span class="cls_029">Rheumazentrum Favoriten, Vienna, Austria,</span></div>
<div style="position:absolute;left:50.00px;top:561.25px" class="cls_025"><span class="cls_025">STUDY FOR THE TREATMENT OF MODERATE-TO-</span></div>
<div style="position:absolute;left:306.64px;top:563.14px" class="cls_028"><span class="cls_028"><sup>9</sup></span><span class="cls_029">University of Santo Tomas Hospital, Manila, Philippines, </span><span class="cls_028"><sup>10</sup></span><span class="cls_029">Novartis Phar-</span></div>
<div style="position:absolute;left:50.00px;top:572.15px" class="cls_025"><span class="cls_025">SEVERE PLAQUE PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:572.74px" class="cls_029"><span class="cls_029">maceuticals Corporation, East Hanover, NJ, USA</span></div>
<div style="position:absolute;left:50.00px;top:582.05px" class="cls_051"><span class="cls_051">Petra Schulz</span><span class="cls_026">, Astrid Kaiser, David Kosel, Sara Schumann, Wolf-</span></div>
<div style="position:absolute;left:306.64px;top:583.61px" class="cls_030"><span class="cls_030">Introduction/Objectives: </span><span class="cls_031">Secukinumab (SEC), a fully human mAb</span></div>
<div style="position:absolute;left:50.01px;top:591.95px" class="cls_026"><span class="cls_026">gang Brysch</span></div>
<div style="position:absolute;left:306.64px;top:593.60px" class="cls_031"><span class="cls_031">to IL-17A, has shown efficacy in psoriatic arthritis (PsA). Here</span></div>
<div style="position:absolute;left:50.00px;top:602.55px" class="cls_029"><span class="cls_029">MetrioPharm GmbH, Berlin, Germany</span></div>
<div style="position:absolute;left:306.64px;top:603.60px" class="cls_031"><span class="cls_031">we present the primary results of FUTURE 5, assessing efficacy,</span></div>
<div style="position:absolute;left:50.00px;top:613.41px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">MP1032 belongs to a new class of anti-inflammatory</span></div>
<div style="position:absolute;left:306.65px;top:613.60px" class="cls_031"><span class="cls_031">including inhibition of radiographic progression of subcutaneous</span></div>
<div style="position:absolute;left:50.00px;top:623.41px" class="cls_031"><span class="cls_031">drugs that modulate the redox state of activated macrophages.</span></div>
<div style="position:absolute;left:306.65px;top:623.60px" class="cls_031"><span class="cls_031">(sc) SEC 300 and 150mg in patients (pts) with PsA (1).</span></div>
<div style="position:absolute;left:50.00px;top:633.41px" class="cls_031"><span class="cls_031">MP1032 attenuates pro-inflammatory cytokine secretion </span><span class="cls_030">in vivo</span></div>
<div style="position:absolute;left:306.65px;top:633.60px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Pts (</span><span class="cls_030">n = </span><span class="cls_031">996) with active PsA, were randomized (2:2:2:3)</span></div>
<div style="position:absolute;left:50.01px;top:643.41px" class="cls_031"><span class="cls_031">and </span><span class="cls_030">in vitro</span><span class="cls_031"> and has pronounced disease-modifying effects in</span></div>
<div style="position:absolute;left:306.65px;top:643.60px" class="cls_031"><span class="cls_031">to sc SEC 300mg with loading dosage (LD; </span><span class="cls_030">n = </span><span class="cls_031">222), 150mg with</span></div>
<div style="position:absolute;left:50.01px;top:653.41px" class="cls_031"><span class="cls_031">various preclinical models.</span></div>
<div style="position:absolute;left:306.65px;top:653.60px" class="cls_031"><span class="cls_031">LD (</span><span class="cls_030">n = </span><span class="cls_031">220), 150mg without LD (</span><span class="cls_030">n = </span><span class="cls_031">222), or placebo (PBO;</span></div>
<div style="position:absolute;left:50.01px;top:663.41px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">This randomized, double-blind, parallel, and placebo-</span></div>
<div style="position:absolute;left:306.65px;top:663.60px" class="cls_030"><span class="cls_030">n = </span><span class="cls_031">332). All groups received SEC or PBO at baseline (BL), Weeks</span></div>
<div style="position:absolute;left:50.01px;top:673.41px" class="cls_031"><span class="cls_031">controlled trial aimed to evaluate pharmacokinetics, safety, and</span></div>
<div style="position:absolute;left:306.65px;top:673.60px" class="cls_031"><span class="cls_031">(Wks) 1, 2, 3, and 4, and then every 4 wks. Primary endpoint</span></div>
<div style="position:absolute;left:50.01px;top:683.41px" class="cls_031"><span class="cls_031">efficacy of orally administered MP1032 in patients with moderate-</span></div>
<div style="position:absolute;left:306.65px;top:683.60px" class="cls_031"><span class="cls_031">was ACR20 at Wk16. Key secondary endpoint was radiographic</span></div>
<div style="position:absolute;left:50.01px;top:693.41px" class="cls_031"><span class="cls_031">to-severe plaque psoriasis.</span></div>
<div style="position:absolute;left:306.65px;top:693.59px" class="cls_031"><span class="cls_031">structural progression, as measured by modified total van der</span></div>
<div style="position:absolute;left:50.01px;top:703.41px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Forty-six patients with chronic plaque psoriasis (PASI </span><span class="cls_030"> ></span></div>
<div style="position:absolute;left:306.66px;top:703.59px" class="cls_031"><span class="cls_031">Heijde Sharp score (mTSS).</span></div>
<div style="position:absolute;left:50.01px;top:713.40px" class="cls_031"><span class="cls_031">10; disease duration ≥ 6 months) were equally randomized to</span></div>
<div style="position:absolute;left:306.66px;top:713.59px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">SEC significantly improved ACR20 at Wk16 vs PBO</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:14454px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background20.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">18</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">(Table). Radiographic progression (mTSS) was significantly</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">A total of 7355 pts receiving secukinumab were asses-</span></div>
<div style="position:absolute;left:49.99px;top:61.41px" class="cls_031"><span class="cls_031">inhibited at Wk24 in all SEC arms vs PBO (Table). A greater pro-</span></div>
<div style="position:absolute;left:306.64px;top:61.51px" class="cls_031"><span class="cls_031">sed for the presence of IBD: 5181 with psoriasis, 1380 with PsA,</span></div>
<div style="position:absolute;left:50.00px;top:71.41px" class="cls_031"><span class="cls_031">portion of pts had no radiographic progression (change from BL</span></div>
<div style="position:absolute;left:306.64px;top:71.61px" class="cls_031"><span class="cls_031">and 794 with AS. Over the entire treatment period, the mean total</span></div>
<div style="position:absolute;left:50.00px;top:81.41px" class="cls_031"><span class="cls_031">in mTSS </span><span class="cls_030"> ≤ </span><span class="cls_031">0.5) with SEC vs PBO: 88% (300mg), 79% (150mg),</span></div>
<div style="position:absolute;left:306.64px;top:81.71px" class="cls_031"><span class="cls_031">exposure to secukinumab was 10,416.9 patient-years (pt-yrs) in</span></div>
<div style="position:absolute;left:50.00px;top:91.41px" class="cls_031"><span class="cls_031">83% (150mg without LD), and 73% (PBO). Results for other</span></div>
<div style="position:absolute;left:306.64px;top:91.81px" class="cls_031"><span class="cls_031">pts with psoriasis, 3866.9 pt-yrs in pts with PsA, and 1943.1 pt-yrs</span></div>
<div style="position:absolute;left:50.00px;top:101.41px" class="cls_031"><span class="cls_031">secondary endpoints are shown in Table. No unexpected safety</span></div>
<div style="position:absolute;left:306.64px;top:101.91px" class="cls_031"><span class="cls_031">in pts with AS. The exposure-adjusted incidence rate (EAIR) per</span></div>
<div style="position:absolute;left:50.00px;top:111.41px" class="cls_031"><span class="cls_031">signals were reported.</span></div>
<div style="position:absolute;left:306.64px;top:112.00px" class="cls_031"><span class="cls_031">100 pt-yrs (95% confidence interval) of CD, UC, and IBD NOS in</span></div>
<div style="position:absolute;left:50.00px;top:121.41px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Subcutaneous SEC 300 mg with LD and 150 mg</span></div>
<div style="position:absolute;left:306.65px;top:122.10px" class="cls_031"><span class="cls_031">secukinumab-treated pts were 0.05 [0.02, 0.11], 0.13 [0.07, 0.23],</span></div>
<div style="position:absolute;left:50.00px;top:131.41px" class="cls_031"><span class="cls_031">with and without LD provided rapid and clinically significant</span></div>
<div style="position:absolute;left:306.65px;top:132.20px" class="cls_031"><span class="cls_031">and 0.01 [0.00, 0.05], respectively in the psoriasis studies; 0.08</span></div>
<div style="position:absolute;left:50.01px;top:141.41px" class="cls_031"><span class="cls_031">improvements in the signs and symptoms of PsA and inhibited</span></div>
<div style="position:absolute;left:306.65px;top:142.30px" class="cls_031"><span class="cls_031">[0.02, 0.23], 0.08 [0.02, 0.23], and 0.05 [0.01, 0.19], respectively</span></div>
<div style="position:absolute;left:50.01px;top:151.41px" class="cls_031"><span class="cls_031">radiographic progression. Safety profile was consistent with that</span></div>
<div style="position:absolute;left:306.65px;top:152.40px" class="cls_031"><span class="cls_031">in the PsA studies; and 0.4 [0.2, 0.8], 0.2 [0.1, 0.5], and 0.1 [0.0,</span></div>
<div style="position:absolute;left:50.01px;top:161.41px" class="cls_031"><span class="cls_031">previously reported.</span></div>
<div style="position:absolute;left:306.65px;top:162.49px" class="cls_031"><span class="cls_031">0.3], respectively in the AS studies. Additionally, the incidence</span></div>
<div style="position:absolute;left:50.01px;top:171.40px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:306.65px;top:172.59px" class="cls_031"><span class="cls_031">of IBD, CD, and UC did not increase over time.</span></div>
<div style="position:absolute;left:50.00px;top:182.43px" class="cls_032"><span class="cls_032">1. Mease PJ, et al. Arthritis Rheumatol.2017;69(suppl 10).</span></div>
<div style="position:absolute;left:306.65px;top:182.69px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Pooled data from 21 studies indicated that the obser-</span></div>
<div style="position:absolute;left:50.00px;top:193.44px" class="cls_036"><span class="cls_036">Table</span></div>
<div style="position:absolute;left:306.64px;top:192.83px" class="cls_031"><span class="cls_031">ved exposure- adjusted incidence rates of IBD, CD, and UC with</span></div>
<div style="position:absolute;left:51.38px;top:204.87px" class="cls_037"><span class="cls_037">Wk 16 data(a)</span></div>
<div style="position:absolute;left:121.72px;top:204.89px" class="cls_037"><span class="cls_037">300 mg</span></div>
<div style="position:absolute;left:166.72px;top:204.91px" class="cls_037"><span class="cls_037">150 mg</span></div>
<div style="position:absolute;left:211.73px;top:204.92px" class="cls_037"><span class="cls_037">150 mg without LD</span></div>
<div style="position:absolute;left:265.73px;top:204.94px" class="cls_037"><span class="cls_037">PBO</span></div>
<div style="position:absolute;left:306.64px;top:202.92px" class="cls_031"><span class="cls_031">secukinumab were low and did not increase over time in pts with</span></div>
<div style="position:absolute;left:51.38px;top:211.87px" class="cls_037"><span class="cls_037">ACR20(b)</span></div>
<div style="position:absolute;left:121.72px;top:211.89px" class="cls_037"><span class="cls_037">62.6***</span></div>
<div style="position:absolute;left:166.72px;top:211.91px" class="cls_037"><span class="cls_037">55.5***</span></div>
<div style="position:absolute;left:211.73px;top:211.93px" class="cls_037"><span class="cls_037">59.5***</span></div>
<div style="position:absolute;left:265.73px;top:211.94px" class="cls_037"><span class="cls_037">27.4</span></div>
<div style="position:absolute;left:51.38px;top:218.87px" class="cls_037"><span class="cls_037">mTSS(c)</span></div>
<div style="position:absolute;left:121.72px;top:218.89px" class="cls_037"><span class="cls_037">0.08*</span></div>
<div style="position:absolute;left:166.72px;top:218.91px" class="cls_037"><span class="cls_037">0.17^</span></div>
<div style="position:absolute;left:211.73px;top:218.93px" class="cls_037"><span class="cls_037">-0.09*</span></div>
<div style="position:absolute;left:265.73px;top:218.95px" class="cls_037"><span class="cls_037">0.5</span></div>
<div style="position:absolute;left:306.64px;top:213.02px" class="cls_031"><span class="cls_031">moderate to severe plaque psoriasis, PsA, or AS.</span></div>
<div style="position:absolute;left:51.38px;top:225.88px" class="cls_037"><span class="cls_037">PASI 75/90(b,d)</span></div>
<div style="position:absolute;left:121.72px;top:225.89px" class="cls_037"><span class="cls_037">70***/53.6***</span></div>
<div style="position:absolute;left:166.72px;top:225.91px" class="cls_037"><span class="cls_037">60***/36.8***</span></div>
<div style="position:absolute;left:211.73px;top:225.93px" class="cls_037"><span class="cls_037">58.1***/31.6***</span></div>
<div style="position:absolute;left:265.73px;top:225.95px" class="cls_037"><span class="cls_037">12.3/9.3</span></div>
<div style="position:absolute;left:306.64px;top:223.12px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:51.38px;top:232.88px" class="cls_037"><span class="cls_037">HAQ-DI(c)</span></div>
<div style="position:absolute;left:121.72px;top:232.90px" class="cls_037"><span class="cls_037">-0.6***</span></div>
<div style="position:absolute;left:166.72px;top:232.91px" class="cls_037"><span class="cls_037">-0.4***</span></div>
<div style="position:absolute;left:211.73px;top:232.93px" class="cls_037"><span class="cls_037">-0.5***</span></div>
<div style="position:absolute;left:265.73px;top:232.95px" class="cls_037"><span class="cls_037">-0.2</span></div>
<div style="position:absolute;left:306.64px;top:233.24px" class="cls_032"><span class="cls_032">1. Augustin M, et al. Acta Derm Venereol. 2010;90(2):147-51</span></div>
<div style="position:absolute;left:51.38px;top:239.88px" class="cls_037"><span class="cls_037">Enthesitis resolution(b,e)</span></div>
<div style="position:absolute;left:121.72px;top:239.90px" class="cls_037"><span class="cls_037">55.7**</span></div>
<div style="position:absolute;left:166.72px;top:239.92px" class="cls_037"><span class="cls_037">54.6**</span></div>
<div style="position:absolute;left:211.73px;top:239.93px" class="cls_037"><span class="cls_037">41.9</span></div>
<div style="position:absolute;left:265.73px;top:239.95px" class="cls_037"><span class="cls_037">35.4</span></div>
<div style="position:absolute;left:51.38px;top:246.88px" class="cls_037"><span class="cls_037">Dactylitis resolution(b,e)</span></div>
<div style="position:absolute;left:121.72px;top:246.90px" class="cls_037"><span class="cls_037">65.9***</span></div>
<div style="position:absolute;left:166.72px;top:246.92px" class="cls_037"><span class="cls_037">57.5**</span></div>
<div style="position:absolute;left:211.73px;top:246.94px" class="cls_037"><span class="cls_037">56.3</span></div>
<div style="position:absolute;left:265.73px;top:246.95px" class="cls_037"><span class="cls_037">32.3</span></div>
<div style="position:absolute;left:306.64px;top:242.35px" class="cls_032"><span class="cls_032">2. Cohen AD, et al. J Eur Acad Dermatol Venereol 2009;23:561-5.</span></div>
<div style="position:absolute;left:51.38px;top:253.88px" class="cls_037"><span class="cls_037">DLQI(c,d)</span></div>
<div style="position:absolute;left:121.72px;top:253.90px" class="cls_037"><span class="cls_037">-8.5***</span></div>
<div style="position:absolute;left:166.72px;top:253.92px" class="cls_037"><span class="cls_037">-7.4***</span></div>
<div style="position:absolute;left:211.73px;top:253.94px" class="cls_037"><span class="cls_037">-7.0***</span></div>
<div style="position:absolute;left:265.73px;top:253.96px" class="cls_037"><span class="cls_037">-2.4</span></div>
<div style="position:absolute;left:306.64px;top:251.45px" class="cls_032"><span class="cls_032">3. Egeberg A, et al. Br J Dermatol. 2016;175(3):487-92. 4. Li WQ, et al.</span></div>
<div style="position:absolute;left:51.38px;top:260.89px" class="cls_037"><span class="cls_037">mNAPSI(c,f)</span></div>
<div style="position:absolute;left:121.72px;top:260.90px" class="cls_037"><span class="cls_037">-9.2***</span></div>
<div style="position:absolute;left:166.72px;top:260.92px" class="cls_037"><span class="cls_037">-9.3***</span></div>
<div style="position:absolute;left:211.73px;top:260.94px" class="cls_037"><span class="cls_037">-7.7***</span></div>
<div style="position:absolute;left:265.73px;top:260.96px" class="cls_037"><span class="cls_037">-2.5</span></div>
<div style="position:absolute;left:306.64px;top:260.56px" class="cls_032"><span class="cls_032">Ann Rheum Dis. 2013;72(7):1200-5.</span></div>
<div style="position:absolute;left:51.38px;top:269.12px" class="cls_037"><span class="cls_037">***</span><span class="cls_038">P &lt; </span><span class="cls_037">0.0001; **</span><span class="cls_038">P &lt; </span><span class="cls_037">0.001; *</span><span class="cls_038">P &lt; </span><span class="cls_037">0.01; ^</span><span class="cls_038">P &lt; </span><span class="cls_037">0.05 un-adjusted </span><span class="cls_038">P</span><span class="cls_037">-values vs PBO. (a)Wk24 data</span></div>
<div style="position:absolute;left:306.64px;top:269.66px" class="cls_032"><span class="cls_032">4. Makredes M, et al. J Am Acad Dermatol. 2009;61(3):405-10.</span></div>
<div style="position:absolute;left:51.39px;top:276.13px" class="cls_037"><span class="cls_037">for mTSS; (b)% responders; (c)mean change from BL; (d)Data from pts with BL psoriasis ≥3%</span></div>
<div style="position:absolute;left:306.64px;top:278.76px" class="cls_032"><span class="cls_032">5. Stolwijk C, et al. Ann Rheum Dis. 2015;74(7):1373-8; 6. Stolwijk C,</span></div>
<div style="position:absolute;left:51.39px;top:283.13px" class="cls_037"><span class="cls_037">body surface area; (e)Data from pts with dactylitis or enthesitis at BL; (f)Data from pts with</span></div>
<div style="position:absolute;left:51.39px;top:290.13px" class="cls_037"><span class="cls_037">nail psoriasis at BL</span></div>
<div style="position:absolute;left:306.64px;top:287.87px" class="cls_032"><span class="cls_032">et al. Ann Rheum Dis. 2015;74(7):1373-8.</span></div>
<div style="position:absolute;left:50.00px;top:304.00px" class="cls_033"><span class="cls_033">P037</span></div>
<div style="position:absolute;left:306.64px;top:307.57px" class="cls_033"><span class="cls_033">P038</span></div>
<div style="position:absolute;left:50.00px;top:315.40px" class="cls_025"><span class="cls_025">INCIDENCE OF INFLAMMATORY BOWEL DISEASE IN</span></div>
<div style="position:absolute;left:306.64px;top:319.07px" class="cls_025"><span class="cls_025">ANALYSIS OF THE POSITION OF THE FUMARIC</span></div>
<div style="position:absolute;left:50.00px;top:326.30px" class="cls_025"><span class="cls_025">PATIENTS TREATED WITH SECUKINUMAB: POOLED</span></div>
<div style="position:absolute;left:306.64px;top:330.07px" class="cls_025"><span class="cls_025">ACID ESTERS IN CURRENT EUROPEAN PSORIASIS</span></div>
<div style="position:absolute;left:50.00px;top:337.20px" class="cls_025"><span class="cls_025">ANALYSIS OF 21 RANDOMISED CONTROLLED PHASE</span></div>
<div style="position:absolute;left:306.64px;top:341.06px" class="cls_025"><span class="cls_025">GUIDELINES</span></div>
<div style="position:absolute;left:50.00px;top:348.10px" class="cls_025"><span class="cls_025">3/4 CLINICAL TRIALS OF PSORIASIS, PSORIATIC</span></div>
<div style="position:absolute;left:306.64px;top:351.06px" class="cls_051"><span class="cls_051">Cecilia Dietrich</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Adria Gual</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Laura Padulles</span><span class="cls_027"><sup>2</sup></span></div>
<div style="position:absolute;left:50.00px;top:359.00px" class="cls_025"><span class="cls_025">ARTHRITIS, AND ANKYLOSING SPONDYLITIS</span></div>
<div style="position:absolute;left:306.64px;top:361.77px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Dermatologikum Hamburg, Germany, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Almirall S.A., Barcelona, Spain</span></div>
<div style="position:absolute;left:50.00px;top:368.90px" class="cls_051"><span class="cls_051">Stefan Schreiber</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Jean-Frederic Colombel</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Brian G Feagan</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:372.74px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Since 1994 a combination of fumaric acid esters</span></div>
<div style="position:absolute;left:50.00px;top:378.80px" class="cls_026"><span class="cls_026">Kristian Reich</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Atul Deodhar</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Iain B McInnes</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Brian Porter</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:382.84px" class="cls_031"><span class="cls_031">(FAEs) (dimethylfumarate [DMF] plus three salts of monoethyl-</span></div>
<div style="position:absolute;left:50.00px;top:388.70px" class="cls_026"><span class="cls_026">Ayan Das Gupta</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, Luminita Pricop</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Todd Fox</span><span class="cls_027"><sup>9</sup></span></div>
<div style="position:absolute;left:306.64px;top:392.94px" class="cls_031"><span class="cls_031">fumarate [MEF]) has been approved in Germany for moderate-</span></div>
<div style="position:absolute;left:50.00px;top:399.30px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Internal Medicine, University Hospital Schleswig-Holstein,</span></div>
<div style="position:absolute;left:306.64px;top:403.04px" class="cls_031"><span class="cls_031">to-severe psoriasis, however is not widely licensed elsewhere.</span></div>
<div style="position:absolute;left:50.00px;top:408.90px" class="cls_029"><span class="cls_029">Kiel, Germany, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Division of Gastroenterology, Icahn School of Medicine at</span></div>
<div style="position:absolute;left:306.64px;top:413.14px" class="cls_031"><span class="cls_031">While a new formulation of DMF has been recently approved by</span></div>
<div style="position:absolute;left:50.00px;top:418.50px" class="cls_029"><span class="cls_029">Mount Sinai, New York, USA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Robarts Clinical Trials Inc., Department of</span></div>
<div style="position:absolute;left:306.64px;top:423.23px" class="cls_031"><span class="cls_031">the European Commission (June 2017) as monotherapy for adults</span></div>
<div style="position:absolute;left:50.00px;top:428.10px" class="cls_029"><span class="cls_029">Epidemiology and Biostatistics, Department of Medicine, Division of Gas-</span></div>
<div style="position:absolute;left:306.64px;top:433.33px" class="cls_031"><span class="cls_031">with moderate-to-severe psoriasis, only UK (NICE) guidelines</span></div>
<div style="position:absolute;left:50.00px;top:437.70px" class="cls_029"><span class="cls_029">troenterology, University of Western Ontario, London, Ontario, Canada,</span></div>
<div style="position:absolute;left:306.64px;top:443.43px" class="cls_031"><span class="cls_031">mention DMF to date.[1]</span></div>
<div style="position:absolute;left:50.00px;top:447.30px" class="cls_028"><span class="cls_028"><sup>4</sup></span><span class="cls_029">Dermatologikum Hamburg and Georg-August-University, Göttingen, Ger-</span></div>
<div style="position:absolute;left:50.00px;top:456.90px" class="cls_029"><span class="cls_029">many, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Oregon Health & Science University, Portland, OR, USA, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Institute</span></div>
<div style="position:absolute;left:306.64px;top:453.53px" class="cls_031"><span class="cls_031">Method: Current treatment guidelines for plaque psoriasis in</span></div>
<div style="position:absolute;left:50.00px;top:466.50px" class="cls_029"><span class="cls_029">of Infection Immunity and Inflammation, University of Glasgow, Glasgow,</span></div>
<div style="position:absolute;left:306.64px;top:463.63px" class="cls_031"><span class="cls_031">several European countries are reviewed to determine if these</span></div>
<div style="position:absolute;left:50.00px;top:476.10px" class="cls_029"><span class="cls_029">UK, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA,</span></div>
<div style="position:absolute;left:306.64px;top:473.72px" class="cls_031"><span class="cls_031">guidelines include therapy with FAEs and how these may guide</span></div>
<div style="position:absolute;left:50.00px;top:485.70px" class="cls_028"><span class="cls_028"><sup>8</sup></span><span class="cls_029">Novartis Healthcare Pvt. Ltd., Hyderabad, India, </span><span class="cls_028"><sup>9</sup></span><span class="cls_029">Novartis Pharma AG,</span></div>
<div style="position:absolute;left:306.64px;top:483.82px" class="cls_031"><span class="cls_031">the use of DMF monotherapy in the future.</span></div>
<div style="position:absolute;left:50.00px;top:495.30px" class="cls_029"><span class="cls_029">Basel, Switzerland</span></div>
<div style="position:absolute;left:306.64px;top:493.92px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">FAE status varies across Europe. Current European gui-</span></div>
<div style="position:absolute;left:50.00px;top:506.17px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Inflammatory bowel disease (IBD) including Crohn’s</span></div>
<div style="position:absolute;left:306.64px;top:504.05px" class="cls_031"><span class="cls_031">delines recommend FAEs for the initial and long-term treatment</span></div>
<div style="position:absolute;left:50.00px;top:516.16px" class="cls_031"><span class="cls_031">disease (CD) and ulcerative colitis (UC) are common comor-</span></div>
<div style="position:absolute;left:306.64px;top:514.15px" class="cls_031"><span class="cls_031">of psoriasis. These guidelines (based on consensus/expert opinion)</span></div>
<div style="position:absolute;left:50.00px;top:526.17px" class="cls_031"><span class="cls_031">bidities associated with psoriasis, psoriatic arthritis (PsA), and</span></div>
<div style="position:absolute;left:306.64px;top:524.24px" class="cls_031"><span class="cls_031">also recommend a gradual increase in dose.[2] Country-specific</span></div>
<div style="position:absolute;left:50.00px;top:536.16px" class="cls_031"><span class="cls_031">ankylosing spondylitis (AS). Compared with the general popula-</span></div>
<div style="position:absolute;left:306.65px;top:534.34px" class="cls_031"><span class="cls_031">guidelines vary in their individual recommendations. German</span></div>
<div style="position:absolute;left:50.00px;top:546.17px" class="cls_031"><span class="cls_031">tion, epidemiological studies have shown that patients (pts) with</span></div>
<div style="position:absolute;left:306.65px;top:544.44px" class="cls_031"><span class="cls_031">guidelines endorse FAEs as 1st-line treatment for moderate-to-</span></div>
<div style="position:absolute;left:50.00px;top:556.16px" class="cls_031"><span class="cls_031">psoriasis or PsA are at a 2-4-fold increased risk of developing CD</span></div>
<div style="position:absolute;left:306.65px;top:554.54px" class="cls_031"><span class="cls_031">severe psoriasis, based on BSA </span><span class="cls_030"> > </span><span class="cls_031">10% or a PASI score of </span><span class="cls_030"> > </span><span class="cls_031">10,</span></div>
<div style="position:absolute;left:50.00px;top:566.16px" class="cls_031"><span class="cls_031">and a 2-3-fold increased risk of developing UC.1-5 Additionally,</span></div>
<div style="position:absolute;left:306.65px;top:564.64px" class="cls_031"><span class="cls_031">and recommend clinical assessments after 16-24 weeks of treat-</span></div>
<div style="position:absolute;left:50.00px;top:576.16px" class="cls_031"><span class="cls_031">in pts with AS, there is a 3-5-fold increased risk of IBD compared</span></div>
<div style="position:absolute;left:306.64px;top:574.75px" class="cls_031"><span class="cls_031">ment.[3] UK guidelines approve FAEs only as a 2nd-line option</span></div>
<div style="position:absolute;left:50.00px;top:586.16px" class="cls_031"><span class="cls_031">with the general population.6 Secukinumab is a fully human mo-</span></div>
<div style="position:absolute;left:306.64px;top:584.85px" class="cls_031"><span class="cls_031">for severe plaque psoriasis (PASI ≥10 or DLQI≥ 10),[1] whilst in</span></div>
<div style="position:absolute;left:50.00px;top:596.17px" class="cls_031"><span class="cls_031">noclonal antibody that neutralizes interleukin-17A and is approved</span></div>
<div style="position:absolute;left:306.66px;top:594.95px" class="cls_031"><span class="cls_031">the Netherlands FAEs are indicated only for initial treatment of</span></div>
<div style="position:absolute;left:50.00px;top:606.16px" class="cls_031"><span class="cls_031">for the treatment of psoriasis, PsA, and AS.</span></div>
<div style="position:absolute;left:306.66px;top:605.05px" class="cls_031"><span class="cls_031">moderate-to-severe disease.[4] Swiss guidelines also recommend</span></div>
<div style="position:absolute;left:50.00px;top:616.16px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To evaluate the incidence of IBD, CD, and UC in pts</span></div>
<div style="position:absolute;left:306.66px;top:615.15px" class="cls_031"><span class="cls_031">the use of FAEs for moderate-to-severe psoriasis, but only in</span></div>
<div style="position:absolute;left:50.00px;top:626.16px" class="cls_031"><span class="cls_031">with psoriasis, PsA, or AS who received IL-17A-inhibition with</span></div>
<div style="position:absolute;left:306.66px;top:625.24px" class="cls_031"><span class="cls_031">patients who are unresponsive to topical therapy.[5] In Sweden,</span></div>
<div style="position:absolute;left:50.00px;top:636.16px" class="cls_031"><span class="cls_031">secukinumab from 21 phase 3/4 clinical trials of secukinumab for</span></div>
<div style="position:absolute;left:306.66px;top:635.34px" class="cls_031"><span class="cls_031">FAEs can be considered as a 2nd-line treatment option.[6]</span></div>
<div style="position:absolute;left:50.00px;top:646.16px" class="cls_031"><span class="cls_031">psoriasis, PsA, or AS.</span></div>
<div style="position:absolute;left:306.66px;top:645.44px" class="cls_031"><span class="cls_031">Other country-specific guidelines are less clear. While Spanish</span></div>
<div style="position:absolute;left:50.00px;top:656.16px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">This analysis evaluated pooled data from fourteen phase</span></div>
<div style="position:absolute;left:306.66px;top:655.54px" class="cls_031"><span class="cls_031">guidelines discuss FAEs as a slower-acting therapy requiring</span></div>
<div style="position:absolute;left:50.00px;top:666.16px" class="cls_031"><span class="cls_031">3 and one phase 4 psoriasis trials, three phase 3 PsA trials, and</span></div>
<div style="position:absolute;left:306.66px;top:665.64px" class="cls_031"><span class="cls_031">treatment goals to be set at week 16, no specific guidance on the</span></div>
<div style="position:absolute;left:50.00px;top:676.16px" class="cls_031"><span class="cls_031">three phase 3 AS trials. Pts with a history of IBD, but not active</span></div>
<div style="position:absolute;left:306.68px;top:675.73px" class="cls_031"><span class="cls_031">use of FAEs is given.[7] Likewise, while Italian guidelines men-</span></div>
<div style="position:absolute;left:50.00px;top:686.16px" class="cls_031"><span class="cls_031">ongoing IBD, were eligible for enrollment in these trials. Data</span></div>
<div style="position:absolute;left:306.64px;top:685.86px" class="cls_031"><span class="cls_031">tion FAEs, they are not included in treatment recommendations as</span></div>
<div style="position:absolute;left:50.00px;top:696.16px" class="cls_031"><span class="cls_031">from all pts that received at least one dose of secukinumab were</span></div>
<div style="position:absolute;left:306.64px;top:695.96px" class="cls_031"><span class="cls_031">they are currently not licensed in Italy.[8] In contrast, there is no</span></div>
<div style="position:absolute;left:50.00px;top:706.15px" class="cls_031"><span class="cls_031">included in this analysis. IBD reporting includes cases of CD, UC,</span></div>
<div style="position:absolute;left:306.64px;top:706.06px" class="cls_031"><span class="cls_031">mention of FAEs in guidelines in Denmark, Portugal and Norway.</span></div>
<div style="position:absolute;left:50.00px;top:716.15px" class="cls_031"><span class="cls_031">and IBD not otherwise specified (NOS).</span></div>
<div style="position:absolute;left:306.64px;top:716.16px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">European guidelines recommend FAEs for both the</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:15257px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background21.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">19</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">initial and long-term treatment of moderate-to-severe psoriasis.</span></div>
<div style="position:absolute;left:306.63px;top:51.39px" class="cls_031"><span class="cls_031">in TNFi-naïve than TNFi-IR pts. Majority of SEC-treated pts with</span></div>
<div style="position:absolute;left:50.00px;top:61.40px" class="cls_031"><span class="cls_031">In Germany, FAEs have been licensed for </span><span class="cls_030">> </span><span class="cls_031">20 years and are</span></div>
<div style="position:absolute;left:306.63px;top:61.46px" class="cls_031"><span class="cls_031">BL EC </span><span class="cls_030"> = </span><span class="cls_031"> 1/2 had FR by Wk 24, with further an improvement</span></div>
<div style="position:absolute;left:50.00px;top:71.40px" class="cls_031"><span class="cls_031">commonly used as 1</span><span class="cls_034"><sup>st</sup></span><span class="cls_031">-line therapy. In the rest of Europe, there</span></div>
<div style="position:absolute;left:306.63px;top:71.54px" class="cls_031"><span class="cls_031">by Wk 104. In pts with BL EC </span><span class="cls_030"> = </span><span class="cls_031"> 3-6, greater improvement was</span></div>
<div style="position:absolute;left:50.00px;top:81.40px" class="cls_031"><span class="cls_031">is growing acceptance of FAEs as a systemic therapy option in</span></div>
<div style="position:absolute;left:306.63px;top:81.61px" class="cls_031"><span class="cls_031">observed with SEC 300 mg vs PBO in the proportion of pts with</span></div>
<div style="position:absolute;left:50.00px;top:91.40px" class="cls_031"><span class="cls_031">moderate-to-severe disease. Guidelines continue to evolve as ex-</span></div>
<div style="position:absolute;left:306.63px;top:91.68px" class="cls_031"><span class="cls_031">FR and PR of enthesitis at Wk 24; further improvements were</span></div>
<div style="position:absolute;left:50.00px;top:101.41px" class="cls_031"><span class="cls_031">perience grows outside Germany, and will need to be updated to</span></div>
<div style="position:absolute;left:306.63px;top:101.75px" class="cls_031"><span class="cls_031">observed in both SEC groups at Wk 104.</span></div>
<div style="position:absolute;left:50.00px;top:111.40px" class="cls_031"><span class="cls_031">guide the use of the newly approved DMF monotherapy in future.</span></div>
<div style="position:absolute;left:306.63px;top:111.82px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.00px;top:121.40px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:306.64px;top:121.93px" class="cls_032"><span class="cls_032">1. Schett G, et al. Nat Rev Rheumatol. 2017;13:731-41.</span></div>
<div style="position:absolute;left:50.00px;top:131.42px" class="cls_032"><span class="cls_032">1. NICE 2017. </span><A HREF="https://www.nice.org.uk/guidance/ta475/">https://www.nice.org.uk/guidance/TA475</A> </div>
<div style="position:absolute;left:306.64px;top:131.00px" class="cls_032"><span class="cls_032">2. Mease PJ, et al. N Engl J Med. 2015;373:1329-39.</span></div>
<div style="position:absolute;left:50.00px;top:140.42px" class="cls_032"><span class="cls_032">2. Nast A, et al. JEADV 2015;29:2277-94</span></div>
<div style="position:absolute;left:306.64px;top:140.07px" class="cls_032"><span class="cls_032">3. McInnes IB, et al. Lancet 2015;386:1137-46.</span></div>
<div style="position:absolute;left:50.00px;top:149.42px" class="cls_032"><span class="cls_032">3. Nast A, et al. 2017 </span><A HREF="https://bit.ly/2esjhv3/">https://bit.ly/2ESJhv3</A> </div>
<div style="position:absolute;left:50.00px;top:158.42px" class="cls_032"><span class="cls_032">4. Zweegers J, et al. 2014 </span><A HREF="https://bit.ly/2gtvwa2/">https://bit.ly/2GtvwA2</A> </div>
<div style="position:absolute;left:306.64px;top:158.76px" class="cls_033"><span class="cls_033">P041</span></div>
<div style="position:absolute;left:50.00px;top:167.42px" class="cls_032"><span class="cls_032">5. Kolios AG, et al. Dermatol 2016. 232:385-406</span></div>
<div style="position:absolute;left:306.64px;top:170.23px" class="cls_025"><span class="cls_025">LONG-TERM SAFETY OF ADALIMUMAB (HUMIRA) IN</span></div>
<div style="position:absolute;left:50.00px;top:176.42px" class="cls_032"><span class="cls_032">6. Krogstad A. Psoriasis 2017 </span><A HREF="https://bit.ly/2f05vbh/">https://bit.ly/2F05vbh</A> </div>
<div style="position:absolute;left:306.64px;top:181.21px" class="cls_025"><span class="cls_025">ADULT PATIENTS FROM GLOBAL CLINICAL TRIALS</span></div>
<div style="position:absolute;left:50.00px;top:185.42px" class="cls_032"><span class="cls_032">7. Dauden E, et al. JEADV 2016;30 Suppl 2:1-18</span></div>
<div style="position:absolute;left:50.00px;top:194.42px" class="cls_032"><span class="cls_032">8. Gisondi P, et al. JEADV 2017;31(5):774-790</span></div>
<div style="position:absolute;left:306.64px;top:192.18px" class="cls_025"><span class="cls_025">ACROSS MULTIPLE INDICATIONS: AN UPDATED</span></div>
<div style="position:absolute;left:306.64px;top:203.15px" class="cls_025"><span class="cls_025">ANALYSIS IN 29,987 PATIENTS REPRESENTING 56,951</span></div>
<div style="position:absolute;left:50.00px;top:213.04px" class="cls_033"><span class="cls_033">P039</span></div>
<div style="position:absolute;left:306.64px;top:214.12px" class="cls_025"><span class="cls_025">PATIENT-YEARS</span></div>
<div style="position:absolute;left:50.00px;top:224.44px" class="cls_025"><span class="cls_025">SECUKINUMAB PROVIDES RAPID AND SUSTAINED</span></div>
<div style="position:absolute;left:306.64px;top:224.09px" class="cls_026"><span class="cls_026">Gerd R. Burmester</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Remo Panaccione</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Kenneth B. Gordon</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Ja-</span></div>
<div style="position:absolute;left:50.00px;top:235.34px" class="cls_025"><span class="cls_025">RESOLUTION OF ENTHESITIS IN PSORIATIC</span></div>
<div style="position:absolute;left:306.64px;top:234.07px" class="cls_026"><span class="cls_026">mes Rosenbaum</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Dilek Arikan</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Winnie L. Lau</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Rita Tarzynski-</span></div>
<div style="position:absolute;left:50.00px;top:246.24px" class="cls_025"><span class="cls_025">ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO</span></div>
<div style="position:absolute;left:306.64px;top:244.04px" class="cls_026"><span class="cls_026">Potempa</span><span class="cls_027"><sup>2</sup></span></div>
<div style="position:absolute;left:306.64px;top:254.71px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Charité - University Medicine Berlin, Berlin, Germany, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">University of Cal-</span></div>
<div style="position:absolute;left:50.00px;top:257.14px" class="cls_025"><span class="cls_025">PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3</span></div>
<div style="position:absolute;left:306.63px;top:264.39px" class="cls_029"><span class="cls_029">gary, Calgary, AB, Canada, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Medical College of Wisconsin, Milwaukee,</span></div>
<div style="position:absolute;left:50.00px;top:267.04px" class="cls_051"><span class="cls_051">Laura C Coates</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Dennis McGonagle</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Georg Schett</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Philip J</span></div>
<div style="position:absolute;left:306.64px;top:274.06px" class="cls_029"><span class="cls_029">WI, USA, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Oregon Health & Science University and Legacy Devers Eye</span></div>
<div style="position:absolute;left:50.01px;top:276.94px" class="cls_026"><span class="cls_026">Mease</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Erhard Quebe-Fehling</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Darren L Asquith</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Lawrence Ra-</span></div>
<div style="position:absolute;left:306.64px;top:283.73px" class="cls_029"><span class="cls_029">Institute, Portland, OR, USA,</span><span class="cls_028"><sup>5</sup></span><span class="cls_029">AbbVie Inc., North Chicago, IL, USA</span></div>
<div style="position:absolute;left:50.00px;top:286.84px" class="cls_026"><span class="cls_026">souliyan</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Shephard Mpofu</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Corine Gaillez</span><span class="cls_027"><sup>5</sup></span></div>
<div style="position:absolute;left:50.00px;top:297.44px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">University of Oxford, Oxford, UK, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">University of Leeds, Leeds, UK, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Uni-</span></div>
<div style="position:absolute;left:306.64px;top:294.67px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Adalimumab is an anti-tumor necrosis factor-α</span></div>
<div style="position:absolute;left:50.00px;top:307.04px" class="cls_029"><span class="cls_029">versity of Erlangen-Nuremberg, Erlangen, Germany, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Swedish Medical</span></div>
<div style="position:absolute;left:306.64px;top:304.74px" class="cls_031"><span class="cls_031">(TNF-α) agent indicated for the treatment of immune-mediated</span></div>
<div style="position:absolute;left:50.00px;top:316.64px" class="cls_029"><span class="cls_029">Centre and University of Washington, Seattle, USA, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Novartis Pharma AG,</span></div>
<div style="position:absolute;left:306.62px;top:314.81px" class="cls_031"><span class="cls_031">diseases. The long-term safety of adalimumab was previously</span></div>
<div style="position:absolute;left:50.00px;top:326.24px" class="cls_029"><span class="cls_029">Basel, Switzerland, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Novartis Pharmaceuticals UK Ltd., Camberley, UK,</span></div>
<div style="position:absolute;left:306.62px;top:324.88px" class="cls_031"><span class="cls_031">reported in 23,458 patients representing up to 12 years of clinical</span></div>
<div style="position:absolute;left:50.00px;top:335.84px" class="cls_028"><span class="cls_028"><sup>7</sup></span><span class="cls_029">RTI Health Solutions, Barcelona, Spain</span></div>
<div style="position:absolute;left:306.62px;top:334.95px" class="cls_031"><span class="cls_031">trial exposure in rheumatoid arthritis (RA), juvenile idiopathic</span></div>
<div style="position:absolute;left:50.00px;top:346.71px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Enthesitis, one of the key features of psoriatic</span></div>
<div style="position:absolute;left:306.62px;top:345.02px" class="cls_031"><span class="cls_031">arthritis, ankylosing spondylitis (AS), psoriatic arthritis (PsA),</span></div>
<div style="position:absolute;left:50.00px;top:356.70px" class="cls_031"><span class="cls_031">arthritis (PsA), shows chronicity in 50-70% of affected patients</span></div>
<div style="position:absolute;left:306.62px;top:355.09px" class="cls_031"><span class="cls_031">plaque psoriasis (Ps), and Crohn’s disease (CD).</span></div>
<div style="position:absolute;left:50.00px;top:366.70px" class="cls_031"><span class="cls_031">(pts).1 Secukinumab (SEC), a fully human monoclonal antibody</span></div>
<div style="position:absolute;left:306.62px;top:365.17px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">Here we report an updated analysis examining the</span></div>
<div style="position:absolute;left:50.00px;top:376.70px" class="cls_031"><span class="cls_031">that selectively neutralises IL-17A, provided significant and sus-</span></div>
<div style="position:absolute;left:306.62px;top:375.24px" class="cls_031"><span class="cls_031">long-term safety of adalimumab in adult patients with RA, AS,</span></div>
<div style="position:absolute;left:50.00px;top:386.71px" class="cls_031"><span class="cls_031">tained improvement in the signs and symptoms of active PsA, with</span></div>
<div style="position:absolute;left:306.62px;top:385.31px" class="cls_031"><span class="cls_031">non-radiographic axial spondyloarthritis (nr-axSpA), peripheral</span></div>
<div style="position:absolute;left:50.00px;top:396.70px" class="cls_031"><span class="cls_031">sustained resolution of enthesitis in Phase 3 studies.2,3</span></div>
<div style="position:absolute;left:306.62px;top:395.38px" class="cls_031"><span class="cls_031">SpA (pSpA), PsA, Ps, hidradenitis suppurativa (HS), CD, ulcera-</span></div>
<div style="position:absolute;left:50.00px;top:406.70px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To evaluate the effect of SEC on resolution of enthesi-</span></div>
<div style="position:absolute;left:306.64px;top:405.46px" class="cls_031"><span class="cls_031">tive colitis (UC), and non-infectious uveitis (UV).</span></div>
<div style="position:absolute;left:50.00px;top:416.71px" class="cls_031"><span class="cls_031">tis count (EC; defined by Leeds Enthesitis Index) in PsA pts using</span></div>
<div style="position:absolute;left:306.64px;top:415.53px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Safety data from 78 clinical trials of adalimumab (RA,</span></div>
<div style="position:absolute;left:50.02px;top:426.70px" class="cls_031"><span class="cls_031">pooled data from two Phase 3 studies, FUTURE 2 (NCT01752634)</span></div>
<div style="position:absolute;left:306.64px;top:425.61px" class="cls_031"><span class="cls_031">33; AS, 5; nr-axSpA, 2; pSpA, 1; PsA, 3; Ps, 13; HS, 3; CD, 11;</span></div>
<div style="position:absolute;left:50.02px;top:436.70px" class="cls_031"><span class="cls_031">and FUTURE 3 (NCT01989468).</span></div>
<div style="position:absolute;left:306.64px;top:435.68px" class="cls_031"><span class="cls_031">UC, 4; UV, 2; other, 1) were included in these analyses, including</span></div>
<div style="position:absolute;left:50.02px;top:446.70px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">SEC and placebo (PBO) were administered weekly</span></div>
<div style="position:absolute;left:306.64px;top:445.75px" class="cls_031"><span class="cls_031">randomized controlled, open-label, and long-term extension stu-</span></div>
<div style="position:absolute;left:50.02px;top:456.70px" class="cls_031"><span class="cls_031">during the first 4 weeks (wks) followed by subcutaneous mainte-</span></div>
<div style="position:absolute;left:306.64px;top:455.83px" class="cls_031"><span class="cls_031">dies conducted in Europe, North America, South America, Asia,</span></div>
<div style="position:absolute;left:50.00px;top:466.71px" class="cls_031"><span class="cls_031">nance dosing every 4 weeks thereafter (PBO until Wk 16/24). The</span></div>
<div style="position:absolute;left:306.64px;top:465.90px" class="cls_031"><span class="cls_031">Australia, New Zealand, and South Africa through December</span></div>
<div style="position:absolute;left:50.00px;top:476.70px" class="cls_031"><span class="cls_031">results are reported only for SEC 300 and 150 mg (approved do-</span></div>
<div style="position:absolute;left:306.64px;top:475.97px" class="cls_031"><span class="cls_031">31, 2016. Adalimumab postmarketing surveillance data were not</span></div>
<div style="position:absolute;left:50.00px;top:486.71px" class="cls_031"><span class="cls_031">ses). Pts with baseline (BL) enthesitis (BLE) or without BLE (No</span></div>
<div style="position:absolute;left:306.64px;top:486.04px" class="cls_031"><span class="cls_031">included in this analysis. Safety assessments included all adverse</span></div>
<div style="position:absolute;left:50.00px;top:496.70px" class="cls_031"><span class="cls_031">BLE) were included. Evaluation through Wk 104 included: time</span></div>
<div style="position:absolute;left:306.64px;top:496.11px" class="cls_031"><span class="cls_031">events (AEs) and serious AEs (SAEs) that occurred after the first</span></div>
<div style="position:absolute;left:50.00px;top:506.70px" class="cls_031"><span class="cls_031">to first resolution of enthesitis (i.e. EC </span><span class="cls_030"> = </span><span class="cls_031"> 0); shift analysis of BL</span></div>
<div style="position:absolute;left:306.63px;top:506.18px" class="cls_031"><span class="cls_031">adalimumab study dose and up to 70 days (5 half-lives) after the</span></div>
<div style="position:absolute;left:50.00px;top:516.70px" class="cls_031"><span class="cls_031">EC (1, 2 or 3-6) to full resolution (FR) and partial resolution (PR;</span></div>
<div style="position:absolute;left:306.63px;top:516.25px" class="cls_031"><span class="cls_031">last study dose.</span></div>
<div style="position:absolute;left:50.00px;top:526.70px" class="cls_031"><span class="cls_031">reduction of EC) at Wks 24 and 104; and number of new enthesitis</span></div>
<div style="position:absolute;left:306.63px;top:526.32px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">This analysis included 29,987 patients, representing 56,951</span></div>
<div style="position:absolute;left:50.00px;top:536.70px" class="cls_031"><span class="cls_031">sites developed in No BLE pts. Data are as observed in the overall</span></div>
<div style="position:absolute;left:306.63px;top:536.39px" class="cls_031"><span class="cls_031">patient-years of exposure. The majority of adalimumab exposure</span></div>
<div style="position:absolute;left:50.00px;top:546.70px" class="cls_031"><span class="cls_031">population; time to first resolution of enthesitis was analysed in</span></div>
<div style="position:absolute;left:306.63px;top:546.46px" class="cls_031"><span class="cls_031">was in RA studies (37,106 PYs). The most frequently reported SAE</span></div>
<div style="position:absolute;left:50.00px;top:556.70px" class="cls_031"><span class="cls_031">the overall population and by prior use of tumour necrosis factor</span></div>
<div style="position:absolute;left:306.63px;top:556.54px" class="cls_031"><span class="cls_031">of interest was infection (highest incidences in CD: 6.9, UV: 4.1,</span></div>
<div style="position:absolute;left:50.00px;top:566.70px" class="cls_031"><span class="cls_031">inhibitor (TNFi-naïve and -inadequate responders [IR]).</span></div>
<div style="position:absolute;left:306.63px;top:566.61px" class="cls_031"><span class="cls_031">RA: 3.9, and UC: 3.5). The overall standardized mortality ratio was</span></div>
<div style="position:absolute;left:50.00px;top:576.70px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">A total of 466 pts had BLE with a mean EC of 3.1</span><span class="cls_035">±</span><span class="cls_031">1.6,</span></div>
<div style="position:absolute;left:306.63px;top:576.68px" class="cls_031"><span class="cls_031">0.65, 95% CI [0.5, 0.74]. For most of the adalimumab populations</span></div>
<div style="position:absolute;left:50.00px;top:586.70px" class="cls_031"><span class="cls_031">and 246 pts had no BLE. Median days to resolution of EC in BLE</span></div>
<div style="position:absolute;left:306.63px;top:586.75px" class="cls_031"><span class="cls_031">(AS, PsA, Ps, UC, CD, and RA), the observed number of deaths</span></div>
<div style="position:absolute;left:50.00px;top:596.70px" class="cls_031"><span class="cls_031">pts for SEC 300, 150 mg and PBO groups were 57, 85 and 167 in</span></div>
<div style="position:absolute;left:306.63px;top:596.82px" class="cls_031"><span class="cls_031">was below what would be expected in an age- and sexadjusted po-</span></div>
<div style="position:absolute;left:50.00px;top:606.70px" class="cls_031"><span class="cls_031">overall population; 57, 85 and 120 in TNFi-naïve pts; and 92, 82</span></div>
<div style="position:absolute;left:306.64px;top:606.91px" class="cls_031"><span class="cls_031">pulation. For HS, nr-axSpA, pSpA, and UV studies, the small size</span></div>
<div style="position:absolute;left:49.99px;top:616.70px" class="cls_031"><span class="cls_031">and 169 in TNFi-IR pts, respectively. In pts with BL EC </span><span class="cls_030"> = </span><span class="cls_031"> 1/2,</span></div>
<div style="position:absolute;left:306.64px;top:616.98px" class="cls_031"><span class="cls_031">of these trials precluded accurate assessment of the standardized</span></div>
<div style="position:absolute;left:49.99px;top:626.70px" class="cls_031"><span class="cls_031">72%/61% (SEC 300 mg), 71%/66% (SEC 150 mg) and 45%/44%</span></div>
<div style="position:absolute;left:306.64px;top:627.05px" class="cls_031"><span class="cls_031">mortality ratio, and the 95% CIs all included 1.0.</span></div>
<div style="position:absolute;left:49.99px;top:636.70px" class="cls_031"><span class="cls_031">(PBO), respectively, achieved FR at Wk 24, with FR in SEC groups</span></div>
<div style="position:absolute;left:306.64px;top:637.12px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">This analysis of data from clinical trials of adali-</span></div>
<div style="position:absolute;left:49.99px;top:646.70px" class="cls_031"><span class="cls_031">sustained or increased to 77%/81% (SEC 300 mg) and 75%/88%</span></div>
<div style="position:absolute;left:306.64px;top:647.20px" class="cls_031"><span class="cls_031">mumab demonstrated an overall safety profile consistent with</span></div>
<div style="position:absolute;left:49.99px;top:656.70px" class="cls_031"><span class="cls_031">(SEC 150 mg) at Wk 104. In BL EC </span><span class="cls_030"> = </span><span class="cls_031"> 3-6, 81% (SEC 300 mg),</span></div>
<div style="position:absolute;left:306.64px;top:657.27px" class="cls_031"><span class="cls_031">previous findings and with the TNF inhibitor class. No new safety</span></div>
<div style="position:absolute;left:49.99px;top:666.70px" class="cls_031"><span class="cls_031">73% (SEC 150 mg) and 71% (PBO) of pts achieved FR and PR</span></div>
<div style="position:absolute;left:306.62px;top:667.34px" class="cls_031"><span class="cls_031">signals or tolerability issues with adalimumab treatment were</span></div>
<div style="position:absolute;left:49.99px;top:676.70px" class="cls_031"><span class="cls_031">at Wk 24, with an increase of FR and PR to 88% (in both SEC</span></div>
<div style="position:absolute;left:306.62px;top:677.41px" class="cls_031"><span class="cls_031">identified and, for most indications, the mortality rate was below</span></div>
<div style="position:absolute;left:49.99px;top:686.69px" class="cls_031"><span class="cls_031">300 and 150 mg) at Wk 104. A total of 89% of pts with No BLE</span></div>
<div style="position:absolute;left:306.63px;top:687.48px" class="cls_031"><span class="cls_031">what would be expected in an age- and sexadjusted population.</span></div>
<div style="position:absolute;left:49.99px;top:696.69px" class="cls_031"><span class="cls_031">did not develop enthesitis by Wk 104.</span></div>
<div style="position:absolute;left:306.63px;top:697.55px" class="cls_031"><span class="cls_031">Efficacy and safety data continue to support the well-established</span></div>
<div style="position:absolute;left:49.99px;top:706.69px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Time to resolution of enthesitis was earlier with SEC</span></div>
<div style="position:absolute;left:306.63px;top:707.63px" class="cls_031"><span class="cls_031">benefits of adalimumab for the approved indications.</span></div>
<div style="position:absolute;left:49.99px;top:716.69px" class="cls_031"><span class="cls_031">than PBO in the overall population, with faster resolution observed</span></div>
<div style="position:absolute;left:306.64px;top:717.72px" class="cls_032"><span class="cls_032">Previously Published Arthritis Rheumatol. 2017; 69 (suppl 10).</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:16060px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background22.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">20</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.23px" class="cls_033"><span class="cls_033">P042</span></div>
<div style="position:absolute;left:306.64px;top:51.42px" class="cls_030"><span class="cls_030">Materials/Methods: </span><span class="cls_031">In VOYAGE 1 (</span><span class="cls_030">n = </span><span class="cls_031">837) and VOYAGE 2</span></div>
<div style="position:absolute;left:50.00px;top:62.67px" class="cls_025"><span class="cls_025">CLINICAL RESPONSE AFTER GUSELKUMAB</span></div>
<div style="position:absolute;left:306.64px;top:61.37px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">n = </span><span class="cls_031">992), patients were randomized to GUS 100 mg at Weeks</span></div>
<div style="position:absolute;left:50.00px;top:73.60px" class="cls_025"><span class="cls_025">TREATMENT AMONG ADALIMUMAB PASI 90 NON-</span></div>
<div style="position:absolute;left:306.64px;top:71.33px" class="cls_031"><span class="cls_031">0/4/12/20; placebo (PBO) at Weeks 0/4/12 followed by GUS 100</span></div>
<div style="position:absolute;left:306.64px;top:81.28px" class="cls_031"><span class="cls_031">mg at Weeks 16/20; or ADA 80 mg at Week 0, 40 mg at Week</span></div>
<div style="position:absolute;left:50.00px;top:84.54px" class="cls_025"><span class="cls_025">RESPONDERS: RESULTS FROM THE VOYAGE 1 AND 2</span></div>
<div style="position:absolute;left:306.64px;top:91.23px" class="cls_031"><span class="cls_031">1, and 40 mg every 2 weeks through Week 23. The co-primary</span></div>
<div style="position:absolute;left:50.00px;top:95.47px" class="cls_025"><span class="cls_025">TRIALS</span></div>
<div style="position:absolute;left:306.64px;top:101.19px" class="cls_031"><span class="cls_031">endpoints were the proportions of GUS vs PBO patients achieving:</span></div>
<div style="position:absolute;left:50.00px;top:105.41px" class="cls_051"><span class="cls_051">Christopher Griffith</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Marc Alexander Radtke</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Sang Woong Youn</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:111.14px" class="cls_031"><span class="cls_031">1) ≥90% improvement in PASI score (PASI 90), and 2) cleared/</span></div>
<div style="position:absolute;left:50.00px;top:115.34px" class="cls_026"><span class="cls_026">Robert Bissonnette</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Michael Song</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Yasmine Wasfi</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Bruce Ran-</span></div>
<div style="position:absolute;left:306.65px;top:121.10px" class="cls_031"><span class="cls_031">minimal disease (IGA 0/1) responses at Week 16. Response rates</span></div>
<div style="position:absolute;left:50.00px;top:125.28px" class="cls_026"><span class="cls_026">dazzo</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Yin You</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Yaung-Kaung Shen</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Bruce Strober</span><span class="cls_027"><sup>6</sup></span></div>
<div style="position:absolute;left:306.65px;top:131.05px" class="cls_031"><span class="cls_031">across endpoints were evaluated for predetermined subgroups by</span></div>
<div style="position:absolute;left:50.00px;top:135.91px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Dermatology Centre, Salford Royal Hospital, University of Manchester,</span></div>
<div style="position:absolute;left:306.65px;top:141.00px" class="cls_031"><span class="cls_031">baseline weight quartiles.</span></div>
<div style="position:absolute;left:50.00px;top:145.54px" class="cls_029"><span class="cls_029">UK, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Universitaetsklinik Hamburg-Eppendorf, Hamburg, Germany, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Seoul</span></div>
<div style="position:absolute;left:306.65px;top:150.96px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Pooled data from the two studies at Week 16 and Week 24</span></div>
<div style="position:absolute;left:50.00px;top:155.18px" class="cls_029"><span class="cls_029">National University College of Medicine, Bundang Hospital, Seongnam</span></div>
<div style="position:absolute;left:50.00px;top:164.81px" class="cls_029"><span class="cls_029">City, South Korea, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Innovaderm Research, Montreal, QC, Canada, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Jans-</span></div>
<div style="position:absolute;left:306.65px;top:160.86px" class="cls_031"><span class="cls_031">demonstrated that patients in the guselkumab group achieved sub-</span></div>
<div style="position:absolute;left:306.64px;top:170.81px" class="cls_031"><span class="cls_031">stantially higher clinical responses compared with placebo at Week</span></div>
<div style="position:absolute;left:50.00px;top:174.45px" class="cls_029"><span class="cls_029">sen Research & Development, LLC, Spring House, PA, USA, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">University of</span></div>
<div style="position:absolute;left:306.64px;top:180.77px" class="cls_031"><span class="cls_031">16 and ADA at Week 24 across all quartiles of weight as cutoffs.</span></div>
<div style="position:absolute;left:50.00px;top:184.08px" class="cls_029"><span class="cls_029">Connecticut Health Center, Farmington, Connecticut and Probity Medical</span></div>
<div style="position:absolute;left:50.00px;top:193.72px" class="cls_029"><span class="cls_029">Research, Waterloo, Ontario, Canada</span></div>
<div style="position:absolute;left:306.64px;top:190.72px" class="cls_031"><span class="cls_031">At Week 16, for each quartile, defined by </span><span class="cls_030"> &lt; </span><span class="cls_031">74.6, ≥74.6-</span><span class="cls_030"> &lt; </span><span class="cls_031">86.4,</span></div>
<div style="position:absolute;left:306.65px;top:200.68px" class="cls_031"><span class="cls_031">≥86.4-</span><span class="cls_030"> &lt; </span><span class="cls_031">100, and ≥100 kg, the proportions of GUS patients with</span></div>
<div style="position:absolute;left:50.00px;top:204.62px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To evaluate the levels of response to guselkumab</span></div>
<div style="position:absolute;left:306.66px;top:210.63px" class="cls_031"><span class="cls_031">a PASI 90 response were 76.0%, 78.6%, 66.2%, and 65.2%,</span></div>
<div style="position:absolute;left:50.00px;top:214.66px" class="cls_031"><span class="cls_031">(GUS) among adalimumab (ADA) PASI 90 non-responders in</span></div>
<div style="position:absolute;left:306.66px;top:220.58px" class="cls_031"><span class="cls_031">respectively and the proportions with an IGA 0/1 response were</span></div>
<div style="position:absolute;left:50.00px;top:224.69px" class="cls_031"><span class="cls_031">the VOYAGE 1 and VOYAGE 2 trials.</span></div>
<div style="position:absolute;left:306.66px;top:230.54px" class="cls_031"><span class="cls_031">89.1%, 88.6%, 78.7%, and 82.6%, respectively. The proportions</span></div>
<div style="position:absolute;left:50.00px;top:234.73px" class="cls_030"><span class="cls_030">Materials/Methods: </span><span class="cls_031">In VOYAGE 1 (</span><span class="cls_030">n = </span><span class="cls_031">837), patients were ran-</span></div>
<div style="position:absolute;left:306.66px;top:240.49px" class="cls_031"><span class="cls_031">of PBO patients with a PASI 90 response by these quartiles were</span></div>
<div style="position:absolute;left:50.00px;top:244.76px" class="cls_031"><span class="cls_031">domized to GUS 100 mg at Weeks (Wks) 0/4/12, then every 8 wks;</span></div>
<div style="position:absolute;left:306.66px;top:250.45px" class="cls_031"><span class="cls_031">5.0%, 2.9%, 1.2%, and 0.9%, respectively and the proportions</span></div>
<div style="position:absolute;left:50.00px;top:254.80px" class="cls_031"><span class="cls_031">placebo (PBO) at Wks 0/4/12 followed by GUS 100 mg at Wks</span></div>
<div style="position:absolute;left:306.66px;top:260.40px" class="cls_031"><span class="cls_031">with an IGA 0/1 response were 11.6%, 10.5%, 4.9%, and 3.5%,</span></div>
<div style="position:absolute;left:50.00px;top:264.83px" class="cls_031"><span class="cls_031">16/20 and then every 8 wks; or ADA 80 mg at Wk 0, 40 mg at Wk</span></div>
<div style="position:absolute;left:306.66px;top:270.35px" class="cls_031"><span class="cls_031">respectively.</span></div>
<div style="position:absolute;left:50.00px;top:274.87px" class="cls_031"><span class="cls_031">1, and 40 mg every 2 wks through Wk 47. In VOYAGE 2 (</span><span class="cls_030">n = </span><span class="cls_031">992),</span></div>
<div style="position:absolute;left:306.66px;top:280.26px" class="cls_031"><span class="cls_031">At Week 24, the proportions of GUS patients with a PASI 90 re-</span></div>
<div style="position:absolute;left:50.00px;top:284.90px" class="cls_031"><span class="cls_031">patients were randomized to GUS 100 mg at Wks 0/4/12/20; PBO</span></div>
<div style="position:absolute;left:306.64px;top:290.21px" class="cls_031"><span class="cls_031">sponse by weight quartile were 79.7%, 81.1%, 75.1%, and 73.4%,</span></div>
<div style="position:absolute;left:50.00px;top:294.94px" class="cls_031"><span class="cls_031">at Wks 0/4/12 then GUS 100 mg at Wks 16/20; or ADA 80 mg at</span></div>
<div style="position:absolute;left:306.64px;top:300.17px" class="cls_031"><span class="cls_031">respectively and the proportions with an IGA 0/1 response were</span></div>
<div style="position:absolute;left:50.00px;top:304.97px" class="cls_031"><span class="cls_031">Wk 0, 40 mg at W1, and then every 2 wks through Wk 23. ADA</span></div>
<div style="position:absolute;left:306.64px;top:310.12px" class="cls_031"><span class="cls_031">85.9%, 88.1%, 83.1%, and 78.3%, respectively. The proportions</span></div>
<div style="position:absolute;left:50.00px;top:315.01px" class="cls_031"><span class="cls_031">PASI 90 non-responders initiated GUS at Wk 52 (VOYAGE 1) or</span></div>
<div style="position:absolute;left:306.64px;top:320.08px" class="cls_031"><span class="cls_031">of ADA patients with a PASI 90 response by these quartiles were</span></div>
<div style="position:absolute;left:50.00px;top:325.04px" class="cls_031"><span class="cls_031">at Wk 28 (VOYAGE 2) and continued GUS treatment through Wk</span></div>
<div style="position:absolute;left:306.64px;top:330.01px" class="cls_031"><span class="cls_031">62.4%, 66.0%, 52.7%, and 35.5%, respectively and the propor-</span></div>
<div style="position:absolute;left:50.00px;top:335.08px" class="cls_031"><span class="cls_031">100. Here we report PASI 100, PASI 90, IGA 0 (cleared) and IGA</span></div>
<div style="position:absolute;left:306.64px;top:339.96px" class="cls_031"><span class="cls_031">tions with an IGA 0/1 response were 70.9%, 76.5%, 61.1%, and</span></div>
<div style="position:absolute;left:50.00px;top:345.11px" class="cls_031"><span class="cls_031">0/1 (cleared/minimal disease), Dermatology Quality of Life Index</span></div>
<div style="position:absolute;left:306.64px;top:349.92px" class="cls_031"><span class="cls_031">45.2%, respectively.</span></div>
<div style="position:absolute;left:50.00px;top:355.15px" class="cls_031"><span class="cls_031">(DLQI), and Psoriasis Symptom and Sign Diary (PSSD) outcomes</span></div>
<div style="position:absolute;left:306.64px;top:359.87px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">The efficacy of GUS treatment was demonstrated</span></div>
<div style="position:absolute;left:50.00px;top:365.18px" class="cls_031"><span class="cls_031">among these ADA PASI 90 non-responders after initiating GUS</span></div>
<div style="position:absolute;left:306.63px;top:369.83px" class="cls_031"><span class="cls_031">across all predefined weight quartiles and high efficacy responses</span></div>
<div style="position:absolute;left:50.00px;top:375.22px" class="cls_031"><span class="cls_031">treatment through Wk 100.</span></div>
<div style="position:absolute;left:306.64px;top:379.78px" class="cls_031"><span class="cls_031">were observed in psoriasis patients without regard to weight.</span></div>
<div style="position:absolute;left:50.00px;top:385.25px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">In VOYAGE 1, among 138 ADA-treated PASI 90 non-</span></div>
<div style="position:absolute;left:50.00px;top:395.29px" class="cls_031"><span class="cls_031">responders who initiated GUS treatment at Wk 52, a PASI 90</span></div>
<div style="position:absolute;left:306.64px;top:397.40px" class="cls_033"><span class="cls_033">P044</span></div>
<div style="position:absolute;left:50.00px;top:405.32px" class="cls_031"><span class="cls_031">response was achieved by 75.0% of patients at Wk 76, and 72.6%</span></div>
<div style="position:absolute;left:306.64px;top:408.80px" class="cls_025"><span class="cls_025">IMPACT OF CLINICAL SPECIALTY SETTING ON</span></div>
<div style="position:absolute;left:50.00px;top:415.36px" class="cls_031"><span class="cls_031">of patients at Wk 100. At Wk 100, 78.5% of patients achieved an</span></div>
<div style="position:absolute;left:306.64px;top:419.70px" class="cls_025"><span class="cls_025">DISEASE MANAGEMENT IN PATIENTS WITH</span></div>
<div style="position:absolute;left:50.00px;top:425.39px" class="cls_031"><span class="cls_031">IGA 0/1 response, 74.8% of patients reported a DLQI 0/1 score,</span></div>
<div style="position:absolute;left:306.64px;top:430.60px" class="cls_025"><span class="cls_025">PSORIATIC ARTHRITIS</span></div>
<div style="position:absolute;left:50.00px;top:435.43px" class="cls_031"><span class="cls_031">33.3% of patients reported a PSSD symptom score of 0, and</span></div>
<div style="position:absolute;left:306.64px;top:440.50px" class="cls_026"><span class="cls_026">Wolf-Henning Boehncke</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Rudolf Horváth</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Ediz Dalkiliç</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Sónia</span></div>
<div style="position:absolute;left:50.00px;top:445.46px" class="cls_031"><span class="cls_031">18.9% reported a PSSD sign score of 0. In VOYAGE 2, among</span></div>
<div style="position:absolute;left:306.64px;top:450.40px" class="cls_026"><span class="cls_026">A. L. Lima</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Masato Okada</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Maja Hojnik</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Fabiana Ganz</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Ennio</span></div>
<div style="position:absolute;left:50.00px;top:455.50px" class="cls_031"><span class="cls_031">112 ADA-treated PASI 90 non-responders who initiated GUS at</span></div>
<div style="position:absolute;left:306.64px;top:460.30px" class="cls_026"><span class="cls_026">Lubrano</span><span class="cls_027"><sup>8</sup></span></div>
<div style="position:absolute;left:50.00px;top:465.53px" class="cls_031"><span class="cls_031">Wk 28, a PASI 90 response was achieved by 66.1% of patients</span></div>
<div style="position:absolute;left:306.64px;top:470.90px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Geneva Univ. Hospitals and Univ. of Geneva, Geneva, Switzerland, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Univ.</span></div>
<div style="position:absolute;left:50.00px;top:475.57px" class="cls_031"><span class="cls_031">at Wk 48 and 75.5% of patients at Wk 100. At Wk 100, 81.0% of</span></div>
<div style="position:absolute;left:306.64px;top:480.50px" class="cls_029"><span class="cls_029">Hospital Motol, Prague, Czech Republic, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Uludağ Univ. Sch. of Med.,</span></div>
<div style="position:absolute;left:50.00px;top:485.60px" class="cls_031"><span class="cls_031">patients achieved an IGA 0/1 response, 65.3% of patients reported</span></div>
<div style="position:absolute;left:306.64px;top:490.10px" class="cls_029"><span class="cls_029">Gorukle, Bursa, Turkey, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">ABC Med. Sch., Santo André, Brazil, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">St. Luke’s</span></div>
<div style="position:absolute;left:50.00px;top:495.64px" class="cls_031"><span class="cls_031">a DLQI 0/1 score, 32.6% of patients reported a PSSD symptom</span></div>
<div style="position:absolute;left:306.63px;top:499.70px" class="cls_029"><span class="cls_029">International Hospital, Tokyo, Japan, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">AbbVie, Ljubljana, Slovenia, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Ab-</span></div>
<div style="position:absolute;left:50.00px;top:505.67px" class="cls_031"><span class="cls_031">score of 0, and patients 18.0% reported a PSSD sign score of 0.</span></div>
<div style="position:absolute;left:306.64px;top:509.30px" class="cls_029"><span class="cls_029">bVie AG, Baar, Switzerland, </span><span class="cls_028"><sup>8</sup></span><span class="cls_029">Univ. of Molise, Campobasso, Italy</span></div>
<div style="position:absolute;left:50.00px;top:515.70px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Among ADA PASI 90 non-responders, GUS treat-</span></div>
<div style="position:absolute;left:306.64px;top:520.06px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Evidence suggests that timely and effective mana-</span></div>
<div style="position:absolute;left:50.00px;top:525.74px" class="cls_031"><span class="cls_031">ment provided robust levels of efficacy, which were maintained</span></div>
<div style="position:absolute;left:306.64px;top:529.96px" class="cls_031"><span class="cls_031">gement can improve long-term outcomes in patients (pts) with</span></div>
<div style="position:absolute;left:50.02px;top:535.77px" class="cls_031"><span class="cls_031">through Wk 100.</span></div>
<div style="position:absolute;left:306.64px;top:539.86px" class="cls_031"><span class="cls_031">psoriatic arthritis (PsA); however factors influencing treatment</span></div>
<div style="position:absolute;left:306.64px;top:549.76px" class="cls_031"><span class="cls_031">management decisions are not well understood.</span></div>
<div style="position:absolute;left:50.00px;top:554.44px" class="cls_033"><span class="cls_033">P043</span></div>
<div style="position:absolute;left:306.64px;top:559.66px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To evaluate the association between the clinical speci-</span></div>
<div style="position:absolute;left:50.00px;top:565.88px" class="cls_025"><span class="cls_025">CONSISTENCY OF RESPONSE BY WEIGHT ACROSS</span></div>
<div style="position:absolute;left:306.64px;top:569.56px" class="cls_031"><span class="cls_031">alty setting and time from inflammatory musculoskeletal symptom</span></div>
<div style="position:absolute;left:50.00px;top:576.81px" class="cls_025"><span class="cls_025">SUBGROUPS OF PATIENTS WITH PSORIASIS TREATED</span></div>
<div style="position:absolute;left:306.64px;top:579.46px" class="cls_031"><span class="cls_031">onset to PsA diagnosis and to different management steps in pts</span></div>
<div style="position:absolute;left:50.00px;top:587.75px" class="cls_025"><span class="cls_025">WITH GUSELKUMAB: RESULTS FROM THE VOYAGE 1</span></div>
<div style="position:absolute;left:306.64px;top:589.36px" class="cls_031"><span class="cls_031">with a diagnosis of PsA.</span></div>
<div style="position:absolute;left:50.00px;top:598.68px" class="cls_025"><span class="cls_025">AND 2 TRIALS</span></div>
<div style="position:absolute;left:306.64px;top:599.26px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">LOOP is a large cross-sectional, multi-center, observa-</span></div>
<div style="position:absolute;left:50.00px;top:608.61px" class="cls_051"><span class="cls_051">Kim Papp</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Jeffrey Crowley</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Diana Rubel</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Ian Landells</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Michael</span></div>
<div style="position:absolute;left:306.64px;top:609.16px" class="cls_031"><span class="cls_031">tional study conducted in 17 countries across Western and Eastern</span></div>
<div style="position:absolute;left:50.00px;top:618.55px" class="cls_026"><span class="cls_026">Song</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Yasmine Wasfi</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Yin You</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Yaung-Kaung Shen</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Diamant</span></div>
<div style="position:absolute;left:306.64px;top:619.06px" class="cls_031"><span class="cls_031">Europe, Latin America, and Asia. Adult pts (≥18 years) with a</span></div>
<div style="position:absolute;left:50.00px;top:628.49px" class="cls_026"><span class="cls_026">Thaci</span><span class="cls_027"><sup>6</sup></span></div>
<div style="position:absolute;left:306.65px;top:628.96px" class="cls_031"><span class="cls_031">suspected or an established diagnosis of PsA routinely visiting a</span></div>
<div style="position:absolute;left:50.00px;top:639.12px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Clinical Research and Probity Research, Inc., Waterloo, Ontario, Canada,</span></div>
<div style="position:absolute;left:306.65px;top:638.86px" class="cls_031"><span class="cls_031">rheumatologist (rheum), dermatologist (derm) or non-rheum/non-</span></div>
<div style="position:absolute;left:50.00px;top:648.75px" class="cls_028"><span class="cls_028"><sup>2</sup></span><span class="cls_029">Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield,</span></div>
<div style="position:absolute;left:306.65px;top:648.76px" class="cls_031"><span class="cls_031">derm site were eligible to participate in this study. Each enrolled</span></div>
<div style="position:absolute;left:50.00px;top:658.39px" class="cls_029"><span class="cls_029">CA, USA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Woden Dermatology, Phillip ACT 2606, Australia, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Nexus Clini-</span></div>
<div style="position:absolute;left:306.65px;top:658.66px" class="cls_031"><span class="cls_031">patient in the study was assessed by both rheum and derm. Main</span></div>
<div style="position:absolute;left:50.00px;top:668.02px" class="cls_029"><span class="cls_029">cal Research, St. John’s Newfoundland, CA, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Janssen Research & Devel-</span></div>
<div style="position:absolute;left:306.65px;top:668.56px" class="cls_031"><span class="cls_031">endpoints assessed were time from inflammatory musculoskeletal</span></div>
<div style="position:absolute;left:50.00px;top:677.66px" class="cls_029"><span class="cls_029">opment, LLC, Spring House, PA, USA, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Universitatsklinikum Schleswig-</span></div>
<div style="position:absolute;left:306.67px;top:678.46px" class="cls_031"><span class="cls_031">symptom onset to PsA diagnosis, time from PsA diagnosis to first</span></div>
<div style="position:absolute;left:50.00px;top:687.29px" class="cls_029"><span class="cls_029">Holstein-Lubeck, Germany</span></div>
<div style="position:absolute;left:306.64px;top:688.36px" class="cls_031"><span class="cls_031">csDMARD and to first bDMARD, and time from first csDMARD</span></div>
<div style="position:absolute;left:50.00px;top:698.19px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To evaluate the consistency of response of guselku-</span></div>
<div style="position:absolute;left:306.64px;top:698.26px" class="cls_031"><span class="cls_031">to first bDMARD.</span></div>
<div style="position:absolute;left:50.00px;top:708.23px" class="cls_031"><span class="cls_031">mab (GUS) across predetermined weight quartile subgroups of</span></div>
<div style="position:absolute;left:306.64px;top:708.16px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Of the 1483 pts enrolled in this study, 1273 pts with a</span></div>
<div style="position:absolute;left:50.00px;top:718.26px" class="cls_031"><span class="cls_031">psoriasis patients.</span></div>
<div style="position:absolute;left:306.64px;top:718.06px" class="cls_031"><span class="cls_031">confirmed diagnosis of PsA were included in this analysis. A ma-</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:16863px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background23.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">21</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">jority of pts were recruited by rheums (671, 52.7%), followed by</span></div>
<div style="position:absolute;left:306.64px;top:51.23px" class="cls_033"><span class="cls_033">P046</span></div>
<div style="position:absolute;left:50.00px;top:61.40px" class="cls_031"><span class="cls_031">derms (541, 42.5%), physiatrists (36, 2.8%), and other specialties</span></div>
<div style="position:absolute;left:306.64px;top:62.63px" class="cls_025"><span class="cls_025">SAFETY OF CERTOLIZUMAB PEGOL OVER 48 WEEKS</span></div>
<div style="position:absolute;left:50.00px;top:71.40px" class="cls_031"><span class="cls_031">(25, 2.0%). PsA was first suspected by a rheum in 726 (57.0%) pts</span></div>
<div style="position:absolute;left:306.64px;top:73.53px" class="cls_025"><span class="cls_025">IN CHRONIC PLAQUE PSORIASIS PHASE 3 TRIALS</span></div>
<div style="position:absolute;left:50.01px;top:81.40px" class="cls_031"><span class="cls_031">and by a derm in 541 pts (42.5%). Pt demographics and disease</span></div>
<div style="position:absolute;left:306.64px;top:83.43px" class="cls_026"><span class="cls_026">Andrew  Blauvelt</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">,  Bruce  Strober</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">,  Richard  Langley</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">,  Daniel</span></div>
<div style="position:absolute;left:50.01px;top:91.40px" class="cls_031"><span class="cls_031">characteristics were mostly comparable between rheum and derm</span></div>
<div style="position:absolute;left:306.64px;top:93.33px" class="cls_026"><span class="cls_026">Burge</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, </span><span class="cls_051">Lisa Pisenti</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Mohamed Yassine</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Sarah Kavanagh</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Cath-</span></div>
<div style="position:absolute;left:50.01px;top:101.40px" class="cls_031"><span class="cls_031">settings. Disease activity was higher in PsA pts in derm setting</span></div>
<div style="position:absolute;left:306.64px;top:103.23px" class="cls_026"><span class="cls_026">erine Arendt</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Robert Roller</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Mark Lebwohl</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, Kristian Reich</span><span class="cls_027"><sup>9</sup></span></div>
<div style="position:absolute;left:50.01px;top:111.40px" class="cls_031"><span class="cls_031">compared with rheum setting. The mean time from symptom onset</span></div>
<div style="position:absolute;left:306.64px;top:113.83px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Oregon Medical Research Center, Portland, OR, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">University of Connecti-</span></div>
<div style="position:absolute;left:50.01px;top:121.40px" class="cls_031"><span class="cls_031">to PsA diagnosis was 24 months (mo) in rheum setting and 1 mo</span></div>
<div style="position:absolute;left:306.64px;top:123.43px" class="cls_029"><span class="cls_029">cut Health Center, Farmington, CT, USA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Dalhousie University, Nova</span></div>
<div style="position:absolute;left:50.01px;top:131.40px" class="cls_031"><span class="cls_031">longer for derms. In rheum and derm settings, the mean time from</span></div>
<div style="position:absolute;left:306.64px;top:133.03px" class="cls_029"><span class="cls_029">Scotia, Canada, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Demira, Inc., Menlo Park, CA, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">UCB Pharma, Smyrna,</span></div>
<div style="position:absolute;left:50.01px;top:141.40px" class="cls_031"><span class="cls_031">PsA diagnosis to first csDMARD were 11 and 25 mo, respectively;</span></div>
<div style="position:absolute;left:306.64px;top:142.63px" class="cls_029"><span class="cls_029">GA, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">UCB Pharma, Raleigh, NC, USA, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">UCB Pharma, Brussels, Belgium,</span></div>
<div style="position:absolute;left:50.02px;top:151.40px" class="cls_031"><span class="cls_031">whereas the mean time to first bDMARD were 52 and 55 mo, re-</span></div>
<div style="position:absolute;left:306.64px;top:152.23px" class="cls_028"><span class="cls_028"><sup>8</sup></span><span class="cls_029">Icahn School of Medicine at Mount Sinai, New York, NY, USA, </span><span class="cls_028"><sup>9</sup></span><span class="cls_029">SCIderm</span></div>
<div style="position:absolute;left:50.00px;top:161.41px" class="cls_031"><span class="cls_031">spectively. The mean time from first csDMARD to first bDMARD</span></div>
<div style="position:absolute;left:306.63px;top:161.83px" class="cls_029"><span class="cls_029">Research Institute, Hamburg, and Dermatologikum Berlin, Germany</span></div>
<div style="position:absolute;left:50.00px;top:171.40px" class="cls_031"><span class="cls_031">was 42 mo for rheums; while it was 3 months shorter for derms.</span></div>
<div style="position:absolute;left:306.64px;top:172.70px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">The Fc-free, PEGylated, anti-tumor necrosis factor</span></div>
<div style="position:absolute;left:50.00px;top:181.40px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Although the duration from symptom onset to PsA</span></div>
<div style="position:absolute;left:306.64px;top:182.70px" class="cls_031"><span class="cls_031">certolizumab pegol (CZP) has shown efficacy in chronic plaque</span></div>
<div style="position:absolute;left:50.00px;top:191.40px" class="cls_031"><span class="cls_031">diagnosis was similar between rheum and derm setting, there were</span></div>
<div style="position:absolute;left:306.64px;top:192.70px" class="cls_031"><span class="cls_031">psoriasis (PSO) over 48 weeks’ treatment.[1,2]</span></div>
<div style="position:absolute;left:50.00px;top:201.40px" class="cls_031"><span class="cls_031">differences in the timing of introduction of different DMARD</span></div>
<div style="position:absolute;left:306.64px;top:202.70px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To report 48-week safety data for CZP in PSO.</span></div>
<div style="position:absolute;left:50.00px;top:211.40px" class="cls_031"><span class="cls_031">classes. Notably, mean time to first csDMARD was significantly</span></div>
<div style="position:absolute;left:306.64px;top:212.69px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Data were pooled from ongoing phase 3 trials of CZP</span></div>
<div style="position:absolute;left:50.00px;top:221.40px" class="cls_031"><span class="cls_031">shorter in rheum setting. PsA pts in derm setting had significantly</span></div>
<div style="position:absolute;left:306.64px;top:222.69px" class="cls_031"><span class="cls_031">in adults with PSO (</span><span class="cls_030">n = </span><span class="cls_031">962): CIMPASI-1 (NCT02326298), CIM-</span></div>
<div style="position:absolute;left:50.01px;top:231.40px" class="cls_031"><span class="cls_031">higher disease activity. These data lend further support to the need</span></div>
<div style="position:absolute;left:306.64px;top:232.70px" class="cls_031"><span class="cls_031">PASI-2 (NCT02326272), CIMPACT (NCT02346240). Patients</span></div>
<div style="position:absolute;left:50.01px;top:241.40px" class="cls_031"><span class="cls_031">for rheum-derm collaborative approach to optimize management</span></div>
<div style="position:absolute;left:306.64px;top:242.70px" class="cls_031"><span class="cls_031">(pts) had PSO ≥6 months (Psoriasis Area Severity Index ≥12,</span></div>
<div style="position:absolute;left:50.01px;top:251.40px" class="cls_031"><span class="cls_031">of pts with PsA.</span></div>
<div style="position:absolute;left:306.65px;top:252.70px" class="cls_031"><span class="cls_031">≥10% body surface area affected, physician’s global assessment</span></div>
<div style="position:absolute;left:306.65px;top:262.70px" class="cls_031"><span class="cls_031">≥3/5) and were randomized to CZP 400 mg every 2 weeks (Q2W)</span></div>
<div style="position:absolute;left:50.00px;top:270.54px" class="cls_033"><span class="cls_033">P045</span></div>
<div style="position:absolute;left:306.63px;top:272.70px" class="cls_031"><span class="cls_031">or 200 mg Q2W (400 mg loading dose at Weeks 0/2/4), placebo</span></div>
<div style="position:absolute;left:50.00px;top:281.94px" class="cls_025"><span class="cls_025">SPEED OF RESPONSE OF GUSELKUMAB COMPARED</span></div>
<div style="position:absolute;left:306.63px;top:282.69px" class="cls_031"><span class="cls_031">(PBO) for 16 weeks, or etanercept for 12 weeks (CIMPACT</span></div>
<div style="position:absolute;left:50.00px;top:292.84px" class="cls_025"><span class="cls_025">WITH ADALIMUMAB FOR THE TREATMENT OF</span></div>
<div style="position:absolute;left:306.63px;top:292.69px" class="cls_031"><span class="cls_031">only). We present data for pts receiving ≥1 CZP dose during initial</span></div>
<div style="position:absolute;left:50.00px;top:303.74px" class="cls_025"><span class="cls_025">MODERATE-TO-SEVERE PSORIASIS: RESULTS</span></div>
<div style="position:absolute;left:306.61px;top:302.69px" class="cls_031"><span class="cls_031">and/or maintenance periods with up to 48 weeks’ exposure as of</span></div>
<div style="position:absolute;left:50.00px;top:314.64px" class="cls_025"><span class="cls_025">THROUGH WEEK 24 FROM THE PHASE 3, DOUBLE-</span></div>
<div style="position:absolute;left:306.61px;top:312.69px" class="cls_031"><span class="cls_031">20Oct2016 (CIMPASI-1), 16Aug2016 (CIMPASI-2), 05Dec2016</span></div>
<div style="position:absolute;left:306.61px;top:322.69px" class="cls_031"><span class="cls_031">(CIMPACT). Adverse events (AEs) were classified using Med-</span></div>
<div style="position:absolute;left:50.00px;top:325.54px" class="cls_025"><span class="cls_025">BLINDED, PLACEBO- AND ACTIVE COMPARATOR-</span></div>
<div style="position:absolute;left:306.64px;top:332.70px" class="cls_031"><span class="cls_031">DRAv18.1. Incidence rates (IR) are the incidence of new cases</span></div>
<div style="position:absolute;left:50.00px;top:336.43px" class="cls_025"><span class="cls_025">CONTROLLED VOYAGE 1 AND VOYAGE 2 TRIALS</span></div>
<div style="position:absolute;left:306.64px;top:342.70px" class="cls_031"><span class="cls_031">per 100 patient-years (PY).</span></div>
<div style="position:absolute;left:50.00px;top:346.33px" class="cls_026"><span class="cls_026">Andrew Blauvelt</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Stephen Tyring</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Sandra Philipp</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, David Adam</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:352.70px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Total CZP exposure was 730PY. 709 pts (73.7%) ex-</span></div>
<div style="position:absolute;left:50.00px;top:356.24px" class="cls_026"><span class="cls_026">Michael Song</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Yasmine Wasfi</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Yin You</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Yaung-Kaung Shen</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:362.70px" class="cls_031"><span class="cls_031">perienced ≥1 AE; IRs were similar between pts receiving CZP</span></div>
<div style="position:absolute;left:50.00px;top:366.14px" class="cls_026"><span class="cls_026">Jerry Bagel</span><span class="cls_027"><sup>6</sup></span></div>
<div style="position:absolute;left:306.64px;top:372.70px" class="cls_031"><span class="cls_031">200 mg Q2W and 400 mg Q2W (Table 1). Rates of serious AEs</span></div>
<div style="position:absolute;left:50.00px;top:376.74px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Oregon Medical Research Center, Portland, OR, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Center for Clinical Stu-</span></div>
<div style="position:absolute;left:306.64px;top:382.70px" class="cls_031"><span class="cls_031">were low, including infections and infestations (Table 1). There</span></div>
<div style="position:absolute;left:50.00px;top:386.34px" class="cls_029"><span class="cls_029">dies, Webster, TX, USA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Dermatology, Charité, Universitaetsmedizin Ber-</span></div>
<div style="position:absolute;left:49.99px;top:395.94px" class="cls_029"><span class="cls_029">lin, Berlin, Germany, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">CCA Medical Research Corp. Ajax, ON, and Probity</span></div>
<div style="position:absolute;left:306.64px;top:392.70px" class="cls_031"><span class="cls_031">were 4 malignancies (1 anaplastic oligodendroglioma, 2 basal</span></div>
<div style="position:absolute;left:50.00px;top:405.54px" class="cls_029"><span class="cls_029">Medical Research, Waterloo, ON, Canada, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Janssen Research & Develop-</span></div>
<div style="position:absolute;left:306.64px;top:402.70px" class="cls_031"><span class="cls_031">cell carcinoma, 1 keratoacanthoma), 1 congestive heart failure, 1</span></div>
<div style="position:absolute;left:50.00px;top:415.14px" class="cls_029"><span class="cls_029">ment, LLC, Spring House, PA, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Psoriasis Treatment Center of Central NJ,</span></div>
<div style="position:absolute;left:306.64px;top:412.69px" class="cls_031"><span class="cls_031">death (motor vehicle accident) and 1 case of primary progressive</span></div>
<div style="position:absolute;left:50.00px;top:424.74px" class="cls_029"><span class="cls_029">East Windsor, NJ, USA</span></div>
<div style="position:absolute;left:306.64px;top:422.69px" class="cls_031"><span class="cls_031">multiple sclerosis, all reported in patients receiving CZP 400 mg</span></div>
<div style="position:absolute;left:306.64px;top:432.69px" class="cls_031"><span class="cls_031">Q2W. AE IR did not increase with exposure duration, and at Week</span></div>
<div style="position:absolute;left:50.00px;top:435.61px" class="cls_030"><span class="cls_030">Background: </span><span class="cls_031">VOYAGE 1 and 2 were two phase 3 double-blinded,</span></div>
<div style="position:absolute;left:306.64px;top:442.69px" class="cls_031"><span class="cls_031">16 was comparable for CZP and PBO pts (Table 2).</span></div>
<div style="position:absolute;left:50.00px;top:445.60px" class="cls_031"><span class="cls_031">placebo/active comparator-controlled trials evaluating guselkumab</span></div>
<div style="position:absolute;left:306.64px;top:452.69px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">CZP safety was as expected for this therapeutic class</span></div>
<div style="position:absolute;left:50.00px;top:455.60px" class="cls_031"><span class="cls_031">(GUS), a fully human monoclonal antibody targeting interleukin</span></div>
<div style="position:absolute;left:306.64px;top:462.69px" class="cls_031"><span class="cls_031">in PSO and there were no new safety signals.</span></div>
<div style="position:absolute;left:50.00px;top:465.60px" class="cls_031"><span class="cls_031">(IL)-23, compared with adalimumab (ADA) in the treatment of</span></div>
<div style="position:absolute;left:306.64px;top:472.69px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.00px;top:475.60px" class="cls_031"><span class="cls_031">patients with moderate-to-severe plaque psoriasis. Here, we report</span></div>
<div style="position:absolute;left:306.64px;top:482.71px" class="cls_032"><span class="cls_032">1. Reich K, (2017). Skin,1;24; 2. Augustin M, (2017). Skin,1;s24</span></div>
<div style="position:absolute;left:50.00px;top:485.60px" class="cls_031"><span class="cls_031">speed of response results based on Psoriasis Area and Severity</span></div>
<div style="position:absolute;left:306.64px;top:493.73px" class="cls_036"><span class="cls_036">Table 1 AEs and Serious AEs to Week 48</span></div>
<div style="position:absolute;left:50.00px;top:495.60px" class="cls_031"><span class="cls_031">Index (PASI) outcomes through Week 24 from pooled VOYAGE</span></div>
<div style="position:absolute;left:308.01px;top:504.83px" class="cls_036"><span class="cls_036">IR/100 PY (95% CI)</span></div>
<div style="position:absolute;left:50.00px;top:505.60px" class="cls_031"><span class="cls_031">1 and 2 data.</span></div>
<div style="position:absolute;left:378.36px;top:513.69px" class="cls_036"><span class="cls_036">All CZP</span></div>
<div style="position:absolute;left:439.73px;top:513.69px" class="cls_036"><span class="cls_036">CZP 400 mg</span></div>
<div style="position:absolute;left:493.73px;top:513.69px" class="cls_036"><span class="cls_036">CZP 200 mg</span></div>
<div style="position:absolute;left:50.00px;top:515.60px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">In VOYAGE 1 and 2, patients with plaque psoriasis</span></div>
<div style="position:absolute;left:378.36px;top:520.69px" class="cls_036"><span class="cls_036">(</span><span class="cls_040">n = </span><span class="cls_036">962)</span></div>
<div style="position:absolute;left:439.73px;top:520.69px" class="cls_036"><span class="cls_036">Q2W (</span><span class="cls_040">n = </span><span class="cls_036">627)</span></div>
<div style="position:absolute;left:493.73px;top:520.69px" class="cls_036"><span class="cls_036">Q2W (</span><span class="cls_040">n = </span><span class="cls_036">460)</span></div>
<div style="position:absolute;left:50.00px;top:525.60px" class="cls_031"><span class="cls_031">were randomized at baseline to GUS 100 mg (Weeks 0 and 4, then</span></div>
<div style="position:absolute;left:308.01px;top:528.86px" class="cls_037"><span class="cls_037">AEs</span></div>
<div style="position:absolute;left:378.36px;top:528.86px" class="cls_037"><span class="cls_037">219.6 (203.7-236.4)</span></div>
<div style="position:absolute;left:439.72px;top:528.86px" class="cls_037"><span class="cls_037">228.6 (207.8-250.9)</span></div>
<div style="position:absolute;left:493.72px;top:528.86px" class="cls_037"><span class="cls_037">221.2 (197.6-246.7)</span></div>
<div style="position:absolute;left:308.01px;top:535.02px" class="cls_037"><span class="cls_037">Serious AEs</span></div>
<div style="position:absolute;left:378.36px;top:535.02px" class="cls_037"><span class="cls_037">9.1 (7.0-11.6)</span></div>
<div style="position:absolute;left:439.72px;top:535.02px" class="cls_037"><span class="cls_037">10.1 (7.3-13.8)</span></div>
<div style="position:absolute;left:493.72px;top:535.02px" class="cls_037"><span class="cls_037">7.6 (4.8-11.4)</span></div>
<div style="position:absolute;left:50.00px;top:535.60px" class="cls_031"><span class="cls_031">every 8 weeks [q8w]; pooled </span><span class="cls_030">n = </span><span class="cls_031">825), ADA (80 mg Week 0, 40</span></div>
<div style="position:absolute;left:308.01px;top:541.18px" class="cls_037"><span class="cls_037">Serious infections and</span></div>
<div style="position:absolute;left:378.36px;top:541.18px" class="cls_037"><span class="cls_037">1.5 (0.8-2.7)</span></div>
<div style="position:absolute;left:439.72px;top:541.18px" class="cls_037"><span class="cls_037">1.9 (0.8-3.8)</span></div>
<div style="position:absolute;left:493.72px;top:541.18px" class="cls_037"><span class="cls_037">1.0 (0.2-2.8)</span></div>
<div style="position:absolute;left:50.00px;top:545.59px" class="cls_031"><span class="cls_031">mg Week 1, then 40 mg every 2 weeks [q2w]; pooled </span><span class="cls_030">n = </span><span class="cls_031">582), or</span></div>
<div style="position:absolute;left:308.01px;top:548.19px" class="cls_037"><span class="cls_037">infestations</span></div>
<div style="position:absolute;left:308.01px;top:554.34px" class="cls_037"><span class="cls_037">Active tuberculosis</span></div>
<div style="position:absolute;left:378.36px;top:554.34px" class="cls_037"><span class="cls_037">0.1 (0.0-0.8)</span></div>
<div style="position:absolute;left:439.72px;top:554.34px" class="cls_037"><span class="cls_037">0.2 (0.0-1.3)</span></div>
<div style="position:absolute;left:493.72px;top:554.34px" class="cls_037"><span class="cls_037">0</span></div>
<div style="position:absolute;left:50.00px;top:555.59px" class="cls_031"><span class="cls_031">placebo (Weeks 0, 4, and 12, then GUS 100 mg at Weeks 16 and</span></div>
<div style="position:absolute;left:306.64px;top:561.58px" class="cls_036"><span class="cls_036">Table 2 AEs to Week 16</span></div>
<div style="position:absolute;left:50.00px;top:565.59px" class="cls_031"><span class="cls_031">20; pooled </span><span class="cls_030">n = </span><span class="cls_031">422). Efficacy was evaluated using PASI 75, PASI</span></div>
<div style="position:absolute;left:308.01px;top:572.68px" class="cls_036"><span class="cls_036">IR/100 PY (95% CI)</span></div>
<div style="position:absolute;left:50.01px;top:575.59px" class="cls_031"><span class="cls_031">90, and PASI 100 responses (patients achieving ≥75%, ≥90%, and</span></div>
<div style="position:absolute;left:328.73px;top:581.53px" class="cls_036"><span class="cls_036">PBO</span></div>
<div style="position:absolute;left:383.72px;top:581.53px" class="cls_036"><span class="cls_036">All CZP</span></div>
<div style="position:absolute;left:438.72px;top:581.53px" class="cls_036"><span class="cls_036">CZP 400 mg Q2W</span></div>
<div style="position:absolute;left:492.73px;top:581.53px" class="cls_036"><span class="cls_036">CZP 200 mg Q2W</span></div>
<div style="position:absolute;left:50.02px;top:585.59px" class="cls_031"><span class="cls_031">100% PASI improvement from baseline, respectively) through</span></div>
<div style="position:absolute;left:328.73px;top:588.53px" class="cls_036"><span class="cls_036">(</span><span class="cls_040">n = </span><span class="cls_036">157)</span></div>
<div style="position:absolute;left:383.72px;top:588.53px" class="cls_036"><span class="cls_036">(</span><span class="cls_040">n = </span><span class="cls_036">692)</span></div>
<div style="position:absolute;left:438.72px;top:588.53px" class="cls_036"><span class="cls_036">(</span><span class="cls_040">n = </span><span class="cls_036">342)</span></div>
<div style="position:absolute;left:492.73px;top:588.53px" class="cls_036"><span class="cls_036">(</span><span class="cls_040">n = </span><span class="cls_036">350)</span></div>
<div style="position:absolute;left:50.02px;top:595.59px" class="cls_031"><span class="cls_031">Week 24. Median time to achieve a response was defined as the</span></div>
<div style="position:absolute;left:308.01px;top:597.71px" class="cls_037"><span class="cls_037">AEs</span></div>
<div style="position:absolute;left:328.72px;top:597.71px" class="cls_037"><span class="cls_037">342.6 (277.8-417.9)</span></div>
<div style="position:absolute;left:383.72px;top:597.71px" class="cls_037"><span class="cls_037">319.1 (289.1-351.4)</span></div>
<div style="position:absolute;left:438.73px;top:597.71px" class="cls_037"><span class="cls_037">348.3 (303.5-397.9)</span></div>
<div style="position:absolute;left:492.73px;top:597.71px" class="cls_037"><span class="cls_037">292.1 (252.8-335.9)</span></div>
<div style="position:absolute;left:50.02px;top:605.59px" class="cls_031"><span class="cls_031">time taken for ≥50% of the patients to ever achieve a response.</span></div>
<div style="position:absolute;left:50.02px;top:615.59px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Based on the pooled VOYAGE 1 and 2 data, median</span></div>
<div style="position:absolute;left:306.64px;top:612.55px" class="cls_033"><span class="cls_033">P047</span></div>
<div style="position:absolute;left:50.02px;top:625.59px" class="cls_031"><span class="cls_031">time to achieve a PASI 75 response was </span><span class="cls_030"> ≤ </span><span class="cls_031">8 weeks for both the</span></div>
<div style="position:absolute;left:306.64px;top:623.95px" class="cls_025"><span class="cls_025">SECUKINUMAB PROVIDES SUSTAINED MINIMAL</span></div>
<div style="position:absolute;left:50.02px;top:635.59px" class="cls_031"><span class="cls_031">GUS and ADA groups. However, median time to achieve a PASI</span></div>
<div style="position:absolute;left:306.64px;top:634.85px" class="cls_025"><span class="cls_025">DISEASE ACTIVITY (MDA) AND REMISSION RELATED</span></div>
<div style="position:absolute;left:50.02px;top:645.58px" class="cls_031"><span class="cls_031">90 response was </span><span class="cls_030"> ≤ </span><span class="cls_031">12 weeks for GUS and </span><span class="cls_030"> ≤ </span><span class="cls_031">16 weeks for ADA.</span></div>
<div style="position:absolute;left:306.64px;top:645.75px" class="cls_025"><span class="cls_025">TO DISEASE ACTIVITY INDEX FOR PSORIATIC</span></div>
<div style="position:absolute;left:50.02px;top:655.58px" class="cls_031"><span class="cls_031">Median time to achieve a PASI 100 response was </span><span class="cls_030"> ≤ </span><span class="cls_031">24 weeks for</span></div>
<div style="position:absolute;left:306.64px;top:656.64px" class="cls_025"><span class="cls_025">ARTHRITIS (DAPSA): 2-YEAR RESULTS FROM A PHASE</span></div>
<div style="position:absolute;left:50.02px;top:665.58px" class="cls_031"><span class="cls_031">GUS, but was not achieved for ADA. Median time to achieve any</span></div>
<div style="position:absolute;left:306.64px;top:667.54px" class="cls_025"><span class="cls_025">3 STUDY</span></div>
<div style="position:absolute;left:50.02px;top:675.58px" class="cls_031"><span class="cls_031">defined endpoint was not achieved for the placebo group.</span></div>
<div style="position:absolute;left:306.64px;top:677.44px" class="cls_051"><span class="cls_051">Laura C Coates</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Peter Nash</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Tore Kristian Kvien</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Laure Gos-</span></div>
<div style="position:absolute;left:50.02px;top:685.58px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Taken together, these results demonstrate that pa-</span></div>
<div style="position:absolute;left:306.64px;top:687.35px" class="cls_026"><span class="cls_026">sec</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Philip J Mease</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Lawrence Rasouliyan</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Luminita Pricop</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:50.00px;top:695.61px" class="cls_031"><span class="cls_031">tients with moderate-to-severe psoriasis treated with GUS rapidly</span></div>
<div style="position:absolute;left:306.64px;top:697.25px" class="cls_026"><span class="cls_026">Corine Gaillez</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, Josef S Smolen</span><span class="cls_027"><sup>9</sup></span></div>
<div style="position:absolute;left:50.00px;top:705.60px" class="cls_031"><span class="cls_031">achieved high levels of response, and more efficiently and more</span></div>
<div style="position:absolute;left:306.64px;top:707.85px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Nuffield Department of Orthopaedics, Rheumatology and Musculoske-</span></div>
<div style="position:absolute;left:50.01px;top:715.60px" class="cls_031"><span class="cls_031">quickly than with ADA.</span></div>
<div style="position:absolute;left:306.64px;top:717.45px" class="cls_029"><span class="cls_029">letal Sciences, University of Oxford, Oxford, UK, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">University of Queens-</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:17666px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background24.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">22</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.85px" class="cls_029"><span class="cls_029">land, Brisbane, Australia, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Diakonhjemmet Hospital, Oslo, Norway, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Pitié</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">reSURFACE 2 (phase 3; NCT01729754) [1]. In Part 1 (Week</span></div>
<div style="position:absolute;left:50.00px;top:61.45px" class="cls_029"><span class="cls_029">Salpêtrière Hospital, AP-HP, Paris, France, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Swedish Medical Centre and</span></div>
<div style="position:absolute;left:306.64px;top:61.36px" class="cls_031"><span class="cls_031">[W]1-W12), pts received subcutaneous TIL 200 mg, TIL 100 mg,</span></div>
<div style="position:absolute;left:50.00px;top:71.05px" class="cls_029"><span class="cls_029">University of Washington, Seattle, USA, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">RTI Health Solutions, Barcelona,</span></div>
<div style="position:absolute;left:306.64px;top:71.31px" class="cls_031"><span class="cls_031">or placebo (PBO) at W0 and W4. Pts receiving PBO in Part 1 were</span></div>
<div style="position:absolute;left:50.00px;top:80.65px" class="cls_029"><span class="cls_029">Spain, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Novartis Pharmaceuticals Corp., East Hanover, USA, </span><span class="cls_028"><sup>8</sup></span><span class="cls_029">Novartis</span></div>
<div style="position:absolute;left:306.64px;top:81.27px" class="cls_031"><span class="cls_031">rerandomized to TIL 200 mg or 100 mg in Part 2 (W12-W28). For</span></div>
<div style="position:absolute;left:50.00px;top:90.25px" class="cls_029"><span class="cls_029">Pharma AG, Basel, Switzerland, </span><span class="cls_028"><sup>9</sup></span><span class="cls_029">Medical University of Vienna, Vienna,</span></div>
<div style="position:absolute;left:306.64px;top:91.22px" class="cls_031"><span class="cls_031">each trial, continuous variables of mean baseline Psoriasis Area</span></div>
<div style="position:absolute;left:50.00px;top:99.85px" class="cls_029"><span class="cls_029">Austria</span></div>
<div style="position:absolute;left:306.64px;top:101.18px" class="cls_031"><span class="cls_031">and Severity Index (PASI), body mass index (BMI), Physician’s</span></div>
<div style="position:absolute;left:50.00px;top:110.72px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">DAPSA and MDA are validated composite indices</span></div>
<div style="position:absolute;left:306.64px;top:111.13px" class="cls_031"><span class="cls_031">Global Assessment (PGA), and PASI component for head region</span></div>
<div style="position:absolute;left:50.00px;top:120.62px" class="cls_031"><span class="cls_031">used in psoriatic arthritis (PsA) to measure disease activity states (1).</span></div>
<div style="position:absolute;left:306.64px;top:121.08px" class="cls_031"><span class="cls_031">as well as dichotomous variables of baseline PASI </span><span class="cls_030"> > </span><span class="cls_031">20 or </span><span class="cls_030"> ≤ </span><span class="cls_031">20</span></div>
<div style="position:absolute;left:50.00px;top:130.52px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To assess the proportion of pts treated with secukinu-</span></div>
<div style="position:absolute;left:306.64px;top:131.04px" class="cls_031"><span class="cls_031">and PASI 50 response or nonresponse at W8 were evaluated as</span></div>
<div style="position:absolute;left:50.00px;top:140.42px" class="cls_031"><span class="cls_031">mab (SEC) reaching DAPSA remission (REM) or low disease</span></div>
<div style="position:absolute;left:306.64px;top:140.99px" class="cls_031"><span class="cls_031">predictors of response. Response was defined in this analysis as</span></div>
<div style="position:absolute;left:50.00px;top:150.32px" class="cls_031"><span class="cls_031">activity (LDA) and those who reached either MDA or very low</span></div>
<div style="position:absolute;left:306.65px;top:150.95px" class="cls_031"><span class="cls_031">PASI 50 or PASI 90 at W12 and W28.</span></div>
<div style="position:absolute;left:50.00px;top:160.22px" class="cls_031"><span class="cls_031">disease activity (VLDA) at Weeks (wks) 16 and 104 in the FU-</span></div>
<div style="position:absolute;left:306.65px;top:160.86px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">None of the continuous variables appeared to be consis-</span></div>
<div style="position:absolute;left:50.00px;top:170.12px" class="cls_031"><span class="cls_031">TURE 2 study (2).</span></div>
<div style="position:absolute;left:306.64px;top:170.81px" class="cls_031"><span class="cls_031">tently predictive of PASI 50 or PASI 90 response, nor were baseline</span></div>
<div style="position:absolute;left:50.00px;top:180.02px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">DAPSA-REM, DAPSA-REM/LDA, MDA, and VLDA</span></div>
<div style="position:absolute;left:306.64px;top:180.76px" class="cls_031"><span class="cls_031">PASI </span><span class="cls_030"> > </span><span class="cls_031">20 or </span><span class="cls_030"> ≤ </span><span class="cls_031">20 definitive predictors of response. PASI 50 re-</span></div>
<div style="position:absolute;left:50.00px;top:189.92px" class="cls_031"><span class="cls_031">and their core components were assessed in the overall population</span></div>
<div style="position:absolute;left:306.64px;top:190.71px" class="cls_031"><span class="cls_031">sponse vs nonresponse at W8 with TIL 200 mg appeared to be pre-</span></div>
<div style="position:absolute;left:50.00px;top:199.82px" class="cls_031"><span class="cls_031">and in pts stratified by prior anti-TNF use (TNF-Naïve/IR) and time</span></div>
<div style="position:absolute;left:306.64px;top:200.66px" class="cls_031"><span class="cls_031">dictive of a PASI 50 response at W12 (percentage of patients</span><span class="cls_035">±</span><span class="cls_031">SD:</span></div>
<div style="position:absolute;left:50.02px;top:209.72px" class="cls_031"><span class="cls_031">since first PsA diagnosis (</span><span class="cls_030"> ≤ </span><span class="cls_031">2/</span><span class="cls_030"> > </span><span class="cls_031">2 years) using as observed data.</span></div>
<div style="position:absolute;left:306.64px;top:210.61px" class="cls_031"><span class="cls_031">98%</span><span class="cls_035">±</span><span class="cls_031">0.9% vs 59%</span><span class="cls_035">±</span><span class="cls_031">6.1%, respectively, in reSURFACE 1, and</span></div>
<div style="position:absolute;left:50.02px;top:219.62px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">At Wk16, in the overall population, the proportion of pts</span></div>
<div style="position:absolute;left:306.64px;top:220.56px" class="cls_031"><span class="cls_031">99%</span><span class="cls_035">±</span><span class="cls_031">0.8% vs 57%</span><span class="cls_035">±</span><span class="cls_031">5.7%, respectively, in reSURFACE 2) and of</span></div>
<div style="position:absolute;left:50.02px;top:229.52px" class="cls_031"><span class="cls_031">treated with SEC 300/150 mg achieving remission was 14%/10%</span></div>
<div style="position:absolute;left:306.64px;top:230.51px" class="cls_031"><span class="cls_031">a PASI 90 response at W12 (47%</span><span class="cls_035">±</span><span class="cls_031">3.3% vs 0%</span><span class="cls_035">±</span><span class="cls_031">0%, respectively,</span></div>
<div style="position:absolute;left:50.02px;top:239.42px" class="cls_031"><span class="cls_031">(DAPSA-REM) and 8%/6% (VLDA) and achieving LDA was</span></div>
<div style="position:absolute;left:306.64px;top:240.46px" class="cls_031"><span class="cls_031">in reSURFACE 1, and 50%</span><span class="cls_035">±</span><span class="cls_031">3.3% vs 5%</span><span class="cls_035">±</span><span class="cls_031">2.6%, respectively, in</span></div>
<div style="position:absolute;left:50.02px;top:249.32px" class="cls_031"><span class="cls_031">42%/44% (DAPSA-REM/LDA) and 28%/23% (MDA). A higher</span></div>
<div style="position:absolute;left:306.64px;top:250.41px" class="cls_031"><span class="cls_031">reSURFACE 2). The percentage of patients with PASI 50 response</span></div>
<div style="position:absolute;left:50.02px;top:259.22px" class="cls_031"><span class="cls_031">proportion of anti-TNF-naïve pts and pts with early diagnosis (</span><span class="cls_030"> ≤ </span><span class="cls_031">2</span></div>
<div style="position:absolute;left:306.64px;top:260.36px" class="cls_031"><span class="cls_031">vs nonresponse at W8 with TIL 200 mg who achieved PASI 50 by</span></div>
<div style="position:absolute;left:50.01px;top:269.12px" class="cls_031"><span class="cls_031">years) treated with SEC achieved and sustained DAPSA-REM/</span></div>
<div style="position:absolute;left:306.64px;top:270.31px" class="cls_031"><span class="cls_031">W28 was 99%</span><span class="cls_035">±</span><span class="cls_031">0.6% vs 90%</span><span class="cls_035">±</span><span class="cls_031">3.8%, respectively, in reSURFACE</span></div>
<div style="position:absolute;left:50.01px;top:279.02px" class="cls_031"><span class="cls_031">LDA and MDA than in the overall population (Table). DAPSA-</span></div>
<div style="position:absolute;left:306.64px;top:280.26px" class="cls_031"><span class="cls_031">1, and 99%</span><span class="cls_035">±</span><span class="cls_031">0.8% vs 86%</span><span class="cls_035">±</span><span class="cls_031">4.0%, respectively, in reSURFACE 2;</span></div>
<div style="position:absolute;left:50.01px;top:288.92px" class="cls_031"><span class="cls_031">REM/LDA and MDA responses with SEC were sustained through</span></div>
<div style="position:absolute;left:306.64px;top:290.21px" class="cls_031"><span class="cls_031">the percentage who achieved PASI 90 by W28 was 70%</span><span class="cls_035">±</span><span class="cls_031">3.1%</span></div>
<div style="position:absolute;left:50.01px;top:298.82px" class="cls_031"><span class="cls_031">Wk104.</span></div>
<div style="position:absolute;left:306.64px;top:300.16px" class="cls_031"><span class="cls_031">vs 23%</span><span class="cls_035">±</span><span class="cls_031">5.4%, respectively, in reSURFACE 1, and 70%</span><span class="cls_035">±</span><span class="cls_031">3.1%</span></div>
<div style="position:absolute;left:50.01px;top:308.72px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">In the overall population, a higher proportion</span></div>
<div style="position:absolute;left:306.64px;top:310.11px" class="cls_031"><span class="cls_031">vs 21%</span><span class="cls_035">±</span><span class="cls_031">4.7%, respectively, in reSURFACE 2. Similar trends in</span></div>
<div style="position:absolute;left:50.01px;top:318.62px" class="cls_031"><span class="cls_031">of SEC treated pts at Wk16 achieved DAPSA-REM, VLDA,</span></div>
<div style="position:absolute;left:306.64px;top:320.06px" class="cls_031"><span class="cls_031">predictive responses were observed with TIL 100-mg treatment.</span></div>
<div style="position:absolute;left:50.01px;top:328.52px" class="cls_031"><span class="cls_031">DAPSA-REM/LDA, and MDA than those treated with placebo</span></div>
<div style="position:absolute;left:306.64px;top:330.01px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Achievement of PASI 50 by W8 was predictive of</span></div>
<div style="position:absolute;left:50.01px;top:338.42px" class="cls_031"><span class="cls_031">with a greater number of pts achieving DAPSA-REM or LDA than</span></div>
<div style="position:absolute;left:306.64px;top:339.97px" class="cls_031"><span class="cls_031">a PASI 50 and PASI 90 response at W12 and W28. Most of the</span></div>
<div style="position:absolute;left:50.01px;top:348.32px" class="cls_031"><span class="cls_031">VLDA or MDA, respectively. These responses were sustained</span></div>
<div style="position:absolute;left:306.64px;top:349.92px" class="cls_031"><span class="cls_031">patients who had not achieved PASI 50 by W8 were able to achieve</span></div>
<div style="position:absolute;left:50.01px;top:358.22px" class="cls_031"><span class="cls_031">through Wk104.</span></div>
<div style="position:absolute;left:306.64px;top:359.88px" class="cls_031"><span class="cls_031">a PASI 50 response by W28. Baseline PASI score, PGA, and BMI</span></div>
<div style="position:absolute;left:50.01px;top:368.22px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:306.64px;top:369.83px" class="cls_031"><span class="cls_031">were not predictive of PASI 50 or PASI 90 response.</span></div>
<div style="position:absolute;left:50.00px;top:378.23px" class="cls_032"><span class="cls_032">1.Coates, Helliwell.Ann Rheum Dis 2016;75:640-43.</span></div>
<div style="position:absolute;left:306.64px;top:379.83px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:50.00px;top:387.23px" class="cls_032"><span class="cls_032">2.McInnes et al. Rheumatol.2017;56:1993-2003.</span></div>
<div style="position:absolute;left:306.64px;top:389.82px" class="cls_032"><span class="cls_032">1. Reich K, et al. Lancet. 2017;390:276-288.</span></div>
<div style="position:absolute;left:50.00px;top:396.22px" class="cls_036"><span class="cls_036">Table</span><span class="cls_031">.</span></div>
<div style="position:absolute;left:306.64px;top:398.82px" class="cls_032"><span class="cls_032">Acknowledgements: The studies were funded by Merck Sharp & Dohme,</span></div>
<div style="position:absolute;left:102.36px;top:409.35px" class="cls_036"><span class="cls_036">DAPSA-REM/</span></div>
<div style="position:absolute;left:199.09px;top:409.36px" class="cls_036"><span class="cls_036">DAPSA-REM/</span></div>
<div style="position:absolute;left:306.64px;top:407.82px" class="cls_032"><span class="cls_032">Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.</span></div>
<div style="position:absolute;left:102.36px;top:419.36px" class="cls_036"><span class="cls_036">LDA</span></div>
<div style="position:absolute;left:149.37px;top:419.36px" class="cls_036"><span class="cls_036">MDA</span></div>
<div style="position:absolute;left:199.09px;top:419.36px" class="cls_036"><span class="cls_036">LDA</span></div>
<div style="position:absolute;left:254.79px;top:419.36px" class="cls_040"><span class="cls_040">≤ </span><span class="cls_036">2/</span></div>
<div style="position:absolute;left:275.14px;top:419.36px" class="cls_040"><span class="cls_040">> </span><span class="cls_036">2</span></div>
<div style="position:absolute;left:306.64px;top:416.82px" class="cls_032"><span class="cls_032">Analyses were presented at the American Academy of Dermatology Annual</span></div>
<div style="position:absolute;left:306.64px;top:425.82px" class="cls_032"><span class="cls_032">Meeting, February 16-20, 2018, San Diego, CA, USA.</span></div>
<div style="position:absolute;left:51.38px;top:429.35px" class="cls_036"><span class="cls_036">% Response</span></div>
<div style="position:absolute;left:102.36px;top:429.36px" class="cls_036"><span class="cls_036">TNF-Naïve/IR  TNF-Naïve/IR</span></div>
<div style="position:absolute;left:199.99px;top:429.37px" class="cls_040"><span class="cls_040">≤ </span><span class="cls_036">2/</span><span class="cls_040"> > </span><span class="cls_036">2 years</span></div>
<div style="position:absolute;left:252.09px;top:429.37px" class="cls_036"><span class="cls_036">years</span></div>
<div style="position:absolute;left:51.38px;top:437.53px" class="cls_037"><span class="cls_037">Wk16</span></div>
<div style="position:absolute;left:75.36px;top:437.53px" class="cls_037"><span class="cls_037">300 mg</span></div>
<div style="position:absolute;left:102.36px;top:437.53px" class="cls_037"><span class="cls_037">52/22</span></div>
<div style="position:absolute;left:149.36px;top:437.54px" class="cls_037"><span class="cls_037">34/15</span></div>
<div style="position:absolute;left:199.08px;top:437.55px" class="cls_037"><span class="cls_037">52/40</span></div>
<div style="position:absolute;left:252.08px;top:437.55px" class="cls_037"><span class="cls_037">43/23</span></div>
<div style="position:absolute;left:51.38px;top:444.53px" class="cls_037"><span class="cls_037">Wk104</span></div>
<div style="position:absolute;left:75.36px;top:444.53px" class="cls_037"><span class="cls_037">150 mg</span></div>
<div style="position:absolute;left:102.36px;top:444.54px" class="cls_037"><span class="cls_037">54/27</span></div>
<div style="position:absolute;left:149.36px;top:444.54px" class="cls_037"><span class="cls_037">32/8</span></div>
<div style="position:absolute;left:199.08px;top:444.55px" class="cls_037"><span class="cls_037">42/45</span></div>
<div style="position:absolute;left:252.08px;top:444.55px" class="cls_037"><span class="cls_037">21/24</span></div>
<div style="position:absolute;left:306.64px;top:443.44px" class="cls_033"><span class="cls_033">P049</span></div>
<div style="position:absolute;left:75.36px;top:451.53px" class="cls_037"><span class="cls_037">Placebo</span></div>
<div style="position:absolute;left:102.36px;top:451.54px" class="cls_037"><span class="cls_037">23/10</span></div>
<div style="position:absolute;left:149.36px;top:451.54px" class="cls_037"><span class="cls_037">14/3</span></div>
<div style="position:absolute;left:199.08px;top:451.55px" class="cls_037"><span class="cls_037">17/19</span></div>
<div style="position:absolute;left:252.08px;top:451.56px" class="cls_037"><span class="cls_037">7/12</span></div>
<div style="position:absolute;left:75.36px;top:458.53px" class="cls_037"><span class="cls_037">300 mg</span></div>
<div style="position:absolute;left:102.36px;top:458.54px" class="cls_037"><span class="cls_037">75/46</span></div>
<div style="position:absolute;left:149.36px;top:458.55px" class="cls_037"><span class="cls_037">49/25</span></div>
<div style="position:absolute;left:199.08px;top:458.55px" class="cls_037"><span class="cls_037">63/66</span></div>
<div style="position:absolute;left:252.08px;top:458.56px" class="cls_037"><span class="cls_037">33/43</span></div>
<div style="position:absolute;left:306.64px;top:454.84px" class="cls_025"><span class="cls_025">LONG-TERM EFFICACY OF GUSELKUMAB</span></div>
<div style="position:absolute;left:75.36px;top:465.54px" class="cls_037"><span class="cls_037">150 mg</span></div>
<div style="position:absolute;left:102.36px;top:465.54px" class="cls_037"><span class="cls_037">62/33</span></div>
<div style="position:absolute;left:149.36px;top:465.55px" class="cls_037"><span class="cls_037">37/10</span></div>
<div style="position:absolute;left:199.08px;top:465.55px" class="cls_037"><span class="cls_037">46/57</span></div>
<div style="position:absolute;left:252.08px;top:465.56px" class="cls_037"><span class="cls_037">20/33</span></div>
<div style="position:absolute;left:306.64px;top:465.74px" class="cls_025"><span class="cls_025">TREATMENT AFTER DRUG WITHDRAWAL AND</span></div>
<div style="position:absolute;left:50.00px;top:471.81px" class="cls_037"><span class="cls_037">Total number of pts providing data to the analysis: secukinumab 300 mg (</span><span class="cls_038">n = </span><span class="cls_037">100), 150 mg</span></div>
<div style="position:absolute;left:50.00px;top:478.81px" class="cls_037"><span class="cls_037">(</span><span class="cls_038">n = </span><span class="cls_037">100) and placebo (</span><span class="cls_038">n = </span><span class="cls_037">98).</span></div>
<div style="position:absolute;left:306.64px;top:476.64px" class="cls_025"><span class="cls_025">RETREATMENT IN PATIENTS WITH MODERATE-</span></div>
<div style="position:absolute;left:306.64px;top:487.54px" class="cls_025"><span class="cls_025">SEVERE PLAQUE PSORIASIS: RESULTS FROM</span></div>
<div style="position:absolute;left:50.00px;top:495.37px" class="cls_033"><span class="cls_033">P048</span></div>
<div style="position:absolute;left:306.64px;top:498.44px" class="cls_025"><span class="cls_025">VOYAGE 2</span></div>
<div style="position:absolute;left:50.00px;top:506.77px" class="cls_025"><span class="cls_025">PREDICTORS OF RESPONSE TO TILDRAKIZUMAB</span></div>
<div style="position:absolute;left:306.64px;top:508.34px" class="cls_051"><span class="cls_051">Kenneth Gordon</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, April Armstrong</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Peter Foley</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Yasmine Wasfi</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:50.00px;top:517.67px" class="cls_025"><span class="cls_025">FOR MODERATE TO SEVERE CHRONIC PLAQUE</span></div>
<div style="position:absolute;left:306.64px;top:518.24px" class="cls_026"><span class="cls_026">Michael Song</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Yaung-Kaung Shen</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Shu Li</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Ernesto J Muñoz-</span></div>
<div style="position:absolute;left:50.00px;top:528.57px" class="cls_025"><span class="cls_025">PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:528.14px" class="cls_026"><span class="cls_026">Elías</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Bruce Randazzo</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Kristian Reich</span><span class="cls_027"><sup>5</sup></span></div>
<div style="position:absolute;left:50.00px;top:538.47px" class="cls_026"><span class="cls_026">Andrew Blauvelt</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Kristian Reich</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Kim A Papp</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Stephen K Ty-</span></div>
<div style="position:absolute;left:306.64px;top:538.74px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Medical College of Wisconsin, Milwaukee, WI, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">University of Southern</span></div>
<div style="position:absolute;left:50.00px;top:548.37px" class="cls_026"><span class="cls_026">ring</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Rodney Sinclair</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Diamant Thaçi</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">,</span><span class="cls_051"> Melinda Gooderham</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:548.34px" class="cls_029"><span class="cls_029">California, Los Angeles, CA, USA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">The University of Melbourne, St.</span></div>
<div style="position:absolute;left:50.00px;top:558.27px" class="cls_026"><span class="cls_026">Qing Li</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, Nicole Cichanowitz, Carmen La Rosa</span><span class="cls_027"><sup>8</sup></span></div>
<div style="position:absolute;left:306.64px;top:557.94px" class="cls_029"><span class="cls_029">Vincent’s Hospital, Melbourne and Skin & Cancer Foundation Inc., Carl-</span></div>
<div style="position:absolute;left:50.00px;top:568.87px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Oregon Medical Research Center, Portland, OR, USA, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">SCIderm Research</span></div>
<div style="position:absolute;left:306.64px;top:567.54px" class="cls_029"><span class="cls_029">ton, VIC, Australia, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Janssen Research & Development, LLC, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Dermato-</span></div>
<div style="position:absolute;left:50.00px;top:578.47px" class="cls_029"><span class="cls_029">Institute and Dermatologikum Hamburg, Hamburg, Germany, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Probity</span></div>
<div style="position:absolute;left:306.63px;top:577.14px" class="cls_029"><span class="cls_029">logikum Hamburg and SCIderm Research Institute, Hamburg, Germany</span></div>
<div style="position:absolute;left:50.00px;top:588.07px" class="cls_029"><span class="cls_029">Medical Research, Waterloo, ON, Canada, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Department of Dermatology,</span></div>
<div style="position:absolute;left:306.64px;top:587.91px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To report long-term efficacy of guselkumab (GUS) after</span></div>
<div style="position:absolute;left:50.00px;top:597.67px" class="cls_029"><span class="cls_029">University of Texas, Houston, TX, USA, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">University of Melbourne, Mel-</span></div>
<div style="position:absolute;left:306.65px;top:597.81px" class="cls_031"><span class="cls_031">drug withdrawal and retreatment in patients with moderate-severe</span></div>
<div style="position:absolute;left:50.00px;top:607.27px" class="cls_029"><span class="cls_029">bourne, VIC, Australia, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">University of Lübeck, Lübeck, Germany, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Queens</span></div>
<div style="position:absolute;left:306.65px;top:607.71px" class="cls_031"><span class="cls_031">psoriasis (PsO) in the Phase 3 VOYAGE 2 study.</span></div>
<div style="position:absolute;left:50.00px;top:616.87px" class="cls_029"><span class="cls_029">University, SKiN Centre for Dermatology and Probity Medical Research,</span></div>
<div style="position:absolute;left:306.65px;top:617.61px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">At Wk28, patients initially randomized to GUS who</span></div>
<div style="position:absolute;left:50.00px;top:626.47px" class="cls_029"><span class="cls_029">Peterborough, and Queens University, Kingston, ON, Canada, </span><span class="cls_028"><sup>8</sup></span><span class="cls_029">Merck &</span></div>
<div style="position:absolute;left:306.65px;top:627.51px" class="cls_031"><span class="cls_031">achieved a PASI90 response were re-randomized to either PBO/</span></div>
<div style="position:absolute;left:50.00px;top:636.07px" class="cls_029"><span class="cls_029">Co., Inc., Kenilworth, NJ, USA</span></div>
<div style="position:absolute;left:306.65px;top:637.41px" class="cls_031"><span class="cls_031">withdrawal (with retreatment upon loss of ≥50% PASI improve-</span></div>
<div style="position:absolute;left:50.00px;top:646.93px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Efficacy of tildrakizumab (TIL), a high affinity,</span></div>
<div style="position:absolute;left:306.64px;top:647.31px" class="cls_031"><span class="cls_031">ment achieved at Wk28 or at Wk72 if retreatment criteria were</span></div>
<div style="position:absolute;left:50.00px;top:656.93px" class="cls_031"><span class="cls_031">humanized, immunoglobulin G1κ monoclonal antibody against</span></div>
<div style="position:absolute;left:306.64px;top:657.21px" class="cls_031"><span class="cls_031">not met) or continued GUS treatment through Wk72.</span></div>
<div style="position:absolute;left:50.00px;top:666.93px" class="cls_031"><span class="cls_031">interleukin-23p19, has been evaluated for chronic plaque psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:667.11px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Among 375 patients initially randomized to GUS who</span></div>
<div style="position:absolute;left:50.00px;top:676.93px" class="cls_031"><span class="cls_031">(PsO) in 2 phase 3 randomized controlled trials.</span></div>
<div style="position:absolute;left:306.64px;top:677.01px" class="cls_031"><span class="cls_031">achieved a PASI90 response at Wk28, 182 were re-randomized</span></div>
<div style="position:absolute;left:50.00px;top:686.93px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">The aim of our analysis was to determine predictors of</span></div>
<div style="position:absolute;left:306.64px;top:686.91px" class="cls_031"><span class="cls_031">to PBO/withdrawal and 193 to GUS/maintenance treatment. Ef-</span></div>
<div style="position:absolute;left:50.00px;top:696.93px" class="cls_031"><span class="cls_031">response to TIL treatment in the 2 trials.</span></div>
<div style="position:absolute;left:306.64px;top:696.81px" class="cls_031"><span class="cls_031">ficacy for the continued GUS treatment group was maintained</span></div>
<div style="position:absolute;left:50.00px;top:706.93px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Patients (pts) with moderate to severe PsO were</span></div>
<div style="position:absolute;left:306.64px;top:706.71px" class="cls_031"><span class="cls_031">through Wk72, while responses for the withdrawal group dimi-</span></div>
<div style="position:absolute;left:50.00px;top:716.93px" class="cls_031"><span class="cls_031">randomized in reSURFACE 1 (phase 3; NCT01722331) and</span></div>
<div style="position:absolute;left:306.64px;top:716.61px" class="cls_031"><span class="cls_031">nished, with PASI90 responses of 86.0% vs 11.5% respectively at</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:18469px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background25.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">23</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">Wk72. Among the 182 patients in the withdrawal arm, 117 were</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">In the ADEPT and ACCLAIM cohorts, pts who</span></div>
<div style="position:absolute;left:50.00px;top:61.36px" class="cls_031"><span class="cls_031">retreated with GUS prior to Wk72; 56 did not meet retreatment</span></div>
<div style="position:absolute;left:306.64px;top:61.41px" class="cls_031"><span class="cls_031">achieved DAPSA remission or VLDA demonstrated similar</span></div>
<div style="position:absolute;left:50.00px;top:71.31px" class="cls_031"><span class="cls_031">criteria and initiated retreatment at Wk72 per protocol. Of 173</span></div>
<div style="position:absolute;left:306.64px;top:71.41px" class="cls_031"><span class="cls_031">outcomes with respect to the individual components of both sco-</span></div>
<div style="position:absolute;left:50.00px;top:81.27px" class="cls_031"><span class="cls_031">patients retreated, 87.6% achieved PASI90 within 6 months of</span></div>
<div style="position:absolute;left:306.64px;top:81.41px" class="cls_031"><span class="cls_031">res, despite the omission of several of these within the DAPSA.</span></div>
<div style="position:absolute;left:50.00px;top:91.22px" class="cls_031"><span class="cls_031">commencing retreatment. No new safety signals were observed</span></div>
<div style="position:absolute;left:306.64px;top:91.41px" class="cls_031"><span class="cls_031">Given the DAPSA’s continuous nature, its use may offer a good</span></div>
<div style="position:absolute;left:50.00px;top:101.18px" class="cls_031"><span class="cls_031">with GUS withdrawal and retreatment through Wk100. Mainte-</span></div>
<div style="position:absolute;left:306.64px;top:101.41px" class="cls_031"><span class="cls_031">alternative to fulfillment of the VLDA criteria, but these results</span></div>
<div style="position:absolute;left:50.00px;top:111.13px" class="cls_031"><span class="cls_031">nance of PASI90 response after drug withdrawal was associated</span></div>
<div style="position:absolute;left:306.63px;top:111.41px" class="cls_031"><span class="cls_031">require confirmation in different pt populations.</span></div>
<div style="position:absolute;left:50.00px;top:121.09px" class="cls_031"><span class="cls_031">with continued suppression of IL-17A, IL-17F, & IL-22, while</span></div>
<div style="position:absolute;left:306.64px;top:121.43px" class="cls_032"><span class="cls_032">Previously published Ann Rheum Dis 2017.</span></div>
<div style="position:absolute;left:50.00px;top:131.04px" class="cls_031"><span class="cls_031">loss of response was associated with increased levels of these</span></div>
<div style="position:absolute;left:50.00px;top:141.00px" class="cls_031"><span class="cls_031">circulating cytokines.</span></div>
<div style="position:absolute;left:306.64px;top:141.05px" class="cls_033"><span class="cls_033">P051</span></div>
<div style="position:absolute;left:50.00px;top:150.95px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Superior maintenance of high efficacy response rates</span></div>
<div style="position:absolute;left:306.64px;top:152.45px" class="cls_025"><span class="cls_025">EFFICACY AND SAFETY OF IXEKIZUMAB IN</span></div>
<div style="position:absolute;left:50.01px;top:160.90px" class="cls_031"><span class="cls_031">was achieved with continuous GUS treatment vs withdrawal, and</span></div>
<div style="position:absolute;left:306.64px;top:163.35px" class="cls_025"><span class="cls_025">PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS:</span></div>
<div style="position:absolute;left:50.01px;top:170.86px" class="cls_031"><span class="cls_031">the majority of retreated patients achieved PASI90. Maintenance</span></div>
<div style="position:absolute;left:306.64px;top:174.25px" class="cls_025"><span class="cls_025">THREE YEAR RESULTS FROM A PHASE 3 STUDY</span></div>
<div style="position:absolute;left:50.01px;top:180.81px" class="cls_031"><span class="cls_031">of PASI90 after drug withdrawal was associated with continued</span></div>
<div style="position:absolute;left:306.64px;top:185.15px" class="cls_025"><span class="cls_025">(SPIRIT-P1)</span></div>
<div style="position:absolute;left:50.01px;top:190.77px" class="cls_031"><span class="cls_031">suppression of IL-17A, IL-17F, and IL-22.</span></div>
<div style="position:absolute;left:306.64px;top:195.05px" class="cls_051"><span class="cls_051">Vinod Chandran</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Roy Fleischmann</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Eric Lespessailles</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Philip</span></div>
<div style="position:absolute;left:542.65px;top:205.70px" class="cls_027"><span class="cls_027">5</span></div>
<div style="position:absolute;left:306.64px;top:204.95px" class="cls_026"><span class="cls_026">Helliwell</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Olivier Benichou</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Janelle Erickson</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Catherine Shuler</span></div>
<div style="position:absolute;left:50.00px;top:209.46px" class="cls_033"><span class="cls_033">P050</span></div>
<div style="position:absolute;left:306.64px;top:215.55px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Krembil Research Institute, University of Toronto, Toronto, Canada,</span></div>
<div style="position:absolute;left:50.00px;top:220.92px" class="cls_025"><span class="cls_025">OUTCOMES ASSOCIATED WITH ACHIEVEMENT OF</span></div>
<div style="position:absolute;left:306.64px;top:225.15px" class="cls_028"><span class="cls_028"><sup>2</sup></span><span class="cls_029">Metroplex Clinical Research Center, Dallas, USA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">University Orléans,</span></div>
<div style="position:absolute;left:50.00px;top:231.87px" class="cls_025"><span class="cls_025">VARIOUS TREATMENT TARGETS IN PATIENTS WITH</span></div>
<div style="position:absolute;left:306.64px;top:234.75px" class="cls_029"><span class="cls_029">Orléans, France, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">University of Leeds, UK, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Eli Lilly and Company, India-</span></div>
<div style="position:absolute;left:50.00px;top:242.82px" class="cls_025"><span class="cls_025">PSORIATIC ARTHRITIS RECEIVING ADALIMUMAB</span></div>
<div style="position:absolute;left:306.64px;top:244.35px" class="cls_029"><span class="cls_029">napolis, USA</span></div>
<div style="position:absolute;left:50.00px;top:252.78px" class="cls_026"><span class="cls_026">Josef S. Smolen</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Daniel Aletaha</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, </span><span class="cls_051">Dafna D. Gladman</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Ying</span></div>
<div style="position:absolute;left:306.64px;top:255.21px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Ixekizumab (IXE), an interleukin-17A antagonist,</span></div>
<div style="position:absolute;left:50.00px;top:262.73px" class="cls_026"><span class="cls_026">Zhang</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Fabiana Ganz</span><span class="cls_027"><sup>4</sup></span></div>
<div style="position:absolute;left:306.64px;top:265.21px" class="cls_031"><span class="cls_031">was superior to placebo (PBO) in improving the signs and symp-</span></div>
<div style="position:absolute;left:50.00px;top:273.39px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Medical University of Vienna, Vienna, Austria, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">University of Toronto, To-</span></div>
<div style="position:absolute;left:306.64px;top:275.21px" class="cls_031"><span class="cls_031">toms of psoriatic arthritis (PsA) at Week 24 in biologic-naïve</span></div>
<div style="position:absolute;left:50.00px;top:283.04px" class="cls_029"><span class="cls_029">ronto Western Hospital, Toronto, Ontario, Canada, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">AbbVie, Inc., North</span></div>
<div style="position:absolute;left:306.64px;top:285.21px" class="cls_031"><span class="cls_031">patients (pts).</span></div>
<div style="position:absolute;left:50.00px;top:292.70px" class="cls_029"><span class="cls_029">Chicago, IL, USA, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">AbbVie, Inc., Baar, Switzerland</span></div>
<div style="position:absolute;left:306.64px;top:295.21px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To determine the efficacy and safety of IXE treatment</span></div>
<div style="position:absolute;left:50.00px;top:303.62px" class="cls_030"><span class="cls_030">Background: </span><span class="cls_031">Various instruments are currently used for disease</span></div>
<div style="position:absolute;left:306.65px;top:305.21px" class="cls_031"><span class="cls_031">up to 3 years in biologic-naïve pts with PsA. </span><span class="cls_030">Methods: </span><span class="cls_031">In the</span></div>
<div style="position:absolute;left:50.00px;top:313.67px" class="cls_031"><span class="cls_031">activity and outcome assessment in psoriatic arthritis (PsA). Some</span></div>
<div style="position:absolute;left:306.62px;top:315.21px" class="cls_031"><span class="cls_031">SPIRIT-P1 Phase 3 trial (NCT01695239), 210 pts were randomi-</span></div>
<div style="position:absolute;left:50.00px;top:323.73px" class="cls_031"><span class="cls_031">measures attempt to incorporate the total spectrum of psoriatic</span></div>
<div style="position:absolute;left:306.64px;top:325.21px" class="cls_031"><span class="cls_031">zed to IXE (80 mg every 4 [Q4W] or 2 [Q2W] weeks), 101 pts to</span></div>
<div style="position:absolute;left:50.00px;top:333.78px" class="cls_031"><span class="cls_031">disease manifestations [eg, minimal disease activity (MDA)] while</span></div>
<div style="position:absolute;left:306.64px;top:335.21px" class="cls_031"><span class="cls_031">adalimumab (active reference arm), and 106 pts to PBO at Week</span></div>
<div style="position:absolute;left:50.00px;top:343.83px" class="cls_031"><span class="cls_031">others focus on arthritis assessments [eg, disease activity index</span></div>
<div style="position:absolute;left:306.64px;top:345.21px" class="cls_031"><span class="cls_031">0. ADA and PBO patients were re-randomized to IXE at the end</span></div>
<div style="position:absolute;left:50.00px;top:353.89px" class="cls_031"><span class="cls_031">for PsA (DAPSA)]. Whether in patients (pts) with PsA it is suf-</span></div>
<div style="position:absolute;left:306.64px;top:355.21px" class="cls_031"><span class="cls_031">of the double-blind treatment period. Ad-hoc efficacy for all pts</span></div>
<div style="position:absolute;left:50.00px;top:363.95px" class="cls_031"><span class="cls_031">ficient to primarily consider joint disease aspects remains unclear.</span></div>
<div style="position:absolute;left:306.65px;top:365.21px" class="cls_031"><span class="cls_031">initially randomized to IXE (intent-to-treat [ITT]) is presented.</span></div>
<div style="position:absolute;left:50.00px;top:374.00px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To compare DAPSA remission and low disease activity</span></div>
<div style="position:absolute;left:306.65px;top:375.21px" class="cls_031"><span class="cls_031">Modified non-responder imputation (missing data considered non-</span></div>
<div style="position:absolute;left:50.00px;top:384.05px" class="cls_031"><span class="cls_031">(LDA) with MDA and very low disease activity (VLDA) for the</span></div>
<div style="position:absolute;left:306.65px;top:385.21px" class="cls_031"><span class="cls_031">response for pts discontinued due to lack of efficacy or adverse</span></div>
<div style="position:absolute;left:50.00px;top:394.11px" class="cls_031"><span class="cls_031">presence of residual abnormalities of the respective composing</span></div>
<div style="position:absolute;left:306.65px;top:395.21px" class="cls_031"><span class="cls_031">events [AEs]; multiple imputation for all other missing data) was</span></div>
<div style="position:absolute;left:50.00px;top:404.16px" class="cls_031"><span class="cls_031">variables.</span></div>
<div style="position:absolute;left:306.65px;top:405.21px" class="cls_031"><span class="cls_031">applied to efficacy response outcomes. Ad hoc safety data, for all</span></div>
<div style="position:absolute;left:50.00px;top:414.21px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">This post hoc analysis included pts with PsA receiving</span></div>
<div style="position:absolute;left:306.64px;top:415.21px" class="cls_031"><span class="cls_031">pts who received at least one IXE dose during the trial (</span><span class="cls_030">n = </span><span class="cls_031">386),</span></div>
<div style="position:absolute;left:50.00px;top:424.27px" class="cls_031"><span class="cls_031">adalimumab (ADA) in one of two multicenter studies: ADEPT was</span></div>
<div style="position:absolute;left:306.64px;top:425.20px" class="cls_031"><span class="cls_031">are presented as exposure-adjusted incidence rates (IRs; number</span></div>
<div style="position:absolute;left:50.00px;top:434.32px" class="cls_031"><span class="cls_031">a 24-week (wk), randomized, double-blind, placebo-controlled</span></div>
<div style="position:absolute;left:306.64px;top:435.20px" class="cls_031"><span class="cls_031">of pts with events*100 /total pt years [PY]).</span></div>
<div style="position:absolute;left:50.00px;top:444.37px" class="cls_031"><span class="cls_031">trial; ACCLAIM was a 12-wk, open-label study conducted in</span></div>
<div style="position:absolute;left:306.64px;top:445.20px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Efficacy results are summarized for ITT IXE-treated pts</span></div>
<div style="position:absolute;left:50.00px;top:454.43px" class="cls_031"><span class="cls_031">Canada in care settings that reflected usual practice. Frequencies</span></div>
<div style="position:absolute;left:306.64px;top:455.20px" class="cls_031"><span class="cls_031">(Table 1). Improvements in ACR (American College of Rheu-</span></div>
<div style="position:absolute;left:50.00px;top:464.48px" class="cls_031"><span class="cls_031">of DAPSA remission/LDA and MDA/VLDA were summarized,</span></div>
<div style="position:absolute;left:306.64px;top:465.21px" class="cls_031"><span class="cls_031">matology) responses, enthesitis, dactylitis, PASI (Psoriasis Area</span></div>
<div style="position:absolute;left:50.00px;top:474.53px" class="cls_031"><span class="cls_031">and the individual PsA manifestations within these states were</span></div>
<div style="position:absolute;left:306.64px;top:475.21px" class="cls_031"><span class="cls_031">and Severity Index), and NAPSI (Nail Psoriasis Severity Index)</span></div>
<div style="position:absolute;left:50.00px;top:484.58px" class="cls_031"><span class="cls_031">assessed. DAPSA was summed from the following continuous</span></div>
<div style="position:absolute;left:306.64px;top:485.21px" class="cls_031"><span class="cls_031">persisted up to 3 years. Safety assessments for all pts initially</span></div>
<div style="position:absolute;left:50.00px;top:494.64px" class="cls_031"><span class="cls_031">variables: swollen (66) and tender (68) joints, pt global assess-</span></div>
<div style="position:absolute;left:306.64px;top:495.21px" class="cls_031"><span class="cls_031">randomized to IXE or re-randomized to IXE during SPIRIT-P1 are</span></div>
<div style="position:absolute;left:50.00px;top:504.72px" class="cls_031"><span class="cls_031">ment (PtGA, cm), pt pain (PP, cm), and C-reactive protein (CRP,</span></div>
<div style="position:absolute;left:306.64px;top:505.21px" class="cls_031"><span class="cls_031">summarized (Table 2). IRs of treatment-emergent AEs (TEAEs)</span></div>
<div style="position:absolute;left:50.00px;top:514.77px" class="cls_031"><span class="cls_031">mg/dL). DAPSA remission was defined as </span><span class="cls_030"> ≤ </span><span class="cls_031">4 and DAPSA LDA</span></div>
<div style="position:absolute;left:306.64px;top:515.21px" class="cls_031"><span class="cls_031">were similar between IXE Q4W and Q2W treatment groups.</span></div>
<div style="position:absolute;left:50.00px;top:524.82px" class="cls_031"><span class="cls_031">as </span><span class="cls_030"> > </span><span class="cls_031">4 and </span><span class="cls_030"> ≤ </span><span class="cls_031">14. MDA criteria were as follows:</span><span class="cls_030"> ≤ </span><span class="cls_031">1 tender, </span><span class="cls_030"> ≤ </span><span class="cls_031">1</span></div>
<div style="position:absolute;left:306.64px;top:527.24px" class="cls_036"><span class="cls_036">Table 1. Efficacy Outcome Measures at Week 156 (ITT IXE-Treated Population)</span></div>
<div style="position:absolute;left:50.00px;top:534.87px" class="cls_031"><span class="cls_031">swollen joint, </span><span class="cls_030"> ≤ </span><span class="cls_031">1 entheseal point, PP </span><span class="cls_030"> ≤ </span><span class="cls_031">15mm, PtGA </span><span class="cls_030"> ≤ </span><span class="cls_031">20mm,</span></div>
<div style="position:absolute;left:414.25px;top:538.67px" class="cls_037"><span class="cls_037">IXE Q4W (</span><span class="cls_038">n = </span><span class="cls_037">107)</span></div>
<div style="position:absolute;left:494.25px;top:538.67px" class="cls_037"><span class="cls_037">IXE Q2W (</span><span class="cls_038">n = </span><span class="cls_037">103)</span></div>
<div style="position:absolute;left:50.00px;top:544.93px" class="cls_031"><span class="cls_031">HAQ </span><span class="cls_030"> ≤ </span><span class="cls_031">0.5, and PASI </span><span class="cls_030"> ≤ </span><span class="cls_031">3. MDA was calculated as fulfilling 5</span></div>
<div style="position:absolute;left:308.01px;top:546.83px" class="cls_037"><span class="cls_037">ACR20</span></div>
<div style="position:absolute;left:414.25px;top:546.83px" class="cls_037"><span class="cls_037">69%</span></div>
<div style="position:absolute;left:494.25px;top:546.83px" class="cls_037"><span class="cls_037">62%</span></div>
<div style="position:absolute;left:308.01px;top:553.00px" class="cls_037"><span class="cls_037">ACR50</span></div>
<div style="position:absolute;left:414.25px;top:553.00px" class="cls_037"><span class="cls_037">51%</span></div>
<div style="position:absolute;left:494.25px;top:553.00px" class="cls_037"><span class="cls_037">56%</span></div>
<div style="position:absolute;left:49.99px;top:554.98px" class="cls_031"><span class="cls_031">of the 7 criteria, and VLDA calculated as fulfilling all 7 criteria.</span></div>
<div style="position:absolute;left:308.01px;top:559.16px" class="cls_037"><span class="cls_037">ACR70</span></div>
<div style="position:absolute;left:414.25px;top:559.16px" class="cls_037"><span class="cls_037">33%</span></div>
<div style="position:absolute;left:494.25px;top:559.16px" class="cls_037"><span class="cls_037">44%</span></div>
<div style="position:absolute;left:308.01px;top:565.33px" class="cls_037"><span class="cls_037">LEI</span><span class="cls_038"> = </span><span class="cls_037">0a</span></div>
<div style="position:absolute;left:414.25px;top:565.32px" class="cls_037"><span class="cls_037">47%</span></div>
<div style="position:absolute;left:494.25px;top:565.32px" class="cls_037"><span class="cls_037">40%</span></div>
<div style="position:absolute;left:50.00px;top:565.03px" class="cls_031"><span class="cls_031">Data were as observed.</span></div>
<div style="position:absolute;left:308.01px;top:571.49px" class="cls_037"><span class="cls_037">LDI-B</span><span class="cls_038"> = </span><span class="cls_037">0b</span></div>
<div style="position:absolute;left:414.25px;top:571.49px" class="cls_037"><span class="cls_037">62%</span></div>
<div style="position:absolute;left:494.25px;top:571.49px" class="cls_037"><span class="cls_037">69%</span></div>
<div style="position:absolute;left:50.00px;top:575.09px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Among 151 pts receiving ADA in ADEPT, 33 (22%) each</span></div>
<div style="position:absolute;left:308.01px;top:577.66px" class="cls_037"><span class="cls_037">PASI75c</span></div>
<div style="position:absolute;left:414.25px;top:577.66px" class="cls_037"><span class="cls_037">63%</span></div>
<div style="position:absolute;left:494.25px;top:577.66px" class="cls_037"><span class="cls_037">69%</span></div>
<div style="position:absolute;left:308.01px;top:583.82px" class="cls_037"><span class="cls_037">PASI90c</span></div>
<div style="position:absolute;left:414.25px;top:583.82px" class="cls_037"><span class="cls_037">51%</span></div>
<div style="position:absolute;left:494.25px;top:583.82px" class="cls_037"><span class="cls_037">65%</span></div>
<div style="position:absolute;left:50.00px;top:585.14px" class="cls_031"><span class="cls_031">achieved DAPSA remission and LDA at wk 24, and 20 (14%) and</span></div>
<div style="position:absolute;left:308.01px;top:589.98px" class="cls_037"><span class="cls_037">PASI100c</span></div>
<div style="position:absolute;left:414.25px;top:589.98px" class="cls_037"><span class="cls_037">44%</span></div>
<div style="position:absolute;left:494.25px;top:589.98px" class="cls_037"><span class="cls_037">61%</span></div>
<div style="position:absolute;left:50.00px;top:595.19px" class="cls_031"><span class="cls_031">11 (7%) achieved MDA and VLDA, respectively. Pts achieving</span></div>
<div style="position:absolute;left:308.01px;top:596.15px" class="cls_037"><span class="cls_037">NAPSI</span><span class="cls_038"> = </span><span class="cls_037">0d</span></div>
<div style="position:absolute;left:414.25px;top:596.14px" class="cls_037"><span class="cls_037">54%</span></div>
<div style="position:absolute;left:494.25px;top:596.14px" class="cls_037"><span class="cls_037">57%</span></div>
<div style="position:absolute;left:306.64px;top:603.38px" class="cls_039"><span class="cls_039"><sup>a</sup></span><span class="cls_037">Pts with Leeds Enthesitis Index (LEI)</span><span class="cls_038"> > </span><span class="cls_037">0 at baseline. </span><span class="cls_039"><sup>b</sup></span><span class="cls_037">Pts with Leeds Dactylitis Index-Basic</span></div>
<div style="position:absolute;left:50.00px;top:605.25px" class="cls_031"><span class="cls_031">DAPSA LDA appeared to mirror those in MDA, with the exception</span></div>
<div style="position:absolute;left:306.64px;top:610.38px" class="cls_037"><span class="cls_037">(LDI-B)</span><span class="cls_038"> > </span><span class="cls_037">0 at baseline. </span><span class="cls_039"><sup>c</sup></span><span class="cls_037">Pts with psoriatic lesions ³3% of body surface area at baseline. </span><span class="cls_039"><sup>d</sup></span><span class="cls_037">Pts with</span></div>
<div style="position:absolute;left:50.00px;top:615.30px" class="cls_031"><span class="cls_031">of experiencing numerically higher PP, PtGA, and PASI scores</span></div>
<div style="position:absolute;left:306.64px;top:617.39px" class="cls_037"><span class="cls_037">fingernail psoriasis at baseline.</span></div>
<div style="position:absolute;left:50.00px;top:625.35px" class="cls_031"><span class="cls_031">at wk 24. Pts in DAPSA LDA did experience numerically lower</span></div>
<div style="position:absolute;left:306.64px;top:626.37px" class="cls_036"><span class="cls_036">Table 2.</span></div>
<div style="position:absolute;left:50.00px;top:635.40px" class="cls_031"><span class="cls_031">SJC when compared with the MDA achievers, and, like MDA</span></div>
<div style="position:absolute;left:409.01px;top:637.79px" class="cls_037"><span class="cls_037">Total IXE Q4W</span></div>
<div style="position:absolute;left:479.49px;top:637.79px" class="cls_037"><span class="cls_037">Total IXE Q2W</span></div>
<div style="position:absolute;left:409.01px;top:644.79px" class="cls_037"><span class="cls_037">(</span><span class="cls_038">n = </span><span class="cls_037">195;Total PY</span><span class="cls_038"> = </span><span class="cls_037">450.4)</span></div>
<div style="position:absolute;left:479.49px;top:644.79px" class="cls_037"><span class="cls_037">(</span><span class="cls_038">n = </span><span class="cls_037">191; Total PY</span><span class="cls_038"> = </span><span class="cls_037">442.1)</span></div>
<div style="position:absolute;left:50.00px;top:645.46px" class="cls_031"><span class="cls_031">achievers, displayed little residual enthesitis. Only VLDA, but not</span></div>
<div style="position:absolute;left:308.03px;top:654.95px" class="cls_037"><span class="cls_037">TEAEs</span></div>
<div style="position:absolute;left:409.02px;top:654.95px" class="cls_037"><span class="cls_037">169 (37.5)</span></div>
<div style="position:absolute;left:479.50px;top:654.95px" class="cls_037"><span class="cls_037">168 (38.0)</span></div>
<div style="position:absolute;left:50.00px;top:655.51px" class="cls_031"><span class="cls_031">MDA, could match the stringency of DAPSA remission, a finding</span></div>
<div style="position:absolute;left:308.03px;top:661.11px" class="cls_037"><span class="cls_037">Serious AEs</span></div>
<div style="position:absolute;left:409.02px;top:661.11px" class="cls_037"><span class="cls_037">38 (8.4)</span></div>
<div style="position:absolute;left:479.50px;top:661.11px" class="cls_037"><span class="cls_037">23 (5.2)</span></div>
<div style="position:absolute;left:50.00px;top:665.56px" class="cls_031"><span class="cls_031">that was confirmed through analysis of the ACCLAIM cohort.</span></div>
<div style="position:absolute;left:308.03px;top:667.28px" class="cls_037"><span class="cls_037">Serious Infections</span></div>
<div style="position:absolute;left:409.02px;top:667.28px" class="cls_037"><span class="cls_037">8 (1.8)</span></div>
<div style="position:absolute;left:479.50px;top:667.28px" class="cls_037"><span class="cls_037">2 (0.5)</span></div>
<div style="position:absolute;left:308.03px;top:673.44px" class="cls_037"><span class="cls_037">Discontinued due to AE</span></div>
<div style="position:absolute;left:409.02px;top:673.44px" class="cls_037"><span class="cls_037">17 (3.8)</span></div>
<div style="position:absolute;left:479.50px;top:673.44px" class="cls_037"><span class="cls_037">23 (5.2)</span></div>
<div style="position:absolute;left:50.00px;top:675.62px" class="cls_031"><span class="cls_031">However, VLDA allowed for numerically higher residual PP and</span></div>
<div style="position:absolute;left:308.03px;top:679.60px" class="cls_037"><span class="cls_037">Death</span></div>
<div style="position:absolute;left:409.02px;top:679.60px" class="cls_037"><span class="cls_037">1a (0.2)</span></div>
<div style="position:absolute;left:479.50px;top:679.60px" class="cls_037"><span class="cls_037">0</span></div>
<div style="position:absolute;left:308.03px;top:685.76px" class="cls_037"><span class="cls_037">Infections</span></div>
<div style="position:absolute;left:409.02px;top:685.76px" class="cls_037"><span class="cls_037">111 (24.6)</span></div>
<div style="position:absolute;left:479.50px;top:685.76px" class="cls_037"><span class="cls_037">112 (25.3)</span></div>
<div style="position:absolute;left:50.00px;top:685.67px" class="cls_031"><span class="cls_031">PtGA levels when compared with DAPSA remission. Importantly,</span></div>
<div style="position:absolute;left:308.03px;top:691.92px" class="cls_037"><span class="cls_037">Injection-Site Reactions</span></div>
<div style="position:absolute;left:409.02px;top:691.92px" class="cls_037"><span class="cls_037">40 (8.9)</span></div>
<div style="position:absolute;left:479.50px;top:691.92px" class="cls_037"><span class="cls_037">43 (9.7)</span></div>
<div style="position:absolute;left:50.00px;top:695.72px" class="cls_031"><span class="cls_031">residual enthesitis did not differ among pts achieving DAPSA</span></div>
<div style="position:absolute;left:308.03px;top:698.09px" class="cls_037"><span class="cls_037">Hypersensitivities</span></div>
<div style="position:absolute;left:409.02px;top:698.09px" class="cls_037"><span class="cls_037">10 (2.2)</span></div>
<div style="position:absolute;left:479.50px;top:698.09px" class="cls_037"><span class="cls_037">21 (4.7)</span></div>
<div style="position:absolute;left:306.65px;top:705.33px" class="cls_038"><span class="cls_038">n = </span><span class="cls_037">pts with ≥1 designated AE. Data presented as n (IR). For safety analyses, baseline was defined</span></div>
<div style="position:absolute;left:50.00px;top:705.78px" class="cls_031"><span class="cls_031">remission or VLDA. Irrespective of disease activity assessment,</span></div>
<div style="position:absolute;left:306.65px;top:712.34px" class="cls_037"><span class="cls_037">as the time of the first IXE injection. Total PYs is the total time pts were in the treatment period</span></div>
<div style="position:absolute;left:50.00px;top:715.83px" class="cls_031"><span class="cls_031">pts receiving ADA displayed little to no radiographic progression.</span></div>
<div style="position:absolute;left:306.65px;top:719.34px" class="cls_037"><span class="cls_037">following the first IXE injection. aPt experienced a cerebrocardiovascular accident.</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:19272px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background26.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">24</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">In pts treated with IXE, improvements in the signs</span></div>
<div style="position:absolute;left:306.64px;top:51.85px" class="cls_029"><span class="cls_029">versity Hospital of Schleswig-Holstein Campus Lübeck, Lübeck, Germany,</span></div>
<div style="position:absolute;left:50.00px;top:61.41px" class="cls_031"><span class="cls_031">and symptoms of PsA persisted up to 3 years. The safety profile</span></div>
<div style="position:absolute;left:306.64px;top:61.56px" class="cls_028"><span class="cls_028"><sup>4</sup></span><span class="cls_029">Central Dermatology and Saint Louis University School of Medicine, St.</span></div>
<div style="position:absolute;left:50.01px;top:71.41px" class="cls_031"><span class="cls_031">was consistent with previous studies of IXE.</span></div>
<div style="position:absolute;left:306.64px;top:71.26px" class="cls_029"><span class="cls_029">Louis, MO, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Centre de Recherche Dermatologique du Québec Métropoli-</span></div>
<div style="position:absolute;left:50.00px;top:81.43px" class="cls_032"><span class="cls_032">Previously presented as Chandran et al. 2018 EULAR Congress. June</span></div>
<div style="position:absolute;left:306.64px;top:80.97px" class="cls_029"><span class="cls_029">tain, Québec, Canada, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">UCB Pharma, Raleigh, NC, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">UCB Pharma, Brus-</span></div>
<div style="position:absolute;left:50.00px;top:90.43px" class="cls_032"><span class="cls_032">13-16th</span></div>
<div style="position:absolute;left:306.64px;top:90.67px" class="cls_029"><span class="cls_029">sels, Belgium,</span></div>
<div style="position:absolute;left:357.64px;top:90.68px" class="cls_028"><span class="cls_028"><sup>8</sup></span><span class="cls_029">UCB Pharma, Monheim, </span><span class="cls_028"><sup>9</sup></span><span class="cls_029">SCIderm Research Institute,</span></div>
<div style="position:absolute;left:306.64px;top:100.38px" class="cls_029"><span class="cls_029">Hamburg, and Dermatologikum Berlin, Germany</span></div>
<div style="position:absolute;left:50.00px;top:108.05px" class="cls_033"><span class="cls_033">P052</span></div>
<div style="position:absolute;left:306.64px;top:111.25px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Certolizumab pegol (CZP), an Fc-free, PEGylated,</span></div>
<div style="position:absolute;left:50.00px;top:119.45px" class="cls_025"><span class="cls_025">INCIDENCE OF SERIOUS GASTROINTESTINAL</span></div>
<div style="position:absolute;left:306.64px;top:121.26px" class="cls_031"><span class="cls_031">anti-tumor necrosis factor, has shown efficacy in chronic plaque</span></div>
<div style="position:absolute;left:50.00px;top:130.35px" class="cls_025"><span class="cls_025">EVENTS AMONG TILDRAKIZUMAB-TREATED</span></div>
<div style="position:absolute;left:306.65px;top:131.27px" class="cls_031"><span class="cls_031">psoriasis (PSO).[1,2]</span></div>
<div style="position:absolute;left:50.00px;top:141.25px" class="cls_025"><span class="cls_025">PATIENTS WITH PSORIASIS</span></div>
<div style="position:absolute;left:306.65px;top:141.28px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To assess the proportions of patients (pts) achieving</span></div>
<div style="position:absolute;left:50.00px;top:151.15px" class="cls_051"><span class="cls_051">Melinda Gooderham</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Boni E Elewski</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, David M Pariser</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Howard</span></div>
<div style="position:absolute;left:306.65px;top:151.29px" class="cls_031"><span class="cls_031">selected PASI thresholds over 48 weeks of CZP treatment.</span></div>
<div style="position:absolute;left:50.00px;top:161.05px" class="cls_026"><span class="cls_026">Sofen</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Alan M Mendelsohn</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Nicole Cichanowitz</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Qing Li</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Car-</span></div>
<div style="position:absolute;left:306.65px;top:161.29px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Data were pooled from CIMPASI-1 (NCT02326298)</span></div>
<div style="position:absolute;left:50.00px;top:170.95px" class="cls_026"><span class="cls_026">men La Rosa</span><span class="cls_027"><sup>6</sup></span></div>
<div style="position:absolute;left:306.65px;top:171.30px" class="cls_031"><span class="cls_031">and CIMPASI-2 (NCT02326272), ongoing phase 3 trials in adults</span></div>
<div style="position:absolute;left:50.00px;top:181.55px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Probity Medical Research, Waterloo, and Skin Centre for Dermatology,</span></div>
<div style="position:absolute;left:306.65px;top:181.31px" class="cls_031"><span class="cls_031">with moderate to severe PSO ≥6 months (Psoriasis Area Severity</span></div>
<div style="position:absolute;left:50.00px;top:191.15px" class="cls_029"><span class="cls_029">Peterborough, Canada, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Dermatology, University of Ala-</span></div>
<div style="position:absolute;left:306.63px;top:191.32px" class="cls_031"><span class="cls_031">Index [PASI] ≥12, ≥10% body surface area affected, physician’s</span></div>
<div style="position:absolute;left:50.00px;top:200.75px" class="cls_029"><span class="cls_029">bama at Birmingham School of Medicine, Birmingham, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Eastern Virginia</span></div>
<div style="position:absolute;left:306.62px;top:201.33px" class="cls_031"><span class="cls_031">global assessment ≥3/5). Pts were randomized 2:2:1 to CZP 400</span></div>
<div style="position:absolute;left:50.00px;top:210.35px" class="cls_029"><span class="cls_029">Medical School and Virginia Clinical Research, Inc., Norfolk, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Department</span></div>
<div style="position:absolute;left:306.63px;top:211.33px" class="cls_031"><span class="cls_031">mg every 2 weeks (Q2W), 200 mg Q2W (400 mg loading dose</span></div>
<div style="position:absolute;left:50.00px;top:219.95px" class="cls_029"><span class="cls_029">of Medicine (Dermatology) UCLA, Los Angeles, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Sun Pharmaceutical In-</span></div>
<div style="position:absolute;left:306.63px;top:221.32px" class="cls_031"><span class="cls_031">[LD] at Weeks 0/2/4), or placebo (PBO). Week 16 PASI 50 re-</span></div>
<div style="position:absolute;left:50.00px;top:229.55px" class="cls_029"><span class="cls_029">dustries, Inc., Princeton, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Merck & Co., Inc., Kenilworth, USA</span></div>
<div style="position:absolute;left:306.64px;top:231.32px" class="cls_031"><span class="cls_031">sponders receiving CZP continued the same dose to Week 48. We</span></div>
<div style="position:absolute;left:50.00px;top:240.36px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Tildrakizumab is a high-affinity, humanized, immu-</span></div>
<div style="position:absolute;left:306.64px;top:241.33px" class="cls_031"><span class="cls_031">present the proportions of patients reaching PASI </span><span class="cls_030"> ≤ </span><span class="cls_031">1, 2, 3 and 5 at</span></div>
<div style="position:absolute;left:50.00px;top:250.31px" class="cls_031"><span class="cls_031">noglobulin G1κ monoclonal antibody against interleukin-23p19</span></div>
<div style="position:absolute;left:306.64px;top:251.34px" class="cls_031"><span class="cls_031">Weeks 16 and 48. Responder rate estimates were calculated using</span></div>
<div style="position:absolute;left:50.01px;top:260.27px" class="cls_031"><span class="cls_031">for the treatment of chronic plaque psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:261.35px" class="cls_031"><span class="cls_031">a logistic regression model. Pts not achieving PASI 50 at Weeks</span></div>
<div style="position:absolute;left:50.01px;top:270.22px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">We evaluated gastrointestinal (GI) adverse events (AE)</span></div>
<div style="position:absolute;left:306.64px;top:271.35px" class="cls_031"><span class="cls_031">16/32/40/48 were subsequently classed as non-responders. Other</span></div>
<div style="position:absolute;left:50.01px;top:280.18px" class="cls_031"><span class="cls_031">and, specifically, cases of inflammatory bowel disease (IBD; ie,</span></div>
<div style="position:absolute;left:306.64px;top:281.36px" class="cls_031"><span class="cls_031">missing data were imputed using multiple imputation (Markov</span></div>
<div style="position:absolute;left:50.03px;top:290.13px" class="cls_031"><span class="cls_031">Crohn’s disease or ulcerative colitis) in the clinical development</span></div>
<div style="position:absolute;left:306.64px;top:291.37px" class="cls_031"><span class="cls_031">Chain Monte Carlo method).</span></div>
<div style="position:absolute;left:50.03px;top:300.08px" class="cls_031"><span class="cls_031">program for tildrakizumab.</span></div>
<div style="position:absolute;left:306.64px;top:301.38px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">At Week 0, 175, 186 and 100 pts were randomized to</span></div>
<div style="position:absolute;left:50.03px;top:310.04px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Patients with moderate to severe plaque psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:311.39px" class="cls_031"><span class="cls_031">CZP 400 mg Q2W, CZP 200 mg Q2W, and PBO. Baseline mean</span></div>
<div style="position:absolute;left:50.03px;top:319.99px" class="cls_031"><span class="cls_031">were randomized in 3 large clinical trials: P05495 (phase 2;</span></div>
<div style="position:absolute;left:306.64px;top:321.39px" class="cls_031"><span class="cls_031">PASI was comparable across CZP 400 mg Q2W/CZP 200 mg</span></div>
<div style="position:absolute;left:50.03px;top:329.95px" class="cls_031"><span class="cls_031">NCT01225731), reSURFACE 1 (phase 3; NCT01722331), and</span></div>
<div style="position:absolute;left:306.64px;top:331.40px" class="cls_031"><span class="cls_031">Q2W/PBO pts: 19.6 (SD:7.3)/19.2 (7.2)/18.6 (6.6). At Week 16,</span></div>
<div style="position:absolute;left:50.03px;top:339.90px" class="cls_031"><span class="cls_031">reSURFACE 2 (phase 3; NCT01729754) [1,2]. In this post hoc</span></div>
<div style="position:absolute;left:306.64px;top:341.41px" class="cls_031"><span class="cls_031">PASI </span><span class="cls_030"> ≤ </span><span class="cls_031">1 was achieved by 39.9% pts receiving CZP 400 mg Q2W</span></div>
<div style="position:absolute;left:50.03px;top:349.85px" class="cls_031"><span class="cls_031">analysis, we sought to identify serious GI AEs and new-onset</span></div>
<div style="position:absolute;left:306.65px;top:351.42px" class="cls_031"><span class="cls_031">and 36.2% CZP 200 mg pts, vs 2.6% PBO pts. Similarly, a higher</span></div>
<div style="position:absolute;left:50.03px;top:359.81px" class="cls_031"><span class="cls_031">or exacerbation of pre-existing IBD from a pooled dataset of</span></div>
<div style="position:absolute;left:306.65px;top:361.43px" class="cls_031"><span class="cls_031">proportion of CZP vs PBO pts achieved PASI </span><span class="cls_030"> ≤ </span><span class="cls_031">2, PASI </span><span class="cls_030"> ≤ </span><span class="cls_031">3 and</span></div>
<div style="position:absolute;left:50.03px;top:369.76px" class="cls_031"><span class="cls_031">tildrakizumab-treated patients from these 3 trials, which followed</span></div>
<div style="position:absolute;left:306.65px;top:371.43px" class="cls_031"><span class="cls_031">PASI </span><span class="cls_030"> ≤ </span><span class="cls_031">5 (Table). In CZP-treated pts, PASI was maintained or</span></div>
<div style="position:absolute;left:50.03px;top:379.72px" class="cls_031"><span class="cls_031">patients up to 52 (reSURFACE 2) or 64 (reSURFACE 1) weeks.</span></div>
<div style="position:absolute;left:306.65px;top:381.44px" class="cls_031"><span class="cls_031">further reduced to Week 48, with 48.2% CZP 400 mg Q2W pts</span></div>
<div style="position:absolute;left:50.03px;top:389.67px" class="cls_031"><span class="cls_031">This analysis evaluated patients who received tildrakizumab 100</span></div>
<div style="position:absolute;left:306.65px;top:391.45px" class="cls_031"><span class="cls_031">and 39.9% CZP 200 mg Q2W pts achieving PASI </span><span class="cls_030"> ≤ </span><span class="cls_031">1 after 48</span></div>
<div style="position:absolute;left:50.03px;top:399.62px" class="cls_031"><span class="cls_031">mg and 200 mg in P05495 and the reSURFACE trials.</span></div>
<div style="position:absolute;left:306.65px;top:401.46px" class="cls_031"><span class="cls_031">weeks’ treatment (Table).</span></div>
<div style="position:absolute;left:50.03px;top:409.58px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">In this analysis, we pooled 1911 patients from the 3 trials</span></div>
<div style="position:absolute;left:306.65px;top:411.42px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Higher proportions of CZP vs PBO pts met abso-</span></div>
<div style="position:absolute;left:50.03px;top:419.53px" class="cls_031"><span class="cls_031">who received either tildrakizumab 100 or 200 mg. There were no</span></div>
<div style="position:absolute;left:306.64px;top:421.43px" class="cls_031"><span class="cls_031">lute PASI cut-offs over 16 weeks and response was maintained</span></div>
<div style="position:absolute;left:50.03px;top:429.49px" class="cls_031"><span class="cls_031">new cases of IBD reported; among 6 patients with a history of IBD</span></div>
<div style="position:absolute;left:306.64px;top:431.44px" class="cls_031"><span class="cls_031">or further improved to Week 48. Although durability of response</span></div>
<div style="position:absolute;left:50.03px;top:439.44px" class="cls_031"><span class="cls_031">randomized to tildrakizumab, none experienced an exacerbation.</span></div>
<div style="position:absolute;left:306.64px;top:441.45px" class="cls_031"><span class="cls_031">was observed with both doses, higher proportions of pts treated</span></div>
<div style="position:absolute;left:50.03px;top:449.39px" class="cls_031"><span class="cls_031">The numbers (rate per 100 patient-years) of patients with serious</span></div>
<div style="position:absolute;left:306.64px;top:451.45px" class="cls_031"><span class="cls_031">with CZP 400 mg Q2W than 200 mg Q2W were able to reach the</span></div>
<div style="position:absolute;left:50.03px;top:459.35px" class="cls_031"><span class="cls_031">GI AEs in the pooled dataset were 8 (0.80) for tildrakizumab 100</span></div>
<div style="position:absolute;left:306.64px;top:461.46px" class="cls_031"><span class="cls_031">most stringent cut-offs at Week 48.</span></div>
<div style="position:absolute;left:50.03px;top:469.30px" class="cls_031"><span class="cls_031">mg and 4 (0.43) for tildrakizumab 200 mg. These serious GI AEs</span></div>
<div style="position:absolute;left:306.64px;top:471.57px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:50.03px;top:479.26px" class="cls_031"><span class="cls_031">included abdominal pain, constipation, diverticulum, dyspepsia,</span></div>
<div style="position:absolute;left:306.64px;top:481.68px" class="cls_032"><span class="cls_032">1. Reich K, (2017). Skin,1;s23; 2. Augustin M, (2017). Skin,1;s24</span></div>
<div style="position:absolute;left:50.03px;top:489.21px" class="cls_031"><span class="cls_031">gastritis, thrombosed hemorrhoids, esophageal polyp, pancreatitis</span></div>
<div style="position:absolute;left:306.64px;top:492.80px" class="cls_036"><span class="cls_036">Table. Pts achieving absolute PASI cut-offs at Weeks 16 and 48</span></div>
<div style="position:absolute;left:50.03px;top:499.16px" class="cls_031"><span class="cls_031">(1 patient each) among patients treated with tildrakizumab 100 mg,</span></div>
<div style="position:absolute;left:357.00px;top:504.01px" class="cls_036"><span class="cls_036">PBO</span></div>
<div style="position:absolute;left:420.01px;top:504.01px" class="cls_036"><span class="cls_036">CZP 400 mg Q2W</span></div>
<div style="position:absolute;left:486.78px;top:504.01px" class="cls_036"><span class="cls_036">CZP 200 mg Q2Wa</span></div>
<div style="position:absolute;left:50.03px;top:509.12px" class="cls_031"><span class="cls_031">and abdominal hernia, upper abdominal pain, acute pancreatitis,</span></div>
<div style="position:absolute;left:357.00px;top:511.01px" class="cls_036"><span class="cls_036">(</span><span class="cls_040">n = </span><span class="cls_036">100)</span></div>
<div style="position:absolute;left:420.00px;top:511.01px" class="cls_036"><span class="cls_036">(</span><span class="cls_040">n = </span><span class="cls_036">175)</span></div>
<div style="position:absolute;left:486.78px;top:511.01px" class="cls_036"><span class="cls_036">(</span><span class="cls_040">n = </span><span class="cls_036">186)</span></div>
<div style="position:absolute;left:308.01px;top:518.01px" class="cls_036"><span class="cls_036">PASI  Week</span></div>
<div style="position:absolute;left:357.00px;top:518.01px" class="cls_036"><span class="cls_036">% (95% CI)</span></div>
<div style="position:absolute;left:420.00px;top:518.01px" class="cls_036"><span class="cls_036">% (95% CI)</span></div>
<div style="position:absolute;left:486.78px;top:518.01px" class="cls_036"><span class="cls_036">% (95% CI)</span></div>
<div style="position:absolute;left:50.03px;top:519.07px" class="cls_031"><span class="cls_031">and salivary gland enlargement (1 patient each) among patients</span></div>
<div style="position:absolute;left:308.79px;top:527.19px" class="cls_038"><span class="cls_038">≤ </span><span class="cls_037">1</span></div>
<div style="position:absolute;left:330.00px;top:527.18px" class="cls_037"><span class="cls_037">16</span></div>
<div style="position:absolute;left:357.00px;top:527.18px" class="cls_037"><span class="cls_037">2.6% (0.0-6.2)</span></div>
<div style="position:absolute;left:420.00px;top:527.18px" class="cls_037"><span class="cls_037">39.9% (29.3-50.4)</span></div>
<div style="position:absolute;left:486.78px;top:527.18px" class="cls_037"><span class="cls_037">36.2% (26.5-45.9)</span></div>
<div style="position:absolute;left:50.03px;top:529.03px" class="cls_031"><span class="cls_031">treated with tildrakizumab 200 mg.</span></div>
<div style="position:absolute;left:330.00px;top:533.35px" class="cls_037"><span class="cls_037">48</span></div>
<div style="position:absolute;left:357.00px;top:533.35px" class="cls_037"><span class="cls_037">-</span></div>
<div style="position:absolute;left:420.00px;top:533.35px" class="cls_037"><span class="cls_037">48.2% (37.4-59.0)</span></div>
<div style="position:absolute;left:486.78px;top:533.35px" class="cls_037"><span class="cls_037">39.9% (29.8-50.0)</span></div>
<div style="position:absolute;left:308.79px;top:539.51px" class="cls_038"><span class="cls_038">≤ </span><span class="cls_037">2</span></div>
<div style="position:absolute;left:330.00px;top:539.51px" class="cls_037"><span class="cls_037">16</span></div>
<div style="position:absolute;left:357.00px;top:539.51px" class="cls_037"><span class="cls_037">3.3% (0.0-7.0)</span></div>
<div style="position:absolute;left:420.00px;top:539.51px" class="cls_037"><span class="cls_037">54.5% (43.9-65.1)</span></div>
<div style="position:absolute;left:486.78px;top:539.51px" class="cls_037"><span class="cls_037">46.7% (36.5-56.8)</span></div>
<div style="position:absolute;left:50.03px;top:538.98px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">In this post hoc analysis of patients from 3 large,</span></div>
<div style="position:absolute;left:330.00px;top:545.67px" class="cls_037"><span class="cls_037">48</span></div>
<div style="position:absolute;left:357.00px;top:545.67px" class="cls_037"><span class="cls_037">-</span></div>
<div style="position:absolute;left:420.00px;top:545.67px" class="cls_037"><span class="cls_037">70.5% (60.2-80.8)</span></div>
<div style="position:absolute;left:486.78px;top:545.67px" class="cls_037"><span class="cls_037">55.9% (44.6-67.3)</span></div>
<div style="position:absolute;left:50.03px;top:548.93px" class="cls_031"><span class="cls_031">randomized clinical trials, serious GI AEs were infrequent and</span></div>
<div style="position:absolute;left:308.79px;top:551.84px" class="cls_038"><span class="cls_038">≤ </span><span class="cls_037">3</span></div>
<div style="position:absolute;left:330.00px;top:551.83px" class="cls_037"><span class="cls_037">16</span></div>
<div style="position:absolute;left:357.00px;top:551.83px" class="cls_037"><span class="cls_037">6.8% (1.0-12.5)</span></div>
<div style="position:absolute;left:420.00px;top:551.83px" class="cls_037"><span class="cls_037">70.5% (59.3-81.6)</span></div>
<div style="position:absolute;left:486.78px;top:551.83px" class="cls_037"><span class="cls_037">65.1% (53.4-76.7)</span></div>
<div style="position:absolute;left:330.00px;top:557.99px" class="cls_037"><span class="cls_037">48</span></div>
<div style="position:absolute;left:357.00px;top:557.99px" class="cls_037"><span class="cls_037">-</span></div>
<div style="position:absolute;left:420.00px;top:557.99px" class="cls_037"><span class="cls_037">75.2% (65.5-85.0)</span></div>
<div style="position:absolute;left:486.78px;top:557.99px" class="cls_037"><span class="cls_037">63.7% (52.6-74.8)</span></div>
<div style="position:absolute;left:50.03px;top:558.89px" class="cls_031"><span class="cls_031">there were no new cases of IBD or exacerbations of IBD.</span></div>
<div style="position:absolute;left:308.79px;top:564.16px" class="cls_038"><span class="cls_038">≤ </span><span class="cls_037">5</span></div>
<div style="position:absolute;left:330.00px;top:564.16px" class="cls_037"><span class="cls_037">16</span></div>
<div style="position:absolute;left:357.00px;top:564.16px" class="cls_037"><span class="cls_037">12.2% (4.3-20.1)</span></div>
<div style="position:absolute;left:420.00px;top:564.16px" class="cls_037"><span class="cls_037">83.0% (74.9-91.1)</span></div>
<div style="position:absolute;left:486.78px;top:564.16px" class="cls_037"><span class="cls_037">77.6% (68.4-86.9)</span></div>
<div style="position:absolute;left:50.03px;top:568.84px" class="cls_030"><span class="cls_030">Acknowledgements:</span><span class="cls_031"> The studies were funded by Merck Sharp &</span></div>
<div style="position:absolute;left:330.00px;top:570.32px" class="cls_037"><span class="cls_037">48</span></div>
<div style="position:absolute;left:357.00px;top:570.32px" class="cls_037"><span class="cls_037">-</span></div>
<div style="position:absolute;left:420.00px;top:570.32px" class="cls_037"><span class="cls_037">82.3% (74.4-90.3)</span></div>
<div style="position:absolute;left:486.78px;top:570.32px" class="cls_037"><span class="cls_037">73.1% (63.4-82.7)</span></div>
<div style="position:absolute;left:306.63px;top:577.80px" class="cls_037"><span class="cls_037">aPts received CZP 400 mg Q2W LD at Weeks 0/2/4. CI: Confidence interval.</span></div>
<div style="position:absolute;left:50.03px;top:578.80px" class="cls_031"><span class="cls_031">Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth,</span></div>
<div style="position:absolute;left:50.03px;top:588.75px" class="cls_031"><span class="cls_031">NJ, USA.</span></div>
<div style="position:absolute;left:306.64px;top:593.48px" class="cls_033"><span class="cls_033">P054</span></div>
<div style="position:absolute;left:50.03px;top:598.75px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:306.64px;top:604.99px" class="cls_025"><span class="cls_025">RELATIONSHIPS BETWEEN TILDRAKIZUMAB DOSE,</span></div>
<div style="position:absolute;left:50.00px;top:608.63px" class="cls_032"><span class="cls_032">1. Papp K, et al. Br J Dermatol. 2015;173:930-939. 2. Reich K, et al.</span></div>
<div style="position:absolute;left:50.00px;top:617.63px" class="cls_032"><span class="cls_032">Lancet. 2017;390:276-288.</span></div>
<div style="position:absolute;left:306.64px;top:615.99px" class="cls_025"><span class="cls_025">EXPOSURE, EFFICACY AND SAFETY IN PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:627.00px" class="cls_025"><span class="cls_025">PHASE 3 STUDIES</span></div>
<div style="position:absolute;left:50.00px;top:635.25px" class="cls_033"><span class="cls_033">P053</span></div>
<div style="position:absolute;left:306.64px;top:637.00px" class="cls_026"><span class="cls_026">Bruce Strober</span><span class="cls_041"><sup>1</sup></span><span class="cls_026">, Howard Sofen</span><span class="cls_041"><sup>2</sup></span><span class="cls_026">, Paul Yamauchi</span><span class="cls_041"><sup>3</sup></span><span class="cls_026">, Alan Mendel-</span></div>
<div style="position:absolute;left:50.00px;top:646.65px" class="cls_025"><span class="cls_025">DURABLE REDUCTION IN ABSOLUTE PASI WITH</span></div>
<div style="position:absolute;left:306.64px;top:647.01px" class="cls_026"><span class="cls_026">sohn</span><span class="cls_041"><sup>4</sup></span><span class="cls_026">, Jeff Parno</span><span class="cls_041"><sup>4</sup></span><span class="cls_026">, Simon Lowry</span><span class="cls_041"><sup>4</sup></span><span class="cls_026">,</span><span class="cls_051"> Stephen Rozzo</span><span class="cls_041"><sup>4</sup></span><span class="cls_026">, Boni Elewski</span><span class="cls_041"><sup>5</sup></span></div>
<div style="position:absolute;left:50.00px;top:657.55px" class="cls_025"><span class="cls_025">CERTOLIZUMAB PEGOL IN PATIENTS WITH</span></div>
<div style="position:absolute;left:306.64px;top:657.71px" class="cls_042"><span class="cls_042"><sup>1</sup></span><span class="cls_029">UConn Health, University of Connecticut, Farmington, CT, USA; Probity</span></div>
<div style="position:absolute;left:50.00px;top:668.45px" class="cls_025"><span class="cls_025">CHRONIC PLAQUE PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:667.42px" class="cls_029"><span class="cls_029">Medical Research, Waterloo, ON, Canada, </span><span class="cls_042"><sup>2</sup></span><span class="cls_029">Ronald Reagan UCLA Medical</span></div>
<div style="position:absolute;left:50.00px;top:678.35px" class="cls_051"><span class="cls_051">Alice B Gottlieb</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Andrew Blauvelt</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Diamant Thaçi</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Craig Leo-</span></div>
<div style="position:absolute;left:306.64px;top:677.12px" class="cls_029"><span class="cls_029">Center, Los Angeles, CA, </span><span class="cls_042"><sup>3</sup></span><span class="cls_029">University of California at Los Angeles Medical</span></div>
<div style="position:absolute;left:306.63px;top:686.83px" class="cls_029"><span class="cls_029">Center, Santa Monica, CA, </span><span class="cls_042"><sup>4</sup></span><span class="cls_029">Sun Pharmaceutical Industries, Inc., Prince-</span></div>
<div style="position:absolute;left:50.00px;top:688.25px" class="cls_026"><span class="cls_026">nardi</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Yves Poulin</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Luke Peterson</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Catherine Arendt</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Marion</span></div>
<div style="position:absolute;left:306.64px;top:696.54px" class="cls_029"><span class="cls_029">ton, NJ, </span><span class="cls_042"><sup>5</sup></span><span class="cls_029">University of Alabama at Birmingham Hospital, Birmingham, AL,</span></div>
<div style="position:absolute;left:50.00px;top:698.15px" class="cls_026"><span class="cls_026">Boehnlein</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, Kristian Reich</span><span class="cls_027"><sup>9</sup></span></div>
<div style="position:absolute;left:50.00px;top:708.75px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Dermatology, New York Medical College at Metropolitan</span></div>
<div style="position:absolute;left:306.64px;top:706.24px" class="cls_029"><span class="cls_029">USA</span></div>
<div style="position:absolute;left:50.00px;top:718.35px" class="cls_029"><span class="cls_029">Hospital, NY, NY, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Oregon Medical Research Center, Portland, OR, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Uni-</span></div>
<div style="position:absolute;left:306.64px;top:717.21px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Tildrakizumab (TIL) is a high-affinity, humanized,</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:20075px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background27.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">25</span></div>
<div style="position:absolute;left:49.95px;top:51.18px" class="cls_031"><span class="cls_031">anti-interleukin-23p19 monoclonal antibody that demonstrated</span></div>
<div style="position:absolute;left:306.64px;top:51.40px" class="cls_031"><span class="cls_031">ADA throughout the 52 weeks. Efficacy is reported using multiple</span></div>
<div style="position:absolute;left:49.95px;top:61.18px" class="cls_031"><span class="cls_031">efficacy in phase 3 trials in moderate to severe chronic plaque pso-</span></div>
<div style="position:absolute;left:306.64px;top:61.40px" class="cls_031"><span class="cls_031">imputation (MI) for missing data, and as observed results.</span></div>
<div style="position:absolute;left:49.95px;top:71.18px" class="cls_031"><span class="cls_031">riasis (reSURFACE 1 [NCT01722331] and 2 [NCT01729754]) [1].</span></div>
<div style="position:absolute;left:306.64px;top:71.40px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Of the 217 randomized pts, 203 received at ≥1 dose of</span></div>
<div style="position:absolute;left:49.95px;top:81.18px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">Here we investigated the relationship between TIL</span></div>
<div style="position:absolute;left:306.65px;top:81.40px" class="cls_031"><span class="cls_031">ADA, 188 entered Period B, and 168 completed the trial. Of those</span></div>
<div style="position:absolute;left:49.95px;top:91.18px" class="cls_031"><span class="cls_031">serum concentration, and efficacy and safety outcomes, in re-</span></div>
<div style="position:absolute;left:306.65px;top:91.39px" class="cls_031"><span class="cls_031">receiving continuous ADA treatment through 52 weeks (</span><span class="cls_030">n = </span><span class="cls_031">109),</span></div>
<div style="position:absolute;left:49.95px;top:101.18px" class="cls_031"><span class="cls_031">SURFACE 1 and 2.</span></div>
<div style="position:absolute;left:306.65px;top:101.39px" class="cls_031"><span class="cls_031">response rates (MI) for key efficacy outcomes at weeks 26 and 52,</span></div>
<div style="position:absolute;left:49.95px;top:111.18px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Placebo or TIL 100 mg or 200 mg was administered at</span></div>
<div style="position:absolute;left:306.64px;top:111.39px" class="cls_031"><span class="cls_031">respectively, were as follows. ≥75% improvement from baseline in</span></div>
<div style="position:absolute;left:49.95px;top:121.18px" class="cls_031"><span class="cls_031">Weeks 0 and 4, then every 12 weeks. Endpoints included propor-</span></div>
<div style="position:absolute;left:306.64px;top:121.39px" class="cls_031"><span class="cls_031">modified Nail Ps Severity Index (mNAPSI 75): 47.4% and 54.5%.</span></div>
<div style="position:absolute;left:49.95px;top:131.18px" class="cls_031"><span class="cls_031">tion of patients achieving 75% Psoriasis Area and Severity Index</span></div>
<div style="position:absolute;left:306.64px;top:131.39px" class="cls_031"><span class="cls_031">Physician’s Global Assessment of fingernail Ps of 0 (clear) or 1</span></div>
<div style="position:absolute;left:49.95px;top:141.18px" class="cls_031"><span class="cls_031">(PASI 75) improvement from baseline (PASI 75 responders).</span></div>
<div style="position:absolute;left:306.64px;top:141.39px" class="cls_031"><span class="cls_031">(minimal) with ≥2 grades improvement from baseline (PGA-F</span></div>
<div style="position:absolute;left:49.95px;top:151.18px" class="cls_031"><span class="cls_031">Pooled efficacy data for each dose from reSURFACE 1 and 2</span></div>
<div style="position:absolute;left:306.65px;top:151.39px" class="cls_031"><span class="cls_031">0/1): 51.1% and 55.6%. Mean change (improvement) from base-</span></div>
<div style="position:absolute;left:49.94px;top:161.18px" class="cls_031"><span class="cls_031">were grouped into quartiles based on average (mean) serum TIL</span></div>
<div style="position:absolute;left:306.64px;top:161.41px" class="cls_031"><span class="cls_031">line in nail Ps pain (numerical rating scale [NRS]): 3.6 and 3.8.</span></div>
<div style="position:absolute;left:49.94px;top:171.18px" class="cls_031"><span class="cls_031">concentration during Weeks 0-12 (Cav12). Associations between</span></div>
<div style="position:absolute;left:306.64px;top:171.40px" class="cls_031"><span class="cls_031">Mean change (improvement) from baseline in Nail Ps Physical</span></div>
<div style="position:absolute;left:49.94px;top:181.18px" class="cls_031"><span class="cls_031">median Cav12 for each quartile (Q) and TIL dose were analyzed</span></div>
<div style="position:absolute;left:306.64px;top:181.40px" class="cls_031"><span class="cls_031">Functioning Severity score (NPPFS): 3.4 and 3.9. Mean change</span></div>
<div style="position:absolute;left:49.94px;top:191.18px" class="cls_031"><span class="cls_031">for PASI 75 response at Week 12 and adverse events (AEs).</span></div>
<div style="position:absolute;left:306.64px;top:191.40px" class="cls_031"><span class="cls_031">(improvement) from baseline in Dermatology Life Quality Index</span></div>
<div style="position:absolute;left:49.94px;top:201.17px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">TIL steady-state concentrations were achieved by Week</span></div>
<div style="position:absolute;left:306.64px;top:201.40px" class="cls_031"><span class="cls_031">score (DLQI): 9.1 and 9.0 (</span><span class="cls_030">n = </span><span class="cls_031">94).</span></div>
<div style="position:absolute;left:49.94px;top:211.17px" class="cls_031"><span class="cls_031">16 and were proportional to the dose administered. Median Cav12</span></div>
<div style="position:absolute;left:306.64px;top:211.40px" class="cls_031"><span class="cls_031">As observed response rates at weeks 26 and 52 respectively, were</span></div>
<div style="position:absolute;left:49.94px;top:221.17px" class="cls_031"><span class="cls_031">(range) for TIL Q1-Q4, respectively, were 4.4 (2.1-5.2), 5.7</span></div>
<div style="position:absolute;left:306.64px;top:221.40px" class="cls_031"><span class="cls_031">as follows. mNAPSI 75: 47/88 (53.4%) and 52/80 (65.0%). PGA-F</span></div>
<div style="position:absolute;left:49.94px;top:231.17px" class="cls_031"><span class="cls_031">(5.2-6.4), 7.0 (6.4-7.8), and 8.7 (7.8-16.1) µg/mL for TIL 100 mg</span></div>
<div style="position:absolute;left:306.64px;top:231.40px" class="cls_031"><span class="cls_031">0/1: 48/88 (54.5%) and 49/80 (61.3%). Mean change (improve-</span></div>
<div style="position:absolute;left:49.94px;top:241.17px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">n = </span><span class="cls_031">616) and 8.7 (4.2-10.4), 11.5 (10.4-12.5), 14.1 (12.5-15.5),</span></div>
<div style="position:absolute;left:306.64px;top:241.41px" class="cls_031"><span class="cls_031">ment) from baseline in nail Ps pain (NRS): 3.8 (</span><span class="cls_030">n = </span><span class="cls_031">92) and 4.4</span></div>
<div style="position:absolute;left:49.94px;top:251.17px" class="cls_031"><span class="cls_031">and 17.3 (15.5-30.6) µg/mL for TIL 200 mg (</span><span class="cls_030">n = </span><span class="cls_031">622). PASI</span></div>
<div style="position:absolute;left:306.64px;top:251.40px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">n = </span><span class="cls_031">80). Mean change (improvement) from baseline in NPPFS:</span></div>
<div style="position:absolute;left:49.94px;top:261.17px" class="cls_031"><span class="cls_031">responses were similar for corresponding quartiles across doses,</span></div>
<div style="position:absolute;left:306.64px;top:261.40px" class="cls_031"><span class="cls_031">3.9 (</span><span class="cls_030">n = </span><span class="cls_031">92) and 4.4 (</span><span class="cls_030">n = </span><span class="cls_031">80). Mean change (improvement) from</span></div>
<div style="position:absolute;left:49.94px;top:271.17px" class="cls_031"><span class="cls_031">with no relationship between serum concentration and patient</span></div>
<div style="position:absolute;left:306.64px;top:271.40px" class="cls_031"><span class="cls_031">baseline in DLQI: 9.3 (</span><span class="cls_030">n = </span><span class="cls_031">69) and 9.7 (</span><span class="cls_030">n = </span><span class="cls_031">65).</span></div>
<div style="position:absolute;left:49.94px;top:281.17px" class="cls_031"><span class="cls_031">response for Q1-Q3. Greater PASI 75 responses were associated</span></div>
<div style="position:absolute;left:306.64px;top:281.40px" class="cls_031"><span class="cls_031">Adverse events (AEs) per 100 pt years (E/100PYs; in 140.3 PYs)</span></div>
<div style="position:absolute;left:49.94px;top:291.17px" class="cls_031"><span class="cls_031">with the highest Cav12 (Q4), particularly for TIL 100 mg where</span></div>
<div style="position:absolute;left:306.64px;top:291.40px" class="cls_031"><span class="cls_031">were: any event, 352 (250.9), serious AEs, 21 (15.0); and serious</span></div>
<div style="position:absolute;left:49.94px;top:301.16px" class="cls_031"><span class="cls_031">PASI 75 response rates (95% confidence intervals [CI]) were</span></div>
<div style="position:absolute;left:306.64px;top:301.40px" class="cls_031"><span class="cls_031">infections, 9 (6.4). AE’s were similar to those observed in phase</span></div>
<div style="position:absolute;left:49.95px;top:311.16px" class="cls_031"><span class="cls_031">58.4% (54.6, 62.3), 62.3% (58.4, 66.1), 59.2% (55.3, 63.1), and</span></div>
<div style="position:absolute;left:306.64px;top:311.40px" class="cls_031"><span class="cls_031">3 clinical trials of ADA for Ps.</span></div>
<div style="position:absolute;left:49.95px;top:321.16px" class="cls_031"><span class="cls_031">73.7% (70.1, 77.0) for Q1-Q4, respectively. Corresponding PASI</span></div>
<div style="position:absolute;left:306.64px;top:321.40px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">ADA treatment of nail Ps across 52 weeks demon-</span></div>
<div style="position:absolute;left:49.95px;top:331.16px" class="cls_031"><span class="cls_031">75 rates (95% CIs) for patients receiving 200 mg were 52.9% (49.0,</span></div>
<div style="position:absolute;left:306.64px;top:331.41px" class="cls_031"><span class="cls_031">strated short- and long-term efficacy. No new safety signals were</span></div>
<div style="position:absolute;left:49.95px;top:341.16px" class="cls_031"><span class="cls_031">56.8), 68.6% (64.9, 72.2), 64.5% (60.6, 68.1), and 74.8% (71.2,</span></div>
<div style="position:absolute;left:306.63px;top:341.40px" class="cls_031"><span class="cls_031">identified in these pts receiving ≥1 dose of ADA.</span></div>
<div style="position:absolute;left:49.95px;top:351.16px" class="cls_031"><span class="cls_031">78.0) over Q1-Q4. There were no associations between AE rates</span></div>
<div style="position:absolute;left:49.95px;top:361.16px" class="cls_031"><span class="cls_031">and serum concentrations, and incidence rates of any AE, any</span></div>
<div style="position:absolute;left:306.64px;top:362.04px" class="cls_033"><span class="cls_033">P056</span></div>
<div style="position:absolute;left:49.95px;top:371.16px" class="cls_031"><span class="cls_031">infections, serious infections, upper respiratory tract infections,</span></div>
<div style="position:absolute;left:306.64px;top:373.44px" class="cls_025"><span class="cls_025">EIGHT-YEAR INTERIM RESULTS FROM THE ESPRIT</span></div>
<div style="position:absolute;left:49.95px;top:381.16px" class="cls_031"><span class="cls_031">malignancies, non-melanoma skin cancer, confirmed extended</span></div>
<div style="position:absolute;left:306.64px;top:384.34px" class="cls_025"><span class="cls_025">10-YEAR POSTMARKETING SURVEILLANCE</span></div>
<div style="position:absolute;left:49.93px;top:391.16px" class="cls_031"><span class="cls_031">major cardiovascular events, and drug-related hypersensitivity</span></div>
<div style="position:absolute;left:306.64px;top:395.24px" class="cls_025"><span class="cls_025">REGISTRY OF ADALIMUMAB FOR MODERATE TO</span></div>
<div style="position:absolute;left:49.93px;top:401.15px" class="cls_031"><span class="cls_031">for TIL-treated patients were similar to, or less than, for placebo-</span></div>
<div style="position:absolute;left:306.64px;top:406.14px" class="cls_025"><span class="cls_025">SEVERE PSORIASIS</span></div>
<div style="position:absolute;left:49.93px;top:411.15px" class="cls_031"><span class="cls_031">treated patients.</span></div>
<div style="position:absolute;left:306.64px;top:416.04px" class="cls_026"><span class="cls_026">Jashin J. Wu</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, William Abramovits</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Francisco Kerdel</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Dilek Ari-</span></div>
<div style="position:absolute;left:49.93px;top:421.15px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">No relationship was apparent between TIL dose or</span></div>
<div style="position:absolute;left:306.63px;top:425.94px" class="cls_026"><span class="cls_026">ka</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Dianlin Guo</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Hartmut Kupper</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Vera Kuehnl</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Rakesh Singh</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:49.93px;top:431.15px" class="cls_031"><span class="cls_031">Cav12 and PASI response, although the greatest response was</span></div>
<div style="position:absolute;left:306.64px;top:435.84px" class="cls_026"><span class="cls_026">Alan Fleischer</span><span class="cls_027"><sup>4</sup></span></div>
<div style="position:absolute;left:49.93px;top:441.15px" class="cls_031"><span class="cls_031">seen for the highest serum concentration. Importantly, there were</span></div>
<div style="position:absolute;left:306.64px;top:446.44px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Kaiser Permanente Los Angeles Medical Center, Los Angeles, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Division</span></div>
<div style="position:absolute;left:49.93px;top:451.15px" class="cls_031"><span class="cls_031">no associations between serum concentration and AE incidence.</span></div>
<div style="position:absolute;left:306.64px;top:456.04px" class="cls_029"><span class="cls_029">of Dermatology, Baylor University Medical Center, Dallas, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Florida Aca-</span></div>
<div style="position:absolute;left:49.93px;top:461.15px" class="cls_031"><span class="cls_031">Study sponsored by Merck Sharp & Dohme Corp., a subsidiary</span></div>
<div style="position:absolute;left:306.64px;top:465.64px" class="cls_029"><span class="cls_029">demic Dermatology Centers, Miami, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">AbbVie Inc., North Chicago, USA,</span></div>
<div style="position:absolute;left:49.93px;top:471.15px" class="cls_031"><span class="cls_031">of Merck & Co., Inc., Kenilworth, NJ, USA; analyses funded by</span></div>
<div style="position:absolute;left:306.64px;top:475.24px" class="cls_028"><span class="cls_028"><sup>5</sup></span><span class="cls_029">AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany</span></div>
<div style="position:absolute;left:49.93px;top:481.15px" class="cls_031"><span class="cls_031">Sun Pharmaceutical Industries, Inc.</span></div>
<div style="position:absolute;left:306.64px;top:486.01px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">ESPRIT is a 10-year (y) international prospective</span></div>
<div style="position:absolute;left:49.93px;top:491.15px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:306.64px;top:495.91px" class="cls_031"><span class="cls_031">observational registry evaluating the long-term safety and effec-</span></div>
<div style="position:absolute;left:49.95px;top:501.20px" class="cls_032"><span class="cls_032">1. Reich K, et al. Lancet. 2017;390:276-288.</span></div>
<div style="position:absolute;left:306.64px;top:505.81px" class="cls_031"><span class="cls_031">tiveness of originator adalimumab (ADA) in adult patients (pts)</span></div>
<div style="position:absolute;left:306.64px;top:515.71px" class="cls_031"><span class="cls_031">with moderate to severe chronic plaque psoriasis.</span></div>
<div style="position:absolute;left:49.95px;top:518.82px" class="cls_033"><span class="cls_033">P055</span></div>
<div style="position:absolute;left:306.64px;top:525.61px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To determine safety, effectiveness, and pt-reported</span></div>
<div style="position:absolute;left:49.95px;top:530.22px" class="cls_025"><span class="cls_025">LONG-TERM SAFETY AND EFFICACY OF</span></div>
<div style="position:absolute;left:306.64px;top:535.51px" class="cls_031"><span class="cls_031">outcomes (PROs) over an 8-y period from an interim analysis of</span></div>
<div style="position:absolute;left:49.95px;top:541.11px" class="cls_025"><span class="cls_025">ADALIMUMAB FROM THE PHASE 3 RANDOMIZED,</span></div>
<div style="position:absolute;left:306.64px;top:545.41px" class="cls_031"><span class="cls_031">data collected from the ESPRIT registry.</span></div>
<div style="position:absolute;left:49.95px;top:552.01px" class="cls_025"><span class="cls_025">PLACEBO-CONTROLLED TRIAL IN PATIENTS WITH</span></div>
<div style="position:absolute;left:306.64px;top:555.31px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">ESPRIT enrolled pts who were continuing ADA treat-</span></div>
<div style="position:absolute;left:49.95px;top:562.91px" class="cls_025"><span class="cls_025">NAIL AND SKIN PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:565.21px" class="cls_031"><span class="cls_031">ment from a current prescription or previous study participation, or</span></div>
<div style="position:absolute;left:49.95px;top:572.81px" class="cls_026"><span class="cls_026">Jeff Crowley</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Paolo Gisondi</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Ziqian Geng</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Ofelia Reyes Servin</span><span class="cls_027"><sup>3</sup></span></div>
<div style="position:absolute;left:306.64px;top:575.11px" class="cls_031"><span class="cls_031">initiating ADA </span><span class="cls_030"> ≤ </span><span class="cls_031">4 weeks of entering the registry. The All-Treated</span></div>
<div style="position:absolute;left:49.95px;top:583.41px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Bakersfield Dermatology, Bakersfield, CA, USA, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">University of Verona,</span></div>
<div style="position:absolute;left:306.63px;top:585.01px" class="cls_031"><span class="cls_031">pt population (All-Rx) received at least 1 ADA dose in this registry.</span></div>
<div style="position:absolute;left:49.95px;top:593.02px" class="cls_029"><span class="cls_029">Verona, Italy, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">AbbVie Inc, North Chicago, IL, USA</span></div>
<div style="position:absolute;left:306.63px;top:594.91px" class="cls_031"><span class="cls_031">Pts were evaluated at 3 and 6 months (mos) post-enrollment, and</span></div>
<div style="position:absolute;left:49.95px;top:603.88px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">We evaluated long-term (up to 52 weeks) safety and</span></div>
<div style="position:absolute;left:306.63px;top:604.81px" class="cls_031"><span class="cls_031">then every 6 mos for up to 10 ys. This interim analysis includes</span></div>
<div style="position:absolute;left:49.95px;top:613.88px" class="cls_031"><span class="cls_031">efficacy of originator adalimumab every-other-week treatment</span></div>
<div style="position:absolute;left:306.63px;top:614.71px" class="cls_031"><span class="cls_031">data collected from 26 Sep 2008 through 30 Nov 2016. Incidence</span></div>
<div style="position:absolute;left:49.94px;top:623.88px" class="cls_031"><span class="cls_031">(ADA eow) for fingernail psoriasis (Ps) in patients (pts) with</span></div>
<div style="position:absolute;left:306.63px;top:624.61px" class="cls_031"><span class="cls_031">rates (IR) for all treatment-emergent adverse events (All-TEAEs)</span></div>
<div style="position:absolute;left:49.95px;top:633.88px" class="cls_031"><span class="cls_031">moderate-to-severe Ps with substantial, clinically impactful,</span></div>
<div style="position:absolute;left:306.63px;top:634.51px" class="cls_031"><span class="cls_031">in All-Rx pts are reported as events per 100 pt-ys (E/100PY) of</span></div>
<div style="position:absolute;left:49.95px;top:643.88px" class="cls_031"><span class="cls_031">moderate-to-severe fingernail Ps.</span></div>
<div style="position:absolute;left:306.63px;top:644.41px" class="cls_031"><span class="cls_031">overall exposure to ADA. Physician’s Global Assessment (PGA)</span></div>
<div style="position:absolute;left:49.95px;top:653.88px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">In 26-week Period A, pts were randomized 1:1 to 40 mg</span></div>
<div style="position:absolute;left:306.63px;top:654.31px" class="cls_031"><span class="cls_031">and PROs (US only) were evaluated in as-observed population</span></div>
<div style="position:absolute;left:49.95px;top:663.88px" class="cls_031"><span class="cls_031">ADA after initial 80 mg dose, or matching placebo (pbo). Period</span></div>
<div style="position:absolute;left:306.63px;top:664.21px" class="cls_031"><span class="cls_031">(pt numbers were small at 96 mos).</span></div>
<div style="position:absolute;left:49.95px;top:673.87px" class="cls_031"><span class="cls_031">B (open-label, 26 weeks) entry criteria: completion of Period A,</span></div>
<div style="position:absolute;left:306.63px;top:674.11px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">For the 6045 All-Rx pts enrolled and dosed in ESPRIT,</span></div>
<div style="position:absolute;left:49.95px;top:683.87px" class="cls_031"><span class="cls_031">or ≥25% increase from baseline in affected body surface area</span></div>
<div style="position:absolute;left:306.63px;top:684.01px" class="cls_031"><span class="cls_031">median duration of overall exposure to ADA was 3.9 ys. Registry</span></div>
<div style="position:absolute;left:49.96px;top:693.87px" class="cls_031"><span class="cls_031">(BSA) at week 16. At Period B entry (week 26), Period-A pbo pts</span></div>
<div style="position:absolute;left:306.63px;top:693.91px" class="cls_031"><span class="cls_031">discontinuation rate in All-Rx pts was 39.4%; with the most</span></div>
<div style="position:absolute;left:49.96px;top:703.87px" class="cls_031"><span class="cls_031">received an initial blinded dose of 80 mg ADA; all received ADA</span></div>
<div style="position:absolute;left:306.63px;top:703.81px" class="cls_031"><span class="cls_031">common reason being lost to follow up (18.2%). IR (E/100PY)</span></div>
<div style="position:absolute;left:49.96px;top:713.87px" class="cls_031"><span class="cls_031">eow from weeks 27 through 51. We analyzed all pts who received</span></div>
<div style="position:absolute;left:306.63px;top:713.80px" class="cls_031"><span class="cls_031">for All-TEAEs was: overall 22.0; serious AEs 4.5; malignancies</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:20878px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background28.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">26</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">1.1, serious infections 1.0; non-melanoma skin cancer 0.7; active</span></div>
<div style="position:absolute;left:306.65px;top:51.39px" class="cls_031"><span class="cls_031">at Week 0 who entered the blinded maintenance phase, 132/149 and</span></div>
<div style="position:absolute;left:50.00px;top:61.40px" class="cls_031"><span class="cls_031">TB </span><span class="cls_030"> &lt; </span><span class="cls_031">0.1; and All-TEAEs leading to death 0.2. Standardized</span></div>
<div style="position:absolute;left:306.65px;top:61.51px" class="cls_031"><span class="cls_031">130/150 achieved PASI 75, respectively. Out of Week 16 PASI 75</span></div>
<div style="position:absolute;left:50.00px;top:71.40px" class="cls_031"><span class="cls_031">mortality ratio was 0.34 (95% CI, 0.25-0.46), indicating the ob-</span></div>
<div style="position:absolute;left:306.65px;top:71.62px" class="cls_031"><span class="cls_031">responders, 98.0% of patients treated with CZP 400 mg Q2W and</span></div>
<div style="position:absolute;left:50.00px;top:81.41px" class="cls_031"><span class="cls_031">served number of deaths was below expected in an age-, sex- and</span></div>
<div style="position:absolute;left:306.65px;top:81.75px" class="cls_031"><span class="cls_031">87.5% of patients treated with CZP 200 mq Q2W also reported a</span></div>
<div style="position:absolute;left:50.00px;top:91.40px" class="cls_031"><span class="cls_031">country-matched population. PGA clear/minimal was achieved by</span></div>
<div style="position:absolute;left:306.65px;top:91.86px" class="cls_031"><span class="cls_031">PASI 75 response at Week 48 (Table). Sensitivity analyses using</span></div>
<div style="position:absolute;left:50.00px;top:101.40px" class="cls_031"><span class="cls_031">57.0%, 58.7%, 59.1%, 62.6%, 61.9%, 63.8%, 65.5%, and 45.0% of</span></div>
<div style="position:absolute;left:306.65px;top:101.98px" class="cls_031"><span class="cls_031">NRI showed similar trends with both doses, and similar trends</span></div>
<div style="position:absolute;left:50.00px;top:111.40px" class="cls_031"><span class="cls_031">pts at 12, 24, 36, 48, 60, 72, 84, and 96 mos, respectively. In 4202</span></div>
<div style="position:absolute;left:306.65px;top:112.09px" class="cls_031"><span class="cls_031">were seen in PASI 90 response rates.</span></div>
<div style="position:absolute;left:50.00px;top:121.40px" class="cls_031"><span class="cls_031">US pts, mean change from baseline in Dermatology Quality of</span></div>
<div style="position:absolute;left:306.65px;top:122.22px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">These analyses show that patients in both CZP dose</span></div>
<div style="position:absolute;left:50.00px;top:131.40px" class="cls_031"><span class="cls_031">Life Index, total work productivity impairment, and total activity</span></div>
<div style="position:absolute;left:306.65px;top:132.34px" class="cls_031"><span class="cls_031">groups demonstrate durability of their initial Week 16 high-level</span></div>
<div style="position:absolute;left:50.00px;top:141.40px" class="cls_031"><span class="cls_031">impairment at 12-mo intervals were -3.1/-5.5/-8.3, -3.2/-5.4/-9.1,</span></div>
<div style="position:absolute;left:306.65px;top:142.45px" class="cls_031"><span class="cls_031">response to Week 48, with greatest durability seen in the CZP</span></div>
<div style="position:absolute;left:50.00px;top:151.40px" class="cls_031"><span class="cls_031">-3.3/-5.3/-8.4, -3.5/-5.6/-8.7, -3.9/-5.8/-9.3, -3.7/-6.3/-8.7, -5.1/-</span></div>
<div style="position:absolute;left:306.65px;top:152.57px" class="cls_031"><span class="cls_031">400 mg Q2W dose group (98.0% maintenance between Weeks</span></div>
<div style="position:absolute;left:50.00px;top:161.40px" class="cls_031"><span class="cls_031">9.1/-11.4, and -5.9/-7.5/-13.8.</span></div>
<div style="position:absolute;left:306.65px;top:162.69px" class="cls_031"><span class="cls_031">16 and 48).</span></div>
<div style="position:absolute;left:50.00px;top:171.40px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">In this 8-y interim analysis, no new safety signals</span></div>
<div style="position:absolute;left:306.65px;top:172.81px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:50.00px;top:181.40px" class="cls_031"><span class="cls_031">were observed and safety was consistent with the known safety</span></div>
<div style="position:absolute;left:306.64px;top:182.99px" class="cls_032"><span class="cls_032">1. Blauvelt A (2018). Skin, 2:s16; 2. Reich K (2017). Skin,1;s23; 3. Au-</span></div>
<div style="position:absolute;left:50.00px;top:191.39px" class="cls_031"><span class="cls_031">profile of ADA. The number of TE deaths in the registry was</span></div>
<div style="position:absolute;left:306.64px;top:192.11px" class="cls_032"><span class="cls_032">gustin M (2017). Skin,1;s24</span></div>
<div style="position:absolute;left:50.02px;top:201.39px" class="cls_031"><span class="cls_031">below the expected rate. As-observed effectiveness of ADA and</span></div>
<div style="position:absolute;left:306.64px;top:202.24px" class="cls_036"><span class="cls_036">Table: Pts achieving PASI 75 at Week 48 among Week 16 PASI 75 responders pooled</span></div>
<div style="position:absolute;left:306.64px;top:209.36px" class="cls_036"><span class="cls_036">for CIMPASI-1 and CIMPASI-2</span></div>
<div style="position:absolute;left:50.02px;top:211.39px" class="cls_031"><span class="cls_031">improvement from baseline in PROs were maintained through</span></div>
<div style="position:absolute;left:411.92px;top:220.59px" class="cls_036"><span class="cls_036">CZP 400 mg Q2W</span></div>
<div style="position:absolute;left:487.69px;top:220.59px" class="cls_036"><span class="cls_036">CZP 200 mg Q2Wa</span></div>
<div style="position:absolute;left:50.02px;top:221.39px" class="cls_031"><span class="cls_031">96 mos.</span></div>
<div style="position:absolute;left:308.01px;top:229.76px" class="cls_037"><span class="cls_037">Week 16 responders, n</span></div>
<div style="position:absolute;left:413.46px;top:229.76px" class="cls_037"><span class="cls_037">132</span></div>
<div style="position:absolute;left:487.68px;top:229.76px" class="cls_037"><span class="cls_037">130</span></div>
<div style="position:absolute;left:308.01px;top:235.92px" class="cls_037"><span class="cls_037">Week 48 responders</span></div>
<div style="position:absolute;left:50.00px;top:242.04px" class="cls_033"><span class="cls_033">P057</span></div>
<div style="position:absolute;left:308.01px;top:242.93px" class="cls_037"><span class="cls_037">MCMC, % (95% CI)</span></div>
<div style="position:absolute;left:411.90px;top:242.93px" class="cls_037"><span class="cls_037">98.0% (95.6-100)</span></div>
<div style="position:absolute;left:487.68px;top:242.93px" class="cls_037"><span class="cls_037">87.5% (79.7-95.4)</span></div>
<div style="position:absolute;left:308.01px;top:249.93px" class="cls_037"><span class="cls_037">NRI, % of Week 16 (n)</span></div>
<div style="position:absolute;left:411.90px;top:249.93px" class="cls_037"><span class="cls_037">88.6% (117)</span></div>
<div style="position:absolute;left:487.68px;top:249.93px" class="cls_037"><span class="cls_037">78.5% (102)</span></div>
<div style="position:absolute;left:50.00px;top:253.44px" class="cls_025"><span class="cls_025">DURABILITY OF RESPONSE IN CERTOLIZUMAB</span></div>
<div style="position:absolute;left:306.63px;top:258.30px" class="cls_037"><span class="cls_037">aPts received 400 mg CZP LD at Weeks 0/2/4.</span></div>
<div style="position:absolute;left:50.00px;top:264.34px" class="cls_025"><span class="cls_025">PEGOL-TREATED PATIENTS OVER 48 WEEKS IN</span></div>
<div style="position:absolute;left:50.00px;top:275.24px" class="cls_025"><span class="cls_025">CIMPASI-1 & 2 TRIALS</span></div>
<div style="position:absolute;left:306.64px;top:274.00px" class="cls_033"><span class="cls_033">P058</span></div>
<div style="position:absolute;left:50.00px;top:285.14px" class="cls_051"><span class="cls_051">Kristian Reich</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Andrew Blauvelt</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Diamant Thaçi3, Craig Leo-</span></div>
<div style="position:absolute;left:306.64px;top:285.52px" class="cls_025"><span class="cls_025">PRIMARY EFFICACY AND SAFETY OF ADALIMUMAB</span></div>
<div style="position:absolute;left:50.00px;top:295.04px" class="cls_026"><span class="cls_026">nardi</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Yves Poulin</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Luke Peterson</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Catherine Arendt</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Alice B</span></div>
<div style="position:absolute;left:306.64px;top:296.54px" class="cls_025"><span class="cls_025">IN NAIL PSORIASIS FROM THE FIRST 26 WEEKS OF</span></div>
<div style="position:absolute;left:50.00px;top:304.94px" class="cls_026"><span class="cls_026">Gottlieb</span><span class="cls_027"><sup>8</sup></span></div>
<div style="position:absolute;left:306.64px;top:307.55px" class="cls_025"><span class="cls_025">A  PHASE-3,  RANDOMIZED,  PLACEBO-CONTROLLED</span></div>
<div style="position:absolute;left:50.00px;top:315.54px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">SCIderm Research Institute, Hamburg, and Dermatologikum Berlin, Ger-</span></div>
<div style="position:absolute;left:306.64px;top:318.57px" class="cls_025"><span class="cls_025">TRIAL WITH SUBANALYSIS IN PATIENTS WITH AND</span></div>
<div style="position:absolute;left:50.00px;top:325.14px" class="cls_029"><span class="cls_029">many, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Oregon Medical Research Center, Portland, USA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">University Hos-</span></div>
<div style="position:absolute;left:306.64px;top:329.59px" class="cls_025"><span class="cls_025">WITHOUT PSORIATIC ARTHRITIS</span></div>
<div style="position:absolute;left:50.00px;top:334.74px" class="cls_029"><span class="cls_029">pital of Schleswig-Holstein Campus Lübeck, Lübeck, Germany, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Central</span></div>
<div style="position:absolute;left:306.64px;top:339.60px" class="cls_026"><span class="cls_026">Boni E. Elewski</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Pheobe A. Rich</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Frank Behrens</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Gérard Guil-</span></div>
<div style="position:absolute;left:50.00px;top:344.34px" class="cls_029"><span class="cls_029">Dermatology and Saint Louis University School of Medicine, St. Louis,</span></div>
<div style="position:absolute;left:306.64px;top:349.64px" class="cls_026"><span class="cls_026">let</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Ziqian Geng</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Ofelia Reyes Servin</span><span class="cls_027"><sup>5</sup></span></div>
<div style="position:absolute;left:50.00px;top:353.94px" class="cls_029"><span class="cls_029">USA, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Centre de Recherche Dermatologique du Québec Métropolitain,</span></div>
<div style="position:absolute;left:306.64px;top:360.36px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">University of Alabama at Birmingham, School of Medicine, Birmingham,</span></div>
<div style="position:absolute;left:50.00px;top:363.54px" class="cls_029"><span class="cls_029">Québec, Canada, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">UCB Pharma, Raleigh, USA, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">UCB Pharma, Brussels,</span></div>
<div style="position:absolute;left:306.64px;top:370.08px" class="cls_029"><span class="cls_029">AL, USA, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Oregon Health and Science University Hospital, Portland, OR,</span></div>
<div style="position:absolute;left:50.00px;top:373.14px" class="cls_029"><span class="cls_029">Belgium, </span><span class="cls_028"><sup>8</sup></span><span class="cls_029">Department of Dermatology, New York Medical College at Met-</span></div>
<div style="position:absolute;left:306.64px;top:379.81px" class="cls_029"><span class="cls_029">USA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Goethe University Medical Center, Frankfurt, Germany, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Hopital</span></div>
<div style="position:absolute;left:50.00px;top:382.74px" class="cls_029"><span class="cls_029">ropolitan Hospital, NY, USA</span></div>
<div style="position:absolute;left:306.64px;top:389.53px" class="cls_029"><span class="cls_029">La Miletrie, Service de Dermatologie, CHU Poitiers, France, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">AbbVie Inc,</span></div>
<div style="position:absolute;left:50.00px;top:393.61px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Certolizumab pegol (CZP), the only Fc-free, PE-</span></div>
<div style="position:absolute;left:306.64px;top:399.25px" class="cls_029"><span class="cls_029">North Chicago, IL, USA</span></div>
<div style="position:absolute;left:50.00px;top:403.61px" class="cls_031"><span class="cls_031">Gylated, anti-tumor necrosis factor biologic, has shown clinical</span></div>
<div style="position:absolute;left:306.64px;top:410.23px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis (Ps) disease burden for patients with pso-</span></div>
<div style="position:absolute;left:50.00px;top:413.60px" class="cls_031"><span class="cls_031">improvements and a safety profile consistent with the class in</span></div>
<div style="position:absolute;left:306.64px;top:420.35px" class="cls_031"><span class="cls_031">riasis (Ps) and concomitant fingernail Ps plus psoriatic arthritis</span></div>
<div style="position:absolute;left:50.01px;top:423.60px" class="cls_031"><span class="cls_031">adults with chronic plaque psoriasis (PSO).[1,2,3]</span></div>
<div style="position:absolute;left:306.63px;top:430.47px" class="cls_031"><span class="cls_031">(PsA) is higher compared with patients with Ps alone.</span></div>
<div style="position:absolute;left:50.01px;top:433.60px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To assess durability to Week 48 of the initial Week 16</span></div>
<div style="position:absolute;left:306.63px;top:440.59px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">We report safety and efficacy of originator adalimumab</span></div>
<div style="position:absolute;left:50.01px;top:443.60px" class="cls_031"><span class="cls_031">clinical response with CZP in PSO patients (pts) in two identical</span></div>
<div style="position:absolute;left:306.63px;top:450.71px" class="cls_031"><span class="cls_031">(ADA) in patients with fingernail Ps, and also for patients with or</span></div>
<div style="position:absolute;left:50.01px;top:453.60px" class="cls_031"><span class="cls_031">phase 3 trials.</span></div>
<div style="position:absolute;left:306.64px;top:460.83px" class="cls_031"><span class="cls_031">without concomitant PsA.</span></div>
<div style="position:absolute;left:50.01px;top:463.60px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Data were pooled from CIMPASI-1 (NCT02326298) and</span></div>
<div style="position:absolute;left:50.01px;top:473.60px" class="cls_031"><span class="cls_031">CIMPASI-2 (NCT02326272), ongoing CZP phase 3 trials in adults</span></div>
<div style="position:absolute;left:306.64px;top:470.95px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Results are reported from the double-blind PBO-</span></div>
<div style="position:absolute;left:50.01px;top:483.60px" class="cls_031"><span class="cls_031">with PSO ≥6 months (Psoriasis Area Severity Index [PASI] ≥12,</span></div>
<div style="position:absolute;left:306.64px;top:481.07px" class="cls_031"><span class="cls_031">controlled, Period A in which 217 patients with moderate to</span></div>
<div style="position:absolute;left:49.99px;top:493.60px" class="cls_031"><span class="cls_031">≥10% body surface area affected, physician’s global assessment</span></div>
<div style="position:absolute;left:306.64px;top:491.18px" class="cls_031"><span class="cls_031">severe plaque Ps and fingernail Ps were included and randomized</span></div>
<div style="position:absolute;left:49.99px;top:503.60px" class="cls_031"><span class="cls_031">[PGA] ≥3/5). Pts were randomized 2:2:1 to CZP 400 mg every</span></div>
<div style="position:absolute;left:306.65px;top:501.30px" class="cls_031"><span class="cls_031">1:1 to receive 40 mg ADA every other week (eow) from week 1</span></div>
<div style="position:absolute;left:49.99px;top:513.59px" class="cls_031"><span class="cls_031">two weeks (Q2W), 200 mg Q2W (400 mg loading dose [LD] at</span></div>
<div style="position:absolute;left:306.65px;top:511.42px" class="cls_031"><span class="cls_031">(initial 80mg dose at week 0), or matching PBO, for 26 weeks.</span></div>
<div style="position:absolute;left:49.99px;top:523.59px" class="cls_031"><span class="cls_031">Weeks 0/2/4), or placebo (PBO). At Week 16, PASI 50 responders</span></div>
<div style="position:absolute;left:306.65px;top:521.54px" class="cls_031"><span class="cls_031">The primary endpoints were the proportion of patients with ≥75%</span></div>
<div style="position:absolute;left:49.99px;top:533.59px" class="cls_031"><span class="cls_031">receiving CZP continued the same dose through the maintenance</span></div>
<div style="position:absolute;left:306.65px;top:531.66px" class="cls_031"><span class="cls_031">improvement in modified Nail Ps Severity Index (mNAPSI 75)</span></div>
<div style="position:absolute;left:49.99px;top:543.59px" class="cls_031"><span class="cls_031">period to Week 48. PASI 50 non-responders at Weeks 32/40/48</span></div>
<div style="position:absolute;left:306.64px;top:541.78px" class="cls_031"><span class="cls_031">and the proportion of patients with Physician’s Global Assess-</span></div>
<div style="position:absolute;left:49.99px;top:553.59px" class="cls_031"><span class="cls_031">were classed as non-responders at subsequent time points. These</span></div>
<div style="position:absolute;left:306.64px;top:551.92px" class="cls_031"><span class="cls_031">ment of Fingernail Psoriasis (PGA-F) of clear (0) or minimal</span></div>
<div style="position:absolute;left:49.99px;top:563.59px" class="cls_031"><span class="cls_031">analyses do not include PBO pts or Week 16 PASI 50 non-respon-</span></div>
<div style="position:absolute;left:306.64px;top:562.04px" class="cls_031"><span class="cls_031">(1) with ≥2-grade reduction from baseline (primary in US only;</span></div>
<div style="position:absolute;left:50.00px;top:573.61px" class="cls_031"><span class="cls_031">ders. We report number needed to treat (NNT) to achieve PASI 75</span></div>
<div style="position:absolute;left:306.64px;top:572.16px" class="cls_031"><span class="cls_031">for regulatory purposes). Missing data were handled by multi-</span></div>
<div style="position:absolute;left:50.00px;top:583.60px" class="cls_031"><span class="cls_031">at Week 16, and PASI 75 at Week 48 in pts who achieved PASI 75</span></div>
<div style="position:absolute;left:306.64px;top:582.28px" class="cls_031"><span class="cls_031">ple imputation. Safety was assessed using treatment-emergent</span></div>
<div style="position:absolute;left:50.00px;top:593.60px" class="cls_031"><span class="cls_031">at Week 16. Week 16 NNT, 95% confidence intervals (95% CI) and</span></div>
<div style="position:absolute;left:306.64px;top:592.41px" class="cls_031"><span class="cls_031">adverse events (AEs).</span></div>
<div style="position:absolute;left:50.01px;top:603.60px" class="cls_031"><span class="cls_031">Week 48 PASI 75 responder rates were estimated using logistic</span></div>
<div style="position:absolute;left:306.64px;top:602.52px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Of the 217 randomized patients (108 PBO, 109 ADA),</span></div>
<div style="position:absolute;left:50.01px;top:613.60px" class="cls_031"><span class="cls_031">regression in which missing data and patients withdrawn due to</span></div>
<div style="position:absolute;left:306.64px;top:612.64px" class="cls_031"><span class="cls_031">84.3% were male; mean age was 46.7 years; 188 (86.6%) comple-</span></div>
<div style="position:absolute;left:50.01px;top:623.60px" class="cls_031"><span class="cls_031">relapse (</span><span class="cls_030"> &lt; </span><span class="cls_031">PASI 50 during the maintenance period) were imputed</span></div>
<div style="position:absolute;left:306.64px;top:622.76px" class="cls_031"><span class="cls_031">ted 26 weeks of treatment or early escaped to Period B according</span></div>
<div style="position:absolute;left:50.01px;top:633.60px" class="cls_031"><span class="cls_031">using multiple imputation (Markov Chain Monte Carlo [MCMC]</span></div>
<div style="position:absolute;left:306.64px;top:632.88px" class="cls_031"><span class="cls_031">to protocol. At baseline, 28.6% had PsA (29.6% PBO, 27.5%</span></div>
<div style="position:absolute;left:50.01px;top:643.60px" class="cls_031"><span class="cls_031">method). Sensitivity analyses on PASI 75 were conducted using</span></div>
<div style="position:absolute;left:306.64px;top:643.00px" class="cls_031"><span class="cls_031">ADA) with mean duration 7.91 years [SD 8.314]. Total fingernail</span></div>
<div style="position:absolute;left:50.01px;top:653.60px" class="cls_031"><span class="cls_031">non-responder imputation (NRI).</span></div>
<div style="position:absolute;left:306.62px;top:653.12px" class="cls_031"><span class="cls_031">mNAPSI 75 was achieved by 0.5% PBO vs 61.5% ADA of patients</span></div>
<div style="position:absolute;left:50.01px;top:663.60px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">At Week 16, NNT to achieve a PASI 75 response was 1.41</span></div>
<div style="position:absolute;left:306.62px;top:663.24px" class="cls_031"><span class="cls_031">with PsA and 4.6% PBO vs 40.9% ADA without PsA (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001</span></div>
<div style="position:absolute;left:50.01px;top:673.60px" class="cls_031"><span class="cls_031">(95% CI: 1.26-1.60) for the CZP 400 mg Q2W dose group and</span></div>
<div style="position:absolute;left:306.62px;top:673.35px" class="cls_031"><span class="cls_031">for both groups). PGA-F 0 or 1 with ≥2-grade reduction was</span></div>
<div style="position:absolute;left:50.01px;top:683.59px" class="cls_031"><span class="cls_031">1.53 (1.35-1.77) for the CZP 200 mg Q2W dose group.</span></div>
<div style="position:absolute;left:306.62px;top:683.48px" class="cls_031"><span class="cls_031">achieved by 4.4% PBO vs 59.3% ADA with PsA and 7.9% PBO</span></div>
<div style="position:absolute;left:50.01px;top:693.59px" class="cls_031"><span class="cls_031">Of the pts randomized to CZP 400 mg Q2W and CZP 200 mg Q2W</span></div>
<div style="position:absolute;left:306.62px;top:693.59px" class="cls_031"><span class="cls_031">vs 44.9% ADA without PsA (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001 for both groups). Adverse</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:21681px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background29.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">27</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">events (AEs) in Period A were reported by 55.6% PBO vs 56.9%</span></div>
<div style="position:absolute;left:306.64px;top:52.05px" class="cls_036"><span class="cls_036">Table: Week 48 PASI 75 subgroup responder rates</span></div>
<div style="position:absolute;left:50.00px;top:61.40px" class="cls_031"><span class="cls_031">ADA (with PsA: 56.3% PBO vs 56.7% ADA; without PsA: 55.3%</span></div>
<div style="position:absolute;left:396.01px;top:63.28px" class="cls_036"><span class="cls_036">CZP 400 mg Q2W</span></div>
<div style="position:absolute;left:470.01px;top:63.28px" class="cls_036"><span class="cls_036">CZP 200 mg Q2W</span></div>
<div style="position:absolute;left:396.01px;top:70.28px" class="cls_036"><span class="cls_036">(</span><span class="cls_040">n = </span><span class="cls_036">175</span></div>
<div style="position:absolute;left:470.01px;top:70.28px" class="cls_036"><span class="cls_036">(</span><span class="cls_040">n = </span><span class="cls_036">186)</span></div>
<div style="position:absolute;left:50.00px;top:71.40px" class="cls_031"><span class="cls_031">PBO vs 57.0% ADA without PsA); serious AEs by 4.6% PBO vs</span></div>
<div style="position:absolute;left:411.01px;top:80.53px" class="cls_036"><span class="cls_036">PASI 75 responders</span></div>
<div style="position:absolute;left:487.01px;top:80.53px" class="cls_036"><span class="cls_036">PASI 75 responders</span></div>
<div style="position:absolute;left:50.00px;top:81.40px" class="cls_031"><span class="cls_031">7.3% ADA (with PsA: 9.4% PBO vs 10.0% ADA; without PsA:</span></div>
<div style="position:absolute;left:396.01px;top:87.53px" class="cls_036"><span class="cls_036">N</span></div>
<div style="position:absolute;left:411.01px;top:87.53px" class="cls_036"><span class="cls_036">n (%)</span></div>
<div style="position:absolute;left:470.01px;top:87.53px" class="cls_036"><span class="cls_036">N</span></div>
<div style="position:absolute;left:487.01px;top:87.53px" class="cls_036"><span class="cls_036">n (%)</span></div>
<div style="position:absolute;left:50.00px;top:91.40px" class="cls_031"><span class="cls_031">2.6% PBO vs 6.3% ADA).</span></div>
<div style="position:absolute;left:308.01px;top:96.71px" class="cls_037"><span class="cls_037">Baseline demographics</span></div>
<div style="position:absolute;left:50.00px;top:101.40px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">The results demonstrated that in this population,</span></div>
<div style="position:absolute;left:308.01px;top:102.87px" class="cls_037"><span class="cls_037">Weight (kg)</span></div>
<div style="position:absolute;left:308.79px;top:109.04px" class="cls_038"><span class="cls_038">≤ </span><span class="cls_037">74.00</span></div>
<div style="position:absolute;left:396.02px;top:109.03px" class="cls_037"><span class="cls_037">40</span></div>
<div style="position:absolute;left:411.01px;top:109.03px" class="cls_037"><span class="cls_037">32 (80.0)</span></div>
<div style="position:absolute;left:470.02px;top:109.03px" class="cls_037"><span class="cls_037">32</span></div>
<div style="position:absolute;left:487.02px;top:109.03px" class="cls_037"><span class="cls_037">23 (71.9)</span></div>
<div style="position:absolute;left:50.00px;top:111.40px" class="cls_031"><span class="cls_031">ADA was more effective than PBO for the treatment of fingernail</span></div>
<div style="position:absolute;left:308.79px;top:115.21px" class="cls_038"><span class="cls_038">> </span><span class="cls_037">74.00-</span><span class="cls_038"> ≤ </span><span class="cls_037">85.00</span></div>
<div style="position:absolute;left:396.02px;top:115.20px" class="cls_037"><span class="cls_037">36</span></div>
<div style="position:absolute;left:411.02px;top:115.20px" class="cls_037"><span class="cls_037">28 (77.8)</span></div>
<div style="position:absolute;left:470.02px;top:115.20px" class="cls_037"><span class="cls_037">35</span></div>
<div style="position:absolute;left:487.02px;top:115.20px" class="cls_037"><span class="cls_037">24 (68.6)</span></div>
<div style="position:absolute;left:308.80px;top:121.37px" class="cls_038"><span class="cls_038">> </span><span class="cls_037">85.00-</span><span class="cls_038"> ≤ </span><span class="cls_037">95.40</span></div>
<div style="position:absolute;left:396.03px;top:121.37px" class="cls_037"><span class="cls_037">36</span></div>
<div style="position:absolute;left:411.03px;top:121.37px" class="cls_037"><span class="cls_037">26 (72.2)</span></div>
<div style="position:absolute;left:470.03px;top:121.37px" class="cls_037"><span class="cls_037">34</span></div>
<div style="position:absolute;left:487.03px;top:121.37px" class="cls_037"><span class="cls_037">23 (67.6)</span></div>
<div style="position:absolute;left:50.00px;top:121.40px" class="cls_031"><span class="cls_031">Ps, and significantly improved signs and symptoms, both overall</span></div>
<div style="position:absolute;left:308.80px;top:127.54px" class="cls_038"><span class="cls_038">> </span><span class="cls_037">95.40-</span><span class="cls_038"> ≤ </span><span class="cls_037">109.00</span></div>
<div style="position:absolute;left:396.03px;top:127.54px" class="cls_037"><span class="cls_037">28</span></div>
<div style="position:absolute;left:411.03px;top:127.54px" class="cls_037"><span class="cls_037">18 (64.3)</span></div>
<div style="position:absolute;left:470.03px;top:127.54px" class="cls_037"><span class="cls_037">45</span></div>
<div style="position:absolute;left:487.04px;top:127.54px" class="cls_037"><span class="cls_037">26 (57.8)</span></div>
<div style="position:absolute;left:50.00px;top:131.40px" class="cls_031"><span class="cls_031">and regardless of the presence or abscense of PsA; no new safety</span></div>
<div style="position:absolute;left:308.81px;top:133.71px" class="cls_038"><span class="cls_038">> </span><span class="cls_037">109.00</span></div>
<div style="position:absolute;left:396.03px;top:133.70px" class="cls_037"><span class="cls_037">35</span></div>
<div style="position:absolute;left:411.03px;top:133.70px" class="cls_037"><span class="cls_037">24 (68.6)</span></div>
<div style="position:absolute;left:470.03px;top:133.70px" class="cls_037"><span class="cls_037">40</span></div>
<div style="position:absolute;left:487.04px;top:133.70px" class="cls_037"><span class="cls_037">21 (52.5)</span></div>
<div style="position:absolute;left:308.04px;top:139.86px" class="cls_037"><span class="cls_037">BMI (kg/m</span><span class="cls_039"><sup>2</sup></span><span class="cls_037">)</span></div>
<div style="position:absolute;left:50.00px;top:141.40px" class="cls_031"><span class="cls_031">risks were identified with ADA eow treatment for 26 weeks.</span></div>
<div style="position:absolute;left:308.79px;top:146.03px" class="cls_038"><span class="cls_038">≤ </span><span class="cls_037">25.44</span></div>
<div style="position:absolute;left:396.02px;top:146.02px" class="cls_037"><span class="cls_037">37</span></div>
<div style="position:absolute;left:411.02px;top:146.02px" class="cls_037"><span class="cls_037">30 (81.1)</span></div>
<div style="position:absolute;left:470.02px;top:146.02px" class="cls_037"><span class="cls_037">35</span></div>
<div style="position:absolute;left:487.02px;top:146.02px" class="cls_037"><span class="cls_037">25 (71.4)</span></div>
<div style="position:absolute;left:50.00px;top:151.42px" class="cls_032"><span class="cls_032">Previously published J Am Acad Derm. 2017. 76(6 suppl 1): AB204.</span></div>
<div style="position:absolute;left:308.79px;top:152.19px" class="cls_038"><span class="cls_038">> </span><span class="cls_037">25.44-</span><span class="cls_038"> ≤ </span><span class="cls_037">28.68</span></div>
<div style="position:absolute;left:396.02px;top:152.19px" class="cls_037"><span class="cls_037">39</span></div>
<div style="position:absolute;left:411.02px;top:152.19px" class="cls_037"><span class="cls_037">36 (92.3)</span></div>
<div style="position:absolute;left:470.02px;top:152.19px" class="cls_037"><span class="cls_037">33</span></div>
<div style="position:absolute;left:487.02px;top:152.19px" class="cls_037"><span class="cls_037">25 (75.8)</span></div>
<div style="position:absolute;left:308.80px;top:158.36px" class="cls_038"><span class="cls_038">> </span><span class="cls_037">28.68-</span><span class="cls_038"> ≤ </span><span class="cls_037">31.92</span></div>
<div style="position:absolute;left:396.03px;top:158.36px" class="cls_037"><span class="cls_037">39</span></div>
<div style="position:absolute;left:411.03px;top:158.36px" class="cls_037"><span class="cls_037">26 (66.7)</span></div>
<div style="position:absolute;left:470.03px;top:158.36px" class="cls_037"><span class="cls_037">32</span></div>
<div style="position:absolute;left:487.03px;top:158.36px" class="cls_037"><span class="cls_037">20 (62.5)</span></div>
<div style="position:absolute;left:308.81px;top:164.53px" class="cls_038"><span class="cls_038">> </span><span class="cls_037">31.92-</span><span class="cls_038"> ≤ </span><span class="cls_037">37.16</span></div>
<div style="position:absolute;left:396.04px;top:164.52px" class="cls_037"><span class="cls_037">25</span></div>
<div style="position:absolute;left:411.04px;top:164.52px" class="cls_037"><span class="cls_037">16 (64.0)</span></div>
<div style="position:absolute;left:470.04px;top:164.52px" class="cls_037"><span class="cls_037">48</span></div>
<div style="position:absolute;left:487.04px;top:164.52px" class="cls_037"><span class="cls_037">30 (62.5)</span></div>
<div style="position:absolute;left:308.81px;top:170.70px" class="cls_038"><span class="cls_038">> </span><span class="cls_037">37.16</span></div>
<div style="position:absolute;left:396.04px;top:170.69px" class="cls_037"><span class="cls_037">35</span></div>
<div style="position:absolute;left:411.04px;top:170.69px" class="cls_037"><span class="cls_037">20 (57.1)</span></div>
<div style="position:absolute;left:470.04px;top:170.69px" class="cls_037"><span class="cls_037">38</span></div>
<div style="position:absolute;left:487.04px;top:170.69px" class="cls_037"><span class="cls_037">17 (44.7)</span></div>
<div style="position:absolute;left:50.00px;top:171.04px" class="cls_033"><span class="cls_033">P059</span></div>
<div style="position:absolute;left:308.04px;top:176.86px" class="cls_037"><span class="cls_037">Age (years)</span></div>
<div style="position:absolute;left:50.00px;top:182.44px" class="cls_025"><span class="cls_025">CERTOLIZUMAB PEGOL IS EFFECTIVE FOR</span></div>
<div style="position:absolute;left:308.81px;top:183.03px" class="cls_038"><span class="cls_038">&lt; </span><span class="cls_037">40</span></div>
<div style="position:absolute;left:396.04px;top:183.02px" class="cls_037"><span class="cls_037">65</span></div>
<div style="position:absolute;left:411.04px;top:183.02px" class="cls_037"><span class="cls_037">54 (83.1)</span></div>
<div style="position:absolute;left:470.04px;top:183.02px" class="cls_037"><span class="cls_037">67</span></div>
<div style="position:absolute;left:487.04px;top:183.02px" class="cls_037"><span class="cls_037">45 (67.2)</span></div>
<div style="position:absolute;left:308.04px;top:189.20px" class="cls_037"><span class="cls_037">≥40-</span><span class="cls_038"> &lt; </span><span class="cls_037">64</span></div>
<div style="position:absolute;left:396.04px;top:189.19px" class="cls_037"><span class="cls_037">97</span></div>
<div style="position:absolute;left:411.04px;top:189.19px" class="cls_037"><span class="cls_037">66 (68.0)</span></div>
<div style="position:absolute;left:470.04px;top:189.19px" class="cls_037"><span class="cls_037">107</span></div>
<div style="position:absolute;left:487.04px;top:189.19px" class="cls_037"><span class="cls_037">65 (60.7)</span></div>
<div style="position:absolute;left:50.00px;top:193.34px" class="cls_025"><span class="cls_025">CHRONIC PLAQUE PSORIASIS ACROSS PATIENT</span></div>
<div style="position:absolute;left:308.04px;top:195.36px" class="cls_037"><span class="cls_037">≥65</span></div>
<div style="position:absolute;left:396.04px;top:195.36px" class="cls_037"><span class="cls_037">13</span></div>
<div style="position:absolute;left:411.04px;top:195.36px" class="cls_037"><span class="cls_037">8 (61.5)</span></div>
<div style="position:absolute;left:470.04px;top:195.36px" class="cls_037"><span class="cls_037">12</span></div>
<div style="position:absolute;left:487.04px;top:195.36px" class="cls_037"><span class="cls_037">7 (58.3)</span></div>
<div style="position:absolute;left:308.04px;top:201.52px" class="cls_037"><span class="cls_037">Baseline disease characteristics</span></div>
<div style="position:absolute;left:50.00px;top:204.24px" class="cls_025"><span class="cls_025">SUBGROUPS</span></div>
<div style="position:absolute;left:309.04px;top:207.68px" class="cls_037"><span class="cls_037">PSO duration (years, median)</span></div>
<div style="position:absolute;left:309.81px;top:213.85px" class="cls_038"><span class="cls_038">≤ </span><span class="cls_037">15.00</span></div>
<div style="position:absolute;left:397.04px;top:213.84px" class="cls_037"><span class="cls_037">84</span></div>
<div style="position:absolute;left:412.04px;top:213.84px" class="cls_037"><span class="cls_037">61 (72.6)</span></div>
<div style="position:absolute;left:471.04px;top:213.84px" class="cls_037"><span class="cls_037">96</span></div>
<div style="position:absolute;left:488.04px;top:213.84px" class="cls_037"><span class="cls_037">64 (66.7)</span></div>
<div style="position:absolute;left:50.00px;top:214.14px" class="cls_051"><span class="cls_051">Kristian Reich</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Andrew Blauvelt</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Diamant Thaçi</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Craig Leo-</span></div>
<div style="position:absolute;left:309.82px;top:220.02px" class="cls_038"><span class="cls_038">> </span><span class="cls_037">15.00</span></div>
<div style="position:absolute;left:397.04px;top:220.01px" class="cls_037"><span class="cls_037">91</span></div>
<div style="position:absolute;left:412.04px;top:220.01px" class="cls_037"><span class="cls_037">67 (73.6)</span></div>
<div style="position:absolute;left:471.04px;top:220.01px" class="cls_037"><span class="cls_037">90</span></div>
<div style="position:absolute;left:488.04px;top:220.01px" class="cls_037"><span class="cls_037">53 (58.9)</span></div>
<div style="position:absolute;left:50.00px;top:224.04px" class="cls_026"><span class="cls_026">nardi</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Yves Poulin</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Daniel Burge</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Luke Peterson</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Catherine</span></div>
<div style="position:absolute;left:309.05px;top:226.18px" class="cls_037"><span class="cls_037">PASI (median)</span></div>
<div style="position:absolute;left:309.82px;top:232.35px" class="cls_038"><span class="cls_038">≤ </span><span class="cls_037">17.00</span></div>
<div style="position:absolute;left:397.05px;top:232.34px" class="cls_037"><span class="cls_037">79</span></div>
<div style="position:absolute;left:412.05px;top:232.34px" class="cls_037"><span class="cls_037">55 (69.6)</span></div>
<div style="position:absolute;left:471.05px;top:232.34px" class="cls_037"><span class="cls_037">97</span></div>
<div style="position:absolute;left:488.05px;top:232.34px" class="cls_037"><span class="cls_037">59 (60.8)</span></div>
<div style="position:absolute;left:50.00px;top:233.94px" class="cls_026"><span class="cls_026">Arendt</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, Alice B Gottlieb</span><span class="cls_027"><sup>9</sup></span></div>
<div style="position:absolute;left:309.83px;top:238.52px" class="cls_038"><span class="cls_038">> </span><span class="cls_037">17.00</span></div>
<div style="position:absolute;left:397.05px;top:238.51px" class="cls_037"><span class="cls_037">96</span></div>
<div style="position:absolute;left:412.05px;top:238.51px" class="cls_037"><span class="cls_037">73 (76.0)</span></div>
<div style="position:absolute;left:471.05px;top:238.51px" class="cls_037"><span class="cls_037">89</span></div>
<div style="position:absolute;left:488.05px;top:238.51px" class="cls_037"><span class="cls_037">58 (65.2)</span></div>
<div style="position:absolute;left:50.00px;top:244.54px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">SCIderm Research Institute, Hamburg, and Dermatologikum Berlin, Ger-</span></div>
<div style="position:absolute;left:309.05px;top:244.68px" class="cls_037"><span class="cls_037">BSA (%, median)</span></div>
<div style="position:absolute;left:309.83px;top:250.85px" class="cls_038"><span class="cls_038">≤ </span><span class="cls_037">19.0</span></div>
<div style="position:absolute;left:397.06px;top:250.84px" class="cls_037"><span class="cls_037">88</span></div>
<div style="position:absolute;left:412.05px;top:250.84px" class="cls_037"><span class="cls_037">67 (76.1)</span></div>
<div style="position:absolute;left:471.06px;top:250.84px" class="cls_037"><span class="cls_037">97</span></div>
<div style="position:absolute;left:488.06px;top:250.84px" class="cls_037"><span class="cls_037">60 (61.9)</span></div>
<div style="position:absolute;left:50.00px;top:254.14px" class="cls_029"><span class="cls_029">many, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Oregon Medical Research Center, Portland, OR, USA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">University</span></div>
<div style="position:absolute;left:309.83px;top:257.01px" class="cls_038"><span class="cls_038">> </span><span class="cls_037">19.0</span></div>
<div style="position:absolute;left:397.06px;top:257.01px" class="cls_037"><span class="cls_037">87</span></div>
<div style="position:absolute;left:412.05px;top:257.01px" class="cls_037"><span class="cls_037">61 (70.1)</span></div>
<div style="position:absolute;left:471.06px;top:257.01px" class="cls_037"><span class="cls_037">89</span></div>
<div style="position:absolute;left:488.06px;top:257.01px" class="cls_037"><span class="cls_037">57 (64.0)</span></div>
<div style="position:absolute;left:50.00px;top:263.74px" class="cls_029"><span class="cls_029">Hospital of Schleswig-Holstein Campus Lübeck, Lübeck, Germany, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Cen-</span></div>
<div style="position:absolute;left:50.00px;top:273.34px" class="cls_029"><span class="cls_029">tral Dermatology and Saint Louis University School of Medicine, St. Louis,</span></div>
<div style="position:absolute;left:306.64px;top:271.95px" class="cls_033"><span class="cls_033">P060</span></div>
<div style="position:absolute;left:50.00px;top:282.94px" class="cls_029"><span class="cls_029">MO, USA, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Centre de Recherche Dermatologique du Québec Métropolitain,</span></div>
<div style="position:absolute;left:306.64px;top:283.48px" class="cls_025"><span class="cls_025">DISCONTINUATION OF BIOLOGIC THERAPIES IN</span></div>
<div style="position:absolute;left:50.00px;top:292.54px" class="cls_029"><span class="cls_029">Québec, Canada, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Demira, Inc., Menlo Park, CA, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">UCB Pharma, Raleigh,</span></div>
<div style="position:absolute;left:306.64px;top:294.51px" class="cls_025"><span class="cls_025">CHRONIC PLAQUE PSORIASIS: A RETROSPECTIVE</span></div>
<div style="position:absolute;left:50.00px;top:302.14px" class="cls_029"><span class="cls_029">NC, USA, </span><span class="cls_028"><sup>8</sup></span><span class="cls_029">UCB Pharma, Brussels, Belgium, </span><span class="cls_028"><sup>9</sup></span><span class="cls_029">Department of Dermatology,</span></div>
<div style="position:absolute;left:306.64px;top:305.55px" class="cls_025"><span class="cls_025">COHORT</span></div>
<div style="position:absolute;left:50.00px;top:311.74px" class="cls_029"><span class="cls_029">New York Medical College at Metropolitan Hospital, New York, NY, USA</span></div>
<div style="position:absolute;left:306.64px;top:315.58px" class="cls_051"><span class="cls_051">Susanne Gulliver</span><span class="cls_026">, Wayne Gulliver, Shane Randell</span></div>
<div style="position:absolute;left:50.00px;top:322.61px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">The Fc-free, PEGylated, anti-tumor necrosis factor</span></div>
<div style="position:absolute;left:306.64px;top:326.30px" class="cls_029"><span class="cls_029">NewLab Clinical Research</span></div>
<div style="position:absolute;left:50.00px;top:332.60px" class="cls_031"><span class="cls_031">certolizumab pegol (CZP) has shown efficacy in chronic plaque</span></div>
<div style="position:absolute;left:306.64px;top:337.30px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is a chronic debilitating auto immune</span></div>
<div style="position:absolute;left:50.00px;top:342.60px" class="cls_031"><span class="cls_031">psoriasis (PSO). [1,2]</span></div>
<div style="position:absolute;left:306.64px;top:347.43px" class="cls_031"><span class="cls_031">disease which manifests on the skin through red scaly plaques.</span></div>
<div style="position:absolute;left:50.00px;top:352.60px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To assess the efficacy of CZP to 48 weeks across</span></div>
<div style="position:absolute;left:306.64px;top:357.56px" class="cls_031"><span class="cls_031">Biologic treatment have been very successful in controlling mode-</span></div>
<div style="position:absolute;left:49.99px;top:362.60px" class="cls_031"><span class="cls_031">patient (pt) demographic and baseline disease characteristic sub-</span></div>
<div style="position:absolute;left:306.64px;top:367.69px" class="cls_031"><span class="cls_031">rate to severe psoriasis, however they are quite expensive and not</span></div>
<div style="position:absolute;left:50.00px;top:372.61px" class="cls_031"><span class="cls_031">groups in phase 3 trials.</span></div>
<div style="position:absolute;left:306.64px;top:377.82px" class="cls_031"><span class="cls_031">all treatments work for all patients. This study looks to understand</span></div>
<div style="position:absolute;left:50.00px;top:382.60px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">In this prespecified, pooled subgroup analysis, data</span></div>
<div style="position:absolute;left:306.64px;top:387.96px" class="cls_031"><span class="cls_031">the demographics, treatment patterns, treatment failures, number</span></div>
<div style="position:absolute;left:50.00px;top:392.60px" class="cls_031"><span class="cls_031">were pooled from CIMPASI-1 (NCT02326298) and CIMPASI-2</span></div>
<div style="position:absolute;left:306.64px;top:398.09px" class="cls_031"><span class="cls_031">of therapies and time to switching. A cohort of 459 patients treated</span></div>
<div style="position:absolute;left:50.00px;top:402.60px" class="cls_031"><span class="cls_031">(NCT02326272), ongoing phase 3 trials in adults with moderate</span></div>
<div style="position:absolute;left:306.64px;top:408.22px" class="cls_031"><span class="cls_031">with biologics was examined</span></div>
<div style="position:absolute;left:50.00px;top:412.60px" class="cls_031"><span class="cls_031">to severe PSO ≥6 months (psoriasis area and severity index [PASI]</span></div>
<div style="position:absolute;left:306.64px;top:418.36px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">1. To understand the demographics, treatment patterns,</span></div>
<div style="position:absolute;left:49.99px;top:422.60px" class="cls_031"><span class="cls_031">≥12, affected body surface area [BSA] ≥10%, physician’s global</span></div>
<div style="position:absolute;left:306.64px;top:428.49px" class="cls_031"><span class="cls_031">treatment failures, number of therapies and time to switching.</span></div>
<div style="position:absolute;left:49.99px;top:432.60px" class="cls_031"><span class="cls_031">assessment [PGA] ≥3/5). Pts were randomized 2:2:1 to CZP 400</span></div>
<div style="position:absolute;left:306.64px;top:438.63px" class="cls_031"><span class="cls_031">2. To decipher patterns in biologic use in order to prescribe more</span></div>
<div style="position:absolute;left:49.99px;top:442.60px" class="cls_031"><span class="cls_031">mg every 2 weeks (Q2W), 200 mg Q2W (400 mg loading dose at</span></div>
<div style="position:absolute;left:306.64px;top:448.76px" class="cls_031"><span class="cls_031">efficiently and optimize health care resources.</span></div>
<div style="position:absolute;left:49.99px;top:452.60px" class="cls_031"><span class="cls_031">Weeks 0/2/4), or placebo (PBO). At Week 16, PASI 50 responders</span></div>
<div style="position:absolute;left:306.64px;top:458.89px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">This was a retrospective cohort of all patients exposed</span></div>
<div style="position:absolute;left:49.99px;top:462.60px" class="cls_031"><span class="cls_031">receiving CZP continued the same dose through the maintenance</span></div>
<div style="position:absolute;left:306.64px;top:469.03px" class="cls_031"><span class="cls_031">to biologic or PD-4 inhibitors within a single Dermatologist’s</span></div>
<div style="position:absolute;left:49.99px;top:472.60px" class="cls_031"><span class="cls_031">period to Week 48. PASI 50 nonresponders at Weeks 32/40/48 were</span></div>
<div style="position:absolute;left:306.64px;top:479.16px" class="cls_031"><span class="cls_031">private practice. A simple summary of patient demographics</span></div>
<div style="position:absolute;left:49.99px;top:482.59px" class="cls_031"><span class="cls_031">classed as nonresponders at subsequent time points. Subgroups</span></div>
<div style="position:absolute;left:306.64px;top:489.30px" class="cls_031"><span class="cls_031">including gender, treatment patterns, reasons and length of time</span></div>
<div style="position:absolute;left:49.99px;top:492.59px" class="cls_031"><span class="cls_031">included age, weight, body mass index (BMI), baseline PASI, BSA</span></div>
<div style="position:absolute;left:306.64px;top:499.43px" class="cls_031"><span class="cls_031">before discontinuation was compiled. Reasons for discontinuation</span></div>
<div style="position:absolute;left:49.99px;top:502.59px" class="cls_031"><span class="cls_031">and PSO duration. PASI 75, PGA 0/1, and PASI 90 responder rates</span></div>
<div style="position:absolute;left:306.64px;top:509.56px" class="cls_031"><span class="cls_031">included lack of efficacy (primary or secondary), adverse events</span></div>
<div style="position:absolute;left:49.99px;top:512.59px" class="cls_031"><span class="cls_031">were summarized at Week 16 using a logistic regression model</span></div>
<div style="position:absolute;left:306.63px;top:519.70px" class="cls_031"><span class="cls_031">(AEs), patient choice or other.</span></div>
<div style="position:absolute;left:49.99px;top:522.59px" class="cls_031"><span class="cls_031">with multiple imputation (overall population) and descriptively at</span></div>
<div style="position:absolute;left:306.63px;top:529.83px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">There were 189 females (41.2%) and 270 males (58.8%)</span></div>
<div style="position:absolute;left:49.99px;top:532.59px" class="cls_031"><span class="cls_031">Week 48 based on nonresponse imputation (subgroups).</span></div>
<div style="position:absolute;left:49.99px;top:542.59px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">175/186/100 pts received CZP 400 mg Q2W/CZP 200</span></div>
<div style="position:absolute;left:306.63px;top:539.97px" class="cls_031"><span class="cls_031">with 914 incidences of biologic or PD-4 inhibitor treatment. The</span></div>
<div style="position:absolute;left:49.99px;top:552.59px" class="cls_031"><span class="cls_031">mg Q2W/PBO. Efficacy was observed across all subgroups for</span></div>
<div style="position:absolute;left:306.63px;top:550.04px" class="cls_031"><span class="cls_031">mean age was 53.48</span><span class="cls_035">±</span><span class="cls_031">12.6 and the mean treatment duration was</span></div>
<div style="position:absolute;left:49.99px;top:562.59px" class="cls_031"><span class="cls_031">both CZP 400 mg Q2W and 200 mg Q2W, with higher Week 48</span></div>
<div style="position:absolute;left:306.64px;top:560.17px" class="cls_031"><span class="cls_031">37.3 months</span><span class="cls_035">±</span><span class="cls_031">39.5 (approx. 3000 treatment years).</span></div>
<div style="position:absolute;left:49.99px;top:572.59px" class="cls_031"><span class="cls_031">PASI 75 responder rates in CZP 400 mg Q2W vs CZP 200 mg</span></div>
<div style="position:absolute;left:306.63px;top:570.30px" class="cls_031"><span class="cls_031">39.2% of patients (180) remained on the first biologic (range 0.5</span></div>
<div style="position:absolute;left:49.99px;top:582.58px" class="cls_031"><span class="cls_031">Q2W treated pts (Table). Similar trends were observed for PGA</span></div>
<div style="position:absolute;left:306.62px;top:580.44px" class="cls_031"><span class="cls_031">to 15 years). The mean number of therapies was 1.99 (range 1-8),</span></div>
<div style="position:absolute;left:49.99px;top:592.58px" class="cls_031"><span class="cls_031">0/1 and PASI 90.</span></div>
<div style="position:absolute;left:306.62px;top:590.57px" class="cls_031"><span class="cls_031">but increased to 2.63 if patients were not biologic naive.</span></div>
<div style="position:absolute;left:49.99px;top:602.58px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Treatment with either dose of CZP resulted in</span></div>
<div style="position:absolute;left:306.62px;top:600.71px" class="cls_031"><span class="cls_031">More male patients stayed on their first biologic (74.2% in</span></div>
<div style="position:absolute;left:49.99px;top:612.58px" class="cls_031"><span class="cls_031">clinically meaningful improvements in signs and symptoms of</span></div>
<div style="position:absolute;left:306.62px;top:610.84px" class="cls_031"><span class="cls_031">ustekinumab-treated patients and in the Apremilast group 32.3%).</span></div>
<div style="position:absolute;left:49.99px;top:622.58px" class="cls_031"><span class="cls_031">PSO at Week 16 maintained at Week 48. Similar to the overall</span></div>
<div style="position:absolute;left:306.62px;top:620.97px" class="cls_030"><span class="cls_030">Reasons for discontinuation:</span><span class="cls_031"> AEs (14.69%) and non-response</span></div>
<div style="position:absolute;left:49.99px;top:632.58px" class="cls_031"><span class="cls_031">population, PASI 75, PGA 0/1, and PASI 90 responder rates were</span></div>
<div style="position:absolute;left:306.62px;top:631.11px" class="cls_031"><span class="cls_031">(30%); highest rates were in etanercept (78.0%), and infliximab</span></div>
<div style="position:absolute;left:49.99px;top:642.58px" class="cls_031"><span class="cls_031">greater for CZP 400 mg Q2W versus 200 mg Q2W across most</span></div>
<div style="position:absolute;left:306.61px;top:641.24px" class="cls_031"><span class="cls_031">(75.4%); lowest rates was in etanercept 12.8% (14 of 109 patients),</span></div>
<div style="position:absolute;left:49.99px;top:652.58px" class="cls_031"><span class="cls_031">subgroups at Week 48.</span></div>
<div style="position:absolute;left:306.61px;top:651.38px" class="cls_031"><span class="cls_031">highest in infliximab 34.9%, (44 of 126 patients.</span></div>
<div style="position:absolute;left:49.99px;top:662.58px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:306.61px;top:661.51px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">The most common cause for discontinuation of</span></div>
<div style="position:absolute;left:50.00px;top:672.62px" class="cls_032"><span class="cls_032">1. Reich K (2017). Skin,1;s23; 2. Augustin M (2017). Skin,1;s24</span></div>
<div style="position:absolute;left:306.61px;top:671.64px" class="cls_031"><span class="cls_031">biologics was an AE and non-responsiveness (45.69%). Women</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:22484px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background30.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">28</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">were more likely to discontinue therapy than men. Males were</span></div>
<div style="position:absolute;left:306.64px;top:51.40px" class="cls_031"><span class="cls_031">for TIL 100 mg, TIL 200 mg, ETN, and PBO, respectively. In all,</span></div>
<div style="position:absolute;left:50.00px;top:61.42px" class="cls_031"><span class="cls_031">more likely to remain on the first biologic therapy. Adalimumab</span></div>
<div style="position:absolute;left:306.64px;top:61.40px" class="cls_031"><span class="cls_031">33 severe infections were identified (respiratory: TIL 100 mg, 4</span></div>
<div style="position:absolute;left:50.00px;top:71.44px" class="cls_031"><span class="cls_031">and ustekinumab had lowest rates of discontinuation. Etanercept,</span></div>
<div style="position:absolute;left:306.64px;top:71.39px" class="cls_031"><span class="cls_031">events; TIL 200 mg, 2 events; ETN and PBO, 0 events; skin: TIL</span></div>
<div style="position:absolute;left:50.00px;top:81.46px" class="cls_031"><span class="cls_031">infliximab and apremilast had the highest.</span></div>
<div style="position:absolute;left:306.64px;top:81.39px" class="cls_031"><span class="cls_031">100 mg, 3 events; TIL 200 mg, 6 events; ETN, 2 events; PBO,</span></div>
<div style="position:absolute;left:50.00px;top:91.47px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:306.64px;top:91.39px" class="cls_031"><span class="cls_031">3 events; gastrointestinal: TIL 100 mg, 4 events; TIL 200 mg, 5</span></div>
<div style="position:absolute;left:50.00px;top:101.52px" class="cls_032"><span class="cls_032">1. M. Esposito, et al. Survival rate of antitumour necrosis factor α tre-</span></div>
<div style="position:absolute;left:306.64px;top:101.39px" class="cls_031"><span class="cls_031">events; ETN and PBO, 0 events; urinary tract: TIL 200 mg, 1 event;</span></div>
<div style="position:absolute;left:50.00px;top:110.54px" class="cls_032"><span class="cls_032">atments for psoriasis in routine dermatological practice: a multicentre</span></div>
<div style="position:absolute;left:306.64px;top:111.39px" class="cls_031"><span class="cls_031">ETN, 1 event; TIL 100 mg and PBO, 0 events). One pt had bone</span></div>
<div style="position:absolute;left:50.00px;top:119.55px" class="cls_032"><span class="cls_032">observational study. Br J Dermatol (2013). [Online] </span><A HREF="http://onlinelibrary./">http://onlinelibrary.</A> </div>
<div style="position:absolute;left:306.64px;top:121.39px" class="cls_031"><span class="cls_031">tuberculosis (TIL 200 mg; original purified protein derivative test</span></div>
<div style="position:absolute;left:50.00px;top:128.57px" class="cls_032"><span class="cls_032">wiley.com/doi/10.1111/bjd.12422/full.</span></div>
<div style="position:absolute;left:306.64px;top:131.39px" class="cls_031"><span class="cls_031">was negative); 1 sepsis event (TIL 200 mg) occurred months after</span></div>
<div style="position:absolute;left:50.00px;top:137.58px" class="cls_032"><span class="cls_032">2. R. Gniadecki et al. Comparison of long-term drug survival and safety</span></div>
<div style="position:absolute;left:306.64px;top:141.39px" class="cls_031"><span class="cls_031">ending TIL treatment.</span></div>
<div style="position:absolute;left:50.00px;top:146.60px" class="cls_032"><span class="cls_032">of biologic agents in patients with psoriasis vulgaris. Br J Dermatology</span></div>
<div style="position:absolute;left:306.64px;top:151.39px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Infection rates with TIL treatment were low and</span></div>
<div style="position:absolute;left:50.00px;top:155.62px" class="cls_032"><span class="cls_032">(2014). [Online] </span><A HREF="http://onlinelibrary.wiley.com/doi/10.1111/bjd.13343/full/">http://onlinelibrary.wiley.com/doi/10.1111/bjd.13343/full</A> </div>
<div style="position:absolute;left:50.00px;top:164.63px" class="cls_032"><span class="cls_032">3. A.A. Levin, A.B. Gottlieb, S.C. Au. A comparison of drug failure rates</span></div>
<div style="position:absolute;left:306.64px;top:161.39px" class="cls_031"><span class="cls_031">comparable to PBO and ETN during the PBO-controlled period.</span></div>
<div style="position:absolute;left:50.00px;top:173.65px" class="cls_032"><span class="cls_032">and reasons for discontinuation in biologics versus systemic therapies.</span></div>
<div style="position:absolute;left:306.64px;top:171.38px" class="cls_031"><span class="cls_031">By W52/64, exposure-adjusted rates remained low for all groups.</span></div>
<div style="position:absolute;left:50.00px;top:182.66px" class="cls_032"><span class="cls_032">Journal of Drugs in Dermatology (2014) [Online] </span><A HREF="http://europepmc.org/">http://europepmc.org/</A> </div>
<div style="position:absolute;left:306.64px;top:181.38px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:50.00px;top:191.68px" class="cls_032"><span class="cls_032">abstract/med/25007369</span></div>
<div style="position:absolute;left:306.64px;top:191.42px" class="cls_032"><span class="cls_032">1. Papp K, et al. Br J Dermatol. 2015;173:930-939. 2. Reich K, et al.</span></div>
<div style="position:absolute;left:50.00px;top:200.70px" class="cls_032"><span class="cls_032">4. R.B. Warren, et al. Differential Drug Survival of Biologic therapies for</span></div>
<div style="position:absolute;left:306.64px;top:200.42px" class="cls_032"><span class="cls_032">Lancet. 2017;390:276-288.</span></div>
<div style="position:absolute;left:50.00px;top:209.71px" class="cls_032"><span class="cls_032">the treatment of psoriasis a prospective Observational cohort Study from</span></div>
<div style="position:absolute;left:306.64px;top:209.42px" class="cls_043"><span class="cls_043">Acknowledgements: </span><span class="cls_032">The studies were funded by Merck Sharp & Dohme,</span></div>
<div style="position:absolute;left:50.00px;top:218.73px" class="cls_032"><span class="cls_032">the British association of Dermatologists Biologic interventions register</span></div>
<div style="position:absolute;left:306.64px;top:218.42px" class="cls_032"><span class="cls_032">Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.</span></div>
<div style="position:absolute;left:50.00px;top:227.74px" class="cls_032"><span class="cls_032">(BADBIR). J Invest Dermatol (2015). [Online] </span><A HREF="http://www.sciencedirect./">http://www.sciencedirect.</A> </div>
<div style="position:absolute;left:306.64px;top:227.42px" class="cls_032"><span class="cls_032">Analyses were presented at the American Academy of Dermatology Annual</span></div>
<div style="position:absolute;left:50.00px;top:236.76px" class="cls_032"><span class="cls_032">com/science/article/pii/S0022202X15418494</span></div>
<div style="position:absolute;left:306.64px;top:236.42px" class="cls_032"><span class="cls_032">Meeting, February 16-20, 2018, San Diego, CA, USA.</span></div>
<div style="position:absolute;left:50.00px;top:245.78px" class="cls_032"><span class="cls_032">5. J. Zweegers, et al. Body mass index predicts discontinuation due to inef-</span></div>
<div style="position:absolute;left:50.00px;top:254.85px" class="cls_032"><span class="cls_032">fectiveness and female sex predicts discontinuation due to side-effects in</span></div>
<div style="position:absolute;left:306.64px;top:255.04px" class="cls_033"><span class="cls_033">P062</span></div>
<div style="position:absolute;left:50.00px;top:263.86px" class="cls_032"><span class="cls_032">patients with psoriasis treated with adalimumab, etanercept or ustekinumab</span></div>
<div style="position:absolute;left:306.64px;top:266.44px" class="cls_025"><span class="cls_025">EFFICACY AND SAFETY OF RISANKIZUMAB:</span></div>
<div style="position:absolute;left:50.00px;top:272.88px" class="cls_032"><span class="cls_032">in daily practice: a prospective, comparative, long-term drug-survival study</span></div>
<div style="position:absolute;left:306.64px;top:277.34px" class="cls_025"><span class="cls_025">RESULTS FROM TWO DOUBLE-BLIND, PLACEBO- AND</span></div>
<div style="position:absolute;left:50.00px;top:281.90px" class="cls_032"><span class="cls_032">from the BioCAPTURE registry. Br J Dermatol (2016) 175: 340-347.</span></div>
<div style="position:absolute;left:50.00px;top:290.91px" class="cls_032"><span class="cls_032">doi:10.1111/bjd.14552.</span></div>
<div style="position:absolute;left:306.64px;top:288.24px" class="cls_025"><span class="cls_025">USTEKINUMAB-CONTROLLED, PHASE 3 TRIALS IN</span></div>
<div style="position:absolute;left:306.64px;top:299.14px" class="cls_025"><span class="cls_025">MODERATE-TO-SEVERE PLAQUE PSORIASIS</span></div>
<div style="position:absolute;left:50.00px;top:310.56px" class="cls_033"><span class="cls_033">P061</span></div>
<div style="position:absolute;left:306.64px;top:309.04px" class="cls_026"><span class="cls_026">Kenneth B. Gordon</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Bruce Strober</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Mark Lebwohl</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Matthias Au-</span></div>
<div style="position:absolute;left:306.64px;top:318.94px" class="cls_026"><span class="cls_026">gustin</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Andrew Blauvelt</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Yves Poulin</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Kim A. Papp</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Howard So-</span></div>
<div style="position:absolute;left:50.00px;top:321.98px" class="cls_025"><span class="cls_025">INCIDENCE OF INFECTIONS IN CLINICAL TRIALS</span></div>
<div style="position:absolute;left:306.64px;top:328.84px" class="cls_026"><span class="cls_026">fen</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, Lluis Puig</span><span class="cls_027"><sup>9</sup></span><span class="cls_026">, Peter Foley</span><span class="cls_027"><sup>10</sup></span><span class="cls_026">, Mamitaro Ohtsuki</span><span class="cls_027"><sup>11</sup></span><span class="cls_026">, Mary Flack</span><span class="cls_027"><sup>12</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:50.00px;top:332.90px" class="cls_025"><span class="cls_025">OF TILDRAKIZUMAB FOR MODERATE TO SEVERE</span></div>
<div style="position:absolute;left:306.64px;top:338.74px" class="cls_026"><span class="cls_026">Ziqian Geng</span><span class="cls_027"><sup>13</sup></span><span class="cls_026">, Yihua Gu</span><span class="cls_027"><sup>13</sup></span><span class="cls_026">, Joaquin M. Valdes</span><span class="cls_027"><sup>13</sup></span><span class="cls_026">, Elizabeth H.Z.</span></div>
<div style="position:absolute;left:50.00px;top:343.82px" class="cls_025"><span class="cls_025">PLAQUE PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:348.64px" class="cls_026"><span class="cls_026">Thompson</span><span class="cls_027"><sup>14</sup></span><span class="cls_026">, Hervé Bachelez</span><span class="cls_027"><sup>15</sup></span></div>
<div style="position:absolute;left:50.00px;top:353.73px" class="cls_026"><span class="cls_026">Jeffrey Crowley</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Craig Leonardi</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Sheila Sturgill-Koszycki</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">,</span><span class="cls_051"> Alan</span></div>
<div style="position:absolute;left:306.64px;top:359.24px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Medical College of Wisconsin, Milwaukee, Wisconsin, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">University of Con-</span></div>
<div style="position:absolute;left:49.99px;top:363.66px" class="cls_051"><span class="cls_051">Menter</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Alan Mendelsohn</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Qing Li</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Nicole Cichanowitz</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Car-</span></div>
<div style="position:absolute;left:306.64px;top:368.84px" class="cls_029"><span class="cls_029">necticut Health Center and Probity Medical Research, Farmington, CT,</span></div>
<div style="position:absolute;left:50.00px;top:373.58px" class="cls_026"><span class="cls_026">men La Rosa</span><span class="cls_027"><sup>5</sup></span></div>
<div style="position:absolute;left:306.64px;top:378.44px" class="cls_028"><span class="cls_028"><sup>3</sup></span><span class="cls_029">Icahn School of Medicine at Mount Sinai, New York, NY, USA, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">University</span></div>
<div style="position:absolute;left:50.00px;top:384.20px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Bakersfield Dermatology, Bakersfield, CA, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Central Dermatology, St Lou-</span></div>
<div style="position:absolute;left:306.64px;top:388.04px" class="cls_029"><span class="cls_029">Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Oregon</span></div>
<div style="position:absolute;left:50.00px;top:393.82px" class="cls_029"><span class="cls_029">is, MO, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Sun Pharmaceutical Industries, Inc., Princeton, NJ, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Division of</span></div>
<div style="position:absolute;left:306.64px;top:397.64px" class="cls_029"><span class="cls_029">Medical Research Center, Portland, OR, USA, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Centre Dermatologique du</span></div>
<div style="position:absolute;left:50.00px;top:403.43px" class="cls_029"><span class="cls_029">Dermatology, Baylor Scott & White and Texas A&M College of Medicine,</span></div>
<div style="position:absolute;left:306.64px;top:407.24px" class="cls_029"><span class="cls_029">Québec Métropolitain, Québec, QC, Canada, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">K Papp Clinical Research</span></div>
<div style="position:absolute;left:50.00px;top:413.05px" class="cls_029"><span class="cls_029">Dallas, TX, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Merck & Co., Inc., Kenilworth, NJ, USA</span></div>
<div style="position:absolute;left:306.64px;top:416.84px" class="cls_029"><span class="cls_029">and Probity Medical Research, Waterloo, ON, Canada, </span><span class="cls_028"><sup>8</sup></span><span class="cls_029">University of Cali-</span></div>
<div style="position:absolute;left:50.00px;top:423.94px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Risk of infections is a concern with cytokine inhi-</span></div>
<div style="position:absolute;left:306.63px;top:426.44px" class="cls_029"><span class="cls_029">fornia, Los Angeles, School of Medicine, Los Angeles, CA, USA, </span><span class="cls_028"><sup>9</sup></span><span class="cls_029">Hospital</span></div>
<div style="position:absolute;left:50.00px;top:433.96px" class="cls_031"><span class="cls_031">bitor treatments.</span></div>
<div style="position:absolute;left:306.64px;top:436.04px" class="cls_029"><span class="cls_029">de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Bar-</span></div>
<div style="position:absolute;left:50.00px;top:443.98px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">This analysis assessed infections during phase 2 and</span></div>
<div style="position:absolute;left:306.64px;top:445.64px" class="cls_029"><span class="cls_029">celona, Spain, </span><span class="cls_028"><sup>10</sup></span><span class="cls_029">The University of Melbourne, Parkville, Skin & Cancer</span></div>
<div style="position:absolute;left:50.00px;top:454.00px" class="cls_031"><span class="cls_031">3 trials of tildrakizumab (TIL), a high-affinity, humanized, IgG1κ</span></div>
<div style="position:absolute;left:306.64px;top:455.24px" class="cls_029"><span class="cls_029">Foundation Inc, Carlton, and Probity Medical Research, Carlton, VIC,</span></div>
<div style="position:absolute;left:50.00px;top:464.01px" class="cls_031"><span class="cls_031">monoclonal antibody against IL-23p19 under development for</span></div>
<div style="position:absolute;left:306.64px;top:464.84px" class="cls_029"><span class="cls_029">Australia, </span><span class="cls_028"><sup>11</sup></span><span class="cls_029">Jichi Medical University, Shimotsuke, Japan, </span><span class="cls_028"><sup>12</sup></span><span class="cls_029">Boehringer Ing-</span></div>
<div style="position:absolute;left:50.00px;top:474.03px" class="cls_031"><span class="cls_031">moderate to severe chronic plaque psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:474.44px" class="cls_029"><span class="cls_029">elheim Pharmaceuticals Inc., Ridgefield, CT, </span><span class="cls_028"><sup>13</sup></span><span class="cls_029">AbbVie Inc., North Chicago,</span></div>
<div style="position:absolute;left:50.00px;top:484.05px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Patients (Pts) were randomized in P05495 (phase 2;</span></div>
<div style="position:absolute;left:306.64px;top:484.04px" class="cls_029"><span class="cls_029">IL, USA, </span><span class="cls_028"><sup>14</sup></span><span class="cls_029">AbbVie Inc., Redwood City, CA, USA, </span><span class="cls_028"><sup>15</sup></span><span class="cls_029">Saint-Louis Hospital,</span></div>
<div style="position:absolute;left:50.00px;top:494.06px" class="cls_031"><span class="cls_031">NCT01225731), reSURFACE 1 (phase 3; NCT01722331), and</span></div>
<div style="position:absolute;left:306.64px;top:493.64px" class="cls_029"><span class="cls_029">Sorbonne Paris Cité University Paris Diderot, Paris, France</span></div>
<div style="position:absolute;left:50.00px;top:504.08px" class="cls_031"><span class="cls_031">reSURFACE 2 (phase 3; NCT01729754) [1,2]. In Part 1 (Week</span></div>
<div style="position:absolute;left:306.64px;top:504.51px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Interleukin-23 is a key cytokine in the development</span></div>
<div style="position:absolute;left:50.00px;top:514.10px" class="cls_031"><span class="cls_031">([W]1-16) of P05495, pts received subcutaneous (SC) TIL 5,</span></div>
<div style="position:absolute;left:306.64px;top:514.50px" class="cls_031"><span class="cls_031">and maintenance of psoriatic lesions. Risankizumab is a humani-</span></div>
<div style="position:absolute;left:50.00px;top:524.12px" class="cls_031"><span class="cls_031">25, 100, or 200 mg or placebo (PBO) at W0 and W4 and were</span></div>
<div style="position:absolute;left:306.64px;top:524.51px" class="cls_031"><span class="cls_031">zed IgG1 monoclonal antibody that binds to IL-23’s p19 subunit,</span></div>
<div style="position:absolute;left:50.00px;top:534.13px" class="cls_031"><span class="cls_031">rerandomized to various TIL doses in Part 2 (W16-52). In Part 1</span></div>
<div style="position:absolute;left:306.64px;top:534.50px" class="cls_031"><span class="cls_031">selectively inhibiting this critical cytokine and its role in psoriatic</span></div>
<div style="position:absolute;left:50.00px;top:544.15px" class="cls_031"><span class="cls_031">(W1-12) of reSURFACE 1 and 2, pts received SC TIL 200 mg, TIL</span></div>
<div style="position:absolute;left:306.64px;top:544.50px" class="cls_031"><span class="cls_031">inflammation.</span></div>
<div style="position:absolute;left:50.00px;top:554.17px" class="cls_031"><span class="cls_031">100 mg, or PBO at W0 and W4. Pts were rerandomized in Part 2</span></div>
<div style="position:absolute;left:306.64px;top:554.50px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">UltIMMa-1 (</span><span class="cls_030">n = </span><span class="cls_031">506) and UltIMMa-2 (</span><span class="cls_030">n = </span><span class="cls_031">491) were</span></div>
<div style="position:absolute;left:50.00px;top:564.18px" class="cls_031"><span class="cls_031">(W12-28) and Part 3 (W28-64 or W28-52 in reSURFACE 1 and</span></div>
<div style="position:absolute;left:306.64px;top:564.50px" class="cls_031"><span class="cls_031">replicate, randomized, double-blind, placebo- and active compara-</span></div>
<div style="position:absolute;left:50.00px;top:574.20px" class="cls_031"><span class="cls_031">2, respectively). Etanercept (ETN) 50 mg was an active control in</span></div>
<div style="position:absolute;left:306.64px;top:574.51px" class="cls_031"><span class="cls_031">tor-controlled studies that evaluated efficacy and safety of risanki-</span></div>
<div style="position:absolute;left:50.00px;top:584.22px" class="cls_031"><span class="cls_031">Parts 1-2 of reSURFACE 2. Treatment-emergent adverse event</span></div>
<div style="position:absolute;left:306.64px;top:584.51px" class="cls_031"><span class="cls_031">zumab in adult patients with moderate-to-severe plaque psoriasis.</span></div>
<div style="position:absolute;left:50.00px;top:594.23px" class="cls_031"><span class="cls_031">data pools (</span><span class="cls_030">n = </span><span class="cls_031">2081) for the PBO-controlled and full trial periods</span></div>
<div style="position:absolute;left:306.64px;top:594.50px" class="cls_031"><span class="cls_031">Patients were stratified by weight and prior TNFi-exposure and</span></div>
<div style="position:absolute;left:50.00px;top:604.25px" class="cls_031"><span class="cls_031">(52 weeks for P05495/reSURFACE 2; 64 weeks for reSURFACE</span></div>
<div style="position:absolute;left:306.65px;top:604.50px" class="cls_031"><span class="cls_031">randomized 3:1:1 to receive 150 mg risankizumab, 45/90 mg us-</span></div>
<div style="position:absolute;left:50.00px;top:614.27px" class="cls_031"><span class="cls_031">1) were analyzed. Severe infections met the regulatory definition</span></div>
<div style="position:absolute;left:306.64px;top:614.51px" class="cls_031"><span class="cls_031">tekinumab (weight-based per label) or matching placebo. Patients</span></div>
<div style="position:absolute;left:49.99px;top:624.29px" class="cls_031"><span class="cls_031">of a serious adverse event or required intravenous antibiotics.</span></div>
<div style="position:absolute;left:306.64px;top:624.50px" class="cls_031"><span class="cls_031">were dosed at weeks 0, 4, 16, 28, and 40, with placebo crossover</span></div>
<div style="position:absolute;left:49.99px;top:634.30px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">In the PBO-controlled period, incidences of infections</span></div>
<div style="position:absolute;left:306.64px;top:634.50px" class="cls_031"><span class="cls_031">to risankizumab at week 16. Co-primary endpoints were PASI 90</span></div>
<div style="position:absolute;left:49.99px;top:644.32px" class="cls_031"><span class="cls_031">were comparable for TIL 100 mg and 200 mg (23% and 22%,</span></div>
<div style="position:absolute;left:306.64px;top:644.50px" class="cls_031"><span class="cls_031">and sPGA0/1 at week 16 versus placebo with comparisons between</span></div>
<div style="position:absolute;left:49.99px;top:654.34px" class="cls_031"><span class="cls_031">respectively) and PBO (23%); all were comparable with ETN</span></div>
<div style="position:absolute;left:306.64px;top:654.50px" class="cls_031"><span class="cls_031">risankizumab and ustekinumab as ranked secondary endpoints.</span></div>
<div style="position:absolute;left:49.99px;top:664.35px" class="cls_031"><span class="cls_031">(24%). Incidences of severe infections were low for all treatment</span></div>
<div style="position:absolute;left:306.64px;top:664.50px" class="cls_031"><span class="cls_031">Missing data were imputed as non-response.</span></div>
<div style="position:absolute;left:49.99px;top:674.37px" class="cls_031"><span class="cls_031">groups (range, 0.0%-0.3%; TIL P≥0.6 vs PBO). In the full trial pe-</span></div>
<div style="position:absolute;left:306.64px;top:674.50px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">All primary and ranked secondary endpoints were met</span></div>
<div style="position:absolute;left:50.00px;top:684.45px" class="cls_031"><span class="cls_031">riod, exposure-adjusted rates (pts/100 pt-years) for infections with</span></div>
<div style="position:absolute;left:306.64px;top:684.50px" class="cls_031"><span class="cls_031">for both trials (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001). At week 16 of UltIMMa-1&2 trials,</span></div>
<div style="position:absolute;left:50.00px;top:694.46px" class="cls_031"><span class="cls_031">TIL 100 mg and 200 mg (48.9 and 52.6, respectively) were lower</span></div>
<div style="position:absolute;left:306.64px;top:694.50px" class="cls_031"><span class="cls_031">risankizumab-treated patients achieved significantly higher PASI</span></div>
<div style="position:absolute;left:50.00px;top:704.48px" class="cls_031"><span class="cls_031">than with PBO and ETN (79.5 and 86.0, respectively). Exposure-</span></div>
<div style="position:absolute;left:306.64px;top:704.50px" class="cls_031"><span class="cls_031">90 (75.3%/74.8%) and sPGA0/1 (87.8%/83.7%) response rates</span></div>
<div style="position:absolute;left:50.00px;top:714.50px" class="cls_031"><span class="cls_031">adjusted rates for severe infections were 1.10, 1.61, 1.96, and 0.91</span></div>
<div style="position:absolute;left:306.64px;top:714.50px" class="cls_031"><span class="cls_031">versus placebo- (4.9%/2.0%; 7.8%/5.1%) or ustekinumab-treated</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:23287px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background31.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">29</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">patients (42.0%/47.5%; 63.0%/61.6%). At week 52, risankizumab-</span></div>
<div style="position:absolute;left:306.64px;top:51.55px" class="cls_026"><span class="cls_026">Jeffrey Crowley</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Kim A Papp</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">,</span><span class="cls_051"> Chih-ho Hong</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Jeff Parno</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Alan</span></div>
<div style="position:absolute;left:50.00px;top:61.52px" class="cls_031"><span class="cls_031">treated patients achieved significantly higher response rates versus</span></div>
<div style="position:absolute;left:306.63px;top:61.45px" class="cls_026"><span class="cls_026">M Mendelsohn</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Qing Li</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Nicole Cichanowitz</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Carmen La Rosa</span><span class="cls_027"><sup>5</sup></span></div>
<div style="position:absolute;left:49.99px;top:71.64px" class="cls_031"><span class="cls_031">ustekinumab. In both trials, treatment-emergent adverse event</span></div>
<div style="position:absolute;left:306.64px;top:72.05px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Bakersfield Dermatology, Bakersfield, CA, USA, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Probity Medical Re-</span></div>
<div style="position:absolute;left:49.99px;top:81.75px" class="cls_031"><span class="cls_031">(TEAE) rates were comparable across treatment groups throughout</span></div>
<div style="position:absolute;left:306.64px;top:81.65px" class="cls_029"><span class="cls_029">search, Waterloo, ON, Canada, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">University of British Columbia, Depart-</span></div>
<div style="position:absolute;left:49.99px;top:91.87px" class="cls_031"><span class="cls_031">the study duration. The most frequently reported TEAE was upper</span></div>
<div style="position:absolute;left:306.64px;top:91.25px" class="cls_029"><span class="cls_029">ment of Dermatology and Skin Science and Probity Medical Research,</span></div>
<div style="position:absolute;left:306.64px;top:100.85px" class="cls_029"><span class="cls_029">Surrey, BC, Canada, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Sun Pharmaceutical Industries, Inc., Princeton, NJ,</span></div>
<div style="position:absolute;left:49.99px;top:101.99px" class="cls_031"><span class="cls_031">respiratory tract infection.</span></div>
<div style="position:absolute;left:306.64px;top:110.45px" class="cls_029"><span class="cls_029">USA, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Merck & Co., Inc., Kenilworth, NJ, USA</span></div>
<div style="position:absolute;left:49.99px;top:112.09px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Risankizumab was consistently superior to both pla-</span></div>
<div style="position:absolute;left:50.00px;top:122.21px" class="cls_031"><span class="cls_031">cebo and ustekinumab in the treatment of moderate-to-severe pla-</span></div>
<div style="position:absolute;left:306.64px;top:121.31px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Etanercept (ETN) is an anti-tumor necrosis fac-</span></div>
<div style="position:absolute;left:50.00px;top:132.32px" class="cls_031"><span class="cls_031">que psoriasis. TEAE profiles were similar between risankizumab</span></div>
<div style="position:absolute;left:306.64px;top:131.31px" class="cls_031"><span class="cls_031">tor medication that was among the first biologics approved for</span></div>
<div style="position:absolute;left:50.00px;top:142.44px" class="cls_031"><span class="cls_031">and ustekinumab, and there were no unexpected safety findings.</span></div>
<div style="position:absolute;left:306.64px;top:141.31px" class="cls_031"><span class="cls_031">psoriasis. Additional medications have been developed or are in</span></div>
<div style="position:absolute;left:306.64px;top:151.31px" class="cls_031"><span class="cls_031">development for psoriasis, and patients who do not adequately</span></div>
<div style="position:absolute;left:50.00px;top:162.18px" class="cls_033"><span class="cls_033">P063</span></div>
<div style="position:absolute;left:306.64px;top:161.31px" class="cls_031"><span class="cls_031">respond to ETN may benefit from these more recent biologics.</span></div>
<div style="position:absolute;left:50.00px;top:173.70px" class="cls_025"><span class="cls_025">EFFICACY AND SAFETY OF GUSELKUMAB</span></div>
<div style="position:absolute;left:306.64px;top:171.31px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To evaluate the efficacy of tildrakizumab (TIL), a</span></div>
<div style="position:absolute;left:306.65px;top:181.31px" class="cls_031"><span class="cls_031">high-affinity, humanized, anti-interleukin-23p19 antibody in</span></div>
<div style="position:absolute;left:50.00px;top:184.71px" class="cls_025"><span class="cls_025">ADMINISTERED WITH A NOVEL SELF-INJECTION</span></div>
<div style="position:absolute;left:306.65px;top:191.31px" class="cls_031"><span class="cls_031">patients (pts) with moderate to severe chronic plaque psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:195.73px" class="cls_025"><span class="cls_025">DEVICE FOR THE TREATMENT OF MODERATE-TO-</span></div>
<div style="position:absolute;left:306.65px;top:201.31px" class="cls_031"><span class="cls_031">who were partial responders (Psoriasis Area and Severity Index</span></div>
<div style="position:absolute;left:50.00px;top:206.74px" class="cls_025"><span class="cls_025">SEVERE PSORIASIS: RESULTS FROM THE PHASE III</span></div>
<div style="position:absolute;left:306.65px;top:211.31px" class="cls_031"><span class="cls_031">[PASI] ≥50-</span><span class="cls_030"> &lt; </span><span class="cls_031">75) or nonresponders (PASI </span><span class="cls_030"> &lt; </span><span class="cls_031">50) to ETN and were</span></div>
<div style="position:absolute;left:50.00px;top:217.76px" class="cls_025"><span class="cls_025">ORION SELF-DOSE STUDY THROUGH WEEK 16</span></div>
<div style="position:absolute;left:306.65px;top:221.31px" class="cls_031"><span class="cls_031">subsequently rerandomized to TIL in a phase 3 trial.</span></div>
<div style="position:absolute;left:50.00px;top:227.77px" class="cls_026"><span class="cls_026">Laura Ferris</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Elyssa Ott</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Gigi Jiang</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, H. Chih-Ho Hong</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Woj-</span></div>
<div style="position:absolute;left:306.65px;top:231.30px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Pts with psoriasis (≥10% body surface area, Physician’s</span></div>
<div style="position:absolute;left:50.00px;top:237.79px" class="cls_026"><span class="cls_026">ciech Baran</span><span class="cls_027"><sup>4</sup></span></div>
<div style="position:absolute;left:306.66px;top:241.30px" class="cls_031"><span class="cls_031">Global Assessment [PGA] ≥3, and PASI score ≥12) participated</span></div>
<div style="position:absolute;left:50.00px;top:248.50px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">University of Pittsburgh, Pittsburgh, PA, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Janssen Research & Develop-</span></div>
<div style="position:absolute;left:306.67px;top:251.30px" class="cls_031"><span class="cls_031">in a 3-part, 52-week, randomized controlled trial (reSURFACE</span></div>
<div style="position:absolute;left:50.00px;top:258.21px" class="cls_029"><span class="cls_029">ment, LLC, Spring House, PA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">UBC Department of Dermatology and Skin</span></div>
<div style="position:absolute;left:306.67px;top:261.30px" class="cls_031"><span class="cls_031">2; NCT01729754) [1]. In Part 1 (Week [W]0-W12), pts were</span></div>
<div style="position:absolute;left:50.00px;top:267.92px" class="cls_029"><span class="cls_029">Science, Vancouver, BC and Probity Medical Research, Surrey, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Depart-</span></div>
<div style="position:absolute;left:306.67px;top:271.30px" class="cls_031"><span class="cls_031">randomized to subcutaneous TIL 200 mg, TIL 100 mg, or placebo</span></div>
<div style="position:absolute;left:50.00px;top:277.64px" class="cls_029"><span class="cls_029">ment of Dermatology, Venereology and Allergology, Wroclaw Medical Uni-</span></div>
<div style="position:absolute;left:306.67px;top:281.30px" class="cls_031"><span class="cls_031">(PBO) administered at W0 and W4, or ETN 50 mg administered</span></div>
<div style="position:absolute;left:50.00px;top:287.35px" class="cls_029"><span class="cls_029">versity, Wroclaw, Poland</span></div>
<div style="position:absolute;left:306.67px;top:291.30px" class="cls_031"><span class="cls_031">2x/week. In Part 2 (W12-W28), TIL- and ETN-treated pts remai-</span></div>
<div style="position:absolute;left:50.00px;top:298.33px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To evaluate the efficacy and safety of guselkumab</span></div>
<div style="position:absolute;left:306.64px;top:301.31px" class="cls_031"><span class="cls_031">ned on the same treatment (TIL administered at W16; ETN 1x/</span></div>
<div style="position:absolute;left:50.00px;top:308.45px" class="cls_031"><span class="cls_031">(GUS) administered using a novel, self-injection device in adult</span></div>
<div style="position:absolute;left:306.64px;top:311.31px" class="cls_031"><span class="cls_031">week), whereas PBO-treated pts were rerandomized to TIL 100</span></div>
<div style="position:absolute;left:50.00px;top:318.57px" class="cls_031"><span class="cls_031">patients with moderate-severe plaque psoriasis (PsO).</span></div>
<div style="position:absolute;left:306.64px;top:321.31px" class="cls_031"><span class="cls_031">or 200 mg. In Part 3 (W28-W52), ETN responders (PASI ≥75)</span></div>
<div style="position:absolute;left:50.00px;top:328.68px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">ORION is a Phase 3, multicenter, randomized, double-</span></div>
<div style="position:absolute;left:306.67px;top:331.31px" class="cls_031"><span class="cls_031">were discontinued, partial and nonresponders were switched to</span></div>
<div style="position:absolute;left:50.00px;top:338.80px" class="cls_031"><span class="cls_031">blind, PBO-controlled study evaluating GUS administered using</span></div>
<div style="position:absolute;left:306.67px;top:341.31px" class="cls_031"><span class="cls_031">TIL 200 mg (administered at W32, W36, W48). For this post hoc</span></div>
<div style="position:absolute;left:50.00px;top:348.91px" class="cls_031"><span class="cls_031">a self-SC injection device that delivers the contents of a pre-filled</span></div>
<div style="position:absolute;left:306.67px;top:351.31px" class="cls_031"><span class="cls_031">analysis, the percentages of pts (</span><span class="cls_035">±</span><span class="cls_031">SD) with PASI responses and</span></div>
<div style="position:absolute;left:50.00px;top:359.03px" class="cls_031"><span class="cls_031">syringe. Patients of age≥18 years with moderate-severe PsO for</span></div>
<div style="position:absolute;left:306.64px;top:361.31px" class="cls_031"><span class="cls_031">PGA response (score of 0 [clear] or 1 [minimal] with at least a</span></div>
<div style="position:absolute;left:49.99px;top:369.15px" class="cls_031"><span class="cls_031">at least 6 months, IGA score ≥3, PASI score ≥12, and BSA ≥10%,</span></div>
<div style="position:absolute;left:306.64px;top:371.31px" class="cls_031"><span class="cls_031">2-grade score reduction from baseline) were determined at W52.</span></div>
<div style="position:absolute;left:50.00px;top:379.26px" class="cls_031"><span class="cls_031">and were candidates for/or may have previously received systemic</span></div>
<div style="position:absolute;left:306.64px;top:381.31px" class="cls_031"><span class="cls_031">Primary results from the trial have been previously reported.</span></div>
<div style="position:absolute;left:50.00px;top:389.38px" class="cls_031"><span class="cls_031">therapy or phototherapy, were eligible for the study. At baseline,</span></div>
<div style="position:absolute;left:306.64px;top:391.31px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">In all, 1090 pts were randomized. Of the 313 pts ran-</span></div>
<div style="position:absolute;left:50.00px;top:399.49px" class="cls_031"><span class="cls_031">78 patients were randomized to PBO (</span><span class="cls_030">n = </span><span class="cls_031">16) at wks 0, 4, and</span></div>
<div style="position:absolute;left:306.64px;top:401.31px" class="cls_031"><span class="cls_031">domized to ETN, by W28 there were 83 partial responders and 39</span></div>
<div style="position:absolute;left:50.00px;top:409.61px" class="cls_031"><span class="cls_031">12 with crossover to GUS 100mg at wks 16, 20, and28 or GUS</span></div>
<div style="position:absolute;left:306.64px;top:411.31px" class="cls_031"><span class="cls_031">nonresponders. At W52 (after 20 weeks of TIL treatment) for ETN</span></div>
<div style="position:absolute;left:50.00px;top:419.73px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">n = </span><span class="cls_031">62) at wks 0, 4, 12, 20, and 28. The co-primary endpoints were</span></div>
<div style="position:absolute;left:306.64px;top:421.31px" class="cls_031"><span class="cls_031">partial responders, 75%</span><span class="cls_035">±</span><span class="cls_031">5%, 34%</span><span class="cls_035">±</span><span class="cls_031">5%, 15%</span><span class="cls_035">±</span><span class="cls_031">4%, and 58%</span><span class="cls_035">±</span><span class="cls_031">5%</span></div>
<div style="position:absolute;left:50.00px;top:429.84px" class="cls_031"><span class="cls_031">the proportions of patients achieving 1) an IGA score of cleared</span></div>
<div style="position:absolute;left:306.64px;top:431.31px" class="cls_031"><span class="cls_031">had achieved PASI 75, 90, 100, and PGA responses, respectively,</span></div>
<div style="position:absolute;left:50.00px;top:439.96px" class="cls_031"><span class="cls_031">(0) or minimal (1) and 2) a PASI 90 response at wk16 (GUS vs</span></div>
<div style="position:absolute;left:306.64px;top:441.31px" class="cls_031"><span class="cls_031">with TIL 200-mg treatment. At W52 for ETN nonresponders,</span></div>
<div style="position:absolute;left:50.00px;top:450.07px" class="cls_031"><span class="cls_031">PBO). Major secondary endpoints were the proportions of patients</span></div>
<div style="position:absolute;left:306.64px;top:451.31px" class="cls_031"><span class="cls_031">54%</span><span class="cls_035">±</span><span class="cls_031">6%, 31%</span><span class="cls_035">±</span><span class="cls_031">5%, 10%</span><span class="cls_035">±</span><span class="cls_031">3%, and 56%</span><span class="cls_035">±</span><span class="cls_031">5% had achieved PASI</span></div>
<div style="position:absolute;left:50.00px;top:460.19px" class="cls_031"><span class="cls_031">achieving an IGA score of 0 and a PASI 100 response at wk16.</span></div>
<div style="position:absolute;left:306.64px;top:461.31px" class="cls_031"><span class="cls_031">75, 90, 100, and PGA responses, respectively, with TIL 200-mg</span></div>
<div style="position:absolute;left:50.00px;top:470.31px" class="cls_031"><span class="cls_031">Results through wk16 are presented.</span></div>
<div style="position:absolute;left:306.64px;top:471.31px" class="cls_031"><span class="cls_031">treatment. Adverse events were similar in pts switched from ETN</span></div>
<div style="position:absolute;left:50.00px;top:480.42px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Baseline demographics and PsO disease characteristics</span></div>
<div style="position:absolute;left:306.64px;top:481.31px" class="cls_031"><span class="cls_031">to TIL at W28, compared with the pts who were maintained on</span></div>
<div style="position:absolute;left:50.00px;top:490.54px" class="cls_031"><span class="cls_031">were generally similar between the PBO and GUS-treatment</span></div>
<div style="position:absolute;left:306.64px;top:491.31px" class="cls_031"><span class="cls_031">TIL through W52.</span></div>
<div style="position:absolute;left:50.00px;top:500.65px" class="cls_031"><span class="cls_031">groups. At wk16, significantly higher proportions of GUS vs PBO</span></div>
<div style="position:absolute;left:306.64px;top:501.31px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">A substantial portion of patients with moderate to</span></div>
<div style="position:absolute;left:50.00px;top:510.77px" class="cls_031"><span class="cls_031">patients achieved an IGA score of 0/1 (80.6% vs. 0.0%, </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001)</span></div>
<div style="position:absolute;left:306.64px;top:511.31px" class="cls_031"><span class="cls_031">severe chronic plaque psoriasis who were partial responders or</span></div>
<div style="position:absolute;left:50.00px;top:520.89px" class="cls_031"><span class="cls_031">and a PASI 90 response (75.8% vs. 0.0%, </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001). In addition,</span></div>
<div style="position:absolute;left:306.64px;top:521.31px" class="cls_031"><span class="cls_031">nonresponders to ETN may respond after switching to treatment</span></div>
<div style="position:absolute;left:50.00px;top:530.96px" class="cls_031"><span class="cls_031">significantly higher proportions of GUS vs PBO patients achie-</span></div>
<div style="position:absolute;left:306.64px;top:531.31px" class="cls_031"><span class="cls_031">with TIL 200 mg. TIL may be a reasonable option for those who</span></div>
<div style="position:absolute;left:50.00px;top:541.08px" class="cls_031"><span class="cls_031">ved an IGA score of 0 (56.5% vs 0.0, </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001) and a PASI 100</span></div>
<div style="position:absolute;left:306.64px;top:541.31px" class="cls_031"><span class="cls_031">do not achieve adequate response to ETN.</span></div>
<div style="position:absolute;left:50.00px;top:551.19px" class="cls_031"><span class="cls_031">response (50.0% vs 0.0, </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001) at wk16.</span></div>
<div style="position:absolute;left:306.64px;top:551.30px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:50.00px;top:561.31px" class="cls_031"><span class="cls_031">Through wk16, the proportions of patients with ≥1 AE were</span></div>
<div style="position:absolute;left:306.64px;top:561.33px" class="cls_032"><span class="cls_032">1. Reich K, et al. Lancet. 2017;390:276-288.</span></div>
<div style="position:absolute;left:50.02px;top:571.42px" class="cls_031"><span class="cls_031">comparable between the treatment groups (GUS: 62.9%, PBO:</span></div>
<div style="position:absolute;left:306.64px;top:570.33px" class="cls_043"><span class="cls_043">Acknowledgments:</span><span class="cls_032"> This study was funded by Merck Sharp & Dohme,</span></div>
<div style="position:absolute;left:306.64px;top:579.33px" class="cls_032"><span class="cls_032">Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.</span></div>
<div style="position:absolute;left:50.02px;top:581.54px" class="cls_031"><span class="cls_031">68.8%; respectively). Discontinuation rates due to AEs were 1.6%</span></div>
<div style="position:absolute;left:306.64px;top:588.33px" class="cls_032"><span class="cls_032">Analyses were presented at the American Academy of Dermatology Annual</span></div>
<div style="position:absolute;left:50.02px;top:591.66px" class="cls_031"><span class="cls_031">for GUS patients and 6.3% for PBO patients. Two patients in the</span></div>
<div style="position:absolute;left:306.64px;top:597.33px" class="cls_032"><span class="cls_032">Meeting, February 16-20, 2018, San Diego, CA, USA.</span></div>
<div style="position:absolute;left:50.02px;top:601.77px" class="cls_031"><span class="cls_031">GUS group had SAEs (1 chest discomfort and 1 atypical chest</span></div>
<div style="position:absolute;left:50.02px;top:611.89px" class="cls_031"><span class="cls_031">pain). There were no serious infections, malignancies, or deaths.</span></div>
<div style="position:absolute;left:306.64px;top:613.95px" class="cls_033"><span class="cls_033">P065</span></div>
<div style="position:absolute;left:50.02px;top:622.00px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">GUS administered using a novel self-injection device</span></div>
<div style="position:absolute;left:306.64px;top:625.35px" class="cls_025"><span class="cls_025">EFFICACY OF TILDRAKIZUMAB IN MODERATE</span></div>
<div style="position:absolute;left:50.02px;top:632.12px" class="cls_031"><span class="cls_031">was efficacious and well-tolerated in patients with moderate-severe</span></div>
<div style="position:absolute;left:306.64px;top:636.25px" class="cls_025"><span class="cls_025">TO SEVERE PSORIASIS PATIENTS WITH PRIOR</span></div>
<div style="position:absolute;left:50.03px;top:642.24px" class="cls_031"><span class="cls_031">PsO. The efficacy and safety profile of GUS administered with</span></div>
<div style="position:absolute;left:306.64px;top:647.15px" class="cls_025"><span class="cls_025">EXPOSURE TO APREMILAST</span></div>
<div style="position:absolute;left:50.04px;top:652.35px" class="cls_031"><span class="cls_031">this device was consistent with previously reported findings from</span></div>
<div style="position:absolute;left:306.64px;top:657.05px" class="cls_026"><span class="cls_026">Kenneth Gordon</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Kristian Reich</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, David Pariser</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">,</span><span class="cls_051"> Alan Menter</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:50.04px;top:662.47px" class="cls_031"><span class="cls_031">the pivotal phase 3 studies in which GUS was administered using</span></div>
<div style="position:absolute;left:306.64px;top:666.95px" class="cls_026"><span class="cls_026">Stephen Tyring</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Howard Sofen</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Stephen Rozzo</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Jeffrey Parno</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:50.04px;top:672.58px" class="cls_031"><span class="cls_031">a different self-injection device.</span></div>
<div style="position:absolute;left:306.64px;top:676.85px" class="cls_026"><span class="cls_026">Qing Li</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, Carmen La Rosa</span><span class="cls_027"><sup>8</sup></span></div>
<div style="position:absolute;left:306.64px;top:687.45px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Medical College of Wisconsin, Milwaukee, WI, USA, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">SCIderm Research</span></div>
<div style="position:absolute;left:50.00px;top:693.31px" class="cls_033"><span class="cls_033">P064</span></div>
<div style="position:absolute;left:306.64px;top:697.05px" class="cls_029"><span class="cls_029">Institute and Dermatologikum Hamburg, Hamburg, Germany, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Eastern</span></div>
<div style="position:absolute;left:50.00px;top:704.83px" class="cls_025"><span class="cls_025">EFFICACY OF TILDRAKIZUMAB IN ETANERCEPT</span></div>
<div style="position:absolute;left:306.64px;top:706.65px" class="cls_029"><span class="cls_029">Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA,</span></div>
<div style="position:absolute;left:50.00px;top:715.84px" class="cls_025"><span class="cls_025">PARTIAL RESPONDERS OR NONRESPONDERS</span></div>
<div style="position:absolute;left:306.64px;top:716.25px" class="cls_028"><span class="cls_028"><sup>4</sup></span><span class="cls_029">Division of Dermatology, Baylor University Medical Center, Dallas, TX,</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:24090px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background32.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">30</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.85px" class="cls_028"><span class="cls_028"><sup>5</sup></span><span class="cls_029">Department of Dermatology, University of Texas, Houston, TX, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Depart-</span></div>
<div style="position:absolute;left:306.64px;top:51.85px" class="cls_029"><span class="cls_029">University of Nice-Sophia Antipolis, Nice, France, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Charité Universitäts-</span></div>
<div style="position:absolute;left:50.00px;top:61.45px" class="cls_029"><span class="cls_029">ment of Medicine (Dermatology) UCLA, Los Angeles, CA, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Sun Pharma-</span></div>
<div style="position:absolute;left:306.64px;top:61.53px" class="cls_029"><span class="cls_029">medizin Berlin, Berlin, Germany, </span><span class="cls_028"><sup>8</sup></span><span class="cls_029">University of Texas Health Science Cen-</span></div>
<div style="position:absolute;left:50.00px;top:71.05px" class="cls_029"><span class="cls_029">ceutical Industries, Inc., Princeton, NJ, </span><span class="cls_028"><sup>8</sup></span><span class="cls_029">Merck & Co., Inc., Kenilworth,</span></div>
<div style="position:absolute;left:306.64px;top:71.21px" class="cls_029"><span class="cls_029">ter and Center for Clinical Studies, Houston, TX, </span><span class="cls_028"><sup>9</sup></span><span class="cls_029">Altman Dermatology As-</span></div>
<div style="position:absolute;left:50.00px;top:80.65px" class="cls_029"><span class="cls_029">NJ, USA</span></div>
<div style="position:absolute;left:306.64px;top:80.90px" class="cls_029"><span class="cls_029">sociates, Arlington Heights, IL, </span><span class="cls_028"><sup>10</sup></span><span class="cls_029">Kaiser Permanente Los Angeles Medical</span></div>
<div style="position:absolute;left:50.00px;top:91.52px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Tildrakizumab (TIL) is a high-affinity, anti-inter-</span></div>
<div style="position:absolute;left:306.64px;top:90.58px" class="cls_029"><span class="cls_029">Center, Los Angeles, CA, </span><span class="cls_028"><sup>11</sup></span><span class="cls_029">Psoriasis Treatment Center of Central New Jer-</span></div>
<div style="position:absolute;left:50.00px;top:101.52px" class="cls_031"><span class="cls_031">leukin-23p19 monoclonal antibody for the treatment of chronic</span></div>
<div style="position:absolute;left:306.64px;top:100.26px" class="cls_029"><span class="cls_029">sey, East Windsor, NJ, </span><span class="cls_028"><sup>12</sup></span><span class="cls_029">RISkinDoc, Cranston, RI, </span><span class="cls_028"><sup>13</sup></span><span class="cls_029">Eastern Virginia Medi-</span></div>
<div style="position:absolute;left:306.64px;top:109.94px" class="cls_029"><span class="cls_029">cal School and Virginia Clinical Research Inc, Norfolk, VA, </span><span class="cls_028"><sup>14</sup></span><span class="cls_029">Boehringer</span></div>
<div style="position:absolute;left:50.00px;top:111.52px" class="cls_031"><span class="cls_031">plaque psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:119.62px" class="cls_029"><span class="cls_029">Ingelheim Pharmaceuticals Inc., Ridgefield, CT, </span><span class="cls_028"><sup>15</sup></span><span class="cls_029">AbbVie Inc., North Chi-</span></div>
<div style="position:absolute;left:50.00px;top:121.52px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">We assessed a subgroup of patients with chronic plaque</span></div>
<div style="position:absolute;left:306.64px;top:129.30px" class="cls_029"><span class="cls_029">cago, IL, USA, </span><span class="cls_028"><sup>16</sup></span><span class="cls_029">AbbVie Deutschland GmbH & Co KG, Ludwigshafen,</span></div>
<div style="position:absolute;left:50.00px;top:131.52px" class="cls_031"><span class="cls_031">psoriasis who reported prior treatment with apremilast (APT), a</span></div>
<div style="position:absolute;left:306.64px;top:138.98px" class="cls_029"><span class="cls_029">Germany, </span><span class="cls_028"><sup>17</sup></span><span class="cls_029">AbbVie Inc., Redwood City, CA, USA</span></div>
<div style="position:absolute;left:50.00px;top:141.52px" class="cls_031"><span class="cls_031">phosphodiesterase 4 inhibitor, to evaluate its potential influence</span></div>
<div style="position:absolute;left:50.00px;top:151.51px" class="cls_031"><span class="cls_031">on efficacy in 2 large phase 3 clinical studies of tildrakizumab.</span></div>
<div style="position:absolute;left:306.64px;top:149.93px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Interleukin-23 (IL-23), a key regulator of multiple</span></div>
<div style="position:absolute;left:50.00px;top:161.51px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">The reSURFACE studies were 3-part, double-blind,</span></div>
<div style="position:absolute;left:306.64px;top:160.01px" class="cls_031"><span class="cls_031">effector cytokines (including IL-17, IL-22, and TNF), is thought</span></div>
<div style="position:absolute;left:50.00px;top:171.51px" class="cls_031"><span class="cls_031">randomized controlled studies in patients (≥18 years of age) with</span></div>
<div style="position:absolute;left:306.64px;top:170.09px" class="cls_031"><span class="cls_031">to drive the development and maintenance of psoriatic lesions.</span></div>
<div style="position:absolute;left:50.01px;top:181.51px" class="cls_031"><span class="cls_031">moderate to severe chronic plaque psoriasis [1]. TIL 100 and 200</span></div>
<div style="position:absolute;left:306.64px;top:180.17px" class="cls_031"><span class="cls_031">Risankizumab is a potent humanized IgG1 monoclonal antibody</span></div>
<div style="position:absolute;left:50.01px;top:191.51px" class="cls_031"><span class="cls_031">mg were evaluated for 64 weeks (reSURFACE 1; NCT01722331)</span></div>
<div style="position:absolute;left:306.64px;top:190.25px" class="cls_031"><span class="cls_031">that inhibits IL-23 by specifically binding its p19 subunit.</span></div>
<div style="position:absolute;left:50.01px;top:201.51px" class="cls_031"><span class="cls_031">and 52 weeks (reSURFACE 2; NCT01729754). Part 1 (0-12</span></div>
<div style="position:absolute;left:306.64px;top:200.33px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To report efficacy and safety results of risankizumab</span></div>
<div style="position:absolute;left:50.01px;top:211.51px" class="cls_031"><span class="cls_031">weeks) was placebo (PBO)-controlled, whereas Part 2 (12-28</span></div>
<div style="position:absolute;left:306.64px;top:210.41px" class="cls_031"><span class="cls_031">from initial 16-week (wk) placebo (PBO)-controlled period of</span></div>
<div style="position:absolute;left:50.01px;top:221.51px" class="cls_031"><span class="cls_031">weeks) rerandomized PBO patients to TIL. The washout period</span></div>
<div style="position:absolute;left:306.64px;top:220.49px" class="cls_031"><span class="cls_031">IMMhance trial in patients (pts) with moderate-to-severe chronic</span></div>
<div style="position:absolute;left:50.01px;top:231.51px" class="cls_031"><span class="cls_031">for discontinuation of APT before randomization in these studies</span></div>
<div style="position:absolute;left:306.64px;top:230.57px" class="cls_031"><span class="cls_031">plaque psoriasis (PsO).</span></div>
<div style="position:absolute;left:50.01px;top:241.51px" class="cls_031"><span class="cls_031">was 4 weeks. In this post hoc analysis, we analyzed the efficacy</span></div>
<div style="position:absolute;left:306.64px;top:240.65px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">IMMhance (NCT02672852) is a phase 3 multicenter,</span></div>
<div style="position:absolute;left:49.99px;top:251.50px" class="cls_031"><span class="cls_031">responses to TIL in patients who reported prior exposure to APT.</span></div>
<div style="position:absolute;left:306.64px;top:250.73px" class="cls_031"><span class="cls_031">randomized, double-blind, PBO-controlled trial, evaluating the</span></div>
<div style="position:absolute;left:49.99px;top:261.50px" class="cls_031"><span class="cls_031">Physicians’ Global Assessment (PGA) (0 or 1) and Psoriasis Area</span></div>
<div style="position:absolute;left:306.64px;top:260.81px" class="cls_031"><span class="cls_031">efficacy and safety of risankizumab versus PBO in pts with</span></div>
<div style="position:absolute;left:49.99px;top:271.50px" class="cls_031"><span class="cls_031">and Severity Index (PASI) 75, 90, and 100 responses were assessed</span></div>
<div style="position:absolute;left:306.65px;top:270.89px" class="cls_031"><span class="cls_031">moderate-to-severe chronic plaque PsO. The initial 16-wk PBO-</span></div>
<div style="position:absolute;left:49.99px;top:281.50px" class="cls_031"><span class="cls_031">at Weeks 12 and 28 in this cohort. One patient with missing data</span></div>
<div style="position:absolute;left:306.65px;top:280.97px" class="cls_031"><span class="cls_031">controlled period (507 pts, stratified by weight and prior TNFi-</span></div>
<div style="position:absolute;left:49.99px;top:291.50px" class="cls_031"><span class="cls_031">at Weeks 12 and 28 was considered to be a nonresponder at these</span></div>
<div style="position:absolute;left:306.64px;top:291.05px" class="cls_031"><span class="cls_031">exposure, randomized 4:1 to receive either risankizumab [150 mg</span></div>
<div style="position:absolute;left:49.99px;top:301.50px" class="cls_031"><span class="cls_031">visits. The TIL groups were pooled owing to the small numbers</span></div>
<div style="position:absolute;left:306.64px;top:301.13px" class="cls_031"><span class="cls_031">at wks 0 and 4] or PBO) was followed by randomized withdrawal</span></div>
<div style="position:absolute;left:49.99px;top:311.50px" class="cls_031"><span class="cls_031">reporting prior APT exposure.</span></div>
<div style="position:absolute;left:306.64px;top:311.21px" class="cls_031"><span class="cls_031">and subsequent re-treatment with risankizumab. Co-primary end-</span></div>
<div style="position:absolute;left:49.99px;top:321.50px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">The pooled reSURFACE 1 and 2 dataset includes 1238</span></div>
<div style="position:absolute;left:306.64px;top:321.30px" class="cls_031"><span class="cls_031">points were PASI 90 and sPGA 0/1 responses at wk 16; missing</span></div>
<div style="position:absolute;left:49.99px;top:331.50px" class="cls_031"><span class="cls_031">patients randomized to TIL; of these, prior APT exposure was</span></div>
<div style="position:absolute;left:306.64px;top:331.38px" class="cls_031"><span class="cls_031">data were imputed as non-responders.</span></div>
<div style="position:absolute;left:49.99px;top:341.50px" class="cls_031"><span class="cls_031">reported by 35 patients (</span><span class="cls_030">n = </span><span class="cls_031">21 for 100 mg and </span><span class="cls_030">n = </span><span class="cls_031">14 for 200 mg).</span></div>
<div style="position:absolute;left:306.64px;top:341.46px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">At baseline, the mean age and weight were 49.2 years</span></div>
<div style="position:absolute;left:49.99px;top:351.49px" class="cls_031"><span class="cls_031">In the overall pooled population of TIL-treated patients, PASI 75,</span></div>
<div style="position:absolute;left:306.64px;top:351.54px" class="cls_031"><span class="cls_031">and 92.0 kg, respectively; 70.2% of pts were male. A history of</span></div>
<div style="position:absolute;left:49.99px;top:361.49px" class="cls_031"><span class="cls_031">PASI 90, PASI 100, and PGA (0.1) responses were achieved by</span></div>
<div style="position:absolute;left:306.64px;top:361.62px" class="cls_031"><span class="cls_031">diagnosed or suspected psoriatic arthritis was reported in 34.7%</span></div>
<div style="position:absolute;left:49.99px;top:371.49px" class="cls_031"><span class="cls_031">783 (63%), 450 (36%), 161 (13%), and 715 (58%) at Week 12</span></div>
<div style="position:absolute;left:306.64px;top:371.70px" class="cls_031"><span class="cls_031">of pts and prior TNFi therapy was reported in 36.5% of pts. Mean</span></div>
<div style="position:absolute;left:49.99px;top:381.49px" class="cls_031"><span class="cls_031">and 898 (73%), 647 (52%), 303 (25%), and 784 (63%) at Week</span></div>
<div style="position:absolute;left:306.64px;top:381.78px" class="cls_031"><span class="cls_031">baseline PASI and BSA were 20.2 and 26.1%, respectively. At</span></div>
<div style="position:absolute;left:49.99px;top:391.49px" class="cls_031"><span class="cls_031">28, respectively. In the population of TIL-treated patients with</span></div>
<div style="position:absolute;left:306.64px;top:391.86px" class="cls_031"><span class="cls_031">wk 16, all primary and ranked secondary endpoints were met</span></div>
<div style="position:absolute;left:49.99px;top:401.49px" class="cls_031"><span class="cls_031">prior APT exposure, PASI 75, PASI 90, PASI 100, and PGA (0.1)</span></div>
<div style="position:absolute;left:306.64px;top:401.94px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001). At Wk 16, risankizumab -treated pts achieved signi-</span></div>
<div style="position:absolute;left:49.99px;top:411.49px" class="cls_031"><span class="cls_031">responses were achieved by 21 (60%), 9 (26%), 5 (14%), and 22</span></div>
<div style="position:absolute;left:306.64px;top:412.03px" class="cls_031"><span class="cls_031">ficantly higher PASI 90 (73.2%) and sPGA 0/1 (83.5%) response</span></div>
<div style="position:absolute;left:49.99px;top:421.49px" class="cls_031"><span class="cls_031">(63%) at Week 12 and 27 (77%), 16 (46%), 7 (20%), and 22 (63%)</span></div>
<div style="position:absolute;left:306.65px;top:422.11px" class="cls_031"><span class="cls_031">rates versus PBO-treated pts (2.0%; 7.0%). Treatment-emergent</span></div>
<div style="position:absolute;left:49.99px;top:431.49px" class="cls_031"><span class="cls_031">at Week 28, respectively. There were no discontinuations due to</span></div>
<div style="position:absolute;left:306.65px;top:432.19px" class="cls_031"><span class="cls_031">adverse events (TEAEs) and serious AEs were reported in 45.5%</span></div>
<div style="position:absolute;left:49.99px;top:441.49px" class="cls_031"><span class="cls_031">adverse events (AEs) among patients with prior APT exposure.</span></div>
<div style="position:absolute;left:306.65px;top:442.27px" class="cls_031"><span class="cls_031">and 2.0% of risankizumab-treated pts, respectively. Through 16</span></div>
<div style="position:absolute;left:49.99px;top:451.48px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Efficacy responses with TIL were similar for the</span></div>
<div style="position:absolute;left:306.65px;top:452.35px" class="cls_031"><span class="cls_031">wks, there were no deaths, major adverse cardiovascular events,</span></div>
<div style="position:absolute;left:50.00px;top:461.48px" class="cls_031"><span class="cls_031">small sample of patients with prior exposure to APT and the overall</span></div>
<div style="position:absolute;left:306.65px;top:462.43px" class="cls_031"><span class="cls_031">or cases of tuberculosis in risankizumab-treated pts.</span></div>
<div style="position:absolute;left:50.00px;top:471.48px" class="cls_031"><span class="cls_031">pooled population from reSURFACE 1 and reSURFACE 2. These</span></div>
<div style="position:absolute;left:306.65px;top:472.51px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Risankizumab was superior to PBO in the treatment</span></div>
<div style="position:absolute;left:50.00px;top:481.48px" class="cls_031"><span class="cls_031">results were consistent with the notion that no adverse effect on ef-</span></div>
<div style="position:absolute;left:306.65px;top:482.59px" class="cls_031"><span class="cls_031">of adult pts with moderate-to-severe plaque PsO. The safety profile</span></div>
<div style="position:absolute;left:50.00px;top:491.52px" class="cls_031"><span class="cls_031">ficacy or discontinuations due to AEs are expected when initiating</span></div>
<div style="position:absolute;left:306.65px;top:492.67px" class="cls_031"><span class="cls_031">was consistent with previously reported risankizumab trials with</span></div>
<div style="position:absolute;left:49.99px;top:501.52px" class="cls_031"><span class="cls_031">treatment with TIL among patients with prior exposure to APT.</span></div>
<div style="position:absolute;left:306.65px;top:502.75px" class="cls_031"><span class="cls_031">no new or unexpected safety findings.</span></div>
<div style="position:absolute;left:49.99px;top:511.52px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:50.00px;top:521.53px" class="cls_032"><span class="cls_032">1. Reich K, et al. Lancet. 2017;390:276-288.</span></div>
<div style="position:absolute;left:306.64px;top:521.47px" class="cls_033"><span class="cls_033">P067</span></div>
<div style="position:absolute;left:50.00px;top:530.53px" class="cls_043"><span class="cls_043">Acknowledgements: </span><span class="cls_032">The studies were funded by Merck Sharp & Dohme,</span></div>
<div style="position:absolute;left:306.64px;top:532.95px" class="cls_025"><span class="cls_025">DISEASE SEVERITY AND EFFICACY INSIGHTS:</span></div>
<div style="position:absolute;left:50.00px;top:539.53px" class="cls_032"><span class="cls_032">Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.</span></div>
<div style="position:absolute;left:306.64px;top:543.93px" class="cls_025"><span class="cls_025">PATIENT-LEVEL PASI SCORES IN TILDRAKIZUMAB</span></div>
<div style="position:absolute;left:50.00px;top:548.53px" class="cls_032"><span class="cls_032">Analyses were presented at the American Academy of Dermatology Annual</span></div>
<div style="position:absolute;left:50.00px;top:557.53px" class="cls_032"><span class="cls_032">Meeting, February 16-20, 2018, San Diego, CA, USA.</span></div>
<div style="position:absolute;left:306.64px;top:554.91px" class="cls_025"><span class="cls_025">PSORIASIS TRIALS</span></div>
<div style="position:absolute;left:306.64px;top:564.89px" class="cls_026"><span class="cls_026">Kenneth Gordon</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Jeffrey Crowley</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">,</span><span class="cls_051"> Yves Poulin</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Alan Mendel-</span></div>
<div style="position:absolute;left:50.00px;top:575.15px" class="cls_033"><span class="cls_033">P066</span></div>
<div style="position:absolute;left:306.65px;top:574.87px" class="cls_026"><span class="cls_026">sohn</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Jeff Parno</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Stephen Rozzo</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Charles Ellis</span><span class="cls_027"><sup>5</sup></span></div>
<div style="position:absolute;left:50.00px;top:586.55px" class="cls_025"><span class="cls_025">RISANKIZUMAB EFFICACY/SAFETY IN MODERATE-</span></div>
<div style="position:absolute;left:306.64px;top:585.55px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Medical College of Wisconsin, Milwaukee, WI, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Bakersfield Dermatology</span></div>
<div style="position:absolute;left:306.64px;top:595.23px" class="cls_029"><span class="cls_029">& Skin Cancer Medical Group, Bakersfield, USA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Centre hospitalier de</span></div>
<div style="position:absolute;left:50.00px;top:597.45px" class="cls_025"><span class="cls_025">TO-SEVERE PLAQUE PSORIASIS: 16-WEEK RESULTS</span></div>
<div style="position:absolute;left:306.63px;top:604.91px" class="cls_029"><span class="cls_029">l’université Laval, Hôpital Hôtel-Dieu de Québec, Québec City, Canada,</span></div>
<div style="position:absolute;left:50.00px;top:608.35px" class="cls_025"><span class="cls_025">FROM IMMHANCE</span></div>
<div style="position:absolute;left:306.64px;top:614.59px" class="cls_028"><span class="cls_028"><sup>4</sup></span><span class="cls_029">Sun Pharmaceutical Industries, Inc., Princeton, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Department of Dermato-</span></div>
<div style="position:absolute;left:50.00px;top:618.25px" class="cls_026"><span class="cls_026">Andrew Blauvelt</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Kim A. Papp</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, </span><span class="cls_051">Melinda Gooderham</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Richard</span></div>
<div style="position:absolute;left:306.64px;top:624.27px" class="cls_029"><span class="cls_029">logy, University of Michigan Medical School, Ann Arbor, USA</span></div>
<div style="position:absolute;left:50.00px;top:628.15px" class="cls_026"><span class="cls_026">G. Langley</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Craig Leonardi</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Jean-Philippe Lacour</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Sandra</span></div>
<div style="position:absolute;left:306.64px;top:635.22px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Tildrakizumab (TIL) is a high-affinity anti-IL-23p19</span></div>
<div style="position:absolute;left:50.00px;top:638.05px" class="cls_026"><span class="cls_026">Philipp</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Stephen Tyring</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, Michael Bukhalo</span><span class="cls_027"><sup>9</sup></span><span class="cls_026">, Jashin J. Wu</span><span class="cls_027"><sup>10</sup></span><span class="cls_026">, Jerry</span></div>
<div style="position:absolute;left:50.01px;top:647.95px" class="cls_026"><span class="cls_026">Bagel</span><span class="cls_027"><sup>11</sup></span><span class="cls_026">, Ellen H. Frankel</span><span class="cls_027"><sup>12</sup></span><span class="cls_026">, David Pariser</span><span class="cls_027"><sup>13</sup></span><span class="cls_026">, Mary Flack</span><span class="cls_027"><sup>14</sup></span><span class="cls_026">, Joseph</span></div>
<div style="position:absolute;left:306.65px;top:645.30px" class="cls_031"><span class="cls_031">antibody that showed efficacy in 2 phase 3 chronic plaque psoriasis</span></div>
<div style="position:absolute;left:50.01px;top:657.85px" class="cls_026"><span class="cls_026">Scherer</span><span class="cls_027"><sup>14</sup></span><span class="cls_026">, Ziqian Geng</span><span class="cls_027"><sup>15</sup></span><span class="cls_026">, Yihua Gu</span><span class="cls_027"><sup>15</sup></span><span class="cls_026">, Anne Camez</span><span class="cls_027"><sup>16</sup></span><span class="cls_026">, Elizabeth</span></div>
<div style="position:absolute;left:306.65px;top:655.38px" class="cls_031"><span class="cls_031">studies (reSURFACE 1 [NCT01722331] and 2 [NCT01729754])</span></div>
<div style="position:absolute;left:50.00px;top:667.75px" class="cls_026"><span class="cls_026">H.Z. Thompson</span><span class="cls_027"><sup>17</sup></span></div>
<div style="position:absolute;left:306.65px;top:665.46px" class="cls_031"><span class="cls_031">[1]. Some dichotomous efficacy measures, eg, proportions of pa-</span></div>
<div style="position:absolute;left:50.00px;top:678.35px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Oregon Medical Research Center, Portland, OR, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">K Papp Clinical Re-</span></div>
<div style="position:absolute;left:306.64px;top:675.54px" class="cls_031"><span class="cls_031">tients achieving a 75% Psoriasis Area and Severity Index (PASI)</span></div>
<div style="position:absolute;left:50.00px;top:687.95px" class="cls_029"><span class="cls_029">search and Probity Medical Research, Waterloo, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">School of Medicine,</span></div>
<div style="position:absolute;left:306.64px;top:685.62px" class="cls_031"><span class="cls_031">response, provide limited efficacy and disease severity informa-</span></div>
<div style="position:absolute;left:50.00px;top:697.55px" class="cls_029"><span class="cls_029">Queen’s University, Kingston, and Centre for Dermatology and Probity</span></div>
<div style="position:absolute;left:306.64px;top:695.70px" class="cls_031"><span class="cls_031">tion at a patient level. Analysis of patient-level PASI data could</span></div>
<div style="position:absolute;left:50.00px;top:707.15px" class="cls_029"><span class="cls_029">Medical Research, Peterborough, ON, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Dalhousie University, Halifax, NS,</span></div>
<div style="position:absolute;left:306.64px;top:705.78px" class="cls_031"><span class="cls_031">address these limitations.</span></div>
<div style="position:absolute;left:50.00px;top:716.75px" class="cls_029"><span class="cls_029">Canada, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">St. Louis University, St. Louis, MO, USA, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Hôpital de l’Archet,</span></div>
<div style="position:absolute;left:306.64px;top:715.86px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To identify potential insights into efficacy assessment</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:24893px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background33.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">31</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">and disease severity using a post hoc analysis of patient-level</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">monoclonal antibody, in the treatment of adult patients with</span></div>
<div style="position:absolute;left:50.00px;top:61.48px" class="cls_031"><span class="cls_031">PASI data.</span></div>
<div style="position:absolute;left:306.64px;top:61.33px" class="cls_031"><span class="cls_031">moderate-to-severe plaque psoriasis over 28 weeks1.</span></div>
<div style="position:absolute;left:50.00px;top:71.54px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">ReSURFACE 1 and 2 methods have been described pre-</span></div>
<div style="position:absolute;left:306.64px;top:71.26px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">This analysis evaluated whether the efficacy is sustained</span></div>
<div style="position:absolute;left:50.00px;top:81.61px" class="cls_031"><span class="cls_031">viously [1]. Patients who participated in either TIL phase 3 study</span></div>
<div style="position:absolute;left:306.64px;top:81.19px" class="cls_031"><span class="cls_031">or improved from week 28 through week 52.</span></div>
<div style="position:absolute;left:50.00px;top:91.69px" class="cls_031"><span class="cls_031">received TIL 100 mg or TIL 200 mg at Week (W)0 and W4, and</span></div>
<div style="position:absolute;left:306.64px;top:91.11px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Both trials randomized adult patients with moderate-to-</span></div>
<div style="position:absolute;left:50.00px;top:101.76px" class="cls_031"><span class="cls_031">every 12 weeks thereafter, or placebo (PBO) at W0 and W4 then</span></div>
<div style="position:absolute;left:306.64px;top:101.04px" class="cls_031"><span class="cls_031">severe plaque psoriasis to receive tildrakizumab 100 mg or 200</span></div>
<div style="position:absolute;left:50.00px;top:111.83px" class="cls_031"><span class="cls_031">TIL 100 mg or 200 mg at W12 and W16. PASI score distributions</span></div>
<div style="position:absolute;left:306.64px;top:110.97px" class="cls_031"><span class="cls_031">mg at weeks 0, 4, then every 12 weeks. At week 28, patients with</span></div>
<div style="position:absolute;left:50.00px;top:121.90px" class="cls_031"><span class="cls_031">were analyzed using descriptive statistics.</span></div>
<div style="position:absolute;left:306.64px;top:120.89px" class="cls_031"><span class="cls_031">Psoriasis Area and Severity Index (PASI) response ≥50% were</span></div>
<div style="position:absolute;left:50.00px;top:131.97px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Numbers of patients and mean and median PASI scores</span></div>
<div style="position:absolute;left:306.65px;top:130.82px" class="cls_031"><span class="cls_031">re-randomized, based on their week-28 PASI response, to receive</span></div>
<div style="position:absolute;left:50.00px;top:142.04px" class="cls_031"><span class="cls_031">are shown in the Table. By W4 (1 dose), 55% of patients in both</span></div>
<div style="position:absolute;left:306.65px;top:140.75px" class="cls_031"><span class="cls_031">the same, a higher or a lower dose of tildrakizumab or placebo</span></div>
<div style="position:absolute;left:50.00px;top:152.11px" class="cls_031"><span class="cls_031">TIL arms had PASI </span><span class="cls_030"> &lt; </span><span class="cls_031">12, and would no longer meet clinical trial</span></div>
<div style="position:absolute;left:306.65px;top:150.68px" class="cls_031"><span class="cls_031">(randomized withdrawal in reSURFACE 1 per the trial designs).</span></div>
<div style="position:absolute;left:50.00px;top:162.18px" class="cls_031"><span class="cls_031">entry criteria. The percentage of patients with PASI </span><span class="cls_030"> &lt; </span><span class="cls_031">12 increased</span></div>
<div style="position:absolute;left:306.65px;top:160.60px" class="cls_031"><span class="cls_031">The current analysis evaluated only patients treated with the same</span></div>
<div style="position:absolute;left:50.00px;top:172.25px" class="cls_031"><span class="cls_031">during TIL treatment: 87% at W12, 93% at W28 (100 mg); 90%</span></div>
<div style="position:absolute;left:306.65px;top:170.53px" class="cls_031"><span class="cls_031">dose of tildrakizumab (100 mg or 200 mg) throughout the first</span></div>
<div style="position:absolute;left:50.00px;top:182.32px" class="cls_031"><span class="cls_031">at W12, 97% at W28 (200 mg). At W12, 32% (TIL 100 mg),</span></div>
<div style="position:absolute;left:306.64px;top:180.46px" class="cls_031"><span class="cls_031">52 weeks. Four mutually exclusive groups were created based</span></div>
<div style="position:absolute;left:50.00px;top:192.40px" class="cls_031"><span class="cls_031">29% (TIL 200 mg), and 2% (PBO) of patients had PASI </span><span class="cls_030"> ≤ </span><span class="cls_031">1.0.</span></div>
<div style="position:absolute;left:306.64px;top:190.38px" class="cls_031"><span class="cls_031">on week-28 PASI response: PASI 100, PASI 90-99, PASI 75-89</span></div>
<div style="position:absolute;left:50.00px;top:202.47px" class="cls_031"><span class="cls_031">By W28, 48% (TIL 100 mg) and 52% (TIL 200 mg) of patients</span></div>
<div style="position:absolute;left:306.64px;top:200.31px" class="cls_031"><span class="cls_031">and PASI 50-74. PASI responses at week 52 (observed data) were</span></div>
<div style="position:absolute;left:50.00px;top:212.54px" class="cls_031"><span class="cls_031">had PASI </span><span class="cls_030"> ≤ </span><span class="cls_031">1.0. Median PASI scores at W28 were 2.0 (TIL 100</span></div>
<div style="position:absolute;left:306.64px;top:210.24px" class="cls_031"><span class="cls_031">analyzed for each week-28 PASI-response group.</span></div>
<div style="position:absolute;left:50.00px;top:222.61px" class="cls_031"><span class="cls_031">mg) and 1.0 (TIL 200 mg).</span></div>
<div style="position:absolute;left:306.64px;top:220.16px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">This analysis included 352 patients on tildrakizumab 100</span></div>
<div style="position:absolute;left:50.00px;top:232.68px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">These results suggest that PASI scores may provide</span></div>
<div style="position:absolute;left:306.64px;top:230.09px" class="cls_031"><span class="cls_031">mg (male: 69.9%; mean baseline age: 44.9 years) and 313 on tild-</span></div>
<div style="position:absolute;left:50.00px;top:242.75px" class="cls_031"><span class="cls_031">additional information about disease severity, and resolution with</span></div>
<div style="position:absolute;left:306.64px;top:240.08px" class="cls_031"><span class="cls_031">rakizumab 200 mg (male: 67.1%; mean baseline age: 46.4 years).</span></div>
<div style="position:absolute;left:50.00px;top:252.80px" class="cls_031"><span class="cls_031">treatment, that might not otherwise be available using dichoto-</span></div>
<div style="position:absolute;left:306.64px;top:250.00px" class="cls_031"><span class="cls_031">The proportions of patients achieving PASI 100, PASI 90-99, PASI</span></div>
<div style="position:absolute;left:306.64px;top:259.93px" class="cls_031"><span class="cls_031">75-89 and PASI 50-74 at week 28 were 25.9%, 38.4%, 25.3%</span></div>
<div style="position:absolute;left:50.00px;top:262.87px" class="cls_031"><span class="cls_031">mous PASI assessments. Most TIL-treated patients had clinical</span></div>
<div style="position:absolute;left:306.64px;top:269.86px" class="cls_031"><span class="cls_031">and 10.5% respectively for those on the 100 mg dose, and 24.6%,</span></div>
<div style="position:absolute;left:50.00px;top:272.94px" class="cls_031"><span class="cls_031">improvement by W4, and ≈50% had nominal disease severity</span></div>
<div style="position:absolute;left:306.64px;top:279.78px" class="cls_031"><span class="cls_031">24.3%, 19.5% and 31.6% respectively for those on the 200 mg</span></div>
<div style="position:absolute;left:49.97px;top:283.01px" class="cls_031"><span class="cls_031">(PASI </span><span class="cls_030"> ≤ </span><span class="cls_031">1.0) by W28.</span></div>
<div style="position:absolute;left:306.64px;top:289.71px" class="cls_031"><span class="cls_031">dose. Among patients who achieved week-28 PASI≥90 with either</span></div>
<div style="position:absolute;left:49.97px;top:297.08px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:306.63px;top:299.64px" class="cls_031"><span class="cls_031">dose of tildrakizumab, 88.9-89.4% maintained PASI≥90 at week</span></div>
<div style="position:absolute;left:50.00px;top:307.16px" class="cls_032"><span class="cls_032">1. Reich K, et al. Lancet. 2017;390:276-288.</span></div>
<div style="position:absolute;left:306.63px;top:309.56px" class="cls_031"><span class="cls_031">52. Overall, 91.1% patients on the 100 mg dose and 93.9% on the</span></div>
<div style="position:absolute;left:50.00px;top:316.23px" class="cls_032"><span class="cls_032">Study sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck</span></div>
<div style="position:absolute;left:306.63px;top:319.49px" class="cls_031"><span class="cls_031">200 mg dose with week-28 PASI≥75 maintained PASI≥75 at week</span></div>
<div style="position:absolute;left:50.00px;top:325.31px" class="cls_032"><span class="cls_032">& Co., Inc., Kenilworth, NJ, USA; analyses funded by Sun Pharmaceutical</span></div>
<div style="position:absolute;left:306.65px;top:329.42px" class="cls_031"><span class="cls_031">52. In addition, 39.3-40.4% of patients with week-28 PASI 75-89</span></div>
<div style="position:absolute;left:50.00px;top:334.38px" class="cls_032"><span class="cls_032">Industries, Inc.</span></div>
<div style="position:absolute;left:306.65px;top:339.35px" class="cls_031"><span class="cls_031">remained PASI 75-89 at week 52 and 33.7%-41.0% improved to</span></div>
<div style="position:absolute;left:50.00px;top:344.46px" class="cls_036"><span class="cls_036">Table. PASI Scores</span></div>
<div style="position:absolute;left:306.65px;top:349.27px" class="cls_031"><span class="cls_031">PASI≥90. Among patients with week-28 PASI 50-74, 20.2-29.7%</span></div>
<div style="position:absolute;left:130.72px;top:355.63px" class="cls_036"><span class="cls_036">TIL 100 mg</span></div>
<div style="position:absolute;left:184.72px;top:355.63px" class="cls_036"><span class="cls_036">TIL 200 mg</span></div>
<div style="position:absolute;left:241.00px;top:355.63px" class="cls_036"><span class="cls_036">PBO</span></div>
<div style="position:absolute;left:130.72px;top:362.63px" class="cls_036"><span class="cls_036">(</span><span class="cls_040">n = </span><span class="cls_036">616)</span></div>
<div style="position:absolute;left:184.72px;top:362.63px" class="cls_036"><span class="cls_036">(</span><span class="cls_040">n = </span><span class="cls_036">622)</span></div>
<div style="position:absolute;left:241.00px;top:362.63px" class="cls_036"><span class="cls_036">(</span><span class="cls_040">n = </span><span class="cls_036">309)</span></div>
<div style="position:absolute;left:306.65px;top:359.20px" class="cls_031"><span class="cls_031">achieved PASI≥90 and 52.5-64.9% achieved PASI≥75 at week</span></div>
<div style="position:absolute;left:51.38px;top:371.80px" class="cls_037"><span class="cls_037">W0</span></div>
<div style="position:absolute;left:306.65px;top:369.13px" class="cls_031"><span class="cls_031">52. Overall, only 2.6% of patients on the 100 mg (9 out of 352)</span></div>
<div style="position:absolute;left:52.92px;top:378.81px" class="cls_037"><span class="cls_037">Patients with PASI data, n</span></div>
<div style="position:absolute;left:130.73px;top:378.81px" class="cls_037"><span class="cls_037">616</span></div>
<div style="position:absolute;left:184.73px;top:378.82px" class="cls_037"><span class="cls_037">622</span></div>
<div style="position:absolute;left:241.00px;top:378.82px" class="cls_037"><span class="cls_037">309</span></div>
<div style="position:absolute;left:306.65px;top:379.05px" class="cls_031"><span class="cls_031">or 200 mg (8 out of 313) dose had week-52 PASI</span><span class="cls_030"> &lt; </span><span class="cls_031">50.</span></div>
<div style="position:absolute;left:52.92px;top:385.81px" class="cls_037"><span class="cls_037">Mean (95% CI)</span></div>
<div style="position:absolute;left:130.73px;top:385.81px" class="cls_037"><span class="cls_037">20.2 (19.6, 20.9)</span></div>
<div style="position:absolute;left:184.73px;top:385.82px" class="cls_037"><span class="cls_037">20.3 (19.7, 20.9)</span></div>
<div style="position:absolute;left:241.00px;top:385.83px" class="cls_037"><span class="cls_037">19.7 (18.8, 20.5)</span></div>
<div style="position:absolute;left:52.92px;top:392.81px" class="cls_037"><span class="cls_037">Median (range)</span></div>
<div style="position:absolute;left:130.73px;top:392.82px" class="cls_037"><span class="cls_037">18.0 (8.0-59.0)</span></div>
<div style="position:absolute;left:184.73px;top:392.82px" class="cls_037"><span class="cls_037">18.0 (5.0-66.0)</span></div>
<div style="position:absolute;left:241.00px;top:392.83px" class="cls_037"><span class="cls_037">18.0 (12.0-56.0)</span></div>
<div style="position:absolute;left:306.65px;top:388.98px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Among patients with moderate-to-severe plaque</span></div>
<div style="position:absolute;left:51.38px;top:398.99px" class="cls_037"><span class="cls_037">W4</span></div>
<div style="position:absolute;left:306.65px;top:398.91px" class="cls_031"><span class="cls_031">psoriasis treated with tildrakizumab 100 or 200 mg at weeks 0,</span></div>
<div style="position:absolute;left:52.92px;top:405.99px" class="cls_037"><span class="cls_037">Patients with PASI data, n</span></div>
<div style="position:absolute;left:130.73px;top:406.00px" class="cls_037"><span class="cls_037">610</span></div>
<div style="position:absolute;left:184.73px;top:406.00px" class="cls_037"><span class="cls_037">611</span></div>
<div style="position:absolute;left:241.00px;top:406.01px" class="cls_037"><span class="cls_037">302</span></div>
<div style="position:absolute;left:52.92px;top:412.99px" class="cls_037"><span class="cls_037">Mean (95% CI)</span></div>
<div style="position:absolute;left:130.73px;top:413.00px" class="cls_037"><span class="cls_037">12.1 (11.5, 12.8)</span></div>
<div style="position:absolute;left:184.73px;top:413.01px" class="cls_037"><span class="cls_037">12.0 (11.4, 12.6)</span></div>
<div style="position:absolute;left:241.00px;top:413.01px" class="cls_037"><span class="cls_037">18.0 (17.0, 19.0)</span></div>
<div style="position:absolute;left:306.65px;top:408.83px" class="cls_031"><span class="cls_031">4, then every 12 weeks, those who achieved week-28 PASI≥50</span></div>
<div style="position:absolute;left:52.92px;top:420.00px" class="cls_037"><span class="cls_037">Median (range)</span></div>
<div style="position:absolute;left:130.73px;top:420.00px" class="cls_037"><span class="cls_037">11.0 (0.0-53.0)</span></div>
<div style="position:absolute;left:184.73px;top:420.01px" class="cls_037"><span class="cls_037">11.0 (0.0-54.0)</span></div>
<div style="position:absolute;left:241.00px;top:420.01px" class="cls_037"><span class="cls_037">16.0 (2.0-59.0)</span></div>
<div style="position:absolute;left:306.63px;top:418.76px" class="cls_031"><span class="cls_031">and continued on the same dose had sustained or improved ef-</span></div>
<div style="position:absolute;left:52.92px;top:427.00px" class="cls_037"><span class="cls_037">PASI </span><span class="cls_038"> &lt; </span><span class="cls_037">12, n (%)</span></div>
<div style="position:absolute;left:130.73px;top:427.00px" class="cls_037"><span class="cls_037">337 (55)</span></div>
<div style="position:absolute;left:184.73px;top:427.01px" class="cls_037"><span class="cls_037">335 (55)</span></div>
<div style="position:absolute;left:241.00px;top:427.02px" class="cls_037"><span class="cls_037">60 (20)</span></div>
<div style="position:absolute;left:306.64px;top:428.75px" class="cls_031"><span class="cls_031">ficacy from week 28 through week 52. The majority patients who</span></div>
<div style="position:absolute;left:52.92px;top:434.00px" class="cls_037"><span class="cls_037">PASI </span><span class="cls_038"> ≤ </span><span class="cls_037">1.0, n (%)</span></div>
<div style="position:absolute;left:130.73px;top:434.01px" class="cls_037"><span class="cls_037">8 (1)</span></div>
<div style="position:absolute;left:184.73px;top:434.01px" class="cls_037"><span class="cls_037">11 (2)</span></div>
<div style="position:absolute;left:241.00px;top:434.02px" class="cls_037"><span class="cls_037">0 (0)</span></div>
<div style="position:absolute;left:51.38px;top:440.18px" class="cls_037"><span class="cls_037">W12</span></div>
<div style="position:absolute;left:306.63px;top:438.67px" class="cls_031"><span class="cls_031">achieved week-28 PASI≥75 or PASI≥90 maintained PASI≥75 or</span></div>
<div style="position:absolute;left:52.92px;top:447.18px" class="cls_037"><span class="cls_037">Patients with PASI data, n</span></div>
<div style="position:absolute;left:130.73px;top:447.19px" class="cls_037"><span class="cls_037">598</span></div>
<div style="position:absolute;left:184.73px;top:447.19px" class="cls_037"><span class="cls_037">602</span></div>
<div style="position:absolute;left:241.00px;top:447.20px" class="cls_037"><span class="cls_037">288</span></div>
<div style="position:absolute;left:306.64px;top:448.60px" class="cls_031"><span class="cls_031">PASI≥90 at week 52. More than half of partial responders (PASI</span></div>
<div style="position:absolute;left:52.92px;top:454.18px" class="cls_037"><span class="cls_037">Mean (95% CI)</span></div>
<div style="position:absolute;left:130.73px;top:454.19px" class="cls_037"><span class="cls_037">5.2 (4.7, 5.7)</span></div>
<div style="position:absolute;left:184.73px;top:454.20px" class="cls_037"><span class="cls_037">4.6 (4.2, 5.1)</span></div>
<div style="position:absolute;left:241.00px;top:454.20px" class="cls_037"><span class="cls_037">16.6 (15.6, 17.7)</span></div>
<div style="position:absolute;left:52.92px;top:461.19px" class="cls_037"><span class="cls_037">Median (range)</span></div>
<div style="position:absolute;left:130.73px;top:461.19px" class="cls_037"><span class="cls_037">3.0 (0.0-38.0)</span></div>
<div style="position:absolute;left:184.73px;top:461.20px" class="cls_037"><span class="cls_037">3.0 (0.0-36.0)</span></div>
<div style="position:absolute;left:241.00px;top:461.20px" class="cls_037"><span class="cls_037">15.5 (0.0-57.0)</span></div>
<div style="position:absolute;left:306.65px;top:458.53px" class="cls_031"><span class="cls_031">50-74) at week 28 eventually achieved PASI≥75 and at least 1 in</span></div>
<div style="position:absolute;left:52.92px;top:468.19px" class="cls_037"><span class="cls_037">PASI </span><span class="cls_038"> &lt; </span><span class="cls_037">12, n (%)</span></div>
<div style="position:absolute;left:130.73px;top:468.19px" class="cls_037"><span class="cls_037">521 (87)</span></div>
<div style="position:absolute;left:184.73px;top:468.20px" class="cls_037"><span class="cls_037">539 (90)</span></div>
<div style="position:absolute;left:241.00px;top:468.21px" class="cls_037"><span class="cls_037">73 (25)</span></div>
<div style="position:absolute;left:306.65px;top:468.45px" class="cls_031"><span class="cls_031">5 achieved PASI≥90 at week 52.</span></div>
<div style="position:absolute;left:52.92px;top:475.19px" class="cls_037"><span class="cls_037">PASI </span><span class="cls_038"> ≤ </span><span class="cls_037">1.0, n (%)</span></div>
<div style="position:absolute;left:130.73px;top:475.20px" class="cls_037"><span class="cls_037">189 (32)</span></div>
<div style="position:absolute;left:184.73px;top:475.20px" class="cls_037"><span class="cls_037">175 (29)</span></div>
<div style="position:absolute;left:241.00px;top:475.21px" class="cls_037"><span class="cls_037">5 (2)</span></div>
<div style="position:absolute;left:51.38px;top:481.37px" class="cls_037"><span class="cls_037">W28</span></div>
<div style="position:absolute;left:306.65px;top:478.45px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:52.92px;top:488.37px" class="cls_037"><span class="cls_037">Patients with PASI data, n</span></div>
<div style="position:absolute;left:130.73px;top:488.38px" class="cls_037"><span class="cls_037">575</span></div>
<div style="position:absolute;left:184.73px;top:488.38px" class="cls_037"><span class="cls_037">581</span></div>
<div style="position:absolute;left:241.00px;top:488.39px" class="cls_037"><span class="cls_037">-</span></div>
<div style="position:absolute;left:306.64px;top:488.48px" class="cls_032"><span class="cls_032">1. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo</span></div>
<div style="position:absolute;left:52.92px;top:495.37px" class="cls_037"><span class="cls_037">Mean (95% CI)</span></div>
<div style="position:absolute;left:130.73px;top:495.38px" class="cls_037"><span class="cls_037">3.4 (3.0, 3.8)</span></div>
<div style="position:absolute;left:184.73px;top:495.39px" class="cls_037"><span class="cls_037">2.7 (2.4, 3.0)</span></div>
<div style="position:absolute;left:241.00px;top:495.39px" class="cls_037"><span class="cls_037">-</span></div>
<div style="position:absolute;left:306.64px;top:497.48px" class="cls_032"><span class="cls_032">or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSUR-</span></div>
<div style="position:absolute;left:52.92px;top:502.38px" class="cls_037"><span class="cls_037">Median (range)</span></div>
<div style="position:absolute;left:130.73px;top:502.38px" class="cls_037"><span class="cls_037">2.0 (0.0-26.0)</span></div>
<div style="position:absolute;left:184.73px;top:502.39px" class="cls_037"><span class="cls_037">1.0 (0.0-24.0)</span></div>
<div style="position:absolute;left:241.00px;top:502.39px" class="cls_037"><span class="cls_037">-</span></div>
<div style="position:absolute;left:52.92px;top:509.38px" class="cls_037"><span class="cls_037">PASI </span><span class="cls_038"> &lt; </span><span class="cls_037">12, n (%)</span></div>
<div style="position:absolute;left:130.73px;top:509.38px" class="cls_037"><span class="cls_037">533 (93)</span></div>
<div style="position:absolute;left:184.73px;top:509.39px" class="cls_037"><span class="cls_037">561 (97)</span></div>
<div style="position:absolute;left:241.00px;top:509.40px" class="cls_037"><span class="cls_037">-</span></div>
<div style="position:absolute;left:306.64px;top:506.48px" class="cls_032"><span class="cls_032">FACE 2): results from two randomised controlled, phase 3 trials. Lancet.</span></div>
<div style="position:absolute;left:52.92px;top:516.38px" class="cls_037"><span class="cls_037">PASI </span><span class="cls_038"> ≤ </span><span class="cls_037">1.0, n (%)</span></div>
<div style="position:absolute;left:130.73px;top:516.39px" class="cls_037"><span class="cls_037">278 (48)</span></div>
<div style="position:absolute;left:184.73px;top:516.39px" class="cls_037"><span class="cls_037">303 (52)</span></div>
<div style="position:absolute;left:241.00px;top:516.40px" class="cls_037"><span class="cls_037">-</span></div>
<div style="position:absolute;left:306.64px;top:515.48px" class="cls_032"><span class="cls_032">2017;390(10091):276-288.</span></div>
<div style="position:absolute;left:306.64px;top:524.48px" class="cls_032"><span class="cls_032">This abstract was presented at 2018 Winter Clinical Dermatology</span></div>
<div style="position:absolute;left:50.00px;top:531.19px" class="cls_033"><span class="cls_033">P068</span></div>
<div style="position:absolute;left:306.64px;top:533.48px" class="cls_032"><span class="cls_032">Conference-Hawaii.</span></div>
<div style="position:absolute;left:50.00px;top:542.66px" class="cls_025"><span class="cls_025">SUSTAINED AND IMPROVED EFFICACY OF</span></div>
<div style="position:absolute;left:50.00px;top:553.64px" class="cls_025"><span class="cls_025">TILDRAKIZUMAB FROM WEEK 28 TO WEEK 52</span></div>
<div style="position:absolute;left:306.64px;top:552.10px" class="cls_033"><span class="cls_033">P070</span></div>
<div style="position:absolute;left:50.00px;top:564.61px" class="cls_025"><span class="cls_025">IN TREATING MODERATE-TO-SEVERE PLAQUE</span></div>
<div style="position:absolute;left:306.64px;top:563.50px" class="cls_025"><span class="cls_025">BETTER SKIN CLEARANCE IS ASSOCIATED WITH</span></div>
<div style="position:absolute;left:50.00px;top:575.58px" class="cls_025"><span class="cls_025">PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:574.40px" class="cls_025"><span class="cls_025">IMPROVED QUALITY OF LIFE IN MODERATE-TO-</span></div>
<div style="position:absolute;left:50.00px;top:585.54px" class="cls_026"><span class="cls_026">Boni Elewski</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Alan Menter</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Jeffrey Crowley</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Stephen Tyring</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:585.30px" class="cls_025"><span class="cls_025">SEVERE PSORIASIS PATIENTS TREATED WITH</span></div>
<div style="position:absolute;left:50.00px;top:595.51px" class="cls_051"><span class="cls_051">Yang Zhao</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Simon Lowry</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Stephen Rozzo</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Alan Mendelsohn</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:596.20px" class="cls_025"><span class="cls_025">TILDRAKIZUMAB</span></div>
<div style="position:absolute;left:50.00px;top:605.48px" class="cls_026"><span class="cls_026">Jeffrey Parno</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Kenneth Gordon</span><span class="cls_027"><sup>6</sup></span></div>
<div style="position:absolute;left:306.64px;top:606.10px" class="cls_026"><span class="cls_026">Andrew Blauvelt</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Stephen Tyring</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Melinda Gooderham</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, John</span></div>
<div style="position:absolute;left:50.00px;top:616.15px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Dermatology, The University of Alabama at Birming-</span></div>
<div style="position:absolute;left:306.65px;top:616.00px" class="cls_026"><span class="cls_026">Koo</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span><span class="cls_051"> Yang Zhao</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Simon Lowry</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Stephen Rozzo</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Alan Mendel-</span></div>
<div style="position:absolute;left:50.00px;top:625.82px" class="cls_029"><span class="cls_029">ham, Birmingham, Alabama, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Division of Dermatology, Baylor University</span></div>
<div style="position:absolute;left:306.64px;top:625.90px" class="cls_026"><span class="cls_026">sohn</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Jeffrey Parno</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Kristian Reich</span><span class="cls_027"><sup>6</sup></span></div>
<div style="position:absolute;left:50.00px;top:635.49px" class="cls_029"><span class="cls_029">Medical Center, Dallas, TX, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Bakersfield Dermatology, Bakersfield, CA,</span></div>
<div style="position:absolute;left:306.64px;top:636.50px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Oregon Medical Research Center, Portland, OR, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Der-</span></div>
<div style="position:absolute;left:50.00px;top:645.16px" class="cls_028"><span class="cls_028"><sup>4</sup></span><span class="cls_029">Department of Dermatology, University of Texas Health Science Center,</span></div>
<div style="position:absolute;left:306.64px;top:646.10px" class="cls_029"><span class="cls_029">matology, University of Texas Health Science Center, Houston, TX, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Skin</span></div>
<div style="position:absolute;left:50.00px;top:654.83px" class="cls_029"><span class="cls_029">Houston, TX, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Sun Pharmaceuticals, Princeton, NJ, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Medical College of</span></div>
<div style="position:absolute;left:306.64px;top:655.70px" class="cls_029"><span class="cls_029">Centre for Dermatology, Peterborough, ON, Canada, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Department of Der-</span></div>
<div style="position:absolute;left:50.00px;top:664.50px" class="cls_029"><span class="cls_029">Wisconsin, Milwaukee, WI, USA</span></div>
<div style="position:absolute;left:306.64px;top:665.30px" class="cls_029"><span class="cls_029">matology, University of California at San Francisco, CA, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Sun Pharmaceu-</span></div>
<div style="position:absolute;left:50.00px;top:675.37px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Two phase-3, double-blind, randomized control-</span></div>
<div style="position:absolute;left:306.64px;top:674.90px" class="cls_029"><span class="cls_029">ticals, Princeton, NJ, USA, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">SCIderm Research Institute and Dermatologi-</span></div>
<div style="position:absolute;left:50.00px;top:685.37px" class="cls_031"><span class="cls_031">led trials</span></div>
<div style="position:absolute;left:90.36px;top:685.37px" class="cls_031"><span class="cls_031">(reSURFACE 1: NCT01722331; reSURFACE 2:</span></div>
<div style="position:absolute;left:306.64px;top:684.50px" class="cls_029"><span class="cls_029">kum Hamburg, Hamburg, Germany</span></div>
<div style="position:absolute;left:50.00px;top:695.36px" class="cls_031"><span class="cls_031">NCT01729754) have demonstrated the efficacy and safety of tild-</span></div>
<div style="position:absolute;left:306.64px;top:695.37px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Tildrakizumab, a high affinity, humanized, IgG1 κ,</span></div>
<div style="position:absolute;left:50.00px;top:705.37px" class="cls_031"><span class="cls_031">rakizumab, a high affinity, humanized, IgG1 κ, anti-interleukin-23</span></div>
<div style="position:absolute;left:306.64px;top:705.36px" class="cls_031"><span class="cls_031">anti-interleukin-23 monoclonal antibody, has demonstrated effica-</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:25696px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background34.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">32</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">cy and safety in patients with moderate-to-severe plaque psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Moderate to severe psoriasis was defined by PASI</span><span class="cls_030"> > </span><span class="cls_031">10</span></div>
<div style="position:absolute;left:50.00px;top:61.50px" class="cls_031"><span class="cls_031">in two phase 3, double-blinded, randomized controlled trials (re-</span></div>
<div style="position:absolute;left:306.62px;top:61.44px" class="cls_031"><span class="cls_031">and/or DLQI</span><span class="cls_030"> > </span><span class="cls_031">10 and/or any PASI in a patient with psoriatic</span></div>
<div style="position:absolute;left:50.00px;top:71.59px" class="cls_031"><span class="cls_031">SURFACE 1: NCT01722331; reSURFACE 2: NCT01729754)1.</span></div>
<div style="position:absolute;left:306.62px;top:71.47px" class="cls_031"><span class="cls_031">arthritis.</span></div>
<div style="position:absolute;left:50.00px;top:81.69px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">The analysis examined the association between quality-</span></div>
<div style="position:absolute;left:306.62px;top:81.49px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Most of our patients with mild to moderate psoriasis are</span></div>
<div style="position:absolute;left:50.00px;top:91.79px" class="cls_031"><span class="cls_031">of-life improvements and the degree of skin clearance in patients</span></div>
<div style="position:absolute;left:306.62px;top:91.52px" class="cls_031"><span class="cls_031">using topical and classical therapies. A significant number of pa-</span></div>
<div style="position:absolute;left:50.00px;top:101.89px" class="cls_031"><span class="cls_031">enrolled in the two phase 3 trials and treated with tildrakizumab</span></div>
<div style="position:absolute;left:306.64px;top:101.54px" class="cls_031"><span class="cls_031">tients with severe psoriasis are using biological therapies and about</span></div>
<div style="position:absolute;left:50.00px;top:111.99px" class="cls_031"><span class="cls_031">100 mg or 200 mg at weeks 0, 4, then every 12 weeks.</span></div>
<div style="position:absolute;left:306.64px;top:111.57px" class="cls_031"><span class="cls_031">a half of them were already used a classical or other biologic drug.</span></div>
<div style="position:absolute;left:50.00px;top:122.08px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Both trials used a three-part design: Part 1 (weeks 0-12)</span></div>
<div style="position:absolute;left:306.64px;top:121.59px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Despite the fact that new biological drugs are avai-</span></div>
<div style="position:absolute;left:50.00px;top:132.18px" class="cls_031"><span class="cls_031">was placebo-controlled; Part 2 (weeks 12-28) re-randomized</span></div>
<div style="position:absolute;left:306.64px;top:131.62px" class="cls_031"><span class="cls_031">lable for psoriasis treatment, it seems that the patients with mild</span></div>
<div style="position:absolute;left:50.00px;top:142.28px" class="cls_031"><span class="cls_031">placebo patients to receive tildrakizumab 100 or 200 mg; Part 3</span></div>
<div style="position:absolute;left:306.64px;top:141.64px" class="cls_031"><span class="cls_031">psoriasis are still treating with topical products. At least as far as it</span></div>
<div style="position:absolute;left:50.00px;top:152.38px" class="cls_031"><span class="cls_031">(weeks 28-64, reSURFACE 1; weeks 28-52, reSURFACE 2) re-</span></div>
<div style="position:absolute;left:306.64px;top:151.67px" class="cls_031"><span class="cls_031">concerns our Mediterranean country, it seems that our patients dif-</span></div>
<div style="position:absolute;left:50.00px;top:162.48px" class="cls_031"><span class="cls_031">randomized patients from the tildrakizumab arms with Psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:161.69px" class="cls_031"><span class="cls_031">ficult accept the biological therapies as first choice line treatment.</span></div>
<div style="position:absolute;left:50.00px;top:172.57px" class="cls_031"><span class="cls_031">Area and Severity Index (PASI) response ≥50 at week 28 to receive</span></div>
<div style="position:absolute;left:50.00px;top:182.67px" class="cls_031"><span class="cls_031">the same, a higher, or a lower dose of tildrakizumab, or placebo</span></div>
<div style="position:absolute;left:306.64px;top:181.35px" class="cls_033"><span class="cls_033">P073</span></div>
<div style="position:absolute;left:50.00px;top:192.77px" class="cls_031"><span class="cls_031">(randomized withdrawal in reSURFACE 1). The Dermatology Life</span></div>
<div style="position:absolute;left:306.64px;top:192.78px" class="cls_025"><span class="cls_025">PHARMAKOVIGILANCE OF SYSTEMIC ANTIPSORITIC</span></div>
<div style="position:absolute;left:50.00px;top:202.87px" class="cls_031"><span class="cls_031">Quality Index (DLQI) questionnaire was administered at weeks</span></div>
<div style="position:absolute;left:306.64px;top:203.70px" class="cls_025"><span class="cls_025">DRUGS: AN UPDATE FROM ROUTINE CARE</span></div>
<div style="position:absolute;left:50.00px;top:212.97px" class="cls_031"><span class="cls_031">0, 12, 28, 40, and 52. Tildrakizumab-treated patients were pooled</span></div>
<div style="position:absolute;left:306.64px;top:213.63px" class="cls_026"><span class="cls_026">Christina Sorbe</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Laura Kühl</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Stephan Jeff Rustenbach</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Ralph</span></div>
<div style="position:absolute;left:50.00px;top:223.07px" class="cls_031"><span class="cls_031">from the two trials and classified into 5 mutually exclusive groups</span></div>
<div style="position:absolute;left:306.63px;top:223.55px" class="cls_026"><span class="cls_026">von Kiedrowski</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Marc Alexander Radtke</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">,</span><span class="cls_051"> Matthias Augustin</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:50.01px;top:233.16px" class="cls_031"><span class="cls_031">based on their week-28 PASI response: PASI </span><span class="cls_030"> &lt; </span><span class="cls_031">50, PASI 50-74,</span></div>
<div style="position:absolute;left:306.64px;top:234.18px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">University Medical Center Hamburg-Eppendorf, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Dermatological office,</span></div>
<div style="position:absolute;left:50.01px;top:243.26px" class="cls_031"><span class="cls_031">PASI 75-89, PASI 90-99, and PASI 100. Baseline characteristics,</span></div>
<div style="position:absolute;left:306.64px;top:243.80px" class="cls_029"><span class="cls_029">Selters</span></div>
<div style="position:absolute;left:50.01px;top:253.30px" class="cls_031"><span class="cls_031">the proportion of patients with DLQI 0/1, and mean DLQI chan-</span></div>
<div style="position:absolute;left:306.64px;top:254.70px" class="cls_030"><span class="cls_030">Introduction &</span><span class="cls_031"> </span><span class="cls_030">Objectives: </span><span class="cls_031">The spectrum of antipsoriatic systemic</span></div>
<div style="position:absolute;left:50.00px;top:263.40px" class="cls_031"><span class="cls_031">ges from baseline were examined for each PASI response group.</span></div>
<div style="position:absolute;left:306.63px;top:264.72px" class="cls_031"><span class="cls_031">therapies is constantly changing. The short-term efficacy and</span></div>
<div style="position:absolute;left:50.00px;top:273.49px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Overall, 575 patients on tildrakizumab 100 mg (male:</span></div>
<div style="position:absolute;left:306.64px;top:274.75px" class="cls_031"><span class="cls_031">safety of the various therapies are demonstrated in controlled</span></div>
<div style="position:absolute;left:50.00px;top:283.59px" class="cls_031"><span class="cls_031">69.6%; mean baseline age: 45.6 years) and 581 on tildrakizumab</span></div>
<div style="position:absolute;left:306.64px;top:284.78px" class="cls_031"><span class="cls_031">clinical studies. The German Psoriasis Registry PsoBest aims to</span></div>
<div style="position:absolute;left:50.00px;top:293.68px" class="cls_031"><span class="cls_031">200 mg (male: 73.0%; mean baseline age: 45.9 years) were inclu-</span></div>
<div style="position:absolute;left:306.64px;top:294.80px" class="cls_031"><span class="cls_031">gain long-term evidence of safety and effectiveness in routine</span></div>
<div style="position:absolute;left:50.00px;top:303.77px" class="cls_031"><span class="cls_031">ded. At week 28, 8.3%, 22.0%, 40.9%, 66.3%, and 86.5% (8.7%,</span></div>
<div style="position:absolute;left:306.64px;top:304.83px" class="cls_031"><span class="cls_031">care. Updated interim data of long-term safety of biological and</span></div>
<div style="position:absolute;left:50.00px;top:313.87px" class="cls_031"><span class="cls_031">35.2%, 43.9%, 70.4%, and 85.9%) of patients with PASI </span><span class="cls_030"> &lt; </span><span class="cls_031">50,</span></div>
<div style="position:absolute;left:306.64px;top:314.85px" class="cls_031"><span class="cls_031">non-biological treatment of psoriasis is presented.</span></div>
<div style="position:absolute;left:50.00px;top:323.97px" class="cls_031"><span class="cls_031">50-74, 75-89, 90-99, and 100 achieved DLQI 0/1 for those on</span></div>
<div style="position:absolute;left:306.64px;top:324.88px" class="cls_030"><span class="cls_030">Materials &</span><span class="cls_031"> </span><span class="cls_030">Methods: </span><span class="cls_031">The non-interventional German Psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:334.07px" class="cls_031"><span class="cls_031">100 mg (200 mg), respectively. Patients with higher week-28 PASI</span></div>
<div style="position:absolute;left:306.64px;top:334.91px" class="cls_031"><span class="cls_031">Registry PsoBest observes adult patients with moderate to severe</span></div>
<div style="position:absolute;left:50.00px;top:344.17px" class="cls_031"><span class="cls_031">response also had greater mean DLQI reductions from baseline</span></div>
<div style="position:absolute;left:306.64px;top:344.93px" class="cls_031"><span class="cls_031">psoriasis and/or psoriatic arthritis. Patients are registered at naïve</span></div>
<div style="position:absolute;left:50.00px;top:354.25px" class="cls_031"><span class="cls_031">at week 28 (100 mg: 5.7-13.4; 200 mg: 5.4-12.9). Similar pat-</span></div>
<div style="position:absolute;left:306.64px;top:354.96px" class="cls_031"><span class="cls_031">systemic treatment start and are observed for 10 years in routine</span></div>
<div style="position:absolute;left:50.00px;top:364.34px" class="cls_031"><span class="cls_031">terns were observed among patients continuously treated with</span></div>
<div style="position:absolute;left:306.64px;top:364.98px" class="cls_031"><span class="cls_031">care. The registry aims to gain long-term evidence of safety and</span></div>
<div style="position:absolute;left:50.00px;top:374.44px" class="cls_031"><span class="cls_031">tildrakizumab 100 mg or 200 mg from baseline to week 52, with</span></div>
<div style="position:absolute;left:306.64px;top:375.01px" class="cls_031"><span class="cls_031">effectiveness of systemic antipsoriatic drugs. Data is collected</span></div>
<div style="position:absolute;left:50.00px;top:384.54px" class="cls_031"><span class="cls_031">better PASI-response patients having greater proportions achieving</span></div>
<div style="position:absolute;left:306.64px;top:385.04px" class="cls_031"><span class="cls_031">in dermatological practices and walk-in clinics. Presented are</span></div>
<div style="position:absolute;left:50.00px;top:394.64px" class="cls_031"><span class="cls_031">DLQI 0/1 and greater DLQI reductions sustained from week 28</span></div>
<div style="position:absolute;left:306.64px;top:395.06px" class="cls_031"><span class="cls_031">standardised patient rates per 100 patient years (py) of exposure</span></div>
<div style="position:absolute;left:50.00px;top:404.74px" class="cls_031"><span class="cls_031">through week 52.</span></div>
<div style="position:absolute;left:306.64px;top:405.09px" class="cls_031"><span class="cls_031">classified by system organ classes of MedDRA® (SOC, Medical</span></div>
<div style="position:absolute;left:50.00px;top:414.83px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Tildrakizumab-treated patients with higher levels of</span></div>
<div style="position:absolute;left:306.63px;top:415.11px" class="cls_031"><span class="cls_031">Dictionary for Regulatory Activities).</span></div>
<div style="position:absolute;left:50.00px;top:424.91px" class="cls_031"><span class="cls_031">PASI response also demonstrated better quality-of-life improve-</span></div>
<div style="position:absolute;left:306.63px;top:425.14px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Until June 2017, 5,825 patients were registered and</span></div>
<div style="position:absolute;left:50.00px;top:435.01px" class="cls_031"><span class="cls_031">ments. Achieving PASI 100 was not necessarily associated with</span></div>
<div style="position:absolute;left:306.63px;top:435.17px" class="cls_031"><span class="cls_031">sufficient for analyses. They were predominantly male (58.8%),</span></div>
<div style="position:absolute;left:50.00px;top:445.11px" class="cls_031"><span class="cls_031">achieving DLQI 0/1, therefore both efficacy and quality-of-life</span></div>
<div style="position:absolute;left:306.63px;top:445.19px" class="cls_031"><span class="cls_031">had a mean age of 47.7 years (SD 14.5) and 30.0% of patients</span></div>
<div style="position:absolute;left:50.01px;top:455.20px" class="cls_031"><span class="cls_031">improvements need to be evaluated separately to provide a com-</span></div>
<div style="position:absolute;left:306.63px;top:455.22px" class="cls_031"><span class="cls_031">suffered psoriatic arthritis. 4,729 patient years (py) were observed</span></div>
<div style="position:absolute;left:50.00px;top:465.29px" class="cls_031"><span class="cls_031">plete picture of treatment success.</span></div>
<div style="position:absolute;left:306.63px;top:465.24px" class="cls_031"><span class="cls_031">on biologic treatments and 6,583 py on other systemic treatments.</span></div>
<div style="position:absolute;left:50.00px;top:475.39px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:306.63px;top:475.27px" class="cls_031"><span class="cls_031">For all cause death, malignancies and other serious adverse events</span></div>
<div style="position:absolute;left:50.00px;top:485.50px" class="cls_032"><span class="cls_032">1. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo</span></div>
<div style="position:absolute;left:306.63px;top:485.30px" class="cls_031"><span class="cls_031">(SAE), there were no significant differences between the treatment</span></div>
<div style="position:absolute;left:50.00px;top:494.59px" class="cls_032"><span class="cls_032">or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSUR-</span></div>
<div style="position:absolute;left:306.62px;top:495.32px" class="cls_031"><span class="cls_031">cohorts. Highest SAE rates were observed in the SOCs Surgical</span></div>
<div style="position:absolute;left:50.00px;top:503.69px" class="cls_032"><span class="cls_032">FACE 2): results from two randomised controlled, phase 3 trials. Lancet.</span></div>
<div style="position:absolute;left:306.62px;top:505.35px" class="cls_031"><span class="cls_031">and medical procedures (3.5 and 2.6 patients/ 100 py on biologics</span></div>
<div style="position:absolute;left:50.00px;top:512.78px" class="cls_032"><span class="cls_032">2017;390(10091):276-288.</span></div>
<div style="position:absolute;left:306.62px;top:515.36px" class="cls_031"><span class="cls_031">and non-biologics, respectively), General disorders and adminis-</span></div>
<div style="position:absolute;left:50.00px;top:521.88px" class="cls_032"><span class="cls_032">This abstract has been accepted by 2018 EADV Spring Symposium.</span></div>
<div style="position:absolute;left:306.64px;top:525.38px" class="cls_031"><span class="cls_031">tration site conditions (2.0 and 1.8 patients/ 100 py), Infections</span></div>
<div style="position:absolute;left:306.64px;top:535.41px" class="cls_031"><span class="cls_031">and infestations (1.6 and 1.1 patients/ 100 py) and Neoplasms (1.4</span></div>
<div style="position:absolute;left:50.00px;top:540.59px" class="cls_033"><span class="cls_033">P071</span></div>
<div style="position:absolute;left:306.64px;top:545.44px" class="cls_031"><span class="cls_031">and 1.3 patients/ 100 py). Events from other SOCs were observed</span></div>
<div style="position:absolute;left:50.00px;top:552.08px" class="cls_025"><span class="cls_025">STATISTIC REVIEW OF PSORIASIS SYSTEMATIC</span></div>
<div style="position:absolute;left:306.64px;top:555.46px" class="cls_031"><span class="cls_031">for less than 1 patient/ 100 py.</span></div>
<div style="position:absolute;left:50.00px;top:563.08px" class="cls_025"><span class="cls_025">THERAPIES IN NORTH GREECE</span></div>
<div style="position:absolute;left:306.64px;top:565.48px" class="cls_031"><span class="cls_031">Non-serious adverse events (AE) within the SOCs Skin and sub-</span></div>
<div style="position:absolute;left:50.00px;top:573.08px" class="cls_026"><span class="cls_026">Konstantinos Efthimiadis, </span><span class="cls_051">Florentina-Silvia Delli</span></div>
<div style="position:absolute;left:306.64px;top:575.51px" class="cls_031"><span class="cls_031">cutaneous tissue disorders, Renal and urinary disorders, Blood</span></div>
<div style="position:absolute;left:50.00px;top:583.77px" class="cls_029"><span class="cls_029">State Clinical for Skin and Venereal Diseases Thessaloniki, Greece</span></div>
<div style="position:absolute;left:306.64px;top:585.54px" class="cls_031"><span class="cls_031">and lymphatic system disorders, Gastrointestinal disorders,</span></div>
<div style="position:absolute;left:50.00px;top:594.73px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is a chronic disease that can have a</span></div>
<div style="position:absolute;left:306.64px;top:595.56px" class="cls_031"><span class="cls_031">Nervous system disorders, Vascular disorders as well as Investi-</span></div>
<div style="position:absolute;left:50.00px;top:604.83px" class="cls_031"><span class="cls_031">significant effect on quality of life. Therefore, management of</span></div>
<div style="position:absolute;left:306.64px;top:605.59px" class="cls_031"><span class="cls_031">gations were less frequent in biologic treatment compared to</span></div>
<div style="position:absolute;left:50.02px;top:614.92px" class="cls_031"><span class="cls_031">psoriasis involves both psychosocial and physical aspects of</span></div>
<div style="position:absolute;left:306.64px;top:615.61px" class="cls_031"><span class="cls_031">non-biologics (2.2 vs. 5.3, 0.3 vs. 0.7, 0.4 vs. 2.3, 2.4 vs. 11.3, 1.3</span></div>
<div style="position:absolute;left:50.02px;top:625.02px" class="cls_031"><span class="cls_031">this disease, lately generally admitted as systemic. Numerous</span></div>
<div style="position:absolute;left:306.64px;top:625.64px" class="cls_031"><span class="cls_031">vs. 2.7, 1.2 vs. 2.1 and 2.0 vs. 3.4 patients/ 100 py, respectively,</span></div>
<div style="position:absolute;left:50.02px;top:635.12px" class="cls_031"><span class="cls_031">topical and systemic therapies are available for the treatment of</span></div>
<div style="position:absolute;left:306.64px;top:635.66px" class="cls_030"><span class="cls_030">p ≤ </span><span class="cls_031">0.05). Non-serious infections were observed more often in</span></div>
<div style="position:absolute;left:50.02px;top:645.22px" class="cls_031"><span class="cls_031">the cutaneous manifestations of psoriasis. In our daily clinical</span></div>
<div style="position:absolute;left:306.64px;top:645.69px" class="cls_031"><span class="cls_031">biologics (7.0 vs. 4.8 0 patients/ 100 py, </span><span class="cls_030">p ≤ </span><span class="cls_031">0.05). For the lately</span></div>
<div style="position:absolute;left:50.02px;top:655.32px" class="cls_031"><span class="cls_031">practice, treatment modalities are chosen on the basis of disease</span></div>
<div style="position:absolute;left:306.64px;top:655.72px" class="cls_031"><span class="cls_031">authorized treatments secukinumab and apremilast 253 and 111</span></div>
<div style="position:absolute;left:50.02px;top:665.41px" class="cls_031"><span class="cls_031">severity estimated with PASI and DLQI, relevant comorbidities,</span></div>
<div style="position:absolute;left:306.64px;top:665.74px" class="cls_031"><span class="cls_031">py were observed, for biosimilar treatment 5 py. They showed no</span></div>
<div style="position:absolute;left:50.02px;top:675.51px" class="cls_031"><span class="cls_031">and patient preference.</span></div>
<div style="position:absolute;left:306.64px;top:675.77px" class="cls_031"><span class="cls_031">deviations from the previously observed safety profile of other</span></div>
<div style="position:absolute;left:50.02px;top:685.58px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To assess the frequencies of each systemic drug, clas-</span></div>
<div style="position:absolute;left:306.63px;top:685.79px" class="cls_031"><span class="cls_031">systemic therapies.</span></div>
<div style="position:absolute;left:50.00px;top:695.68px" class="cls_031"><span class="cls_031">sical or biological, used for the treatment of mild, moderate to</span></div>
<div style="position:absolute;left:306.63px;top:695.82px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">In the general, no increased risk of biological or</span></div>
<div style="position:absolute;left:50.00px;top:705.77px" class="cls_031"><span class="cls_031">severe psoriasis in our hospital care unit from January 2016 since</span></div>
<div style="position:absolute;left:306.63px;top:705.85px" class="cls_031"><span class="cls_031">non-biological treatments was observed. The specific differences</span></div>
<div style="position:absolute;left:50.00px;top:715.87px" class="cls_031"><span class="cls_031">December 2016.</span></div>
<div style="position:absolute;left:306.62px;top:715.87px" class="cls_031"><span class="cls_031">in non-serious events will be evaluated in more detail in future</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:26499px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background35.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">33</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">analyses. For robust data on recently authorised therapeutics, more</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">The aim of the present study was to determine whether</span></div>
<div style="position:absolute;left:50.00px;top:61.40px" class="cls_031"><span class="cls_031">observation time is needed, especially with a constantly changing</span></div>
<div style="position:absolute;left:306.64px;top:61.41px" class="cls_031"><span class="cls_031">such patients were at higher risk of developing a KC compared to</span></div>
<div style="position:absolute;left:50.00px;top:71.40px" class="cls_031"><span class="cls_031">spectrum of treatments.</span></div>
<div style="position:absolute;left:306.64px;top:71.41px" class="cls_031"><span class="cls_031">those on conventional therapy.</span></div>
<div style="position:absolute;left:306.64px;top:81.41px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">The British Association of Dermatologists Biologic</span></div>
<div style="position:absolute;left:50.00px;top:90.04px" class="cls_033"><span class="cls_033">P074</span></div>
<div style="position:absolute;left:306.64px;top:91.41px" class="cls_031"><span class="cls_031">Interventions Register (BADBIR), a pharmacovigilance register</span></div>
<div style="position:absolute;left:50.00px;top:101.44px" class="cls_025"><span class="cls_025">THE IMPACT OF PATIENT REQUESTS ON PSORIATIC</span></div>
<div style="position:absolute;left:306.64px;top:101.41px" class="cls_031"><span class="cls_031">of psoriasis patients, explores the long-term safety of systemic</span></div>
<div style="position:absolute;left:50.00px;top:112.34px" class="cls_025"><span class="cls_025">ARTHRITIS TREATMENT</span></div>
<div style="position:absolute;left:306.64px;top:111.41px" class="cls_031"><span class="cls_031">therapies. Patients with chronic plaque psoriasis registering to</span></div>
<div style="position:absolute;left:50.00px;top:122.24px" class="cls_051"><span class="cls_051">Lynn Price</span><span class="cls_026">, Jennifer Robinson, Gianna Melendez</span></div>
<div style="position:absolute;left:306.64px;top:121.41px" class="cls_031"><span class="cls_031">BADBIR on their first biologic or a conventional therapy, who had</span></div>
<div style="position:absolute;left:50.00px;top:132.84px" class="cls_029"><span class="cls_029">Spherix Global Insights</span></div>
<div style="position:absolute;left:306.64px;top:131.41px" class="cls_031"><span class="cls_031">at least one follow-up completed were included in analyses if they</span></div>
<div style="position:absolute;left:50.00px;top:143.71px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">As a result of direct to consumer advertising, pa-</span></div>
<div style="position:absolute;left:306.64px;top:141.41px" class="cls_031"><span class="cls_031">were of white ethnicity, Fitzpatrick skin types 1-4 and reported</span></div>
<div style="position:absolute;left:50.00px;top:153.71px" class="cls_031"><span class="cls_031">tients frequently request well-known brands for the treatment of</span></div>
<div style="position:absolute;left:306.64px;top:151.40px" class="cls_031"><span class="cls_031">no previous cancers. Confounding factors included: age; sex;</span></div>
<div style="position:absolute;left:50.00px;top:163.70px" class="cls_031"><span class="cls_031">psoriatic arthritis, and these patients tend to be highly involved</span></div>
<div style="position:absolute;left:306.64px;top:161.40px" class="cls_031"><span class="cls_031">smoking; and previous exposure to acitretin, psoralen ultraviolet-</span></div>
<div style="position:absolute;left:50.00px;top:173.70px" class="cls_031"><span class="cls_031">in their therapy decisions. Patient requests commonly relate to</span></div>
<div style="position:absolute;left:306.64px;top:171.40px" class="cls_031"><span class="cls_031">A (PUVA), ciclosporin, and/or PUVA and ciclosporin. Propensity</span></div>
<div style="position:absolute;left:50.00px;top:183.70px" class="cls_031"><span class="cls_031">formulation preferences, and in an indication dominated by bio-</span></div>
<div style="position:absolute;left:306.64px;top:181.40px" class="cls_031"><span class="cls_031">score-weighted Cox-proportional hazard models estimated the</span></div>
<div style="position:absolute;left:50.00px;top:193.71px" class="cls_031"><span class="cls_031">logics administered either subcutaneously or intravenously, oral</span></div>
<div style="position:absolute;left:306.64px;top:191.40px" class="cls_031"><span class="cls_031">hazard ratio (HR) for developing a first KC or separately, first</span></div>
<div style="position:absolute;left:50.00px;top:203.70px" class="cls_031"><span class="cls_031">small molecules are in high demand.</span></div>
<div style="position:absolute;left:306.64px;top:201.40px" class="cls_031"><span class="cls_031">BCC or cSCC.</span></div>
<div style="position:absolute;left:50.00px;top:213.70px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">One of the objectives of this study was to gain further</span></div>
<div style="position:absolute;left:306.64px;top:211.40px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">In total, 5672 patients initiating biologic therapy and 3188</span></div>
<div style="position:absolute;left:50.00px;top:223.70px" class="cls_031"><span class="cls_031">insight into patient requests as a main driver for switching to and</span></div>
<div style="position:absolute;left:306.64px;top:221.40px" class="cls_031"><span class="cls_031">patients on conventional therapy who met the entry criteria were</span></div>
<div style="position:absolute;left:50.00px;top:233.70px" class="cls_031"><span class="cls_031">from biologics/apremilast.</span></div>
<div style="position:absolute;left:306.64px;top:231.40px" class="cls_031"><span class="cls_031">identified with 20558 and 7829 person-years of follow-up, respec-</span></div>
<div style="position:absolute;left:50.00px;top:243.70px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">An independent market analytics firm collaborated</span></div>
<div style="position:absolute;left:306.64px;top:241.41px" class="cls_031"><span class="cls_031">tively. During follow-up, 74 (1.3%) patients initiating a biologic</span></div>
<div style="position:absolute;left:50.00px;top:253.70px" class="cls_031"><span class="cls_031">with US rheumatologists (</span><span class="cls_030">n = </span><span class="cls_031">200) to conduct a retrospective</span></div>
<div style="position:absolute;left:306.64px;top:251.41px" class="cls_031"><span class="cls_031">therapy were diagnosed with their first KC (43 BCC; 34 cSCC</span></div>
<div style="position:absolute;left:50.00px;top:263.70px" class="cls_031"><span class="cls_031">chart review of patients diagnosed with psoriatic arthritis (PsA)</span></div>
<div style="position:absolute;left:306.64px;top:261.41px" class="cls_031"><span class="cls_031">first) and 22 (0.7%) patients receiving conventional therapy with</span></div>
<div style="position:absolute;left:50.00px;top:273.70px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">n = </span><span class="cls_031">1,008), who had switched from one biologic therapy or</span></div>
<div style="position:absolute;left:306.63px;top:271.41px" class="cls_031"><span class="cls_031">their first KC (15 BCC; 10 cSCC first). No significant difference</span></div>
<div style="position:absolute;left:50.00px;top:283.70px" class="cls_031"><span class="cls_031">apremilast to another in the prior twelve weeks. Rheumatologists</span></div>
<div style="position:absolute;left:306.64px;top:281.41px" class="cls_031"><span class="cls_031">in risk was observed for developing a KC (adjusted HR 1.05; 95%</span></div>
<div style="position:absolute;left:50.00px;top:293.70px" class="cls_031"><span class="cls_031">were able to submit up to seven PsA patient charts. Data were col-</span></div>
<div style="position:absolute;left:306.64px;top:291.41px" class="cls_031"><span class="cls_031">CI 0.64, 1.73), BCC (0.84; 95% CI 0.45, 1.54) or cSCC (1.20;</span></div>
<div style="position:absolute;left:50.00px;top:303.71px" class="cls_031"><span class="cls_031">lected in April 2017 and included clinical and non-clinical patient</span></div>
<div style="position:absolute;left:306.64px;top:301.41px" class="cls_031"><span class="cls_031">95% CI 0.57, 2.50) on biologic compared to conventional therapy.</span></div>
<div style="position:absolute;left:50.00px;top:313.70px" class="cls_031"><span class="cls_031">demographics, as well as physician demographics and attitudinal</span></div>
<div style="position:absolute;left:306.64px;top:311.41px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Biologic therapy does not appear to confer a higher</span></div>
<div style="position:absolute;left:50.00px;top:323.70px" class="cls_031"><span class="cls_031">survey responses.</span></div>
<div style="position:absolute;left:306.64px;top:321.41px" class="cls_031"><span class="cls_031">risk of developing a first KC as compared to conventional therapy</span></div>
<div style="position:absolute;left:50.00px;top:333.70px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">PsA patients tend to be very involved when it comes to</span></div>
<div style="position:absolute;left:306.65px;top:331.41px" class="cls_031"><span class="cls_031">in psoriasis patients. These data will help inform clinical decision</span></div>
<div style="position:absolute;left:50.00px;top:343.70px" class="cls_031"><span class="cls_031">treatment decisions as 60 percent of patients had significant input</span></div>
<div style="position:absolute;left:306.65px;top:341.40px" class="cls_031"><span class="cls_031">making in psoriasis patients at risk of KC in whom biologic or</span></div>
<div style="position:absolute;left:50.01px;top:353.70px" class="cls_031"><span class="cls_031">or were the primary driver behind the recent decision to switch</span></div>
<div style="position:absolute;left:306.65px;top:351.40px" class="cls_031"><span class="cls_031">conventional therapy is being considered.</span></div>
<div style="position:absolute;left:306.64px;top:361.43px" class="cls_032"><span class="cls_032">On behalf of the BADBIR Study Group, British Association of Derma-</span></div>
<div style="position:absolute;left:50.01px;top:363.70px" class="cls_031"><span class="cls_031">agents. Of those patient driven switches, only 36 percent of treating</span></div>
<div style="position:absolute;left:306.64px;top:370.43px" class="cls_032"><span class="cls_032">tologists, London, UK</span></div>
<div style="position:absolute;left:50.01px;top:373.70px" class="cls_031"><span class="cls_031">rheumatologists felt there was strong clinical rationale behind the</span></div>
<div style="position:absolute;left:50.01px;top:383.70px" class="cls_031"><span class="cls_031">switch; despite this, nearly half of rheumatologists state they tend</span></div>
<div style="position:absolute;left:306.64px;top:388.05px" class="cls_033"><span class="cls_033">P076</span></div>
<div style="position:absolute;left:50.01px;top:393.70px" class="cls_031"><span class="cls_031">to approve specific patient requests.</span></div>
<div style="position:absolute;left:306.64px;top:399.45px" class="cls_025"><span class="cls_025">PATIENT PERCEPTIONS OF PSORIASIS SEVERITY IN</span></div>
<div style="position:absolute;left:50.01px;top:403.70px" class="cls_031"><span class="cls_031">Two-thirds of collaborating rheumatologists believe patients would</span></div>
<div style="position:absolute;left:306.64px;top:410.35px" class="cls_025"><span class="cls_025">SWEDEN, NORWAY, AND DENMARK</span></div>
<div style="position:absolute;left:50.01px;top:413.69px" class="cls_031"><span class="cls_031">choose an oral agent over one that administered subcutaneously,</span></div>
<div style="position:absolute;left:306.64px;top:420.25px" class="cls_026"><span class="cls_026">Kjersti  Danielsen</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">,  Albert  Duvetorp</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">,  Lars  Iversen</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">,  Mikkel</span></div>
<div style="position:absolute;left:50.01px;top:423.69px" class="cls_031"><span class="cls_031">thus switching to apremilast is particularly common when patients</span></div>
<div style="position:absolute;left:306.64px;top:430.15px" class="cls_026"><span class="cls_026">Østergaard</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Oliver Seifert</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Kåre Steinar Tveit</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, </span><span class="cls_051">Lone Skov</span><span class="cls_027"><sup>7</sup></span></div>
<div style="position:absolute;left:50.01px;top:433.69px" class="cls_031"><span class="cls_031">are involved in the decision. Patient requests were the primary</span></div>
<div style="position:absolute;left:306.64px;top:440.75px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">UiT The Arctic University of Norway, Tromsø, Norway; University Hos-</span></div>
<div style="position:absolute;left:50.01px;top:443.69px" class="cls_031"><span class="cls_031">driver behind 24 percent of all switches to apremilast, compared</span></div>
<div style="position:absolute;left:306.64px;top:450.35px" class="cls_029"><span class="cls_029">pital of North Norway, Tromsø, Norway, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Linköping University, Linköping,</span></div>
<div style="position:absolute;left:50.01px;top:453.69px" class="cls_031"><span class="cls_031">to just 12 percent when switching to a biologic. Furthermore, for</span></div>
<div style="position:absolute;left:306.64px;top:459.95px" class="cls_029"><span class="cls_029">Sweden; Skånes Universitetssjukhus, Malmö, Sweden, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Aarhus University</span></div>
<div style="position:absolute;left:50.01px;top:463.69px" class="cls_031"><span class="cls_031">rheumatologists who are not in favor of an “apremilast before</span></div>
<div style="position:absolute;left:306.64px;top:469.55px" class="cls_029"><span class="cls_029">Hospital, Aarhus, Denmark, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Copenhagen Center for Arthritis Research,</span></div>
<div style="position:absolute;left:50.01px;top:473.69px" class="cls_031"><span class="cls_031">biologics” treatment approach, patient requests are significantly</span></div>
<div style="position:absolute;left:306.64px;top:479.15px" class="cls_029"><span class="cls_029">Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup,</span></div>
<div style="position:absolute;left:50.00px;top:483.69px" class="cls_031"><span class="cls_031">more of a driver for the brand than those who have adopted an</span></div>
<div style="position:absolute;left:306.64px;top:488.75px" class="cls_029"><span class="cls_029">University of Copenhagen, Copenhagen, Denmark, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Linköping University,</span></div>
<div style="position:absolute;left:50.00px;top:493.69px" class="cls_031"><span class="cls_031">“apremilast before biologics” approach.</span></div>
<div style="position:absolute;left:306.64px;top:498.35px" class="cls_029"><span class="cls_029">Linköping, Sweden; Ryhov Hospital, Jönköping, Sweden, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Haukeland Uni-</span></div>
<div style="position:absolute;left:50.00px;top:503.69px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">PsA patients are highly involved in the decision to</span></div>
<div style="position:absolute;left:306.64px;top:507.95px" class="cls_029"><span class="cls_029">versity Hospital, Bergen, Norway, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Herlev and Gentofte Hospital, Univer-</span></div>
<div style="position:absolute;left:50.00px;top:513.68px" class="cls_031"><span class="cls_031">initiate and switch biologic/apremilast therapies, and treating rheu-</span></div>
<div style="position:absolute;left:306.63px;top:517.55px" class="cls_029"><span class="cls_029">sity of Copenhagen, Copenhagen, Denmark</span></div>
<div style="position:absolute;left:50.00px;top:523.71px" class="cls_031"><span class="cls_031">matologists tend to be open to granting such requests, regardless</span></div>
<div style="position:absolute;left:306.64px;top:528.36px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Optimal clinical management of psoriasis (PsO) and</span></div>
<div style="position:absolute;left:50.00px;top:533.70px" class="cls_031"><span class="cls_031">of clinical rationale. When patient requests are a primary driver</span></div>
<div style="position:absolute;left:306.64px;top:538.32px" class="cls_031"><span class="cls_031">psoriatic arthritis (PsA) requires understanding of their impact</span></div>
<div style="position:absolute;left:50.00px;top:543.70px" class="cls_031"><span class="cls_031">for switching, apremilast benefits the most; largely due to the oral</span></div>
<div style="position:absolute;left:306.64px;top:548.27px" class="cls_031"><span class="cls_031">on patients.</span></div>
<div style="position:absolute;left:50.00px;top:553.70px" class="cls_031"><span class="cls_031">formulation. With the new approval of the first JAK inhibitor and</span></div>
<div style="position:absolute;left:306.64px;top:558.23px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">NORPAPP aimed to evaluate disease prevalence and</span></div>
<div style="position:absolute;left:50.01px;top:563.70px" class="cls_031"><span class="cls_031">second oral option in the PsA market, tofacitinib will likely fill a</span></div>
<div style="position:absolute;left:306.64px;top:568.18px" class="cls_031"><span class="cls_031">patient perceptions of severity in Sweden, Denmark, and Norway.</span></div>
<div style="position:absolute;left:50.02px;top:573.70px" class="cls_031"><span class="cls_031">gap for both physicians and patients by introducing a high efficacy</span></div>
<div style="position:absolute;left:306.64px;top:578.13px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">NORPAPP was an on-line survey carried out during</span></div>
<div style="position:absolute;left:50.02px;top:583.70px" class="cls_031"><span class="cls_031">oral option, warranting follow-up analysis on the evolution and</span></div>
<div style="position:absolute;left:306.64px;top:588.09px" class="cls_031"><span class="cls_031">November and December 2015 using YouGov panels in Sweden,</span></div>
<div style="position:absolute;left:50.02px;top:593.70px" class="cls_031"><span class="cls_031">impact of patient requests in PsA.</span></div>
<div style="position:absolute;left:306.64px;top:598.04px" class="cls_031"><span class="cls_031">Denmark, and Norway. The survey included 44 questions covering</span></div>
<div style="position:absolute;left:306.64px;top:608.00px" class="cls_031"><span class="cls_031">self-perceived disease severity/symptoms, quality of life, contact</span></div>
<div style="position:absolute;left:50.00px;top:612.34px" class="cls_033"><span class="cls_033">P075</span></div>
<div style="position:absolute;left:306.64px;top:617.95px" class="cls_031"><span class="cls_031">with the healthcare system, and treatment. The initial survey</span></div>
<div style="position:absolute;left:50.00px;top:623.74px" class="cls_025"><span class="cls_025">THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING</span></div>
<div style="position:absolute;left:306.64px;top:627.90px" class="cls_031"><span class="cls_031">population was randomly selected using framing quotas based</span></div>
<div style="position:absolute;left:50.00px;top:634.64px" class="cls_025"><span class="cls_025">BIOLOGICS COMPARED TO CONVENTIONAL</span></div>
<div style="position:absolute;left:306.64px;top:637.86px" class="cls_031"><span class="cls_031">on population census data to ensure inclusion of a representative</span></div>
<div style="position:absolute;left:50.00px;top:645.54px" class="cls_025"><span class="cls_025">SYSTEMIC THERAPIES</span></div>
<div style="position:absolute;left:306.64px;top:647.76px" class="cls_031"><span class="cls_031">sample of adults (aged 18-74 years) from each country. Partici-</span></div>
<div style="position:absolute;left:50.00px;top:655.44px" class="cls_026"><span class="cls_026">Kayleigh Mason</span></div>
<div style="position:absolute;left:306.64px;top:657.71px" class="cls_031"><span class="cls_031">pants were asked if they had PsO or PsA and if it was physician</span></div>
<div style="position:absolute;left:50.00px;top:666.04px" class="cls_029"><span class="cls_029">The University of Manchester, Manchester, UK</span></div>
<div style="position:absolute;left:306.64px;top:667.66px" class="cls_031"><span class="cls_031">diagnosed: those diagnosed by a physician were invited to partici-</span></div>
<div style="position:absolute;left:50.00px;top:676.91px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Whether psoriasis patients exposed to biologic</span></div>
<div style="position:absolute;left:306.64px;top:677.61px" class="cls_031"><span class="cls_031">pate in the full survey. Final survey data were weighted to match</span></div>
<div style="position:absolute;left:50.00px;top:686.90px" class="cls_031"><span class="cls_031">therapies have an elevated risk of keratinocyte carcinoma (KC),</span></div>
<div style="position:absolute;left:306.64px;top:687.57px" class="cls_031"><span class="cls_031">national sex and age distributions. Self-perceived disease severity</span></div>
<div style="position:absolute;left:50.00px;top:696.90px" class="cls_031"><span class="cls_031">including basal cell carcinoma (BCC) or cutaneous squamous cell</span></div>
<div style="position:absolute;left:306.64px;top:697.52px" class="cls_031"><span class="cls_031">was expressed by a 5-level score. Severity of PsO based on the %</span></div>
<div style="position:absolute;left:50.00px;top:706.90px" class="cls_031"><span class="cls_031">carcinoma (cSCC) remains uncertain.</span></div>
<div style="position:absolute;left:306.64px;top:707.48px" class="cls_031"><span class="cls_031">body surface area (BSA, mild </span><span class="cls_030">≤ </span><span class="cls_031">3%; moderate 4-9%; and severe</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:27302px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background36.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">34</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">≥10%) was based on the respondent’s estimate of palms of affected</span></div>
<div style="position:absolute;left:306.64px;top:51.73px" class="cls_032"><span class="cls_032">rationale for development and clinical profile. Expert Opin Pharmacother.</span></div>
<div style="position:absolute;left:49.99px;top:61.40px" class="cls_031"><span class="cls_031">skin (1 palm </span><span class="cls_030"> = </span><span class="cls_031"> 1% BSA).</span></div>
<div style="position:absolute;left:306.63px;top:60.82px" class="cls_032"><span class="cls_032">2017 Jan;18(1):115-121.</span></div>
<div style="position:absolute;left:49.99px;top:71.40px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Among 22,050 individuals questioned, reported preva-</span></div>
<div style="position:absolute;left:306.63px;top:69.92px" class="cls_032"><span class="cls_032">This survey was sponsored by Eli Lilly and Company, Indianapolis, USA.</span></div>
<div style="position:absolute;left:50.00px;top:81.41px" class="cls_031"><span class="cls_031">lence of PsO and/or PsA was 9.7% (9.4% in Sweden, 9.2% in Den-</span></div>
<div style="position:absolute;left:306.64px;top:86.63px" class="cls_033"><span class="cls_033">P078</span></div>
<div style="position:absolute;left:50.00px;top:91.41px" class="cls_031"><span class="cls_031">mark, and 11.9% in Norway); 1264 (5.7%) individuals reported</span></div>
<div style="position:absolute;left:306.64px;top:98.13px" class="cls_025"><span class="cls_025">SOCIOECONOMIC DETERMINANTS OF PAEDIATRIC</span></div>
<div style="position:absolute;left:50.00px;top:101.41px" class="cls_031"><span class="cls_031">physician diagnosis and 1221 of these completed the full survey.</span></div>
<div style="position:absolute;left:50.00px;top:111.40px" class="cls_031"><span class="cls_031">Among survey participants, 74.6% reported PsO alone, 10.3% PsA</span></div>
<div style="position:absolute;left:306.64px;top:109.13px" class="cls_025"><span class="cls_025">PSORIASIS</span></div>
<div style="position:absolute;left:50.00px;top:121.40px" class="cls_031"><span class="cls_031">alone, and 15.1% both. There was a limited correlation between</span></div>
<div style="position:absolute;left:306.64px;top:119.12px" class="cls_051"><span class="cls_051">Jonathan Groot</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Anne-Marie Nybo Andersen</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Abdulfatah Adam</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:50.00px;top:131.40px" class="cls_031"><span class="cls_031">self-perceived disease severity and estimates of % BSA for PsO</span></div>
<div style="position:absolute;left:306.64px;top:129.12px" class="cls_026"><span class="cls_026">Tilde Elkjær Tind Nielsen</span><span class="cls_027"><sup>2,3</sup></span><span class="cls_026">, Christoffer Blegvad</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Lone Skov</span><span class="cls_027"><sup>3</sup></span></div>
<div style="position:absolute;left:306.64px;top:139.82px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Dermatology and Allergy, Herlev and Gentofte Hospital,</span></div>
<div style="position:absolute;left:50.00px;top:141.40px" class="cls_031"><span class="cls_031">(Spearman’s rho 0.42). Self-perceived PsO severity was related</span></div>
<div style="position:absolute;left:306.64px;top:149.51px" class="cls_029"><span class="cls_029">University of Copenhagen, Hellerup, Denmark, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Section for Epidemiology,</span></div>
<div style="position:absolute;left:50.00px;top:151.40px" class="cls_031"><span class="cls_031">to the most common symptoms (itching and flaking/scales) but %</span></div>
<div style="position:absolute;left:306.63px;top:159.21px" class="cls_029"><span class="cls_029">Department of Public Health, University of Copenhagen, Copenhagen,</span></div>
<div style="position:absolute;left:50.01px;top:161.45px" class="cls_031"><span class="cls_031">BSA-based clinical severity was not. Respondents with PsA+PsO</span></div>
<div style="position:absolute;left:306.63px;top:168.90px" class="cls_029"><span class="cls_029">Department of Dermatology and Allergy, Herlev and Gentofte Hospital,</span></div>
<div style="position:absolute;left:50.01px;top:171.51px" class="cls_031"><span class="cls_031">reported significantly worse self-perceived severity and % BSA</span></div>
<div style="position:absolute;left:306.63px;top:178.60px" class="cls_029"><span class="cls_029">University of Copenhagen, Hellerup, Denmark</span></div>
<div style="position:absolute;left:50.01px;top:181.56px" class="cls_031"><span class="cls_031">of PsO than those with PsO alone. Overall, PsA symptoms were</span></div>
<div style="position:absolute;left:50.01px;top:191.61px" class="cls_031"><span class="cls_031">self-perceived to be more severe than PsO symptoms.</span></div>
<div style="position:absolute;left:306.64px;top:189.56px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriatic comorbidities have been shown to be</span></div>
<div style="position:absolute;left:50.01px;top:201.67px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Patient perceptions of PsO severity differ from their</span></div>
<div style="position:absolute;left:306.64px;top:199.66px" class="cls_031"><span class="cls_031">inversely associated with socioeconomic position (SEP). We hy-</span></div>
<div style="position:absolute;left:50.01px;top:211.72px" class="cls_031"><span class="cls_031">estimates of %BSA and should be considered in the assessment</span></div>
<div style="position:absolute;left:306.64px;top:209.75px" class="cls_031"><span class="cls_031">pothesized that the social patterning of paediatric psoriasis would</span></div>
<div style="position:absolute;left:50.01px;top:221.77px" class="cls_031"><span class="cls_031">and management of PsO.</span></div>
<div style="position:absolute;left:306.64px;top:219.85px" class="cls_031"><span class="cls_031">be similar to that observed for several psoriatic comorbidities, such</span></div>
<div style="position:absolute;left:306.64px;top:229.95px" class="cls_031"><span class="cls_031">as cardiovascular disease and type 2 diabetes mellitus.</span></div>
<div style="position:absolute;left:50.00px;top:241.44px" class="cls_033"><span class="cls_033">P077</span></div>
<div style="position:absolute;left:306.64px;top:240.05px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">Our aim was to investigate whether maternal SEP is</span></div>
<div style="position:absolute;left:50.00px;top:252.89px" class="cls_025"><span class="cls_025">PATIENT EXPECTATIONS AND SATISFACTION IN</span></div>
<div style="position:absolute;left:306.64px;top:250.15px" class="cls_031"><span class="cls_031">a determinant of paediatric psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:260.24px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Data on paediatric psoriasis from 36,003 offspring of a</span></div>
<div style="position:absolute;left:50.00px;top:263.85px" class="cls_025"><span class="cls_025">PSORIASIS TREATMENT: A SURVEY FROM EUROPE</span></div>
<div style="position:absolute;left:306.64px;top:270.34px" class="cls_031"><span class="cls_031">national birth cohort were cross-linked with nation-wide registry</span></div>
<div style="position:absolute;left:50.00px;top:274.80px" class="cls_025"><span class="cls_025">AND CANADA</span></div>
<div style="position:absolute;left:306.64px;top:280.44px" class="cls_031"><span class="cls_031">data on maternal educational attainment, maternal labour market</span></div>
<div style="position:absolute;left:50.00px;top:284.74px" class="cls_026"><span class="cls_026">Jonathan Barker</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, </span><span class="cls_051">Robert McKenzie</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Daniel Saure</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Stefan Wil-</span></div>
<div style="position:absolute;left:306.64px;top:290.52px" class="cls_031"><span class="cls_031">attachment and equivalised household income. We performed lo-</span></div>
<div style="position:absolute;left:49.99px;top:294.69px" class="cls_026"><span class="cls_026">helm</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Kunal Gulati</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Ronald Vender</span><span class="cls_027"><sup>3</sup></span></div>
<div style="position:absolute;left:306.64px;top:300.62px" class="cls_031"><span class="cls_031">gistic regression analyses to test for associations between measures</span></div>
<div style="position:absolute;left:50.00px;top:305.34px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Guy’s Hospital, St. John’s Institute of Dermatology, London, UK, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Eli Lilly</span></div>
<div style="position:absolute;left:306.64px;top:310.72px" class="cls_031"><span class="cls_031">of maternal SEP and paediatric psoriasis. Cohort analyses were</span></div>
<div style="position:absolute;left:50.00px;top:314.99px" class="cls_029"><span class="cls_029">and Company, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Dermatrials Research INC, Hamilton, Ontario, Canada</span></div>
<div style="position:absolute;left:306.64px;top:320.82px" class="cls_031"><span class="cls_031">conducted, estimating the odds ratios (OR) and 95% confidence</span></div>
<div style="position:absolute;left:50.00px;top:325.91px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is a chronic immune-mediated disease that</span></div>
<div style="position:absolute;left:306.65px;top:330.91px" class="cls_031"><span class="cls_031">intervals (CI) of offspring psoriasis. We included maternal age at</span></div>
<div style="position:absolute;left:50.00px;top:335.96px" class="cls_031"><span class="cls_031">negatively affects the quality of life of patients.1 Despite recent</span></div>
<div style="position:absolute;left:306.65px;top:341.01px" class="cls_031"><span class="cls_031">birth and maternal psoriasis as covariates in adjusted analyses.</span></div>
<div style="position:absolute;left:50.00px;top:346.02px" class="cls_031"><span class="cls_031">advancements in treatment, patient expectations may differ from</span></div>
<div style="position:absolute;left:306.65px;top:351.10px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Maternal educational attainment and equivalised hous-</span></div>
<div style="position:absolute;left:50.00px;top:356.07px" class="cls_031"><span class="cls_031">the treatment outcome, potentially leading to dissatisfaction.</span></div>
<div style="position:absolute;left:306.64px;top:361.20px" class="cls_031"><span class="cls_031">ehold income were inversely associated with offspring psoriasis.</span></div>
<div style="position:absolute;left:50.00px;top:366.12px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To evaluate patient expectations on psoriasis treatment</span></div>
<div style="position:absolute;left:306.64px;top:371.29px" class="cls_031"><span class="cls_031">Offspring of mothers with a low educational attainment had an OR</span></div>
<div style="position:absolute;left:50.00px;top:376.17px" class="cls_031"><span class="cls_031">outcomes and to what extent these were met by the treatment.</span></div>
<div style="position:absolute;left:306.64px;top:381.39px" class="cls_031"><span class="cls_031">1.62 (95% CI: 1.20-2.18; </span><span class="cls_030">p &lt; </span><span class="cls_031">0.01) of paediatric psoriasis, after</span></div>
<div style="position:absolute;left:50.00px;top:386.23px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Data were collected from patients with moderate-to-</span></div>
<div style="position:absolute;left:306.64px;top:391.49px" class="cls_031"><span class="cls_031">adjusting for maternal psoriasis and age, compared to offspring</span></div>
<div style="position:absolute;left:50.00px;top:396.26px" class="cls_031"><span class="cls_031">severe psoriasis with ≥ 3% skin involvement. Patients were inclu-</span></div>
<div style="position:absolute;left:306.64px;top:401.59px" class="cls_031"><span class="cls_031">of mothers with a medium educational attainment. Offspring of</span></div>
<div style="position:absolute;left:50.00px;top:406.31px" class="cls_031"><span class="cls_031">ded from 17 European countries and Canada through a structured,</span></div>
<div style="position:absolute;left:306.64px;top:411.69px" class="cls_031"><span class="cls_031">mothers in the highest quartile compared to mothers in the lowest</span></div>
<div style="position:absolute;left:50.00px;top:416.36px" class="cls_031"><span class="cls_031">web-based interview in their local language. Patients were on</span></div>
<div style="position:absolute;left:306.64px;top:421.78px" class="cls_031"><span class="cls_031">quartile of equivalised maternal household income had an OR</span></div>
<div style="position:absolute;left:50.00px;top:426.42px" class="cls_031"><span class="cls_031">topical, PUVA/phototherapy, conventional systemic or biological</span></div>
<div style="position:absolute;left:306.64px;top:431.88px" class="cls_031"><span class="cls_031">0.59 (95% CI: 0.44-0.80; </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001) of paediatric psoriasis, after</span></div>
<div style="position:absolute;left:50.00px;top:436.47px" class="cls_031"><span class="cls_031">treatment. Descriptive statistical analyses were conducted.</span></div>
<div style="position:absolute;left:306.64px;top:441.98px" class="cls_031"><span class="cls_031">adjusting for maternal psoriasis and age.</span></div>
<div style="position:absolute;left:50.00px;top:446.52px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Overall, 1946 patients (mean [SD] age: 42 [13] years,</span></div>
<div style="position:absolute;left:306.64px;top:452.06px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Lifetime prevalence of paediatric psoriasis was inver-</span></div>
<div style="position:absolute;left:50.00px;top:456.58px" class="cls_031"><span class="cls_031">43% male) with psoriasis were surveyed between 6 July 2016 and</span></div>
<div style="position:absolute;left:306.64px;top:462.16px" class="cls_031"><span class="cls_031">sely associated with maternal SEP in our study population. Early</span></div>
<div style="position:absolute;left:50.00px;top:466.63px" class="cls_031"><span class="cls_031">5 May 2017. The vast majority of patients currently on treatment</span></div>
<div style="position:absolute;left:306.64px;top:472.26px" class="cls_031"><span class="cls_031">life exposure to modifiable risk factors associated with SEP may</span></div>
<div style="position:absolute;left:50.00px;top:476.68px" class="cls_031"><span class="cls_031">reported reduced itchiness (69%), reduced flaking (62%), and</span></div>
<div style="position:absolute;left:306.65px;top:482.35px" class="cls_031"><span class="cls_031">play an important role in the development of paediatric psoriasis.</span></div>
<div style="position:absolute;left:50.01px;top:486.73px" class="cls_031"><span class="cls_031">clearer skin/skin that looked better generally (61%) as the main</span></div>
<div style="position:absolute;left:306.65px;top:492.45px" class="cls_031"><span class="cls_031">Future studies are warranted to clarify the role of mediating factors.</span></div>
<div style="position:absolute;left:50.01px;top:496.79px" class="cls_031"><span class="cls_031">expectations of their treatment. In addition, these patients reported</span></div>
<div style="position:absolute;left:50.01px;top:506.84px" class="cls_031"><span class="cls_031">duration of effect (41%), extent of overall skin clearance (36%),</span></div>
<div style="position:absolute;left:306.64px;top:511.18px" class="cls_033"><span class="cls_033">P079</span></div>
<div style="position:absolute;left:50.01px;top:516.89px" class="cls_031"><span class="cls_031">and speed of onset (34%) as the main influences for changing their</span></div>
<div style="position:absolute;left:306.64px;top:522.67px" class="cls_025"><span class="cls_025">OBESITY AND THE RISK OF PSORIASIS: A KOREAN</span></div>
<div style="position:absolute;left:50.02px;top:526.95px" class="cls_031"><span class="cls_031">current treatment. Furthermore, patients were asked whether their</span></div>
<div style="position:absolute;left:306.64px;top:533.67px" class="cls_025"><span class="cls_025">NATIONWIDE, POPULATION-BASED STUDY</span></div>
<div style="position:absolute;left:50.02px;top:537.00px" class="cls_031"><span class="cls_031">achieved results matched with their initial treatment expectations.</span></div>
<div style="position:absolute;left:306.64px;top:543.67px" class="cls_051"><span class="cls_051">Ju Hee Han</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Kyung Do Han</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Chul Hwan Bang</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Young Min</span></div>
<div style="position:absolute;left:50.02px;top:547.01px" class="cls_031"><span class="cls_031">Patients reported that the convenience of dosing (68%) and admi-</span></div>
<div style="position:absolute;left:306.64px;top:553.66px" class="cls_026"><span class="cls_026">Park</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Jun Young Lee</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Yong Gyu Park</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Ji Hyun Lee</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:50.00px;top:557.06px" class="cls_031"><span class="cls_031">nistration method (68%) completely met, or even exceeded their</span></div>
<div style="position:absolute;left:306.64px;top:564.36px" class="cls_029"><span class="cls_029">Department of Dermatology, Seoul St. Mary’s Hospital, College of Medici-</span></div>
<div style="position:absolute;left:50.00px;top:567.12px" class="cls_031"><span class="cls_031">initial expectations for the treatment. Conversely, expectations for</span></div>
<div style="position:absolute;left:306.64px;top:574.05px" class="cls_029"><span class="cls_029">ne, The Catholic University of Korea, Department of Biostatistics, College</span></div>
<div style="position:absolute;left:50.00px;top:577.17px" class="cls_031"><span class="cls_031">reduced itchiness (62%), reduced flaking (62%), clearer skin/ skin</span></div>
<div style="position:absolute;left:306.64px;top:583.75px" class="cls_029"><span class="cls_029">of Medicine, The Catholic University of Korea, Seoul, Korea</span></div>
<div style="position:absolute;left:49.99px;top:587.22px" class="cls_031"><span class="cls_031">that looked better generally (63%) were only partially met or not</span></div>
<div style="position:absolute;left:306.64px;top:594.71px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is a T-helper-1 and -17 cell-mediated,</span></div>
<div style="position:absolute;left:49.99px;top:597.28px" class="cls_031"><span class="cls_031">met at all. Approximately, two-third of patients were dissatisfied</span></div>
<div style="position:absolute;left:306.64px;top:604.81px" class="cls_031"><span class="cls_031">chronic, inflammatory skin disease affecting approximately 1-3%</span></div>
<div style="position:absolute;left:49.99px;top:607.33px" class="cls_031"><span class="cls_031">or only partially satisfied with the extent of their skin clearance</span></div>
<div style="position:absolute;left:49.98px;top:617.38px" class="cls_031"><span class="cls_031">and improvement in at least one specific area. Specifically, scalp</span></div>
<div style="position:absolute;left:306.64px;top:614.91px" class="cls_031"><span class="cls_031">of the general population. Psoriasis is currently considered as a</span></div>
<div style="position:absolute;left:49.98px;top:627.43px" class="cls_031"><span class="cls_031">(48%), legs (42%), and arms (41%) were the highest rated areas</span></div>
<div style="position:absolute;left:306.64px;top:625.01px" class="cls_031"><span class="cls_031">chronic low-grade inflammatory condition that plays an active</span></div>
<div style="position:absolute;left:49.98px;top:637.49px" class="cls_031"><span class="cls_031">if asked for insufficient satisfaction for clearance.</span></div>
<div style="position:absolute;left:306.64px;top:635.10px" class="cls_031"><span class="cls_031">role in the development of the pathophysiologic phenomena</span></div>
<div style="position:absolute;left:49.98px;top:647.54px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Data from this international survey indicate that</span></div>
<div style="position:absolute;left:306.64px;top:645.20px" class="cls_031"><span class="cls_031">responsible for metabolic syndrome and cardiovascular disease.</span></div>
<div style="position:absolute;left:49.98px;top:657.59px" class="cls_031"><span class="cls_031">efficacy and maintenance of response are the patients’ primary</span></div>
<div style="position:absolute;left:306.64px;top:655.30px" class="cls_031"><span class="cls_031">Obesity, as a component of the metabolic syndrome, represents a</span></div>
<div style="position:absolute;left:49.98px;top:667.65px" class="cls_031"><span class="cls_031">expectations of psoriasis treatment whereas, insufficient response</span></div>
<div style="position:absolute;left:306.64px;top:665.40px" class="cls_031"><span class="cls_031">major comorbidity and possibly contributes to reduced treatment</span></div>
<div style="position:absolute;left:49.99px;top:677.70px" class="cls_031"><span class="cls_031">to therapy in difficult-to-treat areas appears to be a major reason</span></div>
<div style="position:absolute;left:306.64px;top:675.50px" class="cls_031"><span class="cls_031">response.</span></div>
<div style="position:absolute;left:50.00px;top:687.75px" class="cls_031"><span class="cls_031">for patient dissatisfaction.</span></div>
<div style="position:absolute;left:306.64px;top:685.59px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">This nationwide, population-based study investigated</span></div>
<div style="position:absolute;left:50.00px;top:697.81px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:306.64px;top:695.69px" class="cls_031"><span class="cls_031">the impact of body mass index (BMI) and waist circumference</span></div>
<div style="position:absolute;left:50.00px;top:707.83px" class="cls_032"><span class="cls_032">1. Paul C, Bang B, Lebwohl M. Fixed combination calcipotriol plus beta-</span></div>
<div style="position:absolute;left:306.64px;top:705.79px" class="cls_031"><span class="cls_031">(WC) on the psoriasis in the Korean population.</span></div>
<div style="position:absolute;left:50.00px;top:716.88px" class="cls_032"><span class="cls_032">methasone dipropionate aerosol foam in the treatment of psoriasis vulgaris:</span></div>
<div style="position:absolute;left:306.64px;top:715.89px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">We used the health check-up database, which is sub-</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:28105px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background37.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">35</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">dataset of the Korean National Health Insurance Service database.</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">model, the only variables that were associated with severe de-</span></div>
<div style="position:absolute;left:50.00px;top:61.40px" class="cls_031"><span class="cls_031">Study population includes subjects who had undergone health</span></div>
<div style="position:absolute;left:306.64px;top:61.41px" class="cls_031"><span class="cls_031">terioration of quality of life were the presence of BMI</span><span class="cls_030"> > </span><span class="cls_031"> 27 and</span></div>
<div style="position:absolute;left:50.00px;top:71.40px" class="cls_031"><span class="cls_031">screenings between January 2009 and December 2012. Patients</span></div>
<div style="position:absolute;left:306.64px;top:71.40px" class="cls_031"><span class="cls_031">on the other side, pain, with BMI</span><span class="cls_030"> > </span><span class="cls_031"> 27 is the factor that mostly</span></div>
<div style="position:absolute;left:50.00px;top:81.40px" class="cls_031"><span class="cls_031">who were diagnosed with psoriasis prior to the health screening</span></div>
<div style="position:absolute;left:306.64px;top:81.40px" class="cls_031"><span class="cls_031">impairs the quality of life.</span></div>
<div style="position:absolute;left:50.00px;top:91.40px" class="cls_031"><span class="cls_031">or who were less than 20 years of age were excluded. This study</span></div>
<div style="position:absolute;left:306.64px;top:91.40px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Prevalence of PsA in this series of patients with skin</span></div>
<div style="position:absolute;left:50.00px;top:101.40px" class="cls_031"><span class="cls_031">investigated newly diagnosed patients with psoriasis (ICD-10</span></div>
<div style="position:absolute;left:306.64px;top:101.40px" class="cls_031"><span class="cls_031">or nail psoriasis was 58.3%. The 45.2% of patients showed severe</span></div>
<div style="position:absolute;left:50.00px;top:111.40px" class="cls_031"><span class="cls_031">code, L40) by dermatologists among subjects during the follow-up</span></div>
<div style="position:absolute;left:306.64px;top:111.40px" class="cls_031"><span class="cls_031">activity and 51.6% severe deterioration in their quality of life, that</span></div>
<div style="position:absolute;left:50.00px;top:121.40px" class="cls_031"><span class="cls_031">period through the claim data.</span></div>
<div style="position:absolute;left:306.64px;top:121.40px" class="cls_031"><span class="cls_031">leads to disability and limitation performing daily activities. An</span></div>
<div style="position:absolute;left:50.00px;top:131.40px" class="cls_030"><span class="cls_030">Result: </span><span class="cls_031">Total 22,633,536 subjects were included and psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:131.40px" class="cls_031"><span class="cls_031">early diagnosis provides the possibility of appropriate treatment</span></div>
<div style="position:absolute;left:50.00px;top:141.40px" class="cls_031"><span class="cls_031">newly developed in 399,461 subjects. Mean BMI among newly de-</span></div>
<div style="position:absolute;left:306.64px;top:141.40px" class="cls_031"><span class="cls_031">to improve function, quality of life and decrease the progression</span></div>
<div style="position:absolute;left:50.00px;top:151.41px" class="cls_031"><span class="cls_031">veloped psoriasis group (23.9</span><span class="cls_035">±</span><span class="cls_031">3.25) was higher than non-psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:151.40px" class="cls_031"><span class="cls_031">and complications of the disease.</span></div>
<div style="position:absolute;left:50.00px;top:161.40px" class="cls_031"><span class="cls_031">group (23.68</span><span class="cls_035">±</span><span class="cls_031">3.27)(</span><span class="cls_030">p &lt; </span><span class="cls_031">0.0001). Mean WC of newly developed</span></div>
<div style="position:absolute;left:50.00px;top:171.40px" class="cls_031"><span class="cls_031">psoriasis group (81.21</span><span class="cls_035">±</span><span class="cls_031">9.27) was higher than non-psoriasis group</span></div>
<div style="position:absolute;left:306.64px;top:170.04px" class="cls_033"><span class="cls_033">P081</span></div>
<div style="position:absolute;left:50.00px;top:181.40px" class="cls_031"><span class="cls_031">(79.99</span><span class="cls_035">±</span><span class="cls_031">9.26) (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.0001). BMI showed J-shaped association with</span></div>
<div style="position:absolute;left:306.64px;top:181.44px" class="cls_025"><span class="cls_025">TRIGGERING FACTORS IN CHILDHOOD PSORIASIS</span></div>
<div style="position:absolute;left:50.00px;top:191.40px" class="cls_031"><span class="cls_031">the risk of psoriasis. Subjects with BMI over 30 had higher risk</span></div>
<div style="position:absolute;left:306.64px;top:191.34px" class="cls_026"><span class="cls_026">Iveta Dencheva</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, </span><span class="cls_051">Ivan Botev</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Lyubka Miteva</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:50.00px;top:201.40px" class="cls_031"><span class="cls_031">of psoriasis (HR 1.118, 95% CI 1.1-1.137). The risk of psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:201.94px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Dermatology clinic “Persenk”, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Dermatology and Venere-</span></div>
<div style="position:absolute;left:50.00px;top:211.40px" class="cls_031"><span class="cls_031">increased in proportion to WC. Subjects with WC over 105 cm</span></div>
<div style="position:absolute;left:306.64px;top:211.54px" class="cls_029"><span class="cls_029">ology, Medical University, Sofia, Bulgaria; Dermatology clinic “Persenk”,</span></div>
<div style="position:absolute;left:50.00px;top:221.40px" class="cls_031"><span class="cls_031">showed highest risk of psoriasis (HR 1.305, 95% CI 1.261-1.349)</span></div>
<div style="position:absolute;left:306.64px;top:221.14px" class="cls_029"><span class="cls_029">Sofia, Bulgaria</span></div>
<div style="position:absolute;left:50.00px;top:231.40px" class="cls_031"><span class="cls_031">after adjusting confounding factors including BMI. The risk of</span></div>
<div style="position:absolute;left:306.64px;top:232.01px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is a chronic multisystem, inflammatory di-</span></div>
<div style="position:absolute;left:50.00px;top:241.40px" class="cls_031"><span class="cls_031">psoriasis increased most in the male group with normal weight,</span></div>
<div style="position:absolute;left:306.64px;top:242.01px" class="cls_031"><span class="cls_031">sease that occurs at any age. It represents about 4% of all dermato-</span></div>
<div style="position:absolute;left:50.00px;top:251.40px" class="cls_031"><span class="cls_031">abdominal obesity (HR 1.175, 95% CI 1.15-1.2).</span></div>
<div style="position:absolute;left:306.64px;top:252.01px" class="cls_031"><span class="cls_031">sis observed in children. Approximately one third of all patients</span></div>
<div style="position:absolute;left:50.00px;top:261.40px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">According to our study, the WC is more likely to affect</span></div>
<div style="position:absolute;left:306.64px;top:262.00px" class="cls_031"><span class="cls_031">have onset of the disease under the age of 16. The most common</span></div>
<div style="position:absolute;left:50.00px;top:271.40px" class="cls_031"><span class="cls_031">the risk of psoriasis than obesity. Our study supports the associa-</span></div>
<div style="position:absolute;left:306.64px;top:272.00px" class="cls_031"><span class="cls_031">triggering factors in children are stress, Koebner phenomenon,</span></div>
<div style="position:absolute;left:50.00px;top:281.41px" class="cls_031"><span class="cls_031">tion between abdominal obesity and psoriasis, which increases</span></div>
<div style="position:absolute;left:306.64px;top:282.00px" class="cls_031"><span class="cls_031">infections and seasonal change.</span></div>
<div style="position:absolute;left:50.00px;top:291.40px" class="cls_031"><span class="cls_031">awareness of the role of abdominal obesity in the pathogenesis</span></div>
<div style="position:absolute;left:306.64px;top:292.00px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">The aim of this study was to assess the most common</span></div>
<div style="position:absolute;left:50.00px;top:301.40px" class="cls_031"><span class="cls_031">and comorbidities of psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:302.00px" class="cls_031"><span class="cls_031">triggering and precipitating factors of psoriasis among Bulgarien</span></div>
<div style="position:absolute;left:306.64px;top:312.00px" class="cls_031"><span class="cls_031">children.</span></div>
<div style="position:absolute;left:50.00px;top:322.04px" class="cls_033"><span class="cls_033">P080</span></div>
<div style="position:absolute;left:306.64px;top:322.00px" class="cls_030"><span class="cls_030">Materials and</span><span class="cls_031"> </span><span class="cls_030">Methods: </span><span class="cls_031">This study included 42 consecutively</span></div>
<div style="position:absolute;left:50.00px;top:333.44px" class="cls_025"><span class="cls_025">CLINICAL CHARACTERIZATION OF PSORIATIC</span></div>
<div style="position:absolute;left:306.64px;top:332.00px" class="cls_031"><span class="cls_031">diagnosed children with psoriasis who presented in the Department</span></div>
<div style="position:absolute;left:50.00px;top:344.34px" class="cls_025"><span class="cls_025">ARTHRITIS IN A MULTIDISCIPLINARY CARE MODEL</span></div>
<div style="position:absolute;left:306.64px;top:342.00px" class="cls_031"><span class="cls_031">of Dermatology and Venereology at Alexandrovska University</span></div>
<div style="position:absolute;left:306.64px;top:352.00px" class="cls_031"><span class="cls_031">Hospital, in Sofia, Bulgaria. The inclusion criteria were a clinical</span></div>
<div style="position:absolute;left:50.00px;top:355.24px" class="cls_025"><span class="cls_025">OF PATIENTS WITH PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:361.99px" class="cls_031"><span class="cls_031">diagnosis of psoriasis and age under 18 years.</span></div>
<div style="position:absolute;left:50.00px;top:365.14px" class="cls_026"><span class="cls_026">Dalila Alejandra Lopez-Rodriguez</span></div>
<div style="position:absolute;left:306.64px;top:371.99px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">A total of 42 children with psoriasis were examined, 18</span></div>
<div style="position:absolute;left:50.00px;top:375.04px" class="cls_026"><span class="cls_026">Dermatologico Country</span></div>
<div style="position:absolute;left:306.64px;top:381.99px" class="cls_031"><span class="cls_031">(42.85%) males and 24 (57.15%) females. The most frequent fac-</span></div>
<div style="position:absolute;left:50.00px;top:384.91px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriatic arthritis (PsA) is an inflammatory arthro-</span></div>
<div style="position:absolute;left:306.64px;top:392.01px" class="cls_031"><span class="cls_031">tors precipitating psoriasis in our group of children were psycho-</span></div>
<div style="position:absolute;left:50.00px;top:394.91px" class="cls_031"><span class="cls_031">pathy that occurs in patients with Psoriasis (PsO). The frequency</span></div>
<div style="position:absolute;left:306.64px;top:402.00px" class="cls_031"><span class="cls_031">emotional stress in 16 (38.09%) cases. Koebner`s phenomenon</span></div>
<div style="position:absolute;left:50.00px;top:404.90px" class="cls_031"><span class="cls_031">of PsA in patients with PsO has been estimated between 10-40%.</span></div>
<div style="position:absolute;left:306.64px;top:412.00px" class="cls_031"><span class="cls_031">was observed in 3 (7.14%) patients. In only two (4.76%) children</span></div>
<div style="position:absolute;left:50.00px;top:414.90px" class="cls_031"><span class="cls_031">The presentation and clinical course are variable, therefore, it is</span></div>
<div style="position:absolute;left:306.64px;top:422.00px" class="cls_031"><span class="cls_031">triggering factors associated with psoriasis were infections. In 17</span></div>
<div style="position:absolute;left:50.00px;top:424.90px" class="cls_031"><span class="cls_031">necessary to understand the clinical behavior, severity and as-</span></div>
<div style="position:absolute;left:306.64px;top:432.00px" class="cls_031"><span class="cls_031">(40.47%) cases aggravating factors could not be identified. The</span></div>
<div style="position:absolute;left:50.00px;top:434.91px" class="cls_031"><span class="cls_031">sociated factors that condition functional impairment, disability</span></div>
<div style="position:absolute;left:306.64px;top:442.00px" class="cls_031"><span class="cls_031">influence of the season on disease activity could be determined</span></div>
<div style="position:absolute;left:50.00px;top:444.90px" class="cls_031"><span class="cls_031">and lost quality of life.</span></div>
<div style="position:absolute;left:306.66px;top:452.00px" class="cls_031"><span class="cls_031">in 25 (59.52%) patients. All of them showed worsening in winter</span></div>
<div style="position:absolute;left:50.00px;top:454.90px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To describe the clinical features of the ApS, in a mul-</span></div>
<div style="position:absolute;left:306.66px;top:462.00px" class="cls_031"><span class="cls_031">and improvement in summer.</span></div>
<div style="position:absolute;left:50.00px;top:464.91px" class="cls_031"><span class="cls_031">tidisciplinary PsO clinic.</span></div>
<div style="position:absolute;left:306.66px;top:472.00px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">The most frequent factors precipitating psoriasis in</span></div>
<div style="position:absolute;left:50.00px;top:474.90px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Prospective study, August 2016-february 2018, patients</span></div>
<div style="position:absolute;left:306.66px;top:482.00px" class="cls_031"><span class="cls_031">children revealed in this study, were stressful life events, Koebner</span></div>
<div style="position:absolute;left:50.00px;top:484.90px" class="cls_031"><span class="cls_031">attending to Multidisciplinary Clinic for psoriasis in Dermatolo-</span></div>
<div style="position:absolute;left:306.66px;top:492.00px" class="cls_031"><span class="cls_031">phenomenon and infectious disease. Among patients who reported</span></div>
<div style="position:absolute;left:50.00px;top:494.91px" class="cls_031"><span class="cls_031">gico Country were included.</span></div>
<div style="position:absolute;left:306.66px;top:501.99px" class="cls_031"><span class="cls_031">triggering factors, stress was the most common cause. The study</span></div>
<div style="position:absolute;left:50.00px;top:504.90px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">A total of 53 participants were included, finding a preva-</span></div>
<div style="position:absolute;left:306.66px;top:511.99px" class="cls_031"><span class="cls_031">showed that psoriasis in children relapses and worsens mainly in</span></div>
<div style="position:absolute;left:50.00px;top:514.91px" class="cls_031"><span class="cls_031">lence of psoriatic arthropathy of 58.5%.</span></div>
<div style="position:absolute;left:306.66px;top:521.99px" class="cls_031"><span class="cls_031">winter season.</span></div>
<div style="position:absolute;left:50.00px;top:524.90px" class="cls_031"><span class="cls_031">The median age was 42 years and 71% were female. Patients with</span></div>
<div style="position:absolute;left:50.00px;top:534.90px" class="cls_031"><span class="cls_031">ApS have higher frequency of DM2, metabolic syndrome and</span></div>
<div style="position:absolute;left:306.64px;top:540.64px" class="cls_033"><span class="cls_033">P082</span></div>
<div style="position:absolute;left:50.00px;top:544.90px" class="cls_031"><span class="cls_031">hepatic steatosis. However, the differences are not statistically</span></div>
<div style="position:absolute;left:306.64px;top:552.04px" class="cls_025"><span class="cls_025">QUALITY OF CARE FOR PSORIASIS IN THE PAST 12</span></div>
<div style="position:absolute;left:50.00px;top:554.90px" class="cls_031"><span class="cls_031">significant, which could be a result of the sample size. According</span></div>
<div style="position:absolute;left:306.64px;top:562.94px" class="cls_025"><span class="cls_025">YEARS - RESULTS FROM A SERIES OF NATIONWIDE</span></div>
<div style="position:absolute;left:49.99px;top:564.90px" class="cls_031"><span class="cls_031">to the activity of PsO the most frequent presentation was plaque</span></div>
<div style="position:absolute;left:49.99px;top:574.90px" class="cls_031"><span class="cls_031">psoriasis in 67.7%. Median PASI was 5.4 (1.5, 16.4). Axial pre-</span></div>
<div style="position:absolute;left:306.64px;top:573.84px" class="cls_025"><span class="cls_025">HEALTH CARE STUDIES IN GERMANY</span></div>
<div style="position:absolute;left:50.00px;top:584.91px" class="cls_031"><span class="cls_031">sentation of ApS was observed in 51.6% and peripheral disease</span></div>
<div style="position:absolute;left:306.64px;top:583.74px" class="cls_026"><span class="cls_026">Matthias Augustin</span></div>
<div style="position:absolute;left:50.00px;top:594.90px" class="cls_031"><span class="cls_031">in 71%, enthesitis was found in 54.8% and dactylitis 16.1%.</span></div>
<div style="position:absolute;left:306.64px;top:594.34px" class="cls_029"><span class="cls_029">Institute for Health Services Research in Dermatology</span></div>
<div style="position:absolute;left:50.00px;top:604.90px" class="cls_031"><span class="cls_031">To determine the severity of PsA according DAS 28 score, we</span></div>
<div style="position:absolute;left:306.64px;top:605.21px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">In Germany, the quality of health care for psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:614.90px" class="cls_031"><span class="cls_031">found 45.2% of patients presented severe activity. One hundred</span></div>
<div style="position:absolute;left:306.64px;top:615.20px" class="cls_031"><span class="cls_031">was very critical in 2005. Most patients lacked of sufficient care</span></div>
<div style="position:absolute;left:50.00px;top:624.90px" class="cls_031"><span class="cls_031">percent of the subjects with peripheral disease did not achieve</span></div>
<div style="position:absolute;left:306.64px;top:625.20px" class="cls_031"><span class="cls_031">and there was only a minor proportion receiving systemic drugs.</span></div>
<div style="position:absolute;left:50.00px;top:634.90px" class="cls_031"><span class="cls_031">low activity criteria of the disease measured by MDA. When</span></div>
<div style="position:absolute;left:306.64px;top:635.20px" class="cls_031"><span class="cls_031">In the mean time, there has been conducted a national psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:644.90px" class="cls_031"><span class="cls_031">calculating the tertiles of the HAQ instrument, it is possible to</span></div>
<div style="position:absolute;left:306.64px;top:645.20px" class="cls_031"><span class="cls_031">program in order to improve the quality of psoriasis care, inclu-</span></div>
<div style="position:absolute;left:50.00px;top:654.90px" class="cls_031"><span class="cls_031">observe that 51.6% of patients presented severe deterioration</span></div>
<div style="position:absolute;left:306.64px;top:655.21px" class="cls_031"><span class="cls_031">ding development of an evidence-based guideline, a consensus of</span></div>
<div style="position:absolute;left:50.00px;top:664.90px" class="cls_031"><span class="cls_031">in the quality of life. In the logistic regression model without</span></div>
<div style="position:absolute;left:306.64px;top:665.20px" class="cls_031"><span class="cls_031">treatment goals, the invention of a “culture of measurement” and</span></div>
<div style="position:absolute;left:50.00px;top:674.90px" class="cls_031"><span class="cls_031">adjustment, the presence of a severe DAS 28 is associated with</span></div>
<div style="position:absolute;left:306.64px;top:675.20px" class="cls_031"><span class="cls_031">consented national goals for psoriasis care. These measures were</span></div>
<div style="position:absolute;left:50.00px;top:684.90px" class="cls_031"><span class="cls_031">an increase in the risk of deterioration in quality of life, with OR</span></div>
<div style="position:absolute;left:306.64px;top:685.20px" class="cls_031"><span class="cls_031">supported by the establishment of 30 regional psoriasis networks</span></div>
<div style="position:absolute;left:50.00px;top:694.89px" class="cls_031"><span class="cls_031">of 6.24 (1.74, 22.2). The presence of BMI</span><span class="cls_030"> > </span><span class="cls_031"> 27 is associated with</span></div>
<div style="position:absolute;left:306.64px;top:695.20px" class="cls_031"><span class="cls_031">involving more than 800 dermatologists.</span></div>
<div style="position:absolute;left:50.00px;top:704.89px" class="cls_031"><span class="cls_031">an increase in the risk of deterioration in quality of life with OR</span></div>
<div style="position:absolute;left:306.64px;top:705.20px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">(1) Presentation of the very recent results on the health</span></div>
<div style="position:absolute;left:50.00px;top:714.89px" class="cls_031"><span class="cls_031">of 6.53 (1.59, 26.8). When performing the adjusted multivariate</span></div>
<div style="position:absolute;left:306.64px;top:715.20px" class="cls_031"><span class="cls_031">care situation of patients with psoriasis vulgaris in dermatological</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:28908px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background38.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">36</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">treatment in Germany 2016/17 (2) Comparison of health care</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">organizations, 230 research institutes (general/psoriasis specific),</span></div>
<div style="position:absolute;left:50.00px;top:61.44px" class="cls_031"><span class="cls_031">quality indicators between the surveys 2004/05, 2007, 2013/14</span></div>
<div style="position:absolute;left:306.64px;top:61.40px" class="cls_031"><span class="cls_031">13 claim data sources and 261 publications on psoriasis. The in-</span></div>
<div style="position:absolute;left:50.00px;top:71.48px" class="cls_031"><span class="cls_031">and 2016/17.</span></div>
<div style="position:absolute;left:306.64px;top:71.41px" class="cls_031"><span class="cls_031">ternal pilot for the global online surveys has been completed by</span></div>
<div style="position:absolute;left:50.00px;top:81.51px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Nationwide, non-interventional, cross-sectional studies.</span></div>
<div style="position:absolute;left:306.64px;top:81.40px" class="cls_031"><span class="cls_031">an international expert team for further improvement. Currently,</span></div>
<div style="position:absolute;left:50.00px;top:91.55px" class="cls_031"><span class="cls_031">In each survey between 71 and 130 centers included patients</span></div>
<div style="position:absolute;left:306.64px;top:91.40px" class="cls_031"><span class="cls_031">the surveys are being sent out to dermatologists and non-dermato-</span></div>
<div style="position:absolute;left:50.00px;top:101.58px" class="cls_031"><span class="cls_031">and data from patients and dermatologists were obtained from a</span></div>
<div style="position:absolute;left:306.64px;top:101.41px" class="cls_031"><span class="cls_031">logists. On a monthly base, both work streams are updating each</span></div>
<div style="position:absolute;left:50.00px;top:111.62px" class="cls_031"><span class="cls_031">minimum of 1500 patients per survey. Quality of care indicators</span></div>
<div style="position:absolute;left:306.64px;top:111.40px" class="cls_031"><span class="cls_031">other about their achievements and issues.</span></div>
<div style="position:absolute;left:50.00px;top:121.65px" class="cls_031"><span class="cls_031">were severity of the psoriasis (PASI and proportion of patients</span></div>
<div style="position:absolute;left:306.64px;top:121.40px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">In the next steps of Work Stream 2, a database will</span></div>
<div style="position:absolute;left:50.00px;top:131.69px" class="cls_031"><span class="cls_031">with PASI</span><span class="cls_030"> > </span><span class="cls_031">20, indicating high severity), quality of life (DLQI</span></div>
<div style="position:absolute;left:306.64px;top:131.40px" class="cls_031"><span class="cls_031">be created in order to insert all identified data sources. Informa-</span></div>
<div style="position:absolute;left:50.00px;top:141.72px" class="cls_031"><span class="cls_031">and proportion of patients with DLQI</span><span class="cls_030"> > </span><span class="cls_031">10, indicating strong</span></div>
<div style="position:absolute;left:306.64px;top:141.41px" class="cls_031"><span class="cls_031">tion from identified data sources will be used to contact (via</span></div>
<div style="position:absolute;left:50.00px;top:151.76px" class="cls_031"><span class="cls_031">impairments in quality of life), previous systemic therapy and</span></div>
<div style="position:absolute;left:306.65px;top:151.40px" class="cls_031"><span class="cls_031">email) the responsible persons to access this data. Additionally,</span></div>
<div style="position:absolute;left:50.00px;top:161.79px" class="cls_031"><span class="cls_031">inpatient treatment in the last five years.</span></div>
<div style="position:absolute;left:306.65px;top:161.40px" class="cls_031"><span class="cls_031">survey responses will be analyzed and added in the database.</span></div>
<div style="position:absolute;left:50.00px;top:171.83px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Between January 2016 and December 2017 </span><span class="cls_030">n = </span><span class="cls_031">1827</span></div>
<div style="position:absolute;left:306.65px;top:171.40px" class="cls_031"><span class="cls_031">This database will be updated regularly and extended to include</span></div>
<div style="position:absolute;left:50.01px;top:181.86px" class="cls_031"><span class="cls_031">patients from 93 dermatological centers were included in the re-</span></div>
<div style="position:absolute;left:306.65px;top:181.40px" class="cls_031"><span class="cls_031">comorbidities in future.</span></div>
<div style="position:absolute;left:50.00px;top:191.94px" class="cls_031"><span class="cls_031">cent survey (mean age 51 years, 45.2% female). 7.5% had severe</span></div>
<div style="position:absolute;left:50.00px;top:201.97px" class="cls_031"><span class="cls_031">psoriasis (PASI</span><span class="cls_030"> > </span><span class="cls_031">20) compared to 9.2% in 2013/14, 11.6% in 2007</span></div>
<div style="position:absolute;left:306.64px;top:201.04px" class="cls_033"><span class="cls_033">P084</span></div>
<div style="position:absolute;left:50.00px;top:212.01px" class="cls_031"><span class="cls_031">and 17.8% in 2004/05. The mean PASI was 7.3 compared to 8.1 in</span></div>
<div style="position:absolute;left:306.64px;top:212.44px" class="cls_025"><span class="cls_025">GLOBAL BURDEN OF DISEASE: A SYSTEMATIC</span></div>
<div style="position:absolute;left:50.00px;top:222.04px" class="cls_031"><span class="cls_031">2013/14, 10.1 in 2007 and 11.4 in 2005. The mean DLQI was 6.1</span></div>
<div style="position:absolute;left:306.64px;top:223.34px" class="cls_025"><span class="cls_025">LITERATURE REVIEW ON DISABILITY WEIGHTS FOR</span></div>
<div style="position:absolute;left:50.00px;top:232.08px" class="cls_031"><span class="cls_031">compared to 5.9 in 2013/14, 7.5 in 2007 and 8.6 in 2005. 21.4%</span></div>
<div style="position:absolute;left:306.64px;top:234.24px" class="cls_025"><span class="cls_025">SKIN DISEASES</span></div>
<div style="position:absolute;left:50.00px;top:242.11px" class="cls_031"><span class="cls_031">reported a strongly impaired quality of life (DLQI</span><span class="cls_030"> > </span><span class="cls_031">10) compared</span></div>
<div style="position:absolute;left:306.64px;top:244.14px" class="cls_051"><span class="cls_051">Nirohshah Suthakharan</span><span class="cls_026">, Matthias Augustin</span></div>
<div style="position:absolute;left:50.00px;top:252.15px" class="cls_031"><span class="cls_031">to 21.3% in 2013/14, 28.2% in 2007 and 34.0% in 2005. 59.5% of</span></div>
<div style="position:absolute;left:306.64px;top:254.74px" class="cls_029"><span class="cls_029">University Medical Center Hamburg, Institute for Health Services Re-</span></div>
<div style="position:absolute;left:50.00px;top:262.18px" class="cls_031"><span class="cls_031">all participants stated that they had received systemic therapy at</span></div>
<div style="position:absolute;left:306.64px;top:264.34px" class="cls_029"><span class="cls_029">search in Dermatology and Nursing (IVDP)</span></div>
<div style="position:absolute;left:50.00px;top:272.22px" class="cls_031"><span class="cls_031">least once within the last five years compared to 59.5% in 2013/14,</span></div>
<div style="position:absolute;left:306.64px;top:275.21px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Skin diseases account for one of the most common</span></div>
<div style="position:absolute;left:50.00px;top:282.25px" class="cls_031"><span class="cls_031">47.3% in 2007 and 32.9% in 2005. 18% received inpatient hospi-</span></div>
<div style="position:absolute;left:306.64px;top:285.20px" class="cls_031"><span class="cls_031">human illnesses globally but in the recent Global Burden of Di-</span></div>
<div style="position:absolute;left:50.00px;top:292.31px" class="cls_031"><span class="cls_031">tal treatment within the last five years at least once, compared to</span></div>
<div style="position:absolute;left:306.64px;top:295.21px" class="cls_031"><span class="cls_031">sease (GBD) study, psoriasis, for example, ranked 144 out of 174</span></div>
<div style="position:absolute;left:49.99px;top:302.35px" class="cls_031"><span class="cls_031">20.1% in 2013/14, 20.1% in 2007 and 26.9% in 2005.</span></div>
<div style="position:absolute;left:306.64px;top:305.20px" class="cls_031"><span class="cls_031">conditions in the DALY rankings. Two components of DALY cal-</span></div>
<div style="position:absolute;left:49.99px;top:312.38px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">It can be assumed that health care quality for pso-</span></div>
<div style="position:absolute;left:306.64px;top:315.21px" class="cls_031"><span class="cls_031">culation are prevalence of the disease and disability weight factor.</span></div>
<div style="position:absolute;left:50.00px;top:322.43px" class="cls_031"><span class="cls_031">riasis patients in Germany has improved within the last 12 years.</span></div>
<div style="position:absolute;left:306.64px;top:325.20px" class="cls_031"><span class="cls_031">The derivation of disability weight (DW) factor depends on many</span></div>
<div style="position:absolute;left:306.64px;top:335.20px" class="cls_031"><span class="cls_031">factors which can lead to wide range of results. GBD methodology</span></div>
<div style="position:absolute;left:50.00px;top:342.10px" class="cls_033"><span class="cls_033">P083</span></div>
<div style="position:absolute;left:306.64px;top:345.20px" class="cls_031"><span class="cls_031">can significantly underestimate the skin disease burden.</span></div>
<div style="position:absolute;left:50.00px;top:353.54px" class="cls_025"><span class="cls_025">GLOBAL PSORIASIS ATLAS - WORK STREAM 2</span></div>
<div style="position:absolute;left:306.64px;top:355.20px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To understand the currently used DWs of skin diseases</span></div>
<div style="position:absolute;left:50.00px;top:363.47px" class="cls_051"><span class="cls_051">Matthias Augustin</span><span class="cls_026">, Nirohshah Suthakharan</span></div>
<div style="position:absolute;left:306.64px;top:365.20px" class="cls_031"><span class="cls_031">in-depth and if these current records of DWs can be solely based</span></div>
<div style="position:absolute;left:50.00px;top:374.11px" class="cls_029"><span class="cls_029">University Medical Center Hamburg, Institute for Health Services Re-</span></div>
<div style="position:absolute;left:306.64px;top:375.20px" class="cls_031"><span class="cls_031">on a survey that was conducted on the general population.</span></div>
<div style="position:absolute;left:50.00px;top:383.75px" class="cls_029"><span class="cls_029">search in Dermatology and Nursing (IVDP)</span></div>
<div style="position:absolute;left:306.64px;top:385.20px" class="cls_031"><span class="cls_031">Methodology: A systematic literature review was performed to</span></div>
<div style="position:absolute;left:50.00px;top:394.65px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is a common, chronic and non-com-</span></div>
<div style="position:absolute;left:306.64px;top:395.20px" class="cls_031"><span class="cls_031">answer the research questions. Comprehensive search of eligible</span></div>
<div style="position:absolute;left:50.00px;top:404.69px" class="cls_031"><span class="cls_031">municable skin disease with an immensely negative impact on</span></div>
<div style="position:absolute;left:306.64px;top:405.20px" class="cls_031"><span class="cls_031">scientific and grey publication in English, from 2007 to 2017, were</span></div>
<div style="position:absolute;left:50.00px;top:414.73px" class="cls_031"><span class="cls_031">people’s lives. There is a lack of standardized case-definition or</span></div>
<div style="position:absolute;left:306.64px;top:415.20px" class="cls_031"><span class="cls_031">conducted in PubMed and EMBASE (Ovid). The studies included</span></div>
<div style="position:absolute;left:50.00px;top:424.76px" class="cls_031"><span class="cls_031">methodology leading to a wide variation in the prevalence estimate</span></div>
<div style="position:absolute;left:306.64px;top:425.19px" class="cls_031"><span class="cls_031">were based on 16 skin condition and other diseases indicating a</span></div>
<div style="position:absolute;left:50.00px;top:434.80px" class="cls_031"><span class="cls_031">between 0.09% and 11.43%. To tackle this knowledge deficit and</span></div>
<div style="position:absolute;left:306.64px;top:435.19px" class="cls_031"><span class="cls_031">re-estimation, alternative approach (also besides DALY) to DWs.</span></div>
<div style="position:absolute;left:49.99px;top:444.83px" class="cls_031"><span class="cls_031">in response to the WHO Global report on Psoriasis (2016), the</span></div>
<div style="position:absolute;left:306.64px;top:445.19px" class="cls_031"><span class="cls_031">20 relevant studies were included and have been elaborated in the</span></div>
<div style="position:absolute;left:49.99px;top:454.87px" class="cls_031"><span class="cls_031">Global Psoriasis Atlas (GPA) will be a first-ever online leading</span></div>
<div style="position:absolute;left:306.64px;top:455.19px" class="cls_031"><span class="cls_031">review based on a ‘conceptual model of assessing DWs and its</span></div>
<div style="position:absolute;left:49.97px;top:464.90px" class="cls_031"><span class="cls_031">epidemiological database on psoriasis. It will inform research,</span></div>
<div style="position:absolute;left:306.64px;top:465.19px" class="cls_031"><span class="cls_031">design choices’ by Haagsma et al., 2014. The health state descrip-</span></div>
<div style="position:absolute;left:49.97px;top:474.94px" class="cls_031"><span class="cls_031">policy and health care provision worldwide. GPA provides a</span></div>
<div style="position:absolute;left:306.64px;top:475.21px" class="cls_031"><span class="cls_031">tions, panel composition, and valuation methods used to derive</span></div>
<div style="position:absolute;left:49.97px;top:484.97px" class="cls_031"><span class="cls_031">detailed disease prevalence and incidence as well as information</span></div>
<div style="position:absolute;left:306.64px;top:485.20px" class="cls_031"><span class="cls_031">DWs in these studies is discussed in detail.</span></div>
<div style="position:absolute;left:49.97px;top:495.01px" class="cls_031"><span class="cls_031">on access to treatment, comorbidities and cost to society which</span></div>
<div style="position:absolute;left:306.64px;top:495.20px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">There was scarce literature available for skin diseases</span></div>
<div style="position:absolute;left:49.97px;top:505.04px" class="cls_031"><span class="cls_031">will enable extensive comparisons between countries over time.</span></div>
<div style="position:absolute;left:306.64px;top:505.20px" class="cls_031"><span class="cls_031">in particular. DW value depends on and can vary with the panel</span></div>
<div style="position:absolute;left:49.97px;top:515.08px" class="cls_031"><span class="cls_031">Furthermore, it will provide accurate health data for decision</span></div>
<div style="position:absolute;left:306.64px;top:515.20px" class="cls_031"><span class="cls_031">composition: general public, health experts or patients. The health</span></div>
<div style="position:absolute;left:49.97px;top:525.11px" class="cls_031"><span class="cls_031">makers, stakeholders and patients worldwide.</span></div>
<div style="position:absolute;left:306.64px;top:525.20px" class="cls_031"><span class="cls_031">state description whether disease specific or generic, with or</span></div>
<div style="position:absolute;left:49.97px;top:535.15px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">The GPA includes two Work Streams (WS) Teams.</span></div>
<div style="position:absolute;left:306.64px;top:535.20px" class="cls_031"><span class="cls_031">without label, describing the course of condition over a period or</span></div>
<div style="position:absolute;left:49.97px;top:545.18px" class="cls_031"><span class="cls_031">WS1 is conducting extensive literature review on psoriasis. In this</span></div>
<div style="position:absolute;left:306.64px;top:545.20px" class="cls_031"><span class="cls_031">only temporarily, can all influence the panel members’ decision.</span></div>
<div style="position:absolute;left:49.97px;top:555.22px" class="cls_031"><span class="cls_031">paper the WS2 is explaining the development of methodology</span></div>
<div style="position:absolute;left:306.65px;top:555.20px" class="cls_031"><span class="cls_031">The valuation methods paired comparison, population health</span></div>
<div style="position:absolute;left:49.97px;top:565.25px" class="cls_031"><span class="cls_031">to serve the framework for compiling the GPA data. Methods:</span></div>
<div style="position:absolute;left:306.65px;top:565.20px" class="cls_031"><span class="cls_031">equivalence, visual analogue scale, standard gambling or person/</span></div>
<div style="position:absolute;left:49.97px;top:575.29px" class="cls_031"><span class="cls_031">Currently, data sources are being collected in two phases and</span></div>
<div style="position:absolute;left:306.65px;top:575.20px" class="cls_031"><span class="cls_031">time trade-off can alter the results to a great extent. The contextual</span></div>
<div style="position:absolute;left:49.97px;top:585.32px" class="cls_031"><span class="cls_031">for the selection of data sources an in-/exclusion criteria were</span></div>
<div style="position:absolute;left:306.65px;top:585.19px" class="cls_031"><span class="cls_031">differences across the countries can also make a difference in the</span></div>
<div style="position:absolute;left:49.97px;top:595.36px" class="cls_031"><span class="cls_031">developed and followed. Firstly, a global online survey on data</span></div>
<div style="position:absolute;left:306.65px;top:595.19px" class="cls_031"><span class="cls_031">calculation. The inclusion of certain skin conditions/health states</span></div>
<div style="position:absolute;left:49.97px;top:605.39px" class="cls_031"><span class="cls_031">source identification is being conducted in </span><span class="cls_030"> > </span><span class="cls_031">150 countries world-</span></div>
<div style="position:absolute;left:306.65px;top:605.19px" class="cls_031"><span class="cls_031">under other medical specialties can be a major factor leading to</span></div>
<div style="position:absolute;left:50.00px;top:615.49px" class="cls_031"><span class="cls_031">wide addressed to dermatologists and non-dermatologists. The</span></div>
<div style="position:absolute;left:306.65px;top:615.19px" class="cls_031"><span class="cls_031">underestimation of overall skin disease burden worldwide.</span></div>
<div style="position:absolute;left:50.00px;top:625.52px" class="cls_031"><span class="cls_031">questionnaire identifies local, regional and national data sources</span></div>
<div style="position:absolute;left:50.00px;top:635.56px" class="cls_031"><span class="cls_031">including registries, research institutes, projects, publications and</span></div>
<div style="position:absolute;left:306.64px;top:633.84px" class="cls_033"><span class="cls_033">P085</span></div>
<div style="position:absolute;left:50.00px;top:645.59px" class="cls_031"><span class="cls_031">other relevant sources supporting the GPA project. Secondly, Desk</span></div>
<div style="position:absolute;left:306.64px;top:645.24px" class="cls_025"><span class="cls_025">MIR-499 POLYMORPHISM IS ASSOCIATED WITH</span></div>
<div style="position:absolute;left:50.00px;top:655.63px" class="cls_031"><span class="cls_031">research on the same data sources is being conducted. Discussion</span></div>
<div style="position:absolute;left:306.64px;top:656.14px" class="cls_025"><span class="cls_025">SUSCEPTIBILITY TO PSORIATIC ARTHRITIS -</span></div>
<div style="position:absolute;left:50.00px;top:665.66px" class="cls_031"><span class="cls_031">on the following aspects: identification of non-published sources,</span></div>
<div style="position:absolute;left:306.64px;top:667.04px" class="cls_025"><span class="cls_025">PRELIMINARY STUDY</span></div>
<div style="position:absolute;left:50.01px;top:675.70px" class="cls_031"><span class="cls_031">integration of different sources, solving interpolation issues of</span></div>
<div style="position:absolute;left:306.64px;top:676.94px" class="cls_051"><span class="cls_051">Renata  Sokolik</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">,  Jerzy  Świerkot</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">,  Milena  Iwaszko</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">,  Mikołaj</span></div>
<div style="position:absolute;left:50.01px;top:685.73px" class="cls_031"><span class="cls_031">hard-to-reach areas and creating database.</span></div>
<div style="position:absolute;left:306.63px;top:686.84px" class="cls_026"><span class="cls_026">Kozłowski</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Lucyna Korman</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Piotr Wiland</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Katarzyna Bogunia-</span></div>
<div style="position:absolute;left:50.01px;top:695.77px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> Desk research has identified potential data sources from</span></div>
<div style="position:absolute;left:306.63px;top:696.74px" class="cls_026"><span class="cls_026">Kubik</span><span class="cls_027"><sup>2</sup></span></div>
<div style="position:absolute;left:50.01px;top:705.80px" class="cls_031"><span class="cls_031">199 countries which includes 194 ministries of health, 97 registries,</span></div>
<div style="position:absolute;left:306.64px;top:707.34px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department and Clinic of Rheumatology and Internal Medicine of Wro-</span></div>
<div style="position:absolute;left:50.01px;top:715.84px" class="cls_031"><span class="cls_031">84 patient associations, 32 statistic institutes, 25 Public Health</span></div>
<div style="position:absolute;left:306.64px;top:716.94px" class="cls_029"><span class="cls_029">claw Medical University, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Laboratory of Clinical Immunogenetics and</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:29711px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background39.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">37</span></div>
<div style="position:absolute;left:50.00px;top:51.85px" class="cls_029"><span class="cls_029">Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">In the study, we found association with different</span></div>
<div style="position:absolute;left:50.00px;top:61.45px" class="cls_029"><span class="cls_029">Therapy, Polish Academy of Sciences, Wroclaw, Poland</span></div>
<div style="position:absolute;left:306.64px;top:61.41px" class="cls_031"><span class="cls_031">phenotypes of PsA and different polymorphisms in inflammasome</span></div>
<div style="position:absolute;left:50.00px;top:72.32px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Polymorphism within the miR-499 has been reported</span></div>
<div style="position:absolute;left:306.65px;top:71.41px" class="cls_031"><span class="cls_031">genes. The results could indicate a possible role of inflammasomes</span></div>
<div style="position:absolute;left:50.00px;top:82.32px" class="cls_031"><span class="cls_031">to be associated with susceptibility to rheumatoid arthritis (RA)</span></div>
<div style="position:absolute;left:306.64px;top:81.41px" class="cls_031"><span class="cls_031">in different disease phenotypes of PsA and make further studies</span></div>
<div style="position:absolute;left:50.00px;top:92.32px" class="cls_031"><span class="cls_031">in various populations.</span></div>
<div style="position:absolute;left:306.64px;top:91.41px" class="cls_031"><span class="cls_031">in the area of interest.</span></div>
<div style="position:absolute;left:50.00px;top:102.32px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">Our study aimed to find out whether similar associa-</span></div>
<div style="position:absolute;left:306.64px;top:101.41px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.00px;top:112.32px" class="cls_031"><span class="cls_031">tion could be observed also in Polish population in both RA and</span></div>
<div style="position:absolute;left:306.64px;top:111.43px" class="cls_032"><span class="cls_032">1. Kastbom A, Verma D, Eriksson P et al. Rheumatol 2008;47:415-7.</span></div>
<div style="position:absolute;left:306.64px;top:120.43px" class="cls_032"><span class="cls_032">2. Carlström M, Ekman AK, Petersson S et al. Exp Dermatol 2012;21:932-</span></div>
<div style="position:absolute;left:50.00px;top:122.32px" class="cls_031"><span class="cls_031">psoriatic arthritis (PsA) patients.</span></div>
<div style="position:absolute;left:306.64px;top:129.43px" class="cls_032"><span class="cls_032">7.</span></div>
<div style="position:absolute;left:50.00px;top:132.32px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">For this purpose 359 individuals were studied, including</span></div>
<div style="position:absolute;left:306.64px;top:138.43px" class="cls_032"><span class="cls_032">3. Ekman AK, Verma D, Fredrikson M, Bivik C and Enerbäck C. Br J</span></div>
<div style="position:absolute;left:50.00px;top:142.32px" class="cls_031"><span class="cls_031">111 RA patients, 86 patients with PsA and 162 healthy blood</span></div>
<div style="position:absolute;left:306.64px;top:147.43px" class="cls_032"><span class="cls_032">Dermatol 2014;171:1517-20.</span></div>
<div style="position:absolute;left:50.00px;top:152.32px" class="cls_031"><span class="cls_031">donors that served as a control group. Genotyping for miR-499</span></div>
<div style="position:absolute;left:306.64px;top:161.44px" class="cls_036"><span class="cls_036">Table 1. Genotype and allele frequencies in different PsA disease expressions</span><span class="cls_044"><sup>#</sup></span></div>
<div style="position:absolute;left:50.00px;top:162.31px" class="cls_031"><span class="cls_031">rs3746444 T/C was performed using a LightSNiP assay.</span></div>
<div style="position:absolute;left:50.00px;top:172.31px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Distribution of the miRNA-499 alleles and genotypes</span></div>
<div style="position:absolute;left:381.02px;top:174.95px" class="cls_037"><span class="cls_037">Genotype</span></div>
<div style="position:absolute;left:50.00px;top:182.31px" class="cls_031"><span class="cls_031">was similar in RA patients and controls. Among RA patients</span></div>
<div style="position:absolute;left:366.00px;top:183.12px" class="cls_038"><span class="cls_038">n</span></div>
<div style="position:absolute;left:381.02px;top:183.11px" class="cls_037"><span class="cls_037">G/G</span></div>
<div style="position:absolute;left:409.50px;top:183.11px" class="cls_037"><span class="cls_037">G/C</span></div>
<div style="position:absolute;left:435.78px;top:183.11px" class="cls_037"><span class="cls_037">C/C</span></div>
<div style="position:absolute;left:460.78px;top:183.11px" class="cls_037"><span class="cls_037">C allele  χ</span><span class="cls_039"><sup>2</sup></span></div>
<div style="position:absolute;left:497.53px;top:185.11px" class="cls_037"><span class="cls_037">OR</span></div>
<div style="position:absolute;left:528.52px;top:185.11px" class="cls_038"><span class="cls_038">p</span><span class="cls_037">-</span></div>
<div style="position:absolute;left:308.01px;top:192.12px" class="cls_037"><span class="cls_037">NLRP1 rs878329</span></div>
<div style="position:absolute;left:381.03px;top:190.11px" class="cls_038"><span class="cls_038">n</span><span class="cls_037"> (%)</span></div>
<div style="position:absolute;left:409.50px;top:190.11px" class="cls_038"><span class="cls_038">n</span><span class="cls_037"> (%)</span></div>
<div style="position:absolute;left:435.78px;top:190.11px" class="cls_038"><span class="cls_038">n</span><span class="cls_037"> (%)</span></div>
<div style="position:absolute;left:497.53px;top:192.12px" class="cls_037"><span class="cls_037">(95% CI)*  value</span></div>
<div style="position:absolute;left:50.00px;top:192.31px" class="cls_031"><span class="cls_031">those carrying the CC homozygous genotype presented with</span></div>
<div style="position:absolute;left:308.01px;top:200.28px" class="cls_037"><span class="cls_037">Axial disease</span></div>
<div style="position:absolute;left:366.00px;top:200.28px" class="cls_037"><span class="cls_037">107</span></div>
<div style="position:absolute;left:381.02px;top:200.28px" class="cls_037"><span class="cls_037">30 (28)</span></div>
<div style="position:absolute;left:409.50px;top:200.28px" class="cls_037"><span class="cls_037">51 (48)</span></div>
<div style="position:absolute;left:435.78px;top:200.28px" class="cls_037"><span class="cls_037">26 (24)</span></div>
<div style="position:absolute;left:460.78px;top:200.28px" class="cls_037"><span class="cls_037">48%</span></div>
<div style="position:absolute;left:484.00px;top:200.28px" class="cls_037"><span class="cls_037">4.44</span></div>
<div style="position:absolute;left:497.53px;top:200.28px" class="cls_037"><span class="cls_037">1.37</span></div>
<div style="position:absolute;left:528.52px;top:200.27px" class="cls_037"><span class="cls_037">0.035</span></div>
<div style="position:absolute;left:50.00px;top:202.31px" class="cls_031"><span class="cls_031">lower DAS28 at diagnosis (0.027) but higher CRP levels after 12</span></div>
<div style="position:absolute;left:497.53px;top:210.28px" class="cls_037"><span class="cls_037">(1.02-1.84)</span></div>
<div style="position:absolute;left:50.00px;top:212.31px" class="cls_031"><span class="cls_031">weeks of anti-TNF treatment (</span><span class="cls_030">p = </span><span class="cls_031">0.042). Interestingly, the TT</span></div>
<div style="position:absolute;left:308.01px;top:216.43px" class="cls_037"><span class="cls_037">Peripheral disease</span></div>
<div style="position:absolute;left:366.00px;top:216.43px" class="cls_037"><span class="cls_037">539</span></div>
<div style="position:absolute;left:381.02px;top:216.43px" class="cls_037"><span class="cls_037">184 (34)</span></div>
<div style="position:absolute;left:409.50px;top:216.43px" class="cls_037"><span class="cls_037">275 (51)</span></div>
<div style="position:absolute;left:435.77px;top:216.43px" class="cls_037"><span class="cls_037">80 (15)</span></div>
<div style="position:absolute;left:460.77px;top:216.43px" class="cls_037"><span class="cls_037">41%</span></div>
<div style="position:absolute;left:50.00px;top:222.31px" class="cls_031"><span class="cls_031">genotype (rs3746444) was overexpressed in patients with PsA</span></div>
<div style="position:absolute;left:308.01px;top:223.28px" class="cls_037"><span class="cls_037">NLRP3 Q705K</span></div>
<div style="position:absolute;left:381.02px;top:223.28px" class="cls_037"><span class="cls_037">C/C</span></div>
<div style="position:absolute;left:409.50px;top:223.28px" class="cls_037"><span class="cls_037">C/A</span></div>
<div style="position:absolute;left:435.77px;top:223.28px" class="cls_037"><span class="cls_037">A/A</span></div>
<div style="position:absolute;left:460.77px;top:223.28px" class="cls_037"><span class="cls_037">C allele</span></div>
<div style="position:absolute;left:308.01px;top:229.28px" class="cls_037"><span class="cls_037">rs35829419</span></div>
<div style="position:absolute;left:50.00px;top:232.31px" class="cls_031"><span class="cls_031">as compared to controls (OR</span><span class="cls_030"> = </span><span class="cls_031">1.85, </span><span class="cls_030">p = </span><span class="cls_031">0.034) but its frequency</span></div>
<div style="position:absolute;left:308.01px;top:236.03px" class="cls_037"><span class="cls_037">Destructive disease</span></div>
<div style="position:absolute;left:366.00px;top:236.03px" class="cls_037"><span class="cls_037">314</span></div>
<div style="position:absolute;left:381.02px;top:236.03px" class="cls_037"><span class="cls_037">282 (90)</span></div>
<div style="position:absolute;left:409.50px;top:236.03px" class="cls_037"><span class="cls_037">32 (10)</span></div>
<div style="position:absolute;left:435.77px;top:236.03px" class="cls_037"><span class="cls_037">0 (0)</span></div>
<div style="position:absolute;left:460.77px;top:236.03px" class="cls_037"><span class="cls_037">95%</span></div>
<div style="position:absolute;left:484.00px;top:236.03px" class="cls_037"><span class="cls_037">4.7</span></div>
<div style="position:absolute;left:497.53px;top:236.03px" class="cls_037"><span class="cls_037">1.61</span></div>
<div style="position:absolute;left:528.52px;top:236.04px" class="cls_037"><span class="cls_037">0.03</span></div>
<div style="position:absolute;left:50.00px;top:242.31px" class="cls_031"><span class="cls_031">was not significantly different when compared to RA cases. This</span></div>
<div style="position:absolute;left:497.53px;top:246.04px" class="cls_037"><span class="cls_037">(1.05-2.57)</span></div>
<div style="position:absolute;left:308.01px;top:252.19px" class="cls_037"><span class="cls_037">No destructive disease 360</span></div>
<div style="position:absolute;left:381.02px;top:252.19px" class="cls_037"><span class="cls_037">304 (84)</span></div>
<div style="position:absolute;left:409.50px;top:252.19px" class="cls_037"><span class="cls_037">54 (15)</span></div>
<div style="position:absolute;left:435.77px;top:252.19px" class="cls_037"><span class="cls_037">2 (0.6)</span></div>
<div style="position:absolute;left:460.77px;top:252.19px" class="cls_037"><span class="cls_037">92%</span></div>
<div style="position:absolute;left:50.00px;top:252.31px" class="cls_031"><span class="cls_031">polymorphism was also not found to be associated with clinical</span></div>
<div style="position:absolute;left:308.01px;top:258.36px" class="cls_037"><span class="cls_037">NLRP3 rs10733113</span></div>
<div style="position:absolute;left:381.02px;top:258.36px" class="cls_037"><span class="cls_037">G/G</span></div>
<div style="position:absolute;left:409.50px;top:258.36px" class="cls_037"><span class="cls_037">G/A</span></div>
<div style="position:absolute;left:435.77px;top:258.36px" class="cls_037"><span class="cls_037">A/A</span></div>
<div style="position:absolute;left:460.77px;top:258.36px" class="cls_037"><span class="cls_037">G allele</span></div>
<div style="position:absolute;left:50.00px;top:262.30px" class="cls_031"><span class="cls_031">parameters in PsA patients.</span></div>
<div style="position:absolute;left:308.01px;top:264.52px" class="cls_037"><span class="cls_037">Pso type1</span></div>
<div style="position:absolute;left:366.00px;top:264.52px" class="cls_037"><span class="cls_037">439</span></div>
<div style="position:absolute;left:381.02px;top:264.52px" class="cls_037"><span class="cls_037">347 (79)</span></div>
<div style="position:absolute;left:409.50px;top:264.52px" class="cls_037"><span class="cls_037">87 (20)</span></div>
<div style="position:absolute;left:435.77px;top:264.52px" class="cls_037"><span class="cls_037">5 (1)</span></div>
<div style="position:absolute;left:460.77px;top:264.52px" class="cls_037"><span class="cls_037">89%</span></div>
<div style="position:absolute;left:484.00px;top:264.52px" class="cls_037"><span class="cls_037">7.4</span></div>
<div style="position:absolute;left:497.53px;top:264.52px" class="cls_037"><span class="cls_037">1.58</span></div>
<div style="position:absolute;left:528.52px;top:264.52px" class="cls_037"><span class="cls_037">0.007</span></div>
<div style="position:absolute;left:50.00px;top:272.30px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">These results show that miR-499 rs3746444 T/C</span></div>
<div style="position:absolute;left:497.53px;top:274.52px" class="cls_037"><span class="cls_037">(1.13-2.21)</span></div>
<div style="position:absolute;left:308.01px;top:280.68px" class="cls_037"><span class="cls_037">Not Pso type1</span></div>
<div style="position:absolute;left:366.00px;top:280.68px" class="cls_037"><span class="cls_037">210</span></div>
<div style="position:absolute;left:381.02px;top:280.68px" class="cls_037"><span class="cls_037">149 (71)</span></div>
<div style="position:absolute;left:409.50px;top:280.68px" class="cls_037"><span class="cls_037">53 (25)</span></div>
<div style="position:absolute;left:435.77px;top:280.68px" class="cls_037"><span class="cls_037">8 (4)</span></div>
<div style="position:absolute;left:460.77px;top:280.68px" class="cls_037"><span class="cls_037">84%</span></div>
<div style="position:absolute;left:50.00px;top:282.30px" class="cls_031"><span class="cls_031">polymorphism may constitute a risk factor for psoriatic arthritis</span></div>
<div style="position:absolute;left:308.01px;top:286.84px" class="cls_037"><span class="cls_037">NLRP1 rs8079034</span></div>
<div style="position:absolute;left:381.02px;top:286.84px" class="cls_037"><span class="cls_037">C/C</span></div>
<div style="position:absolute;left:409.50px;top:286.84px" class="cls_037"><span class="cls_037">C/T</span></div>
<div style="position:absolute;left:435.77px;top:286.84px" class="cls_037"><span class="cls_037">T/T</span></div>
<div style="position:absolute;left:460.77px;top:286.84px" class="cls_037"><span class="cls_037">T allele</span></div>
<div style="position:absolute;left:50.00px;top:292.30px" class="cls_031"><span class="cls_031">development.</span></div>
<div style="position:absolute;left:308.01px;top:293.00px" class="cls_037"><span class="cls_037">csDMARD ever</span></div>
<div style="position:absolute;left:366.00px;top:293.00px" class="cls_037"><span class="cls_037">499</span></div>
<div style="position:absolute;left:381.02px;top:293.00px" class="cls_037"><span class="cls_037">320 (64)</span></div>
<div style="position:absolute;left:409.50px;top:293.00px" class="cls_037"><span class="cls_037">169 (32)</span></div>
<div style="position:absolute;left:435.77px;top:293.00px" class="cls_037"><span class="cls_037">19 (4)</span></div>
<div style="position:absolute;left:460.77px;top:293.00px" class="cls_037"><span class="cls_037">20%</span></div>
<div style="position:absolute;left:484.00px;top:293.00px" class="cls_037"><span class="cls_037">9.1</span></div>
<div style="position:absolute;left:497.53px;top:293.00px" class="cls_037"><span class="cls_037">1.63</span></div>
<div style="position:absolute;left:528.52px;top:293.00px" class="cls_037"><span class="cls_037">0.003</span></div>
<div style="position:absolute;left:497.53px;top:303.00px" class="cls_037"><span class="cls_037">(1.19-2.25)</span></div>
<div style="position:absolute;left:308.01px;top:309.16px" class="cls_037"><span class="cls_037">Never csDMARD</span></div>
<div style="position:absolute;left:366.00px;top:309.16px" class="cls_037"><span class="cls_037">216</span></div>
<div style="position:absolute;left:381.02px;top:309.16px" class="cls_037"><span class="cls_037">164 (76)</span></div>
<div style="position:absolute;left:409.50px;top:309.16px" class="cls_037"><span class="cls_037">47 (22)</span></div>
<div style="position:absolute;left:435.77px;top:309.16px" class="cls_037"><span class="cls_037">5 (2)</span></div>
<div style="position:absolute;left:460.77px;top:309.16px" class="cls_037"><span class="cls_037">13%</span></div>
<div style="position:absolute;left:50.00px;top:311.95px" class="cls_033"><span class="cls_033">P086</span></div>
<div style="position:absolute;left:306.64px;top:319.40px" class="cls_037"><span class="cls_037">*Calculated with χ</span><span class="cls_039"><sup>2</sup></span><span class="cls_037"> test comparing variant allele frequencies between patients and controls.</span></div>
<div style="position:absolute;left:50.00px;top:323.35px" class="cls_025"><span class="cls_025">ASSOCIATION BETWEEN INFLAMMASOME-RELATED</span></div>
<div style="position:absolute;left:306.64px;top:325.41px" class="cls_039"><span class="cls_039"><sup>#</sup></span><span class="cls_037">Only significant association are shown.</span></div>
<div style="position:absolute;left:50.00px;top:334.25px" class="cls_025"><span class="cls_025">POLYMORPHISMS AND CLINICAL PHENOTYPES OF</span></div>
<div style="position:absolute;left:306.64px;top:342.00px" class="cls_033"><span class="cls_033">P088</span></div>
<div style="position:absolute;left:50.00px;top:345.15px" class="cls_025"><span class="cls_025">PSORIATIC ARTHRITIS</span></div>
<div style="position:absolute;left:50.00px;top:355.05px" class="cls_051"><span class="cls_051">Kristina Juneblad</span><span class="cls_026">, Gerd-Marie Alenius</span></div>
<div style="position:absolute;left:306.64px;top:353.40px" class="cls_025"><span class="cls_025">FREQUENCY OF INADEQUATE RESPONSE TO</span></div>
<div style="position:absolute;left:50.00px;top:365.65px" class="cls_029"><span class="cls_029">Department of Public Health and Clinical Mediciine, Rheumatology, Uni-</span></div>
<div style="position:absolute;left:306.64px;top:364.30px" class="cls_025"><span class="cls_025">TREATMENT AMONG PSORIASIS PATIENTS ON FIRST-</span></div>
<div style="position:absolute;left:50.00px;top:375.25px" class="cls_029"><span class="cls_029">versity Hospital, Umeå</span></div>
<div style="position:absolute;left:306.64px;top:375.20px" class="cls_025"><span class="cls_025">LINE BIOLOGICS</span></div>
<div style="position:absolute;left:50.00px;top:386.12px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Psoriatic Arthritis (PsA) disease expression can</span></div>
<div style="position:absolute;left:306.64px;top:385.10px" class="cls_051"><span class="cls_051">Anna Sheahan</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Edward Lee</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Lisa Pisenti</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Mohamed Yassine</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:50.00px;top:396.12px" class="cls_031"><span class="cls_031">vary from mild mono-/oligoarthritis to severe erosive polyarthritis</span></div>
<div style="position:absolute;left:306.64px;top:395.00px" class="cls_026"><span class="cls_026">Robert Suruki</span><span class="cls_027"><sup>3</sup></span></div>
<div style="position:absolute;left:50.00px;top:406.12px" class="cls_031"><span class="cls_031">comparable with Rheumatoid Arthritis (RA), with or without axial</span></div>
<div style="position:absolute;left:306.64px;top:405.60px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">UCB Pharma, Raleigh, NC, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">UCB Pharma, Smyrna, GA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">UCB Pharma,</span></div>
<div style="position:absolute;left:50.00px;top:416.12px" class="cls_031"><span class="cls_031">involvement, and manifestations such as dactylitis and enthesitis</span></div>
<div style="position:absolute;left:306.64px;top:415.20px" class="cls_029"><span class="cls_029">Raleigh, NC</span></div>
<div style="position:absolute;left:50.00px;top:426.12px" class="cls_031"><span class="cls_031">are common. Markers of systemic inflammation (ESR or CRP) are</span></div>
<div style="position:absolute;left:306.64px;top:426.07px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Studies describing the occurrence of inadequate</span></div>
<div style="position:absolute;left:49.99px;top:436.11px" class="cls_031"><span class="cls_031">generally unhelpful as markers of disease severity since elevated</span></div>
<div style="position:absolute;left:306.64px;top:436.06px" class="cls_031"><span class="cls_031">response (IR) to biologic treatments in psoriasis (PSO) in the real-</span></div>
<div style="position:absolute;left:49.99px;top:446.11px" class="cls_031"><span class="cls_031">in only 50% of cases.</span></div>
<div style="position:absolute;left:306.64px;top:446.06px" class="cls_031"><span class="cls_031">world setting are currently lacking. Thus an understanding of IR,</span></div>
<div style="position:absolute;left:49.99px;top:456.11px" class="cls_031"><span class="cls_031">In recent years, research on the interleukin 1β (IL1 β)-regulating</span></div>
<div style="position:absolute;left:306.64px;top:456.06px" class="cls_031"><span class="cls_031">due to the lack of treatment durability, persistence, or access, to</span></div>
<div style="position:absolute;left:50.00px;top:466.11px" class="cls_031"><span class="cls_031">protein complex, called the inflammasome, has shown interesting</span></div>
<div style="position:absolute;left:306.64px;top:466.06px" class="cls_031"><span class="cls_031">1st line biologics in PSO may help to identify and address unmet</span></div>
<div style="position:absolute;left:50.01px;top:476.11px" class="cls_031"><span class="cls_031">associations with various inflammatory diseases. E.g. for RA (1)</span></div>
<div style="position:absolute;left:306.64px;top:476.06px" class="cls_031"><span class="cls_031">treatment needs.</span></div>
<div style="position:absolute;left:50.01px;top:486.11px" class="cls_031"><span class="cls_031">and psoriasis (Pso) (2,3) associations with genetic polymorphisms</span></div>
<div style="position:absolute;left:306.64px;top:486.06px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To assess the frequency of IR in the year after initiation</span></div>
<div style="position:absolute;left:50.01px;top:496.11px" class="cls_031"><span class="cls_031">in genes related to the inflammasome has been discovered. So</span></div>
<div style="position:absolute;left:306.64px;top:496.06px" class="cls_031"><span class="cls_031">of 1st line biologic treatment for PSO. IR was defined as biologic</span></div>
<div style="position:absolute;left:50.02px;top:506.11px" class="cls_031"><span class="cls_031">far, no studies investigating genetic polymorphisms in inflam-</span></div>
<div style="position:absolute;left:306.64px;top:506.06px" class="cls_031"><span class="cls_031">dose increase, biologic discontinuation, or add-on treatment.</span></div>
<div style="position:absolute;left:50.00px;top:516.12px" class="cls_031"><span class="cls_031">masome genes in patients with Psoriatic Arthritis (PsA) have</span></div>
<div style="position:absolute;left:306.64px;top:516.06px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Retrospective analysis of commercial US healthcare</span></div>
<div style="position:absolute;left:50.00px;top:526.12px" class="cls_031"><span class="cls_031">been published.</span></div>
<div style="position:absolute;left:306.64px;top:526.06px" class="cls_031"><span class="cls_031">claims (2012-2016) was conducted. Patients initiating a biologic</span></div>
<div style="position:absolute;left:50.00px;top:536.12px" class="cls_030"><span class="cls_030">Aim:</span><span class="cls_031"> To analyse different single nucleotide polymorphisms</span></div>
<div style="position:absolute;left:306.64px;top:536.05px" class="cls_031"><span class="cls_031">(PSO approved anti-TNF, secukinumab, ustekinumab, apremilast)</span></div>
<div style="position:absolute;left:50.00px;top:546.12px" class="cls_031"><span class="cls_031">(SNP:s) in genes related to the inflammasome in relation to dif-</span></div>
<div style="position:absolute;left:306.64px;top:546.05px" class="cls_031"><span class="cls_031">with ≥ 1 year of database enrolment before and after biologic</span></div>
<div style="position:absolute;left:50.00px;top:556.12px" class="cls_031"><span class="cls_031">ferent disease phenotypes of Psoriatic Arthritis (PsA).</span></div>
<div style="position:absolute;left:306.64px;top:556.05px" class="cls_031"><span class="cls_031">initiation (index date) who had a qualifying PSO ICD 9/10 code</span></div>
<div style="position:absolute;left:50.00px;top:566.12px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> DNA from 771 PsA patients from Northern Sweden were</span></div>
<div style="position:absolute;left:306.64px;top:566.05px" class="cls_031"><span class="cls_031">and no previous biologic exposure in the year prior to the index</span></div>
<div style="position:absolute;left:50.00px;top:576.12px" class="cls_031"><span class="cls_031">analyzed for different single nucleotide polymorphisms (SNPs) in</span></div>
<div style="position:absolute;left:306.64px;top:576.05px" class="cls_031"><span class="cls_031">date were included. Patients experiencing any of the following</span></div>
<div style="position:absolute;left:50.00px;top:586.12px" class="cls_030"><span class="cls_030">NLRP3</span><span class="cls_031"> ( rs35829419 (</span><span class="cls_030">NLRP3</span><span class="cls_031">-Q750K), rs10733113, rs4353135),</span></div>
<div style="position:absolute;left:306.64px;top:586.05px" class="cls_031"><span class="cls_031">were classified as experiencing an IR event: 1) ≥ 1 claim with a</span></div>
<div style="position:absolute;left:50.00px;top:596.12px" class="cls_031"><span class="cls_031">CARD8 (</span><span class="cls_030">CARD8</span><span class="cls_031">-C10X, rs 2043211) and </span><span class="cls_030">NLRP1</span><span class="cls_031"> (rs8079034,</span></div>
<div style="position:absolute;left:306.66px;top:596.05px" class="cls_031"><span class="cls_031">biologic dose </span><span class="cls_030"> > </span><span class="cls_031">110% of the label-recommended dose for ≥30</span></div>
<div style="position:absolute;left:50.00px;top:606.11px" class="cls_031"><span class="cls_031">rs878329) in relation to different phenotypes of PsA.</span></div>
<div style="position:absolute;left:306.67px;top:606.05px" class="cls_031"><span class="cls_031">days, 2) cessation of 1st line biologic (</span><span class="cls_030"> > </span><span class="cls_031">2 months with no tre-</span></div>
<div style="position:absolute;left:50.00px;top:616.11px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> A significant association was seen with </span><span class="cls_030">NLRP1</span><span class="cls_031"> rs878329C</span></div>
<div style="position:absolute;left:306.64px;top:616.07px" class="cls_031"><span class="cls_031">atment) (‘non-switch discontinuation’), 3) cessation of first line</span></div>
<div style="position:absolute;left:49.99px;top:626.11px" class="cls_031"><span class="cls_031">and patients with axial involvement of disease. When different</span></div>
<div style="position:absolute;left:306.63px;top:626.06px" class="cls_031"><span class="cls_031">biologic followed by initiation of a new biologic within 2 months,</span></div>
<div style="position:absolute;left:49.99px;top:636.11px" class="cls_031"><span class="cls_031">genotypes were compared, significantly higher frequency of ge-</span></div>
<div style="position:absolute;left:306.63px;top:636.06px" class="cls_031"><span class="cls_031">or 4) addition of a corticosteroid, immunosuppressant, or biologic</span></div>
<div style="position:absolute;left:50.00px;top:646.12px" class="cls_031"><span class="cls_031">notype CC were detected in the subgroup with axial involvement</span></div>
<div style="position:absolute;left:306.63px;top:646.06px" class="cls_031"><span class="cls_031">(‘add-on treatment’) with any days’ supply overlap.</span></div>
<div style="position:absolute;left:50.00px;top:656.12px" class="cls_031"><span class="cls_031">of disease. In addition, </span><span class="cls_030">NLRP1</span><span class="cls_031"> rs8079034T was significantly</span></div>
<div style="position:absolute;left:306.63px;top:656.06px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Of the 13,995 patients meeting inclusion criteria, 9,520</span></div>
<div style="position:absolute;left:50.00px;top:666.12px" class="cls_031"><span class="cls_031">associated with prescription of a csDMARD. Also, the </span><span class="cls_030">NLRP3</span></div>
<div style="position:absolute;left:306.63px;top:666.06px" class="cls_031"><span class="cls_031">(68.0%) experienced an IR event in the 12-month follow-up period</span></div>
<div style="position:absolute;left:50.00px;top:676.12px" class="cls_031"><span class="cls_031">rs10733113 showed association with the G-allele in patients with</span></div>
<div style="position:absolute;left:306.63px;top:676.06px" class="cls_031"><span class="cls_031">(53.2% female; mean age: 46.2 yrs) and 4,475 (32.0%) did not</span></div>
<div style="position:absolute;left:50.00px;top:686.12px" class="cls_031"><span class="cls_031">a skin disease with an early onset (Pso type1, onset </span><span class="cls_030"> &lt; </span><span class="cls_031">40 years)</span></div>
<div style="position:absolute;left:306.63px;top:686.06px" class="cls_031"><span class="cls_031">experience an IR event (45.2% female; mean age: 46.9 yrs). The</span></div>
<div style="position:absolute;left:50.00px;top:696.11px" class="cls_031"><span class="cls_031">and in the subgroup of PsA with destructive-/deforming disease</span></div>
<div style="position:absolute;left:306.63px;top:696.06px" class="cls_031"><span class="cls_031">most frequently used 1st line biologics were adalimumab (42.5%)</span></div>
<div style="position:absolute;left:50.00px;top:706.11px" class="cls_031"><span class="cls_031">significant association was found with the major allele, C, of</span></div>
<div style="position:absolute;left:306.63px;top:706.06px" class="cls_031"><span class="cls_031">and etanercept (26.5%); the proportion of IR patients was 60.4%</span></div>
<div style="position:absolute;left:50.01px;top:716.11px" class="cls_031"><span class="cls_031">NLRP3 Q705K rs35829419. (Table 1)</span></div>
<div style="position:absolute;left:306.63px;top:716.06px" class="cls_031"><span class="cls_031">in adalimumab and 75.8% in etanercept. Among all IR patients,</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:30514px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background40.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">38</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">non-switch discontinuation was experienced by 63.8% of patients,</span></div>
<div style="position:absolute;left:306.64px;top:51.73px" class="cls_032"><span class="cls_032">Lotti T, et al. European patient perspectives on the impact of psoriasis: the</span></div>
<div style="position:absolute;left:50.00px;top:61.44px" class="cls_031"><span class="cls_031">switch to another biologic by 15.1%, above label dosing by 11.5%,</span></div>
<div style="position:absolute;left:306.64px;top:60.73px" class="cls_032"><span class="cls_032">EUROPSO patient membership survey. Br J Dermatol. 2006;155:729-36.</span></div>
<div style="position:absolute;left:50.00px;top:71.47px" class="cls_031"><span class="cls_031">and add-on treatment by 9.7%. Overall, the mean time from initia-</span></div>
<div style="position:absolute;left:306.64px;top:78.35px" class="cls_033"><span class="cls_033">P090</span></div>
<div style="position:absolute;left:50.00px;top:81.51px" class="cls_031"><span class="cls_031">tion of 1st line treatment to IR event was 4.7 months, ranging from</span></div>
<div style="position:absolute;left:50.00px;top:91.54px" class="cls_031"><span class="cls_031">4.3 months to add-on therapy and 5.7 months for patients switching</span></div>
<div style="position:absolute;left:306.64px;top:89.75px" class="cls_025"><span class="cls_025">INDIVIDUALISED THERAPY FOR PSORIASIS - CASE</span></div>
<div style="position:absolute;left:50.00px;top:101.58px" class="cls_031"><span class="cls_031">to another biologic. Among patients switching to another biologic,</span></div>
<div style="position:absolute;left:306.64px;top:100.65px" class="cls_025"><span class="cls_025">SERIES</span></div>
<div style="position:absolute;left:50.00px;top:111.61px" class="cls_031"><span class="cls_031">70.3% of patients were persistent on the new biologic after three</span></div>
<div style="position:absolute;left:306.64px;top:110.55px" class="cls_051"><span class="cls_051">Seema Mahesh</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Viraj Shah</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Mahesh Mallappa</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, George Vithoul-</span></div>
<div style="position:absolute;left:50.00px;top:121.65px" class="cls_031"><span class="cls_031">months versus 54.0% after 6 months. The most frequent add-on</span></div>
<div style="position:absolute;left:306.63px;top:120.45px" class="cls_026"><span class="cls_026">kas</span><span class="cls_027"><sup>3</sup></span></div>
<div style="position:absolute;left:50.00px;top:131.68px" class="cls_031"><span class="cls_031">therapies were immunosuppressive drugs (63.8%) followed by</span></div>
<div style="position:absolute;left:306.64px;top:131.05px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Centre For Classical Homeopathy, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Shah Homeopathic Clinic, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Interna-</span></div>
<div style="position:absolute;left:50.00px;top:141.72px" class="cls_031"><span class="cls_031">systemic corticosteroids (20.6%), and biologics (15.5%).</span></div>
<div style="position:absolute;left:306.64px;top:140.65px" class="cls_029"><span class="cls_029">tional Academy of Classical Homeopathy</span></div>
<div style="position:absolute;left:50.00px;top:151.75px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">IR in 1st line PSO biologic treatment is common</span></div>
<div style="position:absolute;left:306.64px;top:151.51px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis and its complications are still a challenge</span></div>
<div style="position:absolute;left:50.00px;top:161.79px" class="cls_031"><span class="cls_031">with non-switch discontinuation being the most frequent. This</span></div>
<div style="position:absolute;left:306.64px;top:161.51px" class="cls_031"><span class="cls_031">to clinicians. The autoimmune disorder though targeting the skin,</span></div>
<div style="position:absolute;left:50.00px;top:171.82px" class="cls_031"><span class="cls_031">highlights an opportunity to optimize treatment options currently</span></div>
<div style="position:absolute;left:306.64px;top:171.51px" class="cls_031"><span class="cls_031">involves the immune system as a whole. The inflammatory com-</span></div>
<div style="position:absolute;left:50.00px;top:181.86px" class="cls_031"><span class="cls_031">available and better understand patients’ needs for successful th-</span></div>
<div style="position:absolute;left:306.64px;top:181.51px" class="cls_031"><span class="cls_031">ponent in the pathogenesis of psoriasis has further established the</span></div>
<div style="position:absolute;left:50.00px;top:191.89px" class="cls_031"><span class="cls_031">erapy. Therapeutic options with improved durability may provide</span></div>
<div style="position:absolute;left:306.64px;top:191.51px" class="cls_031"><span class="cls_031">role of aberrant immune system in the process [1, 2, 3].</span></div>
<div style="position:absolute;left:50.00px;top:201.93px" class="cls_031"><span class="cls_031">a clinically meaningful path to optimizing psoriasis management.</span></div>
<div style="position:absolute;left:306.64px;top:201.51px" class="cls_031"><span class="cls_031">Homeopathy addresses every individual’s peculiar combination</span></div>
<div style="position:absolute;left:50.00px;top:211.96px" class="cls_031"><span class="cls_031">Further analysis is necessary to identify underlying causes of IR</span></div>
<div style="position:absolute;left:306.64px;top:211.51px" class="cls_031"><span class="cls_031">of genetic and epigenetic causative factors in the development of</span></div>
<div style="position:absolute;left:50.00px;top:222.00px" class="cls_031"><span class="cls_031">and to guide more effective approaches to treatment.</span></div>
<div style="position:absolute;left:306.64px;top:221.51px" class="cls_031"><span class="cls_031">such auto immune diseases [4, 5]. Therefore it may be considered</span></div>
<div style="position:absolute;left:50.00px;top:232.03px" class="cls_030"><span class="cls_030">Acknowledgements:</span><span class="cls_031"> This study was supported by UCB Pharma.</span></div>
<div style="position:absolute;left:306.64px;top:231.51px" class="cls_031"><span class="cls_031">as a therapy where integrated approach is indicated.</span></div>
<div style="position:absolute;left:306.64px;top:241.51px" class="cls_030"><span class="cls_030">Case series: </span><span class="cls_031">5 cases of psoriasis are presented, two of which</span></div>
<div style="position:absolute;left:50.00px;top:251.70px" class="cls_033"><span class="cls_033">P089</span></div>
<div style="position:absolute;left:306.64px;top:251.51px" class="cls_031"><span class="cls_031">were in erythrodermic state [one also with sepsis superimposed].</span></div>
<div style="position:absolute;left:50.00px;top:263.13px" class="cls_025"><span class="cls_025">BARRIERS OF GUIDELINE-COMPLIANT CARE</span></div>
<div style="position:absolute;left:306.64px;top:261.50px" class="cls_031"><span class="cls_031">Through monitoring of blood markers and documenting on photos</span></div>
<div style="position:absolute;left:306.64px;top:271.50px" class="cls_031"><span class="cls_031">and videos the effect of individualised homeopathic therapy on</span></div>
<div style="position:absolute;left:50.00px;top:274.07px" class="cls_025"><span class="cls_025">FOR PSORIASIS IN GERMANY - RESULTS OF THE</span></div>
<div style="position:absolute;left:306.64px;top:281.50px" class="cls_031"><span class="cls_031">psoriasis and its complications is demonstrated.</span></div>
<div style="position:absolute;left:50.00px;top:285.00px" class="cls_025"><span class="cls_025">EUROPEAN STUDY PSOBARRIER</span></div>
<div style="position:absolute;left:306.64px;top:291.50px" class="cls_031"><span class="cls_031">The theory of Levels of Health can explain the variety in the</span></div>
<div style="position:absolute;left:50.00px;top:294.94px" class="cls_051"><span class="cls_051">Matthias Augustin</span><span class="cls_026">, Anna Langenbruch, Marc Radtke, Nicole Zander</span></div>
<div style="position:absolute;left:306.64px;top:301.50px" class="cls_031"><span class="cls_031">presentation of psoriasis and response to treatment in terms of</span></div>
<div style="position:absolute;left:50.00px;top:305.57px" class="cls_029"><span class="cls_029">University Medical Center Hamburg-Eppendorf</span></div>
<div style="position:absolute;left:306.64px;top:311.50px" class="cls_031"><span class="cls_031">the time taken and number of remedies required. The same theory</span></div>
<div style="position:absolute;left:50.00px;top:316.47px" class="cls_030"><span class="cls_030">Introduction &</span><span class="cls_031"> </span><span class="cls_030">Objectives: </span><span class="cls_031">A series of nation-wide studies in</span></div>
<div style="position:absolute;left:306.64px;top:321.50px" class="cls_031"><span class="cls_031">also helps to assess the prognosis and comprehend the response</span></div>
<div style="position:absolute;left:50.00px;top:326.51px" class="cls_031"><span class="cls_031">Germany over the last years has focused on the quality of psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:331.50px" class="cls_031"><span class="cls_031">to treatment [LOH]. With the help of the evidence of these cases</span></div>
<div style="position:absolute;left:50.00px;top:336.54px" class="cls_031"><span class="cls_031">care. It was found that a significant proportion of psoriasis patients</span></div>
<div style="position:absolute;left:306.64px;top:341.50px" class="cls_031"><span class="cls_031">we may formulate a larger study to ascertain the extent to which</span></div>
<div style="position:absolute;left:49.98px;top:346.58px" class="cls_031"><span class="cls_031">is not treated according to the national guideline1. Similar under-</span></div>
<div style="position:absolute;left:306.64px;top:351.50px" class="cls_031"><span class="cls_031">classical homeopathy may be employed in psoriasis.</span></div>
<div style="position:absolute;left:49.98px;top:356.61px" class="cls_031"><span class="cls_031">provision of care has been identified in other countries as well,</span></div>
<div style="position:absolute;left:306.64px;top:361.49px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">These cases depict the potential for homeopathy in</span></div>
<div style="position:absolute;left:49.99px;top:366.65px" class="cls_031"><span class="cls_031">reflected by patients’ dissatisfaction with the management of their</span></div>
<div style="position:absolute;left:306.64px;top:371.49px" class="cls_031"><span class="cls_031">alleviating the suffering of patients with psoriasis if applied as</span></div>
<div style="position:absolute;left:50.00px;top:376.68px" class="cls_031"><span class="cls_031">disease2. This study aims to identify these barriers of guideline-</span></div>
<div style="position:absolute;left:306.64px;top:381.49px" class="cls_031"><span class="cls_031">individualised therapy and give grounds to further conduct control-</span></div>
<div style="position:absolute;left:50.00px;top:386.72px" class="cls_031"><span class="cls_031">compliant healthcare for psoriasis in Europe.</span></div>
<div style="position:absolute;left:306.64px;top:391.51px" class="cls_031"><span class="cls_031">led studies to confirm the role of homeopathy in psoriatic therapy.</span></div>
<div style="position:absolute;left:50.00px;top:396.75px" class="cls_030"><span class="cls_030">Materials & Methods: </span><span class="cls_031">The study assesses barriers and quality of</span></div>
<div style="position:absolute;left:306.65px;top:401.51px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.00px;top:406.79px" class="cls_031"><span class="cls_031">health care in a multi-centre, cross-sectional study design. Par-</span></div>
<div style="position:absolute;left:306.64px;top:411.53px" class="cls_032"><span class="cls_032">1. Boyd A, Menter A. Erythrodermic psoriasis. Journal of the American</span></div>
<div style="position:absolute;left:50.00px;top:416.82px" class="cls_031"><span class="cls_031">ticipating centres in five European countries (Denmark, Poland,</span></div>
<div style="position:absolute;left:306.64px;top:420.53px" class="cls_032"><span class="cls_032">Academy of Dermatology. 1989;21(5):985-991.</span></div>
<div style="position:absolute;left:50.00px;top:426.86px" class="cls_031"><span class="cls_031">Spain, United Kingdom, and Germany) aim to represent the range</span></div>
<div style="position:absolute;left:306.64px;top:429.53px" class="cls_032"><span class="cls_032">2. Chandra A, Ray A, Senapati S, Chatterjee R. Genetic and epigenetic basis</span></div>
<div style="position:absolute;left:50.00px;top:436.89px" class="cls_031"><span class="cls_031">of dermatological health care-providing outpatient facilities of the</span></div>
<div style="position:absolute;left:306.64px;top:438.53px" class="cls_032"><span class="cls_032">of psoriasis pathogenesis. Molecular Immunology. 2015;64(2):313-323.</span></div>
<div style="position:absolute;left:50.00px;top:446.93px" class="cls_031"><span class="cls_031">respective country. The current analysis includes the data collected</span></div>
<div style="position:absolute;left:306.64px;top:447.53px" class="cls_032"><span class="cls_032">3. Reich K. The concept of psoriasis as a systemic inflammation: impli-</span></div>
<div style="position:absolute;left:50.00px;top:456.96px" class="cls_031"><span class="cls_031">in Germany from January 2016 to May 2017.</span></div>
<div style="position:absolute;left:306.64px;top:456.53px" class="cls_032"><span class="cls_032">cations for disease management. Journal of the European Academy of</span></div>
<div style="position:absolute;left:306.64px;top:465.53px" class="cls_032"><span class="cls_032">Dermatology and Venereology. 2012;26:3-11.</span></div>
<div style="position:absolute;left:50.00px;top:466.94px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Data of </span><span class="cls_030">n = </span><span class="cls_031">497 patients were analysed. Mean age was 49.7</span></div>
<div style="position:absolute;left:306.64px;top:474.53px" class="cls_032"><span class="cls_032">4. Vithoulkas G, Tiller W. The science of homeopathy. Athens: International</span></div>
<div style="position:absolute;left:50.00px;top:476.92px" class="cls_031"><span class="cls_031">years, 41.4% were female. Mean PASI was 7.2 </span><span class="cls_035">± </span><span class="cls_031">9.2, 20.9% had a</span></div>
<div style="position:absolute;left:306.64px;top:483.53px" class="cls_032"><span class="cls_032">Academy of Classical Homeopathy; 2009.</span></div>
<div style="position:absolute;left:50.00px;top:486.91px" class="cls_031"><span class="cls_031">PASI</span><span class="cls_030"> > </span><span class="cls_031">10. The mean DLQI was 6.2 </span><span class="cls_035">± </span><span class="cls_031">6.7. 27.0% were currently</span></div>
<div style="position:absolute;left:306.64px;top:492.53px" class="cls_032"><span class="cls_032">5. Vithoulkas G. Levels of health. Alonissos: International Academy of</span></div>
<div style="position:absolute;left:50.00px;top:496.89px" class="cls_031"><span class="cls_031">treated with systemics (excluding biologics), 22.3% with biolo-</span></div>
<div style="position:absolute;left:306.64px;top:501.53px" class="cls_032"><span class="cls_032">Classical Homeopathy; 2017.</span></div>
<div style="position:absolute;left:50.00px;top:506.88px" class="cls_031"><span class="cls_031">gics. Since the diagnosis of psoriasis, the participants consulted</span></div>
<div style="position:absolute;left:50.00px;top:516.86px" class="cls_031"><span class="cls_031">on average 3.0 </span><span class="cls_035">± </span><span class="cls_031">2.3 different dermatologists (min 0/max 27) and</span></div>
<div style="position:absolute;left:306.64px;top:519.15px" class="cls_033"><span class="cls_033">P091</span></div>
<div style="position:absolute;left:50.00px;top:526.85px" class="cls_031"><span class="cls_031">had 3.5 </span><span class="cls_035">± </span><span class="cls_031">3.7 therapy changes. For 32.0% of the patients the time</span></div>
<div style="position:absolute;left:306.64px;top:530.55px" class="cls_025"><span class="cls_025">A UNIQUE CLINICAL CASE OF PSORIATIC ARTHRITIS</span></div>
<div style="position:absolute;left:50.00px;top:536.83px" class="cls_031"><span class="cls_031">between the first skin changes and the first diagnosis of psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:541.45px" class="cls_025"><span class="cls_025">AND RELAPSING POLYCHONDRITIS</span></div>
<div style="position:absolute;left:49.99px;top:546.81px" class="cls_031"><span class="cls_031">was one year or longer. 7.6% stated that their health insurance</span></div>
<div style="position:absolute;left:306.64px;top:551.35px" class="cls_026"><span class="cls_026">Elena Gubar, Alla Godzenko, </span><span class="cls_051">Tatiana Korotaeva</span></div>
<div style="position:absolute;left:49.99px;top:556.80px" class="cls_031"><span class="cls_031">turned down a therapy, treatment or referral that was recommended</span></div>
<div style="position:absolute;left:306.64px;top:561.95px" class="cls_029"><span class="cls_029">Nasonova Research Institute of Rheumatology, Moscow</span></div>
<div style="position:absolute;left:49.99px;top:566.78px" class="cls_031"><span class="cls_031">by a physician at least once.</span></div>
<div style="position:absolute;left:306.64px;top:572.81px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Relapsing polychondritis (RP) is a rare systemic</span></div>
<div style="position:absolute;left:49.99px;top:576.76px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">The quite high numbers of consultations of different</span></div>
<div style="position:absolute;left:306.64px;top:582.81px" class="cls_031"><span class="cls_031">autoimmune disorder affecting the cartilaginous structures of the</span></div>
<div style="position:absolute;left:49.99px;top:586.74px" class="cls_031"><span class="cls_031">dermatologists, therapy changes and therapies turned down indi-</span></div>
<div style="position:absolute;left:306.64px;top:592.81px" class="cls_031"><span class="cls_031">body and resulting in their destruction. In the literature available</span></div>
<div style="position:absolute;left:50.00px;top:596.75px" class="cls_031"><span class="cls_031">cate that there might be barriers in psoriasis care. The generated</span></div>
<div style="position:absolute;left:306.64px;top:602.81px" class="cls_031"><span class="cls_031">we didn’t find any references to RP occurring together with pso-</span></div>
<div style="position:absolute;left:50.00px;top:606.73px" class="cls_031"><span class="cls_031">data facilitate measures for an improved patient access to systemic</span></div>
<div style="position:absolute;left:306.64px;top:612.81px" class="cls_031"><span class="cls_031">riatic arthritis (PsA).</span></div>
<div style="position:absolute;left:50.00px;top:616.71px" class="cls_031"><span class="cls_031">drugs and biologics. The European comparison will allow for</span></div>
<div style="position:absolute;left:306.64px;top:622.81px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">to demonstrate a rare clinical case of RP and PsA.</span></div>
<div style="position:absolute;left:50.00px;top:626.69px" class="cls_031"><span class="cls_031">the first time the direct description of psoriasis care in a wide</span></div>
<div style="position:absolute;left:306.64px;top:632.81px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Patient (pt) (female), 29 y.o., complained of pain, swel-</span></div>
<div style="position:absolute;left:50.01px;top:636.67px" class="cls_031"><span class="cls_031">variety of European countries. The matching of patient-reported</span></div>
<div style="position:absolute;left:306.64px;top:642.81px" class="cls_031"><span class="cls_031">ling, and hyperemia of both ears, pain in the joints, in heels and</span></div>
<div style="position:absolute;left:50.01px;top:646.65px" class="cls_031"><span class="cls_031">outcomes with data of the health care system and barriers from</span></div>
<div style="position:absolute;left:306.64px;top:652.81px" class="cls_031"><span class="cls_031">toes and pain in cervical spine. Scalp psoriasis (Ps) and Ps in the</span></div>
<div style="position:absolute;left:50.01px;top:656.63px" class="cls_031"><span class="cls_031">the physician’s perspective is a novelty worldwide and the results</span></div>
<div style="position:absolute;left:306.64px;top:662.81px" class="cls_031"><span class="cls_031">external ear canal occurred in April, 2017, nail Ps and dactilitis in</span></div>
<div style="position:absolute;left:50.01px;top:666.61px" class="cls_031"><span class="cls_031">will contribute to developing strategies to overcome these barriers.</span></div>
<div style="position:absolute;left:306.64px;top:672.81px" class="cls_031"><span class="cls_031">October, 2017; in November, asymmetrical polyarthritis, pain in</span></div>
<div style="position:absolute;left:50.01px;top:676.65px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:306.64px;top:682.81px" class="cls_031"><span class="cls_031">heels, pain and limitation of movement in cervical spine develo-</span></div>
<div style="position:absolute;left:50.00px;top:686.72px" class="cls_032"><span class="cls_032">1 Augustin M, Schäfer I, Reich K, Glaeske G, Radtke MA. Systemic tre-</span></div>
<div style="position:absolute;left:50.00px;top:695.76px" class="cls_032"><span class="cls_032">atment with corticosteroids in psoriasis--health care provision far beyond</span></div>
<div style="position:absolute;left:306.64px;top:692.81px" class="cls_031"><span class="cls_031">ped. Besides the pt noticed redness, swelling and pain in pinnas</span></div>
<div style="position:absolute;left:50.00px;top:704.79px" class="cls_032"><span class="cls_032">the S3-guidelines. J Dtsch Dermatol Ges. 2011;9:833-38.</span></div>
<div style="position:absolute;left:306.64px;top:702.81px" class="cls_031"><span class="cls_031">of both ears and impairment of hearing; conjunctivitis, stomatitis</span></div>
<div style="position:absolute;left:50.00px;top:713.82px" class="cls_032"><span class="cls_032">2 Dubertret L, Mrowietz U, Ranki A, van de Kerkhof, P C M, Chimenti S,</span></div>
<div style="position:absolute;left:306.64px;top:712.81px" class="cls_031"><span class="cls_031">and subfebrile temperature developed.</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:31317px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background41.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">39</span></div>
<div style="position:absolute;left:50.23px;top:51.41px" class="cls_031"><span class="cls_031">At presentation: plaque Ps on the face and scalp, nail Ps, palmo-</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">kinase) pathway, which regulates a variety of cellular processes</span></div>
<div style="position:absolute;left:50.23px;top:61.41px" class="cls_031"><span class="cls_031">plantar feet pustulosis (BSA-4%, PASI -2.1); both pinnas of the</span></div>
<div style="position:absolute;left:306.64px;top:61.45px" class="cls_031"><span class="cls_031">including cell division, differentiation and apoptosis.</span></div>
<div style="position:absolute;left:50.23px;top:71.40px" class="cls_031"><span class="cls_031">ears were swollen, painful and red; ear lobes were not involved.</span></div>
<div style="position:absolute;left:306.64px;top:71.49px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Our patient developed SFH possibly due to use of</span></div>
<div style="position:absolute;left:50.23px;top:81.40px" class="cls_031"><span class="cls_031">The pt suffered from conjunctivitis. The pt had asymmetrical</span></div>
<div style="position:absolute;left:306.64px;top:81.54px" class="cls_031"><span class="cls_031">ustekinumab, IL-12 and IL-23 inhibitor. The latter has a role in</span></div>
<div style="position:absolute;left:50.23px;top:91.40px" class="cls_031"><span class="cls_031">polyarthritis, dactylitis, achillobursitis. Painful movements at</span></div>
<div style="position:absolute;left:306.64px;top:91.58px" class="cls_031"><span class="cls_031">differentiation process of the skin (12), suggesting that inhibition of</span></div>
<div style="position:absolute;left:50.23px;top:101.40px" class="cls_031"><span class="cls_031">cervical spine, rotation 30°-35°. ESR 54 mm/h, CRP 99 mg/l,</span></div>
<div style="position:absolute;left:306.64px;top:101.63px" class="cls_031"><span class="cls_031">IL-23 might explain the imperfect keratinization process observed</span></div>
<div style="position:absolute;left:50.23px;top:111.40px" class="cls_031"><span class="cls_031">RF negative, positive HLA B27, HLA B5 not detected. PET-CT</span></div>
<div style="position:absolute;left:306.64px;top:111.67px" class="cls_031"><span class="cls_031">in SFH. Considering that in our patient drug was not stopped and</span></div>
<div style="position:absolute;left:50.23px;top:121.40px" class="cls_031"><span class="cls_031">imaging did not reveal any pathological changes besides bilateral</span></div>
<div style="position:absolute;left:306.64px;top:121.71px" class="cls_031"><span class="cls_031">the condition resolved in several weeks without any treatment,</span></div>
<div style="position:absolute;left:50.23px;top:131.40px" class="cls_031"><span class="cls_031">auricular inflammation.</span></div>
<div style="position:absolute;left:306.64px;top:131.76px" class="cls_031"><span class="cls_031">possible cause could be ustekinumab-induced immunosupression</span></div>
<div style="position:absolute;left:50.23px;top:141.40px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">PsA diagnosis was determined according to CASPAR</span></div>
<div style="position:absolute;left:306.64px;top:141.80px" class="cls_031"><span class="cls_031">and consequent viral infection.</span></div>
<div style="position:absolute;left:50.23px;top:151.40px" class="cls_031"><span class="cls_031">criteria. RP diagnosis was based on the McAdams criteria. The</span></div>
<div style="position:absolute;left:306.64px;top:151.85px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.23px;top:161.40px" class="cls_031"><span class="cls_031">diagnosis is definite when no less than three out of six criteria</span></div>
<div style="position:absolute;left:306.64px;top:161.95px" class="cls_032"><span class="cls_032">1. Yanik ME, Erfan G, Albayrak H, et al. Acitretine-induced spiny follicular</span></div>
<div style="position:absolute;left:50.20px;top:171.39px" class="cls_031"><span class="cls_031">are present: bilateral auricular chondritis, nonerosive serone-</span></div>
<div style="position:absolute;left:306.64px;top:171.00px" class="cls_032"><span class="cls_032">hyperkeratosis. Cutan Ocul Toxicol. 2016;35:165-167.</span></div>
<div style="position:absolute;left:50.23px;top:181.41px" class="cls_031"><span class="cls_031">gative arthritis, nasal septum chondritis, ocular inflammation,</span></div>
<div style="position:absolute;left:306.64px;top:180.05px" class="cls_032"><span class="cls_032">2. DeCrescenzo AJ, Philips EC, Wilkerson MG, et al. Trichodysplasia</span></div>
<div style="position:absolute;left:306.64px;top:189.10px" class="cls_032"><span class="cls_032">spinulosa: A rare complication of immunosuppression. JAAD Case Re-</span></div>
<div style="position:absolute;left:50.26px;top:191.40px" class="cls_031"><span class="cls_031">respiratory tract chondritis, and cochlear disorder. Our pt had</span></div>
<div style="position:absolute;left:306.64px;top:198.15px" class="cls_032"><span class="cls_032">ports. 2016;2:307-309.</span></div>
<div style="position:absolute;left:50.26px;top:201.40px" class="cls_031"><span class="cls_031">bilateral auricular chondritis, conjunctivitis, cochlear disorder.</span></div>
<div style="position:absolute;left:50.26px;top:211.40px" class="cls_031"><span class="cls_031">The diagnosis was confirmed by ear-auricles biopsy which sho-</span></div>
<div style="position:absolute;left:306.64px;top:216.81px" class="cls_033"><span class="cls_033">P093</span></div>
<div style="position:absolute;left:50.23px;top:221.41px" class="cls_031"><span class="cls_031">wed perichondrial inflammation and granulocyte infiltration. The</span></div>
<div style="position:absolute;left:306.64px;top:228.26px" class="cls_025"><span class="cls_025">COMBINATION THERAPY OF APREMILAST AND</span></div>
<div style="position:absolute;left:50.22px;top:231.40px" class="cls_031"><span class="cls_031">therapy delivered: methotrexate s/c 10 mg pw; Solu-Medrol i/v</span></div>
<div style="position:absolute;left:50.22px;top:241.40px" class="cls_031"><span class="cls_031">(750 mg cumulatively); methylprednisolone per os 16 mg per day.</span></div>
<div style="position:absolute;left:306.64px;top:239.21px" class="cls_025"><span class="cls_025">BIOLOGICAL PRODUCT IN A PATIENT WITH</span></div>
<div style="position:absolute;left:50.22px;top:251.40px" class="cls_031"><span class="cls_031">Within days, there was normalization of temperature, ear-auricle</span></div>
<div style="position:absolute;left:306.64px;top:250.15px" class="cls_025"><span class="cls_025">PSORIASIS</span></div>
<div style="position:absolute;left:50.22px;top:261.40px" class="cls_031"><span class="cls_031">swelling, redness and pain had regressed; hearing was restored,</span></div>
<div style="position:absolute;left:306.64px;top:260.10px" class="cls_051"><span class="cls_051">Koji Masuda</span><span class="cls_026">, Fuminao Kanehisa, Norito Katoh</span></div>
<div style="position:absolute;left:50.22px;top:271.40px" class="cls_031"><span class="cls_031">conjunctivitis passed, the intensity of arthritises, dactylitis and</span></div>
<div style="position:absolute;left:306.64px;top:270.76px" class="cls_029"><span class="cls_029">Department of dermatology, Kyoto Prefectural University of Medicine</span></div>
<div style="position:absolute;left:50.22px;top:281.40px" class="cls_031"><span class="cls_031">spondylitis had decreased; the reduction in ESR, CRP was to 14</span></div>
<div style="position:absolute;left:306.64px;top:281.67px" class="cls_031"><span class="cls_031">Apremilast was approved in March 2017 in Japan for the treat-</span></div>
<div style="position:absolute;left:50.22px;top:291.40px" class="cls_031"><span class="cls_031">mm/h, to 7.0 mg/l accordingly.</span></div>
<div style="position:absolute;left:306.64px;top:291.72px" class="cls_031"><span class="cls_031">ment of psoriasis and psoriatic arthritis. Apremilast appears to</span></div>
<div style="position:absolute;left:50.22px;top:301.40px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">As is known, when a pt has PsO, he is twice as</span></div>
<div style="position:absolute;left:306.64px;top:301.76px" class="cls_031"><span class="cls_031">have lower efficacy than biological product. However, its ease</span></div>
<div style="position:absolute;left:50.22px;top:311.40px" class="cls_031"><span class="cls_031">likely to develop additional autoimmune diseases. It is of great</span></div>
<div style="position:absolute;left:306.66px;top:311.81px" class="cls_031"><span class="cls_031">of administration as an oral agent coupled with a mild side ef-</span></div>
<div style="position:absolute;left:50.22px;top:321.40px" class="cls_031"><span class="cls_031">importance to properly diagnose and treat cross autoimmune di-</span></div>
<div style="position:absolute;left:306.64px;top:321.86px" class="cls_031"><span class="cls_031">fect profile makes it an attractive option for psoriasis treatment.</span></div>
<div style="position:absolute;left:50.23px;top:331.41px" class="cls_031"><span class="cls_031">seases. Early diagnosis (within 3 months) and adequate treatment</span></div>
<div style="position:absolute;left:306.64px;top:331.91px" class="cls_031"><span class="cls_031">While monotherapy with biological products is effective for</span></div>
<div style="position:absolute;left:50.23px;top:341.40px" class="cls_031"><span class="cls_031">resulted in rapidly decreased inflammatory process and in escaping</span></div>
<div style="position:absolute;left:306.64px;top:341.95px" class="cls_031"><span class="cls_031">many patients with psoriasis, some patients are not satisfied by</span></div>
<div style="position:absolute;left:50.22px;top:351.40px" class="cls_031"><span class="cls_031">nonreversible changes in cartilage tissues.</span></div>
<div style="position:absolute;left:306.62px;top:352.00px" class="cls_031"><span class="cls_031">the outcome. There are few data or reports about the safety and</span></div>
<div style="position:absolute;left:306.62px;top:362.04px" class="cls_031"><span class="cls_031">efficacy of apremilast in combination of biological product in the</span></div>
<div style="position:absolute;left:50.23px;top:371.04px" class="cls_033"><span class="cls_033">P092</span></div>
<div style="position:absolute;left:306.63px;top:372.08px" class="cls_031"><span class="cls_031">treatment of psoriasis.</span></div>
<div style="position:absolute;left:50.23px;top:382.44px" class="cls_025"><span class="cls_025">SPINY FOLLICULAR HYPERKERATOSIS IN A PSORIA­</span></div>
<div style="position:absolute;left:306.63px;top:382.13px" class="cls_031"><span class="cls_031">We report a 46-year-old man with about a twenty-year history of</span></div>
<div style="position:absolute;left:50.23px;top:393.34px" class="cls_025"><span class="cls_025">SIS PATIENT TREATED WITH USTEKINUMAB</span></div>
<div style="position:absolute;left:306.63px;top:392.17px" class="cls_031"><span class="cls_031">plaque psoriasis and psoriatic arthritis who failed several therapies</span></div>
<div style="position:absolute;left:50.23px;top:403.24px" class="cls_051"><span class="cls_051">Antoanela Carija</span><span class="cls_026">, Adela Markota Cagalj, Neira Puizina Ivic</span></div>
<div style="position:absolute;left:306.63px;top:402.22px" class="cls_031"><span class="cls_031">including topical therapy, phototherapy and etretinate. At the time</span></div>
<div style="position:absolute;left:50.23px;top:413.84px" class="cls_029"><span class="cls_029">University Hospital Centre Split</span></div>
<div style="position:absolute;left:306.63px;top:412.26px" class="cls_031"><span class="cls_031">of presentation, the patient was using secukinumab for 9 months,</span></div>
<div style="position:absolute;left:50.23px;top:424.71px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">We present a psoriasis patient developing asymp-</span></div>
<div style="position:absolute;left:306.63px;top:422.30px" class="cls_031"><span class="cls_031">which had controlled his arthritis. However, the patient noted</span></div>
<div style="position:absolute;left:50.23px;top:434.71px" class="cls_031"><span class="cls_031">tomatic white spiny follicular hyperkeratoses (SFH) after being</span></div>
<div style="position:absolute;left:306.63px;top:432.35px" class="cls_031"><span class="cls_031">plaque remained mainly on his lower legs. Apremilast was added</span></div>
<div style="position:absolute;left:50.23px;top:444.70px" class="cls_031"><span class="cls_031">treated with ustekinumab for 3 months.</span></div>
<div style="position:absolute;left:306.63px;top:442.39px" class="cls_031"><span class="cls_031">and up-titrated to 30 mg twice per day along with his secukinumab</span></div>
<div style="position:absolute;left:50.23px;top:454.70px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">This type of eruption has been described under several</span></div>
<div style="position:absolute;left:306.63px;top:452.44px" class="cls_031"><span class="cls_031">therapy. After two months of combination therapy, the patient’s</span></div>
<div style="position:absolute;left:50.23px;top:464.70px" class="cls_031"><span class="cls_031">names including spiny follicular keratoderma, hyperkeratotic spi-</span></div>
<div style="position:absolute;left:306.63px;top:462.48px" class="cls_031"><span class="cls_031">disease has improved and stabilized with only a few scattered</span></div>
<div style="position:absolute;left:50.23px;top:474.71px" class="cls_031"><span class="cls_031">cules, filiform hyperkeratoses, parakeratotic horns, and follicular</span></div>
<div style="position:absolute;left:306.63px;top:472.52px" class="cls_031"><span class="cls_031">erythematous mildly scaly plaques on his lower legs. The patient</span></div>
<div style="position:absolute;left:50.24px;top:484.70px" class="cls_031"><span class="cls_031">hyperkeratoses (1). Facial hyperkeratotic spicule eruption was re-</span></div>
<div style="position:absolute;left:306.63px;top:482.57px" class="cls_031"><span class="cls_031">denied side effects of nausea, diarrhea or headache. Laboratory-</span></div>
<div style="position:absolute;left:50.23px;top:494.71px" class="cls_031"><span class="cls_031">ported in association with monoclonal gammopathy. Drug-induced</span></div>
<div style="position:absolute;left:306.63px;top:492.61px" class="cls_031"><span class="cls_031">work was within normal limits.</span></div>
<div style="position:absolute;left:50.23px;top:504.70px" class="cls_031"><span class="cls_031">filiform hyperkeratosis has been reported with cyclosporine, with</span></div>
<div style="position:absolute;left:306.63px;top:502.66px" class="cls_031"><span class="cls_031">However, we also experienced two other cases who failed apre-</span></div>
<div style="position:absolute;left:50.24px;top:514.70px" class="cls_031"><span class="cls_031">BRAF inhibitors (vemurafenib), with acitretin and with vismo-</span></div>
<div style="position:absolute;left:306.64px;top:512.79px" class="cls_031"><span class="cls_031">milast add on therapy to biological product because of efficacy or</span></div>
<div style="position:absolute;left:50.23px;top:524.71px" class="cls_031"><span class="cls_031">degib and sorafenib.</span></div>
<div style="position:absolute;left:306.65px;top:522.83px" class="cls_031"><span class="cls_031">side effects. So, this method may be useful for uncontrolled patient</span></div>
<div style="position:absolute;left:50.23px;top:534.70px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Our patient started ustekinumab treatment in June</span></div>
<div style="position:absolute;left:306.65px;top:532.87px" class="cls_031"><span class="cls_031">for psoriasis, more studies are needed to determine the safety and</span></div>
<div style="position:absolute;left:50.23px;top:544.70px" class="cls_031"><span class="cls_031">2015. At the same time he was treated with metothrexate, folic</span></div>
<div style="position:absolute;left:306.65px;top:542.92px" class="cls_031"><span class="cls_031">efficacy of using these drugs together.</span></div>
<div style="position:absolute;left:50.23px;top:554.70px" class="cls_031"><span class="cls_031">acid, metformin and lisinopril/hydrochlorothiazide. Three months</span></div>
<div style="position:absolute;left:50.23px;top:564.70px" class="cls_031"><span class="cls_031">after ustekinumab introduction patient noticed growth of tiny skin</span></div>
<div style="position:absolute;left:306.64px;top:561.61px" class="cls_033"><span class="cls_033">P094</span></div>
<div style="position:absolute;left:50.23px;top:574.70px" class="cls_031"><span class="cls_031">projections located on the face, scalp, upper trunk and upper arms.</span></div>
<div style="position:absolute;left:306.64px;top:573.06px" class="cls_025"><span class="cls_025">PSORIASIS WORST-CASE SCENARIOS: A SERIES OF 3</span></div>
<div style="position:absolute;left:50.23px;top:584.70px" class="cls_031"><span class="cls_031">Each spiny lesion was approximately 0.5 to 1 mm in diameter and</span></div>
<div style="position:absolute;left:306.64px;top:584.01px" class="cls_025"><span class="cls_025">CASE REPORTS</span></div>
<div style="position:absolute;left:50.23px;top:594.70px" class="cls_031"><span class="cls_031">up to 5 mm high. A biopsy of a white spiny keratotic projection sho-</span></div>
<div style="position:absolute;left:306.64px;top:593.95px" class="cls_026"><span class="cls_026">Elena Popa</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Persa Ghitulescu</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Patricia Cristodor</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, </span><span class="cls_051">Caius So-</span></div>
<div style="position:absolute;left:50.23px;top:604.71px" class="cls_031"><span class="cls_031">wed orthokeratosis, achantosis and mild spongiosis in epidermis,</span></div>
<div style="position:absolute;left:306.64px;top:603.90px" class="cls_051"><span class="cls_051">lovan</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:50.23px;top:614.70px" class="cls_031"><span class="cls_031">inflammatory infiltrate in chorium and dilatated acrotrichiums.</span></div>
<div style="position:absolute;left:306.64px;top:614.56px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Dermatology and Venereology, Clinical Emergency Muni-</span></div>
<div style="position:absolute;left:50.23px;top:624.70px" class="cls_031"><span class="cls_031">Condition resolved in several weeks without any treatment and</span></div>
<div style="position:absolute;left:306.64px;top:624.20px" class="cls_029"><span class="cls_029">cipal Hospital Timisoara; University of Medicine and Pharmacy “Victor</span></div>
<div style="position:absolute;left:50.23px;top:634.70px" class="cls_031"><span class="cls_031">without ustekinumab cessation.</span></div>
<div style="position:absolute;left:306.64px;top:633.85px" class="cls_029"><span class="cls_029">Babes” Timisoara, Romania, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Dermatology and Venereo-</span></div>
<div style="position:absolute;left:50.23px;top:644.70px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">A similar condition viral-associated trichodysplasia (TS)</span></div>
<div style="position:absolute;left:306.64px;top:643.50px" class="cls_029"><span class="cls_029">logy, Clinical Emergency Municipal Hospital Timisoara</span></div>
<div style="position:absolute;left:50.23px;top:654.70px" class="cls_031"><span class="cls_031">was originally described in 1999 as a folliculocentric viral infec-</span></div>
<div style="position:absolute;left:306.64px;top:654.41px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is a chronic, immune, inflammatory di-</span></div>
<div style="position:absolute;left:50.23px;top:664.71px" class="cls_031"><span class="cls_031">tion in a patient who was receiving cyclosporine after kidney and</span></div>
<div style="position:absolute;left:306.64px;top:664.46px" class="cls_031"><span class="cls_031">sease, that can occur at any time and it is most common in the age</span></div>
<div style="position:absolute;left:50.23px;top:674.70px" class="cls_031"><span class="cls_031">pancreas transplantation. Trichodysplasia spinulosa associated</span></div>
<div style="position:absolute;left:306.64px;top:674.51px" class="cls_031"><span class="cls_031">group 50-69. The reported prevalence of psoriasis in countries</span></div>
<div style="position:absolute;left:50.23px;top:684.70px" class="cls_031"><span class="cls_031">polyomavirus (TSPyV) was identified in TS lesions and shown</span></div>
<div style="position:absolute;left:306.64px;top:684.55px" class="cls_031"><span class="cls_031">ranges between 0.09% and 11.4%, making psoriasis a serious</span></div>
<div style="position:absolute;left:50.23px;top:694.70px" class="cls_031"><span class="cls_031">to be the probable cause of this disease (2). Pathogenesis both of</span></div>
<div style="position:absolute;left:306.64px;top:694.60px" class="cls_031"><span class="cls_031">global problem.</span></div>
<div style="position:absolute;left:50.23px;top:704.70px" class="cls_031"><span class="cls_031">viral-associated TS and BRAF inhibitor-induced SFH is based on</span></div>
<div style="position:absolute;left:306.64px;top:704.64px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">We present a series of 3 case reports that stand for some</span></div>
<div style="position:absolute;left:50.23px;top:714.70px" class="cls_031"><span class="cls_031">the paradoxical activation of MAPK (mitogen-activated protein</span></div>
<div style="position:absolute;left:306.64px;top:714.68px" class="cls_031"><span class="cls_031">of the worst-case scenarios a Psoriasis patient could end up in.</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:32120px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background42.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">40</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">We won’t be insisting on the treatment nor the outcomes of these</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">structurally distinct from innovator biologic, they may produce</span></div>
<div style="position:absolute;left:50.00px;top:61.40px" class="cls_031"><span class="cls_031">patients whereas the aim of this presentation is to emphasize the</span></div>
<div style="position:absolute;left:306.64px;top:61.40px" class="cls_031"><span class="cls_031">significantly different side effects. Although, data in the literature</span></div>
<div style="position:absolute;left:50.00px;top:71.40px" class="cls_031"><span class="cls_031">importance of patient’s education, prevention, but also of an early</span></div>
<div style="position:absolute;left:306.63px;top:71.40px" class="cls_031"><span class="cls_031">suggest that if a patient experience a severe allergic reaction to</span></div>
<div style="position:absolute;left:50.00px;top:81.40px" class="cls_031"><span class="cls_031">and correct treatment.</span></div>
<div style="position:absolute;left:306.63px;top:81.40px" class="cls_031"><span class="cls_031">the originator drug it is most possible the same reaction to happen</span></div>
<div style="position:absolute;left:50.00px;top:91.40px" class="cls_030"><span class="cls_030">Materials And Methods:</span></div>
<div style="position:absolute;left:306.63px;top:91.40px" class="cls_031"><span class="cls_031">with the biosimilar this may not always be the case.</span></div>
<div style="position:absolute;left:50.00px;top:101.40px" class="cls_031"><span class="cls_031">Case report no.1:</span></div>
<div style="position:absolute;left:306.63px;top:101.40px" class="cls_030"><span class="cls_030">Methods/Results: </span><span class="cls_031">We present a case of a 60 years old female patient</span></div>
<div style="position:absolute;left:50.00px;top:111.40px" class="cls_031"><span class="cls_031">-Patient characteristics: 49-years-old white Caucasian male;</span></div>
<div style="position:absolute;left:306.63px;top:111.40px" class="cls_031"><span class="cls_031">with severe plaque psoriasis from 25 years treated with infliximab</span></div>
<div style="position:absolute;left:50.00px;top:121.40px" class="cls_031"><span class="cls_031">-Clinical presentation: widespread, confluent erythema of the skin,</span></div>
<div style="position:absolute;left:306.64px;top:121.40px" class="cls_031"><span class="cls_031">every eight weeks for the last five years with great therapeutic ef-</span></div>
<div style="position:absolute;left:49.99px;top:131.40px" class="cls_031"><span class="cls_031">large scales, malaise, intense joint pain, shivers, oliguria, marked</span></div>
<div style="position:absolute;left:306.64px;top:131.41px" class="cls_031"><span class="cls_031">ficacy. During the last five infusions she presented mild reaction</span></div>
<div style="position:absolute;left:49.99px;top:141.40px" class="cls_031"><span class="cls_031">onychodystrophy of fingernails and toenails with an evolution of</span></div>
<div style="position:absolute;left:306.64px;top:141.40px" class="cls_031"><span class="cls_031">with itching and facial redness which was treated successfully</span></div>
<div style="position:absolute;left:49.99px;top:151.40px" class="cls_031"><span class="cls_031">about 1 week;</span></div>
<div style="position:absolute;left:306.64px;top:151.40px" class="cls_031"><span class="cls_031">with antihistamines without the need of interrupting the infusion.</span></div>
<div style="position:absolute;left:49.99px;top:161.39px" class="cls_031"><span class="cls_031">-Physical examination: fever, tachycardia, generalized nontender</span></div>
<div style="position:absolute;left:306.64px;top:161.40px" class="cls_031"><span class="cls_031">Patient was also administered pretreatment therapy with a three day</span></div>
<div style="position:absolute;left:49.99px;top:171.39px" class="cls_031"><span class="cls_031">adenopathy;</span></div>
<div style="position:absolute;left:306.64px;top:171.40px" class="cls_031"><span class="cls_031">course of corticosteroids to minimize these reactions. During the</span></div>
<div style="position:absolute;left:49.99px;top:181.39px" class="cls_031"><span class="cls_031">-Patients history: Psoriasis vulgaris and Psoriatic arthritis since</span></div>
<div style="position:absolute;left:306.64px;top:181.40px" class="cls_031"><span class="cls_031">last infusion patient presented severe body rash and hypotension</span></div>
<div style="position:absolute;left:49.99px;top:191.39px" class="cls_031"><span class="cls_031">2003 treated with 8 months Methotrexate switched (due to diges-</span></div>
<div style="position:absolute;left:306.64px;top:191.40px" class="cls_031"><span class="cls_031">which led to the discontinuation of the infusion. Due to the great</span></div>
<div style="position:absolute;left:50.00px;top:201.41px" class="cls_031"><span class="cls_031">tive symptoms) to oral Acitretinum for about 2 months prior the</span></div>
<div style="position:absolute;left:306.64px;top:201.40px" class="cls_031"><span class="cls_031">therapeutic response and because patient had undergone several</span></div>
<div style="position:absolute;left:50.00px;top:211.40px" class="cls_031"><span class="cls_031">current presentation;</span></div>
<div style="position:absolute;left:306.64px;top:211.40px" class="cls_031"><span class="cls_031">therapies in the past which either hadn’t tolerated or hadn’t re-</span></div>
<div style="position:absolute;left:50.00px;top:221.40px" class="cls_031"><span class="cls_031">-Possible cause of the flare-up: lack of compliance to treatment,</span></div>
<div style="position:absolute;left:306.64px;top:221.41px" class="cls_031"><span class="cls_031">sponded to, she was reluctant to change therapy so we decided to</span></div>
<div style="position:absolute;left:50.01px;top:231.40px" class="cls_031"><span class="cls_031">but mostly because of disorderly lifestyle.</span></div>
<div style="position:absolute;left:306.64px;top:231.40px" class="cls_031"><span class="cls_031">switch to a biosimilar. Patient is currently through the eight month</span></div>
<div style="position:absolute;left:50.01px;top:241.40px" class="cls_031"><span class="cls_031">Case report no.2:</span></div>
<div style="position:absolute;left:306.64px;top:241.40px" class="cls_031"><span class="cls_031">of treatment with the biosimilar with no sign of reaction and with</span></div>
<div style="position:absolute;left:50.01px;top:251.40px" class="cls_031"><span class="cls_031">-Patient characteristics: 64-years-old white Caucasian male;</span></div>
<div style="position:absolute;left:306.64px;top:251.40px" class="cls_031"><span class="cls_031">maintenance of the therapeutic response.</span></div>
<div style="position:absolute;left:50.01px;top:261.40px" class="cls_031"><span class="cls_031">-Clinical presentation: widespread, confluent erythema of the skin,</span></div>
<div style="position:absolute;left:306.64px;top:261.40px" class="cls_030"><span class="cls_030">Conclusion:</span><span class="cls_031"> Biologics are much more complex than conventional</span></div>
<div style="position:absolute;left:50.00px;top:271.40px" class="cls_031"><span class="cls_031">large scales, malaise, loss of appetite, marked onychodystrophy</span></div>
<div style="position:absolute;left:306.64px;top:271.40px" class="cls_031"><span class="cls_031">chemical drugs because they are larger and have more complicated</span></div>
<div style="position:absolute;left:50.00px;top:281.40px" class="cls_031"><span class="cls_031">of fingernails and toenails with an evolution of about 2 weeks;</span></div>
<div style="position:absolute;left:306.64px;top:281.40px" class="cls_031"><span class="cls_031">structures, so it is impossible to produce biosimilars that are iden-</span></div>
<div style="position:absolute;left:50.00px;top:291.40px" class="cls_031"><span class="cls_031">-Physical examination: fever, tachycardia;</span></div>
<div style="position:absolute;left:306.64px;top:291.41px" class="cls_031"><span class="cls_031">tical to the originator drug. As a result, the therapeutic efficacy and</span></div>
<div style="position:absolute;left:50.00px;top:301.40px" class="cls_031"><span class="cls_031">-Patients history: Psoriasis vulgaris since 1992 treated with Ada-</span></div>
<div style="position:absolute;left:306.63px;top:301.40px" class="cls_031"><span class="cls_031">safety of a biosimilar could vary from the originator because the</span></div>
<div style="position:absolute;left:50.00px;top:311.41px" class="cls_031"><span class="cls_031">limumb (discontinued after 2 years) and Methotrexate;</span></div>
<div style="position:absolute;left:306.63px;top:311.40px" class="cls_031"><span class="cls_031">end product is highly dependent on a proprietary manufacturing</span></div>
<div style="position:absolute;left:50.00px;top:321.40px" class="cls_031"><span class="cls_031">-Possible cause of the flare-up: voluntarily discontinuation of the</span></div>
<div style="position:absolute;left:306.63px;top:321.40px" class="cls_031"><span class="cls_031">process that differs for each manufacturer. Our case suggests that</span></div>
<div style="position:absolute;left:50.02px;top:331.40px" class="cls_031"><span class="cls_031">treatment (Methotrexate) 3 weeks prior to current presentation.</span></div>
<div style="position:absolute;left:306.63px;top:331.40px" class="cls_031"><span class="cls_031">we may try a switch between reference biologic and its biosimilar</span></div>
<div style="position:absolute;left:50.02px;top:341.40px" class="cls_031"><span class="cls_031">Case report no.3:</span></div>
<div style="position:absolute;left:306.63px;top:341.40px" class="cls_031"><span class="cls_031">even when an allergic reaction to the originator drug had occurred,</span></div>
<div style="position:absolute;left:50.02px;top:351.40px" class="cls_031"><span class="cls_031">-Patient characteristics: 38-years-old white Caucasian female;</span></div>
<div style="position:absolute;left:306.63px;top:351.40px" class="cls_031"><span class="cls_031">especially when we have a great therapeutic efficacy. However,</span></div>
<div style="position:absolute;left:50.02px;top:361.40px" class="cls_031"><span class="cls_031">-Clinical presentation: pustular lesions spread throughout an</span></div>
<div style="position:absolute;left:306.64px;top:361.40px" class="cls_031"><span class="cls_031">more data is needed.</span></div>
<div style="position:absolute;left:50.02px;top:371.40px" class="cls_031"><span class="cls_031">erythematous background intercalated with skin atrophies and</span></div>
<div style="position:absolute;left:50.02px;top:381.40px" class="cls_031"><span class="cls_031">subepidermal pseudocysts disseminated throughout the body,</span></div>
<div style="position:absolute;left:306.64px;top:382.04px" class="cls_033"><span class="cls_033">P096</span></div>
<div style="position:absolute;left:50.02px;top:391.40px" class="cls_031"><span class="cls_031">erythematous, scaly plaque on the scalp;</span></div>
<div style="position:absolute;left:306.64px;top:393.44px" class="cls_025"><span class="cls_025">SAFETY OF APREMILAST IN THE TREATMENT OF A</span></div>
<div style="position:absolute;left:50.02px;top:401.40px" class="cls_031"><span class="cls_031">-Physical examination: vital signs within normal limits;</span></div>
<div style="position:absolute;left:306.64px;top:404.34px" class="cls_025"><span class="cls_025">PSORIASIS PATIENT WITH CHRONIC HEPATITIS B</span></div>
<div style="position:absolute;left:50.02px;top:411.40px" class="cls_031"><span class="cls_031">-Patients history: Pustular Psoriasis from the age of 7 treated with</span></div>
<div style="position:absolute;left:306.64px;top:414.24px" class="cls_051"><span class="cls_051">Christina Fotiadou</span><span class="cls_026">, Myrto Trakatelli, Despina Papathemeli, Eli-</span></div>
<div style="position:absolute;left:50.02px;top:421.39px" class="cls_031"><span class="cls_031">Prednisone, Acitretinum and topical steroids;</span></div>
<div style="position:absolute;left:306.64px;top:424.14px" class="cls_026"><span class="cls_026">zabeth Lazaridou</span></div>
<div style="position:absolute;left:50.02px;top:431.39px" class="cls_031"><span class="cls_031">-Possible cause of the flare-up: voluntarily discontinuation of</span></div>
<div style="position:absolute;left:306.64px;top:434.74px" class="cls_029"><span class="cls_029">Second  Department  of  Dermatology-Venereology, Aristotle  University</span></div>
<div style="position:absolute;left:50.04px;top:441.39px" class="cls_031"><span class="cls_031">the treatment (Acitretinum) 7 months prior to current presenta-</span></div>
<div style="position:absolute;left:306.64px;top:444.34px" class="cls_029"><span class="cls_029">Medical School</span></div>
<div style="position:absolute;left:50.00px;top:451.41px" class="cls_031"><span class="cls_031">tion (the patient wishes to conceive) and long-term use of potent</span></div>
<div style="position:absolute;left:306.64px;top:455.17px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">The treatment of patients with moderate-to-severe</span></div>
<div style="position:absolute;left:50.00px;top:461.40px" class="cls_031"><span class="cls_031">topical steroids.</span></div>
<div style="position:absolute;left:306.64px;top:465.13px" class="cls_031"><span class="cls_031">psoriasis in an everyday clinical setting, sometimes, poses serious</span></div>
<div style="position:absolute;left:50.00px;top:471.40px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">All three cases were treated considering the Psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:475.09px" class="cls_031"><span class="cls_031">challenges. The presence of hepatitis B Virus Infection (HBV) in</span></div>
<div style="position:absolute;left:50.00px;top:481.40px" class="cls_031"><span class="cls_031">type, clinical presentation and symptoms, each of them having a</span></div>
<div style="position:absolute;left:306.64px;top:485.05px" class="cls_031"><span class="cls_031">these patients complicates the therapeutic choices.</span></div>
<div style="position:absolute;left:50.00px;top:491.40px" class="cls_031"><span class="cls_031">positive evolution during the hospitalization and follow-up visits.</span></div>
<div style="position:absolute;left:306.64px;top:495.02px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">We report the case of a female patient, 52 years old,</span></div>
<div style="position:absolute;left:306.64px;top:504.98px" class="cls_031"><span class="cls_031">suffering from moderate-to- severe plaque psoriasis and chronic</span></div>
<div style="position:absolute;left:50.00px;top:510.04px" class="cls_033"><span class="cls_033">P095</span></div>
<div style="position:absolute;left:306.64px;top:514.94px" class="cls_031"><span class="cls_031">hepatitis B.</span></div>
<div style="position:absolute;left:50.00px;top:521.44px" class="cls_025"><span class="cls_025">SUCCESSFUL SWITCHING TO BIOSIMILAR IN</span></div>
<div style="position:absolute;left:306.64px;top:524.91px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">She was referred to our outpatient psoriasis clinic with</span></div>
<div style="position:absolute;left:50.00px;top:532.34px" class="cls_025"><span class="cls_025">PSORIATIC PATIENT WITH SEVERE DRUG REACTION</span></div>
<div style="position:absolute;left:306.64px;top:534.87px" class="cls_031"><span class="cls_031">a Psoriasis Area and Severity Index (PASI) score of 13.2. The</span></div>
<div style="position:absolute;left:50.00px;top:543.24px" class="cls_025"><span class="cls_025">TO INFLIXIMAB. A CASE REPORT</span></div>
<div style="position:absolute;left:306.64px;top:544.83px" class="cls_031"><span class="cls_031">patient’s condition has deteriorated the past year but she had not</span></div>
<div style="position:absolute;left:50.00px;top:553.14px" class="cls_026"><span class="cls_026">Maria Politou</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Maria Pompou</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Dimitrios Rigopoulos</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Nikolaos</span></div>
<div style="position:absolute;left:306.64px;top:554.80px" class="cls_031"><span class="cls_031">received any kind of systemic treatment. During our pre-treatment</span></div>
<div style="position:absolute;left:50.00px;top:563.04px" class="cls_026"><span class="cls_026">Fekkas</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Anastasios Giannoukos</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:306.64px;top:564.76px" class="cls_031"><span class="cls_031">screening tests she was found HBsAg positive although the liver</span></div>
<div style="position:absolute;left:50.00px;top:573.64px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">1</span><span class="cls_028"><sup>st</sup></span><span class="cls_029"> Department of Dermatology-Venereology "Andreas Syggros" Hospital,</span></div>
<div style="position:absolute;left:306.64px;top:574.72px" class="cls_031"><span class="cls_031">function tests were within normal rates. The HBV serological</span></div>
<div style="position:absolute;left:50.00px;top:583.24px" class="cls_029"><span class="cls_029">UOA, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Dermatology-venereology, 401 Military Hospital,</span></div>
<div style="position:absolute;left:306.64px;top:584.68px" class="cls_031"><span class="cls_031">status of the patient (HBsAg, HBeAg, anti-HBc, anti-HBs and</span></div>
<div style="position:absolute;left:50.00px;top:592.84px" class="cls_029"><span class="cls_029">Greece</span></div>
<div style="position:absolute;left:306.64px;top:594.65px" class="cls_031"><span class="cls_031">anti-HBe) was estimated. HBV DNA load was measured with the</span></div>
<div style="position:absolute;left:50.00px;top:603.71px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Biosimilar medicines are drugs which are highly</span></div>
<div style="position:absolute;left:306.64px;top:604.61px" class="cls_031"><span class="cls_031">Polymerase Chain Reaction (PCR) method, in order to confirm</span></div>
<div style="position:absolute;left:50.00px;top:613.70px" class="cls_031"><span class="cls_031">similar to other biological medicines already licensed and that do</span></div>
<div style="position:absolute;left:306.65px;top:614.57px" class="cls_031"><span class="cls_031">that the disease was not active, and it was undetectable.</span></div>
<div style="position:absolute;left:50.00px;top:623.70px" class="cls_031"><span class="cls_031">not have any clinically meaningful difference to the originator</span></div>
<div style="position:absolute;left:306.65px;top:624.54px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">At that point it was decided to treat the patient with</span></div>
<div style="position:absolute;left:50.00px;top:633.70px" class="cls_031"><span class="cls_031">drug in structure, pharmacokinetics, quality, safety or efficacy.</span></div>
<div style="position:absolute;left:306.65px;top:634.50px" class="cls_031"><span class="cls_031">Apremilast using the standard titration dosing schedule (10mg on</span></div>
<div style="position:absolute;left:50.00px;top:643.70px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">Many clinical and observational studies involving a</span></div>
<div style="position:absolute;left:306.65px;top:644.46px" class="cls_031"><span class="cls_031">day one and increasing the dose by 10 mg daily) until reaching</span></div>
<div style="position:absolute;left:50.00px;top:653.70px" class="cls_031"><span class="cls_031">switch between reference infliximab and its biosimilars have been</span></div>
<div style="position:absolute;left:306.65px;top:654.43px" class="cls_031"><span class="cls_031">the maintenance dose of 30mg twice daily on day 6. Antiviral</span></div>
<div style="position:absolute;left:50.01px;top:663.70px" class="cls_031"><span class="cls_031">conducted or are ongoing. Switching between reference biologics</span></div>
<div style="position:absolute;left:306.65px;top:664.39px" class="cls_031"><span class="cls_031">treatment was not given to the patient but liver function tests were</span></div>
<div style="position:absolute;left:50.01px;top:673.70px" class="cls_031"><span class="cls_031">and biosimilars should be performed by the prescriber for clinical</span></div>
<div style="position:absolute;left:306.65px;top:674.35px" class="cls_031"><span class="cls_031">performed at a monthly basis and HBV load every three months</span></div>
<div style="position:absolute;left:50.01px;top:683.70px" class="cls_031"><span class="cls_031">reasons such as optimizing efficacy or minimizing AES. Efficacy</span></div>
<div style="position:absolute;left:306.65px;top:684.25px" class="cls_031"><span class="cls_031">during treatment. All these test from the baseline until last obser-</span></div>
<div style="position:absolute;left:50.01px;top:693.70px" class="cls_031"><span class="cls_031">and clinical measures of safety were similar in the switched and</span></div>
<div style="position:absolute;left:306.64px;top:694.21px" class="cls_031"><span class="cls_031">vation (12 months after) were within normal rates. The patient</span></div>
<div style="position:absolute;left:50.01px;top:703.70px" class="cls_031"><span class="cls_031">not switched groups at studies end. Differences in the type of AES</span></div>
<div style="position:absolute;left:306.64px;top:704.17px" class="cls_031"><span class="cls_031">exhibited an amelioration of her condition from the beginning</span></div>
<div style="position:absolute;left:50.01px;top:713.69px" class="cls_031"><span class="cls_031">upon switching must also be considered. Because biosimilars are</span></div>
<div style="position:absolute;left:306.64px;top:714.13px" class="cls_031"><span class="cls_031">which was confirmed by the significant reduction of her PASI score</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:32923px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background43.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">41</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">which reached PSI75 at week 12 and PASI90 at week 24. At the</span></div>
<div style="position:absolute;left:306.65px;top:51.42px" class="cls_031"><span class="cls_031">direct correlation between IL-22 pathway and miR-31 epidermal</span></div>
<div style="position:absolute;left:50.00px;top:61.48px" class="cls_031"><span class="cls_031">time of this writing, one year after the initiation of treatment, the</span></div>
<div style="position:absolute;left:306.65px;top:61.42px" class="cls_031"><span class="cls_031">expression. In line with these observations, the miR targets (PTEN</span></div>
<div style="position:absolute;left:50.00px;top:71.55px" class="cls_031"><span class="cls_031">patient remains almost clear from her psoriatic lesions. Apremilast</span></div>
<div style="position:absolute;left:306.65px;top:71.42px" class="cls_031"><span class="cls_031">and ppp6c) were contrariwise proportional to miRs expression</span></div>
<div style="position:absolute;left:50.00px;top:81.62px" class="cls_031"><span class="cls_031">was well-tolerated by the patient.</span></div>
<div style="position:absolute;left:306.65px;top:81.42px" class="cls_031"><span class="cls_031">confirming by that the specificity of the IL-22/miR-21 and IL-22/</span></div>
<div style="position:absolute;left:50.00px;top:91.69px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">The treatment of moderate-to-severe psoriasis in the</span></div>
<div style="position:absolute;left:306.65px;top:91.42px" class="cls_031"><span class="cls_031">miR-31 correlation.</span></div>
<div style="position:absolute;left:50.00px;top:101.76px" class="cls_031"><span class="cls_031">background of chronic HBV limits the therapeutic options due</span></div>
<div style="position:absolute;left:306.65px;top:101.41px" class="cls_031"><span class="cls_031">These findings identify IL-22 as a key regulator of miRs implica-</span></div>
<div style="position:absolute;left:50.00px;top:111.83px" class="cls_031"><span class="cls_031">to the possibility of HBV reactivation when the psoriasis patient</span></div>
<div style="position:absolute;left:306.64px;top:111.41px" class="cls_031"><span class="cls_031">ted in multiple signaling pathways that coordinate keratinocytes</span></div>
<div style="position:absolute;left:50.00px;top:121.90px" class="cls_031"><span class="cls_031">is treated with immunosuppressive or even immunomodulatory</span></div>
<div style="position:absolute;left:306.64px;top:121.40px" class="cls_031"><span class="cls_031">proliferation activity</span></div>
<div style="position:absolute;left:50.00px;top:131.97px" class="cls_031"><span class="cls_031">drugs. Apremilast is an oral small-molecule PDE-inhibitor, appro-</span></div>
<div style="position:absolute;left:50.00px;top:142.05px" class="cls_031"><span class="cls_031">ved by the Food and Drug Administration for the treatment of</span></div>
<div style="position:absolute;left:306.64px;top:141.04px" class="cls_033"><span class="cls_033">P099</span></div>
<div style="position:absolute;left:50.00px;top:152.12px" class="cls_031"><span class="cls_031">moderate-to-severe- plaque psoriasis in 2014. It does not target</span></div>
<div style="position:absolute;left:306.64px;top:152.44px" class="cls_025"><span class="cls_025">SERUM CONCENTRACION OF IFN-GAMMA IN</span></div>
<div style="position:absolute;left:50.00px;top:162.19px" class="cls_031"><span class="cls_031">any one cytokine but restores a balance of pro-inflammatory and</span></div>
<div style="position:absolute;left:306.64px;top:163.34px" class="cls_025"><span class="cls_025">PATIENTS WITH PSORIASIS: CORRELATION WITH</span></div>
<div style="position:absolute;left:50.00px;top:172.26px" class="cls_031"><span class="cls_031">anti-inflammatory mediators. The pharmacokinetics of Apre-</span></div>
<div style="position:absolute;left:306.64px;top:174.24px" class="cls_025"><span class="cls_025">CLINICAL TYPE AND SEVERITY OF DISEASE</span></div>
<div style="position:absolute;left:50.00px;top:182.34px" class="cls_031"><span class="cls_031">milast is not affected by hepatic impairment and the drug is not</span></div>
<div style="position:absolute;left:306.64px;top:184.14px" class="cls_026"><span class="cls_026">Nermina Ovčina-Kurtović, Emina Kasumagić-Halilović, Jasmina</span></div>
<div style="position:absolute;left:50.00px;top:192.41px" class="cls_031"><span class="cls_031">hepatotoxic. Moreover, it is not contraindicated in patients with</span></div>
<div style="position:absolute;left:306.65px;top:194.04px" class="cls_026"><span class="cls_026">Muhović</span></div>
<div style="position:absolute;left:50.00px;top:202.48px" class="cls_031"><span class="cls_031">active infection. To our knowledge, this is the first reported case</span></div>
<div style="position:absolute;left:306.64px;top:204.64px" class="cls_029"><span class="cls_029">Dermatovenerology Department Clinical center University of Sarajevo,</span></div>
<div style="position:absolute;left:50.01px;top:212.55px" class="cls_031"><span class="cls_031">of Apremilast psoriasis patient with chronic inactive Hepatitis B.</span></div>
<div style="position:absolute;left:306.64px;top:214.24px" class="cls_029"><span class="cls_029">Bosnia and Herzegovina</span></div>
<div style="position:absolute;left:50.01px;top:222.62px" class="cls_031"><span class="cls_031">It proved to be both safe and efficacious but large, well-organized</span></div>
<div style="position:absolute;left:306.64px;top:225.11px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is a multifactorial chronic inflammatory</span></div>
<div style="position:absolute;left:50.00px;top:232.69px" class="cls_031"><span class="cls_031">studies are needed in order to confirm this conclusion.</span></div>
<div style="position:absolute;left:306.64px;top:235.10px" class="cls_031"><span class="cls_031">disease. The etiopathogenesis of the disease is still unclear but</span></div>
<div style="position:absolute;left:306.64px;top:245.10px" class="cls_031"><span class="cls_031">there is evidence that many of cytokines released by keratinocytes</span></div>
<div style="position:absolute;left:50.00px;top:252.44px" class="cls_033"><span class="cls_033">P098</span></div>
<div style="position:absolute;left:306.64px;top:255.10px" class="cls_031"><span class="cls_031">and inflammatory leukocytes may contribute to the induction or</span></div>
<div style="position:absolute;left:50.00px;top:263.95px" class="cls_025"><span class="cls_025">IL-22 INDUCES KERATINOCYTES</span></div>
<div style="position:absolute;left:306.63px;top:265.10px" class="cls_031"><span class="cls_031">persistence of the inflammatory process in psoriasis.</span></div>
<div style="position:absolute;left:50.00px;top:274.97px" class="cls_025"><span class="cls_025">HYPERPROLIFERATION IN PSORIASIS VIA MIR-21</span></div>
<div style="position:absolute;left:306.63px;top:275.10px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">The aim of the study was to evaluate serum concen-</span></div>
<div style="position:absolute;left:50.00px;top:285.98px" class="cls_025"><span class="cls_025">AND MIR-31 UPREGULATION</span></div>
<div style="position:absolute;left:306.64px;top:285.11px" class="cls_031"><span class="cls_031">trations of INF-gamma in patients with psoriasis and the healthy</span></div>
<div style="position:absolute;left:50.00px;top:295.99px" class="cls_026"><span class="cls_026">Florence Abdallah</span></div>
<div style="position:absolute;left:306.64px;top:295.10px" class="cls_031"><span class="cls_031">subjects and also to assess a possible association between IFN-</span></div>
<div style="position:absolute;left:50.00px;top:306.70px" class="cls_029"><span class="cls_029">Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France</span></div>
<div style="position:absolute;left:306.64px;top:305.10px" class="cls_031"><span class="cls_031">gamma, clinical type and severity of disease.</span></div>
<div style="position:absolute;left:50.00px;top:317.68px" class="cls_031"><span class="cls_031">Psoriasis is a chronic inflammatory skin disease that affects</span></div>
<div style="position:absolute;left:306.64px;top:315.10px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">The study included a total of 60 patients with psoriasis,</span></div>
<div style="position:absolute;left:50.01px;top:327.79px" class="cls_031"><span class="cls_031">people of all ages with an estimated 3% prevalence worldwide.</span></div>
<div style="position:absolute;left:306.64px;top:325.10px" class="cls_031"><span class="cls_031">both genders and all of ages. There were 20 healthy subjects in the</span></div>
<div style="position:absolute;left:306.64px;top:335.10px" class="cls_031"><span class="cls_031">control group. According to the clinical type of disease, patients</span></div>
<div style="position:absolute;left:50.01px;top:337.91px" class="cls_031"><span class="cls_031">It manifests as thick red irritated skin lesions due to imbalanced</span></div>
<div style="position:absolute;left:306.64px;top:345.10px" class="cls_031"><span class="cls_031">with psoriasis were divided into four groups: psoriasis vulgaris,</span></div>
<div style="position:absolute;left:50.01px;top:348.03px" class="cls_031"><span class="cls_031">keratinocytes hyperproliferation and differentiation caused mainly</span></div>
<div style="position:absolute;left:306.64px;top:355.10px" class="cls_031"><span class="cls_031">psoriasis pustulosa, psoriasis erythrodermica and psoriasis arth-</span></div>
<div style="position:absolute;left:50.01px;top:358.12px" class="cls_031"><span class="cls_031">by increased activation of IL-22 pathway in keratinocytes. Emer-</span></div>
<div style="position:absolute;left:306.64px;top:365.11px" class="cls_031"><span class="cls_031">ropatica. Blood samples were collected from all psoriasis patients</span></div>
<div style="position:absolute;left:50.00px;top:368.24px" class="cls_031"><span class="cls_031">ging studies showed a specific psoriatic miRs signature where</span></div>
<div style="position:absolute;left:306.64px;top:375.10px" class="cls_031"><span class="cls_031">and from healthy control subjects. Serum IFN-gamma levels were</span></div>
<div style="position:absolute;left:50.00px;top:378.35px" class="cls_031"><span class="cls_031">miR-21 and miR-31 are one of the most upregulated miRs. The</span></div>
<div style="position:absolute;left:306.64px;top:385.10px" class="cls_031"><span class="cls_031">measured by an enzyme-linked immunosorbent assay (ELISA)</span></div>
<div style="position:absolute;left:50.00px;top:388.47px" class="cls_031"><span class="cls_031">latters act by favoring cellular proliferation and inflammation.</span></div>
<div style="position:absolute;left:306.64px;top:395.10px" class="cls_031"><span class="cls_031">technique. The severity of psoriasis vulgaris was assessed by</span></div>
<div style="position:absolute;left:49.99px;top:398.58px" class="cls_031"><span class="cls_031">Hence, re-conciliating the microRNAs and the immunopathogenic</span></div>
<div style="position:absolute;left:306.64px;top:405.10px" class="cls_031"><span class="cls_031">Psoriasis Area and Severity Index (PASI) score.</span></div>
<div style="position:absolute;left:49.99px;top:408.70px" class="cls_031"><span class="cls_031">occasions responsible for psoriasis development can be a new</span></div>
<div style="position:absolute;left:306.64px;top:415.10px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Of the total number of patients suffering from psoriasis</span></div>
<div style="position:absolute;left:49.99px;top:418.82px" class="cls_031"><span class="cls_031">approach for developing effective mechanism and target-based</span></div>
<div style="position:absolute;left:306.64px;top:425.10px" class="cls_031"><span class="cls_031">42 (70%) had psoriasis vulgaris. The second most frequent was</span></div>
<div style="position:absolute;left:49.99px;top:428.93px" class="cls_031"><span class="cls_031">agents to treat psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:435.10px" class="cls_031"><span class="cls_031">psoriasis erythrodermica 9 (15%), while 6 (10%) patients had</span></div>
<div style="position:absolute;left:49.99px;top:439.05px" class="cls_031"><span class="cls_031">The common hyper-proliferation effect of IL-22, miR-21 and</span></div>
<div style="position:absolute;left:306.64px;top:445.10px" class="cls_031"><span class="cls_031">psoriasis pustulosa and 3 (5%) psoriasis arthropatica. The serum</span></div>
<div style="position:absolute;left:49.99px;top:449.16px" class="cls_031"><span class="cls_031">miR-31 prompted us to look after a potential interaction between</span></div>
<div style="position:absolute;left:306.64px;top:455.10px" class="cls_031"><span class="cls_031">concentartion of IFN-gamma in patients with psoriasis was sig-</span></div>
<div style="position:absolute;left:49.99px;top:459.28px" class="cls_031"><span class="cls_031">these actors. The expression levels of those 2 microRNAs and that</span></div>
<div style="position:absolute;left:306.64px;top:465.11px" class="cls_031"><span class="cls_031">nificialy higher than that in the control group (1.91+1.79 pg/ml</span></div>
<div style="position:absolute;left:49.99px;top:469.40px" class="cls_031"><span class="cls_031">of their targets were evaluated both </span><span class="cls_030">in vitro</span><span class="cls_031"> and </span><span class="cls_030">in vivo</span><span class="cls_031"> studies in</span></div>
<div style="position:absolute;left:306.62px;top:475.10px" class="cls_031"><span class="cls_031">vs 0.91+0.38 pg/ml, respectively). Significantly elevated serum</span></div>
<div style="position:absolute;left:49.99px;top:479.51px" class="cls_031"><span class="cls_031">presence or absence of IL-22.</span></div>
<div style="position:absolute;left:306.63px;top:485.10px" class="cls_031"><span class="cls_031">IFN-gamma concentrations were noticed in patients with psoriasis</span></div>
<div style="position:absolute;left:49.99px;top:489.63px" class="cls_031"><span class="cls_031">We first exploited different skin models to investigate a potential</span></div>
<div style="position:absolute;left:306.63px;top:495.10px" class="cls_031"><span class="cls_031">vulgaris (2.15+0.30 pg/ml), compared with patients suffering from</span></div>
<div style="position:absolute;left:49.98px;top:499.74px" class="cls_031"><span class="cls_031">connection between IL-22 and miR-21 or miR-31. The qPCR</span></div>
<div style="position:absolute;left:306.63px;top:505.10px" class="cls_031"><span class="cls_031">psoriasis erythrodermica (1.57+0.68 pg/ml), psoriasis arthropa-</span></div>
<div style="position:absolute;left:49.98px;top:509.86px" class="cls_031"><span class="cls_031">analysis showed a significant increase in the relative expression</span></div>
<div style="position:absolute;left:306.64px;top:515.11px" class="cls_031"><span class="cls_031">tica (1.33+0.53 pg/ml), and in particular patients suffering from</span></div>
<div style="position:absolute;left:49.98px;top:519.91px" class="cls_031"><span class="cls_031">(RE) of both miRs in the different models upon IL-22 stimula-</span></div>
<div style="position:absolute;left:306.64px;top:525.10px" class="cls_031"><span class="cls_031">psoriasis pustulosa (1.08+0.21 pg/ml) who had the lowest mean</span></div>
<div style="position:absolute;left:50.00px;top:530.02px" class="cls_031"><span class="cls_031">tion during 24h compared to untreated cells. These observations</span></div>
<div style="position:absolute;left:306.64px;top:535.10px" class="cls_031"><span class="cls_031">serum concentration of IFN-gamma. There was no statistically</span></div>
<div style="position:absolute;left:50.00px;top:540.14px" class="cls_031"><span class="cls_031">indicate the implication of miR-21 and miR-31 in proliferation-</span></div>
<div style="position:absolute;left:306.64px;top:545.10px" class="cls_031"><span class="cls_031">significant difference between the mean values of IFN-gamma</span></div>
<div style="position:absolute;left:50.00px;top:550.25px" class="cls_031"><span class="cls_031">differentiation processes in the different layers of the epidermis.</span></div>
<div style="position:absolute;left:306.66px;top:555.10px" class="cls_031"><span class="cls_031">compared to the clinical type of psoriasis (</span><span class="cls_030">p > </span><span class="cls_031">0.05). In the group of</span></div>
<div style="position:absolute;left:50.00px;top:560.37px" class="cls_031"><span class="cls_031">We also examined the miR-21 target RE PTEN involved in cell</span></div>
<div style="position:absolute;left:306.66px;top:565.10px" class="cls_031"><span class="cls_031">patients with psoriasis vulgaris 36 (85.71%) patients had mild form</span></div>
<div style="position:absolute;left:50.00px;top:570.49px" class="cls_031"><span class="cls_031">growth and apoptosis control and the miR-31 target RE ppp6c</span></div>
<div style="position:absolute;left:306.66px;top:575.10px" class="cls_031"><span class="cls_031">of disease with PASI </span><span class="cls_030"> &lt; </span><span class="cls_031">50, and 6 (14.29%) patients had severe</span></div>
<div style="position:absolute;left:50.00px;top:580.60px" class="cls_031"><span class="cls_031">involved in G1 to S phase transition restriction. In line with the</span></div>
<div style="position:absolute;left:306.66px;top:585.10px" class="cls_031"><span class="cls_031">disease with PASI </span><span class="cls_030"> > </span><span class="cls_031">50. It was not found statistically significant</span></div>
<div style="position:absolute;left:50.00px;top:590.72px" class="cls_031"><span class="cls_031">upregulation of miR-21 and miR-31, IL-22 stimulation resulted</span></div>
<div style="position:absolute;left:306.66px;top:595.10px" class="cls_031"><span class="cls_031">correlation between IFN-gamma and PASI score.</span></div>
<div style="position:absolute;left:50.00px;top:600.83px" class="cls_031"><span class="cls_031">in significant downregulation of both targets at the genomic and</span></div>
<div style="position:absolute;left:306.66px;top:605.10px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">The results of this study showed that psoriasis is</span></div>
<div style="position:absolute;left:50.00px;top:610.95px" class="cls_031"><span class="cls_031">proteomic levels.</span></div>
<div style="position:absolute;left:306.66px;top:615.10px" class="cls_031"><span class="cls_031">associated with significant changes in serum concentracion of IFN-</span></div>
<div style="position:absolute;left:50.00px;top:621.07px" class="cls_031"><span class="cls_031">We next investigated the </span><span class="cls_030">in vivo</span><span class="cls_031"> correlation between IL-22 and</span></div>
<div style="position:absolute;left:306.65px;top:625.09px" class="cls_031"><span class="cls_031">gamma. There was no statistically significant correlation between</span></div>
<div style="position:absolute;left:50.00px;top:631.18px" class="cls_031"><span class="cls_031">miR-21 or miR-31 respectively in the development of psoriatic</span></div>
<div style="position:absolute;left:306.66px;top:635.09px" class="cls_031"><span class="cls_031">serum IFN-gamma concentracions, clinical type of psoriasis, and</span></div>
<div style="position:absolute;left:50.00px;top:641.25px" class="cls_031"><span class="cls_031">lesion. We used the imiquimod-induced psoriasiform skin inflam-</span></div>
<div style="position:absolute;left:306.66px;top:645.09px" class="cls_031"><span class="cls_031">also severity of psoriasis vulgaris evaluated by PASI score.</span></div>
<div style="position:absolute;left:50.00px;top:651.36px" class="cls_031"><span class="cls_031">mation in Wild type and IL-22 deficient mice (known to be almost</span></div>
<div style="position:absolute;left:306.66px;top:655.09px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.01px;top:661.48px" class="cls_031"><span class="cls_031">protected from IMQ). Mice displaying a less severe disease form</span></div>
<div style="position:absolute;left:306.64px;top:665.12px" class="cls_032"><span class="cls_032">Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. Cytokine</span></div>
<div style="position:absolute;left:50.01px;top:671.59px" class="cls_031"><span class="cls_031">had less miR-21 expression. By contrast, WT mice treated with</span></div>
<div style="position:absolute;left:306.64px;top:674.12px" class="cls_032"><span class="cls_032">2015; 73 (2):342-350.</span></div>
<div style="position:absolute;left:50.01px;top:681.71px" class="cls_031"><span class="cls_031">IMQ exhibited significantly higher miR-21 RE than IL-22-/- mice.</span></div>
<div style="position:absolute;left:306.64px;top:683.12px" class="cls_032"><span class="cls_032">Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H Serum</span></div>
<div style="position:absolute;left:50.01px;top:691.83px" class="cls_031"><span class="cls_031">Furthermore, miR-31 expression in IL-22-/- mice was identical to</span></div>
<div style="position:absolute;left:306.64px;top:692.12px" class="cls_032"><span class="cls_032">cytokines and growth factor levels in Japanese patients with psoriasis, Clin</span></div>
<div style="position:absolute;left:50.01px;top:701.94px" class="cls_031"><span class="cls_031">miR-31 expression in WT control mice. These results suggest a</span></div>
<div style="position:absolute;left:306.64px;top:701.12px" class="cls_032"><span class="cls_032">Exp Dermatol 2010; 35:645-649.</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:33726px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background44.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">42</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.23px" class="cls_033"><span class="cls_033">P100</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">is considered to have a strong inflammatory component, similar to</span></div>
<div style="position:absolute;left:50.00px;top:62.66px" class="cls_025"><span class="cls_025">IMMUNOLOGICAL MEMORY EXISTS IN THE</span></div>
<div style="position:absolute;left:306.63px;top:61.40px" class="cls_031"><span class="cls_031">psoriasis, e.g. interleukin (IL)-2, IL-6, IL-12, and tumour necrosis</span></div>
<div style="position:absolute;left:50.00px;top:73.59px" class="cls_025"><span class="cls_025">RECURRENT LESION AND NONRECURRENT SKIN</span></div>
<div style="position:absolute;left:306.63px;top:71.40px" class="cls_031"><span class="cls_031">factor (TNF)-α [2-5].</span></div>
<div style="position:absolute;left:306.63px;top:81.40px" class="cls_031"><span class="cls_031">US Veteran population has increased incidence of mental health</span></div>
<div style="position:absolute;left:50.00px;top:84.51px" class="cls_025"><span class="cls_025">AFTER REMISSION IN PSORIATIC PATIENTS</span></div>
<div style="position:absolute;left:306.63px;top:91.40px" class="cls_031"><span class="cls_031">issue as compared to general population. making Veteran group</span></div>
<div style="position:absolute;left:50.00px;top:94.44px" class="cls_026"><span class="cls_026">Zhu Shen</span></div>
<div style="position:absolute;left:306.63px;top:101.40px" class="cls_031"><span class="cls_031">a unique population that warrants investigation.</span></div>
<div style="position:absolute;left:50.00px;top:105.07px" class="cls_029"><span class="cls_029">Institute of Dermatology and Venereology, Sichuan Academy of Medical</span></div>
<div style="position:absolute;left:50.00px;top:114.70px" class="cls_029"><span class="cls_029">Sciences & Sichuan Provincial People’s Hospital</span></div>
<div style="position:absolute;left:306.63px;top:111.40px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">Hypotheses - 1/ Veterans with concomitant depres-</span></div>
<div style="position:absolute;left:306.64px;top:121.41px" class="cls_031"><span class="cls_031">sion and psoriasis/PsA may have elevated inflammatory markers</span></div>
<div style="position:absolute;left:50.00px;top:125.59px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis usually recurs in previously affected areas,</span></div>
<div style="position:absolute;left:306.66px;top:131.40px" class="cls_031"><span class="cls_031">like CRP, ESR, and SPEP. 2/ Depression may improve with the</span></div>
<div style="position:absolute;left:50.00px;top:135.62px" class="cls_031"><span class="cls_031">so a pathogenic memory has been proposed, but the nature of such</span></div>
<div style="position:absolute;left:306.66px;top:141.40px" class="cls_031"><span class="cls_031">treatment of psoriasis/psoriatic arthritis without antidepressant use.</span></div>
<div style="position:absolute;left:50.00px;top:145.65px" class="cls_031"><span class="cls_031">site-specific recurrent memory is not completely known. Tissue-</span></div>
<div style="position:absolute;left:306.66px;top:151.40px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">A 36-month retrospective chart review of 100 veterans</span></div>
<div style="position:absolute;left:50.00px;top:155.67px" class="cls_031"><span class="cls_031">resident memory T (TRM) cells are non-recirculating memory T</span></div>
<div style="position:absolute;left:306.66px;top:161.40px" class="cls_031"><span class="cls_031">with diagnosis of depression and psoriasis/psoriatic arthritis.</span></div>
<div style="position:absolute;left:50.00px;top:165.70px" class="cls_031"><span class="cls_031">cells that persist long-term in epithelial tissues, including the skin.</span></div>
<div style="position:absolute;left:306.66px;top:171.40px" class="cls_031"><span class="cls_031">Elevated inflammatory markers, including sedimentation rate,</span></div>
<div style="position:absolute;left:50.00px;top:175.72px" class="cls_031"><span class="cls_031">Because they can localize in the skin for many months, we spe-</span></div>
<div style="position:absolute;left:306.63px;top:181.40px" class="cls_031"><span class="cls_031">C-reactive protein (CRP) and serum protein electrophoresis</span></div>
<div style="position:absolute;left:50.00px;top:185.76px" class="cls_031"><span class="cls_031">culate that TRM may contribute to recurrent pathology of psoriasis.</span></div>
<div style="position:absolute;left:306.63px;top:191.40px" class="cls_031"><span class="cls_031">(SPEP), as well as longitudinal disease course of depression</span></div>
<div style="position:absolute;left:50.00px;top:195.79px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">The aim of the present study is to compare the dif-</span></div>
<div style="position:absolute;left:306.63px;top:201.40px" class="cls_031"><span class="cls_031">(PHQ-8) and psoriasis/psoriatic arthritis (HAQ-DI); specifically</span></div>
<div style="position:absolute;left:50.00px;top:205.82px" class="cls_031"><span class="cls_031">ferences of quantity proportion and secretion ability of cytokines</span></div>
<div style="position:absolute;left:306.63px;top:211.40px" class="cls_031"><span class="cls_031">disease activity, and depression symptoms will be assessed. We</span></div>
<div style="position:absolute;left:50.00px;top:215.84px" class="cls_031"><span class="cls_031">of the TRM cells between recurrent and nonrecurrent lesions</span></div>
<div style="position:absolute;left:306.63px;top:221.40px" class="cls_031"><span class="cls_031">then aim to draw a correlation between disease activity and active</span></div>
<div style="position:absolute;left:50.00px;top:225.87px" class="cls_031"><span class="cls_031">following remission, as well as to explicit the possible survival</span></div>
<div style="position:absolute;left:306.63px;top:231.39px" class="cls_031"><span class="cls_031">depressive symptoms.</span></div>
<div style="position:absolute;left:50.00px;top:235.89px" class="cls_031"><span class="cls_031">signal for these TRM cells in psoriatic lesion.</span></div>
<div style="position:absolute;left:306.63px;top:241.39px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">to be available</span></div>
<div style="position:absolute;left:50.00px;top:245.92px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">RNA-Seq, Gene Ontology and KEGG analysis, real-time</span></div>
<div style="position:absolute;left:306.63px;top:251.39px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">to be available</span></div>
<div style="position:absolute;left:50.00px;top:255.95px" class="cls_031"><span class="cls_031">PCR, flow cytometer analysis/sorting, cell stimulation assay, and</span></div>
<div style="position:absolute;left:306.63px;top:261.39px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:49.99px;top:265.97px" class="cls_031"><span class="cls_031">western blot were used to explore the immunological memory.</span></div>
<div style="position:absolute;left:306.64px;top:271.42px" class="cls_032"><span class="cls_032">1. Dowlatshahi EA, et al. The prevalence and odds of depressive symptoms</span></div>
<div style="position:absolute;left:49.99px;top:276.00px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Compared with normal skin, there are common shared</span></div>
<div style="position:absolute;left:306.64px;top:280.42px" class="cls_032"><span class="cls_032">and clinical depression in psoriasis patients: a systematic review and meta-</span></div>
<div style="position:absolute;left:49.99px;top:286.02px" class="cls_031"><span class="cls_031">genes significantly upregulated (</span><span class="cls_030"> > </span><span class="cls_031">2 folds, </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001) by recurrent</span></div>
<div style="position:absolute;left:306.64px;top:289.42px" class="cls_032"><span class="cls_032">analysis. J Invest Dermatol 2014; 134: 1542-1551.</span></div>
<div style="position:absolute;left:49.98px;top:296.05px" class="cls_031"><span class="cls_031">and nonrecurrent lesions, including CD69. CD69 mRNA transcrip-</span></div>
<div style="position:absolute;left:306.64px;top:298.42px" class="cls_032"><span class="cls_032">2. Allison DJ, Ditor DS. The common inflammatory etiology of depres-</span></div>
<div style="position:absolute;left:50.00px;top:306.09px" class="cls_031"><span class="cls_031">tion level in nonrecurrent lesions after remission remains as high</span></div>
<div style="position:absolute;left:306.64px;top:307.42px" class="cls_032"><span class="cls_032">sion and cognitive impairment: a therapeutic target. J Neuroinflammation</span></div>
<div style="position:absolute;left:50.00px;top:316.12px" class="cls_031"><span class="cls_031">as in neighboring recurrent lesions. CD8+CD69+ TRM cells exist</span></div>
<div style="position:absolute;left:306.63px;top:316.42px" class="cls_032"><span class="cls_032">2014; 11: 151.</span></div>
<div style="position:absolute;left:50.00px;top:326.15px" class="cls_031"><span class="cls_031">in both lesions, and they can secret almost same amount of IL-17A</span></div>
<div style="position:absolute;left:306.63px;top:325.42px" class="cls_032"><span class="cls_032">3. Dantzer R, et al. From inflammation to sickness and depression: when</span></div>
<div style="position:absolute;left:306.65px;top:334.42px" class="cls_032"><span class="cls_032">the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.</span></div>
<div style="position:absolute;left:50.00px;top:336.17px" class="cls_031"><span class="cls_031">and IL-22 after stimulation. Levels of IL-15, secreted by kerati-</span></div>
<div style="position:absolute;left:306.65px;top:343.42px" class="cls_032"><span class="cls_032">4. Han Q-Q, Yu J. Inflammation: a mechanism of depression? Neurosci</span></div>
<div style="position:absolute;left:50.00px;top:346.20px" class="cls_031"><span class="cls_031">nocytes in psoriasis epidermis, in nonrecurrent lesions remain as</span></div>
<div style="position:absolute;left:306.65px;top:352.42px" class="cls_032"><span class="cls_032">Bull 2014; 30: 515-523.</span></div>
<div style="position:absolute;left:50.00px;top:356.23px" class="cls_031"><span class="cls_031">high as in neighboring recurrent lesions, and recombinant human</span></div>
<div style="position:absolute;left:306.65px;top:361.42px" class="cls_032"><span class="cls_032">5. Dowlati Y, et al. A meta-analysis of cytokines in major depression. Biol</span></div>
<div style="position:absolute;left:50.00px;top:366.26px" class="cls_031"><span class="cls_031">IL-15 can induce CD69 on TRM cells.</span></div>
<div style="position:absolute;left:306.65px;top:370.42px" class="cls_032"><span class="cls_032">Psychiatry [Internet] 2010; 67: 446-457.</span></div>
<div style="position:absolute;left:50.00px;top:376.28px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Our preliminary study shows that CD8+CD69+</span></div>
<div style="position:absolute;left:50.00px;top:386.31px" class="cls_031"><span class="cls_031">TRM cells persist in clinically resolved psoriatic lesions whether it</span></div>
<div style="position:absolute;left:306.64px;top:389.04px" class="cls_033"><span class="cls_033">P102</span></div>
<div style="position:absolute;left:50.00px;top:396.33px" class="cls_031"><span class="cls_031">recurs or not, and they can produce IL-17A and IL-22 with critical</span></div>
<div style="position:absolute;left:306.64px;top:400.44px" class="cls_025"><span class="cls_025">THE IMMUNE-PHENOTYPE OF SMALL PLAQUE</span></div>
<div style="position:absolute;left:50.00px;top:406.36px" class="cls_031"><span class="cls_031">effect on psoriatic recurrence and development. Furthermore, we</span></div>
<div style="position:absolute;left:306.64px;top:411.34px" class="cls_025"><span class="cls_025">PSORIASIS</span></div>
<div style="position:absolute;left:50.00px;top:416.39px" class="cls_031"><span class="cls_031">have indicated the IL-15 may play crucial role in the survival of</span></div>
<div style="position:absolute;left:306.64px;top:421.24px" class="cls_051"><span class="cls_051">Touraj Khosravi-Hafshejani</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Mehran Ghoreishi</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Cristian Vera</span></div>
<div style="position:absolute;left:50.00px;top:426.41px" class="cls_031"><span class="cls_031">CD8+CD69+ TRM cells in psoriatic lesions.</span></div>
<div style="position:absolute;left:306.64px;top:431.14px" class="cls_026"><span class="cls_026">Kellet</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Magdalena Martinka</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Jan Dutz</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:50.00px;top:436.44px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:306.64px;top:441.74px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Undergraduate Medical Program, Faculty of Medicine,</span></div>
<div style="position:absolute;left:50.00px;top:446.50px" class="cls_032"><span class="cls_032">1. Mueller SN, Mackay LK.Tissue-resident memory T cells: local spe-</span></div>
<div style="position:absolute;left:306.64px;top:451.34px" class="cls_028"><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Dermatology, and Skin Science and </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Department of Pat-</span></div>
<div style="position:absolute;left:50.00px;top:455.53px" class="cls_032"><span class="cls_032">cialists in immune defence. Nat Rev Immunol. 2016 Feb;16(2):79-89.</span></div>
<div style="position:absolute;left:306.64px;top:460.94px" class="cls_029"><span class="cls_029">hology and Laboratory Medicine, University of British Columbia, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Depart-</span></div>
<div style="position:absolute;left:50.00px;top:464.55px" class="cls_032"><span class="cls_032">2. Clark RA. Resident memory T cells in human health and disease. Sci</span></div>
<div style="position:absolute;left:306.64px;top:470.54px" class="cls_029"><span class="cls_029">ment of Dermatology, Pontifical Catholic University of Chile</span></div>
<div style="position:absolute;left:50.00px;top:473.57px" class="cls_032"><span class="cls_032">Transl Med. 2015 Jan 7;7(269):269rv1.</span></div>
<div style="position:absolute;left:50.00px;top:482.60px" class="cls_032"><span class="cls_032">3. Park CO, KupperTS. The emerging role of resident memory T cells</span></div>
<div style="position:absolute;left:306.64px;top:481.41px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Small plaque psoriasis (SPP) is a subtype of pso-</span></div>
<div style="position:absolute;left:50.00px;top:491.62px" class="cls_032"><span class="cls_032">in protective immunity and inflammatory disease. Nat Med. 2015</span></div>
<div style="position:absolute;left:306.64px;top:491.41px" class="cls_031"><span class="cls_031">riasis first described by Griffiths et al (2007). It resembles guttate</span></div>
<div style="position:absolute;left:50.00px;top:500.65px" class="cls_032"><span class="cls_032">Jul;21(7):688-97.</span></div>
<div style="position:absolute;left:306.63px;top:501.40px" class="cls_031"><span class="cls_031">psoriasis but lesions are larger, are chronic, and are not associated</span></div>
<div style="position:absolute;left:50.00px;top:509.67px" class="cls_032"><span class="cls_032">4. Cheuk S, Wikén M, Blomqvist L, Nylén S, Talme T, Ståhle M, Eids-</span></div>
<div style="position:absolute;left:306.63px;top:511.40px" class="cls_031"><span class="cls_031">with streptococcal infection. We have observed SPP develop in</span></div>
<div style="position:absolute;left:50.00px;top:518.72px" class="cls_032"><span class="cls_032">moL. Epidermal Th22 and Tc17 cells form a localized disease memory</span></div>
<div style="position:absolute;left:306.63px;top:521.40px" class="cls_031"><span class="cls_031">four different population groups; patients under TNFα-inhibitor</span></div>
<div style="position:absolute;left:50.00px;top:527.74px" class="cls_032"><span class="cls_032">in clinically healed psoriasis. J Immunol. 2014 Apr 1;192(7):3111-20.</span></div>
<div style="position:absolute;left:306.63px;top:531.40px" class="cls_031"><span class="cls_031">therapy, patients under immune checkpoint inhibitor (ICI) th-</span></div>
<div style="position:absolute;left:306.64px;top:541.41px" class="cls_031"><span class="cls_031">erapy, and patients with concurrent SLE or ANA positivity and</span></div>
<div style="position:absolute;left:50.00px;top:546.39px" class="cls_033"><span class="cls_033">P101</span></div>
<div style="position:absolute;left:306.64px;top:551.40px" class="cls_031"><span class="cls_031">psoriasis. Subtypes of psoriasis develop on a spectrum between</span></div>
<div style="position:absolute;left:50.00px;top:557.82px" class="cls_025"><span class="cls_025">INVESTIGATING SYSTEMIC INFLAMMATION AS THE</span></div>
<div style="position:absolute;left:306.64px;top:561.40px" class="cls_031"><span class="cls_031">autoimmune and auto-inflammatory responses and an interplay</span></div>
<div style="position:absolute;left:50.00px;top:568.75px" class="cls_025"><span class="cls_025">COMMON LINK BETWEEN DEPRESSION, PSORIASIS,</span></div>
<div style="position:absolute;left:306.65px;top:571.40px" class="cls_031"><span class="cls_031">between three signalling pathways are involved in their distinct</span></div>
<div style="position:absolute;left:50.00px;top:579.67px" class="cls_025"><span class="cls_025">AND PSORIATIC ARTHRITIS IN US VETERANS</span></div>
<div style="position:absolute;left:306.65px;top:581.40px" class="cls_031"><span class="cls_031">pathogenesis. Chronic plaque psoriasis lesions are on the autoim-</span></div>
<div style="position:absolute;left:50.00px;top:589.60px" class="cls_051"><span class="cls_051">Samar Gupta</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Alicja Wasilewski</span><span class="cls_027"><sup>2</sup></span></div>
<div style="position:absolute;left:306.64px;top:591.41px" class="cls_031"><span class="cls_031">mune spectrum, dominated by a T-cell mediated TNFα/IL-23/</span></div>
<div style="position:absolute;left:50.00px;top:600.23px" class="cls_029"><span class="cls_029">University of Michigan</span><span class="cls_028"><sup>1</sup></span><span class="cls_029">, MI State</span><span class="cls_028"><sup>2</sup></span></div>
<div style="position:absolute;left:306.65px;top:601.40px" class="cls_031"><span class="cls_031">IL-17/IL-22 axis. Pustular psoriasis is a neutrophilic infiltrative</span></div>
<div style="position:absolute;left:50.00px;top:611.13px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psychosocial factors are important in the onset and/</span></div>
<div style="position:absolute;left:306.64px;top:611.40px" class="cls_031"><span class="cls_031">inflammatory skin disease resulting from dysregulation of the</span></div>
<div style="position:absolute;left:50.00px;top:621.15px" class="cls_031"><span class="cls_031">or exacerbation of psoriasis in 40% to 80% of cases. Psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:621.40px" class="cls_031"><span class="cls_031">IL-36/IL-1 axis. Lastly, TNFα-inhibitor (TNFi) induced lesions</span></div>
<div style="position:absolute;left:50.00px;top:631.18px" class="cls_031"><span class="cls_031">has been associated with suicide, and an increased prevalence of</span></div>
<div style="position:absolute;left:306.63px;top:631.40px" class="cls_031"><span class="cls_031">have a SPP morphology and demonstrate increased expression</span></div>
<div style="position:absolute;left:50.00px;top:641.21px" class="cls_031"><span class="cls_031">alcoholism and a range of personality characteristics.</span></div>
<div style="position:absolute;left:306.63px;top:641.40px" class="cls_031"><span class="cls_031">of LL37 by keratinocytes, activated plasmacytoid dendritic cells</span></div>
<div style="position:absolute;left:50.00px;top:651.23px" class="cls_031"><span class="cls_031">A recent systematic meta-analysis of 98 eligible studies with a total</span></div>
<div style="position:absolute;left:306.63px;top:651.40px" class="cls_031"><span class="cls_031">and upregulated type-1 interferons (IFN). These lesions express</span></div>
<div style="position:absolute;left:50.00px;top:661.26px" class="cls_031"><span class="cls_031">of 401,703 psoriasis patients showed that patients with psoriasis</span></div>
<div style="position:absolute;left:306.63px;top:661.40px" class="cls_031"><span class="cls_031">fewer epidermal CD8 T cells.</span></div>
<div style="position:absolute;left:50.00px;top:671.28px" class="cls_031"><span class="cls_031">were approximately one and a half times more likely to exhibit</span></div>
<div style="position:absolute;left:306.63px;top:671.40px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">Our aim is to characterize the immune-phenotype</span></div>
<div style="position:absolute;left:50.00px;top:681.31px" class="cls_031"><span class="cls_031">signs of depression compared with healthy controls. [1].</span></div>
<div style="position:absolute;left:306.63px;top:681.40px" class="cls_031"><span class="cls_031">of SPP in multiple clinical scenarios. We hypothesize that SPP</span></div>
<div style="position:absolute;left:50.00px;top:691.34px" class="cls_031"><span class="cls_031">Emerging evidence suggests that depression, like psoriasis, is</span></div>
<div style="position:absolute;left:306.63px;top:691.40px" class="cls_031"><span class="cls_031">develops as a result of increased expression of cytokines and</span></div>
<div style="position:absolute;left:50.00px;top:701.36px" class="cls_031"><span class="cls_031">associated with systemic inflammation, and the systemic inflam-</span></div>
<div style="position:absolute;left:306.63px;top:701.39px" class="cls_031"><span class="cls_031">antimicrobial peptides involved in the type-1 IFN pathway.</span></div>
<div style="position:absolute;left:50.00px;top:711.41px" class="cls_031"><span class="cls_031">matory profile of the two conditions show similar traits. Depression</span></div>
<div style="position:absolute;left:306.63px;top:711.39px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Skin biopsies were obtained from three patients with</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:34529px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background45.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">43</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">TNFi-induced psoriasis, three patients with SLE and psoriasis,</span></div>
<div style="position:absolute;left:306.64px;top:51.23px" class="cls_033"><span class="cls_033">P105</span></div>
<div style="position:absolute;left:50.00px;top:61.41px" class="cls_031"><span class="cls_031">three patients with positive ANA and psoriasis, two patients with</span></div>
<div style="position:absolute;left:306.64px;top:62.63px" class="cls_025"><span class="cls_025">DIFFERENTIAL NH2-TERMINAL AUTOANTIGEN</span></div>
<div style="position:absolute;left:50.00px;top:71.41px" class="cls_031"><span class="cls_031">ICI-induced psoriasis and two patients with chronic plaque psoria-</span></div>
<div style="position:absolute;left:306.64px;top:73.53px" class="cls_025"><span class="cls_025">TRIMMING MAY EXPLAIN EPISTASIS BETWEEN</span></div>
<div style="position:absolute;left:50.00px;top:81.41px" class="cls_031"><span class="cls_031">sis as control. Immunohistochemistry was performed using anti-</span></div>
<div style="position:absolute;left:306.64px;top:84.43px" class="cls_025"><span class="cls_025">HLA-C*06:02 AND ERAP1 VARIANTS IN PSORIASIS</span></div>
<div style="position:absolute;left:50.00px;top:91.41px" class="cls_031"><span class="cls_031">bodies against type-1 IFN induced MXA, LL37, IL-36 and CD8 T</span></div>
<div style="position:absolute;left:306.64px;top:95.33px" class="cls_025"><span class="cls_025">RISK</span></div>
<div style="position:absolute;left:50.00px;top:101.41px" class="cls_031"><span class="cls_031">cells. The intensity and the area of positively stained samples were</span></div>
<div style="position:absolute;left:306.64px;top:105.23px" class="cls_026"><span class="cls_026">Akiko Arakawa</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Emma Reeves</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Sigrid Vollmer</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Yukiyasu Ara-</span></div>
<div style="position:absolute;left:50.00px;top:111.41px" class="cls_031"><span class="cls_031">each graded from 0-4 and then multiplied to provide a final score.</span></div>
<div style="position:absolute;left:306.64px;top:115.13px" class="cls_026"><span class="cls_026">kawa</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Edd James</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">,</span><span class="cls_051"> Jörg Prinz</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:50.00px;top:121.41px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Small plaque lesions in various clinical scenarios had his-</span></div>
<div style="position:absolute;left:306.64px;top:125.73px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Ludwig-Maximilian-University, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Southampton General Hospital</span></div>
<div style="position:absolute;left:50.00px;top:131.41px" class="cls_031"><span class="cls_031">tologic changes consistent with psoriasis.. Immunohistochemical</span></div>
<div style="position:absolute;left:306.64px;top:136.50px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">NH2-terminal trimming by endoplasmic reticulum</span></div>
<div style="position:absolute;left:50.00px;top:141.41px" class="cls_031"><span class="cls_031">evaluation revealed an increased expression of MXA (TNFi</span><span class="cls_030"> = </span><span class="cls_031">14,</span></div>
<div style="position:absolute;left:306.64px;top:146.40px" class="cls_031"><span class="cls_031">aminopeptidase 1 (ERAP1) generates the appropriate length of</span></div>
<div style="position:absolute;left:50.00px;top:151.41px" class="cls_031"><span class="cls_031">SLE</span><span class="cls_030"> = </span><span class="cls_031">13.3, ANA</span><span class="cls_030"> = </span><span class="cls_031">11.3, ICI</span><span class="cls_030"> = </span><span class="cls_031">16 vs. control</span><span class="cls_030"> = </span><span class="cls_031">6, t-test </span><span class="cls_030">p &lt; </span><span class="cls_031">0.05),</span></div>
<div style="position:absolute;left:306.64px;top:156.30px" class="cls_031"><span class="cls_031">antigenic peptides for binding to and presentation by HLA-class</span></div>
<div style="position:absolute;left:50.00px;top:161.41px" class="cls_031"><span class="cls_031">LL37 (TNFi</span><span class="cls_030"> = </span><span class="cls_031">10.8, SLE</span><span class="cls_030"> = </span><span class="cls_031">6, ANA</span><span class="cls_030"> = </span><span class="cls_031">9.7, ICI</span><span class="cls_030"> = </span><span class="cls_031">12 vs. control</span><span class="cls_030"> = </span><span class="cls_031">2,</span></div>
<div style="position:absolute;left:306.64px;top:166.20px" class="cls_031"><span class="cls_031">I molecules. Genetic interaction between ERAP1 variants and</span></div>
<div style="position:absolute;left:50.00px;top:171.41px" class="cls_031"><span class="cls_031">t-test </span><span class="cls_030">p &lt; </span><span class="cls_031">0.05) and IL-36 (TNFi</span><span class="cls_030"> = </span><span class="cls_031">10.5, SLE</span><span class="cls_030"> = </span><span class="cls_031">13.3, ANA</span><span class="cls_030"> = </span><span class="cls_031">11,</span></div>
<div style="position:absolute;left:306.64px;top:176.10px" class="cls_031"><span class="cls_031">HLA-class I alleles determines the genetic risk for various HLA-</span></div>
<div style="position:absolute;left:50.00px;top:181.41px" class="cls_031"><span class="cls_031">ICI</span><span class="cls_030"> = </span><span class="cls_031">7, control</span><span class="cls_030"> = </span><span class="cls_031">0.25, t-test </span><span class="cls_030">p &lt; </span><span class="cls_031">0.05) in the keratinocytes of</span></div>
<div style="position:absolute;left:306.64px;top:186.00px" class="cls_031"><span class="cls_031">class I-associated inflammatory diseases. Epistasis between HLA-</span></div>
<div style="position:absolute;left:50.00px;top:191.41px" class="cls_031"><span class="cls_031">SPP patients. There was decreased CD8 T cell migration to the</span></div>
<div style="position:absolute;left:306.63px;top:195.90px" class="cls_031"><span class="cls_031">C*06:02 and ERAP1 variants affects also psoriasis risk but the</span></div>
<div style="position:absolute;left:50.00px;top:201.41px" class="cls_031"><span class="cls_031">epidermis in SPP compared to control.</span></div>
<div style="position:absolute;left:306.63px;top:205.80px" class="cls_031"><span class="cls_031">mechanisms of these gene interactions remained unknown. Using</span></div>
<div style="position:absolute;left:50.00px;top:211.41px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">This is the first study to describe the immune-</span></div>
<div style="position:absolute;left:306.63px;top:215.70px" class="cls_031"><span class="cls_031">a pathogenic Vα3S1/Vβ13S1-TCR from a psoriatic CD8+ T-cell</span></div>
<div style="position:absolute;left:50.00px;top:221.41px" class="cls_031"><span class="cls_031">phenotype of SPP and to extend the phenotype observed in TNFi</span></div>
<div style="position:absolute;left:306.62px;top:225.60px" class="cls_031"><span class="cls_031">clone we had shown that in psoriasis, HLA-C*06:02 mediates an</span></div>
<div style="position:absolute;left:50.00px;top:231.40px" class="cls_031"><span class="cls_031">induced psoriasis to varying clinical scenarios. There was an</span></div>
<div style="position:absolute;left:306.62px;top:235.50px" class="cls_031"><span class="cls_031">autoimmune response against melanocytes through autoantigen</span></div>
<div style="position:absolute;left:50.00px;top:241.40px" class="cls_031"><span class="cls_031">increased expression of MXA, LL-37 and IL-36 as well as fewer</span></div>
<div style="position:absolute;left:306.62px;top:245.40px" class="cls_031"><span class="cls_031">presentation and we had identified a peptide from ADAMTS-like</span></div>
<div style="position:absolute;left:50.00px;top:251.40px" class="cls_031"><span class="cls_031">epidermal CD8 T cells than in chronic plaque psoriasis consis-</span></div>
<div style="position:absolute;left:306.63px;top:255.30px" class="cls_031"><span class="cls_031">protein 5 (ADAMTSL5) as HLA-C*06:02-presented melanocyte</span></div>
<div style="position:absolute;left:50.00px;top:261.41px" class="cls_031"><span class="cls_031">tent with the type-1 IFN pathway of psoriasis pathogenesis. This</span></div>
<div style="position:absolute;left:306.63px;top:265.20px" class="cls_031"><span class="cls_031">autoantigen.</span></div>
<div style="position:absolute;left:50.00px;top:271.41px" class="cls_031"><span class="cls_031">immune-phenotypic analysis may suggest tailored therapy for</span></div>
<div style="position:absolute;left:306.63px;top:275.10px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To determine the role of ERAP1 variants in psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:281.41px" class="cls_031"><span class="cls_031">this form of psoriasis.</span></div>
<div style="position:absolute;left:306.63px;top:285.00px" class="cls_031"><span class="cls_031">pathogenesis.</span></div>
<div style="position:absolute;left:306.63px;top:294.90px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">We established ERAP1 knockout cells using CRISPR/</span></div>
<div style="position:absolute;left:50.00px;top:302.05px" class="cls_033"><span class="cls_033">P104</span></div>
<div style="position:absolute;left:306.63px;top:304.80px" class="cls_031"><span class="cls_031">Cas9 system. ERAP1 knockout cells transfected with plasmids</span></div>
<div style="position:absolute;left:50.00px;top:313.45px" class="cls_025"><span class="cls_025">SERUM GLUCOCORTICOID-INDUCIBLE KINASE-</span></div>
<div style="position:absolute;left:306.63px;top:314.70px" class="cls_031"><span class="cls_031">coding for HLA-C*06:02, ERAP1 variants, and antigenic pep-</span></div>
<div style="position:absolute;left:50.00px;top:324.35px" class="cls_025"><span class="cls_025">1(SGK1) LEVELS IN PATIENTS WITH PSORIATIC</span></div>
<div style="position:absolute;left:306.64px;top:324.60px" class="cls_031"><span class="cls_031">tides were co-cultured with the TCR hybridoma to determine</span></div>
<div style="position:absolute;left:50.00px;top:335.25px" class="cls_025"><span class="cls_025">ARTHRITIS</span></div>
<div style="position:absolute;left:306.64px;top:334.50px" class="cls_031"><span class="cls_031">the levels of TCR ligation which reflect the generation of the</span></div>
<div style="position:absolute;left:50.00px;top:345.15px" class="cls_051"><span class="cls_051">Goksal Keskin</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Ali Inal</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Esra Dilek Keskin</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Umit Olmez</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:306.63px;top:344.40px" class="cls_031"><span class="cls_031">antigenic ADAMTSL5 peptide and other Vα3S1/Vβ13S1-TCR</span></div>
<div style="position:absolute;left:50.00px;top:355.75px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Immunology, Medical School of Ankara University, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">De-</span></div>
<div style="position:absolute;left:306.64px;top:354.30px" class="cls_031"><span class="cls_031">ligands from precursors.</span></div>
<div style="position:absolute;left:50.00px;top:365.35px" class="cls_029"><span class="cls_029">partment of Immunology, Medical School of Baskent University, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Depart-</span></div>
<div style="position:absolute;left:306.64px;top:364.20px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Our data show that NH2-terminal trimming by ERPA1</span></div>
<div style="position:absolute;left:50.00px;top:374.95px" class="cls_029"><span class="cls_029">ment of FTR, Medical School of Kırıkkale University</span></div>
<div style="position:absolute;left:306.64px;top:374.10px" class="cls_031"><span class="cls_031">is required to generate the actual antigenic ADAMTSL5 peptide</span></div>
<div style="position:absolute;left:50.00px;top:385.81px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriatic arthritis (PsA) is an inflammatory rheuma-</span></div>
<div style="position:absolute;left:306.64px;top:384.00px" class="cls_031"><span class="cls_031">from NH2-terminally elongated precursors. An ERAP1 variant</span></div>
<div style="position:absolute;left:50.00px;top:395.81px" class="cls_031"><span class="cls_031">tic disorder that occurs in patients with psoriasis. The etiology of</span></div>
<div style="position:absolute;left:306.64px;top:393.90px" class="cls_031"><span class="cls_031">protecting from psoriasis reduced the immunogenicity of the</span></div>
<div style="position:absolute;left:50.00px;top:405.81px" class="cls_031"><span class="cls_031">PsA is not well understood but evidence supports an interplay of</span></div>
<div style="position:absolute;left:306.64px;top:403.80px" class="cls_031"><span class="cls_031">antigenic ADAMTSL5 peptide presumably through overtrimming</span></div>
<div style="position:absolute;left:50.00px;top:415.81px" class="cls_031"><span class="cls_031">genetic, immunologic, and environmental factors which promote</span></div>
<div style="position:absolute;left:306.64px;top:413.70px" class="cls_031"><span class="cls_031">and peptide destruction, whereas a psoriasis risk variant of ERAP1</span></div>
<div style="position:absolute;left:50.00px;top:425.81px" class="cls_031"><span class="cls_031">pathological bone remodeling and joint damage in PsA. The</span></div>
<div style="position:absolute;left:306.64px;top:423.60px" class="cls_031"><span class="cls_031">highly kept the antigenicity of the autoantigen. This effect was</span></div>
<div style="position:absolute;left:50.00px;top:435.81px" class="cls_031"><span class="cls_031">glucocorticoid-inducible kinase-1(SGK1) is genomically upre-</span></div>
<div style="position:absolute;left:306.64px;top:433.50px" class="cls_031"><span class="cls_031">specific for ADAMTSL5. Precursors of other Vα3S1/Vβ13S1-</span></div>
<div style="position:absolute;left:50.00px;top:445.81px" class="cls_031"><span class="cls_031">gulated by cell stress. However, excessive SGK1 expression and</span></div>
<div style="position:absolute;left:306.64px;top:443.40px" class="cls_031"><span class="cls_031">TCR self-ligands were not substrates of ERAP1.</span></div>
<div style="position:absolute;left:50.00px;top:455.81px" class="cls_031"><span class="cls_031">activity participates in the pathophysiology of several disorders,</span></div>
<div style="position:absolute;left:306.64px;top:453.30px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Using a proven psoriatic autoantigen and a cognate</span></div>
<div style="position:absolute;left:50.00px;top:465.81px" class="cls_031"><span class="cls_031">such as inflammation, autoimmune disease, fibrosis, hypertension,</span></div>
<div style="position:absolute;left:306.64px;top:463.20px" class="cls_031"><span class="cls_031">psoriatic TCR, these experiments provide direct evidence that</span></div>
<div style="position:absolute;left:49.99px;top:475.81px" class="cls_031"><span class="cls_031">thrombosis and tumor growth.</span></div>
<div style="position:absolute;left:306.64px;top:473.10px" class="cls_031"><span class="cls_031">gene-gene interaction between ERAP1 and HLA-C*06:02 affects</span></div>
<div style="position:absolute;left:49.99px;top:485.81px" class="cls_030"><span class="cls_030">Objectives:</span><span class="cls_031"> In this study, we analyzed the possible role of serum</span></div>
<div style="position:absolute;left:306.64px;top:483.00px" class="cls_031"><span class="cls_031">the risk for psoriasis through differential autoantigen trimming</span></div>
<div style="position:absolute;left:49.99px;top:495.81px" class="cls_031"><span class="cls_031">SGK-1 levels in the pathogenesis of psoriatic arthritis.</span></div>
<div style="position:absolute;left:306.64px;top:492.90px" class="cls_031"><span class="cls_031">from precursors. These data furthermore propose a model where</span></div>
<div style="position:absolute;left:306.64px;top:502.80px" class="cls_031"><span class="cls_031">ERAP1 function essentially controls the autoantigenic potential</span></div>
<div style="position:absolute;left:49.99px;top:505.81px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> 56 patients with psoriasis (40 patients with psoriatic</span></div>
<div style="position:absolute;left:306.64px;top:512.70px" class="cls_031"><span class="cls_031">of self-peptides in HLA-class I associated CD8+ T-cell mediated</span></div>
<div style="position:absolute;left:49.99px;top:515.81px" class="cls_031"><span class="cls_031">arthritis; 16 female, 24 male, mean age; 46.7</span><span class="cls_035"> ±</span><span class="cls_031"> 6.5 years, mean</span></div>
<div style="position:absolute;left:306.64px;top:522.60px" class="cls_031"><span class="cls_031">autoimmune diseases.</span></div>
<div style="position:absolute;left:50.00px;top:525.81px" class="cls_031"><span class="cls_031">disease duration 17.7</span><span class="cls_035"> ±</span><span class="cls_031"> 4.3 years and 16 patients without arthritis; 8</span></div>
<div style="position:absolute;left:49.99px;top:535.81px" class="cls_031"><span class="cls_031">female, 8 male, mean age; 43.2</span><span class="cls_035"> ±</span><span class="cls_031"> 1.9 years, mean disease duration;</span></div>
<div style="position:absolute;left:306.64px;top:541.23px" class="cls_033"><span class="cls_033">P106</span></div>
<div style="position:absolute;left:50.00px;top:545.81px" class="cls_031"><span class="cls_031">14.1</span><span class="cls_035"> ±</span><span class="cls_031"> 3.9 years) and 19 healthy controls (11 female, 8 male; mean</span></div>
<div style="position:absolute;left:306.64px;top:552.63px" class="cls_025"><span class="cls_025">ENVIRONMENTAL TRIGGERS OF AN HLA-C*06:02-</span></div>
<div style="position:absolute;left:50.00px;top:555.81px" class="cls_031"><span class="cls_031">age 41.3</span><span class="cls_035"> ±</span><span class="cls_031"> 4.7 years) were enrolled in this study. Oligoarthritis was</span></div>
<div style="position:absolute;left:50.00px;top:565.81px" class="cls_031"><span class="cls_031">the commonest clinical presentation (76.4 %). Dactylitis (73.4%)</span></div>
<div style="position:absolute;left:306.64px;top:563.53px" class="cls_025"><span class="cls_025">RESTRICTED AUTOIMMUNE RESPONSE IN PSORIASIS</span></div>
<div style="position:absolute;left:50.00px;top:575.81px" class="cls_031"><span class="cls_031">and enthesitis (48.1%) were frequent extra-articular features.</span></div>
<div style="position:absolute;left:306.64px;top:573.43px" class="cls_051"><span class="cls_051">Secil Vural</span><span class="cls_026">, Yukiyasu Arakawa, Adrian Galinski, Sigrid Vollmer,</span></div>
<div style="position:absolute;left:50.00px;top:585.81px" class="cls_031"><span class="cls_031">All patients were negative for rheumatoid factor. HLA-B27 was</span></div>
<div style="position:absolute;left:306.64px;top:583.33px" class="cls_026"><span class="cls_026">Akiko Arakawa, Jörg Prinz</span></div>
<div style="position:absolute;left:306.64px;top:593.93px" class="cls_029"><span class="cls_029">Ludwig Maximilian University</span></div>
<div style="position:absolute;left:50.00px;top:595.81px" class="cls_031"><span class="cls_031">negative in 14 patients. Serum SGK-1 levels were determined</span></div>
<div style="position:absolute;left:50.00px;top:605.81px" class="cls_031"><span class="cls_031">by ELISA.</span></div>
<div style="position:absolute;left:306.64px;top:604.80px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Psoriasis vulgaris is a multifactorial disease. While</span></div>
<div style="position:absolute;left:50.00px;top:615.81px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> The mean serum SGK-1 levels were 58.4</span><span class="cls_035"> ±</span><span class="cls_031"> 18.1 pg/ml in</span></div>
<div style="position:absolute;left:306.64px;top:614.80px" class="cls_031"><span class="cls_031">the major psoriasis risk gene HLA-C*06:02 accounts for up to</span></div>
<div style="position:absolute;left:50.00px;top:625.81px" class="cls_031"><span class="cls_031">healthy controls, 163.7</span><span class="cls_035"> ±</span><span class="cls_031"> 27.8 pg/ml in patients without arthritis</span></div>
<div style="position:absolute;left:306.64px;top:624.80px" class="cls_031"><span class="cls_031">50% of disease onset, environmental factors are considered to</span></div>
<div style="position:absolute;left:50.00px;top:635.81px" class="cls_031"><span class="cls_031">and 443.9</span><span class="cls_035"> ±</span><span class="cls_031"> 32.1 pg/ml in patients with arthritis. Serum SGK-1</span></div>
<div style="position:absolute;left:306.64px;top:634.80px" class="cls_031"><span class="cls_031">contribute to approximately 30% of disease risk. Psoriatic skin</span></div>
<div style="position:absolute;left:50.00px;top:645.81px" class="cls_031"><span class="cls_031">levels were significantly high in patients with psoriasis compared</span></div>
<div style="position:absolute;left:306.64px;top:644.80px" class="cls_031"><span class="cls_031">inflammation is driven by an HLA-C*06:02-mediated autoimmune</span></div>
<div style="position:absolute;left:49.99px;top:655.81px" class="cls_031"><span class="cls_031">with healthy controls (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001). Serum SGK-1 levels were sig-</span></div>
<div style="position:absolute;left:306.64px;top:654.79px" class="cls_031"><span class="cls_031">response against melanocytes. A pathogenic Vα3S1/Vβ13S1 T-cell</span></div>
<div style="position:absolute;left:50.00px;top:665.81px" class="cls_031"><span class="cls_031">nificantly high in patients with psoriatic arthritis compared with</span></div>
<div style="position:absolute;left:306.64px;top:664.79px" class="cls_031"><span class="cls_031">receptor (TCR), which we had reconstituted from a lesional epi-</span></div>
<div style="position:absolute;left:49.99px;top:675.81px" class="cls_031"><span class="cls_031">in patients without psoriatic arthritis (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001).</span></div>
<div style="position:absolute;left:306.64px;top:674.80px" class="cls_031"><span class="cls_031">dermal CD8</span><span class="cls_034"><sup>+</sup></span><span class="cls_031"> T-cell clone of an HLA-C*06:02-positive psoriasis</span></div>
<div style="position:absolute;left:49.99px;top:685.81px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> The evidence is strong that immunological mecha-</span></div>
<div style="position:absolute;left:306.64px;top:684.80px" class="cls_031"><span class="cls_031">patient in a mouse reporter hybridoma cell line, specifically reacts</span></div>
<div style="position:absolute;left:50.00px;top:695.81px" class="cls_031"><span class="cls_031">nisms are involved in the pathogenesis of psoriasis. In this study,</span></div>
<div style="position:absolute;left:306.64px;top:694.80px" class="cls_031"><span class="cls_031">against melanocytes through HLA-C*06:02 restricted recognition</span></div>
<div style="position:absolute;left:50.00px;top:705.81px" class="cls_031"><span class="cls_031">we demonstrated that serum SGK-1 levels were significantly</span></div>
<div style="position:absolute;left:306.64px;top:704.80px" class="cls_031"><span class="cls_031">of a psoriatic melanocyte autoantigen, ADAMTS-like protein 5</span></div>
<div style="position:absolute;left:50.00px;top:715.81px" class="cls_031"><span class="cls_031">elevated in patients with psoriasis and psoriatic arthritis.</span></div>
<div style="position:absolute;left:306.64px;top:714.80px" class="cls_031"><span class="cls_031">(ADAMTSL5). However, it is unknown whether and how environ-</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:35332px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background46.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">44</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">mental factors may contribute to autoimmunity in psoriasis. TCRs</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">onal skin. Skin resident T cells were skewed with enrichment</span></div>
<div style="position:absolute;left:50.00px;top:61.40px" class="cls_031"><span class="cls_031">are known to be polyspecific, recognizing multiple peptide ligands</span></div>
<div style="position:absolute;left:306.64px;top:61.44px" class="cls_031"><span class="cls_031">of epidermal IL-17 and IL-22 producing CD4+CCR6+ and</span></div>
<div style="position:absolute;left:50.00px;top:71.40px" class="cls_031"><span class="cls_031">which share a conserved amino acid pattern specific for each TCR.</span></div>
<div style="position:absolute;left:306.64px;top:71.48px" class="cls_031"><span class="cls_031">CD8+CD103+CD49a- T cells and IFN-γ producing CD4 T cells</span></div>
<div style="position:absolute;left:50.00px;top:81.40px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To examine the potential role of environmental factors</span></div>
<div style="position:absolute;left:306.64px;top:81.51px" class="cls_031"><span class="cls_031">in never-lesional skin compared to healthy skin. Keratinocytes</span></div>
<div style="position:absolute;left:50.00px;top:91.40px" class="cls_031"><span class="cls_031">in the psoriatic autoimmune response.</span></div>
<div style="position:absolute;left:306.64px;top:91.55px" class="cls_031"><span class="cls_031">from never-lesional psoriasis responded to IFN-γ activation with</span></div>
<div style="position:absolute;left:50.00px;top:101.40px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> We first determined the particular amino acid motif</span></div>
<div style="position:absolute;left:306.63px;top:101.58px" class="cls_031"><span class="cls_031">IFN-α secretion and MX1 upregulation and skin explants exposed</span></div>
<div style="position:absolute;left:50.01px;top:111.40px" class="cls_031"><span class="cls_031">which is recognized by the psoriatic Vα3S1/Vβ13S1 TCR in</span></div>
<div style="position:absolute;left:306.65px;top:111.62px" class="cls_031"><span class="cls_031">to common fungal antigens produced the CCR6-attractant CCL20.</span></div>
<div style="position:absolute;left:50.02px;top:121.40px" class="cls_031"><span class="cls_031">the context of HLA-C*06:02. By homology searches using this</span></div>
<div style="position:absolute;left:306.65px;top:121.65px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Resident T cells poised to induce psoriasiform tissue</span></div>
<div style="position:absolute;left:50.02px;top:131.40px" class="cls_031"><span class="cls_031">conserved amino acid pattern, we selected 57 peptides from</span></div>
<div style="position:absolute;left:306.65px;top:131.69px" class="cls_031"><span class="cls_031">responses accumulate in never-lesional skin of psoriasis-afflicted</span></div>
<div style="position:absolute;left:50.02px;top:141.40px" class="cls_031"><span class="cls_031">food, bacterial, fungal and viral pathogens and from the skin and</span></div>
<div style="position:absolute;left:306.66px;top:141.72px" class="cls_031"><span class="cls_031">individuals. Additionally our data suggest that microbial interplay</span></div>
<div style="position:absolute;left:50.02px;top:151.40px" class="cls_031"><span class="cls_031">intestinal microbiomes as candidate environmental antigens that</span></div>
<div style="position:absolute;left:306.66px;top:151.76px" class="cls_031"><span class="cls_031">with genetically predisposed keratinocytes may shape the local</span></div>
<div style="position:absolute;left:50.02px;top:161.39px" class="cls_031"><span class="cls_031">may trigger the psoriatic autoimmune response. We cloned the</span></div>
<div style="position:absolute;left:306.66px;top:161.79px" class="cls_031"><span class="cls_031">pool of resident T cells.</span></div>
<div style="position:absolute;left:50.02px;top:171.39px" class="cls_031"><span class="cls_031">peptides into expression plasmids, co-transfected them with HLA-</span></div>
<div style="position:absolute;left:306.66px;top:171.83px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.02px;top:181.39px" class="cls_031"><span class="cls_031">C*06:02 into Cos7 cells and used them to stimulate the Vα3S1/</span></div>
<div style="position:absolute;left:306.64px;top:181.92px" class="cls_032"><span class="cls_032">Verma, D., Ekman, A.-K., Bivik Eding, C. & Enerbäck, C. Genome-Wide</span></div>
<div style="position:absolute;left:50.04px;top:191.39px" class="cls_031"><span class="cls_031">Vβ13S1 TCR. TCR ligation was determined by GFP induction</span></div>
<div style="position:absolute;left:306.64px;top:190.96px" class="cls_032"><span class="cls_032">DNA Methylation Profiling Identifies Differential Methylation in Unin-</span></div>
<div style="position:absolute;left:50.01px;top:201.39px" class="cls_031"><span class="cls_031">of TCR hybridoma in FACS analysis. We then stimulated blood</span></div>
<div style="position:absolute;left:306.64px;top:200.00px" class="cls_032"><span class="cls_032">volved Psoriatic Epidermis. J. Invest. Dermatol. (2017). doi:10.1016/j.</span></div>
<div style="position:absolute;left:306.64px;top:209.04px" class="cls_032"><span class="cls_032">jid.2017.11.036</span></div>
<div style="position:absolute;left:50.01px;top:211.39px" class="cls_031"><span class="cls_031">lymphocytes with the candidate peptides that had ligated the</span></div>
<div style="position:absolute;left:306.64px;top:218.08px" class="cls_032"><span class="cls_032">Gudjonsson, J. E. et al. Global gene expression analysis reveals evidence</span></div>
<div style="position:absolute;left:50.01px;top:221.39px" class="cls_031"><span class="cls_031">Vα3S1/Vβ13S1 TCR. Lymphocyte activation was assessed by</span></div>
<div style="position:absolute;left:306.64px;top:227.11px" class="cls_032"><span class="cls_032">for decreased lipid biosynthesis and increased innate immunity in uninvol-</span></div>
<div style="position:absolute;left:50.01px;top:231.39px" class="cls_031"><span class="cls_031">induction of activation markers and proliferation assays using</span></div>
<div style="position:absolute;left:306.64px;top:236.15px" class="cls_032"><span class="cls_032">ved psoriatic skin. J. Invest. Dermatol. 129, 2795-2804 (2009).</span></div>
<div style="position:absolute;left:50.01px;top:241.39px" class="cls_031"><span class="cls_031">thymidine incorporation.</span></div>
<div style="position:absolute;left:306.64px;top:245.19px" class="cls_032"><span class="cls_032">Cheuk, S. et al. Epidermal Th22 and Tc17 Cells Form a Localized Disease</span></div>
<div style="position:absolute;left:50.01px;top:251.39px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">We identified a variety of peptides contained in proteins</span></div>
<div style="position:absolute;left:306.64px;top:254.23px" class="cls_032"><span class="cls_032">Memory in Clinically Healed Psoriasis. J. Immunol. 192, 3111-3120</span></div>
<div style="position:absolute;left:50.01px;top:261.38px" class="cls_031"><span class="cls_031">from food (wheat, coffee, apple, and spinach), microbiota of hu-</span></div>
<div style="position:absolute;left:306.64px;top:263.27px" class="cls_032"><span class="cls_032">(2014).</span></div>
<div style="position:absolute;left:50.00px;top:271.41px" class="cls_031"><span class="cls_031">man skin or gut, and infectious pathogens including </span><span class="cls_030">Chlamydia</span></div>
<div style="position:absolute;left:50.00px;top:281.40px" class="cls_030"><span class="cls_030">trachomatis</span><span class="cls_031">, which ligated the psoriatic TCR in a polyspecific</span></div>
<div style="position:absolute;left:306.64px;top:281.92px" class="cls_033"><span class="cls_033">P108</span></div>
<div style="position:absolute;left:50.00px;top:291.40px" class="cls_031"><span class="cls_031">manner. Stimulation of blood lymphocytes with particular candi-</span></div>
<div style="position:absolute;left:306.64px;top:293.36px" class="cls_025"><span class="cls_025">NAIL INVOLVEMENT IN PSORIASIS; IS IT A</span></div>
<div style="position:absolute;left:50.00px;top:301.41px" class="cls_031"><span class="cls_031">date antigens resulted in significant activation in psoriasis patients,</span></div>
<div style="position:absolute;left:306.64px;top:304.30px" class="cls_025"><span class="cls_025">PREDICTOR OF PSORIATIC ARTHRITIS?</span></div>
<div style="position:absolute;left:50.01px;top:311.40px" class="cls_031"><span class="cls_031">as compared to healthy individuals. Interindividual-correlation</span></div>
<div style="position:absolute;left:306.64px;top:314.23px" class="cls_051"><span class="cls_051">Omid Zargari</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Ehsan Kazemnejad</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Seyyede Zeinab Azimi</span><span class="cls_027"><sup>3</sup></span></div>
<div style="position:absolute;left:50.01px;top:321.40px" class="cls_031"><span class="cls_031">analyses demonstrated cross-reactive immune responses between</span></div>
<div style="position:absolute;left:306.64px;top:324.88px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Dermatology, Skin Research Center, Shahid Beheshti Uni-</span></div>
<div style="position:absolute;left:50.01px;top:331.40px" class="cls_031"><span class="cls_031">environmental antigens and the melanocyte autoantigen presen-</span></div>
<div style="position:absolute;left:306.64px;top:334.52px" class="cls_029"><span class="cls_029">versity of Medical Sciences, Tehran, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Biostatistics, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Depart-</span></div>
<div style="position:absolute;left:50.00px;top:341.41px" class="cls_031"><span class="cls_031">ted by HLA-C*06:02 in psoriasis patients. Among the candidate</span></div>
<div style="position:absolute;left:306.64px;top:344.16px" class="cls_029"><span class="cls_029">ment of Dermatology, Guilan University of Medical Sciences, Rasht, Iran</span></div>
<div style="position:absolute;left:50.00px;top:351.40px" class="cls_031"><span class="cls_031">antigens, wheat peptides induced most robust lymphocyte activa-</span></div>
<div style="position:absolute;left:306.64px;top:355.06px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriatic Arthritis (PsA) arises in an increased burden</span></div>
<div style="position:absolute;left:50.00px;top:361.41px" class="cls_031"><span class="cls_031">tions in psoriasis patients. Moreover, psoriasis was significantly</span></div>
<div style="position:absolute;left:306.64px;top:365.09px" class="cls_031"><span class="cls_031">of psoriasis and impairments in both quality of life and functional</span></div>
<div style="position:absolute;left:50.01px;top:371.40px" class="cls_031"><span class="cls_031">improved by wheat-free diet in several patients with lymphocytes</span></div>
<div style="position:absolute;left:306.64px;top:375.13px" class="cls_031"><span class="cls_031">capacity. The relationship between nail involvement and PsA in</span></div>
<div style="position:absolute;left:50.01px;top:381.40px" class="cls_031"><span class="cls_031">responding to wheat, indicating potential pathogenic contribution</span></div>
<div style="position:absolute;left:306.64px;top:385.16px" class="cls_031"><span class="cls_031">psoriasis is not fully characterized.</span></div>
<div style="position:absolute;left:50.01px;top:391.40px" class="cls_031"><span class="cls_031">of wheat antigens in psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:395.20px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To evaluate the frequency and characteristics of nail</span></div>
<div style="position:absolute;left:50.01px;top:401.40px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> Our results provide unbiased evidence that several</span></div>
<div style="position:absolute;left:306.64px;top:405.23px" class="cls_031"><span class="cls_031">involvement in psoriatic patients and to assess the relationship</span></div>
<div style="position:absolute;left:50.01px;top:411.40px" class="cls_031"><span class="cls_031">environmental antigens may trigger the melanocyte-specific</span></div>
<div style="position:absolute;left:306.64px;top:415.27px" class="cls_031"><span class="cls_031">with joint involvement.</span></div>
<div style="position:absolute;left:50.01px;top:421.40px" class="cls_031"><span class="cls_031">autoimmune response in psoriasis. By identifying and avoiding</span></div>
<div style="position:absolute;left:306.64px;top:425.30px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">A total of 197 patients with moderate-to-severe psoriasis,</span></div>
<div style="position:absolute;left:50.01px;top:431.40px" class="cls_031"><span class="cls_031">those triggers at the molecular level which translate the genetic</span></div>
<div style="position:absolute;left:306.64px;top:435.34px" class="cls_031"><span class="cls_031">were consecutively selected to participate in this cross-sectional</span></div>
<div style="position:absolute;left:50.01px;top:441.40px" class="cls_031"><span class="cls_031">predisposition into disease manifestation, we may develop stra-</span></div>
<div style="position:absolute;left:306.64px;top:445.37px" class="cls_031"><span class="cls_031">study. The patients divided into two groups; with and without</span></div>
<div style="position:absolute;left:50.00px;top:451.41px" class="cls_031"><span class="cls_031">tegies to prevent disease onset and exacerbation.</span></div>
<div style="position:absolute;left:306.64px;top:455.41px" class="cls_031"><span class="cls_031">psoriatic arthritis.</span></div>
<div style="position:absolute;left:306.64px;top:465.44px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">69.5% of psoriatic (137 out of 197) patients had nail in-</span></div>
<div style="position:absolute;left:50.00px;top:471.04px" class="cls_033"><span class="cls_033">P107</span></div>
<div style="position:absolute;left:306.64px;top:475.52px" class="cls_031"><span class="cls_031">volvement. The most common nail abnormality was onycholysis,</span></div>
<div style="position:absolute;left:50.00px;top:482.44px" class="cls_025"><span class="cls_025">A SKEWED POOL OF RESIDENT T CELLS TRIGGERS</span></div>
<div style="position:absolute;left:306.64px;top:485.56px" class="cls_031"><span class="cls_031">followed by pitting and oil drop. Nail changes were more common</span></div>
<div style="position:absolute;left:50.00px;top:493.34px" class="cls_025"><span class="cls_025">DISEASE-ASSOCIATED TISSUE RESPONSES IN NEVER-</span></div>
<div style="position:absolute;left:306.64px;top:495.59px" class="cls_031"><span class="cls_031">in patients with psoriatic arthritis (82.1% vs. 57.8%).</span></div>
<div style="position:absolute;left:50.00px;top:504.24px" class="cls_025"><span class="cls_025">LESIONAL PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:505.63px" class="cls_031"><span class="cls_031">Limitations: Our study had certain limitations. One of them was</span></div>
<div style="position:absolute;left:50.00px;top:514.14px" class="cls_026"><span class="cls_026">Irène Gallais Sérézal</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, </span><span class="cls_051">Elena Hoffer</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, </span><span class="cls_051">Borislav Ignatov</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Elisa</span></div>
<div style="position:absolute;left:306.64px;top:515.66px" class="cls_031"><span class="cls_031">lack of information about the subtypes of PsA. Also, we have not</span></div>
<div style="position:absolute;left:50.00px;top:524.04px" class="cls_026"><span class="cls_026">Martini</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Beatrice Zitti</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Marcus Ehrström</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Liv Eidsmo</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:306.64px;top:525.70px" class="cls_031"><span class="cls_031">recorded the severity of nail involvements. Furthermore, previous</span></div>
<div style="position:absolute;left:50.00px;top:534.64px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Medicine Solna, Karolinska Institutet, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Centre for Haema-</span></div>
<div style="position:absolute;left:306.64px;top:535.73px" class="cls_031"><span class="cls_031">medications may have interfered with the degree of nail changes</span></div>
<div style="position:absolute;left:50.00px;top:544.24px" class="cls_029"><span class="cls_029">tology and Regenerative Medicine, Department of Medicine, Karolinska</span></div>
<div style="position:absolute;left:306.64px;top:545.77px" class="cls_031"><span class="cls_031">in our patients.</span></div>
<div style="position:absolute;left:50.00px;top:553.84px" class="cls_029"><span class="cls_029">Institutet, Karolinska University Hospital Huddinge, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Department of Re-</span></div>
<div style="position:absolute;left:306.64px;top:555.80px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Nail involvement is associated with PsA. Onycho-</span></div>
<div style="position:absolute;left:50.00px;top:563.44px" class="cls_029"><span class="cls_029">constructive Plastic Surgery, Karolinska University Hospital Solna, Stock-</span></div>
<div style="position:absolute;left:306.64px;top:565.87px" class="cls_031"><span class="cls_031">lysis, splinter hemorrhage, and oil drop were significantly more</span></div>
<div style="position:absolute;left:50.00px;top:573.04px" class="cls_029"><span class="cls_029">holm, Sweden</span></div>
<div style="position:absolute;left:306.64px;top:575.90px" class="cls_031"><span class="cls_031">common in PsA group. In general, psoriatic patients with arthritis</span></div>
<div style="position:absolute;left:50.00px;top:583.91px" class="cls_030"><span class="cls_030">Background: </span><span class="cls_031">Psoriasis lesions evolve as a result of cytokine driven</span></div>
<div style="position:absolute;left:306.64px;top:585.94px" class="cls_031"><span class="cls_031">had the more severe disease.</span></div>
<div style="position:absolute;left:50.00px;top:593.90px" class="cls_031"><span class="cls_031">interactions between intralesional immune cells and keratinocytes</span></div>
<div style="position:absolute;left:306.64px;top:595.97px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.00px;top:603.90px" class="cls_031"><span class="cls_031">in genetically predisposed individuals. Skin resident T cells are</span></div>
<div style="position:absolute;left:306.64px;top:606.04px" class="cls_032"><span class="cls_032">1. Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis: a ques-</span></div>
<div style="position:absolute;left:50.00px;top:613.90px" class="cls_031"><span class="cls_031">implicated in maintenance and recurrence of psoriasis plaques</span></div>
<div style="position:absolute;left:306.64px;top:615.07px" class="cls_032"><span class="cls_032">tionnaire-based survey. Br J Dermatol. 2013;169(2):314-319.</span></div>
<div style="position:absolute;left:50.00px;top:623.90px" class="cls_031"><span class="cls_031">but their composition and function in never-lesional psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:624.11px" class="cls_032"><span class="cls_032">2. Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin</span></div>
<div style="position:absolute;left:50.00px;top:633.90px" class="cls_031"><span class="cls_031">skin is less known.</span></div>
<div style="position:absolute;left:306.64px;top:633.15px" class="cls_032"><span class="cls_032">M. Nail involvement as a predictor of concomitant psoriatic arthritis in</span></div>
<div style="position:absolute;left:306.64px;top:642.19px" class="cls_032"><span class="cls_032">patients with psoriasis. Br J Dermatol. 2014;171(5):1123-1128.</span></div>
<div style="position:absolute;left:50.00px;top:643.90px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">Characterisation of T cell driven tissue responses and</span></div>
<div style="position:absolute;left:50.00px;top:653.90px" class="cls_031"><span class="cls_031">subsets of resident T cells in never-lesional psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:660.85px" class="cls_033"><span class="cls_033">P109</span></div>
<div style="position:absolute;left:50.00px;top:663.90px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">T cell driven tissue responses were assessed in explanted</span></div>
<div style="position:absolute;left:50.00px;top:673.90px" class="cls_031"><span class="cls_031">skin biopsies using Nanostring and Multiplex analysis. Epidermal</span></div>
<div style="position:absolute;left:306.64px;top:672.29px" class="cls_025"><span class="cls_025">ABSOLUTE  AND  RELATIVE  PASI  IMPROVEMENTS</span></div>
<div style="position:absolute;left:50.00px;top:683.90px" class="cls_031"><span class="cls_031">and dermal T cells were characterised using flow cytometry in</span></div>
<div style="position:absolute;left:306.64px;top:683.22px" class="cls_025"><span class="cls_025">WITH IXEKIZUMAB TREATMENT: RESULTS AT WEEK</span></div>
<div style="position:absolute;left:50.01px;top:693.89px" class="cls_031"><span class="cls_031">never-lesional skin from patients with mild disease.</span></div>
<div style="position:absolute;left:306.64px;top:694.16px" class="cls_025"><span class="cls_025">12 FROM IXORA-P</span></div>
<div style="position:absolute;left:50.01px;top:703.89px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">T cell activation induced epidermal psoriasiform- and</span></div>
<div style="position:absolute;left:306.64px;top:704.09px" class="cls_026"><span class="cls_026">Kim Papp</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Remus Ioan Orasan</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Paula Polzer</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Carsten Henne-</span></div>
<div style="position:absolute;left:50.01px;top:713.89px" class="cls_031"><span class="cls_031">type-1 interferon tissue responses in explants from never-lesi-</span></div>
<div style="position:absolute;left:306.64px;top:714.04px" class="cls_026"><span class="cls_026">ge</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Radu Dumitru Nica</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Stefan Wilhelm</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">,</span><span class="cls_051"> Ulrich Mrowietz</span><span class="cls_027"><sup>4</sup></span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:36135px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background47.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">45</span></div>
<div style="position:absolute;left:50.00px;top:51.85px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Probity Medical Research, Waterloo, Ontario, Canada, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Human Physio-</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">Statistical Classification of Disease and Related Health Problems</span></div>
<div style="position:absolute;left:50.00px;top:61.45px" class="cls_029"><span class="cls_029">logy, Iuliu Hatieganu University of Medicine and Pharmacy, Romania, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Eli</span></div>
<div style="position:absolute;left:306.64px;top:61.52px" class="cls_031"><span class="cls_031">(ICD-10) between 2010 - 2015 years. PSA was diagnosed after</span></div>
<div style="position:absolute;left:50.00px;top:71.05px" class="cls_029"><span class="cls_029">Lilly and Company, Indianapolis, Indiana, USA, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Department of Derma-</span></div>
<div style="position:absolute;left:306.64px;top:71.64px" class="cls_031"><span class="cls_031">appointment with a rheumatologist and an X-ray examination.</span></div>
<div style="position:absolute;left:50.00px;top:80.65px" class="cls_029"><span class="cls_029">tology, University Medical Centre Schleswig-Holstein, Campus Kiel, Ger-</span></div>
<div style="position:absolute;left:306.64px;top:81.75px" class="cls_031"><span class="cls_031">Diagnosis was carried out according to the criteria of CASPAR.</span></div>
<div style="position:absolute;left:50.00px;top:90.25px" class="cls_029"><span class="cls_029">many</span></div>
<div style="position:absolute;left:306.64px;top:91.87px" class="cls_031"><span class="cls_031">M</span><span class="cls_035">±</span><span class="cls_031">m, t-test, x2, (%) were calculated. All </span><span class="cls_030">p &lt; </span><span class="cls_031">0.05 were considered</span></div>
<div style="position:absolute;left:50.00px;top:101.12px" class="cls_030"><span class="cls_030">Introduction and Objectives: </span><span class="cls_031">Ixekizumab (IXE), an interleukin-</span></div>
<div style="position:absolute;left:306.64px;top:101.99px" class="cls_031"><span class="cls_031">to indicate statistical significance.</span></div>
<div style="position:absolute;left:50.00px;top:111.12px" class="cls_031"><span class="cls_031">17A antagonist, has shown superior efficacy in psoriasis compa-</span></div>
<div style="position:absolute;left:306.64px;top:112.10px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">303 out of 890 pts (34.0%) had psoriatic arthritis (PsA).</span></div>
<div style="position:absolute;left:50.00px;top:121.12px" class="cls_031"><span class="cls_031">red to placebo,1 etanercept,1 and ustekinumab.2 This post hoc</span></div>
<div style="position:absolute;left:306.64px;top:122.22px" class="cls_031"><span class="cls_031">PsA pts were older then PsO pts without arthritis - 55.3</span><span class="cls_035">±</span><span class="cls_031">13.7 years</span></div>
<div style="position:absolute;left:50.00px;top:131.12px" class="cls_031"><span class="cls_031">analysis intended to evaluate absolute and relative Psoriasis Area</span></div>
<div style="position:absolute;left:306.64px;top:132.33px" class="cls_031"><span class="cls_031">and 50.4</span><span class="cls_035">±</span><span class="cls_031">17.6 years accordingly (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001). PsA was found sig-</span></div>
<div style="position:absolute;left:50.00px;top:141.12px" class="cls_031"><span class="cls_031">and Severity Index (PASI) improvements with IXE treatment in</span></div>
<div style="position:absolute;left:306.64px;top:142.45px" class="cls_031"><span class="cls_031">nificantly often in F. pts compare to M. pts - in 143 out of 374 pts</span></div>
<div style="position:absolute;left:50.00px;top:151.12px" class="cls_031"><span class="cls_031">a phase 3 trial (IXORAP).</span></div>
<div style="position:absolute;left:306.66px;top:152.57px" class="cls_031"><span class="cls_031">(38.2%) and in 129 out of 516 pts (25.0%) accordingly (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.05).</span></div>
<div style="position:absolute;left:50.00px;top:161.12px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">In IXORA-P, patients with moderate-to-severe psoriasis</span></div>
<div style="position:absolute;left:306.66px;top:162.68px" class="cls_031"><span class="cls_031">PsA was found significantly often in F. pts over 50 years old (y.o.)</span></div>
<div style="position:absolute;left:50.00px;top:171.11px" class="cls_031"><span class="cls_031">were randomized (2:1:1) to receive any of the 3 dosing regimens</span></div>
<div style="position:absolute;left:306.64px;top:172.80px" class="cls_031"><span class="cls_031">compare to F. pts under 50 y.o. - in 134 out of 261 pts (51.3%) and</span></div>
<div style="position:absolute;left:50.00px;top:181.11px" class="cls_031"><span class="cls_031">of IXE 80 mg: every 2 weeks (Q2W; </span><span class="cls_030">n = </span><span class="cls_031">611), every 4 weeks</span></div>
<div style="position:absolute;left:306.64px;top:182.91px" class="cls_031"><span class="cls_031">in 9 out of 113 pts (7.9%) accordingly (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.05). In old M. and</span></div>
<div style="position:absolute;left:50.00px;top:191.11px" class="cls_031"><span class="cls_031">(Q4W; </span><span class="cls_030">n = </span><span class="cls_031">310), or Q4W/Q2W step-up (</span><span class="cls_030">n = </span><span class="cls_031">306), for 52 weeks.</span></div>
<div style="position:absolute;left:306.64px;top:193.03px" class="cls_031"><span class="cls_031">young M. PsA was found in the same cases - in 58 out of 212 pts</span></div>
<div style="position:absolute;left:50.00px;top:201.11px" class="cls_031"><span class="cls_031">Randomization was stratified by country and weight (</span><span class="cls_030"> &lt; </span><span class="cls_031">80 kg, ≥80</span></div>
<div style="position:absolute;left:306.64px;top:203.15px" class="cls_031"><span class="cls_031">(27.3%) and in 71 out of 304 pts (23.3%) accordingly (p</span><span class="cls_030"> > </span><span class="cls_031">0.05).</span></div>
<div style="position:absolute;left:50.00px;top:211.11px" class="cls_031"><span class="cls_031">to </span><span class="cls_030"> &lt; </span><span class="cls_031">100 kg, or ≥100 kg). The percentage of patients achieving a</span></div>
<div style="position:absolute;left:306.64px;top:213.26px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> PsA was detected in more than a third of patients</span></div>
<div style="position:absolute;left:50.00px;top:221.11px" class="cls_031"><span class="cls_031">75%, 90% or 100% improvement from baseline in PASI (PASI</span></div>
<div style="position:absolute;left:306.64px;top:223.38px" class="cls_031"><span class="cls_031">with severe plaque psoriasis. PSA was found predominantly often</span></div>
<div style="position:absolute;left:50.00px;top:231.11px" class="cls_031"><span class="cls_031">75, 90, and 100) was evaluated using logistic regression with</span></div>
<div style="position:absolute;left:306.64px;top:233.49px" class="cls_031"><span class="cls_031">in F. pts over 50 years of age with severe plaque psoriasis. Future</span></div>
<div style="position:absolute;left:50.00px;top:241.11px" class="cls_031"><span class="cls_031">dosing regimen, country, and baseline weight as factors. Fisher’s</span></div>
<div style="position:absolute;left:306.64px;top:243.61px" class="cls_031"><span class="cls_031">investigation in this field is needed to determine the causes of high</span></div>
<div style="position:absolute;left:50.00px;top:251.11px" class="cls_031"><span class="cls_031">exact test with nonresponder imputation was used to compare the</span></div>
<div style="position:absolute;left:306.62px;top:253.73px" class="cls_031"><span class="cls_031">risks PSA in this age group.</span></div>
<div style="position:absolute;left:50.00px;top:261.11px" class="cls_031"><span class="cls_031">response rates between treatment groups. Here, we present results</span></div>
<div style="position:absolute;left:50.00px;top:271.10px" class="cls_031"><span class="cls_031">at 12 weeks for Q2W (label dose) and Q4W groups; results from</span></div>
<div style="position:absolute;left:306.64px;top:274.48px" class="cls_033"><span class="cls_033">P111</span></div>
<div style="position:absolute;left:50.00px;top:281.10px" class="cls_031"><span class="cls_031">Q4W/Q2W group will be discussed separately.</span></div>
<div style="position:absolute;left:306.64px;top:285.99px" class="cls_025"><span class="cls_025">SKIN LESION SEVERITY IN EARLY AXIAL AND</span></div>
<div style="position:absolute;left:50.00px;top:291.10px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Mean (standard deviation) PASI score at baseline was</span></div>
<div style="position:absolute;left:306.64px;top:297.01px" class="cls_025"><span class="cls_025">PERIPHERAL PSORIATIC ARTHRITIS PATIENTS</span></div>
<div style="position:absolute;left:50.00px;top:301.10px" class="cls_031"><span class="cls_031">20.3 (8.25). Response rates were significantly higher (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001)</span></div>
<div style="position:absolute;left:306.64px;top:307.03px" class="cls_026"><span class="cls_026">Elena Gubar, </span><span class="cls_051">Elena Loginova</span><span class="cls_026">, Svetlana Glukhova, Tatiana Koro-</span></div>
<div style="position:absolute;left:50.01px;top:311.10px" class="cls_031"><span class="cls_031">for Q2W group compared to Q4W group across all cut-off points</span></div>
<div style="position:absolute;left:306.63px;top:317.04px" class="cls_026"><span class="cls_026">taeva</span></div>
<div style="position:absolute;left:50.01px;top:321.10px" class="cls_031"><span class="cls_031">for absolute PASI: absolute PASI </span><span class="cls_030">≤ </span><span class="cls_031">1, 2, 3, and 5 response rates at</span></div>
<div style="position:absolute;left:306.64px;top:327.76px" class="cls_029"><span class="cls_029">Nasonova Research Institute of Rheumatology, Moscow</span></div>
<div style="position:absolute;left:50.01px;top:331.10px" class="cls_031"><span class="cls_031">Week 12 were 61.4%, 76.1%, 84.5%, and 89.4%, respectively, for</span></div>
<div style="position:absolute;left:306.64px;top:338.74px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Comparative analysis of skin lesion severity in early</span></div>
<div style="position:absolute;left:50.01px;top:341.10px" class="cls_031"><span class="cls_031">Q2W group, and 49.7%, 64.5%, 72.6%, and 83.9%, respectively,</span></div>
<div style="position:absolute;left:306.64px;top:348.86px" class="cls_031"><span class="cls_031">PsA patients with and without axial involvement hadn’t been suf-</span></div>
<div style="position:absolute;left:50.01px;top:351.10px" class="cls_031"><span class="cls_031">for Q4W group. At Week 12, PASI 75 response rates in Q2W and</span></div>
<div style="position:absolute;left:50.01px;top:361.10px" class="cls_031"><span class="cls_031">Q4W groups were 89.2% and 83.2%, respectively (</span><span class="cls_030">p = </span><span class="cls_031">0.012).</span></div>
<div style="position:absolute;left:306.64px;top:358.97px" class="cls_031"><span class="cls_031">ficiently studied.</span></div>
<div style="position:absolute;left:50.01px;top:371.09px" class="cls_031"><span class="cls_031">For Q2W and Q4W groups, PASI 90 response rates were 75.3%</span></div>
<div style="position:absolute;left:306.64px;top:369.09px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">to compare skin lesion severity of two early peripheral</span></div>
<div style="position:absolute;left:50.01px;top:381.09px" class="cls_031"><span class="cls_031">and 63.2%, respectively (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001), and PASI 100 response rates</span></div>
<div style="position:absolute;left:306.64px;top:379.20px" class="cls_031"><span class="cls_031">PsA patient populations - with and without axial involvement.</span></div>
<div style="position:absolute;left:50.01px;top:391.09px" class="cls_031"><span class="cls_031">were 46.0% and 32.6%, respectively (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001).</span></div>
<div style="position:absolute;left:306.64px;top:389.32px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">95 patients (pts) (M/F-47 /48) with early PsA according</span></div>
<div style="position:absolute;left:50.01px;top:401.09px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">As reported in psoriasis registration trials, induction</span></div>
<div style="position:absolute;left:306.64px;top:399.44px" class="cls_031"><span class="cls_031">to CASPAR criteria were included; all pts had peripheral arthritis</span></div>
<div style="position:absolute;left:50.01px;top:411.09px" class="cls_031"><span class="cls_031">with IXE Q2W, the labeled dosing regimen, provides better clinical</span></div>
<div style="position:absolute;left:306.64px;top:409.55px" class="cls_031"><span class="cls_031">for </span><span class="cls_030">≤ </span><span class="cls_031">2 years; no inflammatory back pain (IBP) pts were specially</span></div>
<div style="position:absolute;left:50.01px;top:421.09px" class="cls_031"><span class="cls_031">outcomes at Week 12.</span></div>
<div style="position:absolute;left:306.65px;top:419.67px" class="cls_031"><span class="cls_031">selected. Mean age 36.5</span><span class="cls_035">±</span><span class="cls_031">10.7 yrs, disease duration 12.2</span><span class="cls_035">±</span><span class="cls_031">10.3</span></div>
<div style="position:absolute;left:50.01px;top:431.09px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:306.64px;top:429.79px" class="cls_031"><span class="cls_031">mo, disease activity indexes DAS</span><span class="cls_030"> = </span><span class="cls_031">4.0</span><span class="cls_035">±</span><span class="cls_031">1.4, DAS28</span><span class="cls_030"> = </span><span class="cls_031">4.2</span><span class="cls_035">±</span><span class="cls_031"> 1.1,</span></div>
<div style="position:absolute;left:50.00px;top:441.13px" class="cls_032"><span class="cls_032">[1] Griffiths CE, Reich K, Lebwohl M, et al. Lancet 2015;386:541-51.</span></div>
<div style="position:absolute;left:306.64px;top:439.90px" class="cls_031"><span class="cls_031">BASDAI</span><span class="cls_030"> = </span><span class="cls_031">4.5</span><span class="cls_035">±</span><span class="cls_031">1.6. Skin lesion severity was evaluated in terms</span></div>
<div style="position:absolute;left:50.00px;top:450.13px" class="cls_032"><span class="cls_032">[2] Reich K, Pinter A, Lacour JP, et al. Br J Dermatol 2017;177(4):1014-23.</span></div>
<div style="position:absolute;left:306.64px;top:450.02px" class="cls_031"><span class="cls_031">of body surface area (BSA) affected and Psoriasis Area Severity</span></div>
<div style="position:absolute;left:306.64px;top:460.13px" class="cls_031"><span class="cls_031">Index (PASI). When BSA was ≥3%, PASI was calculated. PASI</span></div>
<div style="position:absolute;left:50.00px;top:468.75px" class="cls_033"><span class="cls_033">P110</span></div>
<div style="position:absolute;left:306.66px;top:470.25px" class="cls_031"><span class="cls_031">≥11 indicates moderate and severe psoriasis.</span></div>
<div style="position:absolute;left:50.00px;top:480.15px" class="cls_025"><span class="cls_025">PREVALENCE AND SEX DIFFERENCES OF PSORIATIC</span></div>
<div style="position:absolute;left:306.66px;top:480.37px" class="cls_031"><span class="cls_031">All pts were evaluated for the presence of inflammatory back pain</span></div>
<div style="position:absolute;left:50.00px;top:491.05px" class="cls_025"><span class="cls_025">ARTHRITIS IN PATIENTS WITH SEVERE PLAQUE</span></div>
<div style="position:absolute;left:306.66px;top:490.48px" class="cls_031"><span class="cls_031">(IBP) by ASAS criteria. IBP was observed in 63 (66.3%) cases.</span></div>
<div style="position:absolute;left:50.00px;top:501.95px" class="cls_025"><span class="cls_025">PSORIASIS.</span></div>
<div style="position:absolute;left:306.66px;top:500.60px" class="cls_031"><span class="cls_031">Magnetic resonance imaging (MRI) of SIJs was performed in 79</span></div>
<div style="position:absolute;left:50.00px;top:511.85px" class="cls_026"><span class="cls_026">Nadezhda Batkaeva</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, </span><span class="cls_051">Tatiana Korotaeva</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Edgem Batkaev</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:306.66px;top:510.71px" class="cls_031"><span class="cls_031">pts, regardless of the presence of IBP, on Signa Ovation 0,35T. MRI</span></div>
<div style="position:absolute;left:50.00px;top:522.45px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Peoples’ Friendship University of Russia (RUDN University), </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Research</span></div>
<div style="position:absolute;left:306.66px;top:520.83px" class="cls_031"><span class="cls_031">results were evaluated by an independent reader. Bone marrow</span></div>
<div style="position:absolute;left:50.00px;top:532.05px" class="cls_029"><span class="cls_029">Institute of Rheumatology n. a. V. A. Nasonova</span></div>
<div style="position:absolute;left:306.66px;top:530.95px" class="cls_031"><span class="cls_031">edema on MRI (STIR) was considered as active MRI sacroiliitis</span></div>
<div style="position:absolute;left:50.00px;top:542.92px" class="cls_030"><span class="cls_030">Background: </span><span class="cls_031">Prevalence of psoriatic arthritis in patients with</span></div>
<div style="position:absolute;left:306.66px;top:541.06px" class="cls_031"><span class="cls_031">(MRI-SI). MRI-SI was detected in 28 of 79 (35.4%) examined</span></div>
<div style="position:absolute;left:50.00px;top:552.92px" class="cls_031"><span class="cls_031">psoriasis has conflicting data in different population. But no</span></div>
<div style="position:absolute;left:306.66px;top:551.18px" class="cls_031"><span class="cls_031">cases. The examination also included X-ray of sacroiliac joints</span></div>
<div style="position:absolute;left:50.00px;top:562.92px" class="cls_031"><span class="cls_031">study has been performed in Russian population of prevalence</span></div>
<div style="position:absolute;left:306.66px;top:561.29px" class="cls_031"><span class="cls_031">(SIJs) (pelvic radiographs). Radiographic sacroiliitis (R-SI) was</span></div>
<div style="position:absolute;left:50.00px;top:572.92px" class="cls_031"><span class="cls_031">and sex differences of psoriatic arthritis in patients with severe</span></div>
<div style="position:absolute;left:306.66px;top:571.41px" class="cls_031"><span class="cls_031">considered according to New York criteria (unilateral grade≥3 or</span></div>
<div style="position:absolute;left:50.00px;top:582.92px" class="cls_031"><span class="cls_031">plaque psoriasis.</span></div>
<div style="position:absolute;left:306.65px;top:581.53px" class="cls_031"><span class="cls_031">bilateral grade≥2). R-SI was found in 29 (30.5%) cases. Pts were</span></div>
<div style="position:absolute;left:50.00px;top:592.91px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">to evaluate the prevalence PsA in patients (pts) with</span></div>
<div style="position:absolute;left:306.64px;top:591.64px" class="cls_031"><span class="cls_031">split into two groups: those with axial involvement (axPsA), that</span></div>
<div style="position:absolute;left:50.00px;top:602.91px" class="cls_031"><span class="cls_031">PsO in a dermatological hospital cohort.</span></div>
<div style="position:absolute;left:306.64px;top:601.76px" class="cls_031"><span class="cls_031">is with IBP and/or MRI-SI and/or R-SI; and those without axial</span></div>
<div style="position:absolute;left:50.00px;top:612.91px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">890 pts (Male-516/Female-374) with severy plaque</span></div>
<div style="position:absolute;left:306.64px;top:611.87px" class="cls_031"><span class="cls_031">involvement (having only peripheral PsA [pPsA]). The axPsA</span></div>
<div style="position:absolute;left:50.00px;top:622.91px" class="cls_031"><span class="cls_031">PsO, mean age 50.4</span><span class="cls_035">±</span><span class="cls_031">17.6 years, mean PsO duration 21.5</span><span class="cls_035">±</span><span class="cls_031">14.7,</span></div>
<div style="position:absolute;left:306.64px;top:621.99px" class="cls_031"><span class="cls_031">group included 65 (68.4%) cases, the pPsA one 30 (31.6%) cases.</span></div>
<div style="position:absolute;left:50.00px;top:632.92px" class="cls_031"><span class="cls_031">mean PASI 49.4</span><span class="cls_035">±</span><span class="cls_031">0.5 were included. 374 female were divided into</span></div>
<div style="position:absolute;left:306.64px;top:632.11px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">skin lesions’ severity was higher in the axPsA group than</span></div>
<div style="position:absolute;left:50.00px;top:642.92px" class="cls_031"><span class="cls_031">groups by age. 113 young F. pts with age less than 49 years (mean</span></div>
<div style="position:absolute;left:306.64px;top:642.22px" class="cls_031"><span class="cls_031">in the pPsA group: in axPsA pts BSA median was 3.0 [1.0 - 9.0]</span></div>
<div style="position:absolute;left:50.00px;top:652.92px" class="cls_031"><span class="cls_031">age 36.1</span><span class="cls_035">±</span><span class="cls_031">11.0 years), 261 old F. pts with age more than 50 years</span></div>
<div style="position:absolute;left:306.64px;top:652.34px" class="cls_031"><span class="cls_031">and in pPsA pts it was 1.0 [0.2 - 3.0] (р</span><span class="cls_030"> = </span><span class="cls_031">0.007); in the axPsA</span></div>
<div style="position:absolute;left:50.00px;top:662.92px" class="cls_031"><span class="cls_031">(mean age 63.7</span><span class="cls_035">±</span><span class="cls_031">9.6 years). 516 male were divided into groups</span></div>
<div style="position:absolute;left:306.65px;top:662.45px" class="cls_031"><span class="cls_031">group PASI median was 15.6 [6.6 - 55.2] and in the pPsA group</span></div>
<div style="position:absolute;left:50.00px;top:672.92px" class="cls_031"><span class="cls_031">by age. 304 young M. pts with age less than 54 years (mean age</span></div>
<div style="position:absolute;left:306.65px;top:672.57px" class="cls_031"><span class="cls_031">it was 6.0 [0.0 - 7.2] (р</span><span class="cls_030"> = </span><span class="cls_031">0.006).</span></div>
<div style="position:absolute;left:50.00px;top:682.92px" class="cls_031"><span class="cls_031">38.5</span><span class="cls_035">±</span><span class="cls_031">11.3 years), 212 old M. pts with age more than 55 years</span></div>
<div style="position:absolute;left:306.65px;top:682.69px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Axial involvement in early PsA patients is associated</span></div>
<div style="position:absolute;left:50.00px;top:692.92px" class="cls_031"><span class="cls_031">(mean age 38.5</span><span class="cls_035">±</span><span class="cls_031">11.3 years) were included. PsO and PsA pts were</span></div>
<div style="position:absolute;left:306.65px;top:692.80px" class="cls_031"><span class="cls_031">with skin lesions’ severity. These findings may have a positive</span></div>
<div style="position:absolute;left:50.00px;top:702.92px" class="cls_031"><span class="cls_031">identify in hospital Database reporting and coding by International</span></div>
<div style="position:absolute;left:306.64px;top:702.92px" class="cls_031"><span class="cls_031">impact on the selection of the best therapeutic strategy.</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:36938px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background48.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">46</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.23px" class="cls_033"><span class="cls_033">P112</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">4,674 patients, 10,061 patient-years exposure; secukinumab</span></div>
<div style="position:absolute;left:50.00px;top:62.63px" class="cls_025"><span class="cls_025">GASTROINTESTINAL SYMPTOMS ARE COMMON IN</span></div>
<div style="position:absolute;left:306.64px;top:61.44px" class="cls_031"><span class="cls_031">exposure up to 5 years).</span></div>
<div style="position:absolute;left:50.00px;top:73.53px" class="cls_025"><span class="cls_025">U.S. PATIENTS WITH MODERATE-SEVERE PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:71.48px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">AE IRs were examined per year for subjects receiving</span></div>
<div style="position:absolute;left:50.00px;top:83.43px" class="cls_026"><span class="cls_026">Steven Feldman</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, </span><span class="cls_051">Steve Fakharzadeh</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Jill Abell</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Timothy Hoops</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:81.51px" class="cls_031"><span class="cls_031">secukinumab, and for 52 weeks only for those receiving etanercept</span></div>
<div style="position:absolute;left:50.00px;top:93.33px" class="cls_026"><span class="cls_026">Bhaskar Srivastava</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Erik Muser</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Danielle Dungee</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Sean Quinn</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:91.55px" class="cls_031"><span class="cls_031">(ETN), ustekinumab (UST), or placebo (PBO).</span></div>
<div style="position:absolute;left:50.00px;top:103.23px" class="cls_026"><span class="cls_026">Megan Leone Perkins</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Michael Kappelman</span><span class="cls_027"><sup>4</sup></span></div>
<div style="position:absolute;left:306.64px;top:101.58px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Duration of exposure through 52 weeks of secukinumab</span></div>
<div style="position:absolute;left:50.00px;top:113.83px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Wake Forest School of Medicine, Winston-Salem, NC, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Janssen Scientific</span></div>
<div style="position:absolute;left:306.64px;top:111.62px" class="cls_031"><span class="cls_031">treatment 300 mg, ETN 50 mg, UST 45/90 mg, and PBO was</span></div>
<div style="position:absolute;left:50.00px;top:123.43px" class="cls_029"><span class="cls_029">Affairs, LLC, Horsham PA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">HealthiVibe, LLC, Arlington, VA, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">University</span></div>
<div style="position:absolute;left:306.64px;top:121.62px" class="cls_031"><span class="cls_031">1467.4, 296.9, 318.1, and 301 patient-years, respectively. Expo-</span></div>
<div style="position:absolute;left:50.00px;top:133.03px" class="cls_029"><span class="cls_029">of North Carolina, Chapel Hill, NC, USA</span></div>
<div style="position:absolute;left:306.64px;top:131.65px" class="cls_031"><span class="cls_031">sure duration through 2, 3, 4, and 5 years of secukinumab 300 mg</span></div>
<div style="position:absolute;left:306.64px;top:141.69px" class="cls_031"><span class="cls_031">treatment was 859.6, 423, 377.5, and 90 patient-years.</span></div>
<div style="position:absolute;left:50.00px;top:143.90px" class="cls_030"><span class="cls_030">Background/Objective:</span><span class="cls_031">Patients with moderate-to-severe plaque</span></div>
<div style="position:absolute;left:306.64px;top:151.72px" class="cls_031"><span class="cls_031">Over 52 weeks for secukinumab, ETN, UST, and PBO, respectively,</span></div>
<div style="position:absolute;left:50.00px;top:153.90px" class="cls_031"><span class="cls_031">psoriasis (PsO) are at increased risk of developing inflammatory</span></div>
<div style="position:absolute;left:306.64px;top:161.76px" class="cls_031"><span class="cls_031">exposure adjusted IRs were overall comparable across treatments:</span></div>
<div style="position:absolute;left:49.99px;top:163.90px" class="cls_031"><span class="cls_031">bowel disease (IBD). A survey was conducted to evaluate the</span></div>
<div style="position:absolute;left:306.64px;top:171.79px" class="cls_031"><span class="cls_031">total AEs (275.6, 245.7, 252.2, 355.8); nasopharyngitis (28.4, 35.9,</span></div>
<div style="position:absolute;left:49.99px;top:173.90px" class="cls_031"><span class="cls_031">prevalence of gastrointestinal symptoms in PsO patients.</span></div>
<div style="position:absolute;left:306.64px;top:181.83px" class="cls_031"><span class="cls_031">31.2, 35.9); headache (12.6, 15, 14.6, 23.7); upper respiratory</span></div>
<div style="position:absolute;left:49.99px;top:183.90px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">An electronic survey was available to U.S. PsO patients</span></div>
<div style="position:absolute;left:306.64px;top:191.86px" class="cls_031"><span class="cls_031">infections [URI] (9.1, 5.9, 9.9, 8.8); opportunistic infections (0.2,</span></div>
<div style="position:absolute;left:49.99px;top:193.89px" class="cls_031"><span class="cls_031">with data collected from Jan-Feb. 2017. Patients with moderate-</span></div>
<div style="position:absolute;left:49.99px;top:203.89px" class="cls_031"><span class="cls_031">to-severe plaque PsO and healthy controls (HC), with common</span></div>
<div style="position:absolute;left:306.64px;top:201.90px" class="cls_031"><span class="cls_031">0.3, 0.3, 0.3); </span><span class="cls_030">Candida</span><span class="cls_031"> infections (4.7, 1.4, 1.6, 1.7); neutropenia</span></div>
<div style="position:absolute;left:49.99px;top:213.89px" class="cls_031"><span class="cls_031">co-morbidities allowed in both groups qualified for inclusion in</span></div>
<div style="position:absolute;left:306.64px;top:211.93px" class="cls_031"><span class="cls_031">(0.5, 1.4, 0, 0); major adverse cardiovascular events [MACE] (0.5,</span></div>
<div style="position:absolute;left:50.00px;top:223.89px" class="cls_031"><span class="cls_031">the survey. Psoriasis patients were further categorized as those</span></div>
<div style="position:absolute;left:306.64px;top:221.97px" class="cls_031"><span class="cls_031">0.3, 0.3, 1.3); Crohn’s disease (0.1, 0, 0, 0); ulcerative colitis (0.1,</span></div>
<div style="position:absolute;left:50.00px;top:233.89px" class="cls_031"><span class="cls_031">without recent exposure to biologic therapy (PsO-) vs those with</span></div>
<div style="position:absolute;left:306.64px;top:232.00px" class="cls_031"><span class="cls_031">0.3, 0, 0); and malignant or unspecified tumors [excluding non-</span></div>
<div style="position:absolute;left:50.00px;top:243.89px" class="cls_031"><span class="cls_031">recent (within 4 months) biologic exposure (PsO+). GI symptoms</span></div>
<div style="position:absolute;left:306.65px;top:242.04px" class="cls_031"><span class="cls_031">melanoma skin cancer [NMSC]] (0.4, 0.3, 0.3, 0.3).</span></div>
<div style="position:absolute;left:50.00px;top:253.89px" class="cls_031"><span class="cls_031">and signs, including frequency and severity, were compared across</span></div>
<div style="position:absolute;left:306.65px;top:252.07px" class="cls_031"><span class="cls_031">Secukinumab 300 mg pooled safety remained favorable over time</span></div>
<div style="position:absolute;left:50.00px;top:263.89px" class="cls_031"><span class="cls_031">groups. CalproQuest (CPQ) scores, which have recently been pro-</span></div>
<div style="position:absolute;left:306.65px;top:262.11px" class="cls_031"><span class="cls_031">with no increases in AEs (exposure adjusted IRs for up to Year</span></div>
<div style="position:absolute;left:50.00px;top:273.90px" class="cls_031"><span class="cls_031">posed as a tool to identify patients with elevated fecal calprotectin</span></div>
<div style="position:absolute;left:306.65px;top:272.14px" class="cls_031"><span class="cls_031">1 to Year 5, respectively): total AEs (275.6, 168.1, 160.2, 111.9,</span></div>
<div style="position:absolute;left:50.00px;top:283.90px" class="cls_031"><span class="cls_031">levels and increased risk for IBD, were also calculated. Patients</span></div>
<div style="position:absolute;left:306.65px;top:282.18px" class="cls_031"><span class="cls_031">13.9); nasopharyngitis (28.4, 21.2, 24.1, 11.8, 3.4); headache</span></div>
<div style="position:absolute;left:50.00px;top:293.90px" class="cls_031"><span class="cls_031">with inflammatory bowel disease (IBD), inflammatory bowel</span></div>
<div style="position:absolute;left:306.65px;top:292.21px" class="cls_031"><span class="cls_031">(12.6, 5.4, 4.3, 4.9, 0); URI (9.1, 7.3, 6.1, 5.5, 0); opportunistic</span></div>
<div style="position:absolute;left:50.00px;top:303.90px" class="cls_031"><span class="cls_031">syndrome (IBS), or other gastrointestinal (GI) diagnoses with</span></div>
<div style="position:absolute;left:306.65px;top:302.25px" class="cls_031"><span class="cls_031">infections (0.2, 0.1, 0, 0, 0); </span><span class="cls_030">Candida</span><span class="cls_031"> infections (4.7, 3.6, 1.9, 1.3,</span></div>
<div style="position:absolute;left:50.00px;top:313.89px" class="cls_031"><span class="cls_031">symptoms that overlap with IBD were excluded.</span></div>
<div style="position:absolute;left:306.65px;top:312.28px" class="cls_031"><span class="cls_031">1.1); neutropenia (0.5, 0.1, 0, 0, 0); MACE (0.5, 0.1, 0.5, 0, 0);</span></div>
<div style="position:absolute;left:50.00px;top:323.89px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Overall, 915 patients with self-reported moderate-severe</span></div>
<div style="position:absolute;left:306.65px;top:322.32px" class="cls_031"><span class="cls_031">Crohn’s disease (0.1, 0, 0, 0, 0); ulcerative colitis (0.1, 0.4, 0.2,</span></div>
<div style="position:absolute;left:50.00px;top:333.89px" class="cls_031"><span class="cls_031">PsO and 1,411 healthy controls participated. Demographics were</span></div>
<div style="position:absolute;left:306.65px;top:332.35px" class="cls_031"><span class="cls_031">0.3, 0); and malignant or unspecified tumors [excluding NMSC]</span></div>
<div style="position:absolute;left:50.00px;top:343.89px" class="cls_031"><span class="cls_031">generally comparable between groups. GI symptoms and signs</span></div>
<div style="position:absolute;left:306.65px;top:342.39px" class="cls_031"><span class="cls_031">(0.4, 0.4, 0.2, 0, 0).</span></div>
<div style="position:absolute;left:50.00px;top:353.89px" class="cls_031"><span class="cls_031">were significantly more prevalent in the PsO- and PsO+ groups</span></div>
<div style="position:absolute;left:306.65px;top:352.42px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">This comprehensive pooled analysis supports the</span></div>
<div style="position:absolute;left:50.00px;top:363.89px" class="cls_031"><span class="cls_031">vs the HC group, respectively: pain- 20.6% and 36.9% vs 10.5%;</span></div>
<div style="position:absolute;left:306.65px;top:362.46px" class="cls_031"><span class="cls_031">favorable long-term safety profile of secukinumab in patients with</span></div>
<div style="position:absolute;left:50.00px;top:373.89px" class="cls_031"><span class="cls_031">fullness/bloating- 37.2% and 48.4% vs 25.3%; and diarrhea (16.3%</span></div>
<div style="position:absolute;left:306.66px;top:372.49px" class="cls_031"><span class="cls_031">psoriasis; no new safety signals were identified for up to 5 years</span></div>
<div style="position:absolute;left:50.00px;top:383.89px" class="cls_031"><span class="cls_031">and 29.3% vs 12.2% (all p-values</span><span class="cls_030"> = </span><span class="cls_031">0.002 except diarrhea for</span></div>
<div style="position:absolute;left:306.67px;top:382.53px" class="cls_031"><span class="cls_031">of treatment and secukinumab’s safety profile was consistent with</span></div>
<div style="position:absolute;left:50.00px;top:393.89px" class="cls_031"><span class="cls_031">PsO- vs HC, </span><span class="cls_030">p = </span><span class="cls_031">0.023). Mucous and blood in the stool followed</span></div>
<div style="position:absolute;left:306.67px;top:392.56px" class="cls_031"><span class="cls_031">that established in a large phase 3 program.</span></div>
<div style="position:absolute;left:306.64px;top:402.49px" class="cls_032"><span class="cls_032">Findings previously published at the AAD Annual Meeting, February</span></div>
<div style="position:absolute;left:50.00px;top:403.89px" class="cls_031"><span class="cls_031">a similar pattern. A significantly greater percentage of PsO- and</span></div>
<div style="position:absolute;left:306.64px;top:411.53px" class="cls_032"><span class="cls_032">16-20, 2018, San-Diego, California.</span></div>
<div style="position:absolute;left:49.99px;top:413.89px" class="cls_031"><span class="cls_031">PsO+ patients had positive CPQ scores vs HCs, with the greatest</span></div>
<div style="position:absolute;left:49.99px;top:423.88px" class="cls_031"><span class="cls_031">percentage of positive CPQ scores in the PsO+ group.</span></div>
<div style="position:absolute;left:306.64px;top:430.17px" class="cls_033"><span class="cls_033">P114</span></div>
<div style="position:absolute;left:49.99px;top:433.88px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">GI symptoms and signs are common in patients with</span></div>
<div style="position:absolute;left:306.64px;top:441.60px" class="cls_025"><span class="cls_025">IMPACT OF IMPROVEMENT IN SKIN AND JOINT ON</span></div>
<div style="position:absolute;left:49.99px;top:443.88px" class="cls_031"><span class="cls_031">moderate-to-severe PsO, more so than in healthy controls. This</span></div>
<div style="position:absolute;left:49.99px;top:453.88px" class="cls_031"><span class="cls_031">suggests that physicians caring for patients with PsO may consider</span></div>
<div style="position:absolute;left:306.64px;top:452.54px" class="cls_025"><span class="cls_025">QUALITY OF LIFE IN ACTIVE PSORIATIC ARTHRITIS</span></div>
<div style="position:absolute;left:49.99px;top:463.88px" class="cls_031"><span class="cls_031">assessing for GI symptoms and signs, and monitoring for their</span></div>
<div style="position:absolute;left:306.64px;top:463.47px" class="cls_025"><span class="cls_025">PATIENTS</span></div>
<div style="position:absolute;left:49.99px;top:473.88px" class="cls_031"><span class="cls_031">progression with treatment of PsO to identify patients potentially</span></div>
<div style="position:absolute;left:306.64px;top:473.40px" class="cls_026"><span class="cls_026">Arthur Kavanaugh</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, </span><span class="cls_051">Alice Gottlieb</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Akimichi Morita</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Joseph F</span></div>
<div style="position:absolute;left:49.99px;top:483.88px" class="cls_031"><span class="cls_031">at risk for developing IBD.</span></div>
<div style="position:absolute;left:306.64px;top:483.32px" class="cls_026"><span class="cls_026">Merola</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Julie Birt</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Chen-Yen Lin</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Catherine L Shuler</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Diamant</span></div>
<div style="position:absolute;left:306.64px;top:493.25px" class="cls_026"><span class="cls_026">Thaçi</span><span class="cls_027"><sup>6</sup></span></div>
<div style="position:absolute;left:50.00px;top:503.53px" class="cls_033"><span class="cls_033">P113</span></div>
<div style="position:absolute;left:306.64px;top:503.89px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">University of California, San Diego, CA, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Dermatology,</span></div>
<div style="position:absolute;left:50.00px;top:514.93px" class="cls_025"><span class="cls_025">SECUKINUMAB’S LONG-TERM SAFETY REMAINS</span></div>
<div style="position:absolute;left:306.64px;top:513.52px" class="cls_029"><span class="cls_029">New York Medical College at Metropolitan Hospital, New York, NY, USA,</span></div>
<div style="position:absolute;left:306.64px;top:523.15px" class="cls_028"><span class="cls_028"><sup>3</sup></span><span class="cls_029">Nagoya City University Medical School, Nagoya, Japan, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Harvard Medi-</span></div>
<div style="position:absolute;left:50.00px;top:525.83px" class="cls_025"><span class="cls_025">FAVORABLE UP TO 5 YEARS OF TREATMENT</span></div>
<div style="position:absolute;left:306.64px;top:532.78px" class="cls_029"><span class="cls_029">cal School, Brigham and Women’s Hospital, Boston, MA, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Eli Lilly and</span></div>
<div style="position:absolute;left:50.00px;top:535.73px" class="cls_051"><span class="cls_051">Christopher Griffiths</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, A. Blauvelt</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, K. Reich</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, C. Leonardi</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, N.</span></div>
<div style="position:absolute;left:306.64px;top:542.41px" class="cls_029"><span class="cls_029">Company, Indianapolis, IN, USA, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">University Hospital Schleswig Holstein</span></div>
<div style="position:absolute;left:50.01px;top:545.63px" class="cls_026"><span class="cls_026">Mehta</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, T. Tsai</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, R. You</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, P. Papanastasiou</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, M. Milutinovic</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, P.</span></div>
<div style="position:absolute;left:306.64px;top:552.04px" class="cls_029"><span class="cls_029">Campus Luebeck, Ratzeburger Allee, Germany</span></div>
<div style="position:absolute;left:50.01px;top:555.53px" class="cls_026"><span class="cls_026">van de Kerkhof</span><span class="cls_027"><sup>9</sup></span></div>
<div style="position:absolute;left:50.00px;top:566.13px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Dermatology Centre, Salford Royal Hospital, University of Manchester,</span></div>
<div style="position:absolute;left:306.64px;top:562.94px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriatic arthritis (PsA) is a chronic immune-</span></div>
<div style="position:absolute;left:50.00px;top:575.73px" class="cls_029"><span class="cls_029">Manchester Academic Health Science Centre, Manchester, UK, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Oregon</span></div>
<div style="position:absolute;left:306.64px;top:572.97px" class="cls_031"><span class="cls_031">mediated inflammatory disease affecting peripheral and axial</span></div>
<div style="position:absolute;left:50.00px;top:585.33px" class="cls_029"><span class="cls_029">Medical Research Center, Portland, Oregon, USA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Dermatologikum Ber-</span></div>
<div style="position:absolute;left:306.64px;top:583.01px" class="cls_031"><span class="cls_031">joints. For patients with active psoriasis, the added burden of skin</span></div>
<div style="position:absolute;left:50.00px;top:594.93px" class="cls_029"><span class="cls_029">lin and Georg-August-University, Göttingen, Germany, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Saint Louis Uni-</span></div>
<div style="position:absolute;left:306.64px;top:593.04px" class="cls_031"><span class="cls_031">disease can further reduce health-related quality of life (HRQoL)</span></div>
<div style="position:absolute;left:50.00px;top:604.53px" class="cls_029"><span class="cls_029">versity Health Sciences Center, St. Louis, Missouri, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">National Heart, Lung,</span></div>
<div style="position:absolute;left:306.64px;top:603.08px" class="cls_031"><span class="cls_031">of patients with joint disease.</span></div>
<div style="position:absolute;left:50.00px;top:614.13px" class="cls_029"><span class="cls_029">and Blood Institute, Bethesda, Maryland, USA, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">National Taiwan Univer-</span></div>
<div style="position:absolute;left:306.64px;top:613.09px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To determine the contribution of joint and skin impro-</span></div>
<div style="position:absolute;left:50.00px;top:623.73px" class="cls_029"><span class="cls_029">sity Hospital, National Taiwan University College of Medicine, Taipei, Tai-</span></div>
<div style="position:absolute;left:306.64px;top:623.12px" class="cls_031"><span class="cls_031">vements in HRQoL of patients with active PsA during Phase 3</span></div>
<div style="position:absolute;left:50.00px;top:633.33px" class="cls_029"><span class="cls_029">wan, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">China Novartis Institutes for BioMedical Research, Shanghai, China,</span></div>
<div style="position:absolute;left:306.64px;top:633.16px" class="cls_031"><span class="cls_031">clinical trials investigating ixekizumab (IXE) treatment.</span></div>
<div style="position:absolute;left:50.00px;top:642.93px" class="cls_028"><span class="cls_028"><sup>8</sup></span><span class="cls_029">Novartis Pharma AG, Basel, Switzerland, </span><span class="cls_028"><sup>9</sup></span><span class="cls_029">Department of Dermatology,</span></div>
<div style="position:absolute;left:306.64px;top:643.19px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">The double-blind Phase 3 trials (SPIRIT) investigated</span></div>
<div style="position:absolute;left:50.00px;top:652.53px" class="cls_029"><span class="cls_029">Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands</span></div>
<div style="position:absolute;left:306.64px;top:653.21px" class="cls_031"><span class="cls_031">the treatment of IXE, a high-affinity monoclonal antibody selec-</span></div>
<div style="position:absolute;left:50.00px;top:663.40px" class="cls_030"><span class="cls_030">Introduction and Objectives: </span><span class="cls_031">Psoriasis is a condition typically</span></div>
<div style="position:absolute;left:306.64px;top:663.25px" class="cls_031"><span class="cls_031">tively targeting interleukin-17A, for patients with active PsA.</span></div>
<div style="position:absolute;left:50.00px;top:673.40px" class="cls_031"><span class="cls_031">requiring long-term treatment, thus longitudinal data establishing</span></div>
<div style="position:absolute;left:306.64px;top:673.28px" class="cls_031"><span class="cls_031">The integrated database of 2 SPIRIT trials consisted of biologic</span></div>
<div style="position:absolute;left:50.00px;top:683.40px" class="cls_031"><span class="cls_031">the safety of approved therapies are required. We report exposure</span></div>
<div style="position:absolute;left:306.64px;top:683.32px" class="cls_031"><span class="cls_031">disease-modifying antirheumatic drug (DMARD)-naïve patients</span></div>
<div style="position:absolute;left:50.00px;top:693.40px" class="cls_031"><span class="cls_031">adjusted incidence rates (IRs per 100 patient years) for treatment-</span></div>
<div style="position:absolute;left:306.63px;top:693.35px" class="cls_031"><span class="cls_031">(SPIRIT-P1, NCT01695239) or inadequate responders to tumor</span></div>
<div style="position:absolute;left:50.00px;top:703.40px" class="cls_031"><span class="cls_031">emergent adverse events (AEs) per year of treatment from a pooled</span></div>
<div style="position:absolute;left:306.63px;top:703.39px" class="cls_031"><span class="cls_031">necrosis factor (TNF)-inhibitors (SPIRIT-P2, NCT02349295).</span></div>
<div style="position:absolute;left:50.00px;top:713.39px" class="cls_031"><span class="cls_031">analysis of all secukinumab psoriasis trials to date (19 studies,</span></div>
<div style="position:absolute;left:306.63px;top:713.42px" class="cls_031"><span class="cls_031">Patients were randomized to 80mg IXE every 4 weeks (Q4W,</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:37741px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background49.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">47</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_030"><span class="cls_030">n = </span><span class="cls_031">229) or 2 weeks (Q2W, </span><span class="cls_030">n = </span><span class="cls_031">226) after a 160mg starting dose or</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">continuation improvement of palmoplantar disease for all effi-</span></div>
<div style="position:absolute;left:50.00px;top:61.41px" class="cls_031"><span class="cls_031">placebo (PBO, </span><span class="cls_030">n = </span><span class="cls_031">224). At baseline and Week 24, joint and skin</span></div>
<div style="position:absolute;left:306.64px;top:61.41px" class="cls_031"><span class="cls_031">cacy parameters. The effect was sustained through 2.5 years with</span></div>
<div style="position:absolute;left:50.00px;top:71.41px" class="cls_031"><span class="cls_031">diseases were measured by the Disease Activity index for PSo-</span></div>
<div style="position:absolute;left:306.64px;top:71.40px" class="cls_031"><span class="cls_031">59.2% and 52.5% of subjects in secukinumab 300 and 150 mg</span></div>
<div style="position:absolute;left:50.00px;top:81.41px" class="cls_031"><span class="cls_031">riatic Arthritis (DAPSA; calculated post-hoc) and Psoriasis Area</span></div>
<div style="position:absolute;left:306.64px;top:81.40px" class="cls_031"><span class="cls_031">groups, respectively [multiple imputation (MI)] achieving clear</span></div>
<div style="position:absolute;left:50.00px;top:91.41px" class="cls_031"><span class="cls_031">and Severity Index (PASI), respectively. HRQoL was measured</span></div>
<div style="position:absolute;left:306.64px;top:91.40px" class="cls_031"><span class="cls_031">or almost clear palms and soles (ppIGA 0/1). Consistent with this</span></div>
<div style="position:absolute;left:50.00px;top:101.41px" class="cls_031"><span class="cls_031">by EuroQoL 5 Dimensions Visual Analog Scale (EQ-5D VAS),</span></div>
<div style="position:absolute;left:306.64px;top:101.40px" class="cls_031"><span class="cls_031">observation, the mean palmoplantar Psoriasis Area and Severity</span></div>
<div style="position:absolute;left:50.00px;top:111.41px" class="cls_031"><span class="cls_031">Short Form-36 Health Survey (SF-36), and Work Productivity</span></div>
<div style="position:absolute;left:306.64px;top:111.40px" class="cls_031"><span class="cls_031">Index % change from baseline reached -74.7% and -61.6% for</span></div>
<div style="position:absolute;left:50.00px;top:121.41px" class="cls_031"><span class="cls_031">and Activity Impairment-Specific Health Problem (WPAI). The</span></div>
<div style="position:absolute;left:306.64px;top:121.40px" class="cls_031"><span class="cls_031">secukinumab 300 and 150 mg, respectively, at 2.5 years (MI).</span></div>
<div style="position:absolute;left:50.00px;top:131.41px" class="cls_031"><span class="cls_031">synergistic contribution of skin and joint improvements to HRQoL</span></div>
<div style="position:absolute;left:306.64px;top:131.40px" class="cls_031"><span class="cls_031">The Dermatology Life Quality Index 0/1 response, was achieved</span></div>
<div style="position:absolute;left:50.00px;top:141.41px" class="cls_031"><span class="cls_031">was modeled using smoothing spline method and depicted with</span></div>
<div style="position:absolute;left:306.64px;top:141.40px" class="cls_031"><span class="cls_031">in 45.5% vs. 23.9% of subjects for secukinumab 300 and 150</span></div>
<div style="position:absolute;left:50.00px;top:151.41px" class="cls_031"><span class="cls_031">response surface. Missing data were imputed using last observa-</span></div>
<div style="position:absolute;left:306.64px;top:151.40px" class="cls_031"><span class="cls_031">mg groups respectively (LOCF). Pain and function of palms and</span></div>
<div style="position:absolute;left:50.00px;top:161.41px" class="cls_031"><span class="cls_031">tion carried forward.</span></div>
<div style="position:absolute;left:306.64px;top:161.40px" class="cls_031"><span class="cls_031">soles was markedly improved with secukinumab; as reflected by</span></div>
<div style="position:absolute;left:50.00px;top:171.41px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Of 679 PBO- and IXE-treated patients in the SPIRIT</span></div>
<div style="position:absolute;left:306.64px;top:171.39px" class="cls_031"><span class="cls_031">the Palmoplantar Quality of Life Instrument overall scores with</span></div>
<div style="position:absolute;left:50.00px;top:181.41px" class="cls_031"><span class="cls_031">trials, 402 (65%) and 224 (36%) patients had ≥3% body surface</span></div>
<div style="position:absolute;left:306.64px;top:181.39px" class="cls_031"><span class="cls_031">16.7% and 17.9% subjects experiencing no difficulty in hand and</span></div>
<div style="position:absolute;left:50.01px;top:191.41px" class="cls_031"><span class="cls_031">area (BSA) and ≥10% BSA psoriasis at baseline, respectively. In</span></div>
<div style="position:absolute;left:306.66px;top:191.39px" class="cls_031"><span class="cls_031">feet functionality in secukinumab 300 mg and 150 mg groups</span></div>
<div style="position:absolute;left:50.00px;top:201.41px" class="cls_031"><span class="cls_031">these patients, we applied response surface modeling to investigate</span></div>
<div style="position:absolute;left:306.66px;top:201.39px" class="cls_031"><span class="cls_031">respectively (LOCF). The safety profile was consistent with that</span></div>
<div style="position:absolute;left:50.00px;top:211.41px" class="cls_031"><span class="cls_031">the relationship among DAPSA, PASI, and change from baseline</span></div>
<div style="position:absolute;left:306.66px;top:211.39px" class="cls_031"><span class="cls_031">seen in secukinumab phase 3 trials. The most common adverse</span></div>
<div style="position:absolute;left:50.00px;top:221.41px" class="cls_031"><span class="cls_031">in EQ-5D VAS at Week 24. The greatest improvement in EQ-5D</span></div>
<div style="position:absolute;left:306.66px;top:221.39px" class="cls_031"><span class="cls_031">events across all treatment arms were nasopharyngitis, upper</span></div>
<div style="position:absolute;left:50.00px;top:231.41px" class="cls_031"><span class="cls_031">VAS was associated with the largest percent improvements in</span></div>
<div style="position:absolute;left:306.66px;top:231.39px" class="cls_031"><span class="cls_031">respiratory tract infection and headache.</span></div>
<div style="position:absolute;left:50.00px;top:241.41px" class="cls_031"><span class="cls_031">both DAPSA and PASI together, rather than DAPSA or PASI</span></div>
<div style="position:absolute;left:306.66px;top:241.39px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">GESTURE, the largest and longest duration rando-</span></div>
<div style="position:absolute;left:50.00px;top:251.41px" class="cls_031"><span class="cls_031">alone. Similar observations, regardless of ≥3% or ≥10% BSA ba-</span></div>
<div style="position:absolute;left:306.64px;top:251.41px" class="cls_031"><span class="cls_031">mised controlled trial to date, revealed that secukinumab provides</span></div>
<div style="position:absolute;left:50.00px;top:261.41px" class="cls_031"><span class="cls_031">seline psoriasis, were made in domains of SF-36 (General Health,</span></div>
<div style="position:absolute;left:306.64px;top:261.40px" class="cls_031"><span class="cls_031">a novel treatment option for the challenging and infrequently</span></div>
<div style="position:absolute;left:50.00px;top:271.41px" class="cls_031"><span class="cls_031">Physical Functioning, Social Functioning, and Vitality; data not</span></div>
<div style="position:absolute;left:306.64px;top:271.40px" class="cls_031"><span class="cls_031">studied ppPsO population by providing a strong and sustained</span></div>
<div style="position:absolute;left:50.00px;top:281.41px" class="cls_031"><span class="cls_031">shown) and WPAI (Activity Impairment; data not shown).</span></div>
<div style="position:absolute;left:306.64px;top:281.40px" class="cls_031"><span class="cls_031">response through 2.5 years.</span></div>
<div style="position:absolute;left:50.00px;top:291.41px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">For PsA patients with psoriasis, optimal improve-</span></div>
<div style="position:absolute;left:306.64px;top:291.40px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.00px;top:301.41px" class="cls_031"><span class="cls_031">ments in patients’ HRQoL, as measured by select domains of</span></div>
<div style="position:absolute;left:306.64px;top:301.42px" class="cls_032"><span class="cls_032">1. Kumar B, et al. Acta Dermatol Venereol. 2002; 82:192-5.</span></div>
<div style="position:absolute;left:50.00px;top:311.41px" class="cls_031"><span class="cls_031">patient-reported outcomes, were dependent on successful treatment</span></div>
<div style="position:absolute;left:306.64px;top:310.42px" class="cls_032"><span class="cls_032">2. Gottlieb A, et al. J Am Acad Dermatol. 2017; 76:70-80.</span></div>
<div style="position:absolute;left:306.64px;top:319.42px" class="cls_032"><span class="cls_032">This investigation was sponsored by Novartis Pharma AG, Basel, Swit-</span></div>
<div style="position:absolute;left:50.00px;top:321.41px" class="cls_031"><span class="cls_031">of both joint and skin symptoms.</span></div>
<div style="position:absolute;left:50.00px;top:331.43px" class="cls_032"><span class="cls_032">Kavanaugh A, Gottlieb A, Morita A, Merola J, Birt J, Lin C-Y, Shuler</span></div>
<div style="position:absolute;left:306.64px;top:328.41px" class="cls_032"><span class="cls_032">zerland</span><span class="cls_031">.</span></div>
<div style="position:absolute;left:50.00px;top:340.43px" class="cls_032"><span class="cls_032">CL, Thaci D. The Contribution of Skin and Joint Improvements to the</span></div>
<div style="position:absolute;left:50.00px;top:349.43px" class="cls_032"><span class="cls_032">Health-Related Quality of Life of Patients with Active Psoriatic Arthritis.</span></div>
<div style="position:absolute;left:306.64px;top:347.04px" class="cls_033"><span class="cls_033">P116</span></div>
<div style="position:absolute;left:50.00px;top:358.43px" class="cls_032"><span class="cls_032">Arthritis Rheumatol. 2017;69(Suppl 10).</span></div>
<div style="position:absolute;left:306.64px;top:358.44px" class="cls_025"><span class="cls_025">SECUKINUMAB SHOWS HIGH AND SUSTAINED</span></div>
<div style="position:absolute;left:306.64px;top:369.34px" class="cls_025"><span class="cls_025">EFFICACY IN NAIL PSORIASIS: 2.5-YEAR</span></div>
<div style="position:absolute;left:50.00px;top:377.05px" class="cls_033"><span class="cls_033">P115</span></div>
<div style="position:absolute;left:306.64px;top:380.24px" class="cls_025"><span class="cls_025">TRANSFIGURE STUDY RESULTS</span></div>
<div style="position:absolute;left:50.00px;top:388.45px" class="cls_025"><span class="cls_025">SECUKINUMAB SHOWS HIGH AND SUSTAINED</span></div>
<div style="position:absolute;left:306.64px;top:390.84px" class="cls_052"><span class="cls_052">Kristian Reich</span><span class="cls_028"><sup>1</sup></span><span class="cls_029">, Petr Arenberger</span><span class="cls_028"><sup>2</sup></span><span class="cls_029">, Ulrich Mrowietz</span><span class="cls_028"><sup>3</sup></span><span class="cls_029">, Sasha Jazayeri</span><span class="cls_028"><sup>4</sup></span><span class="cls_029">, Mat-</span></div>
<div style="position:absolute;left:50.00px;top:399.35px" class="cls_025"><span class="cls_025">EFFICACY IN SUBJECTS WITH MODERATE TO</span></div>
<div style="position:absolute;left:306.64px;top:400.44px" class="cls_029"><span class="cls_029">thias Augustin</span><span class="cls_028"><sup>5</sup></span><span class="cls_029">, Anne Parneix-Spake</span><span class="cls_028"><sup>6</sup></span><span class="cls_029">, Pascaline Regnault</span><span class="cls_028"><sup>7</sup></span><span class="cls_029">, Ruquan You</span><span class="cls_028"><sup>8</sup></span><span class="cls_029">,</span></div>
<div style="position:absolute;left:50.00px;top:410.25px" class="cls_025"><span class="cls_025">SEVERE PALMOPLANTAR PSORIASIS: 2.5-YEAR</span></div>
<div style="position:absolute;left:306.64px;top:410.04px" class="cls_029"><span class="cls_029">Jennifer Frueh</span><span class="cls_028"><sup>7</sup></span></div>
<div style="position:absolute;left:50.00px;top:421.15px" class="cls_025"><span class="cls_025">RESULTS FROM THE GESTURE STUDY</span></div>
<div style="position:absolute;left:306.64px;top:421.64px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Ger-</span></div>
<div style="position:absolute;left:50.00px;top:431.05px" class="cls_051"><span class="cls_051">Alice B Gottlieb</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, John Sullivan</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Alexey Kubanov</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Ruquan You</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.63px;top:431.24px" class="cls_029"><span class="cls_029">many, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Dermatology, Charles University, 3rd Faculty of</span></div>
<div style="position:absolute;left:50.00px;top:440.95px" class="cls_026"><span class="cls_026">Pascaline Regnault</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Jennifer Frueh</span><span class="cls_027"><sup>5</sup></span></div>
<div style="position:absolute;left:306.64px;top:440.84px" class="cls_029"><span class="cls_029">Medicine, Prague, Czech Republic, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Psoriasis Center at the Department</span></div>
<div style="position:absolute;left:50.00px;top:451.55px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Dermatology, New York Medical College, Metropolitan</span></div>
<div style="position:absolute;left:306.64px;top:450.44px" class="cls_029"><span class="cls_029">of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Ger-</span></div>
<div style="position:absolute;left:50.00px;top:461.15px" class="cls_029"><span class="cls_029">Hospital, NY, USA, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Holdsworth House Medical Practice, Darlinghurst,</span></div>
<div style="position:absolute;left:306.64px;top:460.04px" class="cls_029"><span class="cls_029">many, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Alliance Dermatology and MOHS Center, Phoenix, USA, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Univer-</span></div>
<div style="position:absolute;left:50.00px;top:470.75px" class="cls_029"><span class="cls_029">Australia, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">State Scientific Center of Dermatology, Venereology and Cos-</span></div>
<div style="position:absolute;left:306.64px;top:469.64px" class="cls_029"><span class="cls_029">sität Hamburg, Hamburg, Germany, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Novartis Pharmaceuticals Corpora-</span></div>
<div style="position:absolute;left:50.00px;top:480.35px" class="cls_029"><span class="cls_029">metology, Moscow, Russia, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">China Novartis Institutes for BioMedical Re-</span></div>
<div style="position:absolute;left:306.64px;top:479.24px" class="cls_029"><span class="cls_029">tion, East Hanover, USA, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Novartis Pharma AG, Basel, Switzerland, </span><span class="cls_028"><sup>8</sup></span><span class="cls_029">China</span></div>
<div style="position:absolute;left:50.00px;top:489.95px" class="cls_029"><span class="cls_029">search, Shanghai, China, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Novartis Pharma AG, Basel, Switzerland</span></div>
<div style="position:absolute;left:306.64px;top:488.84px" class="cls_029"><span class="cls_029">Novartis Institutes for BioMedical Research, Shanghai, China</span></div>
<div style="position:absolute;left:50.00px;top:500.81px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Palmoplantar psoriasis (ppPsO) occurs in up to 40%</span></div>
<div style="position:absolute;left:306.64px;top:499.71px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Nail psoriasis is associated with decreased finger</span></div>
<div style="position:absolute;left:50.00px;top:510.81px" class="cls_031"><span class="cls_031">of plaque psoriasis subjects and is often resistant to treatment. It</span></div>
<div style="position:absolute;left:306.63px;top:509.70px" class="cls_031"><span class="cls_031">mobility, functional impairment, pain and reduced quality of life</span></div>
<div style="position:absolute;left:50.00px;top:520.81px" class="cls_031"><span class="cls_031">is associated with pain, functional limitations, and greater impair-</span></div>
<div style="position:absolute;left:306.63px;top:519.70px" class="cls_031"><span class="cls_031">(QoL) and is often challenging to treat. It correlates with more</span></div>
<div style="position:absolute;left:50.00px;top:530.81px" class="cls_031"><span class="cls_031">ment of health related quality of life compared with plaque pso-</span></div>
<div style="position:absolute;left:306.63px;top:529.70px" class="cls_031"><span class="cls_031">severe psoriatic disease and is an important predictor of psoriatic</span></div>
<div style="position:absolute;left:50.00px;top:540.81px" class="cls_031"><span class="cls_031">riasis on other parts of the body (1). Secukinumab, a fully human</span></div>
<div style="position:absolute;left:306.63px;top:539.70px" class="cls_031"><span class="cls_031">arthritis (PsA). Nails are affected in up to 50% of psoriasis patients,</span></div>
<div style="position:absolute;left:50.00px;top:550.81px" class="cls_031"><span class="cls_031">monoclonal antibody which selectively neutralises IL-17A, has</span></div>
<div style="position:absolute;left:306.63px;top:549.70px" class="cls_031"><span class="cls_031">with a lifetime incidence as high as 90%</span><span class="cls_034"><sup>1</sup></span><span class="cls_031">. Secukinumab, a fully</span></div>
<div style="position:absolute;left:50.00px;top:560.81px" class="cls_031"><span class="cls_031">shown long lasting efficacy and safety in the complete spectrum</span></div>
<div style="position:absolute;left:306.64px;top:559.70px" class="cls_031"><span class="cls_031">human monoclonal antibody that selectively neutralises IL-17A,</span></div>
<div style="position:absolute;left:50.00px;top:570.81px" class="cls_031"><span class="cls_031">of psoriasis manifestations, including nails, scalp, palms and soles</span></div>
<div style="position:absolute;left:306.64px;top:569.70px" class="cls_031"><span class="cls_031">has shown long lasting efficacy and safety in the complete spec-</span></div>
<div style="position:absolute;left:50.00px;top:580.81px" class="cls_031"><span class="cls_031">and psoriatic arthritis.</span></div>
<div style="position:absolute;left:306.64px;top:579.71px" class="cls_031"><span class="cls_031">trum of psoriasis manifestations, including nails, scalp, palms and</span></div>
<div style="position:absolute;left:50.00px;top:590.81px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">Here we report, the long-term follow-up efficacy and</span></div>
<div style="position:absolute;left:306.64px;top:589.70px" class="cls_031"><span class="cls_031">soles and psoriatic arthritis.</span></div>
<div style="position:absolute;left:50.00px;top:600.81px" class="cls_031"><span class="cls_031">safety results from the GESTURE study, the first robust (2.5-year)</span></div>
<div style="position:absolute;left:306.64px;top:599.70px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">Here, we report the long-term follow-up efficacy and</span></div>
<div style="position:absolute;left:49.98px;top:610.81px" class="cls_031"><span class="cls_031">data reported in subjects with moderate to severe ppPsO treated</span></div>
<div style="position:absolute;left:306.64px;top:609.70px" class="cls_031"><span class="cls_031">safety results from the TRANSFIGURE study, the first robust</span></div>
<div style="position:absolute;left:49.98px;top:620.81px" class="cls_031"><span class="cls_031">with secukinumab.</span></div>
<div style="position:absolute;left:306.65px;top:619.70px" class="cls_031"><span class="cls_031">(2.5-year) data reported in subjects with nail psoriasis treated</span></div>
<div style="position:absolute;left:49.98px;top:630.81px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">GESTURE is a double blind, randomised, placebo-con-</span></div>
<div style="position:absolute;left:306.65px;top:629.70px" class="cls_031"><span class="cls_031">with secukinumab.</span></div>
<div style="position:absolute;left:50.00px;top:640.81px" class="cls_031"><span class="cls_031">trolled, parallel-group, multicentre phase 3b study to investigate</span></div>
<div style="position:absolute;left:306.65px;top:639.70px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">TRANSFIGURE is a double blind, randomised,</span></div>
<div style="position:absolute;left:50.00px;top:650.81px" class="cls_031"><span class="cls_031">safety and efficacy of secukinumab 150 and 300 mg s.c. in 205</span></div>
<div style="position:absolute;left:306.65px;top:649.70px" class="cls_031"><span class="cls_031">placebo-controlled, parallel group, multi-centre phase 3b study,</span></div>
<div style="position:absolute;left:49.97px;top:660.81px" class="cls_031"><span class="cls_031">subjects with moderate to severe ppPsO.</span></div>
<div style="position:absolute;left:306.65px;top:659.70px" class="cls_031"><span class="cls_031">to investigate safety and efficacy of secukinumab 150 and 300 mg</span></div>
<div style="position:absolute;left:49.97px;top:670.81px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">As previously reported, after 16 weeks placebo-controlled</span></div>
<div style="position:absolute;left:306.65px;top:669.70px" class="cls_031"><span class="cls_031">s.c. in moderate to severe nail psoriasis, involving 198 subjects.</span></div>
<div style="position:absolute;left:49.97px;top:680.81px" class="cls_031"><span class="cls_031">treatment, the primary endpoint palmoplantar Investigator’s Global</span></div>
<div style="position:absolute;left:306.65px;top:679.70px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">As previously reported, at week 16 the primary end-</span></div>
<div style="position:absolute;left:49.97px;top:690.81px" class="cls_031"><span class="cls_031">Assessment (ppIGA) 0/1 and all secondary endpoints of this study</span></div>
<div style="position:absolute;left:306.64px;top:689.71px" class="cls_031"><span class="cls_031">point NAPSI (NAil Psoriasis Severity Index) and all secondary</span></div>
<div style="position:absolute;left:49.97px;top:700.81px" class="cls_031"><span class="cls_031">were met, demonstrating superiority of secukinumab to placebo</span></div>
<div style="position:absolute;left:306.64px;top:699.70px" class="cls_031"><span class="cls_031">endpoints of this study was met, demonstrating superiority of</span></div>
<div style="position:absolute;left:49.97px;top:710.81px" class="cls_031"><span class="cls_031">at week 16 (2). An interim analysis at week 80 established the</span></div>
<div style="position:absolute;left:306.64px;top:709.70px" class="cls_031"><span class="cls_031">secukinumab to placebo after 16 weeks placebo-controlled treat-</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:38544px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background50.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">48</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:49.79px;top:51.41px" class="cls_031"><span class="cls_031">ment</span><span class="cls_034"><sup>2</sup></span><span class="cls_031">. An interim analysis at week 80 demonstrated the continua-</span></div>
<div style="position:absolute;left:306.64px;top:51.55px" class="cls_026"><span class="cls_026">Kim Papp</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">,</span><span class="cls_051"> Melinda Gooderham</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Jennifer Beecker</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Charles Lyn-</span></div>
<div style="position:absolute;left:49.79px;top:61.41px" class="cls_031"><span class="cls_031">tion of improvement in nail psoriasis for all efficacy parameters.</span></div>
<div style="position:absolute;left:306.64px;top:61.45px" class="cls_026"><span class="cls_026">de</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Isabelle Delorme</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Ignacio Dei-Cas</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Emmanouil Rampaka-</span></div>
<div style="position:absolute;left:49.79px;top:71.40px" class="cls_031"><span class="cls_031">The effect was sustained through 2.5 years with a large mean</span></div>
<div style="position:absolute;left:306.64px;top:71.35px" class="cls_026"><span class="cls_026">kis</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Lenka Rihakova</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, Shamiza Hussein</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, Antonio Vieira</span><span class="cls_027"><sup>8</sup></span></div>
<div style="position:absolute;left:49.79px;top:81.40px" class="cls_031"><span class="cls_031">NAPSI improvement from baseline (BL) of −73.3% and −63.6%</span></div>
<div style="position:absolute;left:306.64px;top:81.95px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">K Papp Clinical Research and Probity Medical Research, Waterloo, ON,</span></div>
<div style="position:absolute;left:49.78px;top:91.40px" class="cls_031"><span class="cls_031">with secukinumab 300 and 150 mg, respectively (as observed).</span></div>
<div style="position:absolute;left:306.64px;top:91.55px" class="cls_028"><span class="cls_028"><sup>2</sup></span><span class="cls_029">SKiN Center for Dermatology, Queen’s University and Probity Medical</span></div>
<div style="position:absolute;left:49.78px;top:101.40px" class="cls_031"><span class="cls_031">Secukinumab demonstrated sustained reductions (improvements)</span></div>
<div style="position:absolute;left:306.64px;top:101.15px" class="cls_029"><span class="cls_029">Research, Peterborough, ON, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">University of Ottawa, Division of Dermato-</span></div>
<div style="position:absolute;left:49.78px;top:111.40px" class="cls_031"><span class="cls_031">in total mean NAPPA (Nail Assessment in Psoriasis and Psoria-</span></div>
<div style="position:absolute;left:306.64px;top:110.75px" class="cls_029"><span class="cls_029">logy, Ottawa, ON, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Lynde Institute for Dermatology, University of Toronto</span></div>
<div style="position:absolute;left:49.79px;top:121.41px" class="cls_031"><span class="cls_031">tic Arthritis) QoL scores from BL to 2.5 years by −52.4% and</span></div>
<div style="position:absolute;left:306.64px;top:120.35px" class="cls_029"><span class="cls_029">and Probity Medical Research, Markham, ON, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Dr. Isabelle Delorm Inc,</span></div>
<div style="position:absolute;left:306.63px;top:129.95px" class="cls_029"><span class="cls_029">Drummondville, QC, Canada, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Facultad de Medicina de la Universidad de</span></div>
<div style="position:absolute;left:49.82px;top:131.40px" class="cls_031"><span class="cls_031">−18.1%, and 70.2% and 71.0% of subjects achieved a weighted</span></div>
<div style="position:absolute;left:306.64px;top:139.55px" class="cls_029"><span class="cls_029">Buenos Aires, Buenos Aires, Argentina, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">JSS Medical, Saint-Laurent, QC,</span></div>
<div style="position:absolute;left:49.82px;top:141.40px" class="cls_031"><span class="cls_031">NAPPA-PBI (Patient Benefit Index) global score of ≥2 (at least</span></div>
<div style="position:absolute;left:306.64px;top:149.15px" class="cls_028"><span class="cls_028"><sup>8</sup></span><span class="cls_029">Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada</span></div>
<div style="position:absolute;left:49.82px;top:151.40px" class="cls_031"><span class="cls_031">moderate benefits) with secukinumab 300 and 150 mg, respec-</span></div>
<div style="position:absolute;left:49.79px;top:161.41px" class="cls_031"><span class="cls_031">tively (LOCF). Subjects showed considerable improvements in</span></div>
<div style="position:absolute;left:306.64px;top:160.01px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Secukinumab (SEC) is a fully human monoclonal</span></div>
<div style="position:absolute;left:49.79px;top:171.40px" class="cls_031"><span class="cls_031">EQ-5D (EuroQOL 5-Dimension Health Status Questionnaire)</span></div>
<div style="position:absolute;left:306.64px;top:170.01px" class="cls_031"><span class="cls_031">antibody that selectively neutralizes IL-17A, a key cytokine</span></div>
<div style="position:absolute;left:49.79px;top:181.40px" class="cls_031"><span class="cls_031">compared with BL reporting decreased pain and discomfort. The</span></div>
<div style="position:absolute;left:306.64px;top:180.01px" class="cls_031"><span class="cls_031">involved in the development of psoriasis (PsO). SEC has shown</span></div>
<div style="position:absolute;left:49.79px;top:191.40px" class="cls_031"><span class="cls_031">safety profile was consistent with that observed in previous phase</span></div>
<div style="position:absolute;left:306.64px;top:190.01px" class="cls_031"><span class="cls_031">long lasting efficacy and safety in the complete spectrum of PsO</span></div>
<div style="position:absolute;left:49.78px;top:201.40px" class="cls_031"><span class="cls_031">3 trials of psoriasis and PsA.</span></div>
<div style="position:absolute;left:306.64px;top:200.01px" class="cls_031"><span class="cls_031">manifestations, including nails, scalp, palms and soles and psoriatic</span></div>
<div style="position:absolute;left:49.78px;top:211.40px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">TRANSFIGURE is the first large, randomised con-</span></div>
<div style="position:absolute;left:306.64px;top:210.01px" class="cls_031"><span class="cls_031">arthritis (PsA). PURE is an international registry of adult patients</span></div>
<div style="position:absolute;left:49.79px;top:221.41px" class="cls_031"><span class="cls_031">trolled trial to report long-term results in subjects with nail psoria-</span></div>
<div style="position:absolute;left:306.64px;top:220.01px" class="cls_031"><span class="cls_031">(pts) from Canada and Latin America with moderate to severe PsO</span></div>
<div style="position:absolute;left:49.79px;top:231.41px" class="cls_031"><span class="cls_031">sis. Secukinumab demonstrated strong sustainability of clinically</span></div>
<div style="position:absolute;left:306.64px;top:230.01px" class="cls_031"><span class="cls_031">treated with SEC vs other approved therapies (other Tx).</span></div>
<div style="position:absolute;left:49.79px;top:241.40px" class="cls_031"><span class="cls_031">meaningful efficacy, large QoL improvement and a favourable</span></div>
<div style="position:absolute;left:306.64px;top:240.01px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To describe and compare the baseline demographic,</span></div>
<div style="position:absolute;left:49.79px;top:251.40px" class="cls_031"><span class="cls_031">safety profile up to 2.5 years in this challenging form of psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:250.01px" class="cls_031"><span class="cls_031">disease, and clinical characteristics - specifically, the history of</span></div>
<div style="position:absolute;left:49.77px;top:261.40px" class="cls_031"><span class="cls_031">This investigation was sponsored by Novartis Pharma AG, Basel,</span></div>
<div style="position:absolute;left:306.63px;top:260.00px" class="cls_031"><span class="cls_031">a PsA diagnosis among PsO pts treated with SEC vs other Tx.</span></div>
<div style="position:absolute;left:49.77px;top:271.40px" class="cls_031"><span class="cls_031">Switzerland.</span></div>
<div style="position:absolute;left:306.63px;top:270.00px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Approximately 2,500 adult pts (1:1 ratio, SEC: other Tx)</span></div>
<div style="position:absolute;left:49.77px;top:281.40px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:306.63px;top:280.00px" class="cls_031"><span class="cls_031">will be recruited. A decision regarding treatment must have been</span></div>
<div style="position:absolute;left:49.79px;top:291.42px" class="cls_032"><span class="cls_032">Baran R. Dermatology. 2010; 221 Suppl 1:1-5.</span></div>
<div style="position:absolute;left:306.63px;top:290.00px" class="cls_031"><span class="cls_031">reached prior to enrollment. The independent-samples and Chi-</span></div>
<div style="position:absolute;left:49.79px;top:300.42px" class="cls_032"><span class="cls_032">Reich K. Ann Rheum Dis. 2016;75:603.</span></div>
<div style="position:absolute;left:306.63px;top:300.00px" class="cls_031"><span class="cls_031">square tests were used for continuous and categorical variables,</span></div>
<div style="position:absolute;left:306.63px;top:310.00px" class="cls_031"><span class="cls_031">respectively, for treatment group comparison.</span></div>
<div style="position:absolute;left:49.79px;top:319.04px" class="cls_033"><span class="cls_033">P117</span></div>
<div style="position:absolute;left:306.63px;top:320.00px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">As of Nov 27, 2017, 1032 pts (397 SEC vs 635 other Tx)</span></div>
<div style="position:absolute;left:49.79px;top:330.44px" class="cls_025"><span class="cls_025">THE OBESITY AND PREVALENCE PSORIATIC</span></div>
<div style="position:absolute;left:306.63px;top:330.00px" class="cls_031"><span class="cls_031">had been enrolled. Mean age (50.5 vs 49.4 years), time since diag-</span></div>
<div style="position:absolute;left:49.79px;top:341.34px" class="cls_025"><span class="cls_025">ARTHRITIS IN PATIENTS WITH PLAQUE PSORIASIS:</span></div>
<div style="position:absolute;left:306.64px;top:340.01px" class="cls_031"><span class="cls_031">nosis (18.5 vs 16.9 years), duration since symptom onset (20.5 vs</span></div>
<div style="position:absolute;left:49.79px;top:352.24px" class="cls_025"><span class="cls_025">DERMATOLOGICAL REAL-SETTING DATA</span></div>
<div style="position:absolute;left:306.64px;top:350.01px" class="cls_031"><span class="cls_031">19 years), and race (78.6% vs 83.8% Caucasian) were comparable</span></div>
<div style="position:absolute;left:49.79px;top:362.14px" class="cls_026"><span class="cls_026">Maria Chamurlieva, </span><span class="cls_051">Tatiana Korotaeva</span></div>
<div style="position:absolute;left:306.64px;top:360.01px" class="cls_031"><span class="cls_031">between groups. The percentage of females was lower in the SEC</span></div>
<div style="position:absolute;left:49.79px;top:372.74px" class="cls_029"><span class="cls_029">N.A.Nasonova Research Institute of Rheumatology</span></div>
<div style="position:absolute;left:306.64px;top:370.01px" class="cls_031"><span class="cls_031">group (38.0%) vs other Tx (45.5%; </span><span class="cls_030">p = </span><span class="cls_031">0.037). At baseline, the</span></div>
<div style="position:absolute;left:306.64px;top:380.01px" class="cls_031"><span class="cls_031">majority of SEC-treated pts (66.2%) were employed, and 23.7%</span></div>
<div style="position:absolute;left:49.79px;top:383.61px" class="cls_030"><span class="cls_030">Background: </span><span class="cls_031">Psoriasis (PsO) is a chronic inflammatory disease,</span></div>
<div style="position:absolute;left:306.64px;top:390.01px" class="cls_031"><span class="cls_031">vs 34.8% vs 34.3% had public vs private vs combined coverage,</span></div>
<div style="position:absolute;left:49.79px;top:393.60px" class="cls_031"><span class="cls_031">which can be associated with the obesity. A link between body</span></div>
<div style="position:absolute;left:306.64px;top:400.01px" class="cls_031"><span class="cls_031">respectively. There was no difference between cohorts. A higher</span></div>
<div style="position:absolute;left:49.79px;top:403.60px" class="cls_031"><span class="cls_031">mass index (BMI) and psoriatic arthritis (PsA) has been found</span></div>
<div style="position:absolute;left:306.64px;top:410.01px" class="cls_031"><span class="cls_031">proportion of SEC pts had a history of PsA (23.2% vs 15.0%;</span></div>
<div style="position:absolute;left:49.79px;top:413.60px" class="cls_031"><span class="cls_031">recently. But there is limited data about this association in Russian</span></div>
<div style="position:absolute;left:306.64px;top:420.01px" class="cls_030"><span class="cls_030">p = </span><span class="cls_031">0.001) or diabetes (18.1% vs 13.4%; </span><span class="cls_030">p = </span><span class="cls_031">0.072) compared to pts</span></div>
<div style="position:absolute;left:49.79px;top:423.60px" class="cls_031"><span class="cls_031">population and from real-world data.</span></div>
<div style="position:absolute;left:306.64px;top:430.01px" class="cls_031"><span class="cls_031">on other Tx. About 87.9% pts with PsA history and 34.1% pts wit-</span></div>
<div style="position:absolute;left:49.79px;top:433.60px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To study the incidence of PsA in PsO patients (pts)</span></div>
<div style="position:absolute;left:306.64px;top:440.01px" class="cls_031"><span class="cls_031">hout had a Psoriasis Epidemiology Screening Tool (PEST) score</span></div>
<div style="position:absolute;left:49.79px;top:443.60px" class="cls_031"><span class="cls_031">with/without obesity.</span></div>
<div style="position:absolute;left:306.64px;top:450.01px" class="cls_031"><span class="cls_031">≥3 at baseline; however, the diagnosis of PsA in these pts needs to</span></div>
<div style="position:absolute;left:49.79px;top:453.60px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">103 pts (male-47/female-56) with different forms of</span></div>
<div style="position:absolute;left:306.67px;top:460.01px" class="cls_031"><span class="cls_031">be confirmed. In terms of prior PsO treatments, 52.4% vs 29.9%</span></div>
<div style="position:absolute;left:49.79px;top:463.60px" class="cls_031"><span class="cls_031">plaque PsO, mean age 44</span><span class="cls_035">±</span><span class="cls_031">13.69 years (yrs.), mean PsO duration</span></div>
<div style="position:absolute;left:306.67px;top:470.01px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001) of SEC vs other Tx pts had been previously treated</span></div>
<div style="position:absolute;left:49.79px;top:473.60px" class="cls_031"><span class="cls_031">10.7</span><span class="cls_035">±</span><span class="cls_031">10.2 yrs., mean PASI 15.39</span><span class="cls_035">±</span><span class="cls_031">12.51 were included. 61 out of</span></div>
<div style="position:absolute;left:306.67px;top:480.01px" class="cls_031"><span class="cls_031">with methotrexate, and 50.6% vs 18.0% (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.001) with a biolo-</span></div>
<div style="position:absolute;left:49.78px;top:483.60px" class="cls_031"><span class="cls_031">103 pts with PsO (59.2%) had psoriatic arthritis (PsA) by CASPAR</span></div>
<div style="position:absolute;left:306.64px;top:490.01px" class="cls_031"><span class="cls_031">gic. Prior to enrollment, 4.7%, 13.2% and 4.7% pts in the other</span></div>
<div style="position:absolute;left:49.78px;top:493.60px" class="cls_031"><span class="cls_031">criteria. In all pts BMI was calculated. If the BMI was more than</span></div>
<div style="position:absolute;left:306.64px;top:500.01px" class="cls_031"><span class="cls_031">Tx group received anti-IL-12/23, anti-TNF-α, and anti-IL-17A,</span></div>
<div style="position:absolute;left:49.78px;top:503.60px" class="cls_031"><span class="cls_031">30 it was regarded as obesity. M</span><span class="cls_035">±</span><span class="cls_031">m, %, t-test were peformed. All</span></div>
<div style="position:absolute;left:306.64px;top:510.01px" class="cls_031"><span class="cls_031">respectively. Pts treated with SEC had a higher historical Psoriasis</span></div>
<div style="position:absolute;left:49.79px;top:513.60px" class="cls_030"><span class="cls_030">p &lt; </span><span class="cls_031">0.05 were considered to indicate statistical significance.</span></div>
<div style="position:absolute;left:306.64px;top:520.01px" class="cls_031"><span class="cls_031">Area and Severity Index (PASI) score (16.5 vs 14.2; </span><span class="cls_030">p = </span><span class="cls_031">0.005),</span></div>
<div style="position:absolute;left:49.79px;top:523.60px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">The overweight in both groups of pts with PsO and PsA</span></div>
<div style="position:absolute;left:306.64px;top:530.01px" class="cls_031"><span class="cls_031">baseline PASI (13.6 vs 12.0; </span><span class="cls_030">p = </span><span class="cls_031">0.001) and Investigator’s Global</span></div>
<div style="position:absolute;left:49.79px;top:533.60px" class="cls_031"><span class="cls_031">was not significantly different: in 30 pts without PsA and in 48</span></div>
<div style="position:absolute;left:306.64px;top:540.01px" class="cls_031"><span class="cls_031">Assessment score (severe disease [score</span><span class="cls_030"> = </span><span class="cls_031">4]: 25.4% vs 20.1%)</span></div>
<div style="position:absolute;left:49.81px;top:543.60px" class="cls_031"><span class="cls_031">with PsA, 71.4% and 78.7% respectively. However, there was a</span></div>
<div style="position:absolute;left:306.64px;top:550.01px" class="cls_031"><span class="cls_031">at enrollment compared to pts on other Tx.</span></div>
<div style="position:absolute;left:49.81px;top:553.60px" class="cls_031"><span class="cls_031">significant difference in the frequency of PsA in the group of pts</span></div>
<div style="position:absolute;left:306.64px;top:560.01px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Pts with moderate to severe PsO selected for treat-</span></div>
<div style="position:absolute;left:49.81px;top:563.60px" class="cls_031"><span class="cls_031">with a BMI </span><span class="cls_030"> = </span><span class="cls_031"> 30-35 (obesity 1 degree). Thus, it was more than 4</span></div>
<div style="position:absolute;left:306.64px;top:570.01px" class="cls_031"><span class="cls_031">ment with SEC were more likely to have been previously exposed</span></div>
<div style="position:absolute;left:49.81px;top:573.60px" class="cls_031"><span class="cls_031">times higher the pts with PsA, compared with pts without PsA - 19</span></div>
<div style="position:absolute;left:306.64px;top:580.01px" class="cls_031"><span class="cls_031">to another biologic, have comorbid PsA and had more severe</span></div>
<div style="position:absolute;left:49.81px;top:583.60px" class="cls_031"><span class="cls_031">and 4 pts (31.2% vs. 9.5%) respectively (</span><span class="cls_030">p = </span><span class="cls_031">0.06).</span></div>
<div style="position:absolute;left:306.64px;top:590.01px" class="cls_031"><span class="cls_031">skin disease, compared to pts treated with other Tx. A significant</span></div>
<div style="position:absolute;left:49.81px;top:593.60px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">There is a higher incidence of PsA in PsO pts with</span></div>
<div style="position:absolute;left:306.64px;top:600.01px" class="cls_031"><span class="cls_031">proportion of PsO pts may have their PsA undiagnosed in routine</span></div>
<div style="position:absolute;left:49.81px;top:603.60px" class="cls_031"><span class="cls_031">obesity. It should be taken into account during choice of treatment</span></div>
<div style="position:absolute;left:306.64px;top:610.01px" class="cls_031"><span class="cls_031">clinical care.</span></div>
<div style="position:absolute;left:49.81px;top:613.59px" class="cls_031"><span class="cls_031">and evaluation of efficiency of therapy in real-world dermatologi-</span></div>
<div style="position:absolute;left:306.64px;top:620.01px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:49.79px;top:623.61px" class="cls_031"><span class="cls_031">cal setting. Russian population - based studies are needed.</span></div>
<div style="position:absolute;left:306.64px;top:630.03px" class="cls_032"><span class="cls_032">Langley R, et al. NEJM 2014;371:326.</span></div>
<div style="position:absolute;left:306.64px;top:639.03px" class="cls_032"><span class="cls_032">Armstrong AW, et al. J Clin Aesthet Dermatol 2016; S12-S16</span></div>
<div style="position:absolute;left:49.79px;top:643.24px" class="cls_033"><span class="cls_033">P118</span></div>
<div style="position:absolute;left:306.64px;top:648.03px" class="cls_032"><span class="cls_032">McInnes IB, et al. Lancet 2015;386:1137 Mease PJ, et a</span></div>
<div style="position:absolute;left:49.79px;top:653.74px" class="cls_046"><span class="cls_046">DIAGNOSIS OF PSORIATIC ARTHRITIS IN</span></div>
<div style="position:absolute;left:49.79px;top:664.64px" class="cls_046"><span class="cls_046">PATIENTS WITH MODERATE TO SEVERE</span></div>
<div style="position:absolute;left:306.64px;top:665.65px" class="cls_033"><span class="cls_033">P119</span></div>
<div style="position:absolute;left:49.79px;top:675.54px" class="cls_046"><span class="cls_046">CHRONIC PLAQUE PSORIASIS TREATED WITH</span></div>
<div style="position:absolute;left:306.64px;top:677.05px" class="cls_025"><span class="cls_025">EFFICACY AND SAFETY RESULTS OF GUSELKUMAB</span></div>
<div style="position:absolute;left:49.79px;top:686.44px" class="cls_046"><span class="cls_046">SECUKINUMAB VS. OTHER TREATMENTS IN THE</span></div>
<div style="position:absolute;left:306.64px;top:687.95px" class="cls_025"><span class="cls_025">IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS</span></div>
<div style="position:absolute;left:49.79px;top:697.34px" class="cls_046"><span class="cls_046">PURE REGISTRY: INDICATION OF SELECTION</span></div>
<div style="position:absolute;left:306.64px;top:698.85px" class="cls_025"><span class="cls_025">OVER 56 WEEKS</span></div>
<div style="position:absolute;left:49.79px;top:708.24px" class="cls_046"><span class="cls_046">PREFERENCES AND UNDERDIAGNOSIS</span></div>
<div style="position:absolute;left:306.64px;top:708.75px" class="cls_026"><span class="cls_026">Wolf Henning Boehncke</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Alice Gottlieb</span><span class="cls_027"><sup>2,</sup></span><span class="cls_026"> Atul Deodhar</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Bin</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:39347px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background51.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">49</span></div>
<div style="position:absolute;left:50.00px;top:51.55px" class="cls_026"><span class="cls_026">Dong</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Yuhua Wang</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Yanli Zhuang</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, William Barchuk</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Xie L. Xu</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:51.85px" class="cls_029"><span class="cls_029">Waterloo, ON, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Skin Centre for Dermatology, Peterborough, ON, Canada,</span></div>
<div style="position:absolute;left:50.00px;top:61.45px" class="cls_026"><span class="cls_026">Elizabeth Hsia</span><span class="cls_027"><sup>4</sup></span></div>
<div style="position:absolute;left:306.64px;top:61.51px" class="cls_028"><span class="cls_028"><sup>5</sup></span><span class="cls_029">Sun Pharmaceuticals, Princeton, NJ, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Merck & Co., Inc., Kenilworth, NJ,</span></div>
<div style="position:absolute;left:50.00px;top:72.05px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Division of Dermatology and Venereology, Geneva University Hospital,</span></div>
<div style="position:absolute;left:306.64px;top:71.17px" class="cls_029"><span class="cls_029">USA, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">SCIderm Research Institute and Dermatologikum Hamburg, Ham-</span></div>
<div style="position:absolute;left:50.00px;top:81.65px" class="cls_029"><span class="cls_029">and Department of Pathology and Immunology, University of Geneva, Ge-</span></div>
<div style="position:absolute;left:306.63px;top:80.83px" class="cls_029"><span class="cls_029">burg, Germany</span></div>
<div style="position:absolute;left:50.00px;top:91.25px" class="cls_029"><span class="cls_029">neva, Switzerland, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Dermatology, New York Medical Col-</span></div>
<div style="position:absolute;left:306.64px;top:91.76px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Tildrakizumab (TIL), a humanized, IgG1/κ mono-</span></div>
<div style="position:absolute;left:50.00px;top:100.85px" class="cls_029"><span class="cls_029">lege at Metropolitan Hospital, New York, NY, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Oregon Health & Science</span></div>
<div style="position:absolute;left:306.64px;top:101.82px" class="cls_031"><span class="cls_031">clonal antibody for IL-23p19, recently demonstrated its efficacy</span></div>
<div style="position:absolute;left:50.00px;top:110.45px" class="cls_029"><span class="cls_029">University, Portland, OR, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Janssen Research & Development, LLC, Spring</span></div>
<div style="position:absolute;left:306.64px;top:111.88px" class="cls_031"><span class="cls_031">in subjects with chronic plaque psoriasis in two, phase 3 clinical</span></div>
<div style="position:absolute;left:50.00px;top:120.05px" class="cls_029"><span class="cls_029">House, PA, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Janssen Research & Development, LLC, San Diego, CA, USA</span></div>
<div style="position:absolute;left:306.64px;top:121.94px" class="cls_031"><span class="cls_031">studies1.</span></div>
<div style="position:absolute;left:50.00px;top:130.91px" class="cls_030"><span class="cls_030">Introduction/Objective:</span><span class="cls_031">To evaluate the efficacy, safety & tolera-</span></div>
<div style="position:absolute;left:306.64px;top:132.00px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">In this analysis, we examined efficacy from baseline</span></div>
<div style="position:absolute;left:50.00px;top:140.91px" class="cls_031"><span class="cls_031">bility of guselkumab (GUS) in patients (pts) w/ PsA.</span></div>
<div style="position:absolute;left:306.63px;top:142.06px" class="cls_031"><span class="cls_031">to week 52 among TIL patients achieving various Psoriasis Area</span></div>
<div style="position:absolute;left:50.00px;top:150.91px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">In this double-blind, PBO-controlled study, pts w/active</span></div>
<div style="position:absolute;left:306.63px;top:152.13px" class="cls_031"><span class="cls_031">and Severity Index (PASI) responses at week 28.</span></div>
<div style="position:absolute;left:50.00px;top:160.91px" class="cls_031"><span class="cls_031">PsA & ≥3% BSA of PsO despite treatment were randomized 2:1</span></div>
<div style="position:absolute;left:306.63px;top:162.19px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> ReSURFACE 1 (NCT01722331) and reSURFACE 2</span></div>
<div style="position:absolute;left:50.00px;top:170.91px" class="cls_031"><span class="cls_031">to SC GUS 100mg or PBO at wks0, 4, & q8w thereafter through</span></div>
<div style="position:absolute;left:306.63px;top:172.25px" class="cls_031"><span class="cls_031">(NCT01729754) were double-blind, randomized controlled studies</span></div>
<div style="position:absolute;left:50.00px;top:180.91px" class="cls_031"><span class="cls_031">wk44. At wk16, pts w/</span><span class="cls_030"> &lt; </span><span class="cls_031">5% improvement from baseline (BL)</span></div>
<div style="position:absolute;left:306.63px;top:182.31px" class="cls_031"><span class="cls_031">in subjects with moderate-to-severe chronic plaque psoriasis. Part</span></div>
<div style="position:absolute;left:50.00px;top:190.91px" class="cls_031"><span class="cls_031">in swollen & tender joint counts were eligible for early escape</span></div>
<div style="position:absolute;left:306.63px;top:192.37px" class="cls_031"><span class="cls_031">1 (0-12 weeks) was placebo controlled; Part 2 (12-28 weeks)</span></div>
<div style="position:absolute;left:50.00px;top:200.91px" class="cls_031"><span class="cls_031">(EE) to open-label ustekinumab. At wk24, PBO pts crossed-over</span></div>
<div style="position:absolute;left:306.63px;top:202.44px" class="cls_031"><span class="cls_031">re-randomized placebo patients to TIL; Part 3 (28-64 weeks,</span></div>
<div style="position:absolute;left:50.00px;top:210.91px" class="cls_031"><span class="cls_031">to GUS 100mg (PBO to GUS). The primary endpoint was ACR</span></div>
<div style="position:absolute;left:306.63px;top:212.47px" class="cls_031"><span class="cls_031">reSURFACE 1; 28-52 weeks, reSURFACE 2) re-randomized pa-</span></div>
<div style="position:absolute;left:50.00px;top:220.91px" class="cls_031"><span class="cls_031">20 at wk24. Major secondary endpoints were PASI 75 & ACR</span></div>
<div style="position:absolute;left:306.64px;top:222.53px" class="cls_031"><span class="cls_031">tients with ≥PASI 50 to continue or increase TIL dose or to placebo</span></div>
<div style="position:absolute;left:50.00px;top:230.91px" class="cls_031"><span class="cls_031">50 responses, change from BL in HAQ-DI, & improvement in</span></div>
<div style="position:absolute;left:306.66px;top:232.59px" class="cls_031"><span class="cls_031">based on their PASI response at week 28. In this post-hoc pooled</span></div>
<div style="position:absolute;left:50.00px;top:240.90px" class="cls_031"><span class="cls_031">enthesitis (Leeds enthesitis index [LEI]) & dactylitis score (by</span></div>
<div style="position:absolute;left:306.66px;top:242.65px" class="cls_031"><span class="cls_031">analysis, patients consistently on TIL 100 mg and 200 mg from</span></div>
<div style="position:absolute;left:50.00px;top:250.90px" class="cls_031"><span class="cls_031">a 0-3 scoring system) at wk24; & ACR 20 response at wk16.</span></div>
<div style="position:absolute;left:306.66px;top:252.71px" class="cls_031"><span class="cls_031">baseline to week 52 were classified in 5 mutually exclusive groups</span></div>
<div style="position:absolute;left:50.00px;top:260.90px" class="cls_031"><span class="cls_031">Through wk24, efficacy analyses were performed in a modified</span></div>
<div style="position:absolute;left:306.67px;top:262.77px" class="cls_031"><span class="cls_031">based on their week-28 PASI response: PASI </span><span class="cls_030"> &lt; </span><span class="cls_031">50, PASI 50-74,</span></div>
<div style="position:absolute;left:50.01px;top:270.90px" class="cls_031"><span class="cls_031">Intent-to-Treat (mITT) population. Pts who met treatment failure</span></div>
<div style="position:absolute;left:306.67px;top:272.84px" class="cls_031"><span class="cls_031">PASI 75-89, PASI 90-99, and PASI 100. Baseline characteristics</span></div>
<div style="position:absolute;left:50.01px;top:280.90px" class="cls_031"><span class="cls_031">criteria, EE or had missing data at wk24 were considered non-</span></div>
<div style="position:absolute;left:306.67px;top:282.90px" class="cls_031"><span class="cls_031">and % PASI improvement from baseline up to week 52 (observed</span></div>
<div style="position:absolute;left:50.01px;top:290.90px" class="cls_031"><span class="cls_031">responders for ACR/MDA endpoints at wk24. Efficacy post wk24</span></div>
<div style="position:absolute;left:306.67px;top:292.96px" class="cls_031"><span class="cls_031">data) were examined for each group.</span></div>
<div style="position:absolute;left:50.01px;top:300.90px" class="cls_031"><span class="cls_031">was evaluated in pts who did not EE & continued treatment at</span></div>
<div style="position:absolute;left:306.67px;top:303.02px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">This analysis included 575 (TIL 100 mg) and 581 (TIL</span></div>
<div style="position:absolute;left:50.01px;top:310.90px" class="cls_031"><span class="cls_031">wk24 based on observed data.</span></div>
<div style="position:absolute;left:306.67px;top:313.08px" class="cls_031"><span class="cls_031">200 mg) patients; the proportions of patients with week-28 PASI</span></div>
<div style="position:absolute;left:50.01px;top:320.90px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Of 149 pts (PBO:49, GUS:100), BL demographics & ACR</span></div>
<div style="position:absolute;left:306.67px;top:323.15px" class="cls_031"><span class="cls_031">75/90/100 responses were 77%/54%/23% (TIL 100 mg) and</span></div>
<div style="position:absolute;left:50.01px;top:330.90px" class="cls_031"><span class="cls_031">component measures were generally similar between the 2 groups.</span></div>
<div style="position:absolute;left:306.67px;top:333.21px" class="cls_031"><span class="cls_031">78%/58%/29% (TIL 200 mg). At week 28, 133 (23.1%), 175</span></div>
<div style="position:absolute;left:50.01px;top:340.89px" class="cls_031"><span class="cls_031">4 PBO & 9 GUS pts were previously exposed to anti-TNFα agents.</span></div>
<div style="position:absolute;left:306.67px;top:343.27px" class="cls_031"><span class="cls_031">(30.4%), 137 (23.8%), 82 (14.3%), and 48 (8.3%) TIL 100 mg</span></div>
<div style="position:absolute;left:50.02px;top:350.89px" class="cls_031"><span class="cls_031">At wk24, significantly more GUS pts achieved ACR 20 (58.0% vs</span></div>
<div style="position:absolute;left:306.67px;top:353.33px" class="cls_031"><span class="cls_031">patients and 170 (29.3%), 169 (29.1%), 114 (19.6%), 105 (18.1%),</span></div>
<div style="position:absolute;left:50.02px;top:360.89px" class="cls_031"><span class="cls_031">18.4%, </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001), PASI 75 (78.6% vs 12.5%, </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001), & ACR</span></div>
<div style="position:absolute;left:306.67px;top:363.39px" class="cls_031"><span class="cls_031">and 23 (4.0%) TIL 200mg achieved PASI 100, PASI 90-99, PASI</span></div>
<div style="position:absolute;left:50.02px;top:370.89px" class="cls_031"><span class="cls_031">50 (34.0% vs 10.2%, </span><span class="cls_030">p = </span><span class="cls_031">0.002) responses vs PBO. At wk24, mean</span></div>
<div style="position:absolute;left:306.67px;top:373.46px" class="cls_031"><span class="cls_031">75-89, PASI 50-74, and PASI </span><span class="cls_030"> &lt; </span><span class="cls_031">50, respectively. On average,</span></div>
<div style="position:absolute;left:50.02px;top:380.89px" class="cls_031"><span class="cls_031">decrease in HAQ-DI score from BL (-0.42 vs. -0.06, </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001),</span></div>
<div style="position:absolute;left:306.67px;top:383.52px" class="cls_031"><span class="cls_031">PASI 100 patients were younger, lighter, and had shorter disease</span></div>
<div style="position:absolute;left:50.02px;top:390.89px" class="cls_031"><span class="cls_031">& median percent improvement in enthesitis (100% vs 33.33%,</span></div>
<div style="position:absolute;left:306.67px;top:393.58px" class="cls_031"><span class="cls_031">duration at baseline compared to other response groups. For TIL</span></div>
<div style="position:absolute;left:50.02px;top:400.89px" class="cls_030"><span class="cls_030">p = </span><span class="cls_031">0.009) & dactylitis (100% vs 33.33%, </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001) scores (among</span></div>
<div style="position:absolute;left:306.67px;top:403.64px" class="cls_031"><span class="cls_031">100 mg, % PASI improvement was highest for PASI 100 and least</span></div>
<div style="position:absolute;left:50.02px;top:410.89px" class="cls_031"><span class="cls_031">pts w/ BL enthesitis and dactylitis) were significantly greater in</span></div>
<div style="position:absolute;left:306.67px;top:413.70px" class="cls_031"><span class="cls_031">for PASI</span><span class="cls_030"> &lt; </span><span class="cls_031">50 patients on all visits up to week 28 (week 4: 53%,</span></div>
<div style="position:absolute;left:50.03px;top:420.89px" class="cls_031"><span class="cls_031">GUS group vs. PBO. Significantly more GUS pts achieved ACR</span></div>
<div style="position:absolute;left:306.67px;top:423.77px" class="cls_031"><span class="cls_031">46%, 38%, 30%, and 16%; week 28: 100%, 95%, 83%, 64%, and</span></div>
<div style="position:absolute;left:50.03px;top:430.89px" class="cls_031"><span class="cls_031">20 at wk16 (60.0% vs 16.3%, </span><span class="cls_030">p &lt; </span><span class="cls_031">0.001) and MDA at wk24 (23.0%</span></div>
<div style="position:absolute;left:306.67px;top:433.83px" class="cls_031"><span class="cls_031">33% for PASI 100, PASI 90-99, PASI 75-89, PASI 50-74, and</span></div>
<div style="position:absolute;left:50.03px;top:440.88px" class="cls_031"><span class="cls_031">vs. 2.0%, </span><span class="cls_030">p = </span><span class="cls_031">0.001) vs. PBO. Post wk24, efficacy improved in</span></div>
<div style="position:absolute;left:306.67px;top:443.89px" class="cls_031"><span class="cls_031">PASI </span><span class="cls_030"> &lt; </span><span class="cls_031">50 categories, respectively). Among patients achieving</span></div>
<div style="position:absolute;left:50.03px;top:450.88px" class="cls_031"><span class="cls_031">PBO to GUS crossover pts as expected and were well-maintained</span></div>
<div style="position:absolute;left:306.67px;top:453.95px" class="cls_031"><span class="cls_031">PASI </span><span class="cls_030"> > </span><span class="cls_031">50 at week 28 and continued up to 52 weeks, % PASI</span></div>
<div style="position:absolute;left:50.03px;top:460.88px" class="cls_031"><span class="cls_031">in GUS pts through wk56.</span></div>
<div style="position:absolute;left:306.67px;top:464.01px" class="cls_031"><span class="cls_031">improvement maintained or improved from week 28 to week 52.</span></div>
<div style="position:absolute;left:50.03px;top:470.88px" class="cls_031"><span class="cls_031">Through wk24, the frequencies of AEs & infections were compa-</span></div>
<div style="position:absolute;left:306.67px;top:474.08px" class="cls_031"><span class="cls_031">Similar results were observed for TIL 200 mg as well as a subgroup</span></div>
<div style="position:absolute;left:50.00px;top:480.91px" class="cls_031"><span class="cls_031">rable (AEs: PBO 32.7%; GUS 36.0%; infections: PBO: 20.4%;</span></div>
<div style="position:absolute;left:306.67px;top:484.14px" class="cls_031"><span class="cls_031">analysis with bio-naive and bio-experienced patients respectively.</span></div>
<div style="position:absolute;left:50.00px;top:490.91px" class="cls_031"><span class="cls_031">GUS: 16.0%). Post wk24, there was no disproportional increase</span></div>
<div style="position:absolute;left:306.67px;top:494.12px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">The majority of TIL 100 and 200 mg patients achie-</span></div>
<div style="position:absolute;left:50.00px;top:500.91px" class="cls_031"><span class="cls_031">in AE frequency or infections among GUS pts w/ longer exposure.</span></div>
<div style="position:absolute;left:306.64px;top:504.18px" class="cls_031"><span class="cls_031">ved PASI</span><span class="cls_030"> > </span><span class="cls_031">50 response at week 28, and PASI improvement was</span></div>
<div style="position:absolute;left:50.00px;top:510.91px" class="cls_031"><span class="cls_031">Through wk56, there was 1 malignancy (basal cell carcinoma), 6</span></div>
<div style="position:absolute;left:306.64px;top:514.24px" class="cls_031"><span class="cls_031">maintained from week 28 to week 52. Among patients achieving</span></div>
<div style="position:absolute;left:50.00px;top:520.91px" class="cls_031"><span class="cls_031">SAEs (myocardial infarction, osteoarthritis, pupils unequal, radius</span></div>
<div style="position:absolute;left:306.64px;top:524.31px" class="cls_031"><span class="cls_031">PASI </span><span class="cls_030"> > </span><span class="cls_031">90 at week 28, TIL 100 and 200 mg were associated with</span></div>
<div style="position:absolute;left:50.00px;top:530.91px" class="cls_031"><span class="cls_031">fracture, pneumonia, ulcerative keratitis), 2 pts discontinued treat-</span></div>
<div style="position:absolute;left:306.64px;top:534.37px" class="cls_031"><span class="cls_031">a rapid PASI improvement by week 4.</span></div>
<div style="position:absolute;left:50.00px;top:540.91px" class="cls_031"><span class="cls_031">ment due to AEs, 1 grade 3 neutropenia, & 6 pts were positive for</span></div>
<div style="position:absolute;left:306.64px;top:544.43px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:50.00px;top:550.91px" class="cls_031"><span class="cls_031">antibodies to GUS. No deaths occurred through wk56.</span></div>
<div style="position:absolute;left:306.64px;top:554.49px" class="cls_032"><span class="cls_032">1. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo</span></div>
<div style="position:absolute;left:50.00px;top:560.91px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">GUS demonstrated significant improvement on joint</span></div>
<div style="position:absolute;left:306.64px;top:563.55px" class="cls_032"><span class="cls_032">or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSUR-</span></div>
<div style="position:absolute;left:49.99px;top:570.91px" class="cls_031"><span class="cls_031">symptoms, physical function, PsO, enthesitis, dactylitis & quality</span></div>
<div style="position:absolute;left:306.64px;top:572.61px" class="cls_032"><span class="cls_032">FACE 2): results from two randomised controlled, phase 3 trials. Lancet.</span></div>
<div style="position:absolute;left:49.99px;top:580.91px" class="cls_031"><span class="cls_031">of life; efficacy was well-maintained through wk56. GUS was well</span></div>
<div style="position:absolute;left:306.64px;top:581.67px" class="cls_032"><span class="cls_032">2017;390(10091):276-288.</span></div>
<div style="position:absolute;left:50.00px;top:590.91px" class="cls_031"><span class="cls_031">tolerated in this population after ~1 year of exposure.</span></div>
<div style="position:absolute;left:306.64px;top:590.72px" class="cls_032"><span class="cls_032">This abstract was presented at 2018 Annual Meeting of American Academy</span></div>
<div style="position:absolute;left:50.00px;top:600.93px" class="cls_032"><span class="cls_032">Data has been previously presented at EULAR 2017 & ACR 2017</span></div>
<div style="position:absolute;left:306.64px;top:599.78px" class="cls_032"><span class="cls_032">of Dermatology.Note: This abstract was presented at 2018 Annual Meeting</span></div>
<div style="position:absolute;left:306.64px;top:608.83px" class="cls_032"><span class="cls_032">of American Academy of Dermatology.</span></div>
<div style="position:absolute;left:50.00px;top:619.55px" class="cls_033"><span class="cls_033">P120</span></div>
<div style="position:absolute;left:50.00px;top:630.95px" class="cls_025"><span class="cls_025">TILDRAKIZUMAB EFFICACY OVER TIME BY WEEK</span></div>
<div style="position:absolute;left:306.64px;top:627.53px" class="cls_033"><span class="cls_033">P122</span></div>
<div style="position:absolute;left:306.64px;top:638.98px" class="cls_025"><span class="cls_025">POTENTIAL DISCONNECT: CO-MANAGEMENT OF</span></div>
<div style="position:absolute;left:50.00px;top:641.85px" class="cls_025"><span class="cls_025">28 RESPONSE LEVELS IN TWO PHASE 3 CLINICAL</span></div>
<div style="position:absolute;left:306.64px;top:649.95px" class="cls_025"><span class="cls_025">PATIENTS WITH PSORIATIC ARTHRITIS BETWEEN</span></div>
<div style="position:absolute;left:50.00px;top:652.75px" class="cls_025"><span class="cls_025">TRIALS IN PATIENTS WITH CHRONIC PLAQUE</span></div>
<div style="position:absolute;left:306.64px;top:660.91px" class="cls_025"><span class="cls_025">RHEUMATOLOGISTS AND DERMATOLOGISTS</span></div>
<div style="position:absolute;left:50.00px;top:663.65px" class="cls_025"><span class="cls_025">PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:670.87px" class="cls_051"><span class="cls_051">Lynn Price</span><span class="cls_026">, Jennifer Robinson, Gianna Melendez</span></div>
<div style="position:absolute;left:50.00px;top:673.55px" class="cls_026"><span class="cls_026">Andrew Blauvelt</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Howard Sofen</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Kim Papp</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Melinda Gooder-</span></div>
<div style="position:absolute;left:306.64px;top:681.52px" class="cls_029"><span class="cls_029">Spherix Global Insights</span></div>
<div style="position:absolute;left:50.00px;top:683.45px" class="cls_026"><span class="cls_026">ham</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span><span class="cls_051"> Yang Zhao</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Simon Lowry</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Jeff Parno</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Qing Li</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Carmen</span></div>
<div style="position:absolute;left:50.00px;top:693.35px" class="cls_026"><span class="cls_026">La Rosa</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Kristian Reich</span><span class="cls_027"><sup>7</sup></span></div>
<div style="position:absolute;left:306.64px;top:692.40px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">On average, the majority of psoriasis (PSO) patients</span></div>
<div style="position:absolute;left:50.00px;top:703.95px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Oregon Medical Research Center, Portland, OR, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Medicine</span></div>
<div style="position:absolute;left:306.64px;top:702.40px" class="cls_031"><span class="cls_031">are diagnosed a year prior to a psoriatic arthritis (PsA) diagnosis,</span></div>
<div style="position:absolute;left:50.00px;top:713.55px" class="cls_029"><span class="cls_029">(Dermatology) UCLA, Los Angeles, CA, USA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Probity Medical Research,</span></div>
<div style="position:absolute;left:306.64px;top:712.41px" class="cls_031"><span class="cls_031">making the referral patterns and co-management between derma-</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:40150px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background52.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">50</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">tologists and rheumatologists an important aspect to understanding</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">increased in recent years across indications and the practice of</span></div>
<div style="position:absolute;left:50.00px;top:61.36px" class="cls_031"><span class="cls_031">the management of these diseases. Dermatologists represent an</span></div>
<div style="position:absolute;left:306.64px;top:61.40px" class="cls_031"><span class="cls_031">sequential TNF prescribing after an initial TNF is less common.</span></div>
<div style="position:absolute;left:50.00px;top:71.31px" class="cls_031"><span class="cls_031">important referral-base for rheumatologists, accounting for over</span></div>
<div style="position:absolute;left:306.64px;top:71.40px" class="cls_031"><span class="cls_031">Though TNFs are still the preferred first-line agent, there are dis-</span></div>
<div style="position:absolute;left:50.00px;top:81.26px" class="cls_031"><span class="cls_031">one-quarter of all new PsA patients. However, there are discrepan-</span></div>
<div style="position:absolute;left:306.64px;top:81.41px" class="cls_031"><span class="cls_031">crepancies between specialists on the use of AMOA agents in the</span></div>
<div style="position:absolute;left:50.00px;top:91.21px" class="cls_031"><span class="cls_031">cies between the specialists regarding the timing in which these</span></div>
<div style="position:absolute;left:306.64px;top:91.40px" class="cls_031"><span class="cls_031">second-line setting. This research sought to understand the extent</span></div>
<div style="position:absolute;left:50.00px;top:101.16px" class="cls_031"><span class="cls_031">referrals take place.</span></div>
<div style="position:absolute;left:306.64px;top:101.40px" class="cls_031"><span class="cls_031">to which AMOA agents are prescribed after an initial TNF, and</span></div>
<div style="position:absolute;left:50.00px;top:111.11px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">One objective of the study was to gain further insight</span></div>
<div style="position:absolute;left:306.64px;top:111.40px" class="cls_031"><span class="cls_031">how this varies across PSO and PsA.</span></div>
<div style="position:absolute;left:50.00px;top:121.07px" class="cls_031"><span class="cls_031">into rheumatologist and dermatologist co-management of patients</span></div>
<div style="position:absolute;left:306.64px;top:121.40px" class="cls_031"><span class="cls_031">An independent market analytics firm collaborated with US der-</span></div>
<div style="position:absolute;left:50.00px;top:131.02px" class="cls_031"><span class="cls_031">with PsA.</span></div>
<div style="position:absolute;left:306.64px;top:131.41px" class="cls_031"><span class="cls_031">matologists (</span><span class="cls_030">n = </span><span class="cls_031">201) and US rheumatologists (</span><span class="cls_030">n = </span><span class="cls_031">200) to con-</span></div>
<div style="position:absolute;left:50.00px;top:140.98px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">An independent market analytics firm collaborated with</span></div>
<div style="position:absolute;left:306.64px;top:141.41px" class="cls_031"><span class="cls_031">duct a retrospective chart review of patients diagnosed with PSO</span></div>
<div style="position:absolute;left:50.00px;top:150.93px" class="cls_031"><span class="cls_031">US rheumatologists (</span><span class="cls_030">n = </span><span class="cls_031">101) and US dermatologists (</span><span class="cls_030">n = </span><span class="cls_031">101) to</span></div>
<div style="position:absolute;left:306.64px;top:151.40px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">n = </span><span class="cls_031">950) and PsA (</span><span class="cls_030">n = </span><span class="cls_031">1,008) who had switched from one biologic/</span></div>
<div style="position:absolute;left:50.00px;top:160.88px" class="cls_031"><span class="cls_031">conduct analysis of both the PsA and PSO markets. Data were</span></div>
<div style="position:absolute;left:306.65px;top:161.40px" class="cls_031"><span class="cls_031">apremilast to another agent in the prior 12 weeks. Physicians were</span></div>
<div style="position:absolute;left:50.00px;top:170.84px" class="cls_031"><span class="cls_031">collected via an online survey fielded in November/December</span></div>
<div style="position:absolute;left:306.65px;top:171.40px" class="cls_031"><span class="cls_031">able to submit up to 7 patient charts. PSO data was collected in</span></div>
<div style="position:absolute;left:50.00px;top:180.79px" class="cls_031"><span class="cls_031">2017 and included patient demographics, as well as physician</span></div>
<div style="position:absolute;left:306.65px;top:181.40px" class="cls_031"><span class="cls_031">September 2017 and PsA data was collected in April 2017.</span></div>
<div style="position:absolute;left:50.00px;top:190.75px" class="cls_031"><span class="cls_031">demographics, and attitudinal survey responses.</span></div>
<div style="position:absolute;left:306.65px;top:191.40px" class="cls_031"><span class="cls_031">Analysis of patients recently switched from one biologic/apre-</span></div>
<div style="position:absolute;left:50.00px;top:200.70px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Rheumatologists indicate that 51 percent of referrals result</span></div>
<div style="position:absolute;left:306.64px;top:201.41px" class="cls_031"><span class="cls_031">milast to a different brand revealed the majority of patients were</span></div>
<div style="position:absolute;left:50.00px;top:210.61px" class="cls_031"><span class="cls_031">from primary care physicians, 28 percent result from a dermato-</span></div>
<div style="position:absolute;left:306.64px;top:211.40px" class="cls_031"><span class="cls_031">treated with a TNF in the first-line biologic/small molecule set-</span></div>
<div style="position:absolute;left:50.00px;top:220.56px" class="cls_031"><span class="cls_031">logist, and 13 percent are self-referred. The majority (73%) of</span></div>
<div style="position:absolute;left:306.64px;top:221.41px" class="cls_031"><span class="cls_031">ting, though this varies by indication. Rheumatologists prescribe</span></div>
<div style="position:absolute;left:50.00px;top:230.51px" class="cls_031"><span class="cls_031">PsA patients under the care of collaborating rheumatologists had</span></div>
<div style="position:absolute;left:306.64px;top:231.40px" class="cls_031"><span class="cls_031">first-line TNFs significantly more than dermatologists. 83% of</span></div>
<div style="position:absolute;left:50.00px;top:240.46px" class="cls_031"><span class="cls_031">previously been diagnosed with PSO prior to PsA. Dermatologists</span></div>
<div style="position:absolute;left:306.64px;top:241.40px" class="cls_031"><span class="cls_031">PsA patients are prescribed TNFs first-line compared to just 69%</span></div>
<div style="position:absolute;left:50.00px;top:250.42px" class="cls_031"><span class="cls_031">state that one-quarter of their patients with severe PSO also have</span></div>
<div style="position:absolute;left:306.64px;top:251.40px" class="cls_031"><span class="cls_031">of PSO patients. Furthermore, rheumatologists are significantly</span></div>
<div style="position:absolute;left:50.00px;top:260.37px" class="cls_031"><span class="cls_031">PsA, with more than one-third of severe PSO patients also being</span></div>
<div style="position:absolute;left:306.63px;top:261.40px" class="cls_031"><span class="cls_031">more likely to practice TNF-sequencing than dermatologists.</span></div>
<div style="position:absolute;left:50.00px;top:270.31px" class="cls_031"><span class="cls_031">co-managed with a rheumatologist. The majority of rheumatolo-</span></div>
<div style="position:absolute;left:306.63px;top:271.40px" class="cls_031"><span class="cls_031">Indeed, 44% of PsA patients treated with a first-line TNF were</span></div>
<div style="position:absolute;left:50.00px;top:280.26px" class="cls_031"><span class="cls_031">gists believe that dermatologists refer patients at the first sign of</span></div>
<div style="position:absolute;left:306.64px;top:281.40px" class="cls_031"><span class="cls_031">prescribed a second TNF, compared to 6% of PSO patients. Ad-</span></div>
<div style="position:absolute;left:49.99px;top:290.21px" class="cls_031"><span class="cls_031">joint involvement and do not attempt to treat joint pain; however,</span></div>
<div style="position:absolute;left:306.64px;top:291.41px" class="cls_031"><span class="cls_031">ditionally, certain TNF brands have experienced recent declines</span></div>
<div style="position:absolute;left:49.99px;top:300.16px" class="cls_031"><span class="cls_031">31 percent of dermatologists report they do not refer PSO patients</span></div>
<div style="position:absolute;left:306.64px;top:301.40px" class="cls_031"><span class="cls_031">in first line use, though this varies by indication as well. For rheu-</span></div>
<div style="position:absolute;left:49.99px;top:310.12px" class="cls_031"><span class="cls_031">to rheumatologists until patients have failed biologics or are not</span></div>
<div style="position:absolute;left:306.64px;top:311.41px" class="cls_031"><span class="cls_031">matologists, use of first-line etanercept has declined, 38% of PsA</span></div>
<div style="position:absolute;left:49.99px;top:320.07px" class="cls_031"><span class="cls_031">improving on their current systemic regimen, while an additional</span></div>
<div style="position:absolute;left:306.64px;top:321.40px" class="cls_031"><span class="cls_031">patients were initiated on etanercept at least 24 months prior to</span></div>
<div style="position:absolute;left:49.99px;top:330.03px" class="cls_031"><span class="cls_031">35 percent report they refer only severe arthritis/patients with</span></div>
<div style="position:absolute;left:306.64px;top:331.40px" class="cls_031"><span class="cls_031">the study, compared to just 28% initiated on etanercept within 12</span></div>
<div style="position:absolute;left:49.99px;top:339.98px" class="cls_031"><span class="cls_031">worsening disease. Furthermore, only 35 percent of dermatologists</span></div>
<div style="position:absolute;left:306.64px;top:341.40px" class="cls_031"><span class="cls_031">months of the study. For dermatologists, there were significantly</span></div>
<div style="position:absolute;left:49.99px;top:349.93px" class="cls_031"><span class="cls_031">agree that they refer their PSO patients to a rheumatologists at the</span></div>
<div style="position:absolute;left:306.62px;top:351.40px" class="cls_031"><span class="cls_031">more PSO patients initiated on etanercept in the first-line setting</span></div>
<div style="position:absolute;left:49.99px;top:359.89px" class="cls_031"><span class="cls_031">first sign of joint involvement.</span></div>
<div style="position:absolute;left:306.62px;top:361.40px" class="cls_031"><span class="cls_031">24 months or more prior to the study compared to those initiated</span></div>
<div style="position:absolute;left:52.11px;top:369.84px" class="cls_031"><span class="cls_031">At the time of dermatologist referral, rheumatologists state that</span></div>
<div style="position:absolute;left:306.62px;top:371.40px" class="cls_031"><span class="cls_031">within 12 months of the study, (45% vs 31%.) This pattern also</span></div>
<div style="position:absolute;left:49.99px;top:379.80px" class="cls_031"><span class="cls_031">two-thirds of referred patients are biologic/apremilast naïve, with</span></div>
<div style="position:absolute;left:306.62px;top:381.40px" class="cls_031"><span class="cls_031">held true for adalimumab, where 42% of first-line PSO patients</span></div>
<div style="position:absolute;left:49.99px;top:389.75px" class="cls_031"><span class="cls_031">only 6 percent having controlled PSO and joint pain. However,</span></div>
<div style="position:absolute;left:306.62px;top:391.40px" class="cls_031"><span class="cls_031">initiated more than 24 months prior to the study were prescribed</span></div>
<div style="position:absolute;left:49.99px;top:399.70px" class="cls_031"><span class="cls_031">dermatologists state that 40 percent the patients that they referred</span></div>
<div style="position:absolute;left:306.62px;top:401.40px" class="cls_031"><span class="cls_031">adalimumab, a figure that drops to just 27% for patients initiated</span></div>
<div style="position:absolute;left:49.99px;top:409.66px" class="cls_031"><span class="cls_031">to rheumatologists were treated with biologics and 15 percent of</span></div>
<div style="position:absolute;left:306.61px;top:411.40px" class="cls_031"><span class="cls_031">within 12 months.</span></div>
<div style="position:absolute;left:49.99px;top:419.61px" class="cls_031"><span class="cls_031">said referred patients were treated with apremilast. Indeed, 76</span></div>
<div style="position:absolute;left:306.61px;top:421.39px" class="cls_031"><span class="cls_031">Though the position of TNFs as first-line agents remains dominant,</span></div>
<div style="position:absolute;left:49.99px;top:429.57px" class="cls_031"><span class="cls_031">percent of dermatologists agree with the statement, “I</span><span class="cls_030"> believe that</span></div>
<div style="position:absolute;left:306.61px;top:431.39px" class="cls_031"><span class="cls_031">the treating specialist and indication influence how widespread and</span></div>
<div style="position:absolute;left:49.99px;top:439.52px" class="cls_030"><span class="cls_030">starting my PSO patients earlier on biologic therapy will slow</span></div>
<div style="position:absolute;left:306.61px;top:441.39px" class="cls_031"><span class="cls_031">continuous TNF use is. Specifically, dermatologists are less likely</span></div>
<div style="position:absolute;left:49.99px;top:449.47px" class="cls_030"><span class="cls_030">the development and progression of the arthritic component of</span></div>
<div style="position:absolute;left:306.62px;top:451.39px" class="cls_031"><span class="cls_031">to prescribe TNFs as first-line agents and are also significantly</span></div>
<div style="position:absolute;left:49.99px;top:459.43px" class="cls_030"><span class="cls_030">the disease (PsA),</span><span class="cls_031">” while 57 percent of dermatologists agree </span><span class="cls_030">“I</span></div>
<div style="position:absolute;left:306.62px;top:461.39px" class="cls_031"><span class="cls_031">less likely to partake in the sequencing of TNFs in the first- and</span></div>
<div style="position:absolute;left:49.99px;top:469.38px" class="cls_030"><span class="cls_030">prefer to use biologics that are indicated in both PSO and PsA.”</span></div>
<div style="position:absolute;left:306.62px;top:471.39px" class="cls_031"><span class="cls_031">second-line setting than rheumatologists. The introduction of</span></div>
<div style="position:absolute;left:49.99px;top:479.34px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">With many patients diagnosed with both PSO and</span></div>
<div style="position:absolute;left:306.62px;top:481.39px" class="cls_031"><span class="cls_031">several agents in PSO reporting substantially higher rates of skin</span></div>
<div style="position:absolute;left:49.99px;top:489.21px" class="cls_031"><span class="cls_031">PsA, co-management between dermatologists and rheumatolo-</span></div>
<div style="position:absolute;left:306.62px;top:491.39px" class="cls_031"><span class="cls_031">clearance compared to TNFs could potentially be the source of</span></div>
<div style="position:absolute;left:50.00px;top:499.21px" class="cls_031"><span class="cls_031">gists is common. While rheumatologists appear to be under the</span></div>
<div style="position:absolute;left:306.62px;top:501.39px" class="cls_031"><span class="cls_031">increased switching to AMOAs compared to other specialties;</span></div>
<div style="position:absolute;left:50.00px;top:509.20px" class="cls_031"><span class="cls_031">impression that they are receiving the majority of dermatologist-</span></div>
<div style="position:absolute;left:306.62px;top:511.39px" class="cls_031"><span class="cls_031">whereas superior efficacy of AMOA agents over TNFs in PsA</span></div>
<div style="position:absolute;left:50.00px;top:519.20px" class="cls_031"><span class="cls_031">treated patients with PsA at the first sign of joint involvement,</span></div>
<div style="position:absolute;left:306.63px;top:521.38px" class="cls_031"><span class="cls_031">may be less apparent.</span></div>
<div style="position:absolute;left:50.00px;top:529.20px" class="cls_031"><span class="cls_031">dermatologists largely report that they are managing and treating</span></div>
<div style="position:absolute;left:50.00px;top:539.20px" class="cls_031"><span class="cls_031">PsA patients. Furthermore, most dermatologists believe early ag-</span></div>
<div style="position:absolute;left:306.64px;top:540.04px" class="cls_033"><span class="cls_033">P124</span></div>
<div style="position:absolute;left:50.00px;top:549.21px" class="cls_031"><span class="cls_031">gressive use of biologic treatments will mitigate the development</span></div>
<div style="position:absolute;left:306.64px;top:551.44px" class="cls_025"><span class="cls_025">IMPACT OF GUSELKUMAB VERSUS PLACEBO AND</span></div>
<div style="position:absolute;left:50.00px;top:559.20px" class="cls_031"><span class="cls_031">and/or progression of joint involvement, implying their willingness</span></div>
<div style="position:absolute;left:306.64px;top:562.34px" class="cls_025"><span class="cls_025">ADALIMUMAB ON PATIENT REPORTED OUTCOMES</span></div>
<div style="position:absolute;left:50.00px;top:569.20px" class="cls_031"><span class="cls_031">to manage their patients with PsA, particularly at early stages.</span></div>
<div style="position:absolute;left:306.64px;top:573.24px" class="cls_025"><span class="cls_025">IN PATIENTS WITH AND WITHOUT PSORIATIC</span></div>
<div style="position:absolute;left:306.64px;top:584.14px" class="cls_025"><span class="cls_025">ARTHRITIS IN VOYAGE 2</span></div>
<div style="position:absolute;left:50.00px;top:588.84px" class="cls_033"><span class="cls_033">P123</span></div>
<div style="position:absolute;left:306.64px;top:594.04px" class="cls_051"><span class="cls_051">Luis Puig</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Chenglong Han</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Ron Vender</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Michael Song</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Yin</span></div>
<div style="position:absolute;left:50.00px;top:600.24px" class="cls_025"><span class="cls_025">THE USE OF TUMOR NECROSIS FACTOR INHIBITORS</span></div>
<div style="position:absolute;left:306.64px;top:603.94px" class="cls_026"><span class="cls_026">You</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Yaung-Kaung Shen</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Peter Foley</span><span class="cls_027"><sup>4</sup></span></div>
<div style="position:absolute;left:50.00px;top:611.14px" class="cls_025"><span class="cls_025">(TNF) IN THE SECOND-LINE BIOLOGIC/SMALL</span></div>
<div style="position:absolute;left:306.64px;top:614.54px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Bar-</span></div>
<div style="position:absolute;left:50.00px;top:622.04px" class="cls_025"><span class="cls_025">MOLECULE SETTING: A CROSS-SPECIALTY</span></div>
<div style="position:absolute;left:306.63px;top:624.14px" class="cls_029"><span class="cls_029">celona Medical School, Barcelona, Spain, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Janssen Research & Develop-</span></div>
<div style="position:absolute;left:50.00px;top:632.94px" class="cls_025"><span class="cls_025">COMPARISON</span></div>
<div style="position:absolute;left:306.64px;top:633.74px" class="cls_029"><span class="cls_029">ment, LLC, Spring House, PA, USA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">McMaster University, Hamilton, ON,</span></div>
<div style="position:absolute;left:50.00px;top:642.84px" class="cls_051"><span class="cls_051">Lynn Price</span><span class="cls_026">, Jennifer Robinson, Gianna Melendez</span></div>
<div style="position:absolute;left:306.63px;top:643.34px" class="cls_029"><span class="cls_029">Canada, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">University of Melbourne, St. Vincent’s Hospital, Melbourne and</span></div>
<div style="position:absolute;left:50.00px;top:653.44px" class="cls_029"><span class="cls_029">Spherix Global Insights</span></div>
<div style="position:absolute;left:306.64px;top:652.94px" class="cls_029"><span class="cls_029">Skin & Cancer Foundation Inc., Carlton, Victoria, Australia</span></div>
<div style="position:absolute;left:50.00px;top:664.31px" class="cls_031"><span class="cls_031">TNF therapy has been the standard of care for adult patients</span></div>
<div style="position:absolute;left:306.64px;top:663.81px" class="cls_030"><span class="cls_030">Introduction/Objective:</span><span class="cls_031">VOYAGE 2 is a phase 3 double-blind,</span></div>
<div style="position:absolute;left:50.00px;top:674.30px" class="cls_031"><span class="cls_031">diagnosed with autoimmune conditions, resulting in familiarity,</span></div>
<div style="position:absolute;left:306.64px;top:673.80px" class="cls_031"><span class="cls_031">placebo/active comparator-controlled trial comparing guselkumab</span></div>
<div style="position:absolute;left:50.00px;top:684.30px" class="cls_031"><span class="cls_031">comfort, and satisfaction among physicians. TNFs are typically</span></div>
<div style="position:absolute;left:306.64px;top:683.80px" class="cls_031"><span class="cls_031">(GUS) with placebo (PBO) and adalimumab (ADA) in patients</span></div>
<div style="position:absolute;left:50.00px;top:694.30px" class="cls_031"><span class="cls_031">used as a first-line biologic/small molecule in the treatment of</span></div>
<div style="position:absolute;left:306.64px;top:693.80px" class="cls_031"><span class="cls_031">(pts) with moderate-to-severe PsO. The impact of treatment on</span></div>
<div style="position:absolute;left:50.01px;top:704.30px" class="cls_031"><span class="cls_031">psoriasis (PSO) and psoriatic arthritis (PsA). However, the adop-</span></div>
<div style="position:absolute;left:306.64px;top:703.80px" class="cls_031"><span class="cls_031">patient-reported outcomes (PROs) was evaluated.</span></div>
<div style="position:absolute;left:50.00px;top:714.31px" class="cls_031"><span class="cls_031">tion of agents with alternate mechanisms of action (AMOA) has</span></div>
<div style="position:absolute;left:306.64px;top:713.80px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Pts were randomized to GUS 100mg (wks 0 & 4, then</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:40953px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background53.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">51</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">q8wks), ADA (80 mg wk 0, 40 mg wk 1, then 40 mg q2 wks),</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">n = </span><span class="cls_031">50). The group of patients with PsA was older than the group</span></div>
<div style="position:absolute;left:50.00px;top:61.40px" class="cls_031"><span class="cls_031">or PBO (wks 0, 4, & 12, then GUS 100 mg wks 16 & 20). We</span></div>
<div style="position:absolute;left:306.64px;top:61.49px" class="cls_031"><span class="cls_031">PsO patients by age. PASI </span><span class="cls_030"> > </span><span class="cls_031"> 10. The quality of life was assessed</span></div>
<div style="position:absolute;left:50.00px;top:71.40px" class="cls_031"><span class="cls_031">evaluated PROs using the Work Limitations Questionnaire [WLQ;</span></div>
<div style="position:absolute;left:306.64px;top:71.56px" class="cls_031"><span class="cls_031">using the Dermatology Life Quality Index (DLQI) questionnaire.</span></div>
<div style="position:absolute;left:50.00px;top:81.40px" class="cls_031"><span class="cls_031">work productivity], the Hospital Anxiety & Depression Scale</span></div>
<div style="position:absolute;left:306.64px;top:81.63px" class="cls_031"><span class="cls_031">The results were evaluated: from 0 to 1 score - cutaneous disease</span></div>
<div style="position:absolute;left:50.00px;top:91.40px" class="cls_031"><span class="cls_031">[HADS], and the Medical Outcomes Study 36-Item Short Form</span></div>
<div style="position:absolute;left:306.64px;top:91.70px" class="cls_031"><span class="cls_031">does not affect the patient's life, from 2 to 5 scores - the disease</span></div>
<div style="position:absolute;left:50.00px;top:101.40px" class="cls_031"><span class="cls_031">(SF-36; health related quality of life) at wk16 (GUS vs PBO) and</span></div>
<div style="position:absolute;left:306.64px;top:101.77px" class="cls_031"><span class="cls_031">has a minor effect on the patient's life, from 6 to 10 scores - the</span></div>
<div style="position:absolute;left:50.00px;top:111.40px" class="cls_031"><span class="cls_031">wk24 (GUS vs ADA) in pts with and without PsA.</span></div>
<div style="position:absolute;left:306.64px;top:111.84px" class="cls_031"><span class="cls_031">disease has a moderate effect on the patient's life, from 11 to 20</span></div>
<div style="position:absolute;left:50.00px;top:121.40px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">In all, 18% of pts reported a history of PsA. At wk16,</span></div>
<div style="position:absolute;left:306.64px;top:121.91px" class="cls_031"><span class="cls_031">scores - the disease has a very strong effect on the patient's life,</span></div>
<div style="position:absolute;left:50.00px;top:131.40px" class="cls_031"><span class="cls_031">GUS pts had numerically greater improvements vs PBO in work</span></div>
<div style="position:absolute;left:306.64px;top:131.98px" class="cls_031"><span class="cls_031">from 21 to 30 scores - the disease has an extremely strong effect</span></div>
<div style="position:absolute;left:50.00px;top:141.40px" class="cls_031"><span class="cls_031">productivity, anxiety and depression, and SF-36 PCS & MCS</span></div>
<div style="position:absolute;left:306.64px;top:142.05px" class="cls_031"><span class="cls_031">on the patient's life. Statistical processing of the data was carried</span></div>
<div style="position:absolute;left:50.00px;top:151.40px" class="cls_031"><span class="cls_031">scores regardless of PsA status. The least square (LS) mean dif-</span></div>
<div style="position:absolute;left:306.64px;top:152.12px" class="cls_031"><span class="cls_031">out using the Excel analysis package. All </span><span class="cls_030">p &lt; </span><span class="cls_031">0.05 were considered</span></div>
<div style="position:absolute;left:50.00px;top:161.41px" class="cls_031"><span class="cls_031">ferences (95% CI; adjusted for baseline value) for GUS vs PBO</span></div>
<div style="position:absolute;left:306.64px;top:162.20px" class="cls_031"><span class="cls_031">to indicate statistical significance.</span></div>
<div style="position:absolute;left:50.00px;top:171.40px" class="cls_031"><span class="cls_031">for all PROs were generally similar between pts with and without</span></div>
<div style="position:absolute;left:306.64px;top:172.27px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">120 (100%) patients suffering from PsO were taken for</span></div>
<div style="position:absolute;left:50.00px;top:181.40px" class="cls_031"><span class="cls_031">PsA. At wk24, GUS pts had numerically greater improvements</span></div>
<div style="position:absolute;left:306.64px;top:182.34px" class="cls_031"><span class="cls_031">analysis. The duration of PsO was: for more than 15 years - 25</span></div>
<div style="position:absolute;left:50.00px;top:191.40px" class="cls_031"><span class="cls_031">vs ADA in all PROs regardless of PsA status. The LS mean dif-</span></div>
<div style="position:absolute;left:306.64px;top:192.41px" class="cls_031"><span class="cls_031">people (35.7%), 10-15 years - 18 people (25.7%); 3-10 years -</span></div>
<div style="position:absolute;left:50.00px;top:201.41px" class="cls_031"><span class="cls_031">ferences for GUS vs ADA were generally greater for pts with PsA</span></div>
<div style="position:absolute;left:306.64px;top:202.48px" class="cls_031"><span class="cls_031">15 people (21.4%), 1-3 years - 12 people (17.1%). The duration</span></div>
<div style="position:absolute;left:50.00px;top:211.40px" class="cls_031"><span class="cls_031">vs pts without PsA (Table).</span></div>
<div style="position:absolute;left:306.64px;top:212.55px" class="cls_031"><span class="cls_031">of PsA was: for more than 15 years - 5 people (10.0%), 10-15</span></div>
<div style="position:absolute;left:50.00px;top:221.40px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">GUS showed better improvements in all PROs vs</span></div>
<div style="position:absolute;left:306.64px;top:222.62px" class="cls_031"><span class="cls_031">years - 7 people (14.0%); 3-10 years - 20 people (40.0%), 1-3</span></div>
<div style="position:absolute;left:50.00px;top:231.40px" class="cls_031"><span class="cls_031">PBO at wk16 and vs ADA at wk24. Improvements vs PBO were</span></div>
<div style="position:absolute;left:306.64px;top:232.69px" class="cls_031"><span class="cls_031">years - 18 people (36.0%). Heredity was aggravated in 35 (29.1%)</span></div>
<div style="position:absolute;left:50.00px;top:241.40px" class="cls_031"><span class="cls_031">similar regardless of PsA status, while improvements vs ADA</span></div>
<div style="position:absolute;left:306.64px;top:242.76px" class="cls_031"><span class="cls_031">out of 120 patients. Comorbidity was presented in 112 (93.3%) out</span></div>
<div style="position:absolute;left:50.00px;top:251.40px" class="cls_031"><span class="cls_031">were greater for pts with PsA.</span></div>
<div style="position:absolute;left:306.64px;top:252.83px" class="cls_031"><span class="cls_031">of 120 patients. Gastrointestinal and liver diseases were found in</span></div>
<div style="position:absolute;left:50.00px;top:263.44px" class="cls_036"><span class="cls_036">Table: Summary of Change from Baseline in WLQ, HADS and SF-36 Scores from</span></div>
<div style="position:absolute;left:306.64px;top:262.91px" class="cls_031"><span class="cls_031">48 (42.8%) out of 120 patients. Type 2 diabetes was observed in</span></div>
<div style="position:absolute;left:50.00px;top:273.44px" class="cls_036"><span class="cls_036">VOYAGE 2</span></div>
<div style="position:absolute;left:306.64px;top:272.98px" class="cls_031"><span class="cls_031">45 (40.1%) out of 120 patients, cardiovascular diseases - in 100</span></div>
<div style="position:absolute;left:91.36px;top:284.54px" class="cls_036"><span class="cls_036">Week 16 GUS vs PBO</span></div>
<div style="position:absolute;left:194.75px;top:284.54px" class="cls_036"><span class="cls_036">Week 24 GUS vs ADA</span></div>
<div style="position:absolute;left:306.64px;top:283.05px" class="cls_031"><span class="cls_031">(89.2%) out of 120 patients, diseases of the nervous system - in 59</span></div>
<div style="position:absolute;left:91.36px;top:293.39px" class="cls_036"><span class="cls_036">w/ PSA</span></div>
<div style="position:absolute;left:142.37px;top:293.39px" class="cls_036"><span class="cls_036">w/out PSA</span></div>
<div style="position:absolute;left:194.75px;top:293.39px" class="cls_036"><span class="cls_036">w/ PSA</span></div>
<div style="position:absolute;left:241.76px;top:293.39px" class="cls_036"><span class="cls_036">w/out PSA</span></div>
<div style="position:absolute;left:306.64px;top:293.12px" class="cls_031"><span class="cls_031">(52.6%) out of 120 patients, and diseases of the urinary system - in</span></div>
<div style="position:absolute;left:91.37px;top:302.25px" class="cls_036"><span class="cls_036">N,</span></div>
<div style="position:absolute;left:142.37px;top:302.25px" class="cls_036"><span class="cls_036">N,</span></div>
<div style="position:absolute;left:194.76px;top:302.25px" class="cls_036"><span class="cls_036">N,</span></div>
<div style="position:absolute;left:241.76px;top:302.25px" class="cls_036"><span class="cls_036">N,</span></div>
<div style="position:absolute;left:306.64px;top:303.19px" class="cls_031"><span class="cls_031">20 (17.8%) out of 120 patients.</span></div>
<div style="position:absolute;left:91.37px;top:309.25px" class="cls_036"><span class="cls_036">LSMean</span></div>
<div style="position:absolute;left:142.37px;top:309.25px" class="cls_036"><span class="cls_036">LSMean</span></div>
<div style="position:absolute;left:194.76px;top:309.25px" class="cls_036"><span class="cls_036">LSMean</span></div>
<div style="position:absolute;left:241.76px;top:309.25px" class="cls_036"><span class="cls_036">LSMean</span></div>
<div style="position:absolute;left:91.37px;top:316.25px" class="cls_036"><span class="cls_036">Diff</span></div>
<div style="position:absolute;left:142.37px;top:316.25px" class="cls_036"><span class="cls_036">Diff</span></div>
<div style="position:absolute;left:194.76px;top:316.25px" class="cls_036"><span class="cls_036">Diff</span></div>
<div style="position:absolute;left:241.76px;top:316.25px" class="cls_036"><span class="cls_036">Diff</span></div>
<div style="position:absolute;left:306.64px;top:313.26px" class="cls_031"><span class="cls_031">The total score DLQI in the psoriasis group was 15.8</span><span class="cls_035">±</span><span class="cls_031">5.2. The</span></div>
<div style="position:absolute;left:91.37px;top:323.25px" class="cls_036"><span class="cls_036">(95%</span></div>
<div style="position:absolute;left:142.37px;top:323.25px" class="cls_036"><span class="cls_036">(95%</span></div>
<div style="position:absolute;left:194.76px;top:323.25px" class="cls_036"><span class="cls_036">(95%</span></div>
<div style="position:absolute;left:222.76px;top:323.25px" class="cls_036"><span class="cls_036">p-</span></div>
<div style="position:absolute;left:241.76px;top:323.25px" class="cls_036"><span class="cls_036">(95%</span></div>
<div style="position:absolute;left:269.76px;top:323.25px" class="cls_036"><span class="cls_036">p-</span></div>
<div style="position:absolute;left:306.64px;top:323.36px" class="cls_031"><span class="cls_031">score DLQI in PsO patients was 12.5</span><span class="cls_035">±</span><span class="cls_031">3.4 and in PsA patients was</span></div>
<div style="position:absolute;left:91.37px;top:330.25px" class="cls_036"><span class="cls_036">CI)</span></div>
<div style="position:absolute;left:118.37px;top:330.25px" class="cls_036"><span class="cls_036">p-value</span></div>
<div style="position:absolute;left:142.37px;top:330.25px" class="cls_036"><span class="cls_036">CI)</span></div>
<div style="position:absolute;left:170.76px;top:330.25px" class="cls_036"><span class="cls_036">p-value</span></div>
<div style="position:absolute;left:194.76px;top:330.25px" class="cls_036"><span class="cls_036">CI)</span></div>
<div style="position:absolute;left:222.76px;top:330.25px" class="cls_036"><span class="cls_036">value</span></div>
<div style="position:absolute;left:241.76px;top:330.25px" class="cls_036"><span class="cls_036">CI)</span></div>
<div style="position:absolute;left:269.76px;top:330.25px" class="cls_036"><span class="cls_036">value</span></div>
<div style="position:absolute;left:306.64px;top:333.43px" class="cls_031"><span class="cls_031">20.4</span><span class="cls_035">±</span><span class="cls_031">3.7. The total score DLQI in PsO patients with comorbidity</span></div>
<div style="position:absolute;left:51.38px;top:339.42px" class="cls_037"><span class="cls_037">WLQ Physical 86, -7.1</span></div>
<div style="position:absolute;left:118.36px;top:339.43px" class="cls_037"><span class="cls_037">0.0249</span></div>
<div style="position:absolute;left:142.36px;top:339.43px" class="cls_037"><span class="cls_037">446, -7.7</span></div>
<div style="position:absolute;left:170.75px;top:339.43px" class="cls_038"><span class="cls_038">&lt; </span><span class="cls_037">0.0001 79, -1.6</span></div>
<div style="position:absolute;left:222.75px;top:339.44px" class="cls_037"><span class="cls_037">0.7152 445, -2.6</span></div>
<div style="position:absolute;left:269.75px;top:339.44px" class="cls_037"><span class="cls_037">0.0769</span></div>
<div style="position:absolute;left:51.38px;top:346.42px" class="cls_037"><span class="cls_037">Demands</span></div>
<div style="position:absolute;left:91.36px;top:346.42px" class="cls_037"><span class="cls_037">(-13.21,</span></div>
<div style="position:absolute;left:142.36px;top:346.43px" class="cls_037"><span class="cls_037">(-10.56,</span></div>
<div style="position:absolute;left:194.75px;top:346.43px" class="cls_037"><span class="cls_037">(-10.58,</span></div>
<div style="position:absolute;left:241.75px;top:346.44px" class="cls_037"><span class="cls_037">(-5.39,</span></div>
<div style="position:absolute;left:306.64px;top:343.51px" class="cls_031"><span class="cls_031">was 16.1</span><span class="cls_035">±</span><span class="cls_031">5.3.</span></div>
<div style="position:absolute;left:91.36px;top:353.42px" class="cls_037"><span class="cls_037">-0.92)</span></div>
<div style="position:absolute;left:142.36px;top:353.43px" class="cls_037"><span class="cls_037">-4.88)</span></div>
<div style="position:absolute;left:194.75px;top:353.44px" class="cls_037"><span class="cls_037">7.29)</span></div>
<div style="position:absolute;left:241.75px;top:353.44px" class="cls_037"><span class="cls_037">0.28)</span></div>
<div style="position:absolute;left:306.64px;top:353.58px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">The total score DLQI was significantly higher in</span></div>
<div style="position:absolute;left:51.38px;top:359.58px" class="cls_037"><span class="cls_037">WLQ Time</span></div>
<div style="position:absolute;left:91.36px;top:359.58px" class="cls_037"><span class="cls_037">85, -6.6</span></div>
<div style="position:absolute;left:118.36px;top:359.58px" class="cls_037"><span class="cls_037">0.1326</span></div>
<div style="position:absolute;left:142.36px;top:359.58px" class="cls_037"><span class="cls_037">419, -7.0</span></div>
<div style="position:absolute;left:170.75px;top:359.59px" class="cls_038"><span class="cls_038">&lt; </span><span class="cls_037">0.0001 79, -4.3</span></div>
<div style="position:absolute;left:222.75px;top:359.60px" class="cls_037"><span class="cls_037">0.3996 420, -0.6</span></div>
<div style="position:absolute;left:269.75px;top:359.60px" class="cls_037"><span class="cls_037">0.6931</span></div>
<div style="position:absolute;left:51.38px;top:366.58px" class="cls_037"><span class="cls_037">Management</span></div>
<div style="position:absolute;left:91.36px;top:366.58px" class="cls_037"><span class="cls_037">(-15.35,</span></div>
<div style="position:absolute;left:142.36px;top:366.59px" class="cls_037"><span class="cls_037">(-10.31,</span></div>
<div style="position:absolute;left:194.75px;top:366.59px" class="cls_037"><span class="cls_037">(-14.40,</span></div>
<div style="position:absolute;left:241.75px;top:366.60px" class="cls_037"><span class="cls_037">(-3.46,</span></div>
<div style="position:absolute;left:306.65px;top:363.65px" class="cls_031"><span class="cls_031">patients with PsA compare to PsO patients. This result revealed</span></div>
<div style="position:absolute;left:91.36px;top:373.58px" class="cls_037"><span class="cls_037">2.06)</span></div>
<div style="position:absolute;left:142.36px;top:373.59px" class="cls_037"><span class="cls_037">-3.79)</span></div>
<div style="position:absolute;left:194.75px;top:373.59px" class="cls_037"><span class="cls_037">5.81)</span></div>
<div style="position:absolute;left:241.75px;top:373.60px" class="cls_037"><span class="cls_037">2.30)</span></div>
<div style="position:absolute;left:306.65px;top:373.72px" class="cls_031"><span class="cls_031">the existence of an inferior quality of life for the PsO patients with</span></div>
<div style="position:absolute;left:51.38px;top:379.76px" class="cls_037"><span class="cls_037">WLQ Mental-</span></div>
<div style="position:absolute;left:91.36px;top:379.76px" class="cls_037"><span class="cls_037">83, -3.8</span></div>
<div style="position:absolute;left:118.36px;top:379.77px" class="cls_037"><span class="cls_037">0.2913</span></div>
<div style="position:absolute;left:142.36px;top:379.77px" class="cls_037"><span class="cls_037">439, -4.9</span></div>
<div style="position:absolute;left:170.75px;top:379.77px" class="cls_037"><span class="cls_037">0.0002</span></div>
<div style="position:absolute;left:194.75px;top:379.77px" class="cls_037"><span class="cls_037">78, -11.4</span></div>
<div style="position:absolute;left:222.75px;top:379.78px" class="cls_037"><span class="cls_037">0.0061 436, -1.5</span></div>
<div style="position:absolute;left:269.75px;top:379.79px" class="cls_037"><span class="cls_037">0.2569</span></div>
<div style="position:absolute;left:51.38px;top:386.76px" class="cls_037"><span class="cls_037">Interpersonal</span></div>
<div style="position:absolute;left:91.36px;top:386.76px" class="cls_037"><span class="cls_037">(-11.03,</span></div>
<div style="position:absolute;left:142.36px;top:386.77px" class="cls_037"><span class="cls_037">(-7.54,</span></div>
<div style="position:absolute;left:194.75px;top:386.78px" class="cls_037"><span class="cls_037">(-19.37,</span></div>
<div style="position:absolute;left:241.75px;top:386.78px" class="cls_037"><span class="cls_037">(-4.16,</span></div>
<div style="position:absolute;left:306.65px;top:383.79px" class="cls_031"><span class="cls_031">comorbidity disease, compared with pts without comorbidity di-</span></div>
<div style="position:absolute;left:91.36px;top:393.77px" class="cls_037"><span class="cls_037">3.35)</span></div>
<div style="position:absolute;left:142.36px;top:393.77px" class="cls_037"><span class="cls_037">-2.35)</span></div>
<div style="position:absolute;left:194.75px;top:393.78px" class="cls_037"><span class="cls_037">-3.34)</span></div>
<div style="position:absolute;left:241.75px;top:393.78px" class="cls_037"><span class="cls_037">1.11)</span></div>
<div style="position:absolute;left:306.64px;top:393.87px" class="cls_031"><span class="cls_031">sease. The score of DLQI is affected the development and progress</span></div>
<div style="position:absolute;left:51.38px;top:399.95px" class="cls_037"><span class="cls_037">WLQ Ouput</span></div>
<div style="position:absolute;left:91.36px;top:399.95px" class="cls_037"><span class="cls_037">84, -7.9</span></div>
<div style="position:absolute;left:118.36px;top:399.95px" class="cls_037"><span class="cls_037">0.0211</span></div>
<div style="position:absolute;left:142.36px;top:399.95px" class="cls_037"><span class="cls_037">440, -3.5</span></div>
<div style="position:absolute;left:170.75px;top:399.96px" class="cls_037"><span class="cls_037">0.0089</span></div>
<div style="position:absolute;left:194.75px;top:399.96px" class="cls_037"><span class="cls_037">79, -14.7</span></div>
<div style="position:absolute;left:222.75px;top:399.96px" class="cls_037"><span class="cls_037">0.0030 437, -1.2</span></div>
<div style="position:absolute;left:269.75px;top:399.97px" class="cls_037"><span class="cls_037">0.4136</span></div>
<div style="position:absolute;left:51.38px;top:406.95px" class="cls_037"><span class="cls_037">Demands</span></div>
<div style="position:absolute;left:91.36px;top:406.95px" class="cls_037"><span class="cls_037">(-14.51,</span></div>
<div style="position:absolute;left:142.36px;top:406.95px" class="cls_037"><span class="cls_037">(-6.11,</span></div>
<div style="position:absolute;left:194.75px;top:406.96px" class="cls_037"><span class="cls_037">(-24.29,</span></div>
<div style="position:absolute;left:241.75px;top:406.97px" class="cls_037"><span class="cls_037">(-3.94,</span></div>
<div style="position:absolute;left:306.64px;top:403.94px" class="cls_031"><span class="cls_031">of the psoriasis and comorbidity pathology. Then higher DLQI</span></div>
<div style="position:absolute;left:91.36px;top:413.95px" class="cls_037"><span class="cls_037">-1.21)</span></div>
<div style="position:absolute;left:142.36px;top:413.96px" class="cls_037"><span class="cls_037">-0.88)</span></div>
<div style="position:absolute;left:194.75px;top:413.96px" class="cls_037"><span class="cls_037">-5.17)</span></div>
<div style="position:absolute;left:241.75px;top:413.97px" class="cls_037"><span class="cls_037">1.62)</span></div>
<div style="position:absolute;left:306.64px;top:414.01px" class="cls_031"><span class="cls_031">value, the more it affects experience considerable physical and/</span></div>
<div style="position:absolute;left:51.38px;top:420.06px" class="cls_037"><span class="cls_037">Anxiety</span></div>
<div style="position:absolute;left:91.36px;top:420.06px" class="cls_037"><span class="cls_037">135, -1.2</span></div>
<div style="position:absolute;left:118.36px;top:420.07px" class="cls_037"><span class="cls_037">0.0584</span></div>
<div style="position:absolute;left:142.36px;top:420.07px" class="cls_037"><span class="cls_037">608, -1.6</span></div>
<div style="position:absolute;left:170.75px;top:420.07px" class="cls_038"><span class="cls_038">&lt; </span><span class="cls_037">0.0001 133, -2.1</span></div>
<div style="position:absolute;left:222.75px;top:420.08px" class="cls_037"><span class="cls_037">0.0012 608, -0.8</span></div>
<div style="position:absolute;left:269.75px;top:420.08px" class="cls_037"><span class="cls_037">0.0025</span></div>
<div style="position:absolute;left:51.38px;top:427.06px" class="cls_037"><span class="cls_037">Score</span></div>
<div style="position:absolute;left:91.36px;top:427.06px" class="cls_037"><span class="cls_037">(-2.45,</span></div>
<div style="position:absolute;left:142.36px;top:427.07px" class="cls_037"><span class="cls_037">(-2.05,</span></div>
<div style="position:absolute;left:194.75px;top:427.07px" class="cls_037"><span class="cls_037">(-3.33,</span></div>
<div style="position:absolute;left:241.75px;top:427.08px" class="cls_037"><span class="cls_037">(-1.29,</span></div>
<div style="position:absolute;left:306.64px;top:424.08px" class="cls_031"><span class="cls_031">or psychological discomfort, difficulties in social and professional</span></div>
<div style="position:absolute;left:91.36px;top:434.06px" class="cls_037"><span class="cls_037">0.04)</span></div>
<div style="position:absolute;left:142.36px;top:434.07px" class="cls_037"><span class="cls_037">-1.07)</span></div>
<div style="position:absolute;left:194.75px;top:434.08px" class="cls_037"><span class="cls_037">-0.83)</span></div>
<div style="position:absolute;left:241.75px;top:434.08px" class="cls_037"><span class="cls_037">-0.28)</span></div>
<div style="position:absolute;left:306.66px;top:434.15px" class="cls_031"><span class="cls_031">adaptation, which subsequently cause significant distress and even</span></div>
<div style="position:absolute;left:51.38px;top:440.22px" class="cls_037"><span class="cls_037">Depression</span></div>
<div style="position:absolute;left:91.36px;top:440.22px" class="cls_037"><span class="cls_037">135, -1.2</span></div>
<div style="position:absolute;left:118.36px;top:440.23px" class="cls_037"><span class="cls_037">0.0611</span></div>
<div style="position:absolute;left:142.36px;top:440.23px" class="cls_037"><span class="cls_037">608, -1.5</span></div>
<div style="position:absolute;left:170.75px;top:440.23px" class="cls_038"><span class="cls_038">&lt; </span><span class="cls_037">0.0001 133, -1.5</span></div>
<div style="position:absolute;left:222.75px;top:440.24px" class="cls_037"><span class="cls_037">0.0374 608, -0.4</span></div>
<div style="position:absolute;left:269.75px;top:440.24px" class="cls_037"><span class="cls_037">0.1158</span></div>
<div style="position:absolute;left:51.38px;top:447.22px" class="cls_037"><span class="cls_037">Score</span></div>
<div style="position:absolute;left:91.36px;top:447.22px" class="cls_037"><span class="cls_037">(-2.55,</span></div>
<div style="position:absolute;left:142.36px;top:447.23px" class="cls_037"><span class="cls_037">(-1.96,</span></div>
<div style="position:absolute;left:194.75px;top:447.23px" class="cls_037"><span class="cls_037">(-2.85,</span></div>
<div style="position:absolute;left:241.75px;top:447.24px" class="cls_037"><span class="cls_037">(-0.91,</span></div>
<div style="position:absolute;left:306.66px;top:444.22px" class="cls_031"><span class="cls_031">social phobia. All these conditions psoriasis are interrelated by</span></div>
<div style="position:absolute;left:91.36px;top:454.22px" class="cls_037"><span class="cls_037">0.06)</span></div>
<div style="position:absolute;left:142.36px;top:454.23px" class="cls_037"><span class="cls_037">-0.98)</span></div>
<div style="position:absolute;left:194.75px;top:454.24px" class="cls_037"><span class="cls_037">-0.09)</span></div>
<div style="position:absolute;left:241.75px;top:454.24px" class="cls_037"><span class="cls_037">0.10)</span></div>
<div style="position:absolute;left:306.66px;top:454.29px" class="cls_031"><span class="cls_031">genetic and immunopathogenetic mechanisms. Thus, patients with</span></div>
<div style="position:absolute;left:51.38px;top:460.40px" class="cls_037"><span class="cls_037">SF-36 Physical 135, 5.7</span></div>
<div style="position:absolute;left:118.36px;top:460.41px" class="cls_038"><span class="cls_038">&lt; </span><span class="cls_037">0.0001 607, 4.4</span></div>
<div style="position:absolute;left:170.75px;top:460.42px" class="cls_038"><span class="cls_038">&lt; </span><span class="cls_037">0.0001 132, 2.9</span></div>
<div style="position:absolute;left:222.75px;top:460.42px" class="cls_037"><span class="cls_037">0.0346 608, 1.0</span></div>
<div style="position:absolute;left:269.75px;top:460.43px" class="cls_037"><span class="cls_037">0.0753</span></div>
<div style="position:absolute;left:51.38px;top:467.41px" class="cls_037"><span class="cls_037">Score</span></div>
<div style="position:absolute;left:91.36px;top:467.41px" class="cls_037"><span class="cls_037">(2.94,</span></div>
<div style="position:absolute;left:142.36px;top:467.41px" class="cls_037"><span class="cls_037">(3.31,</span></div>
<div style="position:absolute;left:194.75px;top:467.42px" class="cls_037"><span class="cls_037">(0.21,</span></div>
<div style="position:absolute;left:241.75px;top:467.42px" class="cls_037"><span class="cls_037">(-0.10,</span></div>
<div style="position:absolute;left:306.66px;top:464.36px" class="cls_031"><span class="cls_031">psoriasis require an integrated approach and dynamic observation</span></div>
<div style="position:absolute;left:91.36px;top:474.41px" class="cls_037"><span class="cls_037">8.43)</span></div>
<div style="position:absolute;left:142.36px;top:474.41px" class="cls_037"><span class="cls_037">5.39)</span></div>
<div style="position:absolute;left:194.75px;top:474.42px" class="cls_037"><span class="cls_037">5.57)</span></div>
<div style="position:absolute;left:241.75px;top:474.43px" class="cls_037"><span class="cls_037">2.04)</span></div>
<div style="position:absolute;left:306.66px;top:474.44px" class="cls_031"><span class="cls_031">by dermatologists and doctors of related specialties.</span></div>
<div style="position:absolute;left:51.38px;top:480.59px" class="cls_037"><span class="cls_037">SF-36 Mental</span></div>
<div style="position:absolute;left:91.36px;top:480.59px" class="cls_037"><span class="cls_037">135, 4.5</span></div>
<div style="position:absolute;left:118.36px;top:480.59px" class="cls_037"><span class="cls_037">0.0026</span></div>
<div style="position:absolute;left:142.36px;top:480.59px" class="cls_037"><span class="cls_037">607, 4.8</span></div>
<div style="position:absolute;left:170.75px;top:480.60px" class="cls_038"><span class="cls_038">&lt; </span><span class="cls_037">0.0001 132, 3.2</span></div>
<div style="position:absolute;left:222.75px;top:480.61px" class="cls_037"><span class="cls_037">0.0591 608, 1.8</span></div>
<div style="position:absolute;left:269.75px;top:480.61px" class="cls_037"><span class="cls_037">0.0092</span></div>
<div style="position:absolute;left:51.38px;top:487.59px" class="cls_037"><span class="cls_037">Score</span></div>
<div style="position:absolute;left:91.36px;top:487.59px" class="cls_037"><span class="cls_037">(1.61,</span></div>
<div style="position:absolute;left:142.36px;top:487.60px" class="cls_037"><span class="cls_037">(3.53,</span></div>
<div style="position:absolute;left:194.75px;top:487.60px" class="cls_037"><span class="cls_037">(-0.12,</span></div>
<div style="position:absolute;left:241.75px;top:487.61px" class="cls_037"><span class="cls_037">(0.45,</span></div>
<div style="position:absolute;left:91.36px;top:494.59px" class="cls_037"><span class="cls_037">7.48)</span></div>
<div style="position:absolute;left:142.36px;top:494.60px" class="cls_037"><span class="cls_037">6.15)</span></div>
<div style="position:absolute;left:194.75px;top:494.60px" class="cls_037"><span class="cls_037">6.53)</span></div>
<div style="position:absolute;left:241.75px;top:494.61px" class="cls_037"><span class="cls_037">3.15)</span></div>
<div style="position:absolute;left:306.64px;top:494.15px" class="cls_033"><span class="cls_033">P126</span></div>
<div style="position:absolute;left:51.38px;top:501.77px" class="cls_037"><span class="cls_037">N is the sample size across two groups.</span></div>
<div style="position:absolute;left:306.64px;top:505.62px" class="cls_025"><span class="cls_025">EFFECTS OF MINDFULNESS-BASED COGNITIVE</span></div>
<div style="position:absolute;left:50.00px;top:515.67px" class="cls_033"><span class="cls_033">P125</span></div>
<div style="position:absolute;left:306.64px;top:516.59px" class="cls_025"><span class="cls_025">THERAPY ON SELF-REPORTED PSORIASIS AND</span></div>
<div style="position:absolute;left:50.00px;top:527.07px" class="cls_025"><span class="cls_025">THE DERMATOLOGY LIFE QUALITY INDEX IN</span></div>
<div style="position:absolute;left:306.64px;top:527.57px" class="cls_025"><span class="cls_025">PSYCHOLOGICAL SYMPTOMS</span></div>
<div style="position:absolute;left:50.00px;top:537.97px" class="cls_025"><span class="cls_025">RUSSIAN PATIENTS WITH PSORIASIS AND PSORIATIC</span></div>
<div style="position:absolute;left:306.64px;top:537.54px" class="cls_051"><span class="cls_051">Alan Maddock</span><span class="cls_026">, David Hevey</span></div>
<div style="position:absolute;left:50.00px;top:548.86px" class="cls_025"><span class="cls_025">ARTHRITIS.</span></div>
<div style="position:absolute;left:306.64px;top:548.21px" class="cls_029"><span class="cls_029">School of Psychology, Trinity College Dublin</span></div>
<div style="position:absolute;left:50.00px;top:558.76px" class="cls_051"><span class="cls_051">Nadezhda Batkaeva</span><span class="cls_026">, Edgem Batkaev, Muslimat Gitinova</span></div>
<div style="position:absolute;left:306.64px;top:559.15px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis can have a profound impact on a patient’s</span></div>
<div style="position:absolute;left:50.00px;top:569.37px" class="cls_029"><span class="cls_029">Peoples' Friendship University of Russia (RUDN University)</span></div>
<div style="position:absolute;left:306.64px;top:569.22px" class="cls_031"><span class="cls_031">life, with the prevalence of anxiety, depression, poor wellbeing</span></div>
<div style="position:absolute;left:50.00px;top:580.23px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">The most severe form of psoriasis is psoriatic arthritis</span></div>
<div style="position:absolute;left:306.64px;top:579.29px" class="cls_031"><span class="cls_031">and quality of life generally found to be high in psoriasis popula-</span></div>
<div style="position:absolute;left:50.00px;top:590.23px" class="cls_031"><span class="cls_031">(PsA), which belongs to the seronegative spondyloarthritis group,</span></div>
<div style="position:absolute;left:306.64px;top:589.37px" class="cls_031"><span class="cls_031">tions. Mindfulness based interventions have been shown to have</span></div>
<div style="position:absolute;left:50.00px;top:600.23px" class="cls_031"><span class="cls_031">characterized by chronic inflammation of the joints, spine, enthe-</span></div>
<div style="position:absolute;left:306.64px;top:599.44px" class="cls_031"><span class="cls_031">positive impacts on anxiety, depression, wellbeing and quality of</span></div>
<div style="position:absolute;left:50.00px;top:610.23px" class="cls_031"><span class="cls_031">sis. The frequency of PsA in the population is 0.06-1.4%. PSA is</span></div>
<div style="position:absolute;left:306.64px;top:609.51px" class="cls_031"><span class="cls_031">life in various populations.</span></div>
<div style="position:absolute;left:50.00px;top:620.23px" class="cls_031"><span class="cls_031">comparable to rheumatoid arthritis (RA) in terms of progression,</span></div>
<div style="position:absolute;left:306.64px;top:619.58px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">The aim of the present study was to investigate the ef-</span></div>
<div style="position:absolute;left:50.00px;top:630.23px" class="cls_031"><span class="cls_031">disability and quality of life (QOL) in patients.</span></div>
<div style="position:absolute;left:306.64px;top:629.66px" class="cls_031"><span class="cls_031">fect of mindfulness-based cognitive therapy (MBCT) on psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:640.23px" class="cls_030"><span class="cls_030">Objectives:</span><span class="cls_031"> Compare the quality of life index of patients with</span></div>
<div style="position:absolute;left:306.64px;top:639.73px" class="cls_031"><span class="cls_031">symptoms and psychological symptoms associated with psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:650.23px" class="cls_031"><span class="cls_031">severe forms of psoriasis (PsO) with psoriatic arthritis patients’</span></div>
<div style="position:absolute;left:306.64px;top:649.80px" class="cls_031"><span class="cls_031">including anxiety, depression, reduced wellbeing and QoL. The</span></div>
<div style="position:absolute;left:50.00px;top:660.23px" class="cls_031"><span class="cls_031">index.</span></div>
<div style="position:absolute;left:306.64px;top:659.87px" class="cls_031"><span class="cls_031">study also aimed to investigate if MBCT significantly impacted</span></div>
<div style="position:absolute;left:50.00px;top:670.23px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> 120 (100%) patients suffering from PsO and PsA</span></div>
<div style="position:absolute;left:306.64px;top:669.94px" class="cls_031"><span class="cls_031">the potential mediating variables of a new theory of mindfulness</span></div>
<div style="position:absolute;left:50.00px;top:680.23px" class="cls_031"><span class="cls_031">(Male-87/female - 33) were analyzed. 70 (54.2%) patients were</span></div>
<div style="position:absolute;left:306.64px;top:680.01px" class="cls_031"><span class="cls_031">mechanisms the ‘Clinically Modified Buddhist Psychological</span></div>
<div style="position:absolute;left:50.00px;top:690.22px" class="cls_031"><span class="cls_031">diagnosed PsO, 50 (41.7%) were diagnosed PsA. The average</span></div>
<div style="position:absolute;left:306.65px;top:690.08px" class="cls_031"><span class="cls_031">Model (CBPM)’, these variables being acceptance, mindfulness,</span></div>
<div style="position:absolute;left:50.00px;top:700.22px" class="cls_031"><span class="cls_031">age of patients with skin manifestations PsO was 54.0</span><span class="cls_035">±</span><span class="cls_031">14.2 years</span></div>
<div style="position:absolute;left:306.65px;top:700.15px" class="cls_031"><span class="cls_031">self-compassion, aversion, non-attachment, attention, rumination</span></div>
<div style="position:absolute;left:50.00px;top:710.23px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">n = </span><span class="cls_031">70). The average age of patients with PsA was 49.1</span><span class="cls_035">±</span><span class="cls_031">15.9 years</span></div>
<div style="position:absolute;left:306.65px;top:710.22px" class="cls_031"><span class="cls_031">and worry.</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:41756px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background54.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">52</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">101 participants were randomly allocated to a treatment</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">impact and treatment satisfaction in pts who report good commu-</span></div>
<div style="position:absolute;left:50.00px;top:61.46px" class="cls_031"><span class="cls_031">arm (MBCT) or a TAU arm. Participants were measured pre, post-</span></div>
<div style="position:absolute;left:306.64px;top:61.41px" class="cls_031"><span class="cls_031">nication with their HCP vs suboptimal communication.</span></div>
<div style="position:absolute;left:50.00px;top:71.50px" class="cls_031"><span class="cls_031">treatment and after a 3-month follow up period. Data were analysed</span></div>
<div style="position:absolute;left:306.64px;top:71.41px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">An online pt-based survey was conducted in the US</span></div>
<div style="position:absolute;left:50.00px;top:81.55px" class="cls_031"><span class="cls_031">using intention-to-treat analysis and the ANCOVA method with</span></div>
<div style="position:absolute;left:306.64px;top:81.41px" class="cls_031"><span class="cls_031">from 2 Nov-1 Dec 2017. Pts had reported having PsA for </span><span class="cls_030"> > </span><span class="cls_031">1</span></div>
<div style="position:absolute;left:50.00px;top:91.59px" class="cls_031"><span class="cls_031">baseline scores entered as covariates.</span></div>
<div style="position:absolute;left:306.64px;top:91.41px" class="cls_031"><span class="cls_031">year, taken ≥1 synthetic(s) or biologic(b) DMARD for PsA. Pts</span></div>
<div style="position:absolute;left:50.00px;top:101.63px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">There was a significant group×time (pre vs. post) interac-</span></div>
<div style="position:absolute;left:306.64px;top:101.41px" class="cls_031"><span class="cls_031">reported overall health, PsA severity/symptoms/life impact, tre-</span></div>
<div style="position:absolute;left:50.00px;top:111.67px" class="cls_031"><span class="cls_031">tion on all variables except QoL, indicating a significant reduction</span></div>
<div style="position:absolute;left:306.64px;top:111.41px" class="cls_031"><span class="cls_031">atment satisfaction and communication experience. We evaluated</span></div>
<div style="position:absolute;left:50.01px;top:121.72px" class="cls_031"><span class="cls_031">of each variable except QoL over time in the MBCT group, but not</span></div>
<div style="position:absolute;left:306.64px;top:121.41px" class="cls_031"><span class="cls_031">differences by pt-HCP communication status.</span></div>
<div style="position:absolute;left:50.01px;top:131.76px" class="cls_031"><span class="cls_031">in the control group. When baseline variables were controlled for,</span></div>
<div style="position:absolute;left:306.64px;top:131.41px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Overall, 301 pts with PsA responded, mean age 45 years,</span></div>
<div style="position:absolute;left:50.01px;top:141.80px" class="cls_031"><span class="cls_031">the participants in the MBCT group achieved small statistically</span></div>
<div style="position:absolute;left:306.64px;top:141.41px" class="cls_031"><span class="cls_031">61% female, 89% self-reported moderate/severe PsA. Current PsA</span></div>
<div style="position:absolute;left:50.01px;top:151.85px" class="cls_031"><span class="cls_031">significant changes across all variables post intervention versus</span></div>
<div style="position:absolute;left:306.64px;top:151.41px" class="cls_031"><span class="cls_031">treatments included bDMARD (52%), sDMARD (25%), combi-</span></div>
<div style="position:absolute;left:50.00px;top:161.89px" class="cls_031"><span class="cls_031">the TAU group.</span></div>
<div style="position:absolute;left:306.64px;top:161.41px" class="cls_031"><span class="cls_031">nation b/sDMARD (15%). Overall, 256 (85%) of PsA pts were</span></div>
<div style="position:absolute;left:50.00px;top:171.93px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">The results suggest that MBCT may be a useful ad-</span></div>
<div style="position:absolute;left:306.64px;top:171.41px" class="cls_031"><span class="cls_031">managed by a rheumatologist and 15% by a dermatologist. Of the</span></div>
<div style="position:absolute;left:50.00px;top:181.97px" class="cls_031"><span class="cls_031">junct therapy for those suffering from psoriasis and the associated</span></div>
<div style="position:absolute;left:306.64px;top:181.41px" class="cls_031"><span class="cls_031">256, </span><span class="cls_030"> > </span><span class="cls_031">40% reported suboptimal pt-HCP communication. Pts in</span></div>
<div style="position:absolute;left:50.00px;top:192.02px" class="cls_031"><span class="cls_031">psychological symptoms relating to the condition. The results</span></div>
<div style="position:absolute;left:306.64px;top:191.41px" class="cls_031"><span class="cls_031">the suboptimal vs good communication subgroups were typically</span></div>
<div style="position:absolute;left:50.00px;top:202.06px" class="cls_031"><span class="cls_031">also indicate that each of the mechanisms outlined in the CBPM</span></div>
<div style="position:absolute;left:306.64px;top:201.41px" class="cls_031"><span class="cls_031">younger, more likely to be Hispanic and reported greater life im-</span></div>
<div style="position:absolute;left:50.00px;top:212.11px" class="cls_031"><span class="cls_031">change significantly for patients who engage in the intervention.</span></div>
<div style="position:absolute;left:306.64px;top:211.41px" class="cls_031"><span class="cls_031">pact and lower satisfaction with pt-HCP communication (Table).</span></div>
<div style="position:absolute;left:308.01px;top:224.55px" class="cls_036"><span class="cls_036">Table. Pts with PsA managed by rheumatologist (</span><span class="cls_040">n = </span><span class="cls_036">256)</span></div>
<div style="position:absolute;left:50.00px;top:232.78px" class="cls_033"><span class="cls_033">P127</span></div>
<div style="position:absolute;left:406.64px;top:233.41px" class="cls_036"><span class="cls_036">“I worry that if I ask too</span></div>
<div style="position:absolute;left:406.64px;top:240.41px" class="cls_036"><span class="cls_036">many questions my healt-</span></div>
<div style="position:absolute;left:487.87px;top:240.41px" class="cls_036"><span class="cls_036">“I often tell my</span></div>
<div style="position:absolute;left:50.00px;top:244.22px" class="cls_025"><span class="cls_025">A MIXED METHODS STUDY EXPLORING THE</span></div>
<div style="position:absolute;left:406.64px;top:247.41px" class="cls_036"><span class="cls_036">hcare professional will see</span></div>
<div style="position:absolute;left:487.87px;top:247.41px" class="cls_036"><span class="cls_036">healthcare professi-</span></div>
<div style="position:absolute;left:406.64px;top:254.41px" class="cls_036"><span class="cls_036">me as a difficult patient and</span></div>
<div style="position:absolute;left:487.86px;top:254.41px" class="cls_036"><span class="cls_036">onal I am fine when</span></div>
<div style="position:absolute;left:50.00px;top:255.17px" class="cls_025"><span class="cls_025">IMPACT OF MINDFULNESS ON PSORIASIS, ANXIETY,</span></div>
<div style="position:absolute;left:406.64px;top:261.41px" class="cls_036"><span class="cls_036">it will affect the quality of</span></div>
<div style="position:absolute;left:487.85px;top:261.41px" class="cls_036"><span class="cls_036">I am really expe-</span></div>
<div style="position:absolute;left:50.00px;top:266.11px" class="cls_025"><span class="cls_025">DEPRESSION AND QOL</span></div>
<div style="position:absolute;left:406.64px;top:268.41px" class="cls_036"><span class="cls_036">care I receive”</span></div>
<div style="position:absolute;left:487.86px;top:268.41px" class="cls_036"><span class="cls_036">riencing symptoms”</span></div>
<div style="position:absolute;left:50.00px;top:276.06px" class="cls_051"><span class="cls_051">Alan Maddock</span><span class="cls_026">, David Hevey</span></div>
<div style="position:absolute;left:452.64px;top:277.26px" class="cls_036"><span class="cls_036">Disagree</span></div>
<div style="position:absolute;left:487.87px;top:277.26px" class="cls_036"><span class="cls_036">Agree</span></div>
<div style="position:absolute;left:514.87px;top:277.26px" class="cls_036"><span class="cls_036">Disagree</span></div>
<div style="position:absolute;left:406.64px;top:284.26px" class="cls_036"><span class="cls_036">Agree</span></div>
<div style="position:absolute;left:452.64px;top:284.26px" class="cls_040"><span class="cls_040">n = </span><span class="cls_036">151</span></div>
<div style="position:absolute;left:487.87px;top:284.26px" class="cls_040"><span class="cls_040">n = </span><span class="cls_036">118</span></div>
<div style="position:absolute;left:514.87px;top:284.26px" class="cls_040"><span class="cls_040">n = </span><span class="cls_036">138</span></div>
<div style="position:absolute;left:50.00px;top:286.69px" class="cls_029"><span class="cls_029">School of Psychology, Trinity College Dublin</span></div>
<div style="position:absolute;left:406.64px;top:291.26px" class="cls_040"><span class="cls_040">n = </span><span class="cls_036">105 (41%)</span></div>
<div style="position:absolute;left:452.64px;top:291.26px" class="cls_036"><span class="cls_036">(59%)</span></div>
<div style="position:absolute;left:487.87px;top:291.26px" class="cls_036"><span class="cls_036">(46%)</span></div>
<div style="position:absolute;left:514.87px;top:291.26px" class="cls_036"><span class="cls_036">(54%)</span></div>
<div style="position:absolute;left:50.00px;top:297.60px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is a common condition with recognised</span></div>
<div style="position:absolute;left:406.64px;top:298.26px" class="cls_036"><span class="cls_036">%</span></div>
<div style="position:absolute;left:452.64px;top:298.26px" class="cls_036"><span class="cls_036">%</span></div>
<div style="position:absolute;left:487.87px;top:298.26px" class="cls_036"><span class="cls_036">%</span></div>
<div style="position:absolute;left:514.87px;top:298.26px" class="cls_036"><span class="cls_036">%</span></div>
<div style="position:absolute;left:308.01px;top:307.44px" class="cls_037"><span class="cls_037">Mean age (years)</span></div>
<div style="position:absolute;left:406.64px;top:307.44px" class="cls_037"><span class="cls_037">41.9</span></div>
<div style="position:absolute;left:452.64px;top:307.44px" class="cls_037"><span class="cls_037">46.8*</span></div>
<div style="position:absolute;left:487.86px;top:307.44px" class="cls_037"><span class="cls_037">41.6</span></div>
<div style="position:absolute;left:514.86px;top:307.44px" class="cls_037"><span class="cls_037">47.5*</span></div>
<div style="position:absolute;left:50.00px;top:307.65px" class="cls_031"><span class="cls_031">psychological comorbidity. Psoriasis can have a profound impact</span></div>
<div style="position:absolute;left:308.01px;top:314.59px" class="cls_037"><span class="cls_037">White</span></div>
<div style="position:absolute;left:406.64px;top:314.60px" class="cls_037"><span class="cls_037">66</span></div>
<div style="position:absolute;left:452.64px;top:314.61px" class="cls_037"><span class="cls_037">73</span></div>
<div style="position:absolute;left:487.86px;top:314.61px" class="cls_037"><span class="cls_037">58</span></div>
<div style="position:absolute;left:514.86px;top:314.62px" class="cls_037"><span class="cls_037">80*</span></div>
<div style="position:absolute;left:50.00px;top:317.69px" class="cls_031"><span class="cls_031">on a patient’s life, with the prevalence of anxiety, depression, poor</span></div>
<div style="position:absolute;left:308.01px;top:321.60px" class="cls_037"><span class="cls_037">Hispanic</span></div>
<div style="position:absolute;left:406.64px;top:321.60px" class="cls_037"><span class="cls_037">20</span></div>
<div style="position:absolute;left:452.64px;top:321.61px" class="cls_037"><span class="cls_037">15</span></div>
<div style="position:absolute;left:487.86px;top:321.61px" class="cls_037"><span class="cls_037">26*</span></div>
<div style="position:absolute;left:514.86px;top:321.62px" class="cls_037"><span class="cls_037">9</span></div>
<div style="position:absolute;left:50.00px;top:327.74px" class="cls_031"><span class="cls_031">wellbeing and quality of life generally found to be high in psoriasis</span></div>
<div style="position:absolute;left:308.01px;top:328.60px" class="cls_037"><span class="cls_037">Black</span></div>
<div style="position:absolute;left:406.64px;top:328.60px" class="cls_037"><span class="cls_037">10</span></div>
<div style="position:absolute;left:452.64px;top:328.61px" class="cls_037"><span class="cls_037">7</span></div>
<div style="position:absolute;left:487.86px;top:328.62px" class="cls_037"><span class="cls_037">11</span></div>
<div style="position:absolute;left:514.86px;top:328.62px" class="cls_037"><span class="cls_037">7</span></div>
<div style="position:absolute;left:308.01px;top:334.78px" class="cls_037"><span class="cls_037">Symptoms in past 12 months</span></div>
<div style="position:absolute;left:406.64px;top:334.79px" class="cls_037"><span class="cls_037">85</span></div>
<div style="position:absolute;left:452.64px;top:334.80px" class="cls_037"><span class="cls_037">90</span></div>
<div style="position:absolute;left:487.86px;top:334.80px" class="cls_037"><span class="cls_037">86</span></div>
<div style="position:absolute;left:50.00px;top:337.78px" class="cls_031"><span class="cls_031">populations. Based on Buddhist psychology, mindfulness based</span></div>
<div style="position:absolute;left:308.01px;top:341.79px" class="cls_037"><span class="cls_037">Joint pain</span></div>
<div style="position:absolute;left:406.64px;top:341.79px" class="cls_037"><span class="cls_037">83</span></div>
<div style="position:absolute;left:452.64px;top:341.80px" class="cls_037"><span class="cls_037">84</span></div>
<div style="position:absolute;left:487.86px;top:341.80px" class="cls_037"><span class="cls_037">84</span></div>
<div style="position:absolute;left:514.86px;top:341.81px" class="cls_037"><span class="cls_037">89</span></div>
<div style="position:absolute;left:50.00px;top:347.82px" class="cls_031"><span class="cls_031">interventions have been shown to have positive impacts on anxiety,</span></div>
<div style="position:absolute;left:308.01px;top:348.79px" class="cls_037"><span class="cls_037">Skin/nail symptoms</span></div>
<div style="position:absolute;left:406.64px;top:348.79px" class="cls_037"><span class="cls_037">74</span></div>
<div style="position:absolute;left:452.64px;top:348.80px" class="cls_037"><span class="cls_037">79</span></div>
<div style="position:absolute;left:487.86px;top:348.81px" class="cls_037"><span class="cls_037">72</span></div>
<div style="position:absolute;left:514.86px;top:348.81px" class="cls_037"><span class="cls_037">83</span></div>
<div style="position:absolute;left:308.01px;top:355.79px" class="cls_037"><span class="cls_037">Stiffness</span></div>
<div style="position:absolute;left:406.64px;top:355.80px" class="cls_037"><span class="cls_037">70</span></div>
<div style="position:absolute;left:452.64px;top:355.80px" class="cls_037"><span class="cls_037">72</span></div>
<div style="position:absolute;left:487.86px;top:355.81px" class="cls_037"><span class="cls_037">75</span></div>
<div style="position:absolute;left:514.86px;top:355.81px" class="cls_037"><span class="cls_037">82</span></div>
<div style="position:absolute;left:50.00px;top:357.87px" class="cls_031"><span class="cls_031">depression, wellbeing and quality of life in various populations.</span></div>
<div style="position:absolute;left:309.56px;top:362.79px" class="cls_037"><span class="cls_037">Joint swelling</span></div>
<div style="position:absolute;left:514.86px;top:362.82px" class="cls_037"><span class="cls_037">68</span></div>
<div style="position:absolute;left:50.00px;top:367.91px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Mixed methods explored the impact of a mindfulness</span></div>
<div style="position:absolute;left:308.01px;top:368.98px" class="cls_037"><span class="cls_037">Moderate PsA</span></div>
<div style="position:absolute;left:406.64px;top:368.98px" class="cls_037"><span class="cls_037">70*</span></div>
<div style="position:absolute;left:452.64px;top:368.98px" class="cls_037"><span class="cls_037">55</span></div>
<div style="position:absolute;left:487.86px;top:368.98px" class="cls_037"><span class="cls_037">58</span></div>
<div style="position:absolute;left:514.86px;top:368.98px" class="cls_037"><span class="cls_037">64</span></div>
<div style="position:absolute;left:308.01px;top:375.14px" class="cls_037"><span class="cls_037">Severe PsA</span></div>
<div style="position:absolute;left:406.64px;top:375.14px" class="cls_037"><span class="cls_037">23</span></div>
<div style="position:absolute;left:452.64px;top:375.14px" class="cls_037"><span class="cls_037">32</span></div>
<div style="position:absolute;left:487.86px;top:375.14px" class="cls_037"><span class="cls_037">33</span></div>
<div style="position:absolute;left:514.86px;top:375.14px" class="cls_037"><span class="cls_037">25</span></div>
<div style="position:absolute;left:50.00px;top:377.96px" class="cls_031"><span class="cls_031">based cognitive therapy (MBCT) intervention on 10 psoriasis</span></div>
<div style="position:absolute;left:308.01px;top:381.30px" class="cls_037"><span class="cls_037">Reported impact on</span></div>
<div style="position:absolute;left:406.64px;top:381.31px" class="cls_037"><span class="cls_037">76*</span></div>
<div style="position:absolute;left:452.64px;top:381.32px" class="cls_037"><span class="cls_037">59</span></div>
<div style="position:absolute;left:487.86px;top:381.33px" class="cls_037"><span class="cls_037">78*</span></div>
<div style="position:absolute;left:514.86px;top:381.33px" class="cls_037"><span class="cls_037">56</span></div>
<div style="position:absolute;left:308.01px;top:388.30px" class="cls_037"><span class="cls_037">-emotional well being</span></div>
<div style="position:absolute;left:406.64px;top:388.32px" class="cls_037"><span class="cls_037">69*</span></div>
<div style="position:absolute;left:452.64px;top:388.32px" class="cls_037"><span class="cls_037">56</span></div>
<div style="position:absolute;left:487.86px;top:388.33px" class="cls_037"><span class="cls_037">69*</span></div>
<div style="position:absolute;left:514.86px;top:388.33px" class="cls_037"><span class="cls_037">54</span></div>
<div style="position:absolute;left:50.00px;top:388.00px" class="cls_031"><span class="cls_031">patients using a Buddhist Psychological Model (BPM) as a</span></div>
<div style="position:absolute;left:308.01px;top:395.31px" class="cls_037"><span class="cls_037">-work productivity</span></div>
<div style="position:absolute;left:406.64px;top:395.32px" class="cls_037"><span class="cls_037">67*</span></div>
<div style="position:absolute;left:452.64px;top:395.32px" class="cls_037"><span class="cls_037">48</span></div>
<div style="position:absolute;left:487.86px;top:395.33px" class="cls_037"><span class="cls_037">66*</span></div>
<div style="position:absolute;left:514.86px;top:395.34px" class="cls_037"><span class="cls_037">46</span></div>
<div style="position:absolute;left:50.00px;top:398.04px" class="cls_031"><span class="cls_031">theoretical framework to understand changes in these variables.</span></div>
<div style="position:absolute;left:308.01px;top:402.31px" class="cls_037"><span class="cls_037">-romance/intimacy</span></div>
<div style="position:absolute;left:406.64px;top:402.32px" class="cls_037"><span class="cls_037">40*</span></div>
<div style="position:absolute;left:452.64px;top:402.33px" class="cls_037"><span class="cls_037">24</span></div>
<div style="position:absolute;left:487.86px;top:402.33px" class="cls_037"><span class="cls_037">42*</span></div>
<div style="position:absolute;left:514.86px;top:402.34px" class="cls_037"><span class="cls_037">21</span></div>
<div style="position:absolute;left:50.00px;top:408.08px" class="cls_031"><span class="cls_031">Quantitative measures of acceptance, attention regulation, at-</span></div>
<div style="position:absolute;left:308.01px;top:409.31px" class="cls_037"><span class="cls_037">-decision to start family</span></div>
<div style="position:absolute;left:406.64px;top:409.32px" class="cls_037"><span class="cls_037">35*</span></div>
<div style="position:absolute;left:452.64px;top:409.33px" class="cls_037"><span class="cls_037">17</span></div>
<div style="position:absolute;left:487.86px;top:409.33px" class="cls_037"><span class="cls_037">36*</span></div>
<div style="position:absolute;left:514.86px;top:409.34px" class="cls_037"><span class="cls_037">15</span></div>
<div style="position:absolute;left:308.01px;top:416.31px" class="cls_037"><span class="cls_037">-education</span></div>
<div style="position:absolute;left:50.00px;top:418.12px" class="cls_031"><span class="cls_031">tachment, aversion, self-compassion, mindfulness, rumination,</span></div>
<div style="position:absolute;left:308.01px;top:422.50px" class="cls_037"><span class="cls_037">Very satisfied with HCP communication 43</span></div>
<div style="position:absolute;left:452.64px;top:422.50px" class="cls_037"><span class="cls_037">75*</span></div>
<div style="position:absolute;left:487.86px;top:422.50px" class="cls_037"><span class="cls_037">52</span></div>
<div style="position:absolute;left:514.86px;top:422.50px" class="cls_037"><span class="cls_037">71*</span></div>
<div style="position:absolute;left:308.01px;top:428.66px" class="cls_037"><span class="cls_037">Very satisfied with treatment</span></div>
<div style="position:absolute;left:406.64px;top:428.66px" class="cls_037"><span class="cls_037">29</span></div>
<div style="position:absolute;left:452.64px;top:428.66px" class="cls_037"><span class="cls_037">45*</span></div>
<div style="position:absolute;left:487.86px;top:428.66px" class="cls_037"><span class="cls_037">36</span></div>
<div style="position:absolute;left:514.86px;top:428.66px" class="cls_037"><span class="cls_037">40</span></div>
<div style="position:absolute;left:50.00px;top:428.16px" class="cls_031"><span class="cls_031">worry, wellbeing, anxiety, depression and psoriasis symptoms</span></div>
<div style="position:absolute;left:308.01px;top:434.82px" class="cls_037"><span class="cls_037">Stopped taking treatment</span></div>
<div style="position:absolute;left:406.64px;top:434.82px" class="cls_037"><span class="cls_037">22*</span></div>
<div style="position:absolute;left:452.64px;top:434.82px" class="cls_037"><span class="cls_037">8</span></div>
<div style="position:absolute;left:487.86px;top:434.82px" class="cls_037"><span class="cls_037">19*</span></div>
<div style="position:absolute;left:514.86px;top:434.82px" class="cls_037"><span class="cls_037">9</span></div>
<div style="position:absolute;left:50.00px;top:438.21px" class="cls_031"><span class="cls_031">were completed pre and post intervention, and participants were</span></div>
<div style="position:absolute;left:306.64px;top:443.07px" class="cls_037"><span class="cls_037">*</span><span class="cls_038">p &lt; </span><span class="cls_037">0.05</span></div>
<div style="position:absolute;left:50.00px;top:448.25px" class="cls_031"><span class="cls_031">interviewed about their experiences of MBCT.</span></div>
<div style="position:absolute;left:306.64px;top:450.92px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Pts who reported suboptimal communication with</span></div>
<div style="position:absolute;left:50.00px;top:458.30px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Statistically significant changes in attention, mindfulness,</span></div>
<div style="position:absolute;left:306.64px;top:460.92px" class="cls_031"><span class="cls_031">their HCP may have greater healthcare needs for their PsA vs</span></div>
<div style="position:absolute;left:49.99px;top:468.34px" class="cls_031"><span class="cls_031">attachment, aversion, rumination, quality of life, anxiety and</span></div>
<div style="position:absolute;left:306.64px;top:470.92px" class="cls_031"><span class="cls_031">other pts.</span></div>
<div style="position:absolute;left:49.99px;top:478.38px" class="cls_031"><span class="cls_031">psoriasis were found. The qualitative data provided support for</span></div>
<div style="position:absolute;left:49.99px;top:488.43px" class="cls_031"><span class="cls_031">the BPM as a theoretical lens with which to understand the way</span></div>
<div style="position:absolute;left:306.64px;top:489.56px" class="cls_033"><span class="cls_033">P129</span></div>
<div style="position:absolute;left:49.99px;top:498.47px" class="cls_031"><span class="cls_031">in which mindfulness impacts on patient quality of life, anxiety</span></div>
<div style="position:absolute;left:306.64px;top:500.96px" class="cls_025"><span class="cls_025">PSORIASIS PATIENTS POINT OF VIEW: WHAT ARE WE</span></div>
<div style="position:absolute;left:49.99px;top:508.52px" class="cls_031"><span class="cls_031">and psoriasis symptoms.</span></div>
<div style="position:absolute;left:306.64px;top:511.86px" class="cls_025"><span class="cls_025">MISSING WHEN MANAGING THEM?</span></div>
<div style="position:absolute;left:49.99px;top:518.56px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">This study gives support to the promising potential</span></div>
<div style="position:absolute;left:306.64px;top:521.76px" class="cls_026"><span class="cls_026">Elena Popa</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Alexandra Brahas</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, </span><span class="cls_051">Caius Solovan</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:49.99px;top:528.60px" class="cls_031"><span class="cls_031">of mindfulness interventions being implemented by mental health</span></div>
<div style="position:absolute;left:306.64px;top:532.36px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Dermatology and Venereology, Clinical Emergency City</span></div>
<div style="position:absolute;left:49.99px;top:538.65px" class="cls_031"><span class="cls_031">care professionals with psoriasis patients.</span></div>
<div style="position:absolute;left:306.64px;top:541.96px" class="cls_029"><span class="cls_029">Hospital Timisoara; University of Medicine and Pharmacy “Victor Babes”</span></div>
<div style="position:absolute;left:306.64px;top:551.56px" class="cls_029"><span class="cls_029">Timisoara, Romania, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">University of Medicine and Pharmacy “Victor Ba-</span></div>
<div style="position:absolute;left:50.00px;top:559.31px" class="cls_033"><span class="cls_033">P128</span></div>
<div style="position:absolute;left:306.64px;top:561.16px" class="cls_029"><span class="cls_029">bes” Timisoara, Romania</span></div>
<div style="position:absolute;left:50.00px;top:570.76px" class="cls_025"><span class="cls_025">A LINK BETWEEN QUALITY OF PATIENT-PHYSICIAN</span></div>
<div style="position:absolute;left:306.64px;top:572.02px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is a skin disease that can occur at any</span></div>
<div style="position:absolute;left:50.00px;top:581.70px" class="cls_025"><span class="cls_025">COMMUNICATION AND PATIENT HEALTHCARE</span></div>
<div style="position:absolute;left:306.64px;top:582.02px" class="cls_031"><span class="cls_031">time and it is most common in the age group 50-69. The reported</span></div>
<div style="position:absolute;left:50.00px;top:592.64px" class="cls_025"><span class="cls_025">NEEDS IN PSA</span></div>
<div style="position:absolute;left:306.64px;top:592.02px" class="cls_031"><span class="cls_031">prevalence of Psoriasis in countries ranges between 0.09% and</span></div>
<div style="position:absolute;left:50.00px;top:602.58px" class="cls_026"><span class="cls_026">A-M Orbai</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, </span><span class="cls_051">L Coates</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, VF Azevedo</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, A Garg</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, A Majjhoo</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, CEM</span></div>
<div style="position:absolute;left:306.64px;top:602.02px" class="cls_031"><span class="cls_031">11.4%, making it a serious global problem.</span></div>
<div style="position:absolute;left:50.01px;top:612.53px" class="cls_026"><span class="cls_026">Griffiths</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, P Young</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, JC Cappelleri</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, J Moser</span><span class="cls_027"><sup>9</sup></span><span class="cls_026">, L Fallon</span><span class="cls_027"><sup>10</sup></span></div>
<div style="position:absolute;left:306.64px;top:612.02px" class="cls_031"><span class="cls_031">Psoriasis affects the quality of life and it is associated with many</span></div>
<div style="position:absolute;left:50.00px;top:623.17px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Johns Hopkins University School of Medicine, Baltimore, MD, USA,</span></div>
<div style="position:absolute;left:306.64px;top:622.02px" class="cls_031"><span class="cls_031">comorbidities such as depression, diabetes, cardiovascular disease</span></div>
<div style="position:absolute;left:50.00px;top:632.81px" class="cls_028"><span class="cls_028"><sup>2</sup></span><span class="cls_029">University of Oxford, Oxford, UK, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Universidade Federal do Paraná,</span></div>
<div style="position:absolute;left:306.64px;top:632.02px" class="cls_031"><span class="cls_031">and psoriatic arthritis.</span></div>
<div style="position:absolute;left:50.00px;top:642.45px" class="cls_029"><span class="cls_029">Curitiba, Brazil, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Donald and Barbara Zucker School of Medicine at</span></div>
<div style="position:absolute;left:306.64px;top:642.02px" class="cls_031"><span class="cls_031">To evaluate the severity and the efficiency of the treatment applied</span></div>
<div style="position:absolute;left:50.00px;top:652.10px" class="cls_029"><span class="cls_029">Hofstra/Northwell, Hempstead, NY, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Shores Rheumatology, MI, USA,</span></div>
<div style="position:absolute;left:306.65px;top:652.02px" class="cls_031"><span class="cls_031">to patients with Psoriasis, in practice it is used PASI (Psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:661.74px" class="cls_028"><span class="cls_028"><sup>6</sup></span><span class="cls_029">University of Manchester, Manchester, UK, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Pfizer Inc, Collegeville, PA,</span></div>
<div style="position:absolute;left:306.65px;top:662.01px" class="cls_031"><span class="cls_031">Area and Severity Index). The value may vary, for example, in this</span></div>
<div style="position:absolute;left:50.00px;top:671.39px" class="cls_028"><span class="cls_028"><sup>8</sup></span><span class="cls_029">Pfizer Inc, Groton, CT, </span><span class="cls_028"><sup>9</sup></span><span class="cls_029">The Harris Poll, Rochester, NY, USA, </span><span class="cls_028"><sup>10</sup></span><span class="cls_029">Pfizer</span></div>
<div style="position:absolute;left:306.65px;top:672.01px" class="cls_031"><span class="cls_031">study, PASI 75 represents the percentage (or number) of patients</span></div>
<div style="position:absolute;left:50.00px;top:681.03px" class="cls_029"><span class="cls_029">Canada, Montréal, QC, Canada</span></div>
<div style="position:absolute;left:306.65px;top:682.01px" class="cls_031"><span class="cls_031">that have achieved a 75% or more reduction in their PASI score</span></div>
<div style="position:absolute;left:50.00px;top:691.94px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Patient(pt)-physician(HCP) communication may</span></div>
<div style="position:absolute;left:306.65px;top:692.01px" class="cls_031"><span class="cls_031">in 12 weeks from baseline.</span></div>
<div style="position:absolute;left:50.00px;top:701.98px" class="cls_031"><span class="cls_031">influence symptom reporting and disease control.</span></div>
<div style="position:absolute;left:306.65px;top:702.01px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">Aim of this study is to gain a better perspective on</span></div>
<div style="position:absolute;left:50.00px;top:712.03px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To evaluate psoriatic arthritis (PsA) symptoms, life</span></div>
<div style="position:absolute;left:306.65px;top:712.01px" class="cls_031"><span class="cls_031">the Psoriasis patient’s point of view when seeking a physician’s</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:42559px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background55.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">53</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">help, therefore, to try and minimize the gaps that exist when</span></div>
<div style="position:absolute;left:306.64px;top:51.40px" class="cls_031"><span class="cls_031">(44.5%), and limitations on clothing (41.8%) for respondents</span></div>
<div style="position:absolute;left:50.00px;top:61.40px" class="cls_031"><span class="cls_031">managing them.</span></div>
<div style="position:absolute;left:306.64px;top:61.40px" class="cls_031"><span class="cls_031">with PsA</span><span class="cls_035">±</span><span class="cls_031">PsO. Regarding the impacts on work/career or educa-</span></div>
<div style="position:absolute;left:50.00px;top:71.40px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">This study was based on a custom questionnaire which</span></div>
<div style="position:absolute;left:306.64px;top:71.41px" class="cls_031"><span class="cls_031">tion since development of symptoms, 6.4% of respondents with</span></div>
<div style="position:absolute;left:50.00px;top:81.40px" class="cls_031"><span class="cls_031">included 14 questions for each patient. The responses were</span></div>
<div style="position:absolute;left:306.64px;top:81.40px" class="cls_031"><span class="cls_031">PsO alone and 30.3% of those with PsA</span><span class="cls_035">±</span><span class="cls_031">PsO reported a strong</span></div>
<div style="position:absolute;left:50.00px;top:91.40px" class="cls_031"><span class="cls_031">gathered from 20 patients (and it is still ongoing) diagnosed in</span></div>
<div style="position:absolute;left:306.64px;top:91.40px" class="cls_031"><span class="cls_031">negative impact. Of the 82.2% of respondents who were working</span></div>
<div style="position:absolute;left:50.00px;top:101.40px" class="cls_031"><span class="cls_031">our Department of Dermatology and Venereology Timisoara, each</span></div>
<div style="position:absolute;left:306.64px;top:101.40px" class="cls_031"><span class="cls_031">or studying, frequency of absences in the previous 12 months</span></div>
<div style="position:absolute;left:50.00px;top:111.40px" class="cls_031"><span class="cls_031">in different stages of disease. All the answers are confidential</span></div>
<div style="position:absolute;left:306.64px;top:111.40px" class="cls_031"><span class="cls_031">were significantly higher (Bonferroni corrected z-tests, total α </span><span class="cls_030"> =</span></div>
<div style="position:absolute;left:50.00px;top:121.40px" class="cls_031"><span class="cls_031">and anonymous. An informed consent was signed prior to any</span></div>
<div style="position:absolute;left:306.64px;top:121.40px" class="cls_031"><span class="cls_031">0.05) among those who: had PsA</span><span class="cls_035">±</span><span class="cls_031">PsO vs PsO alone; perceived</span></div>
<div style="position:absolute;left:50.00px;top:131.40px" class="cls_031"><span class="cls_031">taken actions. To achieve meaningful results, we asked patients</span></div>
<div style="position:absolute;left:306.64px;top:131.40px" class="cls_031"><span class="cls_031">their symptoms to be severe vs non-severe; used systemic vs</span></div>
<div style="position:absolute;left:50.00px;top:141.40px" class="cls_031"><span class="cls_031">to be honest and to present the situation in a real way. The most</span></div>
<div style="position:absolute;left:306.64px;top:141.40px" class="cls_031"><span class="cls_031">only topical treatments; were aged 18-44 years vs 45-74; were</span></div>
<div style="position:absolute;left:50.00px;top:151.40px" class="cls_031"><span class="cls_031">important question on the questionnaire was “Which of the three</span></div>
<div style="position:absolute;left:306.64px;top:151.40px" class="cls_031"><span class="cls_031">members of patient groups vs non-members; saw a dermatologist</span></div>
<div style="position:absolute;left:50.00px;top:161.39px" class="cls_031"><span class="cls_031">options represents the PASI score you would like to achieve?</span></div>
<div style="position:absolute;left:306.64px;top:161.40px" class="cls_031"><span class="cls_031">or rheumatologist at least annually vs those who did not.</span></div>
<div style="position:absolute;left:50.00px;top:171.39px" class="cls_031"><span class="cls_031">50/75/90?”. In addition to this question, we provided the patients</span></div>
<div style="position:absolute;left:306.64px;top:171.40px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">PsO has a profound impact on the HRQoL and career/</span></div>
<div style="position:absolute;left:50.00px;top:181.39px" class="cls_031"><span class="cls_031">with three pictures each of them showing a different PASI score,</span></div>
<div style="position:absolute;left:306.64px;top:181.40px" class="cls_031"><span class="cls_031">education of individuals with these conditions in Scandinavia. The</span></div>
<div style="position:absolute;left:50.00px;top:191.39px" class="cls_031"><span class="cls_031">so they can choose the proper answer much easier.</span></div>
<div style="position:absolute;left:306.64px;top:191.40px" class="cls_031"><span class="cls_031">impact is greater among individuals with PsA</span><span class="cls_035">±</span><span class="cls_031">PsO.</span></div>
<div style="position:absolute;left:50.00px;top:201.39px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">80% of the patients chose PASI 90, 15% chose PASI 75</span></div>
<div style="position:absolute;left:50.00px;top:211.39px" class="cls_031"><span class="cls_031">and only 5% chose PASI 50.</span></div>
<div style="position:absolute;left:306.64px;top:210.04px" class="cls_033"><span class="cls_033">P131</span></div>
<div style="position:absolute;left:50.00px;top:221.39px" class="cls_031"><span class="cls_031">In addition to this, the gender distribution showed us that 100%</span></div>
<div style="position:absolute;left:306.64px;top:221.44px" class="cls_025"><span class="cls_025">QUALITY OF LIFE OF PATIENTS WITH PSORIASIS IN</span></div>
<div style="position:absolute;left:50.00px;top:231.39px" class="cls_031"><span class="cls_031">of the female patients chose PASI 90, proving how important</span></div>
<div style="position:absolute;left:306.64px;top:232.34px" class="cls_025"><span class="cls_025">KHARTOUM DERMATOLOGY HOSPITAL, DECEMBER</span></div>
<div style="position:absolute;left:50.00px;top:241.39px" class="cls_031"><span class="cls_031">appearance is for them, and how much of a weight it is for them</span></div>
<div style="position:absolute;left:306.64px;top:243.24px" class="cls_025"><span class="cls_025">2017</span></div>
<div style="position:absolute;left:50.00px;top:251.39px" class="cls_031"><span class="cls_031">to have disease that is in the limelight. On the other hand, the</span></div>
<div style="position:absolute;left:306.64px;top:253.14px" class="cls_026"><span class="cls_026">Hind Madani</span></div>
<div style="position:absolute;left:50.00px;top:261.38px" class="cls_031"><span class="cls_031">male patients were divided into three groups. 69% said that the</span></div>
<div style="position:absolute;left:306.64px;top:263.74px" class="cls_029"><span class="cls_029">University of Khartoum- faculty of medicine</span></div>
<div style="position:absolute;left:50.00px;top:271.38px" class="cls_031"><span class="cls_031">efficiency of the therapy is very good, choosing PASI 90. Only</span></div>
<div style="position:absolute;left:306.64px;top:274.61px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is a common chronic non-contagious skin</span></div>
<div style="position:absolute;left:50.01px;top:281.38px" class="cls_031"><span class="cls_031">23% of male patients consider PASI 75 satisfying and the last 8%</span></div>
<div style="position:absolute;left:306.64px;top:284.60px" class="cls_031"><span class="cls_031">disease, affecting 1-3% of the world population. Defects in the</span></div>
<div style="position:absolute;left:50.01px;top:291.38px" class="cls_031"><span class="cls_031">represents PASI 50.</span></div>
<div style="position:absolute;left:306.64px;top:294.60px" class="cls_031"><span class="cls_031">immune regulation and the control of inflammation are thought</span></div>
<div style="position:absolute;left:50.01px;top:301.38px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Psoriasis is a chronic inflammatory disease, which</span></div>
<div style="position:absolute;left:306.65px;top:304.60px" class="cls_031"><span class="cls_031">to play major roles. Quality of life (QOL) is increasingly recog-</span></div>
<div style="position:absolute;left:50.01px;top:311.38px" class="cls_031"><span class="cls_031">is intensively studied at the cellular and molecular level. What is</span></div>
<div style="position:absolute;left:306.64px;top:314.61px" class="cls_031"><span class="cls_031">nized as an important outcome measure in dermatology. Psoriasis</span></div>
<div style="position:absolute;left:50.01px;top:321.38px" class="cls_031"><span class="cls_031">considered a good response to a treatment is sometimes different</span></div>
<div style="position:absolute;left:306.64px;top:324.60px" class="cls_031"><span class="cls_031">although it doesn’t affect the survival it has a great impact on qua-</span></div>
<div style="position:absolute;left:50.01px;top:331.38px" class="cls_031"><span class="cls_031">from the perception of a patient vs. a physician, therefore we must</span></div>
<div style="position:absolute;left:306.64px;top:334.61px" class="cls_031"><span class="cls_031">lity of life of patients, and has a strong effect on social relations,</span></div>
<div style="position:absolute;left:50.01px;top:341.38px" class="cls_031"><span class="cls_031">always keep a balance between aiming high (and maybe risking to</span></div>
<div style="position:absolute;left:306.64px;top:344.60px" class="cls_031"><span class="cls_031">psychological status, daily activities and thought to be associated</span></div>
<div style="position:absolute;left:50.01px;top:351.38px" class="cls_031"><span class="cls_031">over-treat some patients) and meeting the patient’s expectations.</span></div>
<div style="position:absolute;left:306.64px;top:354.60px" class="cls_031"><span class="cls_031">with depression.</span></div>
<div style="position:absolute;left:306.64px;top:364.60px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">The aim of this study was to determine the impact of</span></div>
<div style="position:absolute;left:50.00px;top:371.04px" class="cls_033"><span class="cls_033">P130</span></div>
<div style="position:absolute;left:306.64px;top:374.60px" class="cls_031"><span class="cls_031">psoriasis on the quality of life(QOL) of the patients in Khartoum</span></div>
<div style="position:absolute;left:50.00px;top:382.44px" class="cls_025"><span class="cls_025">THE IMPACT OF PSORIASIS AND PSORIATIC</span></div>
<div style="position:absolute;left:306.64px;top:384.60px" class="cls_031"><span class="cls_031">dermatology hospital, 2017.</span></div>
<div style="position:absolute;left:50.00px;top:393.34px" class="cls_025"><span class="cls_025">ARTHRITIS ON QUALITY OF LIFE AND CAREER IN</span></div>
<div style="position:absolute;left:306.64px;top:394.60px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Descriptive case series study, hospital based survey</span></div>
<div style="position:absolute;left:50.00px;top:404.24px" class="cls_025"><span class="cls_025">SCANDINAVIA</span></div>
<div style="position:absolute;left:306.64px;top:404.60px" class="cls_031"><span class="cls_031">conducted among 70 participants from psoriasis patients aged</span></div>
<div style="position:absolute;left:50.00px;top:414.14px" class="cls_026"><span class="cls_026">Albert Duvetorp</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Mikkel Østergaard</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Lone Skov</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Oliver Seifert</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:414.60px" class="cls_031"><span class="cls_031">above 18 years in Khartoum dermatology hospital, through self-</span></div>
<div style="position:absolute;left:50.00px;top:424.04px" class="cls_026"><span class="cls_026">Kåre Steinar Tveit</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Kjersti Danielsen</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, </span><span class="cls_051">Lars Iversen</span><span class="cls_027"><sup>7</sup></span></div>
<div style="position:absolute;left:306.64px;top:424.60px" class="cls_031"><span class="cls_031">administered standard questionnaire, which was developed after</span></div>
<div style="position:absolute;left:50.00px;top:434.64px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Skånes Universitetssjukhus, Malmö, Sweden; Linköping University, Lin-</span></div>
<div style="position:absolute;left:306.64px;top:434.60px" class="cls_031"><span class="cls_031">extensive literature reviewing, comprised of Socio-demographic</span></div>
<div style="position:absolute;left:50.00px;top:444.24px" class="cls_029"><span class="cls_029">köping, Sweden, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Copenhagen Center for Arthritis Research, Center for</span></div>
<div style="position:absolute;left:306.64px;top:444.59px" class="cls_031"><span class="cls_031">data, psoriasis life stress inventory(PLSI), psoriasis disability</span></div>
<div style="position:absolute;left:50.00px;top:453.84px" class="cls_029"><span class="cls_029">Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, University</span></div>
<div style="position:absolute;left:306.64px;top:454.59px" class="cls_031"><span class="cls_031">index(PDI) and depression assessment.</span></div>
<div style="position:absolute;left:50.00px;top:463.44px" class="cls_029"><span class="cls_029">of Copenhagen Copenhagen, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Herlev and Gentofte Hospital, University of</span></div>
<div style="position:absolute;left:306.64px;top:464.59px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">64.3% of the participants have a high psoriasis-related</span></div>
<div style="position:absolute;left:50.00px;top:473.04px" class="cls_029"><span class="cls_029">Copenhagen, Denmark, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Linköping University, Linköping, Sweden; Ryhov</span></div>
<div style="position:absolute;left:306.64px;top:474.59px" class="cls_031"><span class="cls_031">stress (PLSI) and 35.7% have a low psoriasis-related stress. 21.4%</span></div>
<div style="position:absolute;left:50.00px;top:482.64px" class="cls_029"><span class="cls_029">Hospital, Jönköping, Sweden, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">Haukeland University Hospital, Bergen,</span></div>
<div style="position:absolute;left:306.64px;top:484.59px" class="cls_031"><span class="cls_031">of the participants have a very large disability in daily activities</span></div>
<div style="position:absolute;left:50.00px;top:492.24px" class="cls_028"><span class="cls_028"><sup>6</sup></span><span class="cls_029">UiT The Arctic University of Norway; University Hospital of North Nor-</span></div>
<div style="position:absolute;left:306.64px;top:494.59px" class="cls_031"><span class="cls_031">(PDI), 37.1% have a large disability, 24.3% have a moderate disa-</span></div>
<div style="position:absolute;left:50.00px;top:501.84px" class="cls_029"><span class="cls_029">way, Tromsø, Norway, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Aarhus University Hospital, Aarhus, Denmark</span></div>
<div style="position:absolute;left:306.64px;top:504.61px" class="cls_031"><span class="cls_031">bility, 14.3% have a mild disability and 2.9% have no disability at</span></div>
<div style="position:absolute;left:50.00px;top:512.71px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Patients’ perspectives on the effects of psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:514.60px" class="cls_031"><span class="cls_031">all.7.1% of the participants have a moderately severe depression,</span></div>
<div style="position:absolute;left:50.00px;top:522.70px" class="cls_031"><span class="cls_031">(PsO) and psoriatic arthritis (PsA) on health-related quality of</span></div>
<div style="position:absolute;left:306.64px;top:524.60px" class="cls_031"><span class="cls_031">15.7% have a moderate depression, 35.7% have a mild depres-</span></div>
<div style="position:absolute;left:50.00px;top:532.70px" class="cls_031"><span class="cls_031">life (HRQoL) are important in establishing better approaches to</span></div>
<div style="position:absolute;left:306.64px;top:534.61px" class="cls_031"><span class="cls_031">sion, 41.4% have none or minimal depression and none of the</span></div>
<div style="position:absolute;left:50.00px;top:542.70px" class="cls_031"><span class="cls_031">their care and treatment.</span></div>
<div style="position:absolute;left:306.64px;top:544.60px" class="cls_031"><span class="cls_031">participants has a severe depression.</span></div>
<div style="position:absolute;left:50.00px;top:552.70px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To better understand the impact of PsO and PsA on</span></div>
<div style="position:absolute;left:306.64px;top:554.60px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">the study concluded that psoriasis has impacts on</span></div>
<div style="position:absolute;left:50.00px;top:562.70px" class="cls_031"><span class="cls_031">daily life, education and work in Scandinavian countries.</span></div>
<div style="position:absolute;left:306.64px;top:564.60px" class="cls_031"><span class="cls_031">the quality of life, causing high stress and high disability in daily</span></div>
<div style="position:absolute;left:50.00px;top:572.70px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">The NORdic PAtient survey of PsOriasis and Psoriatic</span></div>
<div style="position:absolute;left:306.64px;top:574.60px" class="cls_031"><span class="cls_031">activities with variable degrees of depression.</span></div>
<div style="position:absolute;left:50.00px;top:582.70px" class="cls_031"><span class="cls_031">arthritis (NORPAPP) was an on-line survey carried out in Nov/</span></div>
<div style="position:absolute;left:306.64px;top:584.60px" class="cls_030"><span class="cls_030">Key words:</span><span class="cls_031"> psoriasis, QOL, PLSI, PDI, depression.</span></div>
<div style="position:absolute;left:50.00px;top:592.70px" class="cls_031"><span class="cls_031">Dec 2015 using YouGov panels in Sweden, Denmark, and Norway.</span></div>
<div style="position:absolute;left:306.64px;top:594.60px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.00px;top:602.70px" class="cls_031"><span class="cls_031">Adults (18-74 years old), with physician-diagnosed PsO or PsA</span></div>
<div style="position:absolute;left:306.64px;top:604.62px" class="cls_032"><span class="cls_032">1. El-Moselhy EA, Atlam SA, Mohammed AS, Hassan HM, Ebrahim AM</span></div>
<div style="position:absolute;left:50.00px;top:612.70px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">n = </span><span class="cls_031">1221), answered questions about the impact of disease on 10</span></div>
<div style="position:absolute;left:306.64px;top:613.62px" class="cls_032"><span class="cls_032">(2015) Psychosocial Impact and Quality of Life among Adult Egyptian</span></div>
<div style="position:absolute;left:50.00px;top:622.69px" class="cls_031"><span class="cls_031">aspects of daily activity/mood and on work/education; 5-point</span></div>
<div style="position:absolute;left:306.64px;top:622.62px" class="cls_032"><span class="cls_032">with Psoriasis. Dermatol Case Rep 1: 104. 2. Abbas Darjani N. Quality</span></div>
<div style="position:absolute;left:50.00px;top:632.69px" class="cls_031"><span class="cls_031">Likert scale responses were dichotomised into “no/minor impact”</span></div>
<div style="position:absolute;left:306.64px;top:631.62px" class="cls_032"><span class="cls_032">of Life in Psoriatic Patients: A Study Using the Short Form-36 [Internet].</span></div>
<div style="position:absolute;left:306.64px;top:640.62px" class="cls_032"><span class="cls_032">PubMed Central (PMC). 2017 [cited 30 March 2017]. Available from:</span></div>
<div style="position:absolute;left:50.00px;top:642.69px" class="cls_031"><span class="cls_031">(1-3 or “don’t know”) and “strong impact” (4-5).</span></div>
<div style="position:absolute;left:306.64px;top:649.62px" class="cls_032"><span class="cls_032"> </span><A HREF="https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4192777/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192777/</A> </div>
<div style="position:absolute;left:50.00px;top:652.69px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">For the 10 aspects of activity/mood a “strong impact” was</span></div>
<div style="position:absolute;left:306.64px;top:658.62px" class="cls_032"><span class="cls_032">3. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of</span></div>
<div style="position:absolute;left:50.00px;top:662.69px" class="cls_031"><span class="cls_031">reported for ≥4, 1-3 or 0 aspects by 22.8%, 24.2%, and 61.9% of</span></div>
<div style="position:absolute;left:306.64px;top:667.62px" class="cls_032"><span class="cls_032">life of 369 patients. Br J Dermatol\1995;132:236-44. CrossRef PubMed</span></div>
<div style="position:absolute;left:50.01px;top:672.69px" class="cls_031"><span class="cls_031">respondents with PsO alone and 44.5%, 63.0%, and 27.0% of those</span></div>
<div style="position:absolute;left:306.64px;top:676.62px" class="cls_032"><span class="cls_032">WebofScience GoogleScholar</span></div>
<div style="position:absolute;left:50.01px;top:682.69px" class="cls_031"><span class="cls_031">with PsA</span><span class="cls_035">±</span><span class="cls_031">PsO. The most commonly reported strong impacts were</span></div>
<div style="position:absolute;left:306.64px;top:685.62px" class="cls_032"><span class="cls_032">4. Tang M, Chang C, Chan L, Heng A. Quality of life and cost of illness</span></div>
<div style="position:absolute;left:50.00px;top:692.70px" class="cls_031"><span class="cls_031">limitations on dress (22.6%), sleep disorders (16.3%) and depres-</span></div>
<div style="position:absolute;left:306.64px;top:694.62px" class="cls_032"><span class="cls_032">in patients with psoriasis in Malaysia: a multicenterr study. 2018</span></div>
<div style="position:absolute;left:50.00px;top:702.71px" class="cls_031"><span class="cls_031">sion and/or anxiety (16.2%) for respondents with PsO alone; and,</span></div>
<div style="position:absolute;left:306.64px;top:703.62px" class="cls_032"><span class="cls_032">5. Langley R. Psoriasis: epidemiology, clinical features, and quality of life.</span></div>
<div style="position:absolute;left:50.00px;top:712.70px" class="cls_031"><span class="cls_031">daily routine (45.1%), leisure/sports (44.0%), sleeping disorders</span></div>
<div style="position:absolute;left:306.64px;top:712.62px" class="cls_032"><span class="cls_032">Annals of the Rheumatic Diseases. 2005;64(suppl_2):ii18-ii23.</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:43362px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background56.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">54</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.23px" class="cls_033"><span class="cls_033">P132</span></div>
<div style="position:absolute;left:306.64px;top:51.85px" class="cls_029"><span class="cls_029">Australia, </span><span class="cls_028"><sup>8</sup></span><span class="cls_029">University of Lübeck, Lübeck, Germany, </span><span class="cls_028"><sup>9</sup></span><span class="cls_029">Sun Pharmaceutical</span></div>
<div style="position:absolute;left:50.00px;top:62.63px" class="cls_025"><span class="cls_025">MIRIKIZUMAB SIGNIFICANTLY IMPROVES SELF-</span></div>
<div style="position:absolute;left:306.64px;top:61.45px" class="cls_029"><span class="cls_029">Industries, Inc., Princeton, NJ, </span><span class="cls_028"><sup>10</sup></span><span class="cls_029">Merck & Co., Inc., Kenilworth, NJ, USA</span></div>
<div style="position:absolute;left:50.00px;top:73.53px" class="cls_025"><span class="cls_025">REPORTED DISEASE SEVERITY AND GENERAL</span></div>
<div style="position:absolute;left:306.64px;top:72.32px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">The negative impact of psoriasis extends beyond</span></div>
<div style="position:absolute;left:50.00px;top:84.43px" class="cls_025"><span class="cls_025">HEALTH STATUS IN PATIENTS WITH MODERATE-TO-</span></div>
<div style="position:absolute;left:306.64px;top:82.32px" class="cls_031"><span class="cls_031">the patient, affecting his/her social interactions and the quality</span></div>
<div style="position:absolute;left:306.64px;top:92.32px" class="cls_031"><span class="cls_031">of life of cohabitants. Furthermore, patients with psoriasis often</span></div>
<div style="position:absolute;left:50.00px;top:95.33px" class="cls_025"><span class="cls_025">SEVERE PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:102.32px" class="cls_031"><span class="cls_031">experience sexual difficulties because of their disease.</span></div>
<div style="position:absolute;left:50.00px;top:105.23px" class="cls_051"><span class="cls_051">Melinda Gooderham</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Paul Klekotka</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Emily Edson Heredia</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:112.32px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">This analysis examined the effect of treatment with</span></div>
<div style="position:absolute;left:50.00px;top:115.13px" class="cls_026"><span class="cls_026">Joanne Li</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Baojin Zhu</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Jiaying Guo</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Jerry Bagel</span><span class="cls_027"><sup>3</sup></span></div>
<div style="position:absolute;left:50.00px;top:125.73px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">SKiN Centre for Dermatology, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Eli Lilly & Company, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Windsor Derma-</span></div>
<div style="position:absolute;left:306.64px;top:122.31px" class="cls_031"><span class="cls_031">tildrakizumab (TIL) on personal relationships of patients with</span></div>
<div style="position:absolute;left:50.00px;top:135.33px" class="cls_029"><span class="cls_029">tology</span></div>
<div style="position:absolute;left:306.64px;top:132.31px" class="cls_031"><span class="cls_031">moderate-to-severe chronic plaque psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:142.31px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Patients in two phase 3 trials reSURFACE 1</span></div>
<div style="position:absolute;left:50.00px;top:146.15px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">In a randomized, placebo-controlled, phase 2 trial</span></div>
<div style="position:absolute;left:306.64px;top:152.31px" class="cls_031"><span class="cls_031">(NCT01722331) and reSURFACE 2 (NCT01729754) were</span></div>
<div style="position:absolute;left:50.00px;top:156.10px" class="cls_031"><span class="cls_031">(NCT02899988), mirikizumab met its primary efficacy endpoint</span></div>
<div style="position:absolute;left:306.64px;top:162.31px" class="cls_031"><span class="cls_031">randomized to subcutaneous TIL 200 mg, 100 mg, or placebo</span></div>
<div style="position:absolute;left:49.99px;top:166.06px" class="cls_031"><span class="cls_031">at Week 16.1</span></div>
<div style="position:absolute;left:306.64px;top:172.31px" class="cls_031"><span class="cls_031">(PBO) and received treatment at weeks 0 and 4. PBO patients</span></div>
<div style="position:absolute;left:49.99px;top:176.01px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To determine if mirikizumab improves patient-reported</span></div>
<div style="position:absolute;left:306.64px;top:182.31px" class="cls_031"><span class="cls_031">were re-randomized at week 12 to either TIL 200 mg or 100 mg.</span></div>
<div style="position:absolute;left:49.99px;top:185.96px" class="cls_031"><span class="cls_031">disease severity and general health status in psoriasis patients at</span></div>
<div style="position:absolute;left:306.64px;top:192.31px" class="cls_031"><span class="cls_031">Etanercept (ETN) 50 mg (semiweekly until week 12 then weekly</span></div>
<div style="position:absolute;left:49.99px;top:195.92px" class="cls_031"><span class="cls_031">Week 16.</span></div>
<div style="position:absolute;left:306.64px;top:202.31px" class="cls_031"><span class="cls_031">until week 28) was also a treatment arm in reSURFACE 2. Data on</span></div>
<div style="position:absolute;left:49.99px;top:205.85px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Adults with moderate-to-severe psoriasis were ran-</span></div>
<div style="position:absolute;left:306.64px;top:212.31px" class="cls_031"><span class="cls_031">personal relationships were collected at weeks 12 and 28 from the</span></div>
<div style="position:absolute;left:50.00px;top:215.80px" class="cls_031"><span class="cls_031">domized 1:1:1:1 to receive placebo (</span><span class="cls_030">n = </span><span class="cls_031">52), mirikizumab 30 mg</span></div>
<div style="position:absolute;left:306.64px;top:222.30px" class="cls_031"><span class="cls_031">Dermatology Life Quality Index (DLQI) questionnaire question</span></div>
<div style="position:absolute;left:50.00px;top:225.75px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">n = </span><span class="cls_031">51), 100 mg (</span><span class="cls_030">n = </span><span class="cls_031">51), or 300 mg (</span><span class="cls_030">n = </span><span class="cls_031">51) at Weeks 0 and 8.</span></div>
<div style="position:absolute;left:306.64px;top:232.30px" class="cls_031"><span class="cls_031">8 (Q8) “Over the last week, how much has your skin created pro-</span></div>
<div style="position:absolute;left:50.00px;top:235.71px" class="cls_031"><span class="cls_031">At baseline and Weeks 2, 4, 8, 12, and 16, patients completed the</span></div>
<div style="position:absolute;left:306.64px;top:242.32px" class="cls_031"><span class="cls_031">blems with your partner or any of your close friends or relatives”</span></div>
<div style="position:absolute;left:50.00px;top:245.65px" class="cls_031"><span class="cls_031">Patient Global Assessment of psoriasis (PtGA) (0</span><span class="cls_030"> = </span><span class="cls_031">clear, 5</span><span class="cls_030"> = </span><span class="cls_031">se-</span></div>
<div style="position:absolute;left:306.64px;top:252.32px" class="cls_031"><span class="cls_031">and question 9 (Q9) “Over the last week, how much has your skin</span></div>
<div style="position:absolute;left:50.00px;top:255.60px" class="cls_031"><span class="cls_031">vere). At baseline and Week 16, patients completed the Medical</span></div>
<div style="position:absolute;left:306.64px;top:262.32px" class="cls_031"><span class="cls_031">caused any sexual difficulties”. Each question was scored on a</span></div>
<div style="position:absolute;left:50.00px;top:265.55px" class="cls_031"><span class="cls_031">Outcomes Study 36-Item Short Form Health Survey (SF-36;</span></div>
<div style="position:absolute;left:306.63px;top:272.32px" class="cls_031"><span class="cls_031">scale of 0 (not affected at all) to 3 (very much affected). The data</span></div>
<div style="position:absolute;left:50.00px;top:275.51px" class="cls_031"><span class="cls_031">[range 0-100]) which measures 8 general health status domains</span></div>
<div style="position:absolute;left:306.63px;top:282.32px" class="cls_031"><span class="cls_031">were pooled from reSURFACE 1 and 2.</span></div>
<div style="position:absolute;left:50.00px;top:285.46px" class="cls_031"><span class="cls_031">that can be scored as mental component and physical component</span></div>
<div style="position:absolute;left:306.63px;top:292.31px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">In all, 1,820 patients had DLQI data. All patients repor-</span></div>
<div style="position:absolute;left:50.00px;top:295.42px" class="cls_031"><span class="cls_031">summaries. For continuous measures, comparisons were made</span></div>
<div style="position:absolute;left:306.64px;top:302.32px" class="cls_031"><span class="cls_031">ted a negative effect for Q8 and Q9 at baseline. At week 12, the</span></div>
<div style="position:absolute;left:50.00px;top:305.37px" class="cls_031"><span class="cls_031">by a mixed-effects for repeated measures model (PtGA) or an</span></div>
<div style="position:absolute;left:306.64px;top:312.32px" class="cls_031"><span class="cls_031">proportion of patients with no negative effect (score of 0) on per-</span></div>
<div style="position:absolute;left:50.00px;top:315.32px" class="cls_031"><span class="cls_031">analysis of covariance model (SF-36). Comparisons of categorical</span></div>
<div style="position:absolute;left:306.64px;top:322.32px" class="cls_031"><span class="cls_031">sonal relationships (Q8 and Q9) was higher for TIL 200 mg, TIL</span></div>
<div style="position:absolute;left:50.00px;top:325.28px" class="cls_031"><span class="cls_031">efficacy variables were conducted by logistic regression analysis</span></div>
<div style="position:absolute;left:306.64px;top:332.32px" class="cls_031"><span class="cls_031">100 mg, and ETN than for PBO (76%, 72%, and 64% vs. 39%,</span></div>
<div style="position:absolute;left:50.00px;top:335.23px" class="cls_031"><span class="cls_031">with non-responder imputation (NRI).</span></div>
<div style="position:absolute;left:306.64px;top:342.32px" class="cls_031"><span class="cls_031">respectively). A similar trend was observed for individual questions</span></div>
<div style="position:absolute;left:50.00px;top:345.18px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">At Week 16, mirikizumab-treated patients reported greater</span></div>
<div style="position:absolute;left:306.64px;top:352.32px" class="cls_031"><span class="cls_031">Q8 and Q9. At week 28, more patients on TIL 200 mg and TIL</span></div>
<div style="position:absolute;left:50.00px;top:355.10px" class="cls_031"><span class="cls_031">improvements in psoriasis severity and aspects of physical functio-</span></div>
<div style="position:absolute;left:306.64px;top:362.32px" class="cls_031"><span class="cls_031">100 mg reported no negative effect on personal relationships than</span></div>
<div style="position:absolute;left:50.00px;top:365.05px" class="cls_031"><span class="cls_031">ning versus placebo (Table).</span></div>
<div style="position:absolute;left:306.64px;top:372.31px" class="cls_031"><span class="cls_031">those on ETN (85% and 77% vs. 66%; respectively). More patients</span></div>
<div style="position:absolute;left:50.00px;top:375.00px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Mirikizumab treatment at various doses significantly</span></div>
<div style="position:absolute;left:306.64px;top:382.31px" class="cls_031"><span class="cls_031">on TIL 200 mg and TIL 100 mg reported no negative effect than</span></div>
<div style="position:absolute;left:50.00px;top:385.00px" class="cls_031"><span class="cls_031">improved psoriatic disease severity and physical health status.</span></div>
<div style="position:absolute;left:306.64px;top:392.31px" class="cls_031"><span class="cls_031">those on ETN for Q8 (89% and 81% vs. 70%; respectively) and</span></div>
<div style="position:absolute;left:50.00px;top:395.00px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:50.00px;top:405.01px" class="cls_032"><span class="cls_032">1. Reich K et al. Programme and abstracts of Psoriasis from Gene to Clinic;</span></div>
<div style="position:absolute;left:306.64px;top:402.31px" class="cls_031"><span class="cls_031">for Q9 (89% and 84% vs. 75%, respectively).</span></div>
<div style="position:absolute;left:50.00px;top:414.01px" class="cls_032"><span class="cls_032">Nov. 30-Dec. 2, 2017; Abstract FC31.</span></div>
<div style="position:absolute;left:306.64px;top:412.31px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">TIL had a beneficial effect on psoriasis-related</span></div>
<div style="position:absolute;left:50.00px;top:422.03px" class="cls_036"><span class="cls_036">Table. Patient-Reported Outcomes (Week 16)</span></div>
<div style="position:absolute;left:306.60px;top:422.31px" class="cls_031"><span class="cls_031">personal relationship problems and sexual difficulties, compared</span></div>
<div style="position:absolute;left:180.11px;top:433.13px" class="cls_036"><span class="cls_036">Mirikizumab</span></div>
<div style="position:absolute;left:306.59px;top:432.31px" class="cls_031"><span class="cls_031">to placebo and ETN.</span></div>
<div style="position:absolute;left:150.11px;top:441.99px" class="cls_036"><span class="cls_036">Placebo</span></div>
<div style="position:absolute;left:180.11px;top:441.99px" class="cls_036"><span class="cls_036">30 mg</span></div>
<div style="position:absolute;left:216.11px;top:441.99px" class="cls_036"><span class="cls_036">100 mg</span></div>
<div style="position:absolute;left:253.66px;top:441.99px" class="cls_036"><span class="cls_036">300 mg</span></div>
<div style="position:absolute;left:306.64px;top:442.33px" class="cls_032"><span class="cls_032">This abstract was presented at 2018 Annual Meeting of American Academy</span></div>
<div style="position:absolute;left:150.11px;top:448.99px" class="cls_040"><span class="cls_040">n = </span><span class="cls_036">51</span></div>
<div style="position:absolute;left:180.11px;top:448.99px" class="cls_040"><span class="cls_040">n = </span><span class="cls_036">48</span></div>
<div style="position:absolute;left:216.11px;top:448.99px" class="cls_040"><span class="cls_040">n = </span><span class="cls_036">51</span></div>
<div style="position:absolute;left:253.66px;top:448.99px" class="cls_040"><span class="cls_040">n = </span><span class="cls_036">51</span></div>
<div style="position:absolute;left:306.64px;top:451.33px" class="cls_032"><span class="cls_032">of Dermatology.</span></div>
<div style="position:absolute;left:51.38px;top:458.16px" class="cls_037"><span class="cls_037">PtGA, least squares mean(SE)</span></div>
<div style="position:absolute;left:150.11px;top:458.16px" class="cls_037"><span class="cls_037">0.4</span></div>
<div style="position:absolute;left:159.38px;top:458.16px" class="cls_037"><span class="cls_037">(0.16)</span></div>
<div style="position:absolute;left:180.11px;top:458.16px" class="cls_037"><span class="cls_037">2.2 (0.16)*** 2.9 (0.16)***</span></div>
<div style="position:absolute;left:253.66px;top:458.16px" class="cls_037"><span class="cls_037">2.8 (0.16)***</span></div>
<div style="position:absolute;left:51.37px;top:464.32px" class="cls_037"><span class="cls_037">Change from Baseline in SF-36 Domains, LSM (SE)</span></div>
<div style="position:absolute;left:52.91px;top:470.48px" class="cls_037"><span class="cls_037">Physical functioning</span></div>
<div style="position:absolute;left:150.11px;top:470.48px" class="cls_037"><span class="cls_037">2.8</span></div>
<div style="position:absolute;left:159.38px;top:470.48px" class="cls_037"><span class="cls_037">(1.9)</span></div>
<div style="position:absolute;left:180.10px;top:470.48px" class="cls_037"><span class="cls_037">7.2</span></div>
<div style="position:absolute;left:189.37px;top:470.48px" class="cls_037"><span class="cls_037">(2.0)</span></div>
<div style="position:absolute;left:216.10px;top:470.48px" class="cls_037"><span class="cls_037">8.2 (1.9)*</span></div>
<div style="position:absolute;left:253.65px;top:470.48px" class="cls_037"><span class="cls_037">7.2</span></div>
<div style="position:absolute;left:262.92px;top:470.48px" class="cls_037"><span class="cls_037">(2.0)</span></div>
<div style="position:absolute;left:52.91px;top:476.65px" class="cls_037"><span class="cls_037">Role-physical</span></div>
<div style="position:absolute;left:150.10px;top:476.65px" class="cls_037"><span class="cls_037">1.2</span></div>
<div style="position:absolute;left:159.37px;top:476.65px" class="cls_037"><span class="cls_037">(2.4)</span></div>
<div style="position:absolute;left:180.10px;top:476.65px" class="cls_037"><span class="cls_037">11.4 (2.5)**</span></div>
<div style="position:absolute;left:216.10px;top:476.65px" class="cls_037"><span class="cls_037">11.5 (2.5)**</span></div>
<div style="position:absolute;left:253.65px;top:476.65px" class="cls_037"><span class="cls_037">12.3 (2.5)**</span></div>
<div style="position:absolute;left:306.64px;top:471.45px" class="cls_033"><span class="cls_033">P134</span></div>
<div style="position:absolute;left:52.90px;top:482.81px" class="cls_037"><span class="cls_037">Bodily pain</span></div>
<div style="position:absolute;left:150.09px;top:482.81px" class="cls_037"><span class="cls_037">5.7</span></div>
<div style="position:absolute;left:159.36px;top:482.81px" class="cls_037"><span class="cls_037">(2.8)</span></div>
<div style="position:absolute;left:180.09px;top:482.81px" class="cls_037"><span class="cls_037">17.6 (2.9)**</span></div>
<div style="position:absolute;left:216.09px;top:482.81px" class="cls_037"><span class="cls_037">19.2 (2.9)***</span></div>
<div style="position:absolute;left:253.64px;top:482.81px" class="cls_037"><span class="cls_037">18.9 (2.9)**</span></div>
<div style="position:absolute;left:306.64px;top:482.85px" class="cls_025"><span class="cls_025">PRURITUS SEVERITY ASSESSMENT AND</span></div>
<div style="position:absolute;left:52.90px;top:488.97px" class="cls_037"><span class="cls_037">General health</span></div>
<div style="position:absolute;left:150.09px;top:488.97px" class="cls_037"><span class="cls_037">1.4</span></div>
<div style="position:absolute;left:159.36px;top:488.97px" class="cls_037"><span class="cls_037">(1.9)</span></div>
<div style="position:absolute;left:180.09px;top:488.97px" class="cls_037"><span class="cls_037">5.8</span></div>
<div style="position:absolute;left:189.36px;top:488.97px" class="cls_037"><span class="cls_037">(2.0)</span></div>
<div style="position:absolute;left:216.08px;top:488.97px" class="cls_037"><span class="cls_037">3.2</span></div>
<div style="position:absolute;left:225.35px;top:488.97px" class="cls_037"><span class="cls_037">(1.9)</span></div>
<div style="position:absolute;left:253.63px;top:488.97px" class="cls_037"><span class="cls_037">5.4</span></div>
<div style="position:absolute;left:262.90px;top:488.97px" class="cls_037"><span class="cls_037">(1.9)</span></div>
<div style="position:absolute;left:52.78px;top:495.13px" class="cls_037"><span class="cls_037">Vitality</span></div>
<div style="position:absolute;left:150.08px;top:495.13px" class="cls_037"><span class="cls_037">1.0</span></div>
<div style="position:absolute;left:159.35px;top:495.13px" class="cls_037"><span class="cls_037">(2.0)</span></div>
<div style="position:absolute;left:180.08px;top:495.13px" class="cls_037"><span class="cls_037">6.9 (2.1)*</span></div>
<div style="position:absolute;left:216.08px;top:495.13px" class="cls_037"><span class="cls_037">4.7</span></div>
<div style="position:absolute;left:225.35px;top:495.13px" class="cls_037"><span class="cls_037">(2.0)</span></div>
<div style="position:absolute;left:253.63px;top:495.13px" class="cls_037"><span class="cls_037">6.2</span></div>
<div style="position:absolute;left:262.90px;top:495.13px" class="cls_037"><span class="cls_037">(2.0)</span></div>
<div style="position:absolute;left:306.64px;top:493.75px" class="cls_025"><span class="cls_025">CORRELATION WITH BASELINE CHARACTERISTICS</span></div>
<div style="position:absolute;left:52.88px;top:501.29px" class="cls_037"><span class="cls_037">Social functioning</span></div>
<div style="position:absolute;left:150.08px;top:501.29px" class="cls_037"><span class="cls_037">-0.2</span></div>
<div style="position:absolute;left:161.40px;top:501.29px" class="cls_037"><span class="cls_037">(2.4)</span></div>
<div style="position:absolute;left:180.07px;top:501.29px" class="cls_037"><span class="cls_037">10.5 (2.4)**</span></div>
<div style="position:absolute;left:216.07px;top:501.29px" class="cls_037"><span class="cls_037">13.4 (2.4)***</span></div>
<div style="position:absolute;left:253.62px;top:501.29px" class="cls_037"><span class="cls_037">8.2 (2.4)*</span></div>
<div style="position:absolute;left:52.88px;top:507.46px" class="cls_037"><span class="cls_037">Role-emotional</span></div>
<div style="position:absolute;left:150.07px;top:507.46px" class="cls_037"><span class="cls_037">1.3</span></div>
<div style="position:absolute;left:159.34px;top:507.46px" class="cls_037"><span class="cls_037">(2.0)</span></div>
<div style="position:absolute;left:180.07px;top:507.46px" class="cls_037"><span class="cls_037">5.2</span></div>
<div style="position:absolute;left:189.34px;top:507.46px" class="cls_037"><span class="cls_037">(2.1)</span></div>
<div style="position:absolute;left:216.07px;top:507.46px" class="cls_037"><span class="cls_037">6.1</span></div>
<div style="position:absolute;left:225.34px;top:507.46px" class="cls_037"><span class="cls_037">(2.0)</span></div>
<div style="position:absolute;left:253.62px;top:507.46px" class="cls_037"><span class="cls_037">6.0</span></div>
<div style="position:absolute;left:262.89px;top:507.46px" class="cls_037"><span class="cls_037">(2.0)</span></div>
<div style="position:absolute;left:306.64px;top:504.65px" class="cls_025"><span class="cls_025">OF PATIENTS WITH PSORIASIS VULGARIS: AN</span></div>
<div style="position:absolute;left:52.87px;top:513.62px" class="cls_037"><span class="cls_037">Mental health</span></div>
<div style="position:absolute;left:150.06px;top:513.62px" class="cls_037"><span class="cls_037">1.7</span></div>
<div style="position:absolute;left:159.33px;top:513.62px" class="cls_037"><span class="cls_037">(1.8)</span></div>
<div style="position:absolute;left:180.06px;top:513.62px" class="cls_037"><span class="cls_037">5.5</span></div>
<div style="position:absolute;left:189.33px;top:513.62px" class="cls_037"><span class="cls_037">(1.8)</span></div>
<div style="position:absolute;left:216.06px;top:513.62px" class="cls_037"><span class="cls_037">6.6</span></div>
<div style="position:absolute;left:225.33px;top:513.62px" class="cls_037"><span class="cls_037">(1.8)</span></div>
<div style="position:absolute;left:253.61px;top:513.62px" class="cls_037"><span class="cls_037">3.2</span></div>
<div style="position:absolute;left:262.88px;top:513.62px" class="cls_037"><span class="cls_037">(1.8)</span></div>
<div style="position:absolute;left:51.32px;top:519.78px" class="cls_037"><span class="cls_037">≥2.5 point improvement in SF-36</span></div>
<div style="position:absolute;left:150.06px;top:519.78px" class="cls_037"><span class="cls_037">36.5</span></div>
<div style="position:absolute;left:180.05px;top:519.78px" class="cls_037"><span class="cls_037">37.3</span></div>
<div style="position:absolute;left:216.05px;top:519.78px" class="cls_037"><span class="cls_037">45.1</span></div>
<div style="position:absolute;left:253.60px;top:519.78px" class="cls_037"><span class="cls_037">33.3</span></div>
<div style="position:absolute;left:306.64px;top:515.55px" class="cls_025"><span class="cls_025">EXPLORATORY ANALYSIS OF THE PHASE IIIB,</span></div>
<div style="position:absolute;left:51.32px;top:526.78px" class="cls_037"><span class="cls_037">MCS, % (NRI)</span></div>
<div style="position:absolute;left:306.64px;top:526.45px" class="cls_025"><span class="cls_025">PSORITUS STUDY</span></div>
<div style="position:absolute;left:51.31px;top:532.94px" class="cls_037"><span class="cls_037">≥2.5 point improvement in SF-36</span></div>
<div style="position:absolute;left:150.05px;top:532.94px" class="cls_037"><span class="cls_037">42.3</span></div>
<div style="position:absolute;left:180.05px;top:532.94px" class="cls_037"><span class="cls_037">52.9</span></div>
<div style="position:absolute;left:216.05px;top:532.94px" class="cls_037"><span class="cls_037">56.9</span></div>
<div style="position:absolute;left:253.60px;top:532.94px" class="cls_037"><span class="cls_037">62.7*</span></div>
<div style="position:absolute;left:51.31px;top:539.94px" class="cls_037"><span class="cls_037">PCS, % (NRI)</span></div>
<div style="position:absolute;left:306.64px;top:536.35px" class="cls_026"><span class="cls_026">Sonja Ständer</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Sabine Steinke</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Matthias Augustin</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Dieter Me-</span></div>
<div style="position:absolute;left:49.94px;top:547.19px" class="cls_037"><span class="cls_037">MCS, mental component summary; PtGa, Patient Global Assessment; PCS, physical component</span></div>
<div style="position:absolute;left:306.64px;top:546.25px" class="cls_026"><span class="cls_026">tze</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Karin Loser</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, </span><span class="cls_051">Daniel Baeumer</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Thomas Luger</span><span class="cls_027"><sup>4</sup></span></div>
<div style="position:absolute;left:49.94px;top:554.19px" class="cls_037"><span class="cls_037">summary; SE, standard error; SF-36, 36-Item Short Form Health Survey.</span></div>
<div style="position:absolute;left:306.64px;top:556.85px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Dermatology and Competence Center Chronic Pruritus</span></div>
<div style="position:absolute;left:49.94px;top:561.19px" class="cls_037"><span class="cls_037">*</span><span class="cls_038">p &lt; </span><span class="cls_037"> .05 vs placebo; **</span><span class="cls_038">p &lt; </span><span class="cls_037"> .01 vs placebo; ***</span><span class="cls_038">p &lt; </span><span class="cls_037"> .001 vs placebo.</span></div>
<div style="position:absolute;left:306.64px;top:566.45px" class="cls_029"><span class="cls_029">and </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Department of Dermatology, University hospital Münster, Münster,</span></div>
<div style="position:absolute;left:50.00px;top:576.76px" class="cls_033"><span class="cls_033">P133</span></div>
<div style="position:absolute;left:306.64px;top:576.05px" class="cls_028"><span class="cls_028"><sup>2</sup></span><span class="cls_029">Institute for Health Services Research in Dermatology and Nursing, Ham-</span></div>
<div style="position:absolute;left:306.64px;top:585.65px" class="cls_029"><span class="cls_029">burg, and </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Novartis Pharma, Nuernberg, Germany</span></div>
<div style="position:absolute;left:50.00px;top:588.16px" class="cls_025"><span class="cls_025">EFFECT    OF    TILDRAKIZUMAB    ON    PERSONAL</span></div>
<div style="position:absolute;left:306.64px;top:596.52px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Chronic pruritus lasts for at least 6 weeks and is a</span></div>
<div style="position:absolute;left:50.00px;top:599.06px" class="cls_025"><span class="cls_025">RELATIONSHIPS IN PATIENTS WITH MODERATE-TO-</span></div>
<div style="position:absolute;left:306.64px;top:606.52px" class="cls_031"><span class="cls_031">most common symptom in patients with psoriasis. Pruritus is a</span></div>
<div style="position:absolute;left:50.00px;top:609.96px" class="cls_025"><span class="cls_025">SEVERE CHRONIC PLAQUE PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:616.52px" class="cls_031"><span class="cls_031">highly prevalent and troublesome symptom and has a negative</span></div>
<div style="position:absolute;left:50.00px;top:619.86px" class="cls_026"><span class="cls_026">Kim Papp</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Alexa Kimball</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Andrew Blauvelt</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Kristian Reich</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.64px;top:626.52px" class="cls_031"><span class="cls_031">impact upon patients’ health-related quality of life (QoL). The</span></div>
<div style="position:absolute;left:50.00px;top:629.76px" class="cls_026"><span class="cls_026">Melinda Gooderham</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Stephen Tyring</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Rodney Sinclair</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Diamant</span></div>
<div style="position:absolute;left:306.64px;top:636.52px" class="cls_031"><span class="cls_031">ItchyQoL is a pruritus-specific QoL questionnaire that can be app-</span></div>
<div style="position:absolute;left:50.00px;top:639.66px" class="cls_026"><span class="cls_026">Thaci</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">,</span><span class="cls_051"> Yang Zhao</span><span class="cls_027"><sup>9</sup></span><span class="cls_026">, Nicole Cichanowitz</span><span class="cls_027"><sup>10</sup></span><span class="cls_026">, Qing Li</span><span class="cls_027"><sup>10</sup></span><span class="cls_026">, Carmen La</span></div>
<div style="position:absolute;left:306.64px;top:646.52px" class="cls_031"><span class="cls_031">lied to patients with pruritus independent of the underlying disease.</span></div>
<div style="position:absolute;left:50.00px;top:649.56px" class="cls_026"><span class="cls_026">Rosa</span><span class="cls_027"><sup>10</sup></span></div>
<div style="position:absolute;left:306.64px;top:656.52px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To assess the impact of pruritus on QoL in patients with</span></div>
<div style="position:absolute;left:50.00px;top:660.16px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">K Papp Clinical Research and Probity Medical Research, Waterloo, On-</span></div>
<div style="position:absolute;left:50.00px;top:669.76px" class="cls_029"><span class="cls_029">tario, Canada, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Harvard Medical School, Boston, MA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Oregon Medical</span></div>
<div style="position:absolute;left:306.64px;top:666.52px" class="cls_031"><span class="cls_031">psoriasis by an exploratory analysis of baseline characteristics of</span></div>
<div style="position:absolute;left:50.00px;top:679.36px" class="cls_029"><span class="cls_029">Research Center, Portland, OR, USA, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">ScIderm Research Institute and</span></div>
<div style="position:absolute;left:306.64px;top:676.52px" class="cls_031"><span class="cls_031">subjects from the PSORITUS study.</span></div>
<div style="position:absolute;left:50.00px;top:688.96px" class="cls_029"><span class="cls_029">Dermatologikum Hamburg, Hamburg, Germany, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">SKiN Centre for Derma-</span></div>
<div style="position:absolute;left:306.64px;top:686.52px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">PSORITUS was an exploratory, randomized, double-</span></div>
<div style="position:absolute;left:50.00px;top:698.56px" class="cls_029"><span class="cls_029">tology and Probity Medical Research, Peterborough, and Queen’s Univer-</span></div>
<div style="position:absolute;left:306.64px;top:696.51px" class="cls_031"><span class="cls_031">blind, placebo-controlled 16-week drug withdrawal study with a</span></div>
<div style="position:absolute;left:50.00px;top:708.16px" class="cls_029"><span class="cls_029">sity, Kingston, Ontario, Canada, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">Department of Dermatology, University</span></div>
<div style="position:absolute;left:306.64px;top:706.51px" class="cls_031"><span class="cls_031">16-week open-label run-in phase, to assess the kinetics of psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:717.76px" class="cls_029"><span class="cls_029">of Texas, Houston, TX, USA, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">University of Melbourne, Melbourne, VIC,</span></div>
<div style="position:absolute;left:306.64px;top:716.51px" class="cls_031"><span class="cls_031">symptoms, pruritus intensity, and lesional biomarkers. Subjects</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:44165px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background57.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">55</span></div>
<div style="position:absolute;left:50.09px;top:51.41px" class="cls_031"><span class="cls_031">≥18 years of age with chronic moderate-to-severe psoriasis at least</span></div>
<div style="position:absolute;left:306.64px;top:51.23px" class="cls_033"><span class="cls_033">P136</span></div>
<div style="position:absolute;left:50.10px;top:61.31px" class="cls_031"><span class="cls_031">6 months prior to baseline, with a Psoriasis Area and Severity</span></div>
<div style="position:absolute;left:306.64px;top:62.63px" class="cls_025"><span class="cls_025">SWEDISH PSORIATIC PATIENTS’ PERSPECTIVE OF</span></div>
<div style="position:absolute;left:50.10px;top:71.21px" class="cls_031"><span class="cls_031">Index (PASI) score </span><span class="cls_030"> > </span><span class="cls_031">10 at baseline, and pruritus intensity ≥30 on</span></div>
<div style="position:absolute;left:306.64px;top:73.53px" class="cls_025"><span class="cls_025">THEIR DISEASE. RESULTS FROM AN OBSERVATIONAL</span></div>
<div style="position:absolute;left:50.10px;top:81.11px" class="cls_031"><span class="cls_031">a 100-point Visual Analogue Scale (VAS, the worst itching within</span></div>
<div style="position:absolute;left:306.64px;top:84.43px" class="cls_025"><span class="cls_025">PATIENT SURVEY</span></div>
<div style="position:absolute;left:50.10px;top:91.01px" class="cls_031"><span class="cls_031">a recall period of 24 hours), were included. In an exploratory ba-</span></div>
<div style="position:absolute;left:306.64px;top:94.33px" class="cls_026"><span class="cls_026">Charlotta Enerbäck</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Sofie Fors</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, </span><span class="cls_051">Anna-Karin Dahlborn</span><span class="cls_027"><sup>2</sup></span></div>
<div style="position:absolute;left:50.09px;top:100.91px" class="cls_031"><span class="cls_031">seline analysis, correlation coefficients were calculated between</span></div>
<div style="position:absolute;left:306.64px;top:104.93px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Department of Dermatology, Linköping University Hospital, Linköping,</span></div>
<div style="position:absolute;left:50.09px;top:110.81px" class="cls_031"><span class="cls_031">ItchyQoL outputs and individual baseline characteristics based</span></div>
<div style="position:absolute;left:306.64px;top:114.53px" class="cls_029"><span class="cls_029">Sweden, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Novartis</span></div>
<div style="position:absolute;left:50.09px;top:120.71px" class="cls_031"><span class="cls_031">on Spearman‘s (r) and Kendall rank correlations (t). A multiple</span></div>
<div style="position:absolute;left:306.64px;top:125.40px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">A global patient survey was adapted and implemen-</span></div>
<div style="position:absolute;left:50.09px;top:130.61px" class="cls_031"><span class="cls_031">linear regression model was performed to assess the effect of</span></div>
<div style="position:absolute;left:306.64px;top:135.40px" class="cls_031"><span class="cls_031">ted in Sweden, in order to explore and understand the patients’ view</span></div>
<div style="position:absolute;left:50.09px;top:140.51px" class="cls_031"><span class="cls_031">exploratory variables correlating with the ItchyQoL score and</span></div>
<div style="position:absolute;left:306.64px;top:145.40px" class="cls_031"><span class="cls_031">on their disease, as well as the personal and emotional impact of</span></div>
<div style="position:absolute;left:50.09px;top:150.41px" class="cls_031"><span class="cls_031">achieving statistical significance (</span><span class="cls_030">p</span><span class="cls_031">-value </span><span class="cls_030"> &lt; </span><span class="cls_031">0.05).</span></div>
<div style="position:absolute;left:306.64px;top:155.40px" class="cls_031"><span class="cls_031">their psoriasis. The focus of the survey was the patient’s perception</span></div>
<div style="position:absolute;left:50.09px;top:160.31px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">The study included 130 subjects with psoriasis. The</span></div>
<div style="position:absolute;left:306.64px;top:165.40px" class="cls_031"><span class="cls_031">of the possibility to achieve clear skin, and how having clear skin</span></div>
<div style="position:absolute;left:50.09px;top:170.21px" class="cls_031"><span class="cls_031">subjects had a mean age of 46.8 years (standard deviation [SD],</span></div>
<div style="position:absolute;left:306.64px;top:175.40px" class="cls_031"><span class="cls_031">could affect their quality of life. A publication based on earlier</span></div>
<div style="position:absolute;left:50.09px;top:180.11px" class="cls_031"><span class="cls_031">12.30) and majority (71.5%) were in the age group of 35-64 years.</span></div>
<div style="position:absolute;left:306.64px;top:185.39px" class="cls_031"><span class="cls_031">data is under review.</span></div>
<div style="position:absolute;left:50.09px;top:190.01px" class="cls_031"><span class="cls_031">The mean (SD) time since first diagnosis of psoriasis and psoriatic</span></div>
<div style="position:absolute;left:306.64px;top:195.39px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">The Swedish “Clear about Psoriasis” survey was conduc-</span></div>
<div style="position:absolute;left:50.09px;top:199.91px" class="cls_031"><span class="cls_031">arthritis (PsA) was 19.5 (13.81) and 17.2 (18.30) years, respectively;</span></div>
<div style="position:absolute;left:306.64px;top:205.40px" class="cls_031"><span class="cls_031">ted from June 16 2017 to August 8 2017. Recruitment was made</span></div>
<div style="position:absolute;left:50.09px;top:209.81px" class="cls_031"><span class="cls_031">13.8% of subjects had PsA. The mean (SD) baseline PASI, patient</span></div>
<div style="position:absolute;left:306.64px;top:215.40px" class="cls_031"><span class="cls_031">via online panels and patient organizations. Validated methods</span></div>
<div style="position:absolute;left:50.09px;top:219.71px" class="cls_031"><span class="cls_031">benefit index (PBI), and ItchyQoL score was 23.9 (10.85), 84.2</span></div>
<div style="position:absolute;left:306.64px;top:225.40px" class="cls_031"><span class="cls_031">were used to assess severity of disease and health-related quality</span></div>
<div style="position:absolute;left:50.11px;top:229.61px" class="cls_031"><span class="cls_031">(24.17), and 78.7 (17.42) respectively, indicating severe disease</span></div>
<div style="position:absolute;left:306.64px;top:235.40px" class="cls_031"><span class="cls_031">of life. The survey consisted of multiple-choice questions, no</span></div>
<div style="position:absolute;left:50.11px;top:239.51px" class="cls_031"><span class="cls_031">activity and pruritus. The baseline ItchyQoL score showed moderate</span></div>
<div style="position:absolute;left:306.64px;top:245.40px" class="cls_031"><span class="cls_031">definition of clear skin was given, and spontaneous feelings/per-</span></div>
<div style="position:absolute;left:50.11px;top:249.41px" class="cls_031"><span class="cls_031">correlation with baseline VAS scores for average and worst pruritus</span></div>
<div style="position:absolute;left:306.64px;top:255.40px" class="cls_031"><span class="cls_031">ceptions were reported. Respondents (≥18 years old) were required</span></div>
<div style="position:absolute;left:50.11px;top:259.31px" class="cls_031"><span class="cls_031">(r: 0.542 [95% CI: 0.41, 0.65] and 0.547 [95% CI: 0.41, 0.66]; t:</span></div>
<div style="position:absolute;left:306.63px;top:265.40px" class="cls_031"><span class="cls_031">to have current plaque psoriasis, for which they had received a</span></div>
<div style="position:absolute;left:50.11px;top:269.21px" class="cls_031"><span class="cls_031">0.381 [95% CI: 0.22, 0.52] and 0.383, 95% CI: 0.23, 0.52]) and</span></div>
<div style="position:absolute;left:306.63px;top:275.40px" class="cls_031"><span class="cls_031">medical diagnosis and should not have participated in an online</span></div>
<div style="position:absolute;left:50.11px;top:279.11px" class="cls_031"><span class="cls_031">a strong correlation with baseline dermatology life quality index</span></div>
<div style="position:absolute;left:306.63px;top:285.40px" class="cls_031"><span class="cls_031">survey about psoriasis in the preceding four weeks. The analysis</span></div>
<div style="position:absolute;left:50.11px;top:289.01px" class="cls_031"><span class="cls_031">(DLQI) scores (r: 0.803 [95% CI: 0.73, 0.86]; t: 0.622 [95% CI:</span></div>
<div style="position:absolute;left:306.63px;top:295.39px" class="cls_031"><span class="cls_031">included only patients with moderate-to-severe plaque psoriasis,</span></div>
<div style="position:absolute;left:50.11px;top:298.91px" class="cls_031"><span class="cls_031">0.50, 0.72]. Furthermore the multiple linear regression analysis</span></div>
<div style="position:absolute;left:306.63px;top:305.39px" class="cls_031"><span class="cls_031">defined as a Psoriasis Area Severity Index (PASI) score ≥10, or</span></div>
<div style="position:absolute;left:50.11px;top:308.81px" class="cls_031"><span class="cls_031">showed substantial dependency of QoL measured by ItchyQoL</span></div>
<div style="position:absolute;left:306.61px;top:315.39px" class="cls_031"><span class="cls_031">a PASI score 5.0-9.9 with plaques in visible and/or in sensitive</span></div>
<div style="position:absolute;left:50.11px;top:318.71px" class="cls_031"><span class="cls_031">for VAS (average pruritus last 24 h), duration of psoriasis and</span></div>
<div style="position:absolute;left:306.61px;top:325.39px" class="cls_031"><span class="cls_031">areas, such as the face and genitals.</span></div>
<div style="position:absolute;left:50.11px;top:328.61px" class="cls_031"><span class="cls_031">health-related patient needs as measured by patient benefit index.</span></div>
<div style="position:absolute;left:306.61px;top:335.39px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">In total, 54 patient responses were completed and analy-</span></div>
<div style="position:absolute;left:50.11px;top:338.51px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">ItchyQoL assessment demonstrated that subjects</span></div>
<div style="position:absolute;left:306.64px;top:345.40px" class="cls_031"><span class="cls_031">zed. Mean age was 45 years and 80% were female. The average</span></div>
<div style="position:absolute;left:50.11px;top:348.41px" class="cls_031"><span class="cls_031">with psoriasis are highly burdened by pruritus and show severely</span></div>
<div style="position:absolute;left:306.64px;top:355.40px" class="cls_031"><span class="cls_031">self-assessed PASI score was 16.0, 26% had PASI 5.0-9.9, 74%</span></div>
<div style="position:absolute;left:50.11px;top:358.31px" class="cls_031"><span class="cls_031">impaired quality of life. The correlation between pruritus intensity,</span></div>
<div style="position:absolute;left:306.64px;top:365.40px" class="cls_031"><span class="cls_031">PASI </span><span class="cls_030"> > </span><span class="cls_031">10 and 54% reported to have psoriatic arthritis. Current</span></div>
<div style="position:absolute;left:50.11px;top:368.21px" class="cls_031"><span class="cls_031">ItchyQoL- and DLQI questionnaire results suggests the need for</span></div>
<div style="position:absolute;left:306.64px;top:375.40px" class="cls_031"><span class="cls_031">treatment allowed 44% of patients to achieve clear or almost clear</span></div>
<div style="position:absolute;left:50.11px;top:378.11px" class="cls_031"><span class="cls_031">routine assessment of pruritus in clinical practice.</span></div>
<div style="position:absolute;left:306.64px;top:385.39px" class="cls_031"><span class="cls_031">skin. Clear or almost clear skin was believed to be achievable by</span></div>
<div style="position:absolute;left:50.09px;top:396.74px" class="cls_033"><span class="cls_033">P135</span></div>
<div style="position:absolute;left:306.64px;top:395.39px" class="cls_031"><span class="cls_031">30% of the patients. Of patients reaching clear or almost clear</span></div>
<div style="position:absolute;left:306.64px;top:405.39px" class="cls_031"><span class="cls_031">skin, 71% had talked to their physician about their aim for clear</span></div>
<div style="position:absolute;left:50.09px;top:408.14px" class="cls_025"><span class="cls_025">QUALITY OF LIFE AND PSYCHOSOCIAL</span></div>
<div style="position:absolute;left:306.64px;top:415.39px" class="cls_031"><span class="cls_031">skin. Among patients who have not achieved clear or almost clear</span></div>
<div style="position:absolute;left:50.09px;top:419.04px" class="cls_025"><span class="cls_025">IMPLICATIONS IN PATIENTS WITH PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:425.39px" class="cls_031"><span class="cls_031">skin, 47% had spoken to their physician about their aim. 57% of</span></div>
<div style="position:absolute;left:50.09px;top:428.94px" class="cls_026"><span class="cls_026">Anargyros Kouris</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Eftychia Platsidaki</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Alexandros Katoulis</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Va-</span></div>
<div style="position:absolute;left:306.64px;top:435.39px" class="cls_031"><span class="cls_031">the patients were satisfied with their current treatment. The most</span></div>
<div style="position:absolute;left:50.09px;top:438.84px" class="cls_026"><span class="cls_026">siliki Markanton</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Christos Christodoulou</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Evangelos Balaskas</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:306.62px;top:445.39px" class="cls_031"><span class="cls_031">important reasons for treatment satisfaction were less itching (81%),</span></div>
<div style="position:absolute;left:50.09px;top:448.74px" class="cls_051"><span class="cls_051">Georgios Kontochristopoulos</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:306.62px;top:455.39px" class="cls_031"><span class="cls_031">and the achievement of less pain and soreness (55%). Not achieving</span></div>
<div style="position:absolute;left:50.09px;top:459.34px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Andreas Sygros Skin Hospital,</span></div>
<div style="position:absolute;left:162.56px;top:459.34px" class="cls_028"><span class="cls_028"><sup>2</sup></span><span class="cls_029">Attikon University Hospital, Athens,</span></div>
<div style="position:absolute;left:50.09px;top:468.94px" class="cls_029"><span class="cls_029">Greece</span></div>
<div style="position:absolute;left:306.62px;top:465.39px" class="cls_031"><span class="cls_031">clear skin was the major reason for dissatisfaction. Discrimination</span></div>
<div style="position:absolute;left:306.62px;top:475.39px" class="cls_031"><span class="cls_031">or humiliation has been experienced by 98%. About 69% have</span></div>
<div style="position:absolute;left:50.09px;top:479.71px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is a common, long-term skin disease that</span></div>
<div style="position:absolute;left:306.62px;top:485.39px" class="cls_031"><span class="cls_031">been asked if they are contagious. Relationships were affected and</span></div>
<div style="position:absolute;left:50.09px;top:489.61px" class="cls_031"><span class="cls_031">affects approximately 1.5-3% of the population. The burden of</span></div>
<div style="position:absolute;left:306.62px;top:495.38px" class="cls_031"><span class="cls_031">52% avoided to have sex. Worklife was affected by 65% of the</span></div>
<div style="position:absolute;left:50.09px;top:499.51px" class="cls_031"><span class="cls_031">living with psoriasis is equivalent to or greater than that seen in</span></div>
<div style="position:absolute;left:306.62px;top:505.38px" class="cls_031"><span class="cls_031">respondents. For 58% of patients it took more than 5 years to get</span></div>
<div style="position:absolute;left:50.09px;top:509.41px" class="cls_031"><span class="cls_031">other long-term conditions, such as cardiac failure and chronic</span></div>
<div style="position:absolute;left:306.62px;top:515.38px" class="cls_031"><span class="cls_031">a treatment that resulted in clear or almost clear skin. During the</span></div>
<div style="position:absolute;left:50.09px;top:519.31px" class="cls_031"><span class="cls_031">lung disease. The stigma provoked by the disease, often lead</span></div>
<div style="position:absolute;left:306.62px;top:525.38px" class="cls_031"><span class="cls_031">last 6 months, 24% of employed patients had taken at least one day</span></div>
<div style="position:absolute;left:50.09px;top:529.21px" class="cls_031"><span class="cls_031">to the discontinuation of daily activities and social withdrawal.</span></div>
<div style="position:absolute;left:306.62px;top:535.38px" class="cls_031"><span class="cls_031">off work due to their disease whilst 5% took more than 14 days.</span></div>
<div style="position:absolute;left:50.09px;top:539.11px" class="cls_031"><span class="cls_031">Nevertheless, these effects of psoriasis are seldom recognized and</span></div>
<div style="position:absolute;left:306.62px;top:545.38px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> This survey shows that a majority of patients do not</span></div>
<div style="position:absolute;left:50.09px;top:549.01px" class="cls_031"><span class="cls_031">often undertreated.</span></div>
<div style="position:absolute;left:306.62px;top:555.38px" class="cls_031"><span class="cls_031">believe achieving clear or almost clear skin is possible and they</span></div>
<div style="position:absolute;left:50.09px;top:558.91px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">The aim of the study is to evaluate the quality of life,</span></div>
<div style="position:absolute;left:306.62px;top:565.38px" class="cls_031"><span class="cls_031">are not comfortable to talk to their physician about it. Furthermore,</span></div>
<div style="position:absolute;left:50.09px;top:568.81px" class="cls_031"><span class="cls_031">anxiety and depression, self-esteem and loneliness in patients</span></div>
<div style="position:absolute;left:306.62px;top:575.38px" class="cls_031"><span class="cls_031">patients encounter a stigmatizing environment. Better treatment</span></div>
<div style="position:absolute;left:50.09px;top:578.71px" class="cls_031"><span class="cls_031">with psoriasis.</span></div>
<div style="position:absolute;left:306.62px;top:585.38px" class="cls_031"><span class="cls_031">as well as improved patient information is needed.</span></div>
<div style="position:absolute;left:50.09px;top:588.61px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Ninety-eight patients with psoriasis were enrolled in the</span></div>
<div style="position:absolute;left:306.64px;top:595.41px" class="cls_032"><span class="cls_032">Novartis is grateful to Psoriasisförbundet for facilitating the survey.</span></div>
<div style="position:absolute;left:50.09px;top:598.51px" class="cls_031"><span class="cls_031">study. The quality of life, depression and anxiety, loneliness and</span></div>
<div style="position:absolute;left:50.09px;top:608.41px" class="cls_031"><span class="cls_031">self-esteem of the patient were assessed using the Dermatology</span></div>
<div style="position:absolute;left:306.64px;top:612.03px" class="cls_033"><span class="cls_033">P137</span></div>
<div style="position:absolute;left:50.09px;top:618.31px" class="cls_031"><span class="cls_031">Life Quality Index, Hospital Anxiety and Depression Scale, the</span></div>
<div style="position:absolute;left:306.64px;top:623.43px" class="cls_025"><span class="cls_025">IXEKIZUMAB PROVIDES GREATER CUMULAŦIVE</span></div>
<div style="position:absolute;left:50.09px;top:628.21px" class="cls_031"><span class="cls_031">UCLA loneliness Scale (UCLA-Version 3) and Rosenberg’s Self-</span></div>
<div style="position:absolute;left:306.64px;top:634.33px" class="cls_025"><span class="cls_025">BENEFITS VERSUS USTEKINUMAB OVER 24 WEEKS</span></div>
<div style="position:absolute;left:50.09px;top:638.11px" class="cls_031"><span class="cls_031">esteem Scale, respectively.</span></div>
<div style="position:absolute;left:306.64px;top:645.23px" class="cls_025"><span class="cls_025">FOR PATIENTS WITH MODERATE-TO-SEVERE</span></div>
<div style="position:absolute;left:50.09px;top:648.01px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">The Dermatology Quality of Life Index score among pso-</span></div>
<div style="position:absolute;left:50.09px;top:657.91px" class="cls_031"><span class="cls_031">riasis patients was 13.52</span><span class="cls_035">±</span><span class="cls_031">4.58. They had statistically significantly</span></div>
<div style="position:absolute;left:306.64px;top:656.13px" class="cls_025"><span class="cls_025">PSORIASIS IN A RANDOMIZED, DOUBLE-BLIND</span></div>
<div style="position:absolute;left:50.09px;top:667.81px" class="cls_031"><span class="cls_031">higher scores according to the Hospital Anxiety and Depression</span></div>
<div style="position:absolute;left:306.64px;top:667.03px" class="cls_025"><span class="cls_025">PHASE 3B CLINICAL TRIAL</span></div>
<div style="position:absolute;left:50.09px;top:677.71px" class="cls_031"><span class="cls_031">Scale -anxiety subscale (</span><span class="cls_030">p = </span><span class="cls_031">0.031)-compared with healthy volun-</span></div>
<div style="position:absolute;left:306.64px;top:676.93px" class="cls_026"><span class="cls_026">Andrew Blauvelt</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Mark Lomaga</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, </span><span class="cls_051">Russel Burge</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Baojin Zhu</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:50.09px;top:687.61px" class="cls_031"><span class="cls_031">teers. Moreover, a statistically significant difference was found</span></div>
<div style="position:absolute;left:306.64px;top:686.83px" class="cls_026"><span class="cls_026">Carsten Henneges</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Wei Shen</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, David Shrom</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Martin Dossen-</span></div>
<div style="position:absolute;left:50.10px;top:697.51px" class="cls_031"><span class="cls_031">between the two groups concerning the UCLA-scale (</span><span class="cls_030">p = </span><span class="cls_031">0.032)</span></div>
<div style="position:absolute;left:306.64px;top:696.73px" class="cls_026"><span class="cls_026">bach</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Andreas Pinter</span><span class="cls_027"><sup>4</sup></span></div>
<div style="position:absolute;left:50.10px;top:707.41px" class="cls_031"><span class="cls_031">and RSES-scale (</span><span class="cls_030">p &lt; </span><span class="cls_031">0.0001). Female patients presented with lower</span></div>
<div style="position:absolute;left:306.64px;top:707.33px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Oregon Medical Research Center, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">DermEdge Research, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Eli Lilly and</span></div>
<div style="position:absolute;left:50.10px;top:717.31px" class="cls_031"><span class="cls_031">self-esteem than male patients.</span></div>
<div style="position:absolute;left:306.64px;top:716.93px" class="cls_029"><span class="cls_029">Company, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">University Hospital Frankfurt</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:44968px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background58.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">56</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Ixekizumab, a high-affinity monoclonal antibody</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To assess the baseline characteristics of PsA pts sub-</span></div>
<div style="position:absolute;left:50.00px;top:61.35px" class="cls_031"><span class="cls_031">that selectively targets IL-17A, was shown to be superior to uste-</span></div>
<div style="position:absolute;left:306.64px;top:61.39px" class="cls_031"><span class="cls_031">scribed to c@h, and the level of pt satisfaction with the program</span></div>
<div style="position:absolute;left:50.00px;top:71.29px" class="cls_031"><span class="cls_031">kinumab, an IL-12/23 inhibitor, with respect to skin clearance and</span></div>
<div style="position:absolute;left:306.64px;top:71.37px" class="cls_031"><span class="cls_031">across indications (Sep 2017 data cut).</span></div>
<div style="position:absolute;left:50.00px;top:81.23px" class="cls_031"><span class="cls_031">quality of life up to 24 wks in patients with moderate-to-severe</span></div>
<div style="position:absolute;left:306.64px;top:81.35px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">c@h was launched in Jun 2014, and is available to pts</span></div>
<div style="position:absolute;left:50.00px;top:91.17px" class="cls_031"><span class="cls_031">psoriasis in IXORA-S1.</span></div>
<div style="position:absolute;left:306.64px;top:91.33px" class="cls_031"><span class="cls_031">who are prescribed CZP according to the local product label. Pts</span></div>
<div style="position:absolute;left:50.00px;top:101.10px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">The objective of this analysis was to compare the</span></div>
<div style="position:absolute;left:306.64px;top:101.32px" class="cls_031"><span class="cls_031">must be CZP-naïve when subscribed to the program, and pt consent</span></div>
<div style="position:absolute;left:50.00px;top:111.04px" class="cls_031"><span class="cls_031">cumulative benefits of ixekizumab versus ustekinumab at 12 and</span></div>
<div style="position:absolute;left:306.64px;top:111.30px" class="cls_031"><span class="cls_031">is required prior to subscription by the treating physician. There</span></div>
<div style="position:absolute;left:50.01px;top:120.97px" class="cls_031"><span class="cls_031">24 weeks of treatment in IXORA-S, with respect to skin clearance,</span></div>
<div style="position:absolute;left:306.64px;top:121.28px" class="cls_031"><span class="cls_031">are no additional criteria for enrolment, although the program must</span></div>
<div style="position:absolute;left:50.01px;top:130.91px" class="cls_031"><span class="cls_031">itching, health-related quality of life (HRQoL), and pain.</span></div>
<div style="position:absolute;left:306.64px;top:131.26px" class="cls_031"><span class="cls_031">be recommended to the pt by the treating physician. Pt satisfaction</span></div>
<div style="position:absolute;left:50.01px;top:140.85px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">In the IXORA-S trial, patients were randomized (1:1)</span></div>
<div style="position:absolute;left:306.64px;top:141.21px" class="cls_031"><span class="cls_031">across indications (PsA, rheumatoid arthritis and axial spondylo-</span></div>
<div style="position:absolute;left:50.01px;top:150.78px" class="cls_031"><span class="cls_031">to receive either IXE (160-mg starting dose, then 80-mg every 2</span></div>
<div style="position:absolute;left:306.64px;top:151.19px" class="cls_031"><span class="cls_031">arthritis) was measured at program completion or discontinuation</span></div>
<div style="position:absolute;left:50.01px;top:160.72px" class="cls_031"><span class="cls_031">wks for 12 wks followed by 80-mg every 4 wks; </span><span class="cls_030">n = </span><span class="cls_031">136) or UST</span></div>
<div style="position:absolute;left:306.64px;top:161.17px" class="cls_031"><span class="cls_031">using the net promoter score (NPS), which has previously been</span></div>
<div style="position:absolute;left:50.01px;top:170.65px" class="cls_031"><span class="cls_031">(45-mg/90-mg weight-based dosing per label; </span><span class="cls_030">n = </span><span class="cls_031">166) through</span></div>
<div style="position:absolute;left:306.64px;top:171.15px" class="cls_031"><span class="cls_031">used for this purpose.1 The NPS is derived by asking pts to state</span></div>
<div style="position:absolute;left:50.01px;top:180.59px" class="cls_031"><span class="cls_031">52 wks. Data at week 12 and week 24 were used in this post-hoc</span></div>
<div style="position:absolute;left:306.64px;top:181.13px" class="cls_031"><span class="cls_031">the likelihood that they would recommend c@h to others (on a</span></div>
<div style="position:absolute;left:50.01px;top:190.53px" class="cls_031"><span class="cls_031">analysis. At wks 2, 4, and every 4 wks thereafter, clinical benefits</span></div>
<div style="position:absolute;left:306.64px;top:191.11px" class="cls_031"><span class="cls_031">0-10 scale). Rankings of 9-10 are considered ‘promoters’, 7-8</span></div>
<div style="position:absolute;left:50.01px;top:200.46px" class="cls_031"><span class="cls_031">were measured using percentage improvements in Psoriasis Area</span></div>
<div style="position:absolute;left:306.64px;top:201.09px" class="cls_031"><span class="cls_031">‘passives’, and 0-6 ‘detractors’. Subtracting the percentage of</span></div>
<div style="position:absolute;left:50.01px;top:210.40px" class="cls_031"><span class="cls_031">and Severity Index (PASI 75/90/100); the Itch Numeric Rating</span></div>
<div style="position:absolute;left:306.64px;top:211.08px" class="cls_031"><span class="cls_031">detractors from that of promoters yields the NPS.</span></div>
<div style="position:absolute;left:50.01px;top:220.33px" class="cls_031"><span class="cls_031">Scale (NRS; 0</span><span class="cls_030"> = </span><span class="cls_031">no itch, 10</span><span class="cls_030"> = </span><span class="cls_031">worst itch imaginable); and Skin Pain</span></div>
<div style="position:absolute;left:306.64px;top:221.06px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">A cumulative total of 136 PsA pts had been registered to</span></div>
<div style="position:absolute;left:50.01px;top:230.27px" class="cls_031"><span class="cls_031">VAS (0</span><span class="cls_030"> = </span><span class="cls_031">no pain, 100</span><span class="cls_030"> = </span><span class="cls_031">maximum pain). Health-related quality</span></div>
<div style="position:absolute;left:306.64px;top:231.04px" class="cls_031"><span class="cls_031">c@h by Sep 2017. Mean age at baseline was 52 years; the majority</span></div>
<div style="position:absolute;left:50.01px;top:240.21px" class="cls_031"><span class="cls_031">of life (HRQoL) benefit was measured at wks 2, 4, 12, and 24</span></div>
<div style="position:absolute;left:306.64px;top:241.02px" class="cls_031"><span class="cls_031">were female (69%). Prior biological DMARD exposure was 24%.</span></div>
<div style="position:absolute;left:50.02px;top:250.14px" class="cls_031"><span class="cls_031">using the Dermatology Life Quality Index (DLQI) [DLQI score </span><span class="cls_030"> =</span></div>
<div style="position:absolute;left:306.64px;top:250.96px" class="cls_031"><span class="cls_031">The most common topics discussed on calls were treatment adhe-</span></div>
<div style="position:absolute;left:50.02px;top:260.08px" class="cls_031"><span class="cls_031">0.1 indicates no effect on patient’s life]. Total benefits - PASI</span></div>
<div style="position:absolute;left:306.64px;top:260.94px" class="cls_031"><span class="cls_031">rence (290 calls), CZP maintenance dose (284 calls) and syringe</span></div>
<div style="position:absolute;left:50.03px;top:270.01px" class="cls_031"><span class="cls_031">75/90/100; itch NRS</span><span class="cls_030"> = </span><span class="cls_031">0; DLQI</span><span class="cls_030"> = </span><span class="cls_031">0.1; Pain VAS 0 - were used to</span></div>
<div style="position:absolute;left:306.64px;top:270.92px" class="cls_031"><span class="cls_031">disposal (201 calls). The average length per call was 15.7 min</span></div>
<div style="position:absolute;left:50.03px;top:279.95px" class="cls_031"><span class="cls_031">determine the area-under-the-curve (AUC) of responders for each</span></div>
<div style="position:absolute;left:306.64px;top:280.90px" class="cls_031"><span class="cls_031">(SD: 5.33) at the end of Week 0 (total: 135 calls), and 14.6 min</span></div>
<div style="position:absolute;left:50.03px;top:289.89px" class="cls_031"><span class="cls_031">outcome at 12 and 24 weeks. Missing values were imputed using</span></div>
<div style="position:absolute;left:306.64px;top:290.89px" class="cls_031"><span class="cls_031">(SD: 6.59) at the end of Week 52 (45 calls).</span></div>
<div style="position:absolute;left:50.03px;top:299.82px" class="cls_031"><span class="cls_031">non-responder imputation (NRI). AUC results, capturing the rapid</span></div>
<div style="position:absolute;left:306.64px;top:300.87px" class="cls_031"><span class="cls_031">Across indications, a cumulative total of 272/655 pts had either</span></div>
<div style="position:absolute;left:50.03px;top:309.76px" class="cls_031"><span class="cls_031">and sustained treatment response, were normalized as a percentage</span></div>
<div style="position:absolute;left:306.64px;top:310.85px" class="cls_031"><span class="cls_031">completed the coaching period (</span><span class="cls_030">n = </span><span class="cls_031">70) or discontinued (</span><span class="cls_030">n = </span><span class="cls_031">202)</span></div>
<div style="position:absolute;left:50.03px;top:319.69px" class="cls_031"><span class="cls_031">of maximum possible (0-100%) AUC. The clinical benefit ratios</span></div>
<div style="position:absolute;left:306.64px;top:320.87px" class="cls_031"><span class="cls_031">by 28 Sep 2017, of whom 106 rated the program. Of these, 87.5%</span></div>
<div style="position:absolute;left:50.03px;top:329.63px" class="cls_031"><span class="cls_031">between IXE vs UST were calculated for each outcome to show</span></div>
<div style="position:absolute;left:306.64px;top:330.89px" class="cls_031"><span class="cls_031">gave promoter scores, 10.4% passive, and 3.8% detractor, yiel-</span></div>
<div style="position:absolute;left:50.03px;top:339.57px" class="cls_031"><span class="cls_031">relative cumulative benefit.</span></div>
<div style="position:absolute;left:306.64px;top:340.91px" class="cls_031"><span class="cls_031">ding an NPS of 83.7. The program was still ongoing at the time</span></div>
<div style="position:absolute;left:50.03px;top:349.50px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">At 12 wks, the normalized cumulative clinical benefit</span></div>
<div style="position:absolute;left:306.64px;top:350.94px" class="cls_031"><span class="cls_031">of this data cut.</span></div>
<div style="position:absolute;left:50.03px;top:359.44px" class="cls_031"><span class="cls_031">with IXE vs UST, respectively, was 58.2% and 32.9% (PASI75);</span></div>
<div style="position:absolute;left:306.64px;top:360.96px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">c@h offers support and guidance to CZP-treated pts</span></div>
<div style="position:absolute;left:50.03px;top:369.37px" class="cls_031"><span class="cls_031">36.7% and 15.6% (PASI90); 14.2% and 4.0% (PASI100); 25.3%</span></div>
<div style="position:absolute;left:306.64px;top:370.99px" class="cls_031"><span class="cls_031">in Germany. Feedback from pts willing to provide a rating (39%)</span></div>
<div style="position:absolute;left:50.03px;top:379.31px" class="cls_031"><span class="cls_031">and 14.3% (itch); 36.0% and 23.7% (pain); and 44.9% and 25.2%</span></div>
<div style="position:absolute;left:306.64px;top:381.02px" class="cls_031"><span class="cls_031">indicates a high level of satisfaction with the program.</span></div>
<div style="position:absolute;left:50.03px;top:389.25px" class="cls_031"><span class="cls_031">(DLQI). Cumulative clinical benefits at week 24 for IXE and UST,</span></div>
<div style="position:absolute;left:306.64px;top:391.04px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:50.02px;top:399.18px" class="cls_031"><span class="cls_031">respectively, were 74.3% and 54.3% (PASI75), 58.1% and 32.3%</span></div>
<div style="position:absolute;left:306.64px;top:401.09px" class="cls_032"><span class="cls_032">1. Hamilton DF. Bone Joint J 2014;96-B(5):622-8.</span></div>
<div style="position:absolute;left:50.02px;top:409.12px" class="cls_031"><span class="cls_031">(PASI90), 29.0% and 12.2% (PASI100); 33.5% and 22.1% (itch);</span></div>
<div style="position:absolute;left:306.64px;top:410.12px" class="cls_043"><span class="cls_043">Acknowledgements:</span><span class="cls_032"> c@h is performed by Healthcare@home Deutschland</span></div>
<div style="position:absolute;left:50.02px;top:419.05px" class="cls_031"><span class="cls_031">42.7% and 30.6% (pain); and 54.3% and 37.0% (DLQI). At 12 wks,</span></div>
<div style="position:absolute;left:306.64px;top:419.14px" class="cls_032"><span class="cls_032">GmbH, funded by UCB Pharma, led by Elke Zeise and managed by Karen</span></div>
<div style="position:absolute;left:50.02px;top:428.99px" class="cls_031"><span class="cls_031">clinical benefit ratios (IXE/UST) for PASI 75/90/100 were 1.77,</span></div>
<div style="position:absolute;left:306.64px;top:428.16px" class="cls_032"><span class="cls_032">Thiel and Manh Dan Nguyen. We thank the patients and their caregivers</span></div>
<div style="position:absolute;left:306.64px;top:437.19px" class="cls_032"><span class="cls_032">in addition to the investigators and their teams who contributed to this</span></div>
<div style="position:absolute;left:50.02px;top:438.93px" class="cls_031"><span class="cls_031">2.36, and 3.52; 1.51 for pain; and 1.78 for both itch and DLQI. At</span></div>
<div style="position:absolute;left:306.64px;top:446.21px" class="cls_032"><span class="cls_032">program. Editorial services were provided by Costello Medical.</span></div>
<div style="position:absolute;left:50.02px;top:448.86px" class="cls_031"><span class="cls_031">24 wks, the ratios were 1.37, 1.80, 2.38 (PASI 75/90/100), 1.52</span></div>
<div style="position:absolute;left:50.02px;top:458.80px" class="cls_031"><span class="cls_031">(itch), 1.39 (pain) and 1.47 (DLQI).</span></div>
<div style="position:absolute;left:306.64px;top:463.88px" class="cls_033"><span class="cls_033">P139</span></div>
<div style="position:absolute;left:50.02px;top:468.73px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Cumulative benefits measured by PASI, itch, pain,</span></div>
<div style="position:absolute;left:306.64px;top:475.30px" class="cls_025"><span class="cls_025">A COMPREHENSIVE SURVEY ASSESSING THE FAMILY</span></div>
<div style="position:absolute;left:50.02px;top:478.67px" class="cls_031"><span class="cls_031">and DLQI responders were greater for IXE vs. UST following 12</span></div>
<div style="position:absolute;left:50.02px;top:488.61px" class="cls_031"><span class="cls_031">and 24 wks of treatment. Long-term cumulative benefits will be</span></div>
<div style="position:absolute;left:306.64px;top:486.23px" class="cls_025"><span class="cls_025">PLANNING NEEDS OF WOMEN WITH PSORIASIS</span></div>
<div style="position:absolute;left:50.04px;top:498.54px" class="cls_031"><span class="cls_031">addressed upon publication of Week 52 results from the IXORA-S</span></div>
<div style="position:absolute;left:306.64px;top:496.16px" class="cls_051"><span class="cls_051">Mark Lebwohl</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Abby S Van Voorhees</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Michael Siegel</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Lindsey</span></div>
<div style="position:absolute;left:50.00px;top:508.65px" class="cls_031"><span class="cls_031">trial.</span></div>
<div style="position:absolute;left:306.65px;top:506.09px" class="cls_026"><span class="cls_026">Shankle</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Lisa Pisenti</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Mohamed Yassine</span><span class="cls_027"><sup>4</sup></span></div>
<div style="position:absolute;left:306.64px;top:516.72px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Icahn School of Medicine at Mount Sinai, New York, NY, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Eastern Virginia</span></div>
<div style="position:absolute;left:50.00px;top:518.65px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:50.00px;top:528.67px" class="cls_032"><span class="cls_032">Reich K, et al. Br J Dermatol. 2017;177(4):1014-1023.</span></div>
<div style="position:absolute;left:306.64px;top:526.34px" class="cls_029"><span class="cls_029">Medical School, Norfolk, VA, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">National Psoriasis Foundation, Portland,</span></div>
<div style="position:absolute;left:50.00px;top:537.67px" class="cls_032"><span class="cls_032">Previously presented at AAD, San Diego, CA; February 16 - 20, 2018.</span></div>
<div style="position:absolute;left:306.64px;top:535.97px" class="cls_029"><span class="cls_029">OR, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">UCB Pharma, Smyrna, GA, USA</span></div>
<div style="position:absolute;left:306.64px;top:546.86px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis (PS) in women often overlaps with their</span></div>
<div style="position:absolute;left:50.00px;top:555.29px" class="cls_033"><span class="cls_033">P138</span></div>
<div style="position:absolute;left:306.64px;top:556.89px" class="cls_031"><span class="cls_031">peak reproductive years. Data on the family planning (FP) ex-</span></div>
<div style="position:absolute;left:50.00px;top:566.69px" class="cls_025"><span class="cls_025">COACH@HOME: A SUPPORT PROGRAM FOR</span></div>
<div style="position:absolute;left:306.64px;top:566.92px" class="cls_031"><span class="cls_031">perience of patients (pts) are therefore needed to optimize PS</span></div>
<div style="position:absolute;left:50.00px;top:577.59px" class="cls_025"><span class="cls_025">PATIENTS TREATED WITH CERTOLIZUMAB PEGOL</span></div>
<div style="position:absolute;left:306.64px;top:576.94px" class="cls_031"><span class="cls_031">management.</span></div>
<div style="position:absolute;left:50.00px;top:587.49px" class="cls_026"><span class="cls_026">Nicolai Böhme</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Ann-Dörthe Holst</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Friedrich Dybowski</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Chris-</span></div>
<div style="position:absolute;left:306.64px;top:586.97px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To report the results of a survey evaluating the FP</span></div>
<div style="position:absolute;left:50.01px;top:597.39px" class="cls_026"><span class="cls_026">toph Volberg</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Hans-Georg Pott</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, </span><span class="cls_051">Udo Lendl</span><span class="cls_027"><sup>6</sup></span></div>
<div style="position:absolute;left:306.64px;top:597.00px" class="cls_031"><span class="cls_031">needs of women with PS.</span></div>
<div style="position:absolute;left:50.00px;top:607.99px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Healthcare at Home Deutschland GmbH, Weinheim, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Rheumapraxis, Lud-</span></div>
<div style="position:absolute;left:306.64px;top:607.02px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Women of childbearing potential (WoCP; aged 18-45)</span></div>
<div style="position:absolute;left:50.00px;top:617.59px" class="cls_029"><span class="cls_029">wigslust, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Rheumapraxis Ruhr, Herne, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Rheumatologie in Neuss, Neuss,</span></div>
<div style="position:absolute;left:306.64px;top:617.05px" class="cls_031"><span class="cls_031">diagnosed with PS (including pts with psoriatic arthritis), were</span></div>
<div style="position:absolute;left:50.00px;top:627.19px" class="cls_028"><span class="cls_028"><sup>5</sup></span><span class="cls_029">Rheumatologikum Hannover, Hannover, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">UCB Pharma GmbH, Monheim</span></div>
<div style="position:absolute;left:306.64px;top:627.07px" class="cls_031"><span class="cls_031">recruited to complete a 96-question web-based survey on Sur-</span></div>
<div style="position:absolute;left:50.00px;top:636.79px" class="cls_029"><span class="cls_029">am Rhein, Germany</span></div>
<div style="position:absolute;left:306.64px;top:637.11px" class="cls_031"><span class="cls_031">veyGizmo®. The survey included questions on pts’ experience,</span></div>
<div style="position:absolute;left:50.00px;top:647.60px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Coach@home (c@h) is a German support program</span></div>
<div style="position:absolute;left:306.63px;top:647.14px" class="cls_031"><span class="cls_031">concerns and educational needs, and was disseminated using e-</span></div>
<div style="position:absolute;left:50.00px;top:657.56px" class="cls_031"><span class="cls_031">for certolizumab pegol (CZP)-treated patients (pts) with rheumatic</span></div>
<div style="position:absolute;left:306.63px;top:657.16px" class="cls_031"><span class="cls_031">blasts (the National Psoriasis Foundation, Advance E-News, and</span></div>
<div style="position:absolute;left:50.00px;top:667.51px" class="cls_031"><span class="cls_031">diseases, including psoriatic arthritis (PsA). Eight coaching calls</span></div>
<div style="position:absolute;left:306.63px;top:667.19px" class="cls_031"><span class="cls_031">TalkPsoriasis.org mailing lists) and social media (Facebook and</span></div>
<div style="position:absolute;left:50.00px;top:677.47px" class="cls_031"><span class="cls_031">are offered over one year, scheduled around critical milestones on</span></div>
<div style="position:absolute;left:306.63px;top:677.22px" class="cls_031"><span class="cls_031">Twitter). Responses were collected Dec 2017-Feb 2018.</span></div>
<div style="position:absolute;left:50.00px;top:687.42px" class="cls_031"><span class="cls_031">the therapeutic journey. These are made by trained nurses, who</span></div>
<div style="position:absolute;left:306.63px;top:687.24px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Of 141 pts completing the survey, 91 (65%) were plan-</span></div>
<div style="position:absolute;left:50.00px;top:697.37px" class="cls_031"><span class="cls_031">offer support and information about both the pt’s disease and its</span></div>
<div style="position:absolute;left:306.64px;top:697.28px" class="cls_031"><span class="cls_031">ning to conceive (PTC), and 66 (47%) had experienced pregnancy</span></div>
<div style="position:absolute;left:50.00px;top:707.33px" class="cls_031"><span class="cls_031">treatment with CZP.</span></div>
<div style="position:absolute;left:306.64px;top:707.30px" class="cls_031"><span class="cls_031">(EP) within the last 5 years. Prescribed systemic medications were</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:45771px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background59.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">57</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">being used by 40% of pts PTC and 12% of pts who had EP. Only</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">genders were more concerned by appearance (women: 73%, men:</span></div>
<div style="position:absolute;left:50.00px;top:61.40px" class="cls_031"><span class="cls_031">41% pts who had EP informed the healthcare provider (HCP)</span></div>
<div style="position:absolute;left:306.64px;top:61.40px" class="cls_031"><span class="cls_031">63%) than pain (women: 43%, men: 34%).</span></div>
<div style="position:absolute;left:50.00px;top:71.40px" class="cls_031"><span class="cls_031">treating their PS of their pregnancy right away, while 21% did</span></div>
<div style="position:absolute;left:306.64px;top:71.40px" class="cls_031"><span class="cls_031">A higher proportion of women than men were concerned by their</span></div>
<div style="position:absolute;left:50.00px;top:81.40px" class="cls_031"><span class="cls_031">not notify them at all.</span></div>
<div style="position:absolute;left:306.64px;top:81.40px" class="cls_031"><span class="cls_031">appearance (73% vs 63%), reported a greater impact on their</span></div>
<div style="position:absolute;left:50.00px;top:91.40px" class="cls_031"><span class="cls_031">While PTC, most pts who had not EP (88%), sought FP advice from</span></div>
<div style="position:absolute;left:306.64px;top:91.40px" class="cls_031"><span class="cls_031">choice of clothing (37% vs 21%), and always/usually tried to</span></div>
<div style="position:absolute;left:50.00px;top:101.40px" class="cls_031"><span class="cls_031">the internet; only 21% had consulted the HCP treating their PS,</span></div>
<div style="position:absolute;left:306.64px;top:101.40px" class="cls_031"><span class="cls_031">cover their skin (27% vs 16%). Similarly, psychosocial effects of</span></div>
<div style="position:absolute;left:50.00px;top:111.40px" class="cls_031"><span class="cls_031">compared to 55% of pts who had EP. Of the 96 pts who discussed</span></div>
<div style="position:absolute;left:306.64px;top:111.40px" class="cls_031"><span class="cls_031">disease tended to be greater in women: 16% women vs 8% men</span></div>
<div style="position:absolute;left:50.00px;top:121.40px" class="cls_031"><span class="cls_031">FP with the HCP treating their PS, just 7% said this was initiated by</span></div>
<div style="position:absolute;left:306.64px;top:121.40px" class="cls_031"><span class="cls_031">reported severe/extreme anxiety or depression; 29% women vs</span></div>
<div style="position:absolute;left:50.00px;top:131.40px" class="cls_031"><span class="cls_031">the HCP. Pts PTC were most influenced by their personal network</span></div>
<div style="position:absolute;left:306.64px;top:131.40px" class="cls_031"><span class="cls_031">18% men suffered sexually/in achieving intimacy. Similar pro-</span></div>
<div style="position:absolute;left:50.01px;top:141.40px" class="cls_031"><span class="cls_031">(e.g. family), but of pts who had EP, 41% said the HCP treating</span></div>
<div style="position:absolute;left:306.64px;top:141.41px" class="cls_031"><span class="cls_031">portions had suffered at work (women: 11%, men: 16%), while</span></div>
<div style="position:absolute;left:50.01px;top:151.40px" class="cls_031"><span class="cls_031">their PS was one of the most influential types of support in their</span></div>
<div style="position:absolute;left:306.64px;top:151.40px" class="cls_031"><span class="cls_031">a higher proportion of women (6%) than men (3%) struggled to</span></div>
<div style="position:absolute;left:50.03px;top:161.39px" class="cls_031"><span class="cls_031">FP decisions. Pts reported wanting information on the impact of</span></div>
<div style="position:absolute;left:306.64px;top:161.40px" class="cls_031"><span class="cls_031">live their lives as they did prior to their diagnosis. These findings</span></div>
<div style="position:absolute;left:50.03px;top:171.39px" class="cls_031"><span class="cls_031">PS and treatments on their baby, the heritability of PS, and flare</span></div>
<div style="position:absolute;left:306.61px;top:171.40px" class="cls_031"><span class="cls_031">have been corroborated by ethnography studies.</span></div>
<div style="position:absolute;left:50.04px;top:181.39px" class="cls_031"><span class="cls_031">management during pregnancy. During pregnancy, 65% pts who</span></div>
<div style="position:absolute;left:306.61px;top:181.40px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Despite similar clinical manifestations of PSO,</span></div>
<div style="position:absolute;left:50.04px;top:191.39px" class="cls_031"><span class="cls_031">had EP stopped treatment (of any type), 79% of whom did so out</span></div>
<div style="position:absolute;left:306.61px;top:191.40px" class="cls_031"><span class="cls_031">women in early adulthood tended to report a greater impact of</span></div>
<div style="position:absolute;left:50.04px;top:201.39px" class="cls_031"><span class="cls_031">of fear of harming their baby. In 40% cases where pts had stopped</span></div>
<div style="position:absolute;left:306.61px;top:201.40px" class="cls_031"><span class="cls_031">their disease on their lives, both physically, in terms of pain, and</span></div>
<div style="position:absolute;left:50.04px;top:211.39px" class="cls_031"><span class="cls_031">all and any treatment for PSO, the decision was initiated by the pt,</span></div>
<div style="position:absolute;left:306.61px;top:211.40px" class="cls_031"><span class="cls_031">psychosocially, in terms of effects on relationships and impact on</span></div>
<div style="position:absolute;left:50.04px;top:221.39px" class="cls_031"><span class="cls_031">and in 47%, by their PS treatment provider. Of pts who stopped</span></div>
<div style="position:absolute;left:306.61px;top:221.40px" class="cls_031"><span class="cls_031">their daily lives. Physician awareness of such gender differences</span></div>
<div style="position:absolute;left:50.04px;top:231.39px" class="cls_031"><span class="cls_031">treatment, 44% experienced a worsening in the severity of their</span></div>
<div style="position:absolute;left:306.61px;top:231.40px" class="cls_031"><span class="cls_031">in the impact of the disease on patients’ lives would encourage</span></div>
<div style="position:absolute;left:50.04px;top:241.39px" class="cls_031"><span class="cls_031">PS, yet most pts do/did not have a plan for flare management</span></div>
<div style="position:absolute;left:306.61px;top:241.40px" class="cls_031"><span class="cls_031">a more holistic approach to discussing treatment options with</span></div>
<div style="position:absolute;left:50.03px;top:251.39px" class="cls_031"><span class="cls_031">during pregnancy (PTC: 69%; EP: 65%). Many pts stopping all</span></div>
<div style="position:absolute;left:306.61px;top:251.39px" class="cls_031"><span class="cls_031">their patients.</span></div>
<div style="position:absolute;left:50.03px;top:261.38px" class="cls_031"><span class="cls_031">treatment had not been advised on restarting treatment post-partum</span></div>
<div style="position:absolute;left:306.61px;top:261.39px" class="cls_030"><span class="cls_030">Reference:</span></div>
<div style="position:absolute;left:50.03px;top:271.38px" class="cls_031"><span class="cls_031">(PTC: 42%; EP: 23%).</span></div>
<div style="position:absolute;left:306.64px;top:271.42px" class="cls_032"><span class="cls_032">1. A Conception of Adult Development. Daniel J. Levinson. 1986. Ame-</span></div>
<div style="position:absolute;left:50.03px;top:281.38px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Many WoCP with PS take systemic medications but</span></div>
<div style="position:absolute;left:306.64px;top:280.42px" class="cls_032"><span class="cls_032">rican Psychologist vol. 41, No. 1, 3-13</span></div>
<div style="position:absolute;left:50.03px;top:291.38px" class="cls_031"><span class="cls_031">many do not discuss FP with their PS treatment provider, and if</span></div>
<div style="position:absolute;left:50.03px;top:301.38px" class="cls_031"><span class="cls_031">they do, the discussion is rarely initiated by the HCP. PS treatment</span></div>
<div style="position:absolute;left:306.64px;top:299.04px" class="cls_033"><span class="cls_033">P141</span></div>
<div style="position:absolute;left:50.03px;top:311.38px" class="cls_031"><span class="cls_031">providers should prioritize discussing FP, and plan treatment</span></div>
<div style="position:absolute;left:306.64px;top:310.44px" class="cls_025"><span class="cls_025">CERTOLIZUMAB PEGOL IMPROVES PATIENT-</span></div>
<div style="position:absolute;left:50.03px;top:321.38px" class="cls_031"><span class="cls_031">around and during pregnancy. The educational needs of WoCP</span></div>
<div style="position:absolute;left:306.64px;top:321.34px" class="cls_025"><span class="cls_025">REPORTED OUTCOMES IN CHRONIC PLAQUE</span></div>
<div style="position:absolute;left:50.03px;top:331.38px" class="cls_031"><span class="cls_031">with PS include the impact of treatment on their baby, flare ma-</span></div>
<div style="position:absolute;left:306.64px;top:332.24px" class="cls_025"><span class="cls_025">PSORIASIS OVER 1 YEAR</span></div>
<div style="position:absolute;left:50.00px;top:341.41px" class="cls_031"><span class="cls_031">nagement during pregnancy, and restarting treatment post-partum.</span></div>
<div style="position:absolute;left:306.64px;top:342.14px" class="cls_051"><span class="cls_051">Diamant Thaçi</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Alice B Gottlieb</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Kristian Reich</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Jerry Bagel</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:50.00px;top:351.42px" class="cls_043"><span class="cls_043">Acknowledgements: </span><span class="cls_032">This study was funded by UCB Pharma. The survey</span></div>
<div style="position:absolute;left:306.64px;top:352.04px" class="cls_026"><span class="cls_026">Luke Peterson</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Oana Purcaru</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Jolanta Węgłowska</span><span class="cls_027"><sup>7</sup></span></div>
<div style="position:absolute;left:50.00px;top:360.42px" class="cls_032"><span class="cls_032">was conducted by the National Psoriasis Foundation. We thank the pa-</span></div>
<div style="position:absolute;left:306.64px;top:362.64px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">University Hospital of Schleswig-Holstein Campus Lübeck, Lübeck, Ger-</span></div>
<div style="position:absolute;left:50.00px;top:369.42px" class="cls_032"><span class="cls_032">tients who contributed to this study. Editorial services were provided by</span></div>
<div style="position:absolute;left:306.63px;top:372.24px" class="cls_029"><span class="cls_029">many, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Department of Dermatology, New York Medical College at Met-</span></div>
<div style="position:absolute;left:50.00px;top:378.42px" class="cls_032"><span class="cls_032">Costello Medical.</span></div>
<div style="position:absolute;left:306.64px;top:381.84px" class="cls_029"><span class="cls_029">ropolitan Hospital, NY, NY, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">SCIderm Research Institute, Hamburg, and</span></div>
<div style="position:absolute;left:306.64px;top:391.44px" class="cls_029"><span class="cls_029">Dermatologikum Berlin, Germany, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">Psoriasis Treatment Center of Central</span></div>
<div style="position:absolute;left:50.00px;top:397.04px" class="cls_033"><span class="cls_033">P140</span></div>
<div style="position:absolute;left:306.64px;top:401.04px" class="cls_029"><span class="cls_029">New Jersey, East Windsor, NJ, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">UCB Pharma, Raleigh, NC, USA, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">UCB</span></div>
<div style="position:absolute;left:50.00px;top:408.44px" class="cls_025"><span class="cls_025">THE PSYCHOSOCIAL IMPACT OF PSORIASIS:</span></div>
<div style="position:absolute;left:306.64px;top:410.64px" class="cls_029"><span class="cls_029">Pharma, Brussels, Belgium, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">Niepubliczny Zakład Opieki Zdrowotnej mul-</span></div>
<div style="position:absolute;left:50.00px;top:419.34px" class="cls_025"><span class="cls_025">DIFFERENTIAL EXPERIENCES OF MEN AND WOMEN</span></div>
<div style="position:absolute;left:306.64px;top:420.24px" class="cls_029"><span class="cls_029">tiMedica, Wrocław, Poland</span></div>
<div style="position:absolute;left:50.00px;top:430.24px" class="cls_025"><span class="cls_025">IN EARLY ADULTHOOD</span></div>
<div style="position:absolute;left:306.64px;top:431.11px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Certolizumab pegol (CZP) is an Fc-free, PEGylated,</span></div>
<div style="position:absolute;left:50.00px;top:440.14px" class="cls_026"><span class="cls_026">Caitriona Ryan</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Carl Vandeloo</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Duncan Munro</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">,</span><span class="cls_051"> Alvaro Arjona</span><span class="cls_027"><sup>1</sup></span></div>
<div style="position:absolute;left:306.64px;top:441.10px" class="cls_031"><span class="cls_031">anti-TNF biologic. Here we present patient (pt)-reported quality of</span></div>
<div style="position:absolute;left:50.00px;top:450.74px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Blackrock Clinic, Dublin, Ireland and University College, Dublin, Ireland,</span></div>
<div style="position:absolute;left:306.64px;top:451.10px" class="cls_031"><span class="cls_031">life (QoL), work productivity and social activities over 48 weeks</span></div>
<div style="position:absolute;left:50.00px;top:460.34px" class="cls_028"><span class="cls_028"><sup>2</sup></span><span class="cls_029">UCB Pharma, Brussels, Belgium, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">Cello Health, London, UK</span></div>
<div style="position:absolute;left:306.64px;top:461.10px" class="cls_031"><span class="cls_031">of CZP treatment.</span></div>
<div style="position:absolute;left:50.00px;top:471.21px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Plaque psoriasis (PSO) can have a profound im-</span></div>
<div style="position:absolute;left:306.64px;top:471.10px" class="cls_030"><span class="cls_030">Materials/Methods: </span><span class="cls_031">Data were pooled from CIMPASI-1</span></div>
<div style="position:absolute;left:50.00px;top:481.21px" class="cls_031"><span class="cls_031">pact on patients’ (pts’) psychosocial wellbeing, leading to self-</span></div>
<div style="position:absolute;left:306.64px;top:481.10px" class="cls_031"><span class="cls_031">(NCT02326298) and CIMPASI-2 (NCT02326272) phase 3 trials</span></div>
<div style="position:absolute;left:50.00px;top:491.20px" class="cls_031"><span class="cls_031">consciousness, embarrassment, depression, social isolation and</span></div>
<div style="position:absolute;left:306.64px;top:491.10px" class="cls_031"><span class="cls_031">of adults with PSO ≥6 months (psoriasis area and severity index</span></div>
<div style="position:absolute;left:50.00px;top:501.20px" class="cls_031"><span class="cls_031">stigmatization. However, little is known of how the impact of</span></div>
<div style="position:absolute;left:306.66px;top:501.10px" class="cls_031"><span class="cls_031">[PASI] ≥12, affected body surface area [BSA] ≥10%, physician’s</span></div>
<div style="position:absolute;left:50.00px;top:511.20px" class="cls_031"><span class="cls_031">disease differs between genders.</span></div>
<div style="position:absolute;left:306.65px;top:511.10px" class="cls_031"><span class="cls_031">global assessment [PGA] ≥3/5). Pts were randomized to CZP 400</span></div>
<div style="position:absolute;left:50.00px;top:521.20px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">To evaluate differences in the psychosocial impact of</span></div>
<div style="position:absolute;left:306.66px;top:521.10px" class="cls_031"><span class="cls_031">mg every 2 weeks (Q2W), CZP 200 mg Q2W (following 400 mg</span></div>
<div style="position:absolute;left:50.00px;top:531.20px" class="cls_031"><span class="cls_031">PSO on quality of life in men and women in early adulthood.</span></div>
<div style="position:absolute;left:306.66px;top:531.10px" class="cls_031"><span class="cls_031">loading dose at Weeks 0, 2, 4), or placebo (PBO) Q2W for 16</span></div>
<div style="position:absolute;left:50.00px;top:541.20px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Pts aged ≥18 in the US, Canada, France, Germany and</span></div>
<div style="position:absolute;left:306.66px;top:541.09px" class="cls_031"><span class="cls_031">weeks. Week 16 CZP-treated PASI 50 responders continued initial</span></div>
<div style="position:absolute;left:49.99px;top:551.20px" class="cls_031"><span class="cls_031">Italy without a diagnosis of psoriatic arthritis were invited to</span></div>
<div style="position:absolute;left:306.66px;top:551.09px" class="cls_031"><span class="cls_031">blinded treatment to Week 48 (PBO-treated PASI 50 responders</span></div>
<div style="position:absolute;left:49.99px;top:561.20px" class="cls_031"><span class="cls_031">complete a postal survey (Oct 2016-Jan 2017), in the ratio 3:1</span></div>
<div style="position:absolute;left:306.66px;top:561.09px" class="cls_031"><span class="cls_031">are not included). PASI 50 non-responders at Weeks 32, 40 and</span></div>
<div style="position:absolute;left:49.99px;top:571.20px" class="cls_031"><span class="cls_031">as being treated with advanced therapy (biologic/apremilast),</span></div>
<div style="position:absolute;left:306.66px;top:571.09px" class="cls_031"><span class="cls_031">48 were discontinued.</span></div>
<div style="position:absolute;left:49.99px;top:581.20px" class="cls_031"><span class="cls_031">or eligible for but not yet receiving advanced therapy. Answers</span></div>
<div style="position:absolute;left:306.66px;top:581.09px" class="cls_031"><span class="cls_031">Mean change from baseline (CFB) in Dermatology Life Quality</span></div>
<div style="position:absolute;left:49.99px;top:591.19px" class="cls_031"><span class="cls_031">were given on 5- or 7-point Likert Scale. Percentages shown are</span></div>
<div style="position:absolute;left:306.66px;top:591.09px" class="cls_031"><span class="cls_031">Index (DLQI), rates for DLQI minimally clinically important diffe-</span></div>
<div style="position:absolute;left:49.99px;top:601.19px" class="cls_031"><span class="cls_031">proportions of pts responding using either of the two responses</span></div>
<div style="position:absolute;left:306.64px;top:601.11px" class="cls_031"><span class="cls_031">rence (MCID; ≥4-point improvement) and DLQI remission (score</span></div>
<div style="position:absolute;left:49.99px;top:611.19px" class="cls_031"><span class="cls_031">indicating greatest impact of disease. Data are presented for pts in</span></div>
<div style="position:absolute;left:306.63px;top:611.10px" class="cls_031"><span class="cls_031">of 0/1), and CFB in Work Productivity and Activity Impairment</span></div>
<div style="position:absolute;left:49.99px;top:621.19px" class="cls_031"><span class="cls_031">early adulthood (18-45 years),[1] stratified by gender.</span></div>
<div style="position:absolute;left:306.63px;top:621.10px" class="cls_031"><span class="cls_031">(WPAI) PSO-specific at Weeks 16 and 48 were assessed. Negative</span></div>
<div style="position:absolute;left:49.99px;top:631.19px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">63 women and 73 men completed the survey; mean age</span></div>
<div style="position:absolute;left:306.63px;top:631.10px" class="cls_031"><span class="cls_031">CFB for DLQI and WPAI signifies improvement. CFB DLQI</span></div>
<div style="position:absolute;left:49.99px;top:641.19px" class="cls_031"><span class="cls_031">was 35 and 36 years, respectively, mean age at diagnosis was 28 for</span></div>
<div style="position:absolute;left:306.63px;top:641.10px" class="cls_031"><span class="cls_031">analyses used last observation carried forward (LOCF) imputation</span></div>
<div style="position:absolute;left:49.99px;top:651.19px" class="cls_031"><span class="cls_031">both genders. Disease distribution was similar between genders,</span></div>
<div style="position:absolute;left:306.63px;top:651.10px" class="cls_031"><span class="cls_031">for missing data, DLQI MCID and remission analyses used non-</span></div>
<div style="position:absolute;left:49.99px;top:661.19px" class="cls_031"><span class="cls_031">although women reported more severe disease affecting their arms</span></div>
<div style="position:absolute;left:306.63px;top:661.10px" class="cls_031"><span class="cls_031">responder imputation, WPAI analyses used last observation carried</span></div>
<div style="position:absolute;left:49.99px;top:671.19px" class="cls_031"><span class="cls_031">and males reported more severe scalp disease. Whilst physical</span></div>
<div style="position:absolute;left:306.63px;top:671.10px" class="cls_031"><span class="cls_031">forward imputation at Week 16 and observed data at Week 48.</span></div>
<div style="position:absolute;left:49.99px;top:681.19px" class="cls_031"><span class="cls_031">impacts of disease were similar (</span><span class="cls_030"> ≤ </span><span class="cls_031">2 pts reported severe problems</span></div>
<div style="position:absolute;left:306.63px;top:681.10px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">At Week 16, CZP pts showed greater improvements in</span></div>
<div style="position:absolute;left:49.99px;top:691.18px" class="cls_031"><span class="cls_031">with walking, washing/dressing, carrying out housework/family/</span></div>
<div style="position:absolute;left:306.63px;top:691.10px" class="cls_031"><span class="cls_031">DLQI vs PBO, and higher proportions achieved DLQI MCID and</span></div>
<div style="position:absolute;left:49.99px;top:701.18px" class="cls_031"><span class="cls_031">leisure activities or daily work), a higher proportion of women</span></div>
<div style="position:absolute;left:306.63px;top:701.10px" class="cls_031"><span class="cls_031">DLQI remission (Table). Improvements were maintained to Week</span></div>
<div style="position:absolute;left:49.99px;top:711.18px" class="cls_031"><span class="cls_031">(14% vs 4%) reported severe/extreme pain or discomfort. Both</span></div>
<div style="position:absolute;left:306.63px;top:711.09px" class="cls_031"><span class="cls_031">48 in CZP-treated pts who continued treatment (Table). Improve-</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:46574px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background60.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">58</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">ments in work productivity and reductions in activity impairment</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">First outcomes will be a comprehensive review of papers derived</span></div>
<div style="position:absolute;left:50.00px;top:61.46px" class="cls_031"><span class="cls_031">were seen with both CZP doses vs PBO; and were maintained to</span></div>
<div style="position:absolute;left:306.64px;top:61.40px" class="cls_031"><span class="cls_031">from the systematic literature search in May 2018.</span></div>
<div style="position:absolute;left:50.00px;top:71.51px" class="cls_031"><span class="cls_031">Week 48 in patients remaining in the trial. (Table).</span></div>
<div style="position:absolute;left:50.00px;top:81.56px" class="cls_030"><span class="cls_030">Conclusions: </span><span class="cls_031">Treatment with CZP was associated with improve-</span></div>
<div style="position:absolute;left:306.64px;top:80.04px" class="cls_033"><span class="cls_033">P143</span></div>
<div style="position:absolute;left:50.00px;top:91.61px" class="cls_031"><span class="cls_031">ments in QoL, work productivity and social activities vs PBO at</span></div>
<div style="position:absolute;left:306.64px;top:91.44px" class="cls_025"><span class="cls_025">THE GLOBAL RESEARCH ON THE IMPACT OF</span></div>
<div style="position:absolute;left:50.00px;top:101.67px" class="cls_031"><span class="cls_031">Week 16, which was maintained to Week 48 in patients remaining</span></div>
<div style="position:absolute;left:306.64px;top:102.34px" class="cls_025"><span class="cls_025">DERMATOLOGICAL DISEASES (GRIDD)</span></div>
<div style="position:absolute;left:50.00px;top:111.72px" class="cls_031"><span class="cls_031">in the trials.</span></div>
<div style="position:absolute;left:306.64px;top:112.24px" class="cls_051"><span class="cls_051">Matthias Augustin</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Nirohshah Suthakharan</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Christine Janus</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">,</span></div>
<div style="position:absolute;left:50.00px;top:121.80px" class="cls_036"><span class="cls_036">Table. Improvements in DLQI and WPAI at Weeks 16 and 48</span></div>
<div style="position:absolute;left:306.64px;top:122.14px" class="cls_026"><span class="cls_026">Jennifer Austin</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Christine Bundy</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Rachael Pattinson</span><span class="cls_027"><sup>3</sup></span></div>
<div style="position:absolute;left:117.38px;top:133.27px" class="cls_037"><span class="cls_037">PBO</span></div>
<div style="position:absolute;left:153.37px;top:133.27px" class="cls_037"><span class="cls_037">CZP 400 mg Q2W</span></div>
<div style="position:absolute;left:225.37px;top:133.27px" class="cls_037"><span class="cls_037">CZP 200 mg Q2W</span></div>
<div style="position:absolute;left:306.64px;top:132.74px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">University Medical Center Hamburg, Institute for Health Services Re-</span></div>
<div style="position:absolute;left:117.38px;top:140.28px" class="cls_037"><span class="cls_037">(</span><span class="cls_038">n = </span><span class="cls_037">100)</span></div>
<div style="position:absolute;left:153.37px;top:140.28px" class="cls_037"><span class="cls_037">(</span><span class="cls_038">n = </span><span class="cls_037">175)</span></div>
<div style="position:absolute;left:225.37px;top:140.28px" class="cls_037"><span class="cls_037">(</span><span class="cls_038">n = </span><span class="cls_037">186)</span></div>
<div style="position:absolute;left:306.64px;top:142.34px" class="cls_029"><span class="cls_029">search in Dermatology and Nursing (IVDP), </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">International Alliance of</span></div>
<div style="position:absolute;left:51.37px;top:148.44px" class="cls_037"><span class="cls_037">Week 16</span></div>
<div style="position:absolute;left:117.38px;top:148.44px" class="cls_037"><span class="cls_037">Week 16</span></div>
<div style="position:absolute;left:153.37px;top:148.44px" class="cls_037"><span class="cls_037">Week 48</span></div>
<div style="position:absolute;left:189.37px;top:148.44px" class="cls_037"><span class="cls_037">Week 16</span></div>
<div style="position:absolute;left:225.37px;top:148.44px" class="cls_037"><span class="cls_037">Week 48</span></div>
<div style="position:absolute;left:51.37px;top:154.60px" class="cls_037"><span class="cls_037">DLQI</span></div>
<div style="position:absolute;left:306.64px;top:151.94px" class="cls_029"><span class="cls_029">Dermatology Patient Organisations - IADPO, </span><span class="cls_028"><sup>3</sup></span><span class="cls_029">University of Cardiff</span></div>
<div style="position:absolute;left:51.37px;top:160.76px" class="cls_037"><span class="cls_037">Mean CFB (SD)</span></div>
<div style="position:absolute;left:117.38px;top:160.76px" class="cls_037"><span class="cls_037">-3.1</span></div>
<div style="position:absolute;left:128.70px;top:160.76px" class="cls_037"><span class="cls_037">(6.7)</span></div>
<div style="position:absolute;left:153.37px;top:160.76px" class="cls_037"><span class="cls_037">-9.8</span></div>
<div style="position:absolute;left:164.70px;top:160.76px" class="cls_037"><span class="cls_037">(7.0)</span></div>
<div style="position:absolute;left:189.37px;top:160.76px" class="cls_037"><span class="cls_037">-10.3</span></div>
<div style="position:absolute;left:203.79px;top:160.76px" class="cls_037"><span class="cls_037">(7.5)</span></div>
<div style="position:absolute;left:225.37px;top:160.76px" class="cls_037"><span class="cls_037">-10.0</span></div>
<div style="position:absolute;left:239.79px;top:160.76px" class="cls_037"><span class="cls_037">(8.2)</span></div>
<div style="position:absolute;left:257.37px;top:160.76px" class="cls_037"><span class="cls_037">-9.7</span></div>
<div style="position:absolute;left:268.70px;top:160.76px" class="cls_037"><span class="cls_037">(8.4)</span></div>
<div style="position:absolute;left:51.37px;top:166.92px" class="cls_037"><span class="cls_037">MCID, n (%)</span></div>
<div style="position:absolute;left:117.38px;top:166.92px" class="cls_037"><span class="cls_037">41 (41.0)</span></div>
<div style="position:absolute;left:153.37px;top:166.92px" class="cls_037"><span class="cls_037">135 (77.5)</span></div>
<div style="position:absolute;left:189.37px;top:166.92px" class="cls_037"><span class="cls_037">121 (69.1)</span></div>
<div style="position:absolute;left:225.37px;top:166.92px" class="cls_037"><span class="cls_037">131 (70.4)</span></div>
<div style="position:absolute;left:257.37px;top:166.92px" class="cls_037"><span class="cls_037">113 (60.8)</span></div>
<div style="position:absolute;left:306.64px;top:162.81px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">The Global Research on the Impact of Dermatolo-</span></div>
<div style="position:absolute;left:51.37px;top:173.08px" class="cls_037"><span class="cls_037">DLQI 0/1, n (%)</span></div>
<div style="position:absolute;left:117.38px;top:173.08px" class="cls_037"><span class="cls_037">7 (7.0)</span></div>
<div style="position:absolute;left:153.37px;top:173.08px" class="cls_037"><span class="cls_037">84 (48.0)</span></div>
<div style="position:absolute;left:189.37px;top:173.08px" class="cls_037"><span class="cls_037">90 (51.4)</span></div>
<div style="position:absolute;left:225.37px;top:173.08px" class="cls_037"><span class="cls_037">87 (46.8)</span></div>
<div style="position:absolute;left:257.37px;top:173.08px" class="cls_037"><span class="cls_037">78 (41.9)</span></div>
<div style="position:absolute;left:306.64px;top:172.81px" class="cls_031"><span class="cls_031">gical Diseases (GRIDD) project will be the first global patient-</span></div>
<div style="position:absolute;left:51.37px;top:179.25px" class="cls_037"><span class="cls_037">WPAI Domains, mean change from baseline (SD)</span></div>
<div style="position:absolute;left:51.37px;top:185.41px" class="cls_037"><span class="cls_037">Absenteeism</span></div>
<div style="position:absolute;left:117.38px;top:185.41px" class="cls_037"><span class="cls_037">2.9</span></div>
<div style="position:absolute;left:126.64px;top:185.41px" class="cls_037"><span class="cls_037">(22.1)</span></div>
<div style="position:absolute;left:153.37px;top:185.41px" class="cls_037"><span class="cls_037">4.7</span></div>
<div style="position:absolute;left:162.64px;top:185.41px" class="cls_037"><span class="cls_037">(22.7)</span></div>
<div style="position:absolute;left:189.37px;top:185.41px" class="cls_037"><span class="cls_037">-0.1</span></div>
<div style="position:absolute;left:200.70px;top:185.41px" class="cls_037"><span class="cls_037">(17.5)</span></div>
<div style="position:absolute;left:225.37px;top:185.41px" class="cls_037"><span class="cls_037">0.7</span></div>
<div style="position:absolute;left:234.64px;top:185.41px" class="cls_037"><span class="cls_037">(21.7)</span></div>
<div style="position:absolute;left:257.37px;top:185.41px" class="cls_037"><span class="cls_037">2.6</span></div>
<div style="position:absolute;left:266.64px;top:185.41px" class="cls_037"><span class="cls_037">(15.6)</span></div>
<div style="position:absolute;left:306.64px;top:182.80px" class="cls_031"><span class="cls_031">initiated and patient-led impact research study in dermatology.</span></div>
<div style="position:absolute;left:189.37px;top:192.41px" class="cls_037"><span class="cls_037">[</span><span class="cls_038">n = </span><span class="cls_037">96]</span></div>
<div style="position:absolute;left:257.37px;top:192.41px" class="cls_037"><span class="cls_037">[</span><span class="cls_038">n = </span><span class="cls_037">89]</span></div>
<div style="position:absolute;left:306.64px;top:192.80px" class="cls_031"><span class="cls_031">By including the patient perspective stringently into the burden</span></div>
<div style="position:absolute;left:51.37px;top:198.57px" class="cls_037"><span class="cls_037">Presenteeism</span></div>
<div style="position:absolute;left:117.38px;top:198.57px" class="cls_037"><span class="cls_037">0.7</span></div>
<div style="position:absolute;left:126.64px;top:198.57px" class="cls_037"><span class="cls_037">(21.8)</span></div>
<div style="position:absolute;left:153.37px;top:198.57px" class="cls_037"><span class="cls_037">-12.9</span></div>
<div style="position:absolute;left:167.79px;top:198.57px" class="cls_037"><span class="cls_037">(25.2)</span></div>
<div style="position:absolute;left:189.37px;top:198.57px" class="cls_037"><span class="cls_037">-17.0</span></div>
<div style="position:absolute;left:203.79px;top:198.57px" class="cls_037"><span class="cls_037">(26.1)</span></div>
<div style="position:absolute;left:225.37px;top:198.57px" class="cls_037"><span class="cls_037">-9.6</span></div>
<div style="position:absolute;left:236.70px;top:198.57px" class="cls_037"><span class="cls_037">(25.3)</span></div>
<div style="position:absolute;left:257.37px;top:198.57px" class="cls_037"><span class="cls_037">-9.9</span></div>
<div style="position:absolute;left:268.70px;top:198.57px" class="cls_037"><span class="cls_037">(27.1)</span></div>
<div style="position:absolute;left:189.37px;top:205.57px" class="cls_037"><span class="cls_037">[</span><span class="cls_038">n = </span><span class="cls_037">96]</span></div>
<div style="position:absolute;left:257.37px;top:205.57px" class="cls_037"><span class="cls_037">[</span><span class="cls_038">n = </span><span class="cls_037">89]</span></div>
<div style="position:absolute;left:306.64px;top:202.80px" class="cls_031"><span class="cls_031">metrics, this will be the first program to systematically challenge</span></div>
<div style="position:absolute;left:51.37px;top:211.74px" class="cls_037"><span class="cls_037">Work productivity loss</span></div>
<div style="position:absolute;left:117.38px;top:211.74px" class="cls_037"><span class="cls_037">4.8</span></div>
<div style="position:absolute;left:126.64px;top:211.74px" class="cls_037"><span class="cls_037">(28.5)</span></div>
<div style="position:absolute;left:153.37px;top:211.74px" class="cls_037"><span class="cls_037">-9.0</span></div>
<div style="position:absolute;left:164.70px;top:211.74px" class="cls_037"><span class="cls_037">(32.7)</span></div>
<div style="position:absolute;left:189.37px;top:211.74px" class="cls_037"><span class="cls_037">-16.4</span></div>
<div style="position:absolute;left:203.79px;top:211.74px" class="cls_037"><span class="cls_037">(28.9)</span></div>
<div style="position:absolute;left:225.37px;top:211.74px" class="cls_037"><span class="cls_037">-9.0</span></div>
<div style="position:absolute;left:236.70px;top:211.74px" class="cls_037"><span class="cls_037">(31.5)</span></div>
<div style="position:absolute;left:257.37px;top:211.74px" class="cls_037"><span class="cls_037">-8.0</span></div>
<div style="position:absolute;left:268.70px;top:211.74px" class="cls_037"><span class="cls_037">(30.1)</span></div>
<div style="position:absolute;left:306.63px;top:212.80px" class="cls_031"><span class="cls_031">the current Global Burden of Disease concept, which markedly</span></div>
<div style="position:absolute;left:189.37px;top:218.74px" class="cls_037"><span class="cls_037">[</span><span class="cls_038">n = </span><span class="cls_037">96]</span></div>
<div style="position:absolute;left:257.37px;top:218.74px" class="cls_037"><span class="cls_037">[</span><span class="cls_038">n = </span><span class="cls_037">89]</span></div>
<div style="position:absolute;left:51.37px;top:224.90px" class="cls_037"><span class="cls_037">Activity impairment</span></div>
<div style="position:absolute;left:117.38px;top:224.90px" class="cls_037"><span class="cls_037">-1.5</span></div>
<div style="position:absolute;left:128.70px;top:224.90px" class="cls_037"><span class="cls_037">(25.3)</span></div>
<div style="position:absolute;left:153.37px;top:224.90px" class="cls_037"><span class="cls_037">-23.9</span></div>
<div style="position:absolute;left:167.79px;top:224.90px" class="cls_037"><span class="cls_037">(28.3)</span></div>
<div style="position:absolute;left:189.37px;top:224.90px" class="cls_037"><span class="cls_037">-28.6</span></div>
<div style="position:absolute;left:203.79px;top:224.90px" class="cls_037"><span class="cls_037">(28.9)</span></div>
<div style="position:absolute;left:225.37px;top:224.90px" class="cls_037"><span class="cls_037">-21.0 (31.9) -23.9 (29.4)</span></div>
<div style="position:absolute;left:306.63px;top:222.80px" class="cls_031"><span class="cls_031">underestimates the patient burden of skin diseases.</span></div>
<div style="position:absolute;left:189.37px;top:231.90px" class="cls_037"><span class="cls_037">[</span><span class="cls_038">n = </span><span class="cls_037">129]</span></div>
<div style="position:absolute;left:257.37px;top:231.90px" class="cls_037"><span class="cls_037">[</span><span class="cls_038">n = </span><span class="cls_037">132]</span></div>
<div style="position:absolute;left:306.63px;top:232.80px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">The objective of the GRIDD research project is to</span></div>
<div style="position:absolute;left:306.63px;top:242.80px" class="cls_031"><span class="cls_031">develop a comprehensive measure of the impact of living with</span></div>
<div style="position:absolute;left:50.00px;top:246.77px" class="cls_033"><span class="cls_033">P142</span></div>
<div style="position:absolute;left:306.63px;top:252.80px" class="cls_031"><span class="cls_031">skin diseases instruments by country, regionally and worldwide.</span></div>
<div style="position:absolute;left:50.00px;top:258.22px" class="cls_025"><span class="cls_025">TRANSLATING WHO RESOLUTION INTO THE PUBLIC:</span></div>
<div style="position:absolute;left:306.63px;top:262.80px" class="cls_031"><span class="cls_031">The global instrument, developed with patient organisations,</span></div>
<div style="position:absolute;left:50.00px;top:269.17px" class="cls_025"><span class="cls_025">THE GERMAN PROGRAM AGAINST STIGMATIZATION</span></div>
<div style="position:absolute;left:306.63px;top:272.80px" class="cls_031"><span class="cls_031">will capture patient experiences, including the extent of disease</span></div>
<div style="position:absolute;left:50.00px;top:280.12px" class="cls_025"><span class="cls_025">OF PEOPLE WITH CHRONIC VISIBLE SKIN DISEASES</span></div>
<div style="position:absolute;left:306.63px;top:282.79px" class="cls_031"><span class="cls_031">impact and burden for patients and their families, for generic (i.e.</span></div>
<div style="position:absolute;left:50.00px;top:290.07px" class="cls_051"><span class="cls_051">Matthias Augustin</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Claudia Luck-Sikorski</span><span class="cls_027"><sup>2</sup></span><span class="cls_026">, Rachel Sommer</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Ja-</span></div>
<div style="position:absolute;left:306.63px;top:292.79px" class="cls_031"><span class="cls_031">all dermatological diseases) and specific dermatological disease</span></div>
<div style="position:absolute;left:50.00px;top:300.02px" class="cls_026"><span class="cls_026">nine Topp</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Ines Schaefer</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Marc Radtke</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Sophie Schlette</span><span class="cls_027"><sup>3</sup></span><span class="cls_026">, Nata-</span></div>
<div style="position:absolute;left:306.65px;top:302.79px" class="cls_031"><span class="cls_031">including psoriasis assessment worldwide.</span></div>
<div style="position:absolute;left:50.01px;top:309.98px" class="cls_026"><span class="cls_026">scha Weinberger</span><span class="cls_027"><sup>4</sup></span><span class="cls_026">, Regina Spreckelsen</span><span class="cls_027"><sup>5</sup></span><span class="cls_026">, Anja Hilbert</span><span class="cls_027"><sup>6</sup></span><span class="cls_026">, Alexander</span></div>
<div style="position:absolute;left:306.65px;top:312.75px" class="cls_030"><span class="cls_030">Materials + Methods: </span><span class="cls_031">Development of the comprehensive mea-</span></div>
<div style="position:absolute;left:50.00px;top:319.93px" class="cls_026"><span class="cls_026">Zink</span><span class="cls_027"><sup>7</sup></span><span class="cls_026">, Dagmar Wilsmann-Theis</span><span class="cls_027"><sup>8</sup></span><span class="cls_026">, Eckardt Breitbart</span><span class="cls_027"><sup>9</sup></span><span class="cls_026">, Ulrich Mro-</span></div>
<div style="position:absolute;left:306.64px;top:322.71px" class="cls_031"><span class="cls_031">sure of impact of disease will be based on a novel methodology</span></div>
<div style="position:absolute;left:50.00px;top:329.88px" class="cls_026"><span class="cls_026">wietz</span><span class="cls_027"><sup>10</sup></span></div>
<div style="position:absolute;left:306.64px;top:332.66px" class="cls_031"><span class="cls_031">with several phases. Phase 1 will systematically review existing</span></div>
<div style="position:absolute;left:50.00px;top:340.53px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">University  Medical  Center  Hamburg-Eppendorf,</span></div>
<div style="position:absolute;left:228.12px;top:340.53px" class="cls_028"><span class="cls_028"><sup>2</sup></span><span class="cls_029">University  Gera,</span></div>
<div style="position:absolute;left:306.64px;top:342.61px" class="cls_031"><span class="cls_031">measures of the life impact of skin diseases and conduct a patient-</span></div>
<div style="position:absolute;left:50.00px;top:350.18px" class="cls_028"><span class="cls_028"><sup>3</sup></span><span class="cls_029">BVDD, </span><span class="cls_028"><sup>4</sup></span><span class="cls_029">University of Leipzig, </span><span class="cls_028"><sup>5</sup></span><span class="cls_029">University Hospital Kiel, </span><span class="cls_028"><sup>6</sup></span><span class="cls_029">University Med-</span></div>
<div style="position:absolute;left:306.64px;top:352.57px" class="cls_031"><span class="cls_031">centered item identification exercise. Phase 2 will be informed by</span></div>
<div style="position:absolute;left:50.00px;top:359.83px" class="cls_029"><span class="cls_029">ical Center Leipzig, </span><span class="cls_028"><sup>7</sup></span><span class="cls_029">University Munich, </span><span class="cls_028"><sup>8</sup></span><span class="cls_029">University Bonn, </span><span class="cls_028"><sup>9</sup></span><span class="cls_029">Dermatology</span></div>
<div style="position:absolute;left:306.65px;top:362.52px" class="cls_031"><span class="cls_031">Phase 1 data and will focus on instrument development: develop</span></div>
<div style="position:absolute;left:50.00px;top:369.48px" class="cls_029"><span class="cls_029">Breitbart, </span><span class="cls_028"><sup>10</sup></span><span class="cls_029">University Kiel</span></div>
<div style="position:absolute;left:306.65px;top:372.48px" class="cls_031"><span class="cls_031">the wording for items (i.e. impact categories) and appropriate</span></div>
<div style="position:absolute;left:50.00px;top:380.40px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> The WHO resolution 2014 raised fundamental</span></div>
<div style="position:absolute;left:306.65px;top:382.43px" class="cls_031"><span class="cls_031">item scaling. This measure will describe the impact on life which</span></div>
<div style="position:absolute;left:50.00px;top:390.46px" class="cls_031"><span class="cls_031">demands for the health care system to increase the awareness for</span></div>
<div style="position:absolute;left:306.65px;top:392.38px" class="cls_031"><span class="cls_031">may include economic; psychological and social impacts. Phase</span></div>
<div style="position:absolute;left:50.00px;top:400.51px" class="cls_031"><span class="cls_031">patients with chronic skin diseases such as psoriasis, including its</span></div>
<div style="position:absolute;left:306.65px;top:402.34px" class="cls_031"><span class="cls_031">3 describes the acquisition of real world data to further test the</span></div>
<div style="position:absolute;left:50.00px;top:410.56px" class="cls_031"><span class="cls_031">fight against stigmatization. Single member states were encouraged</span></div>
<div style="position:absolute;left:306.65px;top:412.29px" class="cls_031"><span class="cls_031">validity and acceptability of the new measure. Lastly, phase 4 and</span></div>
<div style="position:absolute;left:49.98px;top:420.62px" class="cls_031"><span class="cls_031">to take action on all levels, including public awareness campaigns.</span></div>
<div style="position:absolute;left:306.65px;top:422.25px" class="cls_031"><span class="cls_031">5 include dissemination and launch of data, the new measure and</span></div>
<div style="position:absolute;left:49.98px;top:430.67px" class="cls_031"><span class="cls_031">After a period of refusal, the German ministry of health approved</span></div>
<div style="position:absolute;left:306.65px;top:432.20px" class="cls_031"><span class="cls_031">an implementation strategy to increase uptake of the measure.</span></div>
<div style="position:absolute;left:49.98px;top:440.72px" class="cls_031"><span class="cls_031">a project submitted by German dermatologists, patient groups and</span></div>
<div style="position:absolute;left:306.65px;top:442.11px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">GRIDD has assembled a scientific advisory board repre-</span></div>
<div style="position:absolute;left:49.98px;top:450.77px" class="cls_031"><span class="cls_031">further experts to develop interventions against stigmatization.</span></div>
<div style="position:absolute;left:306.64px;top:452.06px" class="cls_031"><span class="cls_031">senting different regions worldwide. Currently, we are collabora-</span></div>
<div style="position:absolute;left:49.98px;top:460.83px" class="cls_030"><span class="cls_030">Objectives- Aim of investigation:</span><span class="cls_031"> The project aims to develop and</span></div>
<div style="position:absolute;left:306.64px;top:462.01px" class="cls_031"><span class="cls_031">ting with over 100 patient associations in 32 countries worldwide,</span></div>
<div style="position:absolute;left:49.98px;top:470.88px" class="cls_031"><span class="cls_031">evaluate public interventions against stigmatization of people with</span></div>
<div style="position:absolute;left:306.64px;top:471.96px" class="cls_031"><span class="cls_031">with more than 26 disease areas. Industry funding has been secured</span></div>
<div style="position:absolute;left:49.98px;top:480.93px" class="cls_031"><span class="cls_031">visible skin diseases.</span></div>
<div style="position:absolute;left:306.64px;top:481.91px" class="cls_031"><span class="cls_031">from five different companies for the first phase and a portion of</span></div>
<div style="position:absolute;left:49.98px;top:490.99px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">The project consist of three phases. Within a one-year</span></div>
<div style="position:absolute;left:306.66px;top:491.87px" class="cls_031"><span class="cls_031">phase 2. The GRIDD research team, including researcher from the</span></div>
<div style="position:absolute;left:49.98px;top:501.04px" class="cls_031"><span class="cls_031">period current research will be processed through a systematic</span></div>
<div style="position:absolute;left:306.66px;top:501.82px" class="cls_031"><span class="cls_031">University Medical Center in Hamburg and University of Cardiff,</span></div>
<div style="position:absolute;left:49.98px;top:511.09px" class="cls_031"><span class="cls_031">literature search; recommendations for intervention formats will</span></div>
<div style="position:absolute;left:306.66px;top:511.78px" class="cls_031"><span class="cls_031">met in 2017 to start phases 1 and 2. The systematic literature review</span></div>
<div style="position:absolute;left:49.98px;top:521.15px" class="cls_031"><span class="cls_031">be derived. The consecutive 18 months involve the development</span></div>
<div style="position:absolute;left:306.66px;top:521.73px" class="cls_031"><span class="cls_031">on “Existing patient-centred outcome measures currently used in</span></div>
<div style="position:absolute;left:49.98px;top:531.20px" class="cls_031"><span class="cls_031">of defined intervention formats. The interventions are supposed</span></div>
<div style="position:absolute;left:306.66px;top:531.68px" class="cls_031"><span class="cls_031">dermatology” is currently underway.</span></div>
<div style="position:absolute;left:49.98px;top:541.25px" class="cls_031"><span class="cls_031">to focus on locations of stigma and encounters of stigmatizing</span></div>
<div style="position:absolute;left:306.66px;top:541.61px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">This novel patient-centric methodology will com-</span></div>
<div style="position:absolute;left:49.98px;top:551.30px" class="cls_031"><span class="cls_031">with stigmatized persons.</span></div>
<div style="position:absolute;left:306.64px;top:551.56px" class="cls_031"><span class="cls_031">plement existing concepts of evaluating patient perspective in</span></div>
<div style="position:absolute;left:49.98px;top:561.36px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> The application has been approved and is funded by the</span></div>
<div style="position:absolute;left:306.64px;top:561.51px" class="cls_031"><span class="cls_031">dermatology. GRIDD will provide an extended patient view for</span></div>
<div style="position:absolute;left:49.98px;top:571.41px" class="cls_031"><span class="cls_031">German ministry of health for a period of three years throughout</span></div>
<div style="position:absolute;left:306.64px;top:571.46px" class="cls_031"><span class="cls_031">better decision making in dermatology on a global and country</span></div>
<div style="position:absolute;left:49.98px;top:581.44px" class="cls_031"><span class="cls_031">the years 2018 to 2021. The project group consists of 25 der-</span></div>
<div style="position:absolute;left:306.64px;top:581.42px" class="cls_031"><span class="cls_031">level. It supports local, regional and international attempts to create</span></div>
<div style="position:absolute;left:50.00px;top:591.49px" class="cls_031"><span class="cls_031">matology-, science- and patient-experts who work in operative</span></div>
<div style="position:absolute;left:306.64px;top:591.37px" class="cls_031"><span class="cls_031">awareness, better position psoriasis and other skin diseases and</span></div>
<div style="position:absolute;left:50.00px;top:601.54px" class="cls_031"><span class="cls_031">groups in order to develop the content and the intervention for-</span></div>
<div style="position:absolute;left:306.64px;top:601.31px" class="cls_031"><span class="cls_031">encourage decision-makers and stakeholders to include dermato-</span></div>
<div style="position:absolute;left:50.00px;top:611.59px" class="cls_031"><span class="cls_031">mat. In doing so, different levels of the stigmatization process,</span></div>
<div style="position:absolute;left:306.64px;top:611.26px" class="cls_031"><span class="cls_031">logical diseases in their policies.</span></div>
<div style="position:absolute;left:50.00px;top:621.64px" class="cls_031"><span class="cls_031">namely stereotypes, prejudice, discrimination are considered as</span></div>
<div style="position:absolute;left:50.00px;top:631.70px" class="cls_031"><span class="cls_031">important aspects and will be accounted for in the development</span></div>
<div style="position:absolute;left:306.64px;top:628.89px" class="cls_033"><span class="cls_033">P144</span></div>
<div style="position:absolute;left:50.00px;top:641.75px" class="cls_031"><span class="cls_031">of the intervention. First results of the literature review imply that</span></div>
<div style="position:absolute;left:306.64px;top:640.29px" class="cls_025"><span class="cls_025">TREATMENT OF NAIL PSORIASIS WITH DIFFERENT</span></div>
<div style="position:absolute;left:50.00px;top:651.80px" class="cls_031"><span class="cls_031">people with visible skin disease such as psoriasis are affected by</span></div>
<div style="position:absolute;left:306.64px;top:651.19px" class="cls_025"><span class="cls_025">PULSE DURATIONS OF PULSED DYE LASER</span></div>
<div style="position:absolute;left:50.00px;top:661.86px" class="cls_031"><span class="cls_031">stigmatization in several dimensions and strategies for reducing</span></div>
<div style="position:absolute;left:306.64px;top:661.09px" class="cls_051"><span class="cls_051">Mohamad Goldust</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Homan Alipour</span><span class="cls_027"><sup>2</sup></span></div>
<div style="position:absolute;left:50.00px;top:671.91px" class="cls_031"><span class="cls_031">the stigma are required.</span></div>
<div style="position:absolute;left:306.64px;top:671.69px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">Mazandaran University of Medical Sciences, </span><span class="cls_028"><sup>2</sup></span><span class="cls_029">Tabriz University of Medi-</span></div>
<div style="position:absolute;left:50.00px;top:681.95px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">Following the WHO resolution, this project is an ex-</span></div>
<div style="position:absolute;left:306.64px;top:681.29px" class="cls_029"><span class="cls_029">cal Sciences</span></div>
<div style="position:absolute;left:50.00px;top:692.00px" class="cls_031"><span class="cls_031">ample for successful project initiation of an interdisciplinary team</span></div>
<div style="position:absolute;left:306.64px;top:692.11px" class="cls_030"><span class="cls_030">Background: </span><span class="cls_031">There are different treatment modalities for nail</span></div>
<div style="position:absolute;left:50.00px;top:702.06px" class="cls_031"><span class="cls_031">to develop and implement an intervention against stigmatization.</span></div>
<div style="position:absolute;left:306.64px;top:702.06px" class="cls_031"><span class="cls_031">psoriasis but the treatment of choice is still controversial. Laser</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:47377px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background61.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">59</span></div>
<div style="position:absolute;left:49.43px;top:51.41px" class="cls_031"><span class="cls_031">therapy opened new windows for treatment of nail psoriasis (1,2).</span></div>
<div style="position:absolute;left:306.64px;top:51.85px" class="cls_028"><span class="cls_028"><sup>1</sup></span><span class="cls_029">GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany,</span></div>
<div style="position:absolute;left:49.43px;top:61.44px" class="cls_030"><span class="cls_030">Objective:</span><span class="cls_031">The aim of this study was to evaluate the efficacy of</span></div>
<div style="position:absolute;left:306.64px;top:61.45px" class="cls_028"><span class="cls_028"><sup>2</sup></span><span class="cls_029">University of Applied Sciences, Darmstadt, Germany</span></div>
<div style="position:absolute;left:49.44px;top:71.48px" class="cls_031"><span class="cls_031">different pulse durations in the treatment of nail psoriasis with the</span></div>
<div style="position:absolute;left:306.64px;top:72.32px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriasis is on the indication list for therapy in radon</span></div>
<div style="position:absolute;left:49.44px;top:81.51px" class="cls_031"><span class="cls_031">595-nm PDL to determine the optimal pulse duration.</span></div>
<div style="position:absolute;left:306.64px;top:82.32px" class="cls_031"><span class="cls_031">galleries (1). Radon is a radioactive noble gas evaporating from</span></div>
<div style="position:absolute;left:49.44px;top:91.55px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">In this clinical trial study, 120 patients with bilateral fing-</span></div>
<div style="position:absolute;left:306.64px;top:92.32px" class="cls_031"><span class="cls_031">rocks. It is absorbed through skin or lung epithelium during inha-</span></div>
<div style="position:absolute;left:49.43px;top:101.58px" class="cls_031"><span class="cls_031">ernail psoriasis were evaluated. PDL was applied on the proximal</span></div>
<div style="position:absolute;left:306.64px;top:102.32px" class="cls_031"><span class="cls_031">lation. Radon decays in the tissue under emission of α-particles.</span></div>
<div style="position:absolute;left:49.43px;top:111.62px" class="cls_031"><span class="cls_031">and lateral nailfolds based on random assignment. 240 nails were</span></div>
<div style="position:absolute;left:306.66px;top:112.32px" class="cls_031"><span class="cls_031">The estimated dose received during a radon therapy is in the</span></div>
<div style="position:absolute;left:49.43px;top:121.65px" class="cls_031"><span class="cls_031">treated with 6-millisecond pulse duration and 9 J/cm(2) whereas</span></div>
<div style="position:absolute;left:306.66px;top:122.32px" class="cls_031"><span class="cls_031">order of 1.2 mSv which corresponds to the annual background</span></div>
<div style="position:absolute;left:49.43px;top:131.69px" class="cls_031"><span class="cls_031">240 nails were treated with 0.45-millisecond pulse duration and 6 J/</span></div>
<div style="position:absolute;left:306.66px;top:132.32px" class="cls_031"><span class="cls_031">irradiation caused by radon. Chronic inflammatory diseases such</span></div>
<div style="position:absolute;left:49.43px;top:141.72px" class="cls_031"><span class="cls_031">cm(2). Nail Psoriasis Severity Index (NAPSI) was used to assess the</span></div>
<div style="position:absolute;left:306.66px;top:142.32px" class="cls_031"><span class="cls_031">as rheumatoid arthritis are treated with radon and pain reduction</span></div>
<div style="position:absolute;left:49.43px;top:151.76px" class="cls_031"><span class="cls_031">clinical outcome from pretreatment and posttreatment photographs.</span></div>
<div style="position:absolute;left:306.66px;top:152.31px" class="cls_031"><span class="cls_031">and improvement of mobility are reported (2). Positive effects</span></div>
<div style="position:absolute;left:49.43px;top:161.79px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">After 6 months of first treatment, there was a signifi-</span></div>
<div style="position:absolute;left:306.66px;top:162.31px" class="cls_031"><span class="cls_031">are also reported for psoriasis, but sparely documented. However,</span></div>
<div style="position:absolute;left:49.43px;top:171.83px" class="cls_031"><span class="cls_031">cant reduction in overall NAPSI, nail matrix NAPSI, and nail</span></div>
<div style="position:absolute;left:306.66px;top:172.31px" class="cls_031"><span class="cls_031">for both diseases the mechanisms underlying the clinical benefit</span></div>
<div style="position:absolute;left:49.43px;top:181.86px" class="cls_031"><span class="cls_031">bed NAPSI scores from baseline in both groups; however, no</span></div>
<div style="position:absolute;left:306.66px;top:182.31px" class="cls_031"><span class="cls_031">are unknown.</span></div>
<div style="position:absolute;left:49.43px;top:191.90px" class="cls_031"><span class="cls_031">significant difference was found between the two pulse duration</span></div>
<div style="position:absolute;left:306.66px;top:192.31px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To investigate effects of radon treatment we have</span></div>
<div style="position:absolute;left:49.43px;top:201.93px" class="cls_031"><span class="cls_031">groups. Side effects were mild including transient petechiae and</span></div>
<div style="position:absolute;left:306.66px;top:202.31px" class="cls_031"><span class="cls_031">established a cellular model for psoriasis which can be used for</span></div>
<div style="position:absolute;left:49.43px;top:211.97px" class="cls_031"><span class="cls_031">hyperpigmentation.</span></div>
<div style="position:absolute;left:306.66px;top:212.31px" class="cls_031"><span class="cls_031">irradiation with α-particles. The requirements in using α-particles</span></div>
<div style="position:absolute;left:49.43px;top:222.01px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">PDL was found to be an effective and well-tolerated</span></div>
<div style="position:absolute;left:306.65px;top:222.31px" class="cls_031"><span class="cls_031">are specific due to their short range.</span></div>
<div style="position:absolute;left:49.43px;top:232.04px" class="cls_031"><span class="cls_031">option in the treatment of nail psoriasis. This study demonstrated</span></div>
<div style="position:absolute;left:306.65px;top:232.31px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">Special rings stringed with a 2 µm oxygen plasma</span></div>
<div style="position:absolute;left:49.43px;top:242.07px" class="cls_031"><span class="cls_031">that both the longer 6-millisecond and shorter 0.45-millisecond</span></div>
<div style="position:absolute;left:306.65px;top:242.31px" class="cls_031"><span class="cls_031">treated boPET foil are used to facilitate α-irradiation and growth</span></div>
<div style="position:absolute;left:49.43px;top:252.11px" class="cls_031"><span class="cls_031">pulses of PDL (595 nm) have been clinically proven to be effective</span></div>
<div style="position:absolute;left:306.65px;top:252.30px" class="cls_031"><span class="cls_031">of NHEK (normal human epidermal keratinocytes). Cells were</span></div>
<div style="position:absolute;left:49.43px;top:262.14px" class="cls_031"><span class="cls_031">for the treatment of nail matrix and nail bed psoriasis.</span></div>
<div style="position:absolute;left:306.65px;top:262.30px" class="cls_031"><span class="cls_031">cultured in rings or culture dishes for 24 hours and induced with</span></div>
<div style="position:absolute;left:49.43px;top:272.23px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:306.65px;top:272.30px" class="cls_031"><span class="cls_031">IL-17, IL-22 and TNF-α. Supernatants and cells for protein and</span></div>
<div style="position:absolute;left:49.43px;top:282.33px" class="cls_032"><span class="cls_032">1. Al-Mutairi N, Nour T, Al-Rqobah D. Onychomycosis in patients of</span></div>
<div style="position:absolute;left:306.64px;top:282.30px" class="cls_031"><span class="cls_031">mRNA extraction were collected 24 hours after induction. ELISA,</span></div>
<div style="position:absolute;left:49.43px;top:291.42px" class="cls_032"><span class="cls_032">nail psoriasis on biologic therapy: a randomized, prospective open label</span></div>
<div style="position:absolute;left:306.64px;top:292.30px" class="cls_031"><span class="cls_031">qPCR and Western Blot analysis was performed.</span></div>
<div style="position:absolute;left:49.43px;top:300.51px" class="cls_032"><span class="cls_032">study comparing Etanercept, Infliximab and Adalimumab. Expert Opin</span></div>
<div style="position:absolute;left:306.64px;top:302.30px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">We could show that it is possible to culture primary</span></div>
<div style="position:absolute;left:49.43px;top:309.60px" class="cls_032"><span class="cls_032">Biol Ther 2013;13(5):625-629.</span></div>
<div style="position:absolute;left:306.64px;top:312.30px" class="cls_031"><span class="cls_031">keratinocytes on plasma treated boPET foil with a similar morp-</span></div>
<div style="position:absolute;left:49.43px;top:318.68px" class="cls_032"><span class="cls_032">2. Radtke MA, Beikert FC, Augustin M. Nail psoriasis - a treatment chal-</span></div>
<div style="position:absolute;left:306.64px;top:322.32px" class="cls_031"><span class="cls_031">hology to cells cultured in cell culture dishes. Furthermore, the</span></div>
<div style="position:absolute;left:49.43px;top:327.76px" class="cls_032"><span class="cls_032">lenge. J Dtsch Dermatol Ges 2013;11(3):203-219.</span></div>
<div style="position:absolute;left:306.64px;top:332.32px" class="cls_031"><span class="cls_031">selected cytokines are able to significantly induce psoriasis-related</span></div>
<div style="position:absolute;left:306.63px;top:342.32px" class="cls_031"><span class="cls_031">markers like IL-19 and BDEF2 on mRNA level and the release</span></div>
<div style="position:absolute;left:49.43px;top:346.47px" class="cls_033"><span class="cls_033">P145</span></div>
<div style="position:absolute;left:306.63px;top:352.32px" class="cls_031"><span class="cls_031">of the cytokine IL-6. Testing if culturing of NHEK on the treated</span></div>
<div style="position:absolute;left:49.43px;top:357.95px" class="cls_025"><span class="cls_025">NEUTROPENIA   IN   A   PSORIASIS   PATIENT:   SECU­</span></div>
<div style="position:absolute;left:306.63px;top:362.32px" class="cls_031"><span class="cls_031">boPET foil alone has an inflammatory effect revealed no significant</span></div>
<div style="position:absolute;left:49.43px;top:368.94px" class="cls_025"><span class="cls_025">KINUMAB OR MICRONUTRIENT DEFICIENCY?</span></div>
<div style="position:absolute;left:306.63px;top:372.31px" class="cls_031"><span class="cls_031">differences in the expression or release of markers compared to</span></div>
<div style="position:absolute;left:49.43px;top:378.92px" class="cls_051"><span class="cls_051">Maruska Marovt</span><span class="cls_026">, Katarina Trcko, Pij B. Marko</span></div>
<div style="position:absolute;left:306.63px;top:382.31px" class="cls_031"><span class="cls_031">cells cultured in cell culture dishes.</span></div>
<div style="position:absolute;left:49.43px;top:389.61px" class="cls_029"><span class="cls_029">University Medical Centre Maribor, Maribor, Slovenia</span></div>
<div style="position:absolute;left:306.63px;top:392.31px" class="cls_030"><span class="cls_030">Conclusion: </span><span class="cls_031">We conclude that the plasma treated boPET foil is a</span></div>
<div style="position:absolute;left:49.43px;top:400.56px" class="cls_031"><span class="cls_031">We report a case of severe neutropenia in a psoriasis patient, which</span></div>
<div style="position:absolute;left:306.63px;top:402.31px" class="cls_031"><span class="cls_031">promising tool for a setup, which enables α-irradiation of mono-</span></div>
<div style="position:absolute;left:49.43px;top:410.65px" class="cls_031"><span class="cls_031">developed three months after discontinuation of secukinumab. She</span></div>
<div style="position:absolute;left:306.64px;top:412.32px" class="cls_031"><span class="cls_031">layer cell cultures. The induction of a psoriasis-like phenotype with</span></div>
<div style="position:absolute;left:49.43px;top:420.74px" class="cls_031"><span class="cls_031">had gastric bypass surgery a few years ago and was intermittently</span></div>
<div style="position:absolute;left:306.64px;top:422.32px" class="cls_031"><span class="cls_031">cytokines leads to an enhancement of relevant markers.</span></div>
<div style="position:absolute;left:49.43px;top:430.83px" class="cls_031"><span class="cls_031">treated due to iron deficiency anemia. According to the suggested</span></div>
<div style="position:absolute;left:306.64px;top:432.32px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:49.45px;top:440.91px" class="cls_031"><span class="cls_031">approach to the adult with unexplained neutropenia (1) a range</span></div>
<div style="position:absolute;left:306.64px;top:442.33px" class="cls_032"><span class="cls_032">Gasteiner Kur- Reha- und Heilstollen-Betriebsges.m.b.H. </span><A HREF="http://www.gasteiner-heilstollen.com/">www.gasteiner-</A> </div>
<div style="position:absolute;left:49.45px;top:451.00px" class="cls_031"><span class="cls_031">of diagnostic tests were performed and no abnormalities were</span></div>
<div style="position:absolute;left:306.64px;top:451.33px" class="cls_032"><span class="cls_032"> </span><A HREF="http://www.gasteiner-heilstollen.com/">heilstollen.com</A> </div>
<div style="position:absolute;left:49.45px;top:461.09px" class="cls_031"><span class="cls_031">noticed. Neutropenia still persists, however the patient hasn’t</span></div>
<div style="position:absolute;left:306.64px;top:460.33px" class="cls_032"><span class="cls_032">Cucu et al; Front Immunol. 2017; 8: 882.; doi: 10.3389/fimmu.2017.00882</span></div>
<div style="position:absolute;left:306.65px;top:469.33px" class="cls_032"><span class="cls_032">This work is supported by the Forschungsinstitut Bad Gastein (FOI-15/08-</span></div>
<div style="position:absolute;left:49.45px;top:471.18px" class="cls_031"><span class="cls_031">had any complications. Neutropenia was reported infrequently in</span></div>
<div style="position:absolute;left:306.65px;top:478.33px" class="cls_032"><span class="cls_032">031WIE), EURADON, the Radon Gallery of Bad Gastein and GREWIS</span></div>
<div style="position:absolute;left:49.45px;top:481.27px" class="cls_031"><span class="cls_031">subjects with moderate to severe psoriasis receiving secukinumab</span></div>
<div style="position:absolute;left:306.65px;top:487.33px" class="cls_032"><span class="cls_032">(02NUK017A)</span></div>
<div style="position:absolute;left:49.45px;top:491.36px" class="cls_031"><span class="cls_031">in a pooled analysis of 10 phase II and III clinical studies (2). Most</span></div>
<div style="position:absolute;left:49.45px;top:501.45px" class="cls_031"><span class="cls_031">were grades 1 or 2. Grade 3 neutropenia was uncommon and not</span></div>
<div style="position:absolute;left:306.64px;top:503.95px" class="cls_033"><span class="cls_033">P147</span></div>
<div style="position:absolute;left:49.45px;top:511.54px" class="cls_031"><span class="cls_031">associated with serious infections, and no grade 4 neutropenia was</span></div>
<div style="position:absolute;left:306.64px;top:515.35px" class="cls_025"><span class="cls_025">THE HISTORY OF PSORIASIS</span></div>
<div style="position:absolute;left:49.45px;top:521.63px" class="cls_031"><span class="cls_031">recorded. Deficiencies of dietary vitamins and minerals typically</span></div>
<div style="position:absolute;left:306.64px;top:525.25px" class="cls_026"><span class="cls_026">Selma Poparic</span></div>
<div style="position:absolute;left:49.47px;top:531.72px" class="cls_031"><span class="cls_031">cause neutropenia in association with other cytopenias. Patients</span></div>
<div style="position:absolute;left:306.64px;top:535.85px" class="cls_029"><span class="cls_029">Dermatology Department University Clinical Center of Sarajevo</span></div>
<div style="position:absolute;left:49.47px;top:541.80px" class="cls_031"><span class="cls_031">who have undergone bariatric surgery require lifelong vitamin</span></div>
<div style="position:absolute;left:306.64px;top:546.72px" class="cls_031"><span class="cls_031">Many ancient texts, including the Bible, mention people afflicted</span></div>
<div style="position:absolute;left:49.47px;top:551.89px" class="cls_031"><span class="cls_031">and mineral supplementation. Severe neutropenia in our patient</span></div>
<div style="position:absolute;left:306.63px;top:556.72px" class="cls_031"><span class="cls_031">with diseases and symptoms very much like psoriasis. Ancient</span></div>
<div style="position:absolute;left:49.47px;top:561.98px" class="cls_031"><span class="cls_031">could be due to combination of secukinumab and micronutrient</span></div>
<div style="position:absolute;left:306.63px;top:566.72px" class="cls_031"><span class="cls_031">Egyptians wrote about a salve made with various herbs that would</span></div>
<div style="position:absolute;left:49.47px;top:572.07px" class="cls_031"><span class="cls_031">deficiency, however exact etiology remains unclear.</span></div>
<div style="position:absolute;left:306.63px;top:576.72px" class="cls_031"><span class="cls_031">be spread on the skin, after which the afflicted person would be</span></div>
<div style="position:absolute;left:49.43px;top:582.11px" class="cls_032"><span class="cls_032">Berliner N (2018). Approach to the adult with unexplained neutropenia. In</span></div>
<div style="position:absolute;left:306.64px;top:586.72px" class="cls_031"><span class="cls_031">instructed to sit in the sun to bring relief to symptoms that seem</span></div>
<div style="position:absolute;left:49.43px;top:591.20px" class="cls_032"><span class="cls_032">Newburger P (Ed.), UpToDate. Retrieved February 19, 2018, from </span><A HREF="https://">https://</A> </div>
<div style="position:absolute;left:306.64px;top:596.71px" class="cls_031"><span class="cls_031">to point to psoriasis. The Arabian physicians perhaps first dis-</span></div>
<div style="position:absolute;left:49.43px;top:600.29px" class="cls_032"><span class="cls_032"> </span><A HREF="http://www.uptodate.com/contents/approach-to-the-adult-with-unexplained-/">www.uptodate.com/contents/approach-to-the-adult-with-unexplained-</A> </div>
<div style="position:absolute;left:49.43px;top:609.37px" class="cls_032"><span class="cls_032">neutropenia</span></div>
<div style="position:absolute;left:306.64px;top:606.72px" class="cls_031"><span class="cls_031">tinguished psoriasis from other skin diseases already in the 8th</span></div>
<div style="position:absolute;left:49.43px;top:618.46px" class="cls_032"><span class="cls_032">Van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai</span></div>
<div style="position:absolute;left:306.64px;top:616.72px" class="cls_031"><span class="cls_031">century A.D., but the first written description of psoriasis appears</span></div>
<div style="position:absolute;left:49.41px;top:627.55px" class="cls_032"><span class="cls_032">TF, et al. Secukinumab long-term safety experience: A pooled analysis of 10</span></div>
<div style="position:absolute;left:306.65px;top:626.72px" class="cls_031"><span class="cls_031">during the Roman Empire in the 1st century AD in the books of A.</span></div>
<div style="position:absolute;left:49.41px;top:636.64px" class="cls_032"><span class="cls_032">phase II and III clinical studies in patients with moderate to severe plaque</span></div>
<div style="position:absolute;left:306.65px;top:636.72px" class="cls_031"><span class="cls_031">Cornelius Celsus » De re medica libri octo». Galen (131-201 AD)</span></div>
<div style="position:absolute;left:49.41px;top:645.73px" class="cls_032"><span class="cls_032">psoriasis. J Am Acad Dermatol 2016 Jul;75(1):83-98.e4.</span></div>
<div style="position:absolute;left:306.65px;top:646.72px" class="cls_031"><span class="cls_031">of Pergamon, physician of some Roman imperators, was the first</span></div>
<div style="position:absolute;left:306.65px;top:656.71px" class="cls_031"><span class="cls_031">who used the term psoriasis, but only for an itchy, scaly eruption of</span></div>
<div style="position:absolute;left:49.43px;top:664.41px" class="cls_033"><span class="cls_033">P146</span></div>
<div style="position:absolute;left:306.65px;top:666.71px" class="cls_031"><span class="cls_031">the eyelids and scrotum, that was probably seborrheic dermatitis.</span></div>
<div style="position:absolute;left:49.43px;top:675.90px" class="cls_025"><span class="cls_025">ESTABLISHMENT OF A PSORIATIC SKIN MODEL FOR</span></div>
<div style="position:absolute;left:306.65px;top:676.71px" class="cls_031"><span class="cls_031">Unfortunately, little was known about the origin of the disease for</span></div>
<div style="position:absolute;left:49.43px;top:686.89px" class="cls_025"><span class="cls_025">Α-IRRADIATION</span></div>
<div style="position:absolute;left:306.65px;top:686.71px" class="cls_031"><span class="cls_031">hundreds of years, in the darkness of the Middle Age - a period of</span></div>
<div style="position:absolute;left:49.43px;top:696.87px" class="cls_051"><span class="cls_051">Julia Wiedemann</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Valeria Grünebaum</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Claudius Witzler</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Maxi-</span></div>
<div style="position:absolute;left:306.65px;top:696.71px" class="cls_031"><span class="cls_031">stagnation, and many psoriasis sufferers were thought at the time</span></div>
<div style="position:absolute;left:49.43px;top:706.85px" class="cls_026"><span class="cls_026">milian Dornhecker</span><span class="cls_027"><sup>1</sup></span><span class="cls_026">, Sylvie Lerchl, Claudia Fournier</span><span class="cls_027"><sup>1,2</sup></span></div>
<div style="position:absolute;left:306.65px;top:706.71px" class="cls_031"><span class="cls_031">to have leprosy. Because so little was known about contraction</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:48180px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background62.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">60</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">and treatment, psoriasis patients were often separated from the</span></div>
<div style="position:absolute;left:306.64px;top:51.40px" class="cls_031"><span class="cls_031">of flexural PsO has not been established, it may not encompass</span></div>
<div style="position:absolute;left:50.00px;top:61.40px" class="cls_031"><span class="cls_031">general population for fear of them contaminating others. People</span></div>
<div style="position:absolute;left:306.64px;top:61.40px" class="cls_031"><span class="cls_031">all aspects of inverse/intertiginous disease and the code may be</span></div>
<div style="position:absolute;left:50.00px;top:71.40px" class="cls_031"><span class="cls_031">with psoriasis - thousands in medieval Europe - were forced to</span></div>
<div style="position:absolute;left:306.64px;top:71.40px" class="cls_031"><span class="cls_031">highly underutilized.</span></div>
<div style="position:absolute;left:50.00px;top:81.40px" class="cls_031"><span class="cls_031">warn others of their arrival by ringing a clapper.</span></div>
<div style="position:absolute;left:306.64px;top:81.40px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> Using the code ICD-10-CM L40.8, which is re-</span></div>
<div style="position:absolute;left:50.00px;top:91.40px" class="cls_031"><span class="cls_031">It wasn’t until the early 1800’s that psoriasis was determined to</span></div>
<div style="position:absolute;left:306.64px;top:91.41px" class="cls_031"><span class="cls_031">commended to be used for inverse “flexural” PsO leads to lower</span></div>
<div style="position:absolute;left:50.00px;top:101.40px" class="cls_031"><span class="cls_031">be a condition separate from leprosy. In the cultural movement of</span></div>
<div style="position:absolute;left:306.66px;top:101.40px" class="cls_031"><span class="cls_031">prevalence estimates of inverse PsO than previously reported;</span></div>
<div style="position:absolute;left:50.00px;top:111.40px" class="cls_031"><span class="cls_031">Renaissance some authors mentioned the diseases psora and lepra</span></div>
<div style="position:absolute;left:306.66px;top:111.40px" class="cls_031"><span class="cls_031">this underscores the known underreporting and underdiagnosis</span></div>
<div style="position:absolute;left:50.00px;top:121.40px" class="cls_031"><span class="cls_031">in their books. In the 18th century hospitals or dispensaries were</span></div>
<div style="position:absolute;left:306.66px;top:121.40px" class="cls_031"><span class="cls_031">of this condition. Among those patients diagnosed and coded,</span></div>
<div style="position:absolute;left:50.00px;top:131.40px" class="cls_031"><span class="cls_031">opened only for treatment of skin or venereal diseases giving to</span></div>
<div style="position:absolute;left:306.66px;top:131.40px" class="cls_031"><span class="cls_031">most received topical corticosteroids and/or phototherapy, others</span></div>
<div style="position:absolute;left:50.00px;top:141.40px" class="cls_031"><span class="cls_031">the physicians the opportunity to study more cases of skin diseases</span></div>
<div style="position:absolute;left:306.66px;top:141.40px" class="cls_031"><span class="cls_031">received calcipotriene, ustekinumab, methotrexate, adalimumab,</span></div>
<div style="position:absolute;left:50.00px;top:151.40px" class="cls_031"><span class="cls_031">and psoriasis as well, while the end of the 19th century psoriatic</span></div>
<div style="position:absolute;left:306.66px;top:151.40px" class="cls_031"><span class="cls_031">etanercept, and acitretin. Further work is needed to understand</span></div>
<div style="position:absolute;left:50.00px;top:161.39px" class="cls_031"><span class="cls_031">micro morphology was already described. In 20th century many</span></div>
<div style="position:absolute;left:306.66px;top:161.40px" class="cls_031"><span class="cls_031">how best to capture inverse (intertriginous) / flexural psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:171.39px" class="cls_031"><span class="cls_031">authors studied the genetic alteration, and today there is undisputed</span></div>
<div style="position:absolute;left:306.66px;top:171.40px" class="cls_031"><span class="cls_031">for clinical research work.</span></div>
<div style="position:absolute;left:50.00px;top:181.39px" class="cls_031"><span class="cls_031">evidence that the disease is multifactorial.</span></div>
<div style="position:absolute;left:50.00px;top:191.39px" class="cls_031"><span class="cls_031">Psoriasis, as a common disease, has a significant socio-economic</span></div>
<div style="position:absolute;left:306.64px;top:190.04px" class="cls_033"><span class="cls_033">P150</span></div>
<div style="position:absolute;left:50.00px;top:201.39px" class="cls_031"><span class="cls_031">impact on the individual and on the society. Last decades numerous</span></div>
<div style="position:absolute;left:306.64px;top:201.44px" class="cls_025"><span class="cls_025">DEVELOPMENT OF THE “PSO SLEEPY-Q” AND</span></div>
<div style="position:absolute;left:50.00px;top:211.39px" class="cls_031"><span class="cls_031">immunological researches accumulate evidence of presence of</span></div>
<div style="position:absolute;left:306.64px;top:212.34px" class="cls_025"><span class="cls_025">THE “PSA SLEEPY-Q”: TWO QUESTIONNAIRES</span></div>
<div style="position:absolute;left:50.00px;top:221.39px" class="cls_031"><span class="cls_031">alteration of the innate and adaptive immune response in psoriatic</span></div>
<div style="position:absolute;left:306.64px;top:223.24px" class="cls_025"><span class="cls_025">TO CHARACTERIZE SLEEP IN PATIENTS WITH</span></div>
<div style="position:absolute;left:50.00px;top:231.39px" class="cls_031"><span class="cls_031">patients. This imply a primary disregulation of the immune system</span></div>
<div style="position:absolute;left:306.64px;top:234.14px" class="cls_025"><span class="cls_025">PSORIATIC DISEASE</span></div>
<div style="position:absolute;left:50.00px;top:241.39px" class="cls_031"><span class="cls_031">and permitts a better understanding and new insight in the pathoge-</span></div>
<div style="position:absolute;left:306.64px;top:244.04px" class="cls_026"><span class="cls_026">Lourdes Perez-Chada</span></div>
<div style="position:absolute;left:50.00px;top:251.41px" class="cls_031"><span class="cls_031">nesis and as well new possibilities in the management of psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:254.64px" class="cls_029"><span class="cls_029">Harvard Medical School - Brigham and Women’s Hospital</span></div>
<div style="position:absolute;left:50.00px;top:261.40px" class="cls_031"><span class="cls_031">This article shows a retrospective view of development of our</span></div>
<div style="position:absolute;left:306.64px;top:265.51px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Substantial evidence suggests that psoriasis (PsO)</span></div>
<div style="position:absolute;left:50.00px;top:271.40px" class="cls_031"><span class="cls_031">knowledge on psoriasis through history.</span></div>
<div style="position:absolute;left:306.64px;top:275.50px" class="cls_031"><span class="cls_031">and psoriatic arthritis (PsA) are independently associated with</span></div>
<div style="position:absolute;left:306.64px;top:285.50px" class="cls_031"><span class="cls_031">sleep disturbance, which may result in serious health consequen-</span></div>
<div style="position:absolute;left:50.00px;top:291.04px" class="cls_033"><span class="cls_033">P148</span></div>
<div style="position:absolute;left:306.64px;top:295.51px" class="cls_031"><span class="cls_031">ces including cardiovascular events and mortality. However, the</span></div>
<div style="position:absolute;left:50.00px;top:302.44px" class="cls_025"><span class="cls_025">COMORBIDITIES AND TREATMENTS IN PATIENTS</span></div>
<div style="position:absolute;left:306.64px;top:305.50px" class="cls_031"><span class="cls_031">validity of the sleep measures used in these studies is unknown</span></div>
<div style="position:absolute;left:50.00px;top:313.34px" class="cls_025"><span class="cls_025">WITH INVERSE PSORIASIS</span></div>
<div style="position:absolute;left:306.64px;top:315.50px" class="cls_031"><span class="cls_031">as they have not been validated in patients with psoriatic disease</span></div>
<div style="position:absolute;left:50.00px;top:323.24px" class="cls_051"><span class="cls_051">Mia Schneeweiss</span><span class="cls_026">, Joseph Merola</span></div>
<div style="position:absolute;left:306.64px;top:325.50px" class="cls_031"><span class="cls_031">or included psoriatic patients during their development process.</span></div>
<div style="position:absolute;left:50.00px;top:333.84px" class="cls_029"><span class="cls_029">Brigham and Women’s Hospital</span></div>
<div style="position:absolute;left:306.64px;top:335.50px" class="cls_031"><span class="cls_031">There is a need for validated disease-specific Patient-Reported</span></div>
<div style="position:absolute;left:50.00px;top:344.71px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Inverse (intertriginous) psoriasis is an underdiag-</span></div>
<div style="position:absolute;left:306.65px;top:345.50px" class="cls_031"><span class="cls_031">Outcome Measures (PROMs) to accurately characterize sleep in</span></div>
<div style="position:absolute;left:50.00px;top:354.71px" class="cls_031"><span class="cls_031">nosed, often untreated phenotype of psoriasis (PsO) with a high</span></div>
<div style="position:absolute;left:306.65px;top:355.50px" class="cls_031"><span class="cls_031">this population and to measure the effect of psoriatic therapies on</span></div>
<div style="position:absolute;left:50.00px;top:364.70px" class="cls_031"><span class="cls_031">burden of illness. Inverse PsO may occur in up to 23% of subjects</span></div>
<div style="position:absolute;left:306.65px;top:365.50px" class="cls_031"><span class="cls_031">sleep disturbance.</span></div>
<div style="position:absolute;left:50.00px;top:374.70px" class="cls_031"><span class="cls_031">with psoriasis, higher than previously reported.</span></div>
<div style="position:absolute;left:306.65px;top:375.50px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">This study aimed to develop and establish the content</span></div>
<div style="position:absolute;left:50.00px;top:384.70px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">To characterize the frequency of inverse PsO and</span></div>
<div style="position:absolute;left:306.65px;top:385.50px" class="cls_031"><span class="cls_031">validity of 2 new sleep PROMs: the “PsO Sleepy-Q” and the</span></div>
<div style="position:absolute;left:50.00px;top:394.70px" class="cls_031"><span class="cls_031">patient characteristics and their treatment in a large commercial</span></div>
<div style="position:absolute;left:306.65px;top:395.50px" class="cls_031"><span class="cls_031">“PsA Sleepy-Q”.</span></div>
<div style="position:absolute;left:50.00px;top:404.70px" class="cls_031"><span class="cls_031">insurance claims database.</span></div>
<div style="position:absolute;left:306.65px;top:405.49px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> Following FDA PROM-development guidance, our</span></div>
<div style="position:absolute;left:50.00px;top:414.70px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">We used longitudinal claims data from commercially</span></div>
<div style="position:absolute;left:306.65px;top:415.49px" class="cls_031"><span class="cls_031">study: (</span><span class="cls_030">i</span><span class="cls_031">) hypothesized a conceptual framework and identified</span></div>
<div style="position:absolute;left:50.00px;top:424.70px" class="cls_031"><span class="cls_031">insured patients in the US between 10/2015 and 12/2016 to identify</span></div>
<div style="position:absolute;left:306.65px;top:425.49px" class="cls_031"><span class="cls_031">domains through literature review and patient semi-structured</span></div>
<div style="position:absolute;left:50.00px;top:434.70px" class="cls_031"><span class="cls_031">adults with a diagnosis of flexural psoriasis (ICD-10-CM: L40.8,</span></div>
<div style="position:absolute;left:306.65px;top:435.49px" class="cls_031"><span class="cls_031">interviews using a saturation model (</span><span class="cls_030">n = </span><span class="cls_031">30); (</span><span class="cls_030">ii</span><span class="cls_031">) rated domains</span></div>
<div style="position:absolute;left:50.00px;top:444.70px" class="cls_031"><span class="cls_031">“other psoriasis” which is “recommended to be used for flexural</span></div>
<div style="position:absolute;left:306.65px;top:445.49px" class="cls_031"><span class="cls_031">for importance by patients (</span><span class="cls_030">n = </span><span class="cls_031">42) and an international expert</span></div>
<div style="position:absolute;left:49.99px;top:454.70px" class="cls_031"><span class="cls_031">PsO”) associated with an outpatient or inpatient encounter. A 180-</span></div>
<div style="position:absolute;left:306.65px;top:455.49px" class="cls_031"><span class="cls_031">panel including dermatologists, rheumatologists and sleep experts</span></div>
<div style="position:absolute;left:49.99px;top:464.69px" class="cls_031"><span class="cls_031">day enrollment period was required before the first diagnosis of</span></div>
<div style="position:absolute;left:306.65px;top:465.49px" class="cls_031"><span class="cls_031">(</span><span class="cls_030">n = </span><span class="cls_031">45); (</span><span class="cls_030">iii</span><span class="cls_031">) selected final domains based of the patients’ prefe-</span></div>
<div style="position:absolute;left:50.00px;top:474.69px" class="cls_031"><span class="cls_031">AD. Among those diagnosed we computed the risk of initiating</span></div>
<div style="position:absolute;left:306.64px;top:475.51px" class="cls_031"><span class="cls_031">rence; (</span><span class="cls_030">iv</span><span class="cls_031">) generated item pools and the preliminary versions of</span></div>
<div style="position:absolute;left:50.00px;top:484.69px" class="cls_031"><span class="cls_031">immunomodulating medications during the following 6 months.</span></div>
<div style="position:absolute;left:306.64px;top:485.50px" class="cls_031"><span class="cls_031">the instruments.</span></div>
<div style="position:absolute;left:50.00px;top:494.69px" class="cls_031"><span class="cls_031">All analyses were conducted using the Aetion Evidence Platform.</span></div>
<div style="position:absolute;left:306.64px;top:495.50px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Psoriatic patients reported that sleep maintenance, ade-</span></div>
<div style="position:absolute;left:50.00px;top:504.69px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">Of 1.5million patients with at least one code for PsO, after</span></div>
<div style="position:absolute;left:306.64px;top:505.51px" class="cls_031"><span class="cls_031">quacy, quantity and quality were the most important aspects of</span></div>
<div style="position:absolute;left:50.00px;top:514.69px" class="cls_031"><span class="cls_031">excluding patients with concomitant other autoimmune conditions,</span></div>
<div style="position:absolute;left:306.64px;top:515.50px" class="cls_031"><span class="cls_031">disordered sleep. Regarding causes of disturbed sleep: itch, skin</span></div>
<div style="position:absolute;left:50.00px;top:524.69px" class="cls_031"><span class="cls_031">we identified 5,310 patients with an ICD-10 code of L40.8 used for</span></div>
<div style="position:absolute;left:306.64px;top:525.50px" class="cls_031"><span class="cls_031">and joint pain, stiffness, taking care of psoriatic lesions before</span></div>
<div style="position:absolute;left:50.00px;top:534.69px" class="cls_031"><span class="cls_031">inverse PsO (4/1,000) with a median age of 52 years and an equal</span></div>
<div style="position:absolute;left:306.64px;top:535.50px" class="cls_031"><span class="cls_031">bedtime, worsening of psoriatic symptoms at night, feeling un-</span></div>
<div style="position:absolute;left:50.00px;top:544.69px" class="cls_031"><span class="cls_031">gender distribution. Half of the patients were 41-60 years old.</span></div>
<div style="position:absolute;left:306.64px;top:545.51px" class="cls_031"><span class="cls_031">comfortable in bed due to PsA and sleep apneawere the most out-</span></div>
<div style="position:absolute;left:50.00px;top:554.69px" class="cls_031"><span class="cls_031">Of those, 0.3% generalized pustular, 0.5% guttate, and 0.2%</span></div>
<div style="position:absolute;left:306.64px;top:555.46px" class="cls_031"><span class="cls_031">standing factors selected. Finally, patients reported that disturbed</span></div>
<div style="position:absolute;left:50.00px;top:564.68px" class="cls_031"><span class="cls_031">pustulosis palmaris et plantaris. Prevalent comorbidities included</span></div>
<div style="position:absolute;left:306.64px;top:565.41px" class="cls_031"><span class="cls_031">sleep may increase psoriatic signs and symptomsas well as fatigue,</span></div>
<div style="position:absolute;left:50.00px;top:574.68px" class="cls_031"><span class="cls_031">depression (7%), anxiety (6.5%), and cardiovascular conditions</span></div>
<div style="position:absolute;left:306.64px;top:575.36px" class="cls_031"><span class="cls_031">cognitive impairment and psychological stress. Overall, patients</span></div>
<div style="position:absolute;left:50.00px;top:584.68px" class="cls_031"><span class="cls_031">(5%). 20% received antidepressants. Within 180 days after the</span></div>
<div style="position:absolute;left:306.64px;top:585.32px" class="cls_031"><span class="cls_031">with PsA expressed a higher burden of sleep disturbance compared</span></div>
<div style="position:absolute;left:50.00px;top:594.68px" class="cls_031"><span class="cls_031">diagnosis of flexural PsO, 81% were using high-potency topical</span></div>
<div style="position:absolute;left:306.64px;top:595.27px" class="cls_031"><span class="cls_031">to patients with PsO. Preliminary versions of the “PsO Sleepy-</span></div>
<div style="position:absolute;left:49.98px;top:604.68px" class="cls_031"><span class="cls_031">corticosteroids, 66% phototherapy, 8.6% calcipotriene, 5.6% uste-</span></div>
<div style="position:absolute;left:306.64px;top:605.23px" class="cls_031"><span class="cls_031">Q” and “PsA Sleepy-Q” including 18 and 24 items, respectively,</span></div>
<div style="position:absolute;left:50.00px;top:614.71px" class="cls_031"><span class="cls_031">kinumab, 7.2% methotrexate, 7.3% adalimumab, 3.3% etanercept,</span></div>
<div style="position:absolute;left:306.64px;top:615.18px" class="cls_031"><span class="cls_031">were created. These questionnaires intend to measure the degree</span></div>
<div style="position:absolute;left:50.00px;top:624.70px" class="cls_031"><span class="cls_031">1.3% acitretin, 0.8% infliximab, 0.9% Cyclosporine, 0.1% Sulfa-</span></div>
<div style="position:absolute;left:306.64px;top:625.13px" class="cls_031"><span class="cls_031">of sleep disturbance, the potential causes of sleep disturbance and</span></div>
<div style="position:absolute;left:50.00px;top:634.71px" class="cls_031"><span class="cls_031">salazine, 0.02% topical tacrolimus, 0.5% topical pimecrolimus.</span></div>
<div style="position:absolute;left:306.64px;top:635.09px" class="cls_031"><span class="cls_031">the impairment related to sleep disturbance.</span></div>
<div style="position:absolute;left:50.00px;top:644.70px" class="cls_031"><span class="cls_031">In patients 60+, 83% used high-potency topical corticosteroids,</span></div>
<div style="position:absolute;left:306.64px;top:645.04px" class="cls_030"><span class="cls_030">Conclusion:</span><span class="cls_031"> This study establishes the content validity of the “PsO</span></div>
<div style="position:absolute;left:50.00px;top:654.70px" class="cls_031"><span class="cls_031">7.8% phototherapy, 8.8% calcipotriene, 3.1% ustekinumab, 6.9%</span></div>
<div style="position:absolute;left:306.64px;top:655.00px" class="cls_031"><span class="cls_031">Sleepy-Q” and “PsA Sleepy-Q”, two patient-derived PROMs to</span></div>
<div style="position:absolute;left:50.00px;top:664.70px" class="cls_031"><span class="cls_031">methotrexate, 4.8% adalimumab, 2.9% etanercept, 1.5% acitretin,</span></div>
<div style="position:absolute;left:306.64px;top:664.95px" class="cls_031"><span class="cls_031">characterize sleep in patients with psoriatic disease in research</span></div>
<div style="position:absolute;left:50.00px;top:674.70px" class="cls_031"><span class="cls_031">0.5% infliximab, 0.9% Cyclosporine, 0.6% topical pimecrolimus.</span></div>
<div style="position:absolute;left:306.64px;top:674.90px" class="cls_031"><span class="cls_031">and clinical settings. These questionnaires will undergo cognitive</span></div>
<div style="position:absolute;left:50.02px;top:684.70px" class="cls_030"><span class="cls_030">Limitations: </span><span class="cls_031">Although the ICD-10-CM code L40.8 is recommen-</span></div>
<div style="position:absolute;left:306.64px;top:684.86px" class="cls_031"><span class="cls_031">debriefing and further psychometric testing to define the final</span></div>
<div style="position:absolute;left:50.00px;top:694.71px" class="cls_031"><span class="cls_031">ded for flexural PsO, its sensitivity/specificity for validating cases</span></div>
<div style="position:absolute;left:306.63px;top:694.81px" class="cls_031"><span class="cls_031">instrument forms.</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:48983px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background63.jpg" width=595 height=793></div>
<div style="position:absolute;left:455.59px;top:28.81px" class="cls_019"><span class="cls_019">Poster abstracts</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">61</span></div>
<div style="position:absolute;left:50.00px;top:51.23px" class="cls_033"><span class="cls_033">P151</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">• To deepen the criteria for patient selection for both scientific and</span></div>
<div style="position:absolute;left:50.00px;top:62.71px" class="cls_025"><span class="cls_025">UNSTABLE FORMS OF PSORIASIS - INDICATOR OF AN</span></div>
<div style="position:absolute;left:306.63px;top:61.40px" class="cls_031"><span class="cls_031">therapeutic protocols.</span></div>
<div style="position:absolute;left:50.00px;top:73.68px" class="cls_025"><span class="cls_025">INTERMEDIATE STATE OF SYSTEMIC DISEASE</span></div>
<div style="position:absolute;left:306.63px;top:71.40px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">This poster reviews the literature for evidence that while</span></div>
<div style="position:absolute;left:50.00px;top:83.65px" class="cls_026"><span class="cls_026">Florentina-Silvia Delli</span></div>
<div style="position:absolute;left:306.63px;top:81.40px" class="cls_031"><span class="cls_031">biological agents could improve the mood of patients with psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:94.33px" class="cls_029"><span class="cls_029">State Hospital for Skin and Venereal Diseases - Hippokratia General Hos-</span></div>
<div style="position:absolute;left:306.63px;top:91.40px" class="cls_031"><span class="cls_031">treated with these drugs, this same favourable antidepressant effect</span></div>
<div style="position:absolute;left:50.00px;top:104.01px" class="cls_029"><span class="cls_029">pital, Thessaloniki, Greece</span></div>
<div style="position:absolute;left:306.63px;top:101.40px" class="cls_031"><span class="cls_031">on humor may trigger a switch of mood into mania, favouring</span></div>
<div style="position:absolute;left:306.63px;top:111.40px" class="cls_031"><span class="cls_031">attempted and completed suicide in undiagnosed bipolar patients</span></div>
<div style="position:absolute;left:50.00px;top:114.90px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Erytrodermic psoriasis, inverse psoriasis and gene-</span></div>
<div style="position:absolute;left:306.63px;top:121.40px" class="cls_031"><span class="cls_031">treated for psoriasis with IL17-TNF alpha cytokine blockers.</span></div>
<div style="position:absolute;left:50.00px;top:124.93px" class="cls_031"><span class="cls_031">ralized pustular psoriasis are considered three particular clinical</span></div>
<div style="position:absolute;left:306.63px;top:131.40px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> Evidence gathered so far suggests that common inflam-</span></div>
<div style="position:absolute;left:50.00px;top:134.95px" class="cls_031"><span class="cls_031">forms of psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:141.41px" class="cls_031"><span class="cls_031">matory processes could underpin both bipolar and psoriasis.</span></div>
<div style="position:absolute;left:50.00px;top:144.98px" class="cls_030"><span class="cls_030">Objectives: </span><span class="cls_031">We present two clinical cases in which it is discussed</span></div>
<div style="position:absolute;left:306.64px;top:151.40px" class="cls_031"><span class="cls_031">The current literature is lacking of longitudinal and mechanistic</span></div>
<div style="position:absolute;left:50.00px;top:155.00px" class="cls_031"><span class="cls_031">the possibility of considering these clinical pictures as a manifesta-</span></div>
<div style="position:absolute;left:306.64px;top:161.40px" class="cls_031"><span class="cls_031">studies, as well as comparison studies to explore the magnitude</span></div>
<div style="position:absolute;left:50.00px;top:165.03px" class="cls_031"><span class="cls_031">tion of the immunological switch of psoriasis from an organ-target</span></div>
<div style="position:absolute;left:306.64px;top:171.40px" class="cls_031"><span class="cls_031">of this relation.</span></div>
<div style="position:absolute;left:50.00px;top:175.06px" class="cls_031"><span class="cls_031">(skin or joint) disease, to a systemic form of psoriasis.</span></div>
<div style="position:absolute;left:306.64px;top:181.40px" class="cls_030"><span class="cls_030">Conclusion:</span><span class="cls_031"> Considering both bipolar disorder and psoriasis as a</span></div>
<div style="position:absolute;left:50.00px;top:185.08px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> A 22-year-old-man with erythodermic psoriasis and a</span></div>
<div style="position:absolute;left:306.64px;top:191.40px" class="cls_031"><span class="cls_031">multi-system disorder should help us understand the common phy-</span></div>
<div style="position:absolute;left:50.00px;top:195.11px" class="cls_031"><span class="cls_031">history of inverse psoriasis since childhood was successfully trea-</span></div>
<div style="position:absolute;left:306.64px;top:201.41px" class="cls_031"><span class="cls_031">siopathology of this comorbidity so as not to see them as separated</span></div>
<div style="position:absolute;left:50.00px;top:205.13px" class="cls_031"><span class="cls_031">ted with 60 mg acitretin, until the diagnosis of psoriatic arthritis at</span></div>
<div style="position:absolute;left:306.64px;top:211.40px" class="cls_031"><span class="cls_031">disorders. Consequently, it is vital to emphasize the importance of</span></div>
<div style="position:absolute;left:50.00px;top:215.16px" class="cls_031"><span class="cls_031">the age of 26. The presence of arthritis determined us to change the</span></div>
<div style="position:absolute;left:306.64px;top:221.40px" class="cls_031"><span class="cls_031">the initial psychiatric evaluation for a correct psychiatric/ clinical</span></div>
<div style="position:absolute;left:50.00px;top:225.18px" class="cls_031"><span class="cls_031">therapy. Secukinumab at the classic therapeutic scheme is keeping</span></div>
<div style="position:absolute;left:306.64px;top:231.40px" class="cls_031"><span class="cls_031">diagnosis for patients with Psoriasis to be both admitted to a strict</span></div>
<div style="position:absolute;left:50.00px;top:235.21px" class="cls_031"><span class="cls_031">the patient’s skin clean of psoriatic lesions, except from the arm-</span></div>
<div style="position:absolute;left:306.64px;top:241.40px" class="cls_031"><span class="cls_031">control protocol and treated with biological agents.</span></div>
<div style="position:absolute;left:50.00px;top:245.23px" class="cls_031"><span class="cls_031">pits, and without any arthritic symptoms. A 75-year-old-woman</span></div>
<div style="position:absolute;left:50.00px;top:255.26px" class="cls_031"><span class="cls_031">with psoriatic arthritis and hyperkeratotic palms and soles non-</span></div>
<div style="position:absolute;left:306.64px;top:260.04px" class="cls_033"><span class="cls_033">P153</span></div>
<div style="position:absolute;left:50.00px;top:265.29px" class="cls_031"><span class="cls_031">specific lesions, under infliximab therapy presented generalized</span></div>
<div style="position:absolute;left:306.64px;top:271.44px" class="cls_025"><span class="cls_025">TREATING THE PAIN, NOT THE PROBLEM? RESULTS</span></div>
<div style="position:absolute;left:50.00px;top:275.31px" class="cls_031"><span class="cls_031">pustular psoriasis. After 3 months of acitretin 40mg and etanercept</span></div>
<div style="position:absolute;left:306.64px;top:282.34px" class="cls_025"><span class="cls_025">FROM A SWEDISH ONLINE SURVEY ON PSORIATIC</span></div>
<div style="position:absolute;left:50.00px;top:285.34px" class="cls_031"><span class="cls_031">at the classic dose, the patient remains free of any symptoms.</span></div>
<div style="position:absolute;left:50.00px;top:295.36px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> The majority of psoriasis studies focus on chronic</span></div>
<div style="position:absolute;left:306.64px;top:293.24px" class="cls_025"><span class="cls_025">ARTHRITIS AND PSORIASIS WITH JOINT PAIN</span></div>
<div style="position:absolute;left:50.00px;top:305.39px" class="cls_031"><span class="cls_031">plaque psoriasis. We sustain the opinion that the above unstable</span></div>
<div style="position:absolute;left:306.64px;top:303.14px" class="cls_026"><span class="cls_026">T Norgren, </span><span class="cls_051">B Bohannan</span></div>
<div style="position:absolute;left:306.64px;top:313.74px" class="cls_029"><span class="cls_029">Psoriasisförbundet, Stockholm, Sweden</span></div>
<div style="position:absolute;left:50.00px;top:315.41px" class="cls_031"><span class="cls_031">forms of psoriasis, usually impossible to diagnose by other spe-</span></div>
<div style="position:absolute;left:50.00px;top:325.44px" class="cls_031"><span class="cls_031">cialities than Dermatology, should be consider the main step in</span></div>
<div style="position:absolute;left:306.64px;top:324.61px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriatic arthritis (PsA) is a chronic inflammatory</span></div>
<div style="position:absolute;left:50.00px;top:335.51px" class="cls_031"><span class="cls_031">multidisciplinary approach of psoriasis as a systemic disease.</span></div>
<div style="position:absolute;left:306.64px;top:334.60px" class="cls_031"><span class="cls_031">disease associated with psoriasis, that can cause pain, swelling and,</span></div>
<div style="position:absolute;left:50.00px;top:345.58px" class="cls_030"><span class="cls_030">References:</span></div>
<div style="position:absolute;left:306.64px;top:344.60px" class="cls_031"><span class="cls_031">if untreated, severe joint destruction and disability. The knowledge</span></div>
<div style="position:absolute;left:50.00px;top:355.68px" class="cls_032"><span class="cls_032">1.Kivelevitch D et al. Pharmacotheraputic approaches for treating pso-</span></div>
<div style="position:absolute;left:306.64px;top:354.60px" class="cls_031"><span class="cls_031">about PsA among both the public and healthcare providers is limi-</span></div>
<div style="position:absolute;left:50.00px;top:364.75px" class="cls_032"><span class="cls_032">riasis in difficult-to treat areas. ExpertOpinPharmacother 2018 April;</span></div>
<div style="position:absolute;left:306.64px;top:364.61px" class="cls_031"><span class="cls_031">ted, leading to both underdiagnosis and undertreatment. To raise</span></div>
<div style="position:absolute;left:50.00px;top:373.83px" class="cls_032"><span class="cls_032">19(6); 561-575</span></div>
<div style="position:absolute;left:306.64px;top:374.60px" class="cls_031"><span class="cls_031">awareness of PsA and gather relevant data, the Swedish Psoriasis</span></div>
<div style="position:absolute;left:50.00px;top:382.90px" class="cls_032"><span class="cls_032">2.Sano S et al. Guselkumab, a human interleukin-23 monoclonal antibody</span></div>
<div style="position:absolute;left:306.64px;top:384.60px" class="cls_031"><span class="cls_031">Association (Psoriasisförbundet) and the Swedish Rheumatism</span></div>
<div style="position:absolute;left:50.00px;top:391.97px" class="cls_032"><span class="cls_032">in Japanise patients with generalized pustular psoriasis: efficacy and safety</span></div>
<div style="position:absolute;left:306.64px;top:394.60px" class="cls_031"><span class="cls_031">Association (Reumatikerförbundet) initiated an educational</span></div>
<div style="position:absolute;left:50.00px;top:401.04px" class="cls_032"><span class="cls_032">analyses of a 52-week, phase 3, multicentre, open-label study. JDermatol</span></div>
<div style="position:absolute;left:306.64px;top:404.60px" class="cls_031"><span class="cls_031">awareness campaign on a well-visited online health information</span></div>
<div style="position:absolute;left:50.00px;top:410.11px" class="cls_032"><span class="cls_032">2018 May; 45(5): 529-539</span></div>
<div style="position:absolute;left:306.64px;top:414.60px" class="cls_031"><span class="cls_031">platform, which also featured a survey on healthcare experiences</span></div>
<div style="position:absolute;left:50.00px;top:419.19px" class="cls_032"><span class="cls_032">3.Cafaro G, McInnes IB. Psoriatic arthritis: tissue-directed inflammation?</span></div>
<div style="position:absolute;left:306.64px;top:424.60px" class="cls_031"><span class="cls_031">and Quality of Life.</span></div>
<div style="position:absolute;left:50.00px;top:428.26px" class="cls_032"><span class="cls_032">ClinRheumatol 2018 Apr; 37(4): 859-868.</span></div>
<div style="position:absolute;left:306.64px;top:434.60px" class="cls_030"><span class="cls_030">Objectives:</span><span class="cls_031"> The purpose of the survey was to identify gaps or</span></div>
<div style="position:absolute;left:306.64px;top:444.60px" class="cls_031"><span class="cls_031">discrepancies in the healthcare provided for individuals diagnosed</span></div>
<div style="position:absolute;left:50.00px;top:447.98px" class="cls_033"><span class="cls_033">P152</span></div>
<div style="position:absolute;left:306.64px;top:454.60px" class="cls_031"><span class="cls_031">with PsA and for individuals with psoriasis and joint pain consis-</span></div>
<div style="position:absolute;left:50.00px;top:459.45px" class="cls_025"><span class="cls_025">COULD BIOLOGICAL AGENTS FOSTER SUICIDE</span></div>
<div style="position:absolute;left:306.64px;top:464.61px" class="cls_031"><span class="cls_031">tent with a PsA diagnosis, as well as understanding the impact on</span></div>
<div style="position:absolute;left:50.00px;top:470.42px" class="cls_025"><span class="cls_025">THROUGH ITS POTENTIAL ANTIDEPRESSANT</span></div>
<div style="position:absolute;left:306.64px;top:474.60px" class="cls_031"><span class="cls_031">QoL for both groups.</span></div>
<div style="position:absolute;left:50.00px;top:481.39px" class="cls_025"><span class="cls_025">MECHANISM? A PSYCHODERMATOLOGICAL</span></div>
<div style="position:absolute;left:306.64px;top:484.60px" class="cls_030"><span class="cls_030">Methods: </span><span class="cls_031">The survey consisted of two questionnaires, one for</span></div>
<div style="position:absolute;left:50.00px;top:492.37px" class="cls_025"><span class="cls_025">APPROACH</span></div>
<div style="position:absolute;left:306.64px;top:494.60px" class="cls_031"><span class="cls_031">individuals diagnosed with PsA, group A, and one for individu-</span></div>
<div style="position:absolute;left:50.00px;top:502.34px" class="cls_026"><span class="cls_026">Estela M Malatesta</span></div>
<div style="position:absolute;left:306.64px;top:504.61px" class="cls_031"><span class="cls_031">als diagnosed with psoriasis who have joint pain consistent with</span></div>
<div style="position:absolute;left:50.00px;top:513.03px" class="cls_029"><span class="cls_029">Dermatologist and Psychiatrist, Doctor. Arturo Ameghino Mental Health</span></div>
<div style="position:absolute;left:306.64px;top:514.60px" class="cls_031"><span class="cls_031">a PsA diagnosis (using CASPAR criteria as reference), group</span></div>
<div style="position:absolute;left:50.00px;top:522.70px" class="cls_029"><span class="cls_029">Centre, Buenos Aires, Argentina. President of ADEPSI, Academy of Der-</span></div>
<div style="position:absolute;left:306.64px;top:524.60px" class="cls_031"><span class="cls_031">B. The survey was open from April 6 2017 to March 31 2018.</span></div>
<div style="position:absolute;left:50.00px;top:532.37px" class="cls_029"><span class="cls_029">matology and Psychiatry</span></div>
<div style="position:absolute;left:306.64px;top:534.60px" class="cls_031"><span class="cls_031">The total number of respondents in group A was 5 201, and in</span></div>
<div style="position:absolute;left:50.00px;top:543.32px" class="cls_030"><span class="cls_030">Introduction:</span><span class="cls_031"> Depression and Psoriasis are associated in up to</span></div>
<div style="position:absolute;left:306.64px;top:544.60px" class="cls_031"><span class="cls_031">group B 11 272. It was not mandatory to answer all questions</span></div>
<div style="position:absolute;left:50.00px;top:553.39px" class="cls_031"><span class="cls_031">60% of the cases, with an increased risk of attempted and com-</span></div>
<div style="position:absolute;left:306.64px;top:554.60px" class="cls_031"><span class="cls_031">in the survey. One section of the survey focussed on prescribed</span></div>
<div style="position:absolute;left:50.00px;top:563.47px" class="cls_031"><span class="cls_031">pleted suicide in patients with severe forms of the disease. Bipolar</span></div>
<div style="position:absolute;left:306.64px;top:564.60px" class="cls_031"><span class="cls_031">medication, to specifically identify discrepancies in the treatment</span></div>
<div style="position:absolute;left:50.00px;top:573.54px" class="cls_031"><span class="cls_031">Disorder is a biological condition that affects between 2 and 5%</span></div>
<div style="position:absolute;left:306.63px;top:574.60px" class="cls_031"><span class="cls_031">of the diagnosed (A) and undiagnosed (B) groups. Limitations:</span></div>
<div style="position:absolute;left:50.00px;top:583.62px" class="cls_031"><span class="cls_031">of the population, being an important cause of disability in the</span></div>
<div style="position:absolute;left:306.63px;top:584.60px" class="cls_031"><span class="cls_031">self-reported diagnosis, possible to take survey multiple times</span></div>
<div style="position:absolute;left:50.00px;top:593.69px" class="cls_031"><span class="cls_031">world. In spite of this, Bipolar Disorder is often underdiagnosed as</span></div>
<div style="position:absolute;left:306.63px;top:594.60px" class="cls_031"><span class="cls_031">using different devices.</span></div>
<div style="position:absolute;left:50.00px;top:603.76px" class="cls_031"><span class="cls_031">Unipolar Depression, which increases the possibility of prescribing</span></div>
<div style="position:absolute;left:306.63px;top:604.60px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> In response to the question “Which medication has been</span></div>
<div style="position:absolute;left:50.00px;top:613.83px" class="cls_031"><span class="cls_031">errors, as it occurs when administering only antidepressant agents</span></div>
<div style="position:absolute;left:306.63px;top:614.59px" class="cls_031"><span class="cls_031">prescribed for your joint pain during the past year?” 23.91% of</span></div>
<div style="position:absolute;left:50.00px;top:623.90px" class="cls_031"><span class="cls_031">without accompanying them with mood stabilizers, fostering the</span></div>
<div style="position:absolute;left:306.63px;top:624.59px" class="cls_031"><span class="cls_031">group B (214 of 895) answered that they had been prescribed</span></div>
<div style="position:absolute;left:50.00px;top:633.97px" class="cls_031"><span class="cls_031">appearance of episodes of inverse polarity (SWITCHING) which,</span></div>
<div style="position:absolute;left:306.63px;top:634.59px" class="cls_031"><span class="cls_031">opioid pain medication for their joint pain. In group A only 4.61%</span></div>
<div style="position:absolute;left:50.00px;top:644.04px" class="cls_031"><span class="cls_031">in turn, raises the risk of suicide.</span></div>
<div style="position:absolute;left:306.63px;top:644.59px" class="cls_031"><span class="cls_031">of the respondents (73 out of 1 582) were prescribed opioid pain</span></div>
<div style="position:absolute;left:50.00px;top:654.11px" class="cls_030"><span class="cls_030">Objectives:</span><span class="cls_031"> The “Cytokine Hypothesis” as a cause of depression</span></div>
<div style="position:absolute;left:306.63px;top:654.59px" class="cls_031"><span class="cls_031">medication for their PsA.</span></div>
<div style="position:absolute;left:50.00px;top:664.18px" class="cls_031"><span class="cls_031">suggests the association between the immune system and depres-</span></div>
<div style="position:absolute;left:306.63px;top:664.59px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> The results show a large discrepancy between the</span></div>
<div style="position:absolute;left:50.00px;top:674.30px" class="cls_031"><span class="cls_031">sion through the induction of the indolamine 2, 3- dioxygenase</span></div>
<div style="position:absolute;left:306.63px;top:674.59px" class="cls_031"><span class="cls_031">groups in the prescription of opioid pain medication. The results</span></div>
<div style="position:absolute;left:50.00px;top:684.37px" class="cls_031"><span class="cls_031">enzyme. The objectives of the poster are:</span></div>
<div style="position:absolute;left:306.63px;top:684.59px" class="cls_031"><span class="cls_031">suggest that individuals with psoriasis that have joint pain con-</span></div>
<div style="position:absolute;left:50.00px;top:694.45px" class="cls_031"><span class="cls_031">• To raise the need for new studies to confirm this hypothesis as</span></div>
<div style="position:absolute;left:306.64px;top:694.61px" class="cls_031"><span class="cls_031">sistent with a PsA diagnosis are being over-prescribed potentially</span></div>
<div style="position:absolute;left:49.99px;top:704.52px" class="cls_031"><span class="cls_031">well as the antidepressant effect of biological agents and their</span></div>
<div style="position:absolute;left:306.64px;top:704.60px" class="cls_031"><span class="cls_031">addictive pain medication rather than receiving treatment for their</span></div>
<div style="position:absolute;left:49.99px;top:714.59px" class="cls_031"><span class="cls_031">potential ability to cause a shift into mania.</span></div>
<div style="position:absolute;left:306.64px;top:714.60px" class="cls_031"><span class="cls_031">underlying condition or inflammatory symptoms apart from pain.</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:49786px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background64.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">62</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:51.41px" class="cls_031"><span class="cls_031">As early diagnosis and effective treatment is vital to slow down</span></div>
<div style="position:absolute;left:306.64px;top:51.41px" class="cls_031"><span class="cls_031">as the most appropriate measure, while RAPID3 could be an ac-</span></div>
<div style="position:absolute;left:50.00px;top:61.40px" class="cls_031"><span class="cls_031">disease progression, individuals with psoriasis as well as healt-</span></div>
<div style="position:absolute;left:306.64px;top:61.41px" class="cls_031"><span class="cls_031">ceptable alternative to PsAID9. This will be followed by a work-</span></div>
<div style="position:absolute;left:50.00px;top:71.41px" class="cls_031"><span class="cls_031">hcare providers need to be educated on symptoms and diagnosis</span></div>
<div style="position:absolute;left:306.64px;top:71.41px" class="cls_031"><span class="cls_031">shop at the IDEOM and GRAPPA 2018 annual meetings to review</span></div>
<div style="position:absolute;left:50.00px;top:81.40px" class="cls_031"><span class="cls_031">criteria of PsA to prevent undertreatment or treatment that may</span></div>
<div style="position:absolute;left:306.64px;top:81.40px" class="cls_031"><span class="cls_031">discussion points as well as any need for a second Delphi round.</span></div>
<div style="position:absolute;left:50.00px;top:91.40px" class="cls_031"><span class="cls_031">even be harmful.</span></div>
<div style="position:absolute;left:50.00px;top:101.42px" class="cls_043"><span class="cls_043">Disclosure: </span><span class="cls_032">Project platform and consultancy services were provided</span></div>
<div style="position:absolute;left:306.64px;top:101.04px" class="cls_033"><span class="cls_033">P155</span></div>
<div style="position:absolute;left:50.00px;top:110.42px" class="cls_032"><span class="cls_032">by health portal company Netdoktor. The project received funding from</span></div>
<div style="position:absolute;left:306.64px;top:112.44px" class="cls_025"><span class="cls_025">THE IMPACT OF A DIAGNOSIS ON THE PATIENTS’</span></div>
<div style="position:absolute;left:50.00px;top:120.42px" class="cls_032"><span class="cls_032">Novartis.</span></div>
<div style="position:absolute;left:306.64px;top:123.34px" class="cls_025"><span class="cls_025">PERCEPTION OF TREATMENT AND CARE. RESULTS</span></div>
<div style="position:absolute;left:306.64px;top:134.24px" class="cls_025"><span class="cls_025">FROM AN ONLINE SURVEY ON PSORIATIC ARTHRITIS</span></div>
<div style="position:absolute;left:50.00px;top:139.04px" class="cls_033"><span class="cls_033">P154</span></div>
<div style="position:absolute;left:306.64px;top:145.14px" class="cls_025"><span class="cls_025">AND PSORIASIS WITH JOINT PAIN</span></div>
<div style="position:absolute;left:50.00px;top:150.44px" class="cls_025"><span class="cls_025">AN INTERNATIONAL DELPHI SURVEY TO DEFINE</span></div>
<div style="position:absolute;left:306.64px;top:155.04px" class="cls_026"><span class="cls_026">T Norgren, </span><span class="cls_051">B Bohannan</span></div>
<div style="position:absolute;left:50.00px;top:161.34px" class="cls_025"><span class="cls_025">SCREENING FOR PSORIATIC ARTHRITIS AND</span></div>
<div style="position:absolute;left:306.64px;top:165.64px" class="cls_029"><span class="cls_029">Psoriasisförbundet, Stockholm, Sweden</span></div>
<div style="position:absolute;left:50.00px;top:172.24px" class="cls_025"><span class="cls_025">MEASUREMENT OF PSORIATIC ARTHRITIS</span></div>
<div style="position:absolute;left:306.64px;top:176.51px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">Psoriatic arthritis (PsA) is a chronic inflammatory</span></div>
<div style="position:absolute;left:50.00px;top:183.14px" class="cls_025"><span class="cls_025">SYMPTOMS IN PSORIASIS CLINICAL TRIALS</span></div>
<div style="position:absolute;left:306.64px;top:186.50px" class="cls_031"><span class="cls_031">joint disease that, if untreated, can cause joint destruction and disa-</span></div>
<div style="position:absolute;left:50.00px;top:193.04px" class="cls_026"><span class="cls_026">Lourdes Perez Chada</span></div>
<div style="position:absolute;left:306.64px;top:196.51px" class="cls_031"><span class="cls_031">bility. The knowledge about PsA among both public and healthcare</span></div>
<div style="position:absolute;left:50.00px;top:203.64px" class="cls_029"><span class="cls_029">Harvard Medical School-Brigham and Women’s Hospital</span></div>
<div style="position:absolute;left:306.64px;top:206.50px" class="cls_031"><span class="cls_031">providers is limited, leading to underdiagnosis and undertreatment.</span></div>
<div style="position:absolute;left:50.00px;top:214.51px" class="cls_030"><span class="cls_030">Introduction: </span><span class="cls_031">The International Dermatology Outcome Measures</span></div>
<div style="position:absolute;left:306.64px;top:216.50px" class="cls_031"><span class="cls_031">To raise awareness of PsA and gather relevant data, the Swedish</span></div>
<div style="position:absolute;left:50.00px;top:224.50px" class="cls_031"><span class="cls_031">(IDEOM) group was established to standardize patient-centered</span></div>
<div style="position:absolute;left:306.64px;top:226.50px" class="cls_031"><span class="cls_031">Psoriasis Association and the Swedish Rheumatism Association</span></div>
<div style="position:absolute;left:50.00px;top:234.50px" class="cls_031"><span class="cls_031">outcome measures to improve the assessment of treatment respon-</span></div>
<div style="position:absolute;left:306.64px;top:236.50px" class="cls_031"><span class="cls_031">initiated a web-based educational campaign which also featured</span></div>
<div style="position:absolute;left:50.00px;top:244.51px" class="cls_031"><span class="cls_031">se and disease course in dermatology. To define the measurement</span></div>
<div style="position:absolute;left:306.64px;top:246.50px" class="cls_031"><span class="cls_031">a survey on healthcare experiences and Quality of Life.</span></div>
<div style="position:absolute;left:50.01px;top:254.50px" class="cls_031"><span class="cls_031">set for psoriasis, IDEOM has initially defined a set of domains to</span></div>
<div style="position:absolute;left:306.64px;top:256.50px" class="cls_030"><span class="cls_030">Objectives:</span><span class="cls_031"> The purpose of the survey was to identify the gaps in</span></div>
<div style="position:absolute;left:50.02px;top:264.50px" class="cls_031"><span class="cls_031">be measured in all psoriasis clinical trials representing a “Core Do-</span></div>
<div style="position:absolute;left:306.64px;top:266.50px" class="cls_031"><span class="cls_031">the healthcare provided for individuals diagnosed with PsA and</span></div>
<div style="position:absolute;left:50.00px;top:274.51px" class="cls_031"><span class="cls_031">main Set”. “Psoriatic arthritis (PsA) Symptoms” is part of this set.</span></div>
<div style="position:absolute;left:306.64px;top:276.50px" class="cls_031"><span class="cls_031">individuals with psoriasis and joint pain consistent with a PsA diag-</span></div>
<div style="position:absolute;left:50.00px;top:284.50px" class="cls_030"><span class="cls_030">Objectives:</span><span class="cls_031"> To achieve consensus on whether patients enrolling</span></div>
<div style="position:absolute;left:306.64px;top:286.51px" class="cls_031"><span class="cls_031">nosis, as well as understanding the impact on QoL for both groups.</span></div>
<div style="position:absolute;left:50.00px;top:294.50px" class="cls_031"><span class="cls_031">in a psoriasis clinical trial should first be screened for PsA and</span></div>
<div style="position:absolute;left:306.64px;top:296.50px" class="cls_030"><span class="cls_030">Method:</span><span class="cls_031"> The survey consisted of two questionnaires, one for</span></div>
<div style="position:absolute;left:50.00px;top:304.50px" class="cls_031"><span class="cls_031">then with which measure their PsA symptoms should be assessed.</span></div>
<div style="position:absolute;left:306.64px;top:306.50px" class="cls_031"><span class="cls_031">individuals diagnosed with PsA, group A, and one for individuals</span></div>
<div style="position:absolute;left:50.00px;top:314.50px" class="cls_030"><span class="cls_030">Methods:</span><span class="cls_031"> Following the OMERACT (Outcome Measures in</span></div>
<div style="position:absolute;left:306.64px;top:316.50px" class="cls_031"><span class="cls_031">diagnosed with psoriasis who have joint pain consistent with a PsA</span></div>
<div style="position:absolute;left:50.00px;top:324.50px" class="cls_031"><span class="cls_031">Rheumatology) Filter 2.0, the COSMIN guidelines, and based</span></div>
<div style="position:absolute;left:306.64px;top:326.50px" class="cls_031"><span class="cls_031">diagnosis (using CASPAR criteria), group B. The survey was open</span></div>
<div style="position:absolute;left:50.00px;top:334.50px" class="cls_031"><span class="cls_031">upon the feedback from a consensus meeting held at the IDEOM</span></div>
<div style="position:absolute;left:306.64px;top:336.50px" class="cls_031"><span class="cls_031">from April 6 2017 to March 31 2018. One section of the survey</span></div>
<div style="position:absolute;left:50.00px;top:344.50px" class="cls_031"><span class="cls_031">2017 Annual Meeting, we conducted an international, multidisci-</span></div>
<div style="position:absolute;left:306.64px;top:346.50px" class="cls_031"><span class="cls_031">focussed on time to diagnosis and perception of healthcare. Limi-</span></div>
<div style="position:absolute;left:50.00px;top:354.51px" class="cls_031"><span class="cls_031">plinary and multi-stakeholder on-line Delphi survey. The survey</span></div>
<div style="position:absolute;left:306.64px;top:356.51px" class="cls_031"><span class="cls_031">tations: self-reported diagnosis, possible to take survey multiple</span></div>
<div style="position:absolute;left:50.00px;top:364.50px" class="cls_031"><span class="cls_031">was organized into 3 parts in which participants were asked to</span></div>
<div style="position:absolute;left:306.64px;top:366.50px" class="cls_031"><span class="cls_031">times using different devices.</span></div>
<div style="position:absolute;left:50.00px;top:374.50px" class="cls_031"><span class="cls_031">(1) vote on the role of PsA screening in psoriasis trials, (2) vote</span></div>
<div style="position:absolute;left:306.64px;top:376.50px" class="cls_030"><span class="cls_030">Results:</span><span class="cls_031"> Both groups had seen multiple doctors for their joint</span></div>
<div style="position:absolute;left:50.00px;top:384.50px" class="cls_031"><span class="cls_031">on the quality (measurement properties) of 4 patient-reported</span></div>
<div style="position:absolute;left:306.64px;top:386.50px" class="cls_031"><span class="cls_031">pain. In group A 60% (</span><span class="cls_030">n = </span><span class="cls_031">1 132) had seen </span><span class="cls_030"> > </span><span class="cls_031">4 doctors, with 11%</span></div>
<div style="position:absolute;left:50.00px;top:394.50px" class="cls_031"><span class="cls_031">instruments: Patient Global (PG)-arthritis associated to a pain</span></div>
<div style="position:absolute;left:306.64px;top:396.50px" class="cls_031"><span class="cls_031">reporting having seen</span></div>
<div style="position:absolute;left:396.05px;top:396.50px" class="cls_030"><span class="cls_030">> </span><span class="cls_031">10. In group B 52.5% (</span><span class="cls_030">n = </span><span class="cls_031">824) had</span></div>
<div style="position:absolute;left:50.00px;top:404.50px" class="cls_031"><span class="cls_031">assessment tool, PG-Psoriatic Arthritis (PG-PsA) associated to a</span></div>
<div style="position:absolute;left:306.64px;top:406.50px" class="cls_031"><span class="cls_031">seen </span><span class="cls_030"> > </span><span class="cls_031">4 doctors, with 8% having seen </span><span class="cls_030"> > </span><span class="cls_031">10. In group A nearly</span></div>
<div style="position:absolute;left:50.00px;top:414.50px" class="cls_031"><span class="cls_031">pain assessment tool, Routine Assessment of Patient Index Data-3</span></div>
<div style="position:absolute;left:306.64px;top:416.50px" class="cls_031"><span class="cls_031">51% (</span><span class="cls_030">n = </span><span class="cls_031">1 211) reported having had joint pain/symptoms for at</span></div>
<div style="position:absolute;left:50.00px;top:424.50px" class="cls_031"><span class="cls_031">(RAPID3), and Psoriatic Arthritis Impact of Disease 9 (PsAID9),</span></div>
<div style="position:absolute;left:306.64px;top:426.50px" class="cls_031"><span class="cls_031">least 1 year before receiving a diagnosis, with 12% waiting </span><span class="cls_030"> > </span><span class="cls_031">10</span></div>
<div style="position:absolute;left:50.00px;top:434.50px" class="cls_031"><span class="cls_031">and (3) rank these instruments in order of importance. Additionally,</span></div>
<div style="position:absolute;left:306.64px;top:436.50px" class="cls_031"><span class="cls_031">years. In group B 91% (</span><span class="cls_030">n = </span><span class="cls_031">1 872) reported having had joint pain/</span></div>
<div style="position:absolute;left:50.00px;top:444.50px" class="cls_031"><span class="cls_031">respondents were invited to provide feedback on the survey.</span></div>
<div style="position:absolute;left:306.64px;top:446.50px" class="cls_031"><span class="cls_031">symptoms for at least 1 year, with 35% at </span><span class="cls_030"> > </span><span class="cls_031">10 years.</span></div>
<div style="position:absolute;left:50.00px;top:454.50px" class="cls_030"><span class="cls_030">Results: </span><span class="cls_031">A total of </span><span class="cls_030">n = </span><span class="cls_031">293, </span><span class="cls_030">n = </span><span class="cls_031">233 and </span><span class="cls_030">n = </span><span class="cls_031">218 subjects completed</span></div>
<div style="position:absolute;left:306.64px;top:456.50px" class="cls_031"><span class="cls_031">Perception of healthcare differed greatly between the groups. In</span></div>
<div style="position:absolute;left:49.96px;top:464.49px" class="cls_031"><span class="cls_031">the PsA screening, instrument quality assessment, and ranking</span></div>
<div style="position:absolute;left:306.64px;top:466.49px" class="cls_031"><span class="cls_031">group A over half (</span><span class="cls_030">n = </span><span class="cls_031">1 273) reported that their perception of</span></div>
<div style="position:absolute;left:49.96px;top:474.49px" class="cls_031"><span class="cls_031">sections of the survey, respectively. The group was comprised of</span></div>
<div style="position:absolute;left:306.64px;top:476.49px" class="cls_031"><span class="cls_031">healthcare improved or improved greatly after receiving their</span></div>
<div style="position:absolute;left:49.96px;top:484.49px" class="cls_031"><span class="cls_031">rheumatologists (44.5%), dermatologists (26%), patients (7.5%),</span></div>
<div style="position:absolute;left:306.64px;top:486.49px" class="cls_031"><span class="cls_031">PsA diagnosis. In group B nearly 78% (</span><span class="cls_030">n = </span><span class="cls_031">1 227) reported be-</span></div>
<div style="position:absolute;left:49.96px;top:494.49px" class="cls_031"><span class="cls_031">industry partners (8.9%), dermatologist-rheumatologists (5.1%),</span></div>
<div style="position:absolute;left:306.64px;top:496.51px" class="cls_031"><span class="cls_031">ing dissatisfied or very dissatisfied with the care they receive.</span></div>
<div style="position:absolute;left:49.96px;top:504.49px" class="cls_031"><span class="cls_031">and patient association representatives (3.4%). Results showed that</span></div>
<div style="position:absolute;left:306.64px;top:506.51px" class="cls_030"><span class="cls_030">Conclusions:</span><span class="cls_031"> The results show that the group with a PsA diagnosis</span></div>
<div style="position:absolute;left:49.96px;top:514.49px" class="cls_031"><span class="cls_031">90%of participants agreed that all patients enrolling in a psoriasis</span></div>
<div style="position:absolute;left:306.64px;top:516.50px" class="cls_031"><span class="cls_031">have a much more positive perception of the treatment and care</span></div>
<div style="position:absolute;left:49.96px;top:524.49px" class="cls_031"><span class="cls_031">trial should be screened for PsA. Regarding the quality of the</span></div>
<div style="position:absolute;left:306.64px;top:526.50px" class="cls_031"><span class="cls_031">they receive than the group without a diagnosis. Interestingly, in</span></div>
<div style="position:absolute;left:49.96px;top:534.49px" class="cls_031"><span class="cls_031">instruments, only the PsAID9reached the pre-specified endpoint</span></div>
<div style="position:absolute;left:306.64px;top:536.50px" class="cls_031"><span class="cls_031">another part of the survey group B reported their psoriasis having a</span></div>
<div style="position:absolute;left:49.95px;top:544.49px" class="cls_031"><span class="cls_031">of </span><span class="cls_030"> > </span><span class="cls_031">70% with agreement that the instrument has good-to-excellent</span></div>
<div style="position:absolute;left:306.64px;top:546.50px" class="cls_031"><span class="cls_031">low to medium impact on their lives, indicating that their psoriasis</span></div>
<div style="position:absolute;left:49.95px;top:554.49px" class="cls_031"><span class="cls_031">validity, feasibility, reliability and responsiveness; </span><span class="cls_030"> &lt; </span><span class="cls_031">15% agreed</span></div>
<div style="position:absolute;left:306.64px;top:556.50px" class="cls_031"><span class="cls_031">may be mild enough to be treated in a primary care setting only.</span></div>
<div style="position:absolute;left:49.95px;top:564.48px" class="cls_031"><span class="cls_031">that the quality of the instrument is poor or that there is not enough</span></div>
<div style="position:absolute;left:306.64px;top:566.50px" class="cls_031"><span class="cls_031">In the past few years there have been extensive efforts put into</span></div>
<div style="position:absolute;left:49.95px;top:574.48px" class="cls_031"><span class="cls_031">information to make an informed decision. In the ranking exercise,</span></div>
<div style="position:absolute;left:306.64px;top:576.50px" class="cls_031"><span class="cls_031">educating Swedish dermatologists on recognizing early signs of</span></div>
<div style="position:absolute;left:49.95px;top:584.48px" class="cls_031"><span class="cls_031">PsAID9 was the first choice(voted by 48% of respondents) and</span></div>
<div style="position:absolute;left:306.64px;top:586.50px" class="cls_031"><span class="cls_031">PsA, but steps should also be taken to raise awareness of psoriasis-</span></div>
<div style="position:absolute;left:49.97px;top:594.48px" class="cls_031"><span class="cls_031">RAPID3 represented an acceptable alternative second choice</span></div>
<div style="position:absolute;left:306.64px;top:596.50px" class="cls_031"><span class="cls_031">associated joint pain among general practitioners to ensure timely</span></div>
<div style="position:absolute;left:49.97px;top:604.48px" class="cls_031"><span class="cls_031">(voted by 33% of respondents).</span></div>
<div style="position:absolute;left:306.64px;top:606.50px" class="cls_031"><span class="cls_031">referral to specialist care.</span></div>
<div style="position:absolute;left:49.97px;top:614.48px" class="cls_030"><span class="cls_030">Conclusion:</span><span class="cls_031"> In this Delphi study, most participants agreed that all</span></div>
<div style="position:absolute;left:306.64px;top:616.52px" class="cls_043"><span class="cls_043">Disclosure: </span><span class="cls_032">Project platform and consultancy services were provided</span></div>
<div style="position:absolute;left:49.97px;top:624.48px" class="cls_031"><span class="cls_031">psoriasis trial participants should be screened for PsA. Regarding</span></div>
<div style="position:absolute;left:306.64px;top:625.52px" class="cls_032"><span class="cls_032">by health portal company Netdoktor. The project received funding from</span></div>
<div style="position:absolute;left:49.97px;top:634.48px" class="cls_031"><span class="cls_031">the measurement set for “PsA Symptoms”, PsAID9 was selected</span></div>
<div style="position:absolute;left:306.64px;top:634.51px" class="cls_032"><span class="cls_032">Novartis</span><span class="cls_031">.</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:50589px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background65.jpg" width=595 height=793></div>
<div style="position:absolute;left:492.25px;top:28.81px" class="cls_019"><span class="cls_019">Index</span></div>
<div style="position:absolute;left:536.48px;top:28.81px" class="cls_017"><span class="cls_017">63</span></div>
<div style="position:absolute;left:50.00px;top:50.59px" class="cls_023"><span class="cls_023">Index</span></div>
<div style="position:absolute;left:177.57px;top:52.41px" class="cls_048"><span class="cls_048">Chamurlieva, Maria 48</span></div>
<div style="position:absolute;left:305.14px;top:52.42px" class="cls_048"><span class="cls_048">Glukhova, Svetlana 10</span><span class="cls_049">, </span><span class="cls_048">45</span></div>
<div style="position:absolute;left:432.71px;top:52.42px" class="cls_048"><span class="cls_048">Kazemnejad, Ehsan 6</span><span class="cls_049">, </span><span class="cls_048">44</span></div>
<div style="position:absolute;left:177.57px;top:60.34px" class="cls_048"><span class="cls_048">Chandran, Vinod 14</span><span class="cls_049">, </span><span class="cls_048">23</span></div>
<div style="position:absolute;left:305.14px;top:60.36px" class="cls_048"><span class="cls_048">Godzenko, Alla 38</span></div>
<div style="position:absolute;left:432.71px;top:60.35px" class="cls_048"><span class="cls_048">Kellet, Cristian Vera 42</span></div>
<div style="position:absolute;left:50.00px;top:67.76px" class="cls_050"><span class="cls_050">A</span></div>
<div style="position:absolute;left:177.57px;top:68.29px" class="cls_048"><span class="cls_048">Chan, Henry 5</span></div>
<div style="position:absolute;left:305.14px;top:68.29px" class="cls_048"><span class="cls_048">Gold, Linda Stein 14</span></div>
<div style="position:absolute;left:432.71px;top:68.28px" class="cls_048"><span class="cls_048">Kerdel, Francisco 25</span></div>
<div style="position:absolute;left:50.00px;top:77.66px" class="cls_048"><span class="cls_048">Abdallah, Florence 41</span></div>
<div style="position:absolute;left:177.57px;top:76.23px" class="cls_048"><span class="cls_048">Chaouche-Teyara, Kamel 12</span></div>
<div style="position:absolute;left:305.14px;top:76.22px" class="cls_048"><span class="cls_048">Goldust, Mohamad 10</span><span class="cls_049">, </span><span class="cls_048">58</span></div>
<div style="position:absolute;left:432.71px;top:76.21px" class="cls_048"><span class="cls_048">Kerkhof, P. van de 46</span></div>
<div style="position:absolute;left:50.00px;top:85.57px" class="cls_048"><span class="cls_048">Abell, Jill 46</span></div>
<div style="position:absolute;left:177.57px;top:84.16px" class="cls_048"><span class="cls_048">Chaparro, Elena 9</span></div>
<div style="position:absolute;left:305.14px;top:84.16px" class="cls_048"><span class="cls_048">Gómez, Natalie Núnez 13</span></div>
<div style="position:absolute;left:432.71px;top:84.13px" class="cls_048"><span class="cls_048">Kerr, Lisa 16</span></div>
<div style="position:absolute;left:50.00px;top:93.47px" class="cls_048"><span class="cls_048">Abramovits, William 25</span></div>
<div style="position:absolute;left:177.57px;top:92.10px" class="cls_048"><span class="cls_048">Chow, Andrew 15</span></div>
<div style="position:absolute;left:305.14px;top:92.09px" class="cls_048"><span class="cls_048">Gonzalez, Daniela 9</span></div>
<div style="position:absolute;left:432.71px;top:92.06px" class="cls_048"><span class="cls_048">Keskin, Esra Dilek 43</span></div>
<div style="position:absolute;left:50.00px;top:101.38px" class="cls_048"><span class="cls_048">Abrams, Ken 15</span><span class="cls_049">, </span><span class="cls_048">17</span></div>
<div style="position:absolute;left:177.57px;top:100.03px" class="cls_048"><span class="cls_048">Christodoulou, Christos 55</span></div>
<div style="position:absolute;left:305.14px;top:100.02px" class="cls_048"><span class="cls_048">Gooderham, Melinda 22</span><span class="cls_049">, </span><span class="cls_048">24</span><span class="cls_049">, </span><span class="cls_048">31</span><span class="cls_049">, </span><span class="cls_048">48</span><span class="cls_049">,</span></div>
<div style="position:absolute;left:432.71px;top:99.99px" class="cls_048"><span class="cls_048">Keskin, Goksal 43</span></div>
<div style="position:absolute;left:50.00px;top:109.29px" class="cls_048"><span class="cls_048">Adam, Abdulfatah 7</span><span class="cls_049">, </span><span class="cls_048">34</span></div>
<div style="position:absolute;left:177.57px;top:107.96px" class="cls_048"><span class="cls_048">Cichanowitz, Nicole 22</span><span class="cls_049">, </span><span class="cls_048">24</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">,</span></div>
<div style="position:absolute;left:313.14px;top:107.96px" class="cls_048"><span class="cls_048">49</span><span class="cls_049">, </span><span class="cls_048">54</span></div>
<div style="position:absolute;left:432.71px;top:107.92px" class="cls_048"><span class="cls_048">Khosravi-Hafshejani, Touraj 42</span></div>
<div style="position:absolute;left:50.00px;top:117.19px" class="cls_048"><span class="cls_048">Adam, David 21</span></div>
<div style="position:absolute;left:185.57px;top:115.89px" class="cls_048"><span class="cls_048">29</span><span class="cls_049">, </span><span class="cls_048">54</span></div>
<div style="position:absolute;left:305.14px;top:115.89px" class="cls_048"><span class="cls_048">Gordon, Kenneth 19</span><span class="cls_049">, </span><span class="cls_048">22</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">29</span><span class="cls_049">,</span></div>
<div style="position:absolute;left:432.71px;top:115.83px" class="cls_048"><span class="cls_048">Khraishi, Majed 14</span><span class="cls_049">, </span><span class="cls_048">15</span><span class="cls_049">, </span><span class="cls_048">16</span></div>
<div style="position:absolute;left:50.00px;top:125.10px" class="cls_048"><span class="cls_048">Adams, David 16</span></div>
<div style="position:absolute;left:177.57px;top:123.83px" class="cls_048"><span class="cls_048">Cirulli, Joshua 14</span></div>
<div style="position:absolute;left:313.14px;top:123.83px" class="cls_048"><span class="cls_048">30</span><span class="cls_049">, </span><span class="cls_048">31</span></div>
<div style="position:absolute;left:432.71px;top:123.75px" class="cls_048"><span class="cls_048">Kiedrowski, Ralph von 32</span></div>
<div style="position:absolute;left:50.00px;top:133.00px" class="cls_048"><span class="cls_048">Alenius, Gerd-Marie 37</span></div>
<div style="position:absolute;left:177.57px;top:131.76px" class="cls_048"><span class="cls_048">Coates, Laura C 16</span><span class="cls_049">, </span><span class="cls_048">19</span><span class="cls_049">, </span><span class="cls_048">21</span><span class="cls_049">, </span><span class="cls_048">52</span></div>
<div style="position:absolute;left:305.14px;top:131.76px" class="cls_048"><span class="cls_048">Gossec, Laure 21</span></div>
<div style="position:absolute;left:432.71px;top:131.68px" class="cls_048"><span class="cls_048">Kimball, Alexa 54</span></div>
<div style="position:absolute;left:50.00px;top:140.91px" class="cls_048"><span class="cls_048">Aletaha, Daniel 23</span></div>
<div style="position:absolute;left:177.57px;top:139.69px" class="cls_048"><span class="cls_048">Colombel, Jean-Frederic 18</span></div>
<div style="position:absolute;left:305.14px;top:139.69px" class="cls_048"><span class="cls_048">Gottlieb, Alice 11</span><span class="cls_049">, </span><span class="cls_048">24</span><span class="cls_049">, </span><span class="cls_048">26</span><span class="cls_049">, </span><span class="cls_048">27</span><span class="cls_049">, </span><span class="cls_048">46</span><span class="cls_049">, </span><span class="cls_048">47</span><span class="cls_049">,</span></div>
<div style="position:absolute;left:432.71px;top:139.61px" class="cls_048"><span class="cls_048">Kirkham, Bruce 15</span></div>
<div style="position:absolute;left:50.00px;top:148.81px" class="cls_048"><span class="cls_048">Alikhan, Ali 14</span></div>
<div style="position:absolute;left:177.57px;top:147.63px" class="cls_048"><span class="cls_048">Combe, Bernard 15</span></div>
<div style="position:absolute;left:313.14px;top:147.63px" class="cls_048"><span class="cls_048">48</span><span class="cls_049">, </span><span class="cls_048">57</span></div>
<div style="position:absolute;left:432.71px;top:147.54px" class="cls_048"><span class="cls_048">Kishimoto, Mitsumasha 16</span></div>
<div style="position:absolute;left:50.00px;top:156.72px" class="cls_048"><span class="cls_048">Alipour, Homan 58</span></div>
<div style="position:absolute;left:177.57px;top:155.56px" class="cls_048"><span class="cls_048">Cordey, Myriam 13</span></div>
<div style="position:absolute;left:305.14px;top:155.56px" class="cls_048"><span class="cls_048">Greggio, Chiara 14</span></div>
<div style="position:absolute;left:432.71px;top:155.46px" class="cls_048"><span class="cls_048">Klekotka, Paul 54</span></div>
<div style="position:absolute;left:50.00px;top:164.62px" class="cls_048"><span class="cls_048">Altemeyer, Evelyn 11</span></div>
<div style="position:absolute;left:177.57px;top:163.50px" class="cls_048"><span class="cls_048">Crespo, Alejandra 9</span></div>
<div style="position:absolute;left:305.14px;top:163.50px" class="cls_048"><span class="cls_048">Grendár, Marián 12</span></div>
<div style="position:absolute;left:432.71px;top:163.39px" class="cls_048"><span class="cls_048">Kleyn, C. Elise 13</span></div>
<div style="position:absolute;left:50.00px;top:172.53px" class="cls_048"><span class="cls_048">Andersen, Anne-Marie Nybo 7</span><span class="cls_049">, </span><span class="cls_048">34</span></div>
<div style="position:absolute;left:177.57px;top:171.43px" class="cls_048"><span class="cls_048">Cristodor, Patricia 39</span></div>
<div style="position:absolute;left:305.14px;top:171.43px" class="cls_048"><span class="cls_048">Griffiths, Christopher EM 13</span><span class="cls_049">, </span><span class="cls_048">20</span><span class="cls_049">,</span></div>
<div style="position:absolute;left:432.71px;top:171.32px" class="cls_048"><span class="cls_048">Kontochristopoulos, Georgios 55</span></div>
<div style="position:absolute;left:50.00px;top:180.45px" class="cls_048"><span class="cls_048">Arakawa, Akiko 43</span></div>
<div style="position:absolute;left:177.57px;top:179.36px" class="cls_048"><span class="cls_048">Crowley, Jeffrey 20</span><span class="cls_049">, </span><span class="cls_048">25</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">29</span><span class="cls_049">, </span><span class="cls_048">30</span><span class="cls_049">,</span></div>
<div style="position:absolute;left:313.14px;top:179.36px" class="cls_048"><span class="cls_048">46</span><span class="cls_049">, </span><span class="cls_048">52</span></div>
<div style="position:absolute;left:432.71px;top:179.25px" class="cls_048"><span class="cls_048">Koo, John 31</span></div>
<div style="position:absolute;left:50.00px;top:188.35px" class="cls_048"><span class="cls_048">Arakawa, Yukiyasu 43</span></div>
<div style="position:absolute;left:185.57px;top:187.29px" class="cls_048"><span class="cls_048">31</span></div>
<div style="position:absolute;left:305.14px;top:187.29px" class="cls_048"><span class="cls_048">Groegel, Kathrin 13</span></div>
<div style="position:absolute;left:432.71px;top:187.17px" class="cls_048"><span class="cls_048">Korge, Bernhard 13</span></div>
<div style="position:absolute;left:50.00px;top:196.26px" class="cls_048"><span class="cls_048">Arenberger, Petr 47</span></div>
<div style="position:absolute;left:305.14px;top:195.23px" class="cls_048"><span class="cls_048">Groot, Jonathan 34</span></div>
<div style="position:absolute;left:432.71px;top:195.10px" class="cls_048"><span class="cls_048">Korman, Lucyna 36</span></div>
<div style="position:absolute;left:50.00px;top:204.16px" class="cls_048"><span class="cls_048">Arendt, Catherine 21</span><span class="cls_049">, </span><span class="cls_048">24</span><span class="cls_049">, </span><span class="cls_048">26</span><span class="cls_049">, </span><span class="cls_048">27</span></div>
<div style="position:absolute;left:177.57px;top:200.82px" class="cls_050"><span class="cls_050">D</span></div>
<div style="position:absolute;left:305.14px;top:203.16px" class="cls_048"><span class="cls_048">Grünebaum, Valeria 59</span></div>
<div style="position:absolute;left:432.71px;top:203.03px" class="cls_048"><span class="cls_048">Korman, Neil 14</span></div>
<div style="position:absolute;left:50.00px;top:212.08px" class="cls_048"><span class="cls_048">Arikan, Dilek 19</span><span class="cls_049">, </span><span class="cls_048">25</span></div>
<div style="position:absolute;left:177.57px;top:210.75px" class="cls_048"><span class="cls_048">Dadras, Mohamad Shahidi 6</span></div>
<div style="position:absolute;left:305.14px;top:211.10px" class="cls_048"><span class="cls_048">Gual, Adria 18</span></div>
<div style="position:absolute;left:432.71px;top:210.93px" class="cls_048"><span class="cls_048">Korotaeva, Tatiana 10</span><span class="cls_049">, </span><span class="cls_048">38</span><span class="cls_049">, </span><span class="cls_048">45</span><span class="cls_049">, </span><span class="cls_048">48</span></div>
<div style="position:absolute;left:50.00px;top:219.98px" class="cls_048"><span class="cls_048">Arjona, Alvaro 57</span></div>
<div style="position:absolute;left:177.57px;top:218.69px" class="cls_048"><span class="cls_048">Dahlborn, Anna-Karin 55</span></div>
<div style="position:absolute;left:305.14px;top:219.03px" class="cls_048"><span class="cls_048">Gubar, Elena 10</span><span class="cls_049">, </span><span class="cls_048">38</span><span class="cls_049">, </span><span class="cls_048">45</span></div>
<div style="position:absolute;left:432.71px;top:218.86px" class="cls_048"><span class="cls_048">Koscielny, Volker 13</span></div>
<div style="position:absolute;left:50.00px;top:227.89px" class="cls_048"><span class="cls_048">Armstrong, April 22</span></div>
<div style="position:absolute;left:177.57px;top:226.62px" class="cls_048"><span class="cls_048">Dalkiliç, Ediz 20</span></div>
<div style="position:absolute;left:305.14px;top:226.96px" class="cls_048"><span class="cls_048">Guerette, Benoit 14</span></div>
<div style="position:absolute;left:432.71px;top:226.79px" class="cls_048"><span class="cls_048">Kosel, David 17</span></div>
<div style="position:absolute;left:50.00px;top:235.79px" class="cls_048"><span class="cls_048">Asquith, Darren L 19</span></div>
<div style="position:absolute;left:177.57px;top:234.56px" class="cls_048"><span class="cls_048">Danielsen, Kjersti 12</span><span class="cls_049">, </span><span class="cls_048">33</span><span class="cls_049">, </span><span class="cls_048">53</span></div>
<div style="position:absolute;left:305.14px;top:234.90px" class="cls_048"><span class="cls_048">Guillet, Gérard 26</span></div>
<div style="position:absolute;left:432.71px;top:234.71px" class="cls_048"><span class="cls_048">Kouris, Anargyros 55</span></div>
<div style="position:absolute;left:50.00px;top:243.70px" class="cls_048"><span class="cls_048">Augustin, Matthias 13</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">32</span><span class="cls_049">, </span><span class="cls_048">35</span><span class="cls_049">, </span><span class="cls_048">36</span><span class="cls_049">,</span></div>
<div style="position:absolute;left:177.57px;top:242.50px" class="cls_048"><span class="cls_048">Davenport, Eric K. 14</span></div>
<div style="position:absolute;left:305.14px;top:242.83px" class="cls_048"><span class="cls_048">Gulati, Kunal 34</span></div>
<div style="position:absolute;left:432.71px;top:242.64px" class="cls_048"><span class="cls_048">Kozłowski, Mikołaj 36</span></div>
<div style="position:absolute;left:58.00px;top:251.61px" class="cls_048"><span class="cls_048">38</span><span class="cls_049">, </span><span class="cls_048">47</span><span class="cls_049">, </span><span class="cls_048">54</span><span class="cls_049">, </span><span class="cls_048">58</span></div>
<div style="position:absolute;left:177.57px;top:250.43px" class="cls_048"><span class="cls_048">Dei-Cas, Ignacio 48</span></div>
<div style="position:absolute;left:305.14px;top:250.77px" class="cls_048"><span class="cls_048">Gulliver, Susanne 27</span></div>
<div style="position:absolute;left:432.71px;top:250.57px" class="cls_048"><span class="cls_048">Kreimer, Jennifer 9</span></div>
<div style="position:absolute;left:50.00px;top:259.52px" class="cls_048"><span class="cls_048">Austin, Jennifer 58</span></div>
<div style="position:absolute;left:177.57px;top:258.36px" class="cls_048"><span class="cls_048">Delli, Florentina-Silvia 32</span><span class="cls_049">, </span><span class="cls_048">61</span></div>
<div style="position:absolute;left:305.14px;top:258.70px" class="cls_048"><span class="cls_048">Gulliver, Wayne 27</span></div>
<div style="position:absolute;left:432.71px;top:258.50px" class="cls_048"><span class="cls_048">Kriegel, Martin 5</span></div>
<div style="position:absolute;left:50.00px;top:267.42px" class="cls_048"><span class="cls_048">Azevedo, VF 52</span></div>
<div style="position:absolute;left:177.57px;top:266.30px" class="cls_048"><span class="cls_048">Delorme, Isabelle 48</span></div>
<div style="position:absolute;left:305.14px;top:266.64px" class="cls_048"><span class="cls_048">Guo, Dianlin 25</span></div>
<div style="position:absolute;left:432.71px;top:266.42px" class="cls_048"><span class="cls_048">Krnic, Andrea 8</span></div>
<div style="position:absolute;left:50.00px;top:275.33px" class="cls_048"><span class="cls_048">Azimi, Seyyede Zeinab 6</span><span class="cls_049">, </span><span class="cls_048">44</span></div>
<div style="position:absolute;left:177.57px;top:274.23px" class="cls_048"><span class="cls_048">Dencheva, Iveta 35</span></div>
<div style="position:absolute;left:305.14px;top:274.57px" class="cls_048"><span class="cls_048">Guo, Jiaying 54</span></div>
<div style="position:absolute;left:432.71px;top:274.35px" class="cls_048"><span class="cls_048">Kubanov, Alexey 47</span></div>
<div style="position:absolute;left:177.57px;top:282.16px" class="cls_048"><span class="cls_048">Deodhar, Atul 11</span><span class="cls_049">, </span><span class="cls_048">18</span><span class="cls_049">, </span><span class="cls_048">48</span></div>
<div style="position:absolute;left:305.14px;top:282.51px" class="cls_048"><span class="cls_048">Gupta, Ayan Das 18</span></div>
<div style="position:absolute;left:432.71px;top:282.28px" class="cls_048"><span class="cls_048">Kuehnl, Vera 25</span></div>
<div style="position:absolute;left:50.00px;top:288.84px" class="cls_050"><span class="cls_050">B</span></div>
<div style="position:absolute;left:177.57px;top:290.10px" class="cls_048"><span class="cls_048">Dietrich, Cecilia 18</span></div>
<div style="position:absolute;left:305.14px;top:290.44px" class="cls_048"><span class="cls_048">Gupta, Samar 42</span></div>
<div style="position:absolute;left:432.71px;top:290.21px" class="cls_048"><span class="cls_048">Kühl, Laura 32</span></div>
<div style="position:absolute;left:50.00px;top:298.75px" class="cls_048"><span class="cls_048">Bachelez, Hervé 28</span></div>
<div style="position:absolute;left:177.57px;top:298.03px" class="cls_048"><span class="cls_048">Dong, Bin 48</span></div>
<div style="position:absolute;left:305.14px;top:298.36px" class="cls_048"><span class="cls_048">Gu, Yihua 28</span><span class="cls_049">, </span><span class="cls_048">30</span></div>
<div style="position:absolute;left:432.71px;top:298.13px" class="cls_048"><span class="cls_048">Kupper, Hartmut 25</span></div>
<div style="position:absolute;left:50.00px;top:306.65px" class="cls_048"><span class="cls_048">Bachhuber, Teresa 11</span></div>
<div style="position:absolute;left:177.57px;top:305.97px" class="cls_048"><span class="cls_048">Dornhecker, Maximilian 59</span></div>
<div style="position:absolute;left:432.71px;top:306.06px" class="cls_048"><span class="cls_048">Kvien, Tore Kristian 21</span></div>
<div style="position:absolute;left:50.00px;top:314.56px" class="cls_048"><span class="cls_048">Baeumer, Daniel 54</span></div>
<div style="position:absolute;left:177.57px;top:313.90px" class="cls_048"><span class="cls_048">Dossenbach, Martin 55</span></div>
<div style="position:absolute;left:305.14px;top:311.89px" class="cls_050"><span class="cls_050">H</span></div>
<div style="position:absolute;left:50.00px;top:322.46px" class="cls_048"><span class="cls_048">Bagel, Jerry 14</span><span class="cls_049">, </span><span class="cls_048">21</span><span class="cls_049">, </span><span class="cls_048">30</span><span class="cls_049">, </span><span class="cls_048">54</span><span class="cls_049">, </span><span class="cls_048">57</span></div>
<div style="position:absolute;left:177.57px;top:321.84px" class="cls_048"><span class="cls_048">Duffin, Kristina Callis 14</span></div>
<div style="position:absolute;left:305.14px;top:321.82px" class="cls_048"><span class="cls_048">Han, Chenglong 50</span></div>
<div style="position:absolute;left:432.71px;top:319.58px" class="cls_050"><span class="cls_050">L</span></div>
<div style="position:absolute;left:50.00px;top:330.37px" class="cls_048"><span class="cls_048">Balaskas, Evangelos 55</span></div>
<div style="position:absolute;left:177.57px;top:329.77px" class="cls_048"><span class="cls_048">Dungee, Danielle 46</span></div>
<div style="position:absolute;left:305.14px;top:329.76px" class="cls_048"><span class="cls_048">Han, Ju Hee 34</span></div>
<div style="position:absolute;left:432.71px;top:329.51px" class="cls_048"><span class="cls_048">Lacour, Jean-Philippe 30</span></div>
<div style="position:absolute;left:50.00px;top:338.28px" class="cls_048"><span class="cls_048">Balsa, Alejandro 15</span></div>
<div style="position:absolute;left:177.57px;top:337.71px" class="cls_048"><span class="cls_048">Dutz, Jan 42</span></div>
<div style="position:absolute;left:305.14px;top:337.69px" class="cls_048"><span class="cls_048">Han, Kyung Do 34</span></div>
<div style="position:absolute;left:432.71px;top:337.43px" class="cls_048"><span class="cls_048">Lajevardi, Vahideh 6</span></div>
<div style="position:absolute;left:50.00px;top:346.18px" class="cls_048"><span class="cls_048">Bang, Chul Hwan 34</span></div>
<div style="position:absolute;left:177.57px;top:345.63px" class="cls_048"><span class="cls_048">Duvetorp, Albert 12</span><span class="cls_049">, </span><span class="cls_048">33</span><span class="cls_049">, </span><span class="cls_048">53</span></div>
<div style="position:absolute;left:305.14px;top:345.63px" class="cls_048"><span class="cls_048">Haraoui, Boulos 16</span></div>
<div style="position:absolute;left:432.71px;top:345.36px" class="cls_048"><span class="cls_048">Landells, Ian 20</span></div>
<div style="position:absolute;left:50.00px;top:354.09px" class="cls_048"><span class="cls_048">Bao, Weibin 11</span></div>
<div style="position:absolute;left:177.57px;top:353.56px" class="cls_048"><span class="cls_048">Dybowski, Friedrich 56</span></div>
<div style="position:absolute;left:305.14px;top:353.56px" class="cls_048"><span class="cls_048">Haraouil, Boulos 15</span></div>
<div style="position:absolute;left:432.71px;top:353.29px" class="cls_048"><span class="cls_048">Landewé, R 17</span></div>
<div style="position:absolute;left:50.00px;top:361.99px" class="cls_048"><span class="cls_048">Baran, Wojciech 29</span></div>
<div style="position:absolute;left:305.14px;top:361.50px" class="cls_048"><span class="cls_048">Heijde, D van der 17</span></div>
<div style="position:absolute;left:432.71px;top:361.22px" class="cls_048"><span class="cls_048">Langenbruch, Anna 38</span></div>
<div style="position:absolute;left:50.00px;top:369.90px" class="cls_048"><span class="cls_048">Barat, Tara 6</span></div>
<div style="position:absolute;left:177.57px;top:367.09px" class="cls_050"><span class="cls_050">E</span></div>
<div style="position:absolute;left:305.14px;top:369.43px" class="cls_048"><span class="cls_048">Helliwell, Philip 23</span></div>
<div style="position:absolute;left:432.71px;top:369.14px" class="cls_048"><span class="cls_048">Langley, G. 30</span></div>
<div style="position:absolute;left:50.00px;top:377.80px" class="cls_048"><span class="cls_048">Barchuk, William 49</span></div>
<div style="position:absolute;left:177.57px;top:377.02px" class="cls_048"><span class="cls_048">Efthimiadis, Konstantinos 32</span></div>
<div style="position:absolute;left:305.14px;top:377.36px" class="cls_048"><span class="cls_048">Henneges, Carsten 44</span><span class="cls_049">, </span><span class="cls_048">55</span></div>
<div style="position:absolute;left:432.71px;top:377.04px" class="cls_048"><span class="cls_048">Langley, Richard 11</span><span class="cls_049">, </span><span class="cls_048">21</span></div>
<div style="position:absolute;left:50.00px;top:385.71px" class="cls_048"><span class="cls_048">Barker, Jonathan 34</span></div>
<div style="position:absolute;left:177.57px;top:384.96px" class="cls_048"><span class="cls_048">Ehrström, Marcus 44</span></div>
<div style="position:absolute;left:305.14px;top:385.30px" class="cls_048"><span class="cls_048">Henriksson, Martin 9</span></div>
<div style="position:absolute;left:432.70px;top:384.96px" class="cls_048"><span class="cls_048">Lau, Winnie L. 19</span></div>
<div style="position:absolute;left:50.00px;top:393.61px" class="cls_048"><span class="cls_048">Batkaeva, Nadezhda 45</span><span class="cls_049">, </span><span class="cls_048">51</span></div>
<div style="position:absolute;left:177.57px;top:392.89px" class="cls_048"><span class="cls_048">Eidsmo, Liv 44</span></div>
<div style="position:absolute;left:305.14px;top:393.23px" class="cls_048"><span class="cls_048">Heredia, Emily Edson 54</span></div>
<div style="position:absolute;left:432.70px;top:392.89px" class="cls_048"><span class="cls_048">Lazaridou, Elizabeth 40</span></div>
<div style="position:absolute;left:50.00px;top:401.53px" class="cls_048"><span class="cls_048">Batkaev, Edgem 45</span><span class="cls_049">, </span><span class="cls_048">51</span></div>
<div style="position:absolute;left:177.57px;top:400.83px" class="cls_048"><span class="cls_048">Elewski, Boni 24</span><span class="cls_049">, </span><span class="cls_048">26</span><span class="cls_049">, </span><span class="cls_048">31</span></div>
<div style="position:absolute;left:305.14px;top:401.16px" class="cls_048"><span class="cls_048">Hevey, David 51</span><span class="cls_049">, </span><span class="cls_048">52</span></div>
<div style="position:absolute;left:432.70px;top:400.81px" class="cls_048"><span class="cls_048">Lebwohl, Mark 14</span><span class="cls_049">, </span><span class="cls_048">21</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">56</span></div>
<div style="position:absolute;left:50.00px;top:409.44px" class="cls_048"><span class="cls_048">Beecker, Jennifer 48</span></div>
<div style="position:absolute;left:177.57px;top:408.76px" class="cls_048"><span class="cls_048">Ellis, Charles 30</span></div>
<div style="position:absolute;left:305.14px;top:409.10px" class="cls_048"><span class="cls_048">Hilbert, Anja 58</span></div>
<div style="position:absolute;left:432.71px;top:408.74px" class="cls_048"><span class="cls_048">Lee, Edward 37</span></div>
<div style="position:absolute;left:50.00px;top:417.34px" class="cls_048"><span class="cls_048">Behrens, Frank 26</span></div>
<div style="position:absolute;left:177.57px;top:416.70px" class="cls_048"><span class="cls_048">Enerbäck, Charlotta 55</span></div>
<div style="position:absolute;left:305.14px;top:417.03px" class="cls_048"><span class="cls_048">Hoffer, Elena 44</span></div>
<div style="position:absolute;left:432.71px;top:416.67px" class="cls_048"><span class="cls_048">Lee, Ji Hyun 34</span></div>
<div style="position:absolute;left:50.00px;top:425.25px" class="cls_048"><span class="cls_048">Benichou, Olivier 23</span></div>
<div style="position:absolute;left:177.57px;top:424.63px" class="cls_048"><span class="cls_048">Erickson, Janelle 23</span></div>
<div style="position:absolute;left:305.14px;top:424.97px" class="cls_048"><span class="cls_048">Hojnik, Maja 20</span></div>
<div style="position:absolute;left:432.71px;top:424.60px" class="cls_048"><span class="cls_048">Lee, Jun Young 34</span></div>
<div style="position:absolute;left:50.00px;top:433.15px" class="cls_048"><span class="cls_048">Berianu, Florentina 5</span></div>
<div style="position:absolute;left:177.57px;top:432.57px" class="cls_048"><span class="cls_048">Eyerich, Kilian 13</span></div>
<div style="position:absolute;left:305.14px;top:432.90px" class="cls_048"><span class="cls_048">Holst, Ann-Dörthe 56</span></div>
<div style="position:absolute;left:432.71px;top:432.52px" class="cls_048"><span class="cls_048">Lendl, Udo 56</span></div>
<div style="position:absolute;left:50.00px;top:441.06px" class="cls_048"><span class="cls_048">Bessette, Louis 15</span><span class="cls_049">, </span><span class="cls_048">16</span></div>
<div style="position:absolute;left:305.14px;top:440.84px" class="cls_048"><span class="cls_048">Hong, Chih-ho 29</span></div>
<div style="position:absolute;left:432.71px;top:440.44px" class="cls_048"><span class="cls_048">Leonardi, Craig 24</span><span class="cls_049">, </span><span class="cls_048">26</span><span class="cls_049">, </span><span class="cls_048">27</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">30</span><span class="cls_049">, </span><span class="cls_048">46</span></div>
<div style="position:absolute;left:50.00px;top:448.97px" class="cls_048"><span class="cls_048">Bircan, Ebru 8</span></div>
<div style="position:absolute;left:177.57px;top:446.10px" class="cls_050"><span class="cls_050">F</span></div>
<div style="position:absolute;left:305.14px;top:448.76px" class="cls_048"><span class="cls_048">Hong, H. Chih-Ho 29</span></div>
<div style="position:absolute;left:432.71px;top:448.37px" class="cls_048"><span class="cls_048">Lerchl, Sylvie 59</span></div>
<div style="position:absolute;left:50.00px;top:456.88px" class="cls_048"><span class="cls_048">Birt, Julie 46</span></div>
<div style="position:absolute;left:177.57px;top:456.03px" class="cls_048"><span class="cls_048">Fakharzadeh, Steve 46</span></div>
<div style="position:absolute;left:305.14px;top:456.70px" class="cls_048"><span class="cls_048">Hoops, Timothy 46</span></div>
<div style="position:absolute;left:432.71px;top:456.29px" class="cls_048"><span class="cls_048">Lespessailles, Eric 16</span><span class="cls_049">, </span><span class="cls_048">23</span></div>
<div style="position:absolute;left:50.00px;top:464.78px" class="cls_048"><span class="cls_048">Bissonnette, Robert 20</span></div>
<div style="position:absolute;left:177.57px;top:463.96px" class="cls_048"><span class="cls_048">Fallon, L 52</span></div>
<div style="position:absolute;left:305.14px;top:464.63px" class="cls_048"><span class="cls_048">Horváth, Rudolf 20</span></div>
<div style="position:absolute;left:432.71px;top:464.22px" class="cls_048"><span class="cls_048">Levi, Eugenia 14</span></div>
<div style="position:absolute;left:50.00px;top:472.69px" class="cls_048"><span class="cls_048">Blauvelt, Andrew 21</span><span class="cls_049">, </span><span class="cls_048">22</span><span class="cls_049">, </span><span class="cls_048">24</span><span class="cls_049">, </span><span class="cls_048">26</span><span class="cls_049">, </span><span class="cls_048">27</span><span class="cls_049">,</span></div>
<div style="position:absolute;left:177.57px;top:471.90px" class="cls_048"><span class="cls_048">Feagan, Brian G 18</span></div>
<div style="position:absolute;left:305.14px;top:472.57px" class="cls_048"><span class="cls_048">Hsia, Elizabeth 49</span></div>
<div style="position:absolute;left:432.71px;top:472.14px" class="cls_048"><span class="cls_048">Ligozio, Gregory 15</span></div>
<div style="position:absolute;left:58.00px;top:480.60px" class="cls_048"><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">31</span><span class="cls_049">, </span><span class="cls_048">46</span><span class="cls_049">, </span><span class="cls_048">49</span><span class="cls_049">, </span><span class="cls_048">54</span><span class="cls_049">, </span><span class="cls_048">55</span></div>
<div style="position:absolute;left:177.57px;top:479.83px" class="cls_048"><span class="cls_048">Fekkas, Nikolaos 40</span></div>
<div style="position:absolute;left:305.14px;top:480.50px" class="cls_048"><span class="cls_048">Husni, M. Elaine 16</span></div>
<div style="position:absolute;left:432.71px;top:480.07px" class="cls_048"><span class="cls_048">Li, Joanne 54</span></div>
<div style="position:absolute;left:50.00px;top:488.51px" class="cls_048"><span class="cls_048">Bleakman, Alison Potts 11</span></div>
<div style="position:absolute;left:177.57px;top:487.77px" class="cls_048"><span class="cls_048">Feldman, Steven 46</span></div>
<div style="position:absolute;left:305.14px;top:488.44px" class="cls_048"><span class="cls_048">Hussain, Samina 11</span></div>
<div style="position:absolute;left:432.71px;top:488.00px" class="cls_048"><span class="cls_048">Lima, Sónia A. L. 20</span></div>
<div style="position:absolute;left:50.00px;top:496.41px" class="cls_048"><span class="cls_048">Blegvad, Christoffer 7</span><span class="cls_049">, </span><span class="cls_048">34</span></div>
<div style="position:absolute;left:177.57px;top:495.70px" class="cls_048"><span class="cls_048">Ferris, Laura 29</span></div>
<div style="position:absolute;left:305.14px;top:496.37px" class="cls_048"><span class="cls_048">Hussein, Shamiza 48</span></div>
<div style="position:absolute;left:432.71px;top:495.92px" class="cls_048"><span class="cls_048">Lin, Chen-Yen 11</span><span class="cls_049">, </span><span class="cls_048">46</span></div>
<div style="position:absolute;left:50.00px;top:504.32px" class="cls_048"><span class="cls_048">Boehncke, Wolf Henning 20</span><span class="cls_049">, </span><span class="cls_048">48</span></div>
<div style="position:absolute;left:177.57px;top:503.63px" class="cls_048"><span class="cls_048">Flack, Mary 28</span><span class="cls_049">, </span><span class="cls_048">30</span></div>
<div style="position:absolute;left:432.70px;top:503.84px" class="cls_048"><span class="cls_048">Li, Qing 22</span><span class="cls_049">, </span><span class="cls_048">24</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">29</span><span class="cls_049">, </span><span class="cls_048">49</span><span class="cls_049">, </span><span class="cls_048">54</span></div>
<div style="position:absolute;left:50.00px;top:512.23px" class="cls_048"><span class="cls_048">Boehnlein, Marion 24</span></div>
<div style="position:absolute;left:177.57px;top:511.57px" class="cls_048"><span class="cls_048">Fleischer, Alan 25</span></div>
<div style="position:absolute;left:305.14px;top:509.90px" class="cls_050"><span class="cls_050">I</span></div>
<div style="position:absolute;left:432.71px;top:511.77px" class="cls_048"><span class="cls_048">Li, Shu 22</span></div>
<div style="position:absolute;left:50.00px;top:520.13px" class="cls_048"><span class="cls_048">Boettcher, E 17</span></div>
<div style="position:absolute;left:177.57px;top:519.50px" class="cls_048"><span class="cls_048">Fleischmann, Roy 23</span></div>
<div style="position:absolute;left:305.14px;top:519.83px" class="cls_048"><span class="cls_048">Ignatov, Borislav 44</span></div>
<div style="position:absolute;left:432.71px;top:519.70px" class="cls_048"><span class="cls_048">Liubiankova, Veranika 6</span></div>
<div style="position:absolute;left:50.00px;top:528.04px" class="cls_048"><span class="cls_048">Bogunia-Kubik, Katarzyna 36</span></div>
<div style="position:absolute;left:177.57px;top:527.43px" class="cls_048"><span class="cls_048">Foley, Peter 22</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">50</span></div>
<div style="position:absolute;left:305.14px;top:527.77px" class="cls_048"><span class="cls_048">Inal, Ali 43</span></div>
<div style="position:absolute;left:432.71px;top:527.62px" class="cls_048"><span class="cls_048">Lockshin, Benjamin 14</span></div>
<div style="position:absolute;left:50.00px;top:535.94px" class="cls_048"><span class="cls_048">Bohannan, B 61</span><span class="cls_049">, </span><span class="cls_048">62</span></div>
<div style="position:absolute;left:177.57px;top:535.37px" class="cls_048"><span class="cls_048">Forman, Seth 14</span></div>
<div style="position:absolute;left:305.14px;top:535.70px" class="cls_048"><span class="cls_048">Iversen, Lars 12</span><span class="cls_049">, </span><span class="cls_048">33</span><span class="cls_049">, </span><span class="cls_048">53</span></div>
<div style="position:absolute;left:432.71px;top:535.54px" class="cls_048"><span class="cls_048">Loginova, Elena 10</span><span class="cls_049">, </span><span class="cls_048">45</span></div>
<div style="position:absolute;left:50.00px;top:543.86px" class="cls_048"><span class="cls_048">Böhme, Nicolai 56</span></div>
<div style="position:absolute;left:177.57px;top:543.30px" class="cls_048"><span class="cls_048">Fors, Sofie 55</span></div>
<div style="position:absolute;left:305.14px;top:543.63px" class="cls_048"><span class="cls_048">Ivic, Neira Puizina 39</span></div>
<div style="position:absolute;left:432.71px;top:543.47px" class="cls_048"><span class="cls_048">Lomaga, Mark 55</span></div>
<div style="position:absolute;left:50.00px;top:551.76px" class="cls_048"><span class="cls_048">Bomas, Stefanie 13</span></div>
<div style="position:absolute;left:177.57px;top:551.24px" class="cls_048"><span class="cls_048">Fotiadou, Christina 40</span></div>
<div style="position:absolute;left:305.14px;top:551.57px" class="cls_048"><span class="cls_048">Iwaszko, Milena 36</span></div>
<div style="position:absolute;left:432.71px;top:551.40px" class="cls_048"><span class="cls_048">Lonne-Rahm, Sol-Britt 8</span></div>
<div style="position:absolute;left:50.00px;top:559.67px" class="cls_048"><span class="cls_048">Botev, Ivan 35</span></div>
<div style="position:absolute;left:177.57px;top:559.17px" class="cls_048"><span class="cls_048">Fournier, Claudia 59</span></div>
<div style="position:absolute;left:432.71px;top:559.33px" class="cls_048"><span class="cls_048">Lopez-Rodriguez, Dalila Alejandra</span></div>
<div style="position:absolute;left:50.00px;top:567.57px" class="cls_048"><span class="cls_048">Brahas, Alexandra 52</span></div>
<div style="position:absolute;left:177.57px;top:567.11px" class="cls_048"><span class="cls_048">Fox, Todd 18</span></div>
<div style="position:absolute;left:305.14px;top:565.10px" class="cls_050"><span class="cls_050">J</span></div>
<div style="position:absolute;left:440.71px;top:567.24px" class="cls_048"><span class="cls_048">8</span><span class="cls_049">, </span><span class="cls_048">35</span></div>
<div style="position:absolute;left:50.00px;top:575.48px" class="cls_048"><span class="cls_048">Breitbart, Eckardt 58</span></div>
<div style="position:absolute;left:177.57px;top:575.04px" class="cls_048"><span class="cls_048">Franck, Johan 8</span></div>
<div style="position:absolute;left:305.14px;top:575.03px" class="cls_048"><span class="cls_048">Jackson, J. Mark 14</span></div>
<div style="position:absolute;left:432.71px;top:575.17px" class="cls_048"><span class="cls_048">Loser, Karin 54</span></div>
<div style="position:absolute;left:50.00px;top:583.38px" class="cls_048"><span class="cls_048">Brysch, Wolfgang 17</span></div>
<div style="position:absolute;left:177.57px;top:582.98px" class="cls_048"><span class="cls_048">Frankel, Ellen H. 30</span></div>
<div style="position:absolute;left:305.14px;top:582.96px" class="cls_048"><span class="cls_048">James, Edd 43</span></div>
<div style="position:absolute;left:432.71px;top:583.09px" class="cls_048"><span class="cls_048">Lowry, Simon 24</span><span class="cls_049">, </span><span class="cls_048">31</span><span class="cls_049">, </span><span class="cls_048">49</span></div>
<div style="position:absolute;left:50.00px;top:591.29px" class="cls_048"><span class="cls_048">Bukhalo, Michael 30</span></div>
<div style="position:absolute;left:177.57px;top:590.91px" class="cls_048"><span class="cls_048">Frueh, Jennifer 47</span></div>
<div style="position:absolute;left:305.14px;top:590.90px" class="cls_048"><span class="cls_048">Janus, Christine 58</span></div>
<div style="position:absolute;left:432.71px;top:591.02px" class="cls_048"><span class="cls_048">Lubrano, Ennio 20</span></div>
<div style="position:absolute;left:50.00px;top:599.19px" class="cls_048"><span class="cls_048">Bulic, Suzana Ozanic 7</span></div>
<div style="position:absolute;left:177.57px;top:598.85px" class="cls_048"><span class="cls_048">Fung, Japio 5</span></div>
<div style="position:absolute;left:305.14px;top:598.83px" class="cls_048"><span class="cls_048">Jazayeri, Sasha 47</span></div>
<div style="position:absolute;left:432.71px;top:598.95px" class="cls_048"><span class="cls_048">Luck-Sikorski, Claudia 58</span></div>
<div style="position:absolute;left:50.00px;top:607.10px" class="cls_048"><span class="cls_048">Bundy, Christine 13</span><span class="cls_049">, </span><span class="cls_048">58</span></div>
<div style="position:absolute;left:305.14px;top:606.77px" class="cls_048"><span class="cls_048">Jiang, Gigi 29</span></div>
<div style="position:absolute;left:432.71px;top:606.88px" class="cls_048"><span class="cls_048">Luger, Thomas 54</span></div>
<div style="position:absolute;left:177.57px;top:612.38px" class="cls_050"><span class="cls_050">G</span></div>
<div style="position:absolute;left:50.00px;top:615.02px" class="cls_048"><span class="cls_048">Burge, Daniel 21</span><span class="cls_049">, </span><span class="cls_048">27</span></div>
<div style="position:absolute;left:305.14px;top:614.70px" class="cls_048"><span class="cls_048">Jokinen, Jussi 9</span></div>
<div style="position:absolute;left:432.71px;top:614.80px" class="cls_048"><span class="cls_048">Lynde, Charles 48</span></div>
<div style="position:absolute;left:50.00px;top:622.92px" class="cls_048"><span class="cls_048">Burge, Russel 11</span><span class="cls_049">, </span><span class="cls_048">55</span></div>
<div style="position:absolute;left:177.57px;top:622.30px" class="cls_048"><span class="cls_048">Gaillez, Corine 19</span><span class="cls_049">, </span><span class="cls_048">21</span></div>
<div style="position:absolute;left:305.14px;top:622.64px" class="cls_048"><span class="cls_048">Jukic, Zlatica 8</span></div>
<div style="position:absolute;left:50.00px;top:630.83px" class="cls_048"><span class="cls_048">Burmester, Gerd R. 19</span></div>
<div style="position:absolute;left:177.57px;top:630.23px" class="cls_048"><span class="cls_048">Galinski, Adrian 43</span></div>
<div style="position:absolute;left:305.14px;top:630.57px" class="cls_048"><span class="cls_048">Juneblad, Kristina 37</span></div>
<div style="position:absolute;left:432.71px;top:628.33px" class="cls_050"><span class="cls_050">M</span></div>
<div style="position:absolute;left:50.00px;top:638.74px" class="cls_048"><span class="cls_048">Butrym, Aleksandra 9</span></div>
<div style="position:absolute;left:177.57px;top:638.17px" class="cls_048"><span class="cls_048">Gallo, Gaia 16</span></div>
<div style="position:absolute;left:432.71px;top:638.25px" class="cls_048"><span class="cls_048">Macias-Garcia, Karla Del Rocio 8</span></div>
<div style="position:absolute;left:177.57px;top:646.10px" class="cls_048"><span class="cls_048">Ganz, Fabiana 20</span><span class="cls_049">, </span><span class="cls_048">23</span></div>
<div style="position:absolute;left:305.14px;top:644.10px" class="cls_050"><span class="cls_050">K</span></div>
<div style="position:absolute;left:432.71px;top:646.18px" class="cls_048"><span class="cls_048">Madani, Hind 53</span></div>
<div style="position:absolute;left:50.00px;top:652.24px" class="cls_050"><span class="cls_050">C</span></div>
<div style="position:absolute;left:177.57px;top:654.03px" class="cls_048"><span class="cls_048">Garg, A 52</span></div>
<div style="position:absolute;left:305.14px;top:654.03px" class="cls_048"><span class="cls_048">Kaiser, Astrid 17</span></div>
<div style="position:absolute;left:432.71px;top:654.10px" class="cls_048"><span class="cls_048">Maddock, Alan 51</span><span class="cls_049">, </span><span class="cls_048">52</span></div>
<div style="position:absolute;left:50.00px;top:662.15px" class="cls_048"><span class="cls_048">Cagalj, Adela Markota 39</span></div>
<div style="position:absolute;left:177.57px;top:661.97px" class="cls_048"><span class="cls_048">Geale, Kirk 9</span></div>
<div style="position:absolute;left:305.14px;top:661.97px" class="cls_048"><span class="cls_048">Kanehisa, Fuminao 39</span></div>
<div style="position:absolute;left:432.71px;top:662.03px" class="cls_048"><span class="cls_048">Mahesh, Seema 38</span></div>
<div style="position:absolute;left:50.00px;top:670.06px" class="cls_048"><span class="cls_048">Camez, Anne 30</span></div>
<div style="position:absolute;left:177.57px;top:669.90px" class="cls_048"><span class="cls_048">Geng, Ziqian 25</span><span class="cls_049">, </span><span class="cls_048">26</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">30</span></div>
<div style="position:absolute;left:305.14px;top:669.90px" class="cls_048"><span class="cls_048">Kappelman, Michael 46</span></div>
<div style="position:absolute;left:432.71px;top:669.95px" class="cls_048"><span class="cls_048">Majjhoo, A 52</span></div>
<div style="position:absolute;left:50.00px;top:677.96px" class="cls_048"><span class="cls_048">Cappelleri, JC 52</span></div>
<div style="position:absolute;left:177.57px;top:677.83px" class="cls_048"><span class="cls_048">Ghitulescu, Persa 39</span></div>
<div style="position:absolute;left:305.14px;top:677.84px" class="cls_048"><span class="cls_048">Kasumagić-Halilović, Emina 41</span></div>
<div style="position:absolute;left:432.71px;top:677.88px" class="cls_048"><span class="cls_048">Makarava, Sviatlana 6</span></div>
<div style="position:absolute;left:50.00px;top:685.87px" class="cls_048"><span class="cls_048">Carija, Antoanela 39</span></div>
<div style="position:absolute;left:177.57px;top:685.77px" class="cls_048"><span class="cls_048">Ghoreishi, Mehran 42</span></div>
<div style="position:absolute;left:305.14px;top:685.77px" class="cls_048"><span class="cls_048">Katoh, Norito 39</span></div>
<div style="position:absolute;left:432.71px;top:685.81px" class="cls_048"><span class="cls_048">Malatesta, Estela M 61</span></div>
<div style="position:absolute;left:50.00px;top:693.77px" class="cls_048"><span class="cls_048">Castillo, Inmaculada Lopez 6</span></div>
<div style="position:absolute;left:177.57px;top:693.70px" class="cls_048"><span class="cls_048">Giannoukos, Anastasios 40</span></div>
<div style="position:absolute;left:305.14px;top:693.71px" class="cls_048"><span class="cls_048">Katoulis, Alexandros 55</span></div>
<div style="position:absolute;left:432.71px;top:693.73px" class="cls_048"><span class="cls_048">Mallappa, Mahesh 38</span></div>
<div style="position:absolute;left:50.00px;top:701.68px" class="cls_048"><span class="cls_048">Castillo, Veronica Lopez 6</span></div>
<div style="position:absolute;left:177.57px;top:701.64px" class="cls_048"><span class="cls_048">Gisondi, Paolo 25</span></div>
<div style="position:absolute;left:305.14px;top:701.64px" class="cls_048"><span class="cls_048">Kaura, Satyin 14</span></div>
<div style="position:absolute;left:432.71px;top:701.66px" class="cls_048"><span class="cls_048">Markanton, Vasiliki 55</span></div>
<div style="position:absolute;left:50.00px;top:709.58px" class="cls_048"><span class="cls_048">Cather, Jennifer Clay 11</span></div>
<div style="position:absolute;left:177.57px;top:709.57px" class="cls_048"><span class="cls_048">Gitinova, Muslimat 51</span></div>
<div style="position:absolute;left:305.14px;top:709.58px" class="cls_048"><span class="cls_048">Kavanagh, Sarah 21</span></div>
<div style="position:absolute;left:432.71px;top:709.59px" class="cls_048"><span class="cls_048">Marko, Pij B. 59</span></div>
<div style="position:absolute;left:50.00px;top:717.49px" class="cls_048"><span class="cls_048">Chada, Lourdes Perez 62</span></div>
<div style="position:absolute;left:177.57px;top:717.50px" class="cls_048"><span class="cls_048">Gladman, Dafna 11</span><span class="cls_049">, </span><span class="cls_048">14</span><span class="cls_049">, </span><span class="cls_048">23</span></div>
<div style="position:absolute;left:305.14px;top:717.51px" class="cls_048"><span class="cls_048">Kavanaugh, Arthur 46</span></div>
<div style="position:absolute;left:432.71px;top:717.52px" class="cls_048"><span class="cls_048">Marovt, Maruska 59</span></div>
<div style="position:absolute;left:454.80px;top:739.31px" class="cls_018"><span class="cls_018">Acta Derm Venereol 2018</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:51392px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background66.jpg" width=595 height=793></div>
<div style="position:absolute;left:50.00px;top:28.81px" class="cls_017"><span class="cls_017">64</span></div>
<div style="position:absolute;left:80.50px;top:28.49px" class="cls_019"><span class="cls_019">5</span><span class="cls_020"><sup>th</sup></span><span class="cls_019"> World Psoriasis & Psoriatic Arthritis Conference 2018</span></div>
<div style="position:absolute;left:50.00px;top:52.42px" class="cls_048"><span class="cls_048">Martini, Elisa 44</span></div>
<div style="position:absolute;left:177.56px;top:52.42px" class="cls_048"><span class="cls_048">Parneix-Spake, Anne 47</span></div>
<div style="position:absolute;left:305.14px;top:52.42px" class="cls_048"><span class="cls_048">Rustenbach, Stephan Jeff 32</span></div>
<div style="position:absolute;left:432.70px;top:52.42px" class="cls_048"><span class="cls_048">Topp, Janine 58</span></div>
<div style="position:absolute;left:50.00px;top:60.32px" class="cls_048"><span class="cls_048">Martinka, Magdalena 42</span></div>
<div style="position:absolute;left:177.56px;top:60.31px" class="cls_048"><span class="cls_048">Parno, Jeff 24</span><span class="cls_049">, </span><span class="cls_048">29</span><span class="cls_049">, </span><span class="cls_048">30</span><span class="cls_049">, </span><span class="cls_048">49</span></div>
<div style="position:absolute;left:305.14px;top:60.32px" class="cls_048"><span class="cls_048">Ryan, Caitriona 11</span><span class="cls_049">, </span><span class="cls_048">57</span></div>
<div style="position:absolute;left:432.70px;top:60.32px" class="cls_048"><span class="cls_048">Trakatelli, Myrto 40</span></div>
<div style="position:absolute;left:50.00px;top:68.22px" class="cls_048"><span class="cls_048">Martin, Ruvie 15</span></div>
<div style="position:absolute;left:177.57px;top:68.22px" class="cls_048"><span class="cls_048">Parno, Jeffrey 29</span><span class="cls_049">, </span><span class="cls_048">31</span></div>
<div style="position:absolute;left:432.70px;top:68.22px" class="cls_048"><span class="cls_048">Trcko, Katarina 59</span></div>
<div style="position:absolute;left:50.00px;top:76.12px" class="cls_048"><span class="cls_048">Mason, Kayleigh 33</span></div>
<div style="position:absolute;left:177.57px;top:76.12px" class="cls_048"><span class="cls_048">Patrk, Ivana 8</span></div>
<div style="position:absolute;left:305.14px;top:73.82px" class="cls_050"><span class="cls_050">S</span></div>
<div style="position:absolute;left:432.70px;top:76.11px" class="cls_048"><span class="cls_048">Tsai, T. 46</span></div>
<div style="position:absolute;left:50.00px;top:84.01px" class="cls_048"><span class="cls_048">Masuda, Koji 39</span></div>
<div style="position:absolute;left:177.57px;top:84.02px" class="cls_048"><span class="cls_048">Pattinson, Rachael 58</span></div>
<div style="position:absolute;left:305.14px;top:83.72px" class="cls_048"><span class="cls_048">Safi, Jorge 11</span></div>
<div style="position:absolute;left:432.70px;top:84.01px" class="cls_048"><span class="cls_048">Tveit, Kåre Steinar 12</span><span class="cls_049">, </span><span class="cls_048">33</span><span class="cls_049">, </span><span class="cls_048">53</span></div>
<div style="position:absolute;left:50.00px;top:91.91px" class="cls_048"><span class="cls_048">Maya, Juan J. 5</span></div>
<div style="position:absolute;left:177.57px;top:91.92px" class="cls_048"><span class="cls_048">Paul, Carle 11</span></div>
<div style="position:absolute;left:305.14px;top:91.62px" class="cls_048"><span class="cls_048">Saure, Daniel 34</span></div>
<div style="position:absolute;left:432.71px;top:91.92px" class="cls_048"><span class="cls_048">Tyring, Stephen 21</span><span class="cls_049">, </span><span class="cls_048">22</span><span class="cls_049">, </span><span class="cls_048">29</span><span class="cls_049">, </span><span class="cls_048">30</span><span class="cls_049">, </span><span class="cls_048">31</span><span class="cls_049">, </span><span class="cls_048">54</span></div>
<div style="position:absolute;left:50.00px;top:99.81px" class="cls_048"><span class="cls_048">Mazur, Grzegorz 9</span></div>
<div style="position:absolute;left:177.57px;top:99.81px" class="cls_048"><span class="cls_048">Pavlova, Viktoria 15</span></div>
<div style="position:absolute;left:305.14px;top:99.52px" class="cls_048"><span class="cls_048">Schaefer, Ines 58</span></div>
<div style="position:absolute;left:50.00px;top:107.71px" class="cls_048"><span class="cls_048">McGonagle, Dennis 19</span></div>
<div style="position:absolute;left:177.57px;top:107.71px" class="cls_048"><span class="cls_048">Péč, Juraj 12</span></div>
<div style="position:absolute;left:305.14px;top:107.42px" class="cls_048"><span class="cls_048">Scherer, Joseph 30</span></div>
<div style="position:absolute;left:432.70px;top:105.42px" class="cls_050"><span class="cls_050">V</span></div>
<div style="position:absolute;left:50.00px;top:115.60px" class="cls_048"><span class="cls_048">McInnes, Iain B 18</span></div>
<div style="position:absolute;left:177.57px;top:115.61px" class="cls_048"><span class="cls_048">Péčová, Tatiana 12</span></div>
<div style="position:absolute;left:305.14px;top:115.31px" class="cls_048"><span class="cls_048">Schett, Georg 19</span></div>
<div style="position:absolute;left:432.70px;top:115.32px" class="cls_048"><span class="cls_048">Valdes, Joaquin M. 28</span></div>
<div style="position:absolute;left:50.00px;top:123.50px" class="cls_048"><span class="cls_048">McKenzie, Robert 34</span></div>
<div style="position:absolute;left:177.57px;top:123.51px" class="cls_048"><span class="cls_048">Perez-Chada, Lourdes 60</span></div>
<div style="position:absolute;left:305.14px;top:123.21px" class="cls_048"><span class="cls_048">Schlette, Sophie 58</span></div>
<div style="position:absolute;left:432.70px;top:123.22px" class="cls_048"><span class="cls_048">Vandeloo, Carl 57</span></div>
<div style="position:absolute;left:50.00px;top:131.40px" class="cls_048"><span class="cls_048">Mease, Philip J 14</span><span class="cls_049">, </span><span class="cls_048">15</span><span class="cls_049">, </span><span class="cls_048">17</span><span class="cls_049">, </span><span class="cls_048">19</span><span class="cls_049">, </span><span class="cls_048">21</span></div>
<div style="position:absolute;left:177.57px;top:131.40px" class="cls_048"><span class="cls_048">Perkins, Megan Leone 46</span></div>
<div style="position:absolute;left:305.14px;top:131.11px" class="cls_048"><span class="cls_048">Schmitt-Egenolf, Marcus 9</span></div>
<div style="position:absolute;left:432.70px;top:131.12px" class="cls_048"><span class="cls_048">Vaya, Jose Maria Ricart 6</span></div>
<div style="position:absolute;left:50.00px;top:139.32px" class="cls_048"><span class="cls_048">Meeuwis, Kim 11</span></div>
<div style="position:absolute;left:177.57px;top:139.30px" class="cls_048"><span class="cls_048">Peterson, Luke 24</span><span class="cls_049">, </span><span class="cls_048">26</span><span class="cls_049">, </span><span class="cls_048">27</span><span class="cls_049">, </span><span class="cls_048">57</span></div>
<div style="position:absolute;left:305.14px;top:139.01px" class="cls_048"><span class="cls_048">Schneeweiss, Mia 60</span></div>
<div style="position:absolute;left:432.70px;top:139.02px" class="cls_048"><span class="cls_048">Vender, Ron 50</span></div>
<div style="position:absolute;left:50.00px;top:147.22px" class="cls_048"><span class="cls_048">Mehta, Nehal N. 14</span><span class="cls_049">, </span><span class="cls_048">46</span></div>
<div style="position:absolute;left:177.57px;top:147.22px" class="cls_048"><span class="cls_048">Philipp, Sandra 21</span><span class="cls_049">, </span><span class="cls_048">30</span></div>
<div style="position:absolute;left:305.14px;top:146.90px" class="cls_048"><span class="cls_048">Schreiber, Stefan 18</span></div>
<div style="position:absolute;left:432.70px;top:146.91px" class="cls_048"><span class="cls_048">Vender, Ronald 34</span></div>
<div style="position:absolute;left:50.00px;top:155.12px" class="cls_048"><span class="cls_048">Melendez, Gianna 33</span><span class="cls_049">, </span><span class="cls_048">49</span><span class="cls_049">, </span><span class="cls_048">50</span></div>
<div style="position:absolute;left:177.57px;top:155.12px" class="cls_048"><span class="cls_048">Pinter, Andreas 55</span></div>
<div style="position:absolute;left:305.14px;top:154.80px" class="cls_048"><span class="cls_048">Schulz, Petra 17</span></div>
<div style="position:absolute;left:432.70px;top:154.81px" class="cls_048"><span class="cls_048">Vieira, Antonio 48</span></div>
<div style="position:absolute;left:50.00px;top:163.02px" class="cls_048"><span class="cls_048">Mendelsohn, Alan 24</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">29</span><span class="cls_049">, </span><span class="cls_048">30</span><span class="cls_049">, </span><span class="cls_048">31</span></div>
<div style="position:absolute;left:177.57px;top:163.02px" class="cls_048"><span class="cls_048">Pisenti, Lisa 21</span><span class="cls_049">, </span><span class="cls_048">37</span><span class="cls_049">, </span><span class="cls_048">56</span></div>
<div style="position:absolute;left:305.14px;top:162.70px" class="cls_048"><span class="cls_048">Schumann, Sara 17</span></div>
<div style="position:absolute;left:432.70px;top:162.71px" class="cls_048"><span class="cls_048">Vithoulkas, George 38</span></div>
<div style="position:absolute;left:50.00px;top:170.92px" class="cls_048"><span class="cls_048">Menter, Alan 28</span><span class="cls_049">, </span><span class="cls_048">29</span><span class="cls_049">, </span><span class="cls_048">31</span></div>
<div style="position:absolute;left:177.57px;top:170.92px" class="cls_048"><span class="cls_048">Platsidaki, Eftychia 55</span></div>
<div style="position:absolute;left:305.14px;top:170.60px" class="cls_048"><span class="cls_048">Schwichtenberg, Uwe 13</span></div>
<div style="position:absolute;left:432.70px;top:170.61px" class="cls_048"><span class="cls_048">Volberg, Christoph 56</span></div>
<div style="position:absolute;left:50.00px;top:178.82px" class="cls_048"><span class="cls_048">Mentz, Hannah 13</span></div>
<div style="position:absolute;left:177.57px;top:178.82px" class="cls_048"><span class="cls_048">Polic, Melita Vuksic 8</span></div>
<div style="position:absolute;left:305.14px;top:178.49px" class="cls_048"><span class="cls_048">Seifert, Oliver 12</span><span class="cls_049">, </span><span class="cls_048">33</span><span class="cls_049">, </span><span class="cls_048">53</span></div>
<div style="position:absolute;left:432.70px;top:178.50px" class="cls_048"><span class="cls_048">Vollmer, Sigrid 43</span></div>
<div style="position:absolute;left:50.00px;top:186.72px" class="cls_048"><span class="cls_048">Merola, Joseph F 16</span><span class="cls_049">, </span><span class="cls_048">46</span><span class="cls_049">, </span><span class="cls_048">60</span></div>
<div style="position:absolute;left:177.57px;top:186.72px" class="cls_048"><span class="cls_048">Politou, Maria 40</span></div>
<div style="position:absolute;left:305.14px;top:186.42px" class="cls_048"><span class="cls_048">Sérézal, Irène Gallais 44</span></div>
<div style="position:absolute;left:432.70px;top:186.40px" class="cls_048"><span class="cls_048">Voorhees, Abby S Van 56</span></div>
<div style="position:absolute;left:50.00px;top:194.62px" class="cls_048"><span class="cls_048">Metze, Dieter 54</span></div>
<div style="position:absolute;left:177.57px;top:194.61px" class="cls_048"><span class="cls_048">Polzer, Paula 44</span></div>
<div style="position:absolute;left:305.14px;top:194.32px" class="cls_048"><span class="cls_048">Servin, Ofelia Reyes 25</span><span class="cls_049">, </span><span class="cls_048">26</span></div>
<div style="position:absolute;left:432.70px;top:194.30px" class="cls_048"><span class="cls_048">Vorčáková, Karolína 12</span></div>
<div style="position:absolute;left:50.00px;top:202.52px" class="cls_048"><span class="cls_048">Milutinovic, M. 46</span></div>
<div style="position:absolute;left:177.57px;top:202.51px" class="cls_048"><span class="cls_048">Pompou, Maria 40</span></div>
<div style="position:absolute;left:305.14px;top:202.22px" class="cls_048"><span class="cls_048">Shah, Viraj 38</span></div>
<div style="position:absolute;left:432.70px;top:202.20px" class="cls_048"><span class="cls_048">Vukadin, Renata 8</span></div>
<div style="position:absolute;left:50.00px;top:210.42px" class="cls_048"><span class="cls_048">Miteva, Lyubka 35</span></div>
<div style="position:absolute;left:177.57px;top:210.41px" class="cls_048"><span class="cls_048">Popa, Elena 39</span><span class="cls_049">, </span><span class="cls_048">52</span></div>
<div style="position:absolute;left:305.14px;top:210.12px" class="cls_048"><span class="cls_048">Shankle, Lindsey 56</span></div>
<div style="position:absolute;left:432.70px;top:210.09px" class="cls_048"><span class="cls_048">Vural, Secil 43</span></div>
<div style="position:absolute;left:50.00px;top:218.31px" class="cls_048"><span class="cls_048">Morita, Akimichi 46</span></div>
<div style="position:absolute;left:177.57px;top:218.32px" class="cls_048"><span class="cls_048">Poparic, Selma 7</span><span class="cls_049">, </span><span class="cls_048">59</span></div>
<div style="position:absolute;left:305.14px;top:218.02px" class="cls_048"><span class="cls_048">Sheahan, Anna 37</span></div>
<div style="position:absolute;left:432.70px;top:217.99px" class="cls_048"><span class="cls_048">Wang, Hailun 5</span></div>
<div style="position:absolute;left:50.00px;top:226.21px" class="cls_048"><span class="cls_048">Moser, J 52</span></div>
<div style="position:absolute;left:177.57px;top:226.22px" class="cls_048"><span class="cls_048">Porter, Brian 18</span></div>
<div style="position:absolute;left:305.14px;top:225.91px" class="cls_048"><span class="cls_048">Shen, Wei 55</span></div>
<div style="position:absolute;left:432.70px;top:225.89px" class="cls_048"><span class="cls_048">Wang, Yinpeng 5</span></div>
<div style="position:absolute;left:50.00px;top:234.11px" class="cls_048"><span class="cls_048">Mpofu, Shephard 17</span><span class="cls_049">, </span><span class="cls_048">19</span></div>
<div style="position:absolute;left:177.57px;top:234.12px" class="cls_048"><span class="cls_048">Pott, Hans-Georg 56</span></div>
<div style="position:absolute;left:305.14px;top:233.81px" class="cls_048"><span class="cls_048">Shen, Yaung-Kaung 20</span><span class="cls_049">, </span><span class="cls_048">21</span><span class="cls_049">, </span><span class="cls_048">22</span><span class="cls_049">, </span><span class="cls_048">50</span></div>
<div style="position:absolute;left:432.70px;top:233.79px" class="cls_048"><span class="cls_048">Wang, Yuhua 49</span></div>
<div style="position:absolute;left:50.00px;top:242.02px" class="cls_048"><span class="cls_048">Mrowietz, Ulrich 44</span><span class="cls_049">, </span><span class="cls_048">47</span><span class="cls_049">, </span><span class="cls_048">58</span></div>
<div style="position:absolute;left:177.57px;top:242.02px" class="cls_048"><span class="cls_048">Poulin, Yves 24</span><span class="cls_049">, </span><span class="cls_048">26</span><span class="cls_049">, </span><span class="cls_048">27</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">30</span></div>
<div style="position:absolute;left:305.13px;top:241.72px" class="cls_048"><span class="cls_048">Shen, Zhu 42</span></div>
<div style="position:absolute;left:432.70px;top:241.68px" class="cls_048"><span class="cls_048">Warren, Richard 11</span></div>
<div style="position:absolute;left:50.00px;top:249.92px" class="cls_048"><span class="cls_048">Muhović, Jasmina 5</span><span class="cls_049">, </span><span class="cls_048">41</span></div>
<div style="position:absolute;left:177.57px;top:249.92px" class="cls_048"><span class="cls_048">Price, Lynn 33</span><span class="cls_049">, </span><span class="cls_048">49</span><span class="cls_049">, </span><span class="cls_048">50</span></div>
<div style="position:absolute;left:305.13px;top:249.62px" class="cls_048"><span class="cls_048">Shrom, David 55</span></div>
<div style="position:absolute;left:432.70px;top:249.58px" class="cls_048"><span class="cls_048">Wasfi, Yasmine 20</span><span class="cls_049">, </span><span class="cls_048">21</span><span class="cls_049">, </span><span class="cls_048">22</span></div>
<div style="position:absolute;left:50.00px;top:257.82px" class="cls_048"><span class="cls_048">Muñoz-Elías, Ernesto J 22</span></div>
<div style="position:absolute;left:177.57px;top:257.82px" class="cls_048"><span class="cls_048">Pricop, Luminita 15</span><span class="cls_049">, </span><span class="cls_048">17</span><span class="cls_049">, </span><span class="cls_048">18</span><span class="cls_049">, </span><span class="cls_048">21</span></div>
<div style="position:absolute;left:305.13px;top:257.52px" class="cls_048"><span class="cls_048">Shuler, Catherine 23</span><span class="cls_049">, </span><span class="cls_048">46</span></div>
<div style="position:absolute;left:432.71px;top:257.52px" class="cls_048"><span class="cls_048">Wasilewski, Alicja 42</span></div>
<div style="position:absolute;left:50.00px;top:265.72px" class="cls_048"><span class="cls_048">Munro, Duncan 57</span></div>
<div style="position:absolute;left:177.57px;top:265.72px" class="cls_048"><span class="cls_048">Prinz, Jörg 43</span></div>
<div style="position:absolute;left:305.14px;top:265.42px" class="cls_048"><span class="cls_048">Sieder, Christian 12</span></div>
<div style="position:absolute;left:432.71px;top:265.42px" class="cls_048"><span class="cls_048">Weaver, Jerry 14</span></div>
<div style="position:absolute;left:50.00px;top:273.62px" class="cls_048"><span class="cls_048">Muser, Erik 46</span></div>
<div style="position:absolute;left:177.57px;top:273.62px" class="cls_048"><span class="cls_048">Puig, Lluis 11</span><span class="cls_049">, </span><span class="cls_048">14</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">50</span></div>
<div style="position:absolute;left:305.14px;top:273.32px" class="cls_048"><span class="cls_048">Siegel, Michael 56</span></div>
<div style="position:absolute;left:432.71px;top:273.32px" class="cls_048"><span class="cls_048">Węgłowska, Jolanta 57</span></div>
<div style="position:absolute;left:177.57px;top:281.52px" class="cls_048"><span class="cls_048">Purcaru, Oana 57</span></div>
<div style="position:absolute;left:305.14px;top:281.22px" class="cls_048"><span class="cls_048">Sinclair, Rodney 22</span><span class="cls_049">, </span><span class="cls_048">54</span></div>
<div style="position:absolute;left:432.71px;top:281.21px" class="cls_048"><span class="cls_048">Weinberger, Natascha 58</span></div>
<div style="position:absolute;left:50.00px;top:287.12px" class="cls_050"><span class="cls_050">N</span></div>
<div style="position:absolute;left:305.14px;top:289.12px" class="cls_048"><span class="cls_048">Singhal, A 17</span></div>
<div style="position:absolute;left:432.71px;top:289.11px" class="cls_048"><span class="cls_048">Wiedemann, Julia 59</span></div>
<div style="position:absolute;left:50.00px;top:297.02px" class="cls_048"><span class="cls_048">Nash, Peter 14</span><span class="cls_049">, </span><span class="cls_048">15</span><span class="cls_049">, </span><span class="cls_048">21</span></div>
<div style="position:absolute;left:177.57px;top:295.02px" class="cls_050"><span class="cls_050">Q</span></div>
<div style="position:absolute;left:305.14px;top:297.02px" class="cls_048"><span class="cls_048">Singh, Rakesh 25</span></div>
<div style="position:absolute;left:432.71px;top:297.01px" class="cls_048"><span class="cls_048">Wiland, Piotr 9</span><span class="cls_049">, </span><span class="cls_048">36</span></div>
<div style="position:absolute;left:50.00px;top:304.92px" class="cls_048"><span class="cls_048">Nasonov, Eugeny 10</span></div>
<div style="position:absolute;left:177.57px;top:304.92px" class="cls_048"><span class="cls_048">Quebe-Fehling, Erhard 19</span></div>
<div style="position:absolute;left:305.14px;top:304.92px" class="cls_048"><span class="cls_048">Skov, Lone 7</span><span class="cls_049">, </span><span class="cls_048">12</span><span class="cls_049">, </span><span class="cls_048">33</span><span class="cls_049">, </span><span class="cls_048">34</span><span class="cls_049">, </span><span class="cls_048">53</span></div>
<div style="position:absolute;left:432.71px;top:304.92px" class="cls_048"><span class="cls_048">Wilhelm, Stefan 34</span><span class="cls_049">, </span><span class="cls_048">44</span></div>
<div style="position:absolute;left:50.00px;top:312.82px" class="cls_048"><span class="cls_048">Navarra, S 17</span></div>
<div style="position:absolute;left:177.57px;top:312.82px" class="cls_048"><span class="cls_048">Quinn, Sean 46</span></div>
<div style="position:absolute;left:305.14px;top:312.82px" class="cls_048"><span class="cls_048">Smolen, Josef S. 21</span><span class="cls_049">, </span><span class="cls_048">23</span></div>
<div style="position:absolute;left:432.71px;top:312.82px" class="cls_048"><span class="cls_048">Wilsmann-Theis, Dagmar 58</span></div>
<div style="position:absolute;left:50.00px;top:320.72px" class="cls_048"><span class="cls_048">Nica, Radu Dumitru 44</span></div>
<div style="position:absolute;left:305.14px;top:320.72px" class="cls_048"><span class="cls_048">Sofen, Howard 24</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">29</span><span class="cls_049">, </span><span class="cls_048">49</span></div>
<div style="position:absolute;left:432.71px;top:320.72px" class="cls_048"><span class="cls_048">Witzler, Claudius 59</span></div>
<div style="position:absolute;left:177.57px;top:326.32px" class="cls_050"><span class="cls_050">R</span></div>
<div style="position:absolute;left:50.00px;top:328.61px" class="cls_048"><span class="cls_048">Nielsen, Tilde Elkjær Tind 34</span></div>
<div style="position:absolute;left:305.14px;top:328.62px" class="cls_048"><span class="cls_048">Sokolik, Renata 9</span><span class="cls_049">, </span><span class="cls_048">36</span></div>
<div style="position:absolute;left:432.71px;top:328.62px" class="cls_048"><span class="cls_048">Wu, Jashin J. 25</span><span class="cls_049">, </span><span class="cls_048">30</span></div>
<div style="position:absolute;left:50.00px;top:336.51px" class="cls_048"><span class="cls_048">Ni, Michael 5</span></div>
<div style="position:absolute;left:177.57px;top:336.22px" class="cls_048"><span class="cls_048">Radtke, Marc Alexander 13</span><span class="cls_049">, </span><span class="cls_048">20</span><span class="cls_049">, </span><span class="cls_048">32</span><span class="cls_049">,</span></div>
<div style="position:absolute;left:305.14px;top:336.52px" class="cls_048"><span class="cls_048">Solovan, Caius 39</span><span class="cls_049">, </span><span class="cls_048">52</span></div>
<div style="position:absolute;left:50.00px;top:344.41px" class="cls_048"><span class="cls_048">Nora, Kogan 9</span></div>
<div style="position:absolute;left:185.57px;top:344.12px" class="cls_048"><span class="cls_048">38</span><span class="cls_049">, </span><span class="cls_048">58</span></div>
<div style="position:absolute;left:305.14px;top:344.42px" class="cls_048"><span class="cls_048">Sommer, Rachel 58</span></div>
<div style="position:absolute;left:432.70px;top:342.12px" class="cls_050"><span class="cls_050">X</span></div>
<div style="position:absolute;left:50.00px;top:352.31px" class="cls_048"><span class="cls_048">Nordlind, Klas 8</span></div>
<div style="position:absolute;left:177.57px;top:352.02px" class="cls_048"><span class="cls_048">Rahman, P 17</span></div>
<div style="position:absolute;left:305.14px;top:352.32px" class="cls_048"><span class="cls_048">Song, Michael 20</span><span class="cls_049">, </span><span class="cls_048">21</span><span class="cls_049">, </span><span class="cls_048">22</span><span class="cls_049">, </span><span class="cls_048">50</span></div>
<div style="position:absolute;left:432.70px;top:352.02px" class="cls_048"><span class="cls_048">Xu, Xie L. 49</span></div>
<div style="position:absolute;left:50.00px;top:360.20px" class="cls_048"><span class="cls_048">Norgren, T 61</span><span class="cls_049">, </span><span class="cls_048">62</span></div>
<div style="position:absolute;left:177.57px;top:359.92px" class="cls_048"><span class="cls_048">Rampakakis, Emmanouil 48</span></div>
<div style="position:absolute;left:305.14px;top:360.22px" class="cls_048"><span class="cls_048">Sorbe, Christina 32</span></div>
<div style="position:absolute;left:177.57px;top:367.82px" class="cls_048"><span class="cls_048">Randazzo, Bruce 20</span><span class="cls_049">, </span><span class="cls_048">22</span></div>
<div style="position:absolute;left:305.14px;top:368.12px" class="cls_048"><span class="cls_048">Spreckelsen, Regina 58</span></div>
<div style="position:absolute;left:432.70px;top:365.52px" class="cls_050"><span class="cls_050">Y</span></div>
<div style="position:absolute;left:50.00px;top:373.72px" class="cls_050"><span class="cls_050">O</span></div>
<div style="position:absolute;left:177.57px;top:375.72px" class="cls_048"><span class="cls_048">Randell, Shane 27</span></div>
<div style="position:absolute;left:305.14px;top:376.02px" class="cls_048"><span class="cls_048">Srivastava, Bhaskar 46</span></div>
<div style="position:absolute;left:432.70px;top:375.42px" class="cls_048"><span class="cls_048">Yamauchi, Paul 24</span></div>
<div style="position:absolute;left:50.00px;top:383.62px" class="cls_048"><span class="cls_048">Ohtsuki, Mamitaro 28</span></div>
<div style="position:absolute;left:177.57px;top:383.62px" class="cls_048"><span class="cls_048">Rasouliyan, Lawrence 19</span><span class="cls_049">, </span><span class="cls_048">21</span></div>
<div style="position:absolute;left:305.14px;top:383.91px" class="cls_048"><span class="cls_048">Ståhle, Mona 13</span></div>
<div style="position:absolute;left:432.70px;top:383.32px" class="cls_048"><span class="cls_048">Yan, Kang 5</span></div>
<div style="position:absolute;left:50.00px;top:391.52px" class="cls_048"><span class="cls_048">Okada, Masato 20</span></div>
<div style="position:absolute;left:177.57px;top:391.52px" class="cls_048"><span class="cls_048">Readie, A 17</span></div>
<div style="position:absolute;left:305.14px;top:391.81px" class="cls_048"><span class="cls_048">Ständer, Sonja 54</span></div>
<div style="position:absolute;left:432.70px;top:391.22px" class="cls_048"><span class="cls_048">Yao, Xiaoxin 5</span></div>
<div style="position:absolute;left:50.00px;top:399.42px" class="cls_048"><span class="cls_048">Olmez, Umit 43</span></div>
<div style="position:absolute;left:177.57px;top:399.42px" class="cls_048"><span class="cls_048">Rech, Jürgen 15</span></div>
<div style="position:absolute;left:305.14px;top:399.71px" class="cls_048"><span class="cls_048">Steinke, Sabine 54</span></div>
<div style="position:absolute;left:432.70px;top:399.12px" class="cls_048"><span class="cls_048">Yassine, Mohamed 21</span><span class="cls_049">, </span><span class="cls_048">37</span><span class="cls_049">, </span><span class="cls_048">56</span></div>
<div style="position:absolute;left:50.00px;top:407.32px" class="cls_048"><span class="cls_048">Orasan, Remus Ioan 44</span></div>
<div style="position:absolute;left:177.57px;top:407.32px" class="cls_048"><span class="cls_048">Reeves, Emma 43</span></div>
<div style="position:absolute;left:305.14px;top:407.61px" class="cls_048"><span class="cls_048">Stewart, Jacqueline 15</span></div>
<div style="position:absolute;left:432.70px;top:407.02px" class="cls_048"><span class="cls_048">Young, P 52</span></div>
<div style="position:absolute;left:50.00px;top:415.21px" class="cls_048"><span class="cls_048">Orbai, A-M 52</span></div>
<div style="position:absolute;left:177.57px;top:415.21px" class="cls_048"><span class="cls_048">Regnault, Pascaline 47</span></div>
<div style="position:absolute;left:305.14px;top:415.50px" class="cls_048"><span class="cls_048">Stokkeland, Knut 8</span></div>
<div style="position:absolute;left:432.70px;top:414.92px" class="cls_048"><span class="cls_048">Youn, Sang Woong 20</span></div>
<div style="position:absolute;left:50.00px;top:423.11px" class="cls_048"><span class="cls_048">Orsenigo, Roberto 12</span></div>
<div style="position:absolute;left:177.57px;top:423.11px" class="cls_048"><span class="cls_048">Reich, Kristian 11</span><span class="cls_049">, </span><span class="cls_048">13</span><span class="cls_049">, </span><span class="cls_048">18</span><span class="cls_049">, </span><span class="cls_048">21</span><span class="cls_049">, </span><span class="cls_048">22</span><span class="cls_049">, </span><span class="cls_048">24</span><span class="cls_049">,</span></div>
<div style="position:absolute;left:305.14px;top:423.40px" class="cls_048"><span class="cls_048">Strober, Bruce 11</span><span class="cls_049">, </span><span class="cls_048">20</span><span class="cls_049">, </span><span class="cls_048">21</span><span class="cls_049">, </span><span class="cls_048">24</span><span class="cls_049">, </span><span class="cls_048">28</span></div>
<div style="position:absolute;left:432.70px;top:422.82px" class="cls_048"><span class="cls_048">You, R. 46</span></div>
<div style="position:absolute;left:50.00px;top:431.01px" class="cls_048"><span class="cls_048">Østergaard, Mikkel 12</span><span class="cls_049">, </span><span class="cls_048">33</span><span class="cls_049">, </span><span class="cls_048">53</span></div>
<div style="position:absolute;left:185.57px;top:431.02px" class="cls_048"><span class="cls_048">26</span><span class="cls_049">, </span><span class="cls_048">27</span><span class="cls_049">, </span><span class="cls_048">29</span><span class="cls_049">, </span><span class="cls_048">31</span><span class="cls_049">, </span><span class="cls_048">46</span><span class="cls_049">, </span><span class="cls_048">47</span><span class="cls_049">, </span><span class="cls_048">49</span><span class="cls_049">, </span><span class="cls_048">54</span><span class="cls_049">, </span><span class="cls_048">57</span></div>
<div style="position:absolute;left:305.14px;top:431.32px" class="cls_048"><span class="cls_048">Sturgill-Koszycki, Sheila 28</span></div>
<div style="position:absolute;left:432.70px;top:430.71px" class="cls_048"><span class="cls_048">You, Ruquan 47</span></div>
<div style="position:absolute;left:50.00px;top:438.92px" class="cls_048"><span class="cls_048">Ott, Elyssa 29</span></div>
<div style="position:absolute;left:177.57px;top:438.92px" class="cls_048"><span class="cls_048">Remple, Valencia 15</span><span class="cls_049">, </span><span class="cls_048">16</span></div>
<div style="position:absolute;left:305.14px;top:439.22px" class="cls_048"><span class="cls_048">Sullivan, John 47</span></div>
<div style="position:absolute;left:432.70px;top:438.61px" class="cls_048"><span class="cls_048">You, Yin 20</span><span class="cls_049">, </span><span class="cls_048">21</span><span class="cls_049">, </span><span class="cls_048">50</span></div>
<div style="position:absolute;left:50.00px;top:446.82px" class="cls_048"><span class="cls_048">Ovčina-Kurtović, Nermina 41</span></div>
<div style="position:absolute;left:177.57px;top:446.82px" class="cls_048"><span class="cls_048">Rich, Pheobe A. 26</span></div>
<div style="position:absolute;left:305.14px;top:447.12px" class="cls_048"><span class="cls_048">Suruki, Robert 37</span></div>
<div style="position:absolute;left:432.70px;top:452.12px" class="cls_050"><span class="cls_050">Z</span></div>
<div style="position:absolute;left:177.57px;top:454.72px" class="cls_048"><span class="cls_048">Rigopoulos, Dimitrios 40</span></div>
<div style="position:absolute;left:305.14px;top:455.01px" class="cls_048"><span class="cls_048">Suthakharan, Nirohshah 36</span><span class="cls_049">, </span><span class="cls_048">58</span></div>
<div style="position:absolute;left:50.00px;top:460.32px" class="cls_050"><span class="cls_050">P</span></div>
<div style="position:absolute;left:177.57px;top:462.62px" class="cls_048"><span class="cls_048">Rihakova, Lenka 48</span></div>
<div style="position:absolute;left:305.14px;top:462.92px" class="cls_048"><span class="cls_048">Svanström, Caroline 8</span></div>
<div style="position:absolute;left:432.70px;top:462.02px" class="cls_048"><span class="cls_048">Zachariae, Claus 7</span></div>
<div style="position:absolute;left:50.00px;top:470.22px" class="cls_048"><span class="cls_048">Padulles, Laura 18</span></div>
<div style="position:absolute;left:177.57px;top:470.51px" class="cls_048"><span class="cls_048">Rissler, Michael 12</span></div>
<div style="position:absolute;left:305.14px;top:470.82px" class="cls_048"><span class="cls_048">Świerkot, Jerzy 36</span></div>
<div style="position:absolute;left:432.70px;top:469.92px" class="cls_048"><span class="cls_048">Zander, Nicole 38</span></div>
<div style="position:absolute;left:50.00px;top:478.12px" class="cls_048"><span class="cls_048">Panaccione, Remo 19</span></div>
<div style="position:absolute;left:177.57px;top:478.41px" class="cls_048"><span class="cls_048">Robinson, Jennifer 33</span><span class="cls_049">, </span><span class="cls_048">49</span><span class="cls_049">, </span><span class="cls_048">50</span></div>
<div style="position:absolute;left:305.14px;top:478.72px" class="cls_048"><span class="cls_048">Szepietowski, Jacek 11</span></div>
<div style="position:absolute;left:432.70px;top:477.82px" class="cls_048"><span class="cls_048">Zargari, Omid 6</span><span class="cls_049">, </span><span class="cls_048">44</span></div>
<div style="position:absolute;left:50.00px;top:486.01px" class="cls_048"><span class="cls_048">Pang, Herbert 5</span></div>
<div style="position:absolute;left:177.57px;top:486.32px" class="cls_048"><span class="cls_048">Rodriguez, Pedro 6</span></div>
<div style="position:absolute;left:432.71px;top:485.72px" class="cls_048"><span class="cls_048">Zhang, Ying 23</span></div>
<div style="position:absolute;left:50.00px;top:493.91px" class="cls_048"><span class="cls_048">Papanastasiou, P. 46</span></div>
<div style="position:absolute;left:177.57px;top:494.22px" class="cls_048"><span class="cls_048">Rokni, Ghasem Rahmatpour 10</span></div>
<div style="position:absolute;left:305.14px;top:492.22px" class="cls_050"><span class="cls_050">T</span></div>
<div style="position:absolute;left:432.71px;top:493.62px" class="cls_048"><span class="cls_048">Zhao, Yang 31</span><span class="cls_049">, </span><span class="cls_048">49</span><span class="cls_049">, </span><span class="cls_048">54</span></div>
<div style="position:absolute;left:50.00px;top:501.81px" class="cls_048"><span class="cls_048">Papathemeli, Despina 40</span></div>
<div style="position:absolute;left:177.57px;top:502.12px" class="cls_048"><span class="cls_048">Roller, Robert 21</span></div>
<div style="position:absolute;left:305.14px;top:502.12px" class="cls_048"><span class="cls_048">Tahir, H 17</span></div>
<div style="position:absolute;left:432.71px;top:501.52px" class="cls_048"><span class="cls_048">Zhou, Xiaolei 14</span></div>
<div style="position:absolute;left:50.00px;top:509.71px" class="cls_048"><span class="cls_048">Papp, Kim A. 20</span><span class="cls_049">, </span><span class="cls_048">22</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">29</span><span class="cls_049">, </span><span class="cls_048">44</span><span class="cls_049">, </span><span class="cls_048">48</span><span class="cls_049">,</span></div>
<div style="position:absolute;left:177.57px;top:510.01px" class="cls_048"><span class="cls_048">Rosa, Carmen La 22</span><span class="cls_049">, </span><span class="cls_048">24</span><span class="cls_049">, </span><span class="cls_048">28</span><span class="cls_049">, </span><span class="cls_048">29</span><span class="cls_049">, </span><span class="cls_048">49</span><span class="cls_049">,</span></div>
<div style="position:absolute;left:305.14px;top:510.02px" class="cls_048"><span class="cls_048">Tarzynski-Potempa, Rita 19</span></div>
<div style="position:absolute;left:432.71px;top:509.42px" class="cls_048"><span class="cls_048">Zhuang, Yanli 49</span></div>
<div style="position:absolute;left:58.00px;top:517.62px" class="cls_048"><span class="cls_048">49</span><span class="cls_049">, </span><span class="cls_048">54</span></div>
<div style="position:absolute;left:185.57px;top:517.92px" class="cls_048"><span class="cls_048">54</span></div>
<div style="position:absolute;left:305.14px;top:517.91px" class="cls_048"><span class="cls_048">Teng, Lichen 14</span></div>
<div style="position:absolute;left:432.71px;top:517.32px" class="cls_048"><span class="cls_048">Zhu, Baojin 54</span><span class="cls_049">, </span><span class="cls_048">55</span></div>
<div style="position:absolute;left:50.00px;top:525.52px" class="cls_048"><span class="cls_048">Pariser, David 24</span><span class="cls_049">, </span><span class="cls_048">29</span><span class="cls_049">, </span><span class="cls_048">30</span></div>
<div style="position:absolute;left:177.57px;top:525.82px" class="cls_048"><span class="cls_048">Rosana, Veira 9</span></div>
<div style="position:absolute;left:305.14px;top:525.81px" class="cls_048"><span class="cls_048">Thaçi, Diamant 16</span><span class="cls_049">, </span><span class="cls_048">20</span><span class="cls_049">, </span><span class="cls_048">22</span><span class="cls_049">, </span><span class="cls_048">24</span><span class="cls_049">, </span><span class="cls_048">26</span><span class="cls_049">, </span><span class="cls_048">27</span><span class="cls_049">,</span></div>
<div style="position:absolute;left:432.70px;top:525.22px" class="cls_048"><span class="cls_048">Zhu, X 17</span></div>
<div style="position:absolute;left:50.00px;top:533.42px" class="cls_048"><span class="cls_048">Park, So Young 16</span></div>
<div style="position:absolute;left:177.57px;top:533.72px" class="cls_048"><span class="cls_048">Rosenbaum, James 19</span></div>
<div style="position:absolute;left:313.14px;top:533.72px" class="cls_048"><span class="cls_048">46</span><span class="cls_049">, </span><span class="cls_048">54</span><span class="cls_049">, </span><span class="cls_048">57</span></div>
<div style="position:absolute;left:432.70px;top:533.12px" class="cls_048"><span class="cls_048">Zink, Alexander 58</span></div>
<div style="position:absolute;left:50.00px;top:541.32px" class="cls_048"><span class="cls_048">Park, Yong Gyu 34</span></div>
<div style="position:absolute;left:177.57px;top:541.62px" class="cls_048"><span class="cls_048">Rozzo, Stephen 24</span><span class="cls_049">, </span><span class="cls_048">29</span><span class="cls_049">, </span><span class="cls_048">30</span><span class="cls_049">, </span><span class="cls_048">31</span></div>
<div style="position:absolute;left:305.14px;top:541.62px" class="cls_048"><span class="cls_048">Thompson, Elizabeth H.Z. 28</span><span class="cls_049">, </span><span class="cls_048">30</span></div>
<div style="position:absolute;left:432.70px;top:541.02px" class="cls_048"><span class="cls_048">Zitti, Beatrice 44</span></div>
<div style="position:absolute;left:50.00px;top:549.22px" class="cls_048"><span class="cls_048">Park, Young Min 34</span></div>
<div style="position:absolute;left:177.57px;top:549.52px" class="cls_048"><span class="cls_048">Rubel, Diana 20</span></div>
<div style="position:absolute;left:49.79px;top:739.31px" class="cls_018"><span class="cls_018"> </span><A HREF="http://www.medicaljournals.se/acta/">www.medicaljournals.se/acta</A> </div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:52195px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background67.jpg" width=595 height=793></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:52195px;width:595px;height:793px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="4ae8a640-06d5-11ea-9d71-0cc47a792c0a_id_4ae8a640-06d5-11ea-9d71-0cc47a792c0a_files/background68.jpg" width=595 height=793></div>
</div>

</body>
</html>
